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Abstract 
Infection of bovine leukocytes by the intracellular protozoan parasites Theileria 
annulata and Theileria parva represents a unique model of reversible host cell 
transformation; characterised by uncontrolled proliferation and protection 
against apoptosis. Host cell transformation is known to involve parasite 
dependent manipulation of a number of signalling pathways that result in 
constitutive activation of pro-inflammatory transcription factors. Activation of 
these factors has been shown to confer protection against apoptosis or influence 
the metastatic potential of the infected cell, respectively. However, 
transcription factors have the potential to be detrimental as well as beneficial 
to the infected cell and the infected animal. This study investigated the 
potential of the parasite to manipulate the outcome of cellular activation by 
comparing the outcome of stimulating Theileria-infected and uninfected bovine 
cells with LPS. The results clearly indicate that prolonged stimulation of 
uninfected cells generated a phenotype associated with loss of proliferation, cell 
death and activation of NF- B. In contrast, infected TBL20 cells were refractory 
to stimulation, despite displaying high levels of constitutively activated NF- B.  
Using a microarray approach, expression profiling of infected and uninfected 
cells established that T. annulata infection imposes a remarkable level of 
control over host cell pathways and gene expression networks that are targets of 
transcription factors, typically activated by inflammatory mediators such as LPS. 
Importantly, Ingenuity Pathway Analysis (IPA) of the modulated dataset showed 
enrichment of molecular function and disease categories associated with known 
phenotypic characteristics of the Theileria-transformed cell. Categories included 
inflammatory response, cancer and tissue morphology, allowing postulation that 
parasite manipulates the expression of genes that function in the inflammatory 
response and are associated with cancer to generate a phenotype that is 
beneficial to survival and dissemination of the infected leukocyte. 
Various proteins secreted by the parasite are believed to contribute to 
regulation of the transformed host cell. The majority of parasite candidate 
proteins contain predicted signal peptides, suggesting secretion into the 
infected-host cell cytoplasm or location on the parasite surface. A prime 
v 
candidate for a Theileria encoded regulator of host cell gene expression is 
TashAT2, a protein bearing nuclear localisation/AT-hook DNA binding motifs, 
previously located to the host cell nucleus and shown to bind DNA. A transfected 
bovine macrophage cell line (BoMac) expressing TashAT2 was activated with PMA 
to provide RNA for microarray hybridisation and compared to RNA derived from 
vector alone control cells and non-stimulated transfected cells. Activation of NF-
B by PMA was demonstrated by reporter assay, with TashAT2-transfected cells 
displaying a marked resistance to PMA induced cell death and higher levels of 
NF- B dependent reporter activity relative to PMA stimulated control cells. 
Expression profiling of TashAT2-transfected BoMacs provided evidence for 
TashAT2 associated manipulation of both activated cell and non-activated gene 
expression networks. Furthermore, comparison of the TashAT2-modulated with 
infection-associated gene lists revealed a significant overlap in genes modulated 
by the macroschizont infected cell and TashAT2. IPA analysis of this common 
gene set highlighted biological functions and disease categories previously 
identified for the infection-modulated LPS dataset with some variation in the 
order of significance. Identified categories include cancer, inflammatory 
response and cell death. Comparative analysis of the TashAT2 associated profiles 
also identified a subset of genes that displayed significant modulation of gene 
expression changes in response to PMA stimulation, including reversal of the PMA 
response.  
Taken together, these results of this study provide further evidence that 
TashAT2 proteins are candidate molecules involved in manipulating expression of 
host cell genes that could play an important role in determining establishment of 
infected-transformed cells. The ability of the parasite and potentially TashAT 
family proteins to significantly regulate gene networks that mediate 
inflammatory disease and cancer could provide a platform to investigate how 
these disease outcomes can be manipulated.  
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
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1 Introduction 
1.1 Introduction 
Tropical or Mediterranean theileriosis is an economically important 
lymphoproliferative disorder of cattle that occurs throughout much of the old 
world. It is a tick-borne disease (TBD) of bovines and the prevalence reflects the 
geographical distribution of the tick vector, which is primarily tick species within 
the genus Hyalomma. The range of Hyalomma extends over a wide region of the 
old world including Southern Europe and North Africa through the Middle East 
and Southern Russia into India and Southern China (Uilenberg, 1981). The disease 
is caused by the protozoan parasite Theileria annulata, which for the Theileria 
genus can be considered to be the most important species based on its 
pathogenicity combined with a wide geographical range. 
T. annulata is the predominant species of Theileria in Southeast Asia, Middle 
East, Europe and some parts of Africa. The parasite mainly affects domestic 
cattle (Bos taurus and Bos indicus), zebu (Bos primigenius indicus), Asian buffalo 
(Bubalus bubalis) and wild cattle (Bos bison) (Dumanli et al., 2005;Robinson, 
1982). Tropical theileriosis is an extremely debilitating and often fatal condition 
especially in exotic breeds of cattle imported to improve productivity (Preston 
et al., 1999). It is estimated that over 250 million cattle in disease endemic 
regions are at risk from infection with T. annulata (Robinson, 1982). In several 
developing countries the parasite is a major constraint for improved livestock 
production due to the high morbidity and mortality rates. This is due, in 
particular, to the increased susceptibility of Bos taurus to the disease, limiting 
programmes that have aimed at higher production levels by introduction of 
European breeds.  However there is also a marked loss of production in 
indigenous cattle kept in endemic regions (Irvin et al., 1981), and the disease 
imposes a considerable economic drain on both large scale farming operations 
and, very often, small holder subsistence farmers. 
Of the other the Theileria species of cattle, T. parva is the most important.  T. 
parva shows a higher level of virulence than disease caused by T. annulata but 
has a more limited range, as the Rhipicephalus appendiculatus tick is found only 
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in sub-saharan Africa. T. parva causes a disease, commonly known as East Coast 
Fever (ECF) which is often fatal (Newson et al., 1986;Norval et al., 1992).  Up to 
50 million cattle are at risk and in years of high incidence up to 1 million deaths 
have been recorded. Cattle Theileria parasites described as more benign have 
also been associated with disease. Species include T. mutans and members of 
the T. orientalis group. Of the latter group T. sergenti has been most often 
associated with disease, primarily in Japan, Eastern Russia and Eastern China. 
Clinical episodes of disease attributed to T. orientalis were recently reported in 
South Australia (Islam et al., 2011;Kamau et al., 2011). 
It has been reported that the greatest economic losses from tropical theileriosis 
are due to loss of productivity (beef and milk production), followed by the cost 
of disease control (vaccination and acaricides) and chemotherapy (Cicek et al., 
2009;Gharbi et al., 2006;Inci et al., 2007;Minjauw and McLeod, 2003).  Economic 
losses for tropical theileriosis in India alone have been estimated at US $ 800 
million per year (Wilkie et al., 1998). A recent study performed in Tunisia 
estimated that up to half of the economic losses attributed to tropical 
theileriosis could be accounted for by the reduced productivity of sub clinically 
infected animals (Gharbi et al., 2006). 
T. annulata and T. parva are closely related parasites and considered to be 
among the most recently evolved Theileria species (Allsopp and Allsopp, 2006). 
Both species cause similar disease syndromes marked by a lymphoproliferative 
phase followed by metastasis (Irvin and Morrison, 1987). Following metastasis of 
infected cells, mortality in acute disease cases usually results from respiratory 
failure, due to pulmonary oedema or extensive destruction of lymphoid tissue 
(Irvin and Morrison, 1987). Therefore, much of the information described below 
for T. annulata, with respect to pathology and life cycle is also valid for T. 
parva. Moreover, study of the cellular and molecular biology associated with 
cellular transformation has been conducted on bovine cells infected with either 
species, and many of the mechanisms described are applicable to both. One 
major difference, however, is that T. annulata prefers to infect and transform 
cells of myeloid lineage, and also B cells, whereas T. parva is thought to 
preferentially infect T cells (Baldwin et al., 1988;Glass et al., 1989;Spooner et 
al., 1989). 
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Theileria parasites are unique, as the schizont stage of certain species, including 
T. annulata and T. parva, can induce the host leukocyte to proliferate in an 
uncontrolled manner, causing immortalisation and transformation of infected 
cells (Adamson et al., 2000;Baylis et al., 1995;Hulliger, 1965;Irvin and Morrison, 
1987). The importance of this event to generation of disease pathology 
underscores a requirement to understand how the parasite controls the infected 
host leukocyte. Furthermore, as well as being of inherent biological interest, 
this information has potential to be relevant to design of novel therapeutics. 
 
Figure 1.1:  Geographical distribution of major Theileria species of cattle worldwide   
Theileria annulata, responsible for Tropical Theileriosis and primarily found in Southern Europe and 
North Africa extending up to sub-Saharan Africa in Sudan and Eritrean. It also extends through the 
Middle East and Southern Russian into India and Southern China. Theileria parva is responsible for 
East Cost Fever and primarily found in the African countries highlighted. Theileria sergentii, 
responsible for a disease often termed as persistent Theileriosis, is found in Eastern Asia including 
Korea and Japan. (Source: http://www.Theileria.org/ahdw/background.htm) 
1.2 Theileria and related Apicomplexan parasites 
Theileria is an Apicomplexan hemoparasite of veterinary significance. Members 
of the phylum Apicomplexa comprise more than 5000 species of intracellular, 
protozoan parasites including those placed in the genera: Plasmodium, 
Toxoplasma, Cryptosporodium and Babesia (Noble et al., 1989). All are 
unicellular eukaryotic microbes and, collectively, apicomplexans can be 
classified as one of the most significant groups of infectious pathogens that 
cause disease in humans and domesticated animals. Therefore, the cell and 
molecular biology of Theileria bears similarity to that of other eukaryotes, of 
which the phylogenetic relationship is obviously stronger among closely related 
Chapter 1  31 
apicomplexan species. For Theileria, research conducted on Babesia and 
Plasmodium parasites is likely to be of greatest comparative value with respect 
to processes that allow evolution of their parasitic lifestyle. However Theileria-
infected leukocytes provide a unique model of how one eukaryotic cell can 
transform another, and study of how the parasite transforms its host cell may 
have wider relevance and relationship to cancer biology [reviewed in (Luder et 
al., 2009)]. Host-parasite interactions related to the cancer like pathology of 
tropical theileriosis can be addressed in three phases: the ability of the infected 
leukocyte to survive, proliferate and metastasise. Maintenance of the infected 
host cell in a constantly activated state is likely to be a key mechanism in these 
processes. Other apicomplexan parasites that may modulate the infected 
activated nucleated cell in a similar manner include Toxoplasma gondii and 
Neospora caninum [reviewed in (Hemphill, 1999;Hemphill and Gottstein, 
2006;Melo et al., 2011)]. Comparison of the mechanisms by which these 
different apicomplexan parasites have evolved is relevant to identify key 
modulatory events required for control of the nucleated host cell and survival 
within their mammalian hosts. 
1.3 Life cycle of Theileria annulata 
Theileria annulata has a complex life-cycle, involving both tick (Hyalomma spp) 
and bovine host. As expected, the life cycle of Theileria displays the principal 
stages of general apicomplexan differentiation events such as gametogony, 
sporogony and merogony. However, different apicomplexan life cycles show 
specific variation, two common differences being the host cell types invaded 
after entering the mammalian host and intracellular location of the parasite. For 
example, unlike Plasmodium and Toxoplasma parasites, the macroschizont of 
Theileria does not reside in a parasitophorous vacuole (PV) but lies free in the 
cytoplasm (like Babesia parasites) (Shaw, 1997). Differentiation from one stage 
to another is a vital process for the parasite biology that facilitates the 
transmission and propagation within and between vector and host. The basic life 
cycle of T. annulata is essentially the same for all Theileria species and is 
illustrated in Figure 1.2. Theileria parasites replicate asexually as three 
different stages, by sporogony in the tick vector, and by schizogony and 
merogony in bovine host cells. In T. orientalis proliferation (merogony) occurs 
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within the erythrocyte but this is limited or absent for T. annulata and T. parva 
(Conrad et al., 1985). Sexual reproduction of the parasite occurs in the tick. 
1.3.1  Bovine stages of T. annulata 
Infected ticks inoculate sporozoites (bovine infective stage) into the host blood 
stream during feeding, and the sporozoites rapidly invade host target 
leukocytes. Theileria annulata mainly infects leukocytes of monocyte and B-
lymphocyte lineage (Spooner et al., 1989). Morphologically sporozoites are oval 
shaped bodies measuring approximately 1µm in length that are formed in the 
salivary gland of the infected tick. Upon contact between sporozoite and the 
target leukocyte cell surface, a point of connection is established via MHC class 
ΙΙ receptors, that promotes the invasion of host cell by the parasite (Glass et al., 
1989). The surface coat of the sporozoite becomes closely associated with the 
host membrane and the parasite is internalised by a progressive circumferential 
‘zippering’ process, during which the surface coat of the sporozoite is shed. 
Once internalised the Theileria parasite is able to disrupt the parasitophorous 
vacuole membrane by discharging the contents of the rhoptries and micronemes 
and lies free in the cytoplasm surrounded by host cell microtubules (Mehlhorn 
and Shein, 1984;Shaw and Tilney, 1995).  
Following successful entry the parasite forms a trophozoite, which then 
differentiates into the multinucleated schizont (macroschizont) stage. The 
macroschizont maintains the association with the microtubule network and is 
normally located in the perinuclear region of the host cell. As the schizont 
develops the leukocyte is induced to divide and synchronisation of the parasite’s 
own cell division is achieved by close interaction with the host mitotic and 
central spindles (Shaw, 1997). This interaction allows the successful 
dissemination of the growing macroschizont to each daughter leukocyte.  
Proliferating infected leukocytes rapidly produce a large population of infected 
cells due to clonal expansion. Initially the parasite infects and multiplies in cells 
of the lymph nodes draining the site of inoculation (Forsyth et al., 1999;Glass, 
2001) but subsequently infected cells may be found in the bloodstream or invade 
a variety of tissues and organs, giving the infection ‘cancer-like’ features of 
leukoproliferation and metastasis. Parasite dependent leukocyte transformation 
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generates various phenotypes including a loss of myeloid differentiation status 
(Jensen et al., 2009;Sager et al., 1997), resistance to apoptosis (Heussler et al., 
1999), proliferation to generate immortal cell line cultures in vitro (Baumgartner 
et al., 2000) and the ability to transverse matrigel matrices (Lizundia et al., 
2006). Approximately 7 to 28 days post-infection, macroschizont infected cells 
may be detected in biopsy smears from superficial lymph nodes in live animals 
and impression smears of the lymph node, spleen and liver in dead animals 
(Radley et al., 1974;Young et al., 1977). 
Following a set time period in vivo (between 7-10 days), the macroschizont 
undergoes differentiation to the next life cycle stage, the merozoites (Jarrett et 
al., 1969). This process initially involves a slowing down of proliferation of the 
macroschizont-infected cell (Shiels et al., 1992). The parasite enlarges and 
switches from production of macroschizont to merozoite stage proteins (Shiels et 
al., 1992). Morphological changes to nuclei occur; rhoptry organelles are 
produced and become associated with the merozoite nuclei. Uni-nucleated 
merozoites are then formed by budding of the nuclei and rhoptry complex 
through the plasma membrane of the developing syncytium. Morphologically, 
merozoites of T. annulata contain a single nucleus, 1-2 mitochondria, 
microneme and 3-6 rhoptries and are covered in the major merozoite surface 
protein Tams1 (Mehlhorn and Shein, 1984;Shaw et al., 1991;Shaw and Tilney, 
1995). The mature merozoites are released into the bloodstream following cell 
membrane rupture of infected cells, and rapidly invade erythrocytes, 
subsequently forming intra-erythrocytic forms collectively known as piroplasms. 
Generally two forms of piroplasm may be seen inside erythrocytes a slender 
comma shaped form or spherical ovoid bodies surrounded by a single-layered 
plasma membrane (Mehlhorn and Shein, 1984). The infected erythrocytes are 
long lived and act as a carrier stage in the bovine host. It is likely some 
piroplasms within erythrocytes represent gametocytes and when ingested by the 
ticks during feeding are primed for the continuation of the life-cycle within 
Hyalomma ticks (see Figure 1.2). 
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1.3.2  Tick vector stages of T. annulata 
Following ingestion of the infected mammalian red blood cells (infective 
piroplasm), the sexual stage of the life cycle occurs within the intestinal lumen 
of the tick. Initially the piroplasms develop into slender, spindle-shaped bodies 
called raybodies/microgamonts (Schein et al., 1975). Up to four long flagellum-
like appendages form, which then break off to generate uni-nucleated filiform 
microgametes. At the same time spherical bodies thought to represent the 
macrogamonts can be observed. It is presumed that syngamy occurs with the 
fusion of micro- and macro-gametes forming the zygote (Levine, 1985;Schein et 
al., 1975). The immotile zygotes possess a vacuole-like centre and appear from 
five days post-repletion in the intestinal cells. After 12-15 days the zygote 
transforms into motile elongated shaped bodies, termed kinetes (Mehlhorn and 
Shein, 1984). The kinetes are then released into the haemolymph of ticks and 
following the moult of the tick, migrate to the salivary gland (Schein and 
Friedhoff, 1978). 
During the act of feeding, sporogony is activated in the salivary glands, allowing 
amplification of parasite numbers and generation of the stage infective for the 
bovine host. Interestingly, a study pertaining to Hyalomma anatolicum has 
demonstrated that unfed ticks were incapable of inducing infection in 
experimental calves, sporozoites only appear in the salivary gland after the 
adult ticks had been fed for 2-3 days (Singh et al., 1979). On the other hand it 
has been shown that environmental conditions, such as high temperature (37oC) 
and humidity (95%) can potentially stimulate the production of sporozoites in 
infected Hyalomma excavatum ticks irrespective of blood meal (Singh et al., 
1979), however this usually takes longer and with a reduced output in sporozoite 
number. Sporogony solely occurs within the acini of the salivary glands and once 
initiated gives rise to massive sporozoite production. It is estimated that 
approximately 40,000 sporozoites may be formed from each infected acinus 
(Young et al., 1992). Upon disintegration of the acinar cells sporozoites are 
liberated into the tick saliva, ready to be delivered into the bovine host during 
the blood meal (see Figure 1.2). 
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Figure 1.2:  The life cycle of Theileria annulata  
Bovine stage: Theileria parasite can be found in both erythrocytes and lymphocytes of infected 
bovine host. The infective stages of the life cycle, sprozoites are inoculated by tick during feeding 
that invade leukocytes to form macroschizont stage. Following a phase of uncontrol proliferation a 
proportion of macroschizonts differentiate into merozoites. Consequently, after the cell membrane 
rupture merozoites are liberated into the blood-stream, invading erythrocytes to form piroplasm.  
Tick stage: During the infective stage, piroplasms are ultimately taken by a feeding tick during 
blood meal which develops into gametocytes in the tick gut. The gametocytes then fuse to form 
immotile zygote, which later on transform into motile kinete. Finally the kinetes migrate to the 
salivary gland of the vector where after several cycles of asexual replication, sporozoites are 
formed.  
Adapted from: http://www.Theileria.org/ahdw/pictures/lifecyclelg.gif 
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1.4 Epidemiology of Theileriosis 
T. annulata is transmitted trans-stadially by ticks of the genus Hyalomma and, 
thus, the geographic distribution of the disease is determined by climate (hot, 
dry or humid summer) suitable for tick survival and questing activity. Several 
important Hyalomma species have been reported to transmit Theileria annulata 
in various part of the world; for example Hyaloma detritum in north Africa; H. 
detritum and H. excavatum in the former Soviet States; H. truncatum in parts of 
Africa; H. dromedarii in central Asia; and H. marginatum and H. anatolicum in 
India; (Bouattour et al., 1996;Flach and Ouhelli, 1992;Islam et al., 2006;Taylor 
et al., 2007). Beside factors that contribute to seasonal questing activity of tick 
populations, there are a number of reports suggesting that susceptibility to the 
disease observed in cattle populations is higher in exotic breeds relative to 
indigenous breeds in endemic areas (Minjauw and McLeod, 2003;Preston et al., 
1992). Recently, experimental studies have shown that exotic breeds 
particularly Holstein-Friesians, are associated with poor prognosis and 
detrimental outcome of the disease relative to indigenous breeds (Sahiwal; 
originating from Punjab, India and Kenana cattle; Sudan) (Bakheit and Latif, 
2002;Glass et al., 2005). A number of publications have provided evidence that 
different field strains, and presumably different genotypes, show variable levels 
of virulence (Askarov, 1975;Kamau et al., 2011;Somerville et al., 1998b;Tindih 
et al., 2010). The mechanisms behind such differences are not understood but 
one possibility is that virulence relates to the cytokine profile of the 
macroschizont infected cell line (Brown et al., 1995a). The ability of infection to 
generate a long lasting carrier phase contributes to epidemiology, as there is 
always a risk of disease introduction by importation of cattle that cannot be 
detected as infected using traditional diagnostic procedures (Bilgic et al., 2010). 
1.5 Pathogenesis, clinical signs and diagnosis of Theileria 
infection 
The pathological progression of events in a typical acute, often fatal, infection 
occurs through three stages each spanning about one week. The severity of 
outcome is influenced by breed (see above), immune status and is dependent on 
the number of sporozoites inoculated by feeding ticks (Preston et al., 
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1992;Samantaray et al., 1980). The first stage comprises an incubation period of 
roughly around 7-8 days where neither parasite nor lesions can be detected. 
Following the incubation period, the second phase also of around a week is 
marked by lymphoid hyperplasia, initially in the region of lymph node draining 
the area and later the whole body (Irvin et al., 1981). This phase of infection is 
manifested by the onset of clinical signs including enlarged lymph nodes, 
persistent fever (41oC), anorexia, tachycardia and tachypnea (Beniwal et al., 
1998;Irvin et al., 1981;Preston et al., 1992). During the advanced third stage the 
animal may show severe signs of lymphoid depletion and disorganisation 
associated with massive lymphocytolysis and depressed leucopoiesis causing 
severe leukopenia (Forsyth et al., 1999;Omer et al., 2002;Preston et al., 1992). 
Due to widespread destruction of the immune system encountered during the 
late stage of infection the animal may show clinical signs of severe dyspnoea, 
recumbency and finally death (Irvin and Morrison, 1987). Additionally, T. 
annulata infection is associated with profound changes in haematological and 
biochemical profiles and investigations of peripheral blood may reveal severe 
anaemia, leukopenia, lymphocytopenia, hypocalcaemia and hypoproteinemia 
(Hasanpour et al., 2008;Omer et al., 2002;Sandhu et al., 1998;Singh et al., 
2001). 
Diagnosis of the clinical T. annulata infection can be made based on combined 
clinical signs or pathological findings with confirmation by identification of 
parasitic stages in the blood or infected organs. Preliminary diagnosis of the 
disease is achieved on the basis of case history of a farm, non-specific clinical 
signs (pyrexia, anaemia, and lymphadenopathy) and post-mortem findings. 
Definitive differential diagnosis (Babesiosis, Anaplasmosis) is always based on the 
detection of macroschizonts in Giemsa stained lymph node biopsy smears in live 
animals and impression smears of lymph nodes and spleen in dead animals (Aktas 
et al., 2002). In some cases, microscopic examination of a blood smear may 
reveal intra-erythrocytic piroplasms but this, particularly for ECF, will not 
distinguish between acute current infection and the carrier stage. On the other 
hand, detection of macroschizonts in infected leukocytes along with piroplasms 
in erythrocytes of peripheral blood smears will identify clinical disease and in 
such cases the prognosis is poor (Pipano and Shkap, 2006). 
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Serological based diagnostic tests employing indirect fluorescent antibody test 
(IFAT) has been used in several epidemiological investigations (Dumanli et al., 
2005;Salih et al., 2007). Although utilisation of IFAT for early detection of 
infection has been shown to be more sensitive than examination of blood smears 
(Darghouth et al., 1996;Dhar and Gautam, 1977), there is a potential risk of 
obtaining false positive and negative results due to non-specific reactivity or a 
weak cross reactive immune response. Enzyme-linked immunosorbent assay 
(ELISA) has been developed for serological identification of Theileria infection 
by detecting anti-Theileria antibodies that react against piroplasm antigens 
(Gray et al., 1980). Recently, more robust ELISAs have been developed utilising 
recombinant antigen representing parasite surface proteins, Theileria annulata 
merozoite surface antigen 1 (Tams1) (Gubbels et al., 2000) and macroschizont 
Theileria annulata surface protein (TASP) (Bakheit et al., 2004;Salih et al., 
2005). 
DNA-based identification of parasite infection using polymerase chain reaction 
(PCR) has been recommended as the most sensitive assay and is the method of 
choice for the diagnosis of tropical theileriosis in the carrier state (Bilgic et al., 
2010). Several epidemiological studies have favourably compared the specificity 
and sensitivity of PCR with other conventional methods such as serological or 
microscopic based techniques (Aktas et al., 2002;Aktas et al., 2006;Almeria et 
al., 2001;d'Oliveira et al., 1995;Dumanli et al., 2005;Martin-Sanchez et al., 
1999) and since then this technique is widely in use. Although, DNA-based PCR 
methodology is relatively costly compared to serological and microscopic 
examination, it is highly sensitive and more efficient (Aktas et al., 
2002;d'Oliveira et al., 1995). Thus, using gene specific primers and amplification 
of specific fragments representing the Tams-1 gene has allowed detection of T. 
annulata in blood samples of carrier animals or infected ticks (d'Oliveira et al., 
1995;d'Oliveira et al., 1997). In addition species specific PCR-RFLP tests have 
been developed (d'Oliveira et al., 1995;d'Oliveira et al., 1997;Heidarpour et al., 
2009), as well as a highly sensitive species-specific PCR test using primers 
designed against the cytochrome b gene (Bilgic et al., 2010). 
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1.6 Chemotherapy and available control strategies 
Several chemotherapeutic agents have been used worldwide for the treatment 
of theileriosis including parvaquone, halofuginone lactate, long acting 
oxytetracyclines and buparvaquone. However, most of these drugs have their 
own limitations including a requirement for early administration, repeated 
doses, drug resistance and lack of effectiveness against a particular stage of the 
infection. Previously, halofuginone has been shown to be effective against the 
schizont stage but at the same time the difference between toxic and 
therapeutic doses is marginal (Mbwambo et al., 1986;Schein and Voigt, 1979). In 
the past tetracycline has also been used in large doses but has limited action 
against the piroplasm stage, which can cause pathology in tropical theileriosis 
(Dhar et al., 1990;Gill et al., 1978;Mallick et al., 1987;Singh et al., 1993). 
Research trials conducted for comparing the efficacy of different drugs has 
shown that buparvaquone (BW720c), a second-generation 
hydroxynaphthaquinone, is the drug of choice (Dolan et al., 1984;Hawa et al., 
1988;McHardy et al., 1985;Mutugi et al., 1988;Ngumi et al., 1992;Singh et al., 
1993). However, early treatment of the disease with BW720c has been 
recommended to achieve a rapid and desirable outcome in eliminating the 
parasite from the blood and lymph nodes and improvement of the clinical state 
of the animal. It has been reported that treatment with BW720c in animals in 
the advanced stage of disease failed to improve the clinical condition of the 
animal (Morrison and McKeever, 2006;Osman and Al-Gaabary, 2007). 
Vaccination has been a focus of research and has shown some success in the 
field. Vaccination either in combination with drug treatment and tick control or 
in isolation has been used in different parts of the world for both tropical 
theileriosis and East Coast Fever (ECF). Vaccines against T. annulata are 
generated by attenuation of parasite virulence by prolonged culture in vitro, 
while for T. parva virulence of infection is controlled by co-delivery of a dose of 
long acting tetracycline (Morrison and McKeever, 2006;Morzaria et al., 
1987;Musoke et al., 1993;Radley et al., 1975). A number of authors have 
reviewed various control strategies against theileriosis (Brown, 1990;Dolan, 
1989;Tait and Hall, 1990). Effective control of theileriosis is best achieved 
through a combined strategy of tick vector control and vaccination, while in 
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clinical cases chemotherapy is the only option. However, based on the 
continuing prevalence of the disease in endemic countries there is a dire need 
for improved control strategies because drug resistance against BW720c has been 
reported in vivo (Mhadhbi et al., 2010), acaracides are costly and resistance has 
developed and existing vaccines have production and delivery limitations 
(Boulter and Hall, 1999;Mbassa et al., 1998;McKeever et al., 1999;Tait and Hall, 
1990). 
1.7 Cellular and molecular interactions between the 
Theileria macroschizont and the infected host 
leukocyte 
Bovine leukocytes infected with Theileria have been demonstrated to acquire a 
number of phenotypic changes that involve cellular events induced by the 
presence of the parasite. Upon successful entry into the leukocyte and 
development to the macroschizont stage, the parasite fascinatingly takes control 
over the infected-host cellular machinery resulting, in vitro, in the 
establishment of an immortalised transformed phenotype. 
1.7.1 Host cell transformation 
Theileria-infected leukocytes display characteristic signs of transformed 
mammalian cells. Infected cells can be readily cultured in vitro and display both 
metastatic properties (Heussler and Stanway, 2008;von et al., 2010) and 
resistance to programmed, apoptotic, cell death [reviewed in (Dobbelaere and 
Heussler, 1999)]. However, unlike classical transformation events, parasite 
induced transformation is reversible, as infected cells stop proliferating and die 
upon elimination of the parasite with theilericidal drug BW720c (Dobbelaere and 
Rottenberg, 2003;Rintelen et al., 1990), unless they are supported by the 
addition of exogenous growth factors. At the molecular level transformation is 
known to be associated with modulation of normal host cell signaling pathways 
[reviewed in (Dobbelaere and Kuenzi, 2004;Luder et al., 2009)]. Several of these 
pathways have been shown to result in constitutive activation of bovine 
transcription factors. Moreover, a link between activation and cellular 
proliferation, or proliferation and protection against cell death has been made 
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primarily by using drugs to specifically inhibit steps in the activation pathways. 
Additionally, it has been demonstrated that macroschizont infected leukocytes 
exhibit invasive tumour like growth in vivo when inoculated into immuno-
compromised mice (Fell et al., 1990;Irvin et al., 1975), causing a malignant 
neoplastic like condition similar to human B cell lymphomas. 
Activation of transcription factors can have a detrimental outcome and may act 
as tumour suppressors (Perkins and Gilmore, 2006;Sharpless and Depinho, 2002). 
Evidence has recently been generated that for some of these factors the parasite 
must take action to prevent a manifestation of function, and the best example 
to date concerns the classical tumour suppressor, p53. 
While much information has been gained on pathways associated with Theileria 
mediated transformation, one area where detailed information is lacking is 
identification of parasite genes and proteins that are responsible for initiating 
the transformation event. 
1.7.2  Activation of host cell transcription factors 
It is widely accepted that the alteration of host cell phenotype by a number 
intracellular pathogens (viruses, bacteria and parasites) involves both activation 
and modulation of mammalian transcriptional factors (Gyles et al., 
2007;Julkunen et al., 2001;Luder et al., 2009). As a survival and defence 
strategy it is likely that Theileria, like other pathogens, have attained 
sophisticated mechanisms to interfere with the host response to infection. These 
mechanisms include the unique ability of pathogens to directly and indirectly 
manipulate and evade inflammatory and innate cellular defence pathways 
[reviewed in (Finlay and McFadden, 2006;Leiriao et al., 2004;Luder et al., 
2009;Mogensen, 2009)]. It is clear from a large number of studies that leukocyte 
signal transduction pathways are significantly altered by Theileria parasites. 
Thus, in Theileria transformed cells, activation of c-Jun NH2-terminal kinase 
(JNK), NF- B, casein-kinase 2 (CK2), PI3K-PKB and JAK2/STAT3 pathways have 
been documented [reviewed in (Baumgartner et al., 2000;Dessauge et al., 
2005a;Dessauge et al., 2005b;Dobbelaere and Kuenzi, 2004;Shiels et al., 2006)] 
(see Figure 1.3). These pathways and factors are known to contribute to 
stimulation and regulation of the inflammatory, innate immune and cellular 
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defence responses. A summary of key transcription factors activated in 
Theileria-infected cells studied to date, and the role they play in regulation of 
inflammatory and innate immunity is discussed below. 
 
Figure 1.3:  Pathways implicated in manipulation of Theileria-infected host cell phenotype   
Theileria parasites invade bovine leukocytes and activate a number of signal transduction pathwys 
resulting in translocation of transcription factors to host nucleus. The transcription factors AP-1 and 
ATF-2 are constitutively activated via c-Jun NH2-terminal kinase (JNK) that is permanently 
activated in Theileria infected leukocytes. Constitutive cMyc expression is dependent on the 
JAK2/P-STAT3 pathways and is also influenced by AP1. Constitutive activation of NF- B occurs 
via recruitment of IKK complexes (signalosomes) to the macroschizont surface.  p53 apoptotic 
pathway of host cells is not induced by Theileria and it has been shown that parasite is involved in 
cytoplasmic sequestration of p53. Association of host-cell p53 with the parasite membrane has 
been postulated to either interact directly with p53, or mediate cytoplasmic sequestration of p53 by 
interacting with other host cell proteins regulating p53 localization. Apapted from (Shiels et al., 
2006) 
1.7.2.1 Nuclear Factor kappa B (NF- B) 
NF- B is a family of inducible, dimeric transcription factors that regulate the 
expression of genes involved in the inflammatory response, immune response, 
cell proliferation and apoptosis (Baldwin, Jr., 1996;Barkett and Gilmore, 
1999;Barnes and Karin, 1997;Gilmore, 1999). NF- B was first characterized as a 
transcription factor that constitutively binds to the κB motif in the enhancer 
element within the immunoglobulin κ light-chain gene (Sen and Baltimore, 
1986). The family of NF- B transcription factors consist of five subunits:  RelA 
(also called p65), RelB, c-Rel, NF- B1 (p50) and NF- B2 (p52). The last two 
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proteins are synthesized as larger precursors of 105 (p105) and 100 kDa (p100), 
respectively, which are then proteolytically processed to their sub-unit forms. 
Activated hetero or homodimers of combinations of these subunits are then 
translocated into the nucleus to regulate the expression of a wide range of 
target genes (Hayden and Ghosh, 2004;Karin et al., 2002). In unactivated cells, 
NF- B/Rel dimers are sequestered in the cytoplasm in an inactive form as a 
result of their association with members of another family of proteins called 
Inhibitors of NF- B (IκBs). IκBs form another evolutionary conserved multigenic 
family, composed of IκBα and IκBβ. In response to recognition of a wide variety 
of stimuli via Toll, IL1 and TNF receptors, a multi sub-unit kinase complex called 
IκB kinase (IKK), consisting of two catalytic subunits IKK1 (IKkα) and IKK2 (IKKβ), 
and a modulating subunit NEMO (IKKγ) is generated (see Figure 1.4).  
 
Figure 1.4:  Schematic illustration of NF- B activation pathway in general   
Major signaling pathways that lead to NF- B activation. NF- B can be activated by a variety of 
receptors on the cell surface that transduce the signal via number of adaptor proteins (e.g TRAFs) 
and kinases (IRK and MEKK3/NIK). Classical activation of NF- B occurs via recruitment of IKK 
complexes leading to phosphorylation and degradation of the IkB. Inputs for the classical pathway 
include TNFR1/2, TLR/IL-R. The alternative pathway involves NIK activation of IKKα and leads to 
phosphorylation and processing of p100, activating p52/RelB heterodimers.  
Classical NF-kB 
pathway 
Alternative NF-kB 
pathway 
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The IKK complex phosphorylates specific serine residues within the IκBs, leading 
to their ubiquitination and degradation through the proteasome pathway. 
Ultimately free NF- B dimers translocate to the nucleus to regulate the 
transcription of a large number of target genes (Weil et al., 1997;Whiteside and 
Israel, 1997).  
In uninfected cells the activation of NF- B is usually triggered through a range of 
different surface receptors or intracellular events, including cellular stress 
[reviewed in (Oeckinghaus et al., 2011;Perkins, 2012)]. The parasite factor(s) 
that induces NF- B activation are still unknown but it has been postulated that 
parasite proteins either expressed on the surface of the schizont or secreted into 
the host cell cytoplasm may interfere with the signal-transduction pathway of 
the host cells. Heussler et al., (2002) provided remarkable evidence that 
parasite associated factors almost certainly contribute to NF- B activation, as it 
was shown by immunofluorescence imaging that the macroschizont stage of the 
parasite infected cell is decorated with active IKK Signalosome complexes. Due 
to the apparent proximity of the signalosome formation with the parasite it was 
logical to propose that parasite derived proteins located at the surface of the 
schizont act directly as a ligand for an IKK protein, leading to enforced 
oligomerisation of the signalosome complex and subsequent “proximity induced 
activation”. However, after extensive research it has not yet been possible to 
establish a direct interaction between parasite protein and components of the 
signalosome (Dobbelaere and Kuenzi, 2004;Heussler et al., 2002). One possibility 
is that additional host proteins that act as a scaffold for IKK oligomerisation are 
required, and evidence that the actin cytoskeleton promotes formation of 
parasite dependent IKK signalosomes has been found (Schmuckli-Maurer et al., 
2010). 
A clear role for activated NF- B in preventing apoptosis of Theileria infected 
leukocytes has been established (see below). However, activated NF- B is 
unlikely to be restricted to this role, as NF- B is known to regulate genes that 
are important for several other vital cellular processes such as proliferation, 
differentiation, and development. NF- B is also a critical activator of genes 
involved in inflammation and immunity activated via Toll like receptors, IL1 and 
TNF receptors (Gerondakis et al., 1998;Li and Verma, 2002) and it is well known 
that prolonged activation of NF- B is associated with diseases that result from 
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chronic stimulation of the inflammatory response (Aggarwal et al., 2006;Makarov 
et al., 1997). Thus NF- B is a transcription factor with a wide range of potential 
functions which includes regulation of genes encoding cytokines and growth 
factors, adhesion molecules, acute phase reactants and receptors and 
chemoattractants which influence the outcome of disease (Schwartz et al., 
1999). It has been predicted that NF- B dependent regulation of inflammatory 
genes contributes to the pathogenesis of theileriosis (Heussler et al., 2002). 
1.7.2.2 Activator Protein 1 (AP-1) 
AP-1 is a complex multi-protein transcription factor, composed of proteins from 
a number of families [members of Fos (c-Fos, FOSB, FRA1, FRA2), c-Jun (c-Jun, 
JUNB, JUND), ATF (ATF2, ATFa, ATF3, ATF4, B-ATF) and MAF (c-MAF, MAFA, 
MAFB)] that exists ubiquitously as either a homo- or heterodimeric complex. 
These complexes are formed via the basic leucine zipper, a domain that is 
important for dimerisation and DNA binding, and is represented in a large family 
of proteins that act as DNA binding proteins (Halazonetis et al., 1988;Hess et al., 
2004a). In response to various inflammatory stimuli, activated AP-1 in turn 
regulates the expression of genes that control a number of critical cellular 
events including proliferation, differentiation and apoptosis (Ameyar et al., 
2003;Jacobs-Helber et al., 1998). Furthermore, regulation of these cellular 
events is dependent on the relative abundance of AP-1, the composition of AP-1 
dimers, and the types of stimuli and cellular context of the activation event 
(Kaminska et al., 2000). 
Ap-1 proteins have versatile functions in the regulation of cell proliferation, and 
several direct targets have been identified whose expression is directly linked to 
the cell cycle regulatory apparatus [reviewed in (Jochum et al., 2001)]. 
Normally activation of AP-1 is dependent on activation of various signaling 
cascades including JNK, ErK and mitogen activating protein kinases (MAPKs). It 
has been shown that for Theileria-infected bovine leukocytes, AP-1 activity is 
exclusively dependent on JNK via its main substrate c-jun (Chaussepied and 
Langsley, 1996;Lizundia et al., 2006). Supporting evidence has also been 
provided by Chaussepied et al., (1996) who demonstrated that both JNK activity 
and elevated nuclear localisation of jun proteins occur in T. parva-transformed B 
cells compared to uninfected B cells. The elevated activity of JNK in an infected 
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cell causes constitutive phosphorylation of the N-terminus of c-jun, which in turn 
results in up-regulation of AP-1 driven transcription.  
The constitutive activation of AP-1 is believed to contribute significantly to the 
metastatic potential of the infected cell line. In support of this conclusion, AP1 
has been implicated in induction of host cell metalloprotease-9 (MMP9) gene 
expression (Adamson and Hall, 1997). In addition, attenuated vaccine cell lines 
exhibiting lower metastatic potential display reduced metalloprotease gene 
expression. The reduction was postulated to be associated with loss of a parasite 
induced AP-1 recognition factor, as indicated by an altered (EMSA) profile of 
proteins binding to the AP-1 site in the promoter region of the MMP9 gene 
(Adamson et al., 2000). 
1.7.3  Induction of proliferation by Theileria 
Several studies have shown that resting leukocytes have the ability to proliferate 
after stimulation; however most of the cells are sensitive to inflammatory 
stimuli and die via a special mechanism called activation induced cell death 
(AICD) (Arnold et al., 2006;Donjerkovic and Scott, 2000). In contrast, 
macroschizont-infected cells of T. annulata and T. parva display continuous 
proliferation and are resistant to AICD. Uncontrolled proliferation is one of the 
most important features of Theileria-transformed cells. Previously it has been 
reported that Theileria-transformed leukocytes exhibit moderate but 
constitutive levels of PI3K (Baumgartner et al., 2000). Moreover this study 
showed that this constitutive PI3-kinase activity is essential for proliferation of 
the infected cell using the specific inhibitors LY294002 and wortmannin. It was 
also shown that the granulocyte-monocyte stimulating factor (GM-CSF) is 
induced by PI3-Kinase, allowing postulation that a GM-CSF autocrine loop 
functions to maintain proliferation of the host leukocyte. A second study 
confirmed a role for constitutive PI3-K activity in contributing to proliferation of 
the infected cell (Heussler et al., 2001). Furthermore both studies generated 
evidence through the use of inhibitors that PI-3K activity was not required to 
protect the cell from apoptosis. However discrepancies between the two studies 
were obtained in relation to activation of Akt/PKB and NF- B. Heussler et al., 
found no role for PI3-K in activation of NF- B, while Baumgartner concluded PI3-
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K did not act via PKB. How the PI3-K pathway is activated is not conclusively 
known but an indirect event via surface receptors or adhesion molecules 
upregulated in infected cells have been proposed (Heussler et al., 2001). More 
recent studies proposed a role for the Src family kinase Hck (Baumgartner et al., 
2000), with constitutive activation of PI3-K postulated to result from a loss of 
negative regulation of Hck present in lipid rafts of Theileria infected leukocytes.  
As discussed by Huessler et al., (2001), Akt/PKB could feed into regulation of 
proliferation of Theileria-infected cells at different levels by stimulating 
expression genes that control cell cycle progression such as c-fos, c-myc and the 
G1 cyclins. Regulation of the cell cycle may also be achieved via negative 
regulation of tumour suppressors such as p53 and retinoblastoma protein and 
activation of the E2F transcription factor [reviewed by (Shiels et al., 2006)]. PI3-
K activation may also contribute to metastasis of the infected cell by increased 
expression of c-Fos and inhibition of PI3-K was found to reduce AP-1 
transcriptional activity (Baumgartner et al., 2000). 
1.7.4  Inhibition of host cell apoptosis by Theileria 
Many infections are strongly associated with activation of the NF- B pathway and 
stimulation of the inflammatory response. Upon activation NF- B translocates to 
the nucleus and is found in this location in Theileria infected cells. However, 
after elimination of the parasites by BW720c, NF- B is no longer located in the 
nucleus indicating that a viable parasite is required for its constitutive activation 
(Heussler et al., 1999;Ivanov et al., 1989). Although studies have shown that NF-
B can be involved in promoting proliferation of transformed cells, for the 
Theileria infected cell, the proven role of NF- B is in protecting cells from 
programmed cell death (apoptosis), with a potential to promote proliferation 
presumed but not substantiated (Dessauge et al., 2005b;Guergnon et al., 
2003;Palmer et al., 1997). Thus, inhibition of constitutive NF- B activation by 
dominant negative inhibitors of NF-kB has been shown to induce rapid apoptosis 
of infected cells, supporting the key role of NF- B in the survival of Theileria 
transformed cells (Heussler et al., 1999). Since apoptosis and proliferation are 
two physiologically active phenomena closely linked and regulated (Ginaldi et 
al., 2000), it was difficult to conclude what the effect on proliferation was 
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following inhibition of NF-kB. Constitutive activation of NF- B has been shown to 
protect the Theileria infected cell from apoptosis probably via up-regulation of 
some well known antiapoptotic proteins such as c-FLIP, X-IAP, c-IAP (Dobbelaere 
and Kuenzi, 2004). Regulation of these proteins by NF- B has also been 
demonstrated for other cell types, supporting their role as putative anti-
apoptotic targets of NF- B in Theileria-transformed cells. NF- B mediated 
expression of anti-apoptotic proteins can provide protection against apoptosis at 
different levels. For instance, c-FLIP could block the processing of procaspase 
8/10, triggered upon ligand-induced activation of death receptors (e.g. 
Fas). IAPs counter effector caspases, and pro-survival proteins of the Bcl-
2 family prevent mitochondria-initiated apoptosis, by regulating cytochrome C 
release (Kataoka et al., 2000;Peter, 2004;Schimmer and Dalili, 2005;Tschopp et 
al., 1998;Yang et al., 1997). 
In addition to NF- B, other factors and pathways have also been implicated in 
protecting the infected cell from cellular death. In the study of (Dessauge et al., 
2005a) constitutive expression of the oncogenic protein c-myc via Jak-Stat signal 
transduction was described. Inhibition of c-myc was shown to induce death of 
infected cells and it was postulated that the anti-apoptotic effect could be due 
to c-myc-dependent induction of Bcl-2 family member, Mcl-1. As predicted, 
expression of c-myc was shown to be dependent on the presence of a viable 
parasite (Dessauge et al., 2005b). The transciption factor c-Myc is well 
established as an oncogneic protein with a broad range of cellular functions, 
including regulation of cell cycle progression, cell growth, differentiation, 
transformation, angiogenesis and apoptosis [reviewed in (Gonzalez and Hurley, 
2010)]. C-Myc can act as an inducer and suppressor of its target genes and these 
include: Cyclin A, Cyclin D and Cdk4, p53, MHC class 1, C/EBPα, cdc42 (Dang, 
1999;Dang et al., 2006). 
The tumour suppressor p53 is a key molecule involved in regulation of cell cycle 
progression and cell death and provides a major checkpoint in the prevention of 
cells becoming cancerous (Collins et al., 1997). The function of p53 in normal 
cells is to arrest cell division and initiate apoptosis in response to cellular stress 
and DNA damage [reviewed in (Amaral et al., 2010)]. Loss or block of p53 
function is a common feature of transformed cells and it might be expected that 
Theileria infected leukocytes limit functional expression of this tumour 
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suppressor protein. This prediction was tested by Haller et al., (2010), who 
investigated p53 apoptosis related events as a target of parasite modulation. 
This result indicated that T.annulata infected cells are able to inhibit the p53 
apoptotic pathway, mainly by sequestration of the majority of p53 to the 
cytoplasm of the infected cell. Immunodetection revealed close association of 
p53 with the schizont membrane, and this sequestration was destabilized 
following elimination of the viable parasite with BW720c. This led to nuclear 
translocation of p53 and was associated with upregulation of proapototic 
proteins Bax and Apaf1 and downregulation of anti-apoptotic Bcl-2. It was 
proposed that modulation of p53 activity could occur via direct interaction with 
a parasite surface protein or via other host proteins that regulate localisation of 
p53 (Haller et al., 2010).  
Although, it has been shown that PI3K/PKB pathways in Theileria annulata-is 
primarily linked to the promotion of proliferation some evidence has been 
produced that residual PKB activity can contribute to protection against cell 
death in Theileria-infected BL3 cells. Thus in the study of (Guergnon et al., 
2006) apoptosis could only be inhibited by dual inhibition of PKB together with 
PKA. It was concluded however, that PKA was predominant in the infected cell, 
and functioned by inhibiting the pro-apoptotic molecule Bad (member of the 
BCL-2 family). Taken together these studies indicate the parasite must 
manipulate cellular pathways that promote programmed cell death in response 
to stress or induction of uncontrolled proliferation. 
1.7.5  Manipulation of activated host cell gene expression 
Constitutive activation of inflammatory transcription factors could result in 
events that are detrimental as well as beneficial to the infected cell. Thus, 
constitutive activation of factors primarily associated with anti-apoptotic 
activity may lead to the death of lymphocytes under certain circumstances 
(Dutta et al., 2006). NF- B, for example generally protects cells from apoptosis 
by inducing the expression of genes responsible for encoding anti-apoptotic 
proteins (Dobbelaere and Kuenzi, 2004). However, the role of NF- B in apoptosis 
can vary markedly in different cell contexts and it can sensitize cells to a variety 
of death inducing stimuli like pro-inflammatory cytokines, Tumour Necrosis 
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Factor alpha (TNFα) and inducible Nitric Oxide Synthase (iNOS) (Dutta et al., 
2006). Consequently NF- B was described as a Janus-like transcriptional factor 
(Youssef and Steinman, 2006). Moreover, constant activation of NF- B can lead 
to chronic inflammatory conditions by promoting the expression of cytokine 
genes (Beinke and Ley, 2004) or contributing to pathogenesis associated with 
many tumors (Basseres and Baldwin, 2006). Therefore, parasite associated 
persistent activation of NF- B and other Janus-like transcription factors, c-Jun 
(Chaussepied et al., 1998) and c-Myc (Dessauge et al., 2005a), have the 
potential to be detrimental to the transformed infected leukocyte and the 
infected host. 
The first evidence that Theileria parasites may manipulate the outcome of 
infection was provided by Sager et al., (1997) who demonstrated that 
lipopolysaccharide (LPS) induced expression of pro-inflammatory cytokines IL-1, 
TNFα and iNOS in the Theileria annulata transformed cells were impaired, as 
none of these activities were up regulated following LPS treatment relative to 
significant elevation in uninfected cells. Sager et al., (1997) also provided 
evidence that infection of macrophages by T. annulata induces a reversible 
dedifferentiation event, that may occur as a consequence of, or is involved in 
establishing, cellular transformation. Further evidence for modulation of 
macrophage status has also been provided by the more recent study of Jensen et 
al., (2009) which demonstrated a parasite dependent suppression of MAF 
transcription factors. MAFs are known to be involved in regulating the 
monocyte/macrophage differentiation step from myeloid precursor cells.   
Oura et al., (2006) also demonstrated the ability of parasite infection to down-
regulate the expression of pro-inflammatory genes associated with cellular 
defence. Thus, while infection induced an increase in expression of genes 
involved in the interferon inducible ISGylation pathway, the level of expression 
was significantly lower than that obtained by stimulation of uninfected cells with 
LPS. Furthermore, killing the cell with BW720c led to a significant elevation in 
interferon stimulated gene 15 (ISG15) and ubiquitin like protease (UBP-3) gene 
expression, indicating full expression of these genes is repressed by a viable 
parasite. ISG15 has been shown to be a direct target of NF- B (Li et al., 2001) 
and NF- B and AP-1 are strongly activated via LPS to induce expression of pro-
inflammatory cytokines IL-1, TNFα and iNOS (Cho et al., 2005). Since NF- B and 
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AP-1 are constitutively activated in Theileria transformed cells, it can be 
hypothesised that the attenuated expression profile of genes such as TNFα, iNOS 
and ISG15 (Oura et al., 2006;Sager et al., 1997) is due to active modulation by 
the parasite-infected leukocyte. 
1.7.6  Candidate parasite regulators of the transformation 
phenotype 
Despite the wealth of information on modulation of host cell gene expression, 
parasite factors responsible for controlling these events have not been 
conclusively identified. However, three major points of parasite-host interaction 
(parasite surface, host cytoplasm, and nucleus) are under current investigation, 
with candidate proteins obtained both from experimental work and mining the 
available genome sequences of T. annulata and T. parva (Pain et al., 2005;Shiels 
et al., 2006).  
One of the most obvious points of interaction is the interface between the 
membrane surface of the macroschizont and the host cell cytoplasm. This is a 
key area for the mechanism behind IKK signalosome formation, as it has been 
postulated that the primary event is likely to be an interaction between a 
signalosome component and a parasite-encoded surface ligand. In this context, 
it has recently been shown that the parasite surface protein known as TpSCOP 
(T. parva schizont-derived cytoskeleton binding protein) has the ability to 
interact with F-actin (Hayashida et al., 2010) and activate NF- B in transfected 
mammalian cells. Furthermore, transient transfection of TpSCOP in T. parva-
infected cells also showed enhanced activation of NF- B. However, this protein 
is expressed by the piroplasm stages of Theileria species that are non-
transforming, and it is known that altering actin structure can result in 
activation of host dependent NF-kB signalling. Furthermore, co-localisation of 
TpSCOP and parasite/signalosome complexes was not demonstrated.  
 Additional parasite proteins studied as candidates for interaction with the host 
cytoskeleton include TaSP, TaSE and gp34. T. annulata secretory protein (TaSE) 
is secreted into the host cell compartment and is speculated to have a functional 
role in host-parasite interaction (Schneider et al., 2007). Confocal microscopic 
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examination revealed co-localisation of TaSE with host cell microtubules, 
especially apparent during mitosis. Evidence of specific interaction was provided 
by co-precipitation of TaSE and alpha-tubulin. However, co-localisation and co-
immunoprecipitation experiments showed that only a fraction of the expressed 
TaSE associated with tubulin, suggesting that TaSE may interact via microtubule-
associated proteins. Based on the patterns identified for TaSE during mitosis it 
was postulated that this protein might play a role in ensuring the uniform 
distribution of schizont into the host-daughter cells during cell division 
(Schneider et al., 2007). 
A similar role has been proposed for TaSP, an immunodominant Theileria 
annulata surface protein proposed to be involved in the attachment of the 
parasite to the host cell microtubule network (Seitzer et al., 2010). TaSP was 
shown to co-localise with the mitotic spindle of dividing cells and co-
immunoprecipitated with alpha-tubulin in transiently transfected Cos-7 cells. 
Moreover, results obtained from pull-down assay provided evidence of direct 
interaction between TaSP and polymerised microtubules. Immunofluorescence 
analysis located TaSP at various sites of mitotic cells including spindle poles, 
mitotic spindle apparatus and the mid-body (Seitzer et al., 2010). Based on 
localisation to the microtubule organising centre, it was speculated that TaSP is 
involved in regulation of microtubule assembly in the host cell.  
One further protein identified as potentially interacting with the host cell 
cytoskeleton is gp34, a GPI anchored protein specifically expressed at the 
macroschizont surface (Xue et al., 2010). Tagged T. parva-gp34 but not T. 
annulata-gp34 localised to the central spindle and mid body. Interestingly gp34 
was associated with a disruption of cytokinesis, as over expression of transgene 
increased the number of bi-nucleate cells detected. It was proposed that this 
result could reflect a capacity of gp34 to interact with regulators of host cell 
cytokinesis 
The T. annulata encoded antigen Ta9 is an immunodominant protein recognised 
by CD8 T cells, indicating presentation of peptides at the infected cell surface 
(MacHugh et al., 2011). Sequence analysis of Ta9 genes from field isolates of T. 
annulata revealed extensive divergence, resulting in amino acid polymorphism 
within two distinct major histocompatibility restricted T cell epitopes. 
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Functional studies have confirmed that differences in sequence of this epitope 
correspond with differential recognition of infected cells by individual CD8 T cell 
clones. The Ta9 protein is predicted to have a cleaved signal peptide, indicating 
secretion by the parasite into the cytosolic compartment. Identification of Ta9 
polypeptide in the cytoplasm of macroschizont-infected cells was reported 
(MacHugh et al., 2011). It is unknown what role TA9 plays in the transformation 
process, if any. However, given it is a major antigen it seems reasonable to 
propose that it must bear some important function, since as a presented T cell 
antigen it would appear to generate a selective disadvantage to the survival of 
the infected cell. Conserved signal sequence and partially conserved motifs were 
described at the c-terminus of TA9 and a clear orthologue is present in T. parva. 
Ta9 is a secretome protein and is encoded by a member of a small gene family (5 
genes). Two additional larger secretome gene families have been described in 
some detail (Pain et al., 2005). The subtelomere-encoded variable secreted 
protein (SVSPs) family consists of 85 members in T. parva and 51 members in T. 
annulata (Pain et al., 2005;Schmuckli-Maurer et al., 2009;Shiels et al., 
2006;Weir et al., 2010). Almost all SVSPs are expressed at the RNA level by the 
macroschizont stage. SVSPs consist of a short conserved N-terminal region, 
containing a putative signal peptide for secretion, followed by a highly variable 
QP-rich region which is predicted to be highly unstructured (Pain et al., 
2005;Schmuckli-Maurer et al., 2009). Interestingly, a number of SVSPs also 
contain functional nuclear localisation signals (NLS), suggesting that proteins 
released from the parasite could contribute to phenotypic changes of the host 
cell (Schmuckli-Maurer et al., 2009). This study also suggested that the 
transcript levels of single SVSP genes can vary considerably depending on the 
parasite genotype but no evidence was found for a possible influence of the host 
cell background on differential SVSP mRNA expression (Schmuckli-Maurer et al., 
2009). Despite the identification of conserved motifs, a potential biological 
function for the SVSPs has yet to be proposed. In the study performed by Weir et 
al., 2010, a large number of alleles were sequenced and assessed for evidence of 
selection of amino acid substitutions. None was found and it was proposed that 
SVSP’s have evolved in a neutral manner and may act to subvert protective 
immunity. 
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The second secretome family that has been studied in some detail is the TashAT 
family. In T. annulata this family consists of 17 contiguous genes. The first 
member to be identified encodes the TashAT2 polypeptide that was shown to be 
located to the host cell nucleus of the transformed leukocyte. It has been 
postulated that these parasite polypeptides have the ability to modulate bovine 
gene expression since they contain AT hooks. AT hooks are motifs that primarily 
function in transportation of proteins to the nucleus and bind to AT-rich DNA. AT 
hook domain proteins are conserved in eukaryotes from yeast to humans and 
play critical roles in regulation of gene expression and determination of cell fate 
(Cleynen and Van de Ven, 2008;Reeves, 2010;Reeves and Beckerbauer, 2001). AT 
hook proteins are commonly associated with the generation of neoplasias (Fusco 
and Fedele, 2007). Five AT hook bearing TashAT proteins are encoded in the 
genome: TashAT2, TashAT1/3, TashHN, and SuAT1 (Shiels et al., 2004;Swan et 
al., 1999;Swan et al., 2001;Swan et al., 2003). Interestingly no AT hook motif 
has been identified in T. parva, although an orthologous cluster of 18 TpHN 
genes have been described. The reason for this is not known, but may be due to 
the different preferred lineage of leukocyte infected by either species (Shiels et 
al., 2006). 
Functional data supporting a role of TashAT cluster proteins in manipulating 
bovine gene expression was reported by Shiels et al., (2004) and Oura et al., 
(2006). Thus TashAT 1/3, TashAT2 and SuAT1 have all been shown to bind to AT 
rich DNA. Stable transfections of both TashAT2 and SuAT1 into a bovine 
macrophage cell line was found to be associated with changes to cellular 
morphology, mRNA profile and the proteome of TashAT expressing cells (Shiels 
et al., 2004;Swan et al., 1999). Interestingly SuAT1 promotes changes to the 
level of intermediate proteins that function to control cell shape, and repression 
of these proteins (cytokeratins) was demonstrated to be under control of a 
viable parasite (Shiels et al., 2004). Cytokeratins are a large family of proteins 
which form the intermediate filament (IF) of the cytoskeleton and have been 
found to modulate host-cell proliferation process (Paramio et al., 1999). 
Furthermore it is known that mammalian AT hook genes function to modulate 
the expression of genes targeted by NF- B in myeloid cells. TashAT factor 
proteins can therefore be considered as candidates for parasite-encoded factors 
that function to manipulate the profile of host gene expression resulting from 
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infection associated cellular activation events. Summary of candidate parasite 
proteins released into the host cell cytoplasm and their interactions with the 
transformed-host cell is shown in Table 1.1. 
Table 1.1:  List of Theileria proteins that are candidate manipulators of host cell phenotype 
Parasite 
proteins 
Location SignalP NLS Relationship to host cell transformation 
     
TaSP -Parasite membrane  Yes - Interacts with host cell microtubule 
network. (Seitzer et al., 2010) 
TaSE -Parasite membrane 
-Schizont  
-Host cell cytoplasm  
 
Yes - Close association of TaSE with the host 
tubulin network and co-localization at 
distinct points with host microtubule 
(with centromere, mitotic spindle and mid 
body) has been demonstrated. (Schneider 
et al., 2007) 
gp-34 -Parasite membrane Yes - gp-34 is a GPI-anchored protein that is 
expressed at the schizont surface and 
interacts with regulators of the host cell 
cytokines and localize to the 
central spindle and midbody. Predicted to 
have functional role during host cell 
division. (Xue et al., 2010) 
Ta9 
 
-Parasite 
- Host cell cytoplasm 
Yes - An immunodominent protein recognised 
by CD8+ T cells. The presence of a signal 
peptide indicates that T9 is likely to be 
secreted by the parasite and hence be 
available for cytosolic antigen processing. 
(MacHugh et al., 2011) 
TashATs 
TashAT2 
TashAT1/3 
SuAT1 
TasHN 
Host cell cytoplasm  
Host cell nucleus  
Yes  Yes  Members of TashAT family bearing AT-
hook motifs are secreted by the parasite 
and translocated to the host cell nucleus. 
These proteins are predicted to function 
as accessory factors for regulators of gene 
expression. [reviewed in (Shiels et al., 
2006)] and  (Weir et al., 2010) 
SVSPs * Host cell cytoplasm 
* Host cell nucleus 
 
Yes Yes  SVSPs are sub-telomeric hypothetical 
proteins. A subset of these is predicted to 
be secreted suggesting their role in 
phenotypic changes of the infected host 
cell. (Schmuckli-Maurer et al., 2009) 
TPSCOP Released into the 
cytoplasm of infected 
cells  
Yes  TPSCOP is a schizont derived cytoskeleton 
binding protein and has the ability to 
interact with F-actin and can result in 
activation of host dependent NF-kB 
signaling. (Hayashida et al., 2010) 
Unknown - - - Parasite proteins involved in the 
formation of parasite-dependent IKK 
signalosome and interaction between its 
component  
Unknown - - - Parasite proteins involved in sequestration 
of p53 in host cell cytoplasm 
* Minority of the SVSP family members are secreted into the host cell cytoplasm and translocated 
to the nucleus. However, almost all are expressed at the RNA level by the macroschizont stage.  
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1.8 Aims and objectives 
Theileria is a major pathogen, causing a significant economic burden to 
countries where this parasite is endemic. Research to understand the factors 
contributing to disease pathology is required and is of scientific interest. An aim 
of this thesis was to elucidate one of the primary molecular mechanisms 
implicated in Theileria pathology, the induction of host leukocyte proliferation 
and prevention of apoptosis by the macroschizont stage of the life cycle. 
Evidence from literature has indicated that this may be a two-step process 
involving parasite-induced activation of host transcription factors, particularly 
NF- B and Ap-1, followed by modulation of the outcome of transcription factor 
activation in controlling host cell gene expression. Data supporting this 
postulation at a global level was required particularly with regard to whether 
the parasite is able to alter the outcome of activating inflammatory signal 
transduction pathways. The mechanisms utilised by the parasite in directing host 
cell gene expression have not been identified. However, parasite polypeptides 
(TashATs) that are translocated to the host cell nucleus of the infected 
leukocyte are candidates for this role. 
The main objectives of the work presented in this thesis were as follows: 
I.   Establishment and characterisation of an experimental model for comparison 
of uninfected and Theileria-infected cells activated by stimulation with 
inflammatory mediators. 
II. Identification of host cell gene expression changes representative of 
uninfected and infected cells following stimulation with inflammatory 
mediators and identification of profiles indicating modulation of 
inflammatory gene expression by parasite infection  
III. Bioinformatic analysis of any infection modulated dataset to identify gene 
expression events that can be predicted to benefit the establishment of the 
infected leukocyte: with emphasis on transcription factors and pathways 
known to be associated with Theileria infection. 
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IV. To investigate a parasite protein (TashAT2) as a candidate factor for 
modulation of bovine gene expression profiles associated with infection and 
inflammatory stimulation.  
It was anticipated that by addressing these aims and objectives further insight 
into the complex relationship between Theileria parasites and host cell 
regulatory pathways responsible for the establishment of the activated, 
transformed leukocytes would be gained. Furthermore, knowledge arising from 
this study could lead to the development of novel intervention strategies against 
theileriosis, inflammatory and neoplastic diseases. 
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2 Materials and methods 
2.1 Maintenance of cell culture 
All types of cell lines used in this study were maintained in culture at 37ºC, with 
5 % CO2. Cells were cultured in tissue culture flasks (25cm
2 or 75cm2) and the 
cell number of each culture was started at 2 x 105 cells/ml and maintained by 
feeding with fresh complete medium every two to three days at, usually, a 1 in 5 
dilution. Details of specific cell lines used and their media requirements are 
given in relevant chapters. 
2.1.1 Preparation of cell culture reagents and complete medium 
Reagents used for making complete medium  
1. RPMI-1640 with added L-Glutamine and 25mM HEPES (Gibco) 
2. Heat-inactivated foetal bovine serum (FBS; Sigma) 
3. Streptomycin 8 µg/ml, 
4. Penicillin 8 units/ml  
5. Amphotericin B 0.6 µg/ml  
6. Sterile sodium bicarbonate 0.05%. 
2.1.2 Cryopreservation and thawing of cell lines 
Cell lines were preserved in liquid nitrogen for long term storage. Approximately 
8 ml of cell culture was centrifuged at 750 ×g for 5 min at 4ºC and resuspened in 
3 ml of appropriate complete medium containing 10 % dimethylsulphoxide 
(DMSO). The resuspended cells were split between two 2 ml cryotubes, wrapped 
in cotton wool and frozen in pre chilled polystyrene box at -80ºC freezer 
overnight before transfer to liquid nitrogen.  
To recover cells from liquid nitrogen, cryopreserved tubes were quickly thawed 
at 37ºC and added immediately to 8 ml prewarmed complete medium (37ºC). 
The cells were pelleted by centrifugation at 750 ×g for 5 min at room 
temperature to wash off the traces of DMSO. Cells were washed twice in pre-
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warmed medium with 5 ml of fresh medium to ensure complete removal of 
DMSO. Finally the cell pellet was resuspended in 5 ml fresh complete medium 
and transferred to 25cm2 culture flasks and incubated at above mentioned 
culture conditions. 
2.2 Reagents and Solutions  
The buffers and solutions commonly used in the experimental protocols of this 
thesis are listed below: 
2.2.1  Dual Luciferase Assay 
Luciferase assays in cells transfected with firefly luciferase (NF-B-LUC) and 
Renilla luciferase (phRG-TK renilla) plasmids were carried out using the Dual-
Luciferase® reporter Assay kit (Promega: cat # E1910). 
Dual luciferase® reporter (DLR) assay chemistry  
The DLR assay system provides an efficient means of performing dual reporter 
assay which is based on the simultaneous use and sequential measurement of 
Firefly (Photinus pyralis) luciferase and Renilla (Renilla reniformis) luciferase 
activities in order to directly obtain normalised data. Each luciferase breaks 
down its distinct substrate allowing discrimination between the 2 different 
bioluminescent reactions (Figure 2.1). The Renilla luciferase provides a 
measurement of the amount of cells successfully co-transfected (i.e. that 
contain the firefly vector) and the ratio of Firefly/Renilla gives the actual 
luciferase value that corresponds to the gene of interest being studied (NF- B). 
The Renilla control vector allows measurement of the baseline transcription 
levels and normalises the differences in cell viability, cell lysis efficiency, 
transfection efficiency etc. Thus, using phRG-TK, Renilla luciferase, allows 
efficient use of both the experimental and control vectors to be measured using 
the same apparatus and in the same units. These can then be compared directly 
without any separation of the samples or conversion of the units. 
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Figure 2.1:  Bioluminescent reactions catalysed by firefly and Renilla luciferase 
http://kirschner.med.harvard.edu/files/protocols/Promega_dualluciferase.pdf 
Product Components and Storage Conditions 
Reporter Assay System 100 assays E1910 
Reporter Assays. Includes: 
• 10ml Luciferase Assay Buffer II 
• 1 vial Luciferase Assay Substrate (lyophilized Product) 
• 10ml Stop & Glo® 
Buffer 
• 200µl Stop & Glo® Substrate, 50X 
• 30ml Passive Lysis Buffer, 5X 
Once the Luciferase Assay Substrate were reconstituted, working aliquots were stored at -20°C 
for up to 1 month or at -70°C for up to 1 year. 
2.2.2  Indirect immunofluorescence analysis 
2.2.2.1 Phosphate buffered saline (PBS x 1) 
Dissolve 8g NaCl, 0.2g KCl, 1.15g Na2HPO4 and 0.2g KH2PO4 in dH2O up to 1 L of 
total volume and adjust to pH 7.4. 
2.2.2.2 Paraformaldehyde fixation solution (3.7 %) 
Dissolve 3.7g paraformaldehyde in 100ml of 1 x PBS, Add 150µl of 1M NaOH, heat 
to 50ºC in microwave (do not boil), cool on ice and PH to 7.4 with HCl. Store at 
4oC (lasts for about 1 week). 
Beetle Luciferin Oxyluciferin 
Coelenterazine 
Luciferin 
Coelenteramide 
Luciferin 
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2.2.2.3 Permeabilisation solution (Triton x 0.2) 
Add 200 µl Triton X-100 in 100ml 1 x PBS, Stir contonously until dissolved 
properly and store at room temperature.  
2.2.2.4 Mounting medium 
For 1 ml solution, add 50 % glycerol in 1 x PBS (i.e. 0.5ml glycerol, 0.5ml 1X 
PBS), 10µl of anti-fade reagent (diphenylamine @ 100mg/ml) and 1µl of DAPI (4', 
6-diamidino-2-phenylindole, dihydrochloride) for nuclear staining and store at -
20oC before use (lasts for about 1 month). The antifade working solution was 
stored at 4° C in the dark 
2.2.2.5 0.1% (w/v) Evans blue stain  
Dissolve 0.1g Evans blue in 90ml 1 x PBS and bring to 100 ml with 1 X PBS and 
store at room temperature. 
2.2.3  Caspase 3/7-Glo assay 
In order to measure apoptosis, an assay measuring caspase -3 and -7 activity was 
used. In the presence of these caspases, a substrate containing tetrapeptide 
DEVD sequence is cleaved and light is produced by luciferase (Figure 2.2). Thus, 
luminescence generated is directly proportional to caspase activity. Detailed 
protocol of caspase 3/7 assay is given in respective chapters where subsequent 
experiments were performed. 
Caspase-3/7 reagent kit  
Each system Contains  
1% (v/v) Caspase-Glo® 3/7 substrate Z-DEVD-R110 (lyophilized)  
Caspase-Glo® 3/7 Buffer  
Both components were elements of the Apo-ONE® 
The Caspase-3/7 reagent was prepared freshly before use. 
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Figure 2.2:  Bioluminescent reaction of caspase 3/7 Assay. 
Caspase cleaves a substrate (containing tetrapeptide DEVD sequence) for luciferase (amino-
luciferin) which is then consumed in luciferase reaction to produce luminescence. 
(http://www.promega.com/resources/protocols/technical-bulletins/0/apoone-homogeneous-
caspase-3-7-assay-protocol/) 
2.2.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Western blotting 
Total proteins extract were analysed by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) using the Mini-Protean Cell System (Bio-Rad, UK). 
Separation of proteins was carried out either in 10% or 12% polyacrylamide gels. 
Approximately, equal amounts protein extracts dissoled in 1x PBS was mixed 
with SDS-PAGE sample buffer (Laemmli 2x concentrate (Sigma; S3401), briefly 
sonicated to shear DNA and boiled for 10 min prior to analysis by SDS-PAGE gel 
electrophoresis. For the assessment of equal loadings, gels were stained with 
Coomassie blue (Section 2.2.4.11) for 60 min and destained in the destaining 
solution (Section 2.2.2.13). Proteins separated by SDS-PAGE were transferred 
onto 0.45-µM nitrocellulose membranes (Protan BA 85, Whatman) using the Mini 
Trans-Blot Electrophoretic Transfer Cell System (Bio-Rad, UK). The transfer set 
up consisted of pre-wetting the nitocellulose membrane in transfer buffer 
(Section 2.2.4.9). The transfer sandwich was assembled with a fibre pad pre-
soaked in transfer buffer. Then two pre-soaked filter papers were laid on top, 
followed by the equilibrated membrane. The SDS-PAGE gel, having been 
equilibrated in transfer buffer for 15 min, was then laid on the membrane. 
Another layer of pre-soaked filter papers was laid on the gel and finally, a pre-
soaked fibre pad completing the transfer sandwich. The completed cassette was 
placed in the module and electroblotting was performed at a constant 280 
milliamps current for 60 min. Following protein transfer, the membrane was 
Caspase-3/7 
 
Luminescence 
+ ATP+ O2 
Ultra GloTM 
Luciferase 
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stained with Ponceau S (Section 2.2.4.14) for 5 min with slight agitation to 
confirm that the transfer of protein to the NCP membrane was achieved. The 
membrane then was incubated in blocking solution (Section 2.2.4.10) for 60 min 
at room temperature with gentle agitation. Recipe of various important buffers 
utilised for SDS-PAGE and western blotting are given in the following.  
2.2.4.1 10% (w/v) SDS 
Dissolve 10 g SDS in 90 ml dH2O and bring to 100 ml with dH2O and store at room 
temperature. 
2.2.4.2  10x SDS-PAGE running buffer, pH 8.3 (makes 1 L) 
Dissolve 30.3 g Tris-base, 144.0 g Glycine, and 10.0 g SDS with dH2O up to 1 L of 
total volume and store at 4oC before use. Dilute 50 ml of 10x stock with 450 ml 
dH2O for each electrophoresis.  
2.2.4.3  Western blotting buffer/Transfer buffer (makes 1 L) 
Dissolve 3.0 g Tris-base, 14.0 g Glycine in 200 ml dH2O, add 200 ml Methanol and 
dH2O to make up to 1 L. Store buffer at 4
oC before use. 
2.2.4.4  Separating gel buffer (1.5 M Tris-HCl, pH 8.8)  
Dissolve 18.2 g Tris-base in 80 ml dH2O. Adjust to pH 8.8 with HCl. Bring total 
volume to 100 ml with dH2O and store at 4
oC. 
2.2.4.5  0.25 M Tris-HCl, 0.2 % SDS, pH 6.8/ Stacking gel buffer 
Dissolve 3 g Tris base, 2 ml of 10 % SDS in 60 ml dH2O. Adjust to pH 6.8 with HCl. 
Bring total volume to 100 ml with dH2O and store at 4
oC. 
2.2.4.6  10% (w/v) APS 
Dissolve 0.1 g ammonium persulfate (APS) in 1 ml dH2O. Always prepare fresh as 
required.  
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2.2.4.7  Separating gel formulation (10 or 12 % SDS-PAGE gel) 
For 12% resolving gel, add 3.35 ml dH2O, 4 ml 30% Acrylamide/Bis, 2.5 ml 1.5 M 
Tris-HCl pH 8.8, 100 μl 10% (w/v) SDS, 50 µl 10% (w/v) APS and 5.0 µl TEMED.  
For 10% resolving gel, add 4.05 ml dH2O, 3.3 ml 30% Acrylamide/Bis, 2.5 ml 1.5 
M Tris-HCl pH 8.8, 100 μl 10% (w/v) SDS, 50 µl 10% (w/v) APS and 5 µl TEMED. 
2.2.4.8  5% Stacking gel formulation 
Add 1.8 ml dH2O, 0.63 ml 30% Acrylamide/Bis, 2.5 ml of stacking gel buffer, 50 
μl 10% (w/v) SDS, 50 µl 10% (w/v) APS and 5.0 µl TEMED. 
2.2.4.9 Transfer buffer 
Dissolve 3.03 g Tris-base, 14.0 g Glycine in 200 ml dH2O; add 200 ml Methanol 
and dH2O to make uo to 1 L. Store buffer at 4
oC before use. 
2.2.4.10  5% blocking buffer for Western blotting 
Dissolve 5.0 g of dried milk to 50.0 ml 1 x PBS. Add 10ml of horse serum, 10 ml 
of 10 x Tris-saline, 100 µl of Tween-20, 100 µl of 10% Thimerosol.  Add 1 x PBS to 
give total volume of 100.0 ml. Prepare fresh as required. 
2.2.4.11 Washing buffer 
Dissolve 1 ml of Tween-20 in 1 L 1 x Tris-saline. Store at 4oC.  
2.2.4.12 Coomassie blue staining R-250 (makes 500 ml) 
Dissolve 1.25 g of Coomassie blue in 250 ml methanol, 50 ml acetic acid and 200 
ml dH2O and and keep at room temperature.  
2.2.4.13 Destaining solution (makes 1.7 L, 10% acetic acid solution) 
Add 175 ml of acetic acid and 500 ml methanol to 1.025 L of dH2O and store at 
room temperature. 
Chapter 2  66 
2.2.4.14 Ponceau stain 
Add 3.0 g of TCA (Trichloroacetic acid) to 100 ml of dH2O and add 0.2 g of 
Ponceau S. Store at room temperature. 
2.2.4.15 Antibody detection  
Detection of any bound antibody was achieved by using enhanced 
chemiluminescence PlusTM Western blot detection reagent (ECL; Amersham) and 
exposed to autoradiography. 
2.2.5  Semiquantitative RT-PCR  
2.2.5.1 One-Step Semiquantitative RT-PCR System  
SuperScriptTM One-Step RT-PCR with Platinum® Taq, cat no. 12574-026  
Kit Components 100-rxn kit 
RT/ Platinum® Taq Mix     100 μl 
2X Reaction Mix (a buffer containing 0.4 mM of 
each dNTP, 2.4 mM MgSO4) 
3  × 1 ml 
5 mM Magnesium Sulfate      500 μl 
5 mM Magnesium Sulfate       1 ml 
Store all components at -20°C  
Standard reaction mix used in the RT-
PCR 
Volume/ 50 μL Volume/ 25 μL 
2x Reaction Mix  25 μL 2.5 μl 
Forward primer (10 μM)  1 μL 0.5 μl 
Reverse  primer (10 μM)  1 μL  1 μL 0.5 μl 
Template RNA   (12.5 ng)  2 μL     1 μl 
RT/ Platinum® Taq Mix 1 μL  0.5 μl 
Autoclaved double distilled water to 50 μL  25 μl 
Note: Reactions master mix was made for multiple reactions and aliquots were dispensed in micro 
centrifuge PCR tubes 
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2.2.5.2 Tris-acetate-EDTA (TAE) buffer 50X (makes 1 L) 
Dissolve 242 g Tris in 100 ml of 0.5 M EDTA pH 8.0 with glacial acetic acid, make 
uo to 1 L with sterile dH2O and store at room temperature. Dilute to 1 x for 
working concentration.  
2.2.5.3 DNA  loading buffer  
0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll (type 400; 
Pharmacia) in dH2O and store at room temperature. 
2.2.6 Two step quantitaive RT-PCR system 
2.2.6.1 cDNA synthesis  
AffinityScript QPCR cDNA Synthesis Kit, Cat no 600559, Stratagene. 
Kit Components 100-rxn kit 
cDNA synthesis Master mix  (2x)      500 μl 
AffinityScript RT/ RNasae Block Enzyme mixture      50 μl  
Oligo(dT) primer  (100ng/ μl)      15 μg 
Random primers   (100ng/ μl)     15 μg 
RNase-free H2O    1.2 ml 
Store all components at -20°C  
2.2.6.2 Brilliant SYBR® Green QPCR Master Mix, Cat no. 600548 
Kit Components 100-rxn kit 
2 x Brilliant SYBR Green QPCR master mix      2 x 2.5 ml 
Reference dye, 1 mM           100 μl 
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3 Development of an experimental model for study 
of infection-associated modulation of activation 
status in Theileria annulata infected cells 
3.1 Introduction 
An important and interesting feature of the Theileria parasite is the unique 
ability of the multinucleate intracellular macroschizont stage to induce 
transformation and proliferation of the infected host cell (Spooner et al., 1989). 
However, the transformation state of parasite infected cells is reversible and 
requires the presence of a viable parasite, as treatment of infected cells with 
the theilericidal drug buparvaquone (BW720c) halts the process of proliferation 
and induces cell death (McHardy et al., 1985).  
Transformation of bovine leukocytes infected with T. annulata and the closely 
related species, T. parva, is known to be dependent upon constitutive activation 
of bovine transcription factors and associated signal transduction pathways. The 
mechanism underlying this transformation event has been extensively studied, 
but is not yet fully elucidated [reviewed in (Ahmed et al., 1999;Dessauge et al., 
2005a;Dobbelaere and Heussler, 1999;Dobbelaere and Kuenzi, 2004)]. Previous 
work has demonstrated that an extremely complex network of interactions exists 
between the parasite and infected host cell, involving numerous cellular 
pathways and their associated host cell transcription factors such as; Activator 
protein 1 [AP-1] (Chaussepied et al., 1998), Activating transcription factor 2 
[ATF-2] (Botteron and Dobbelaere, 1998), Signal transducer and activator of 
transcription 3 [STAT3], c-Myc (Dessauge et al., 2005a), Nuclear factor kB [NF-
B] (Heussler et al., 2002;Ivanov et al., 1989), c-jun NH2-terminal kinase [JNK] 
(Galley et al., 1997) phosphoinositide-3 kinase [PI3-K] (Baumgartner et al., 2000) 
and SRC-related tyrosine kinase (Eichhorn and Dobbelaere, 1994). Activation of 
these factors is likely to bring about a range of beneficial phenotypic alterations, 
only some of which have been defined at the cellular level.   
Activation of NF- B involves translocation from the cytosol to the nucleus,  
where it binds to its consensus sequences within the promoter region of target 
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genes, consequently promoting the transcription of a variety of proinflammatory 
genes (Baeuerle and Henkel, 1994). For example, NF- B is known to regulate the 
transcription of a variety of cytokines [Interleukin (IL-1), IL2, IL-6, IL-8, tumor 
necrosis factor (TNF) as well as some adhesion molecules (e.g. intercellular 
adhesion molecules (ICAM-1), vascular adhesion molecule (VCAM-1)] and some 
specific enzymes such as inducible nitric oxide synthase [iNOS] (Baeuerle and 
Henkel, 1994;Collins et al., 1995a;Read et al., 1995;Xie et al., 1994). Similarly 
constitutive activation of AP-1, a dimeric transcription factor composed of 
members of Jun and Fos proto-oncogene families (Curran and Franza, Jr., 1988), 
is also involved in regulating gene expression required for host cell proliferation 
and a transformation state (Kovary and Bravo, 1991) in fibroblast cells. 
Constitutive activation of c-Jun, a dominant component of AP-1, is thought to 
play an important role in metastasis of Theileria infected cells via regulation of 
metalloprotease gene expression (Adamson et al., 2000;Baylis et al., 1995) and 
activation of NF- B confers protection against apoptosis probably by regulating 
anti-apoptotic genes (e.g. c-IAP-1/2, XIAP, TRAF2, Bcl-2 and Bcl-XL) and the 
cell-cycle regulator cyclin D1, which increase cellular survival and proliferation 
respectively (Dessauge et al., 2005b;Heussler et al., 1999;Karin and Lin, 2002).  
Despite the strong evidence of NF- B and c-Jun transcription factors as anti-
apoptotic factors, there is increasing evidence indicating that they also have 
pro-apoptotic functions (Janus-like factors) and have the potential to 
compromise the survival of an infected host cell (Gagliardi et al., 2003;Lindwall 
and Kanje, 2005;Youssef and Steinman, 2006). For example, Kasibhatla et al., 
(1999) have provided evidence that NF- B and Ap-1 induce pro-apoptotic Fas 
ligand protein in response to chemotherapeutic agents or T-cell activation that 
promotes apoptosis. Similarly there is evidence that NF- B can regulate 
expression of the tumour suppressor p53, which is required to induce cell death 
(Dutta et al., 2006;Shishodia and Aggarwal, 2004). Indeed the possibility that the 
transformation event may not be guaranteed was illustrated in a recent study 
which showed that only a proportion of T. parva infected leukocytes successfully 
progress to proliferation, while the rest undergo apoptosis (Rocchi et al., 2006). 
Thus, events that are detrimental to the infected cell occur following sporozoite 
invasion and in order to establish transformation, potential detrimental 
processes may have to be overridden or blocked, suggesting that a delicate 
Chapter 3                                                                                                                                         71 
balance exists between sending a Theileria infected cell towards sustained 
proliferation or death.   
There have been few studies investigating the phenotypic and functional 
alterations imparted in macrophages (m ) by T. annulata. Sager et al., (1997) 
have reported that T. annulata infection is associated with modulation of the 
bovine m  phenotype and impairment of its cellular defence function. In this 
particular study, transformation was associated with a progressive loss of m -
specific properties (e.g phagocytosis, lipopolysaccharide (LPS) induced tumor 
necrosis factor-α (TNF-α) and nitric oxide production) and cell surface markers 
(e.g CD14, CD11b, CD11a/CD18). Furthermore elimination of parasite by 
treatment with BW720c resulted in re-acquisition of monocyte lineage 
properties.  
More recently, a study was also performed by Jensen et al., (2009)  to 
investigate the possible role of T. annulata infection in regulation of m  
differentiation. This work has investigated the effect of T. annulata infection on 
the expression of the m  differentiation markers. It was observed that mRNA 
levels of transcription factor such as Musculoaponeurotic fibrosarcoma oncogene 
(MAF) family, c-MAF associated with bovine monocytes differentiation to m , 
was suppressed by T. annulata infection. c-MAF has been implicated as a 
candidate marker for human m  differentiation studies (Liu et al., 2008). In 
addition to its role in differentiation, c-MAF was originally identified as an 
oncogene (Kataoka et al., 1993). Similarly the down stream targets of c-MAF 
such as integrin B7 (ITGB7) and chemokine receptor 1(CCR1) suppressed by T. 
annulata were increased while Interleukin 12A (IL12A) was decreased upon 
elimination of parasite with buparvaquone treatment (Jensen et al., 2009). This 
supported the hypothesis that the parasite may modulate the differentiation 
state of the host cell, which may be linked to and essential for establishment of 
the parasite-induced transformation event.  
Further evidence for parasite mediated control of the infected host cell has 
recently been provided  by evidence that parasite infected cells are able to 
modulate the expression of LPS and type I interferon inducible pro-inflammatory 
cytokine genes, genes associated with cellular defence, cell growth and 
differentiation. For example, parasite-mediated repression of high-level mRNA 
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expression has been shown to occur for ISGylation pathway genes (UBP43 and 
ISG15), which are co-ordinately induced by IFNs and LPS (Oura et al., 2006). LPS 
is a known inducer of NF- B and in a murine pre-B lymphoma cell line high level 
induction of ISG15 expression was found to be a direct target of LPS induced NF-
κB activation (Li et al., 2001). High level expression of these genes has been 
reported to occur in response to infection of cell by various microorganisms such 
as viruses and bacteria (Kim and Zhang, 2003;Zhang et al., 1999). It has been 
proposed that ISG15 conjugation plays a role in the stress response of cells and 
provides protection against infection. Thus negative control of bISG15 induction 
may allow Theileria-infected cells to bypass a protective immune response (Oura 
et al., 2006), despite constitutive activation of transcription factors (Ap-1 and 
NF- B) associated with this event.  
Taken together the above mentioned findings lead to the hypothesis that 
Theileria parasite may modulate gene expression networks associated with 
activation of host cell transcription factors, and that this manipulation promotes 
an outcome that favours establishment of the transformed cell. In order to test 
this hypothesis it was necessary to develop an experimental system allowing 
comparison of gene expression profiles of Theileria-infected and un-infected 
cells under conditions that induce cellular activation. The ultimate strategy was 
to obtain global expression profiles of activated uninfected cells relative to 
control cells and compare this to the expression profile of infected cells. 
To establish methodology for investigation of the influence of Theileria infection 
on host cellular activation status by gene expression profiling, we utilised an 
available uninfected immortalised bovine lymphosarcoma (BL20) and its in vitro 
T. annulata infected (TBL20) counterpart. Several reasons exist behind selection 
of BL20 cell line as an experimental model in the current study:  BL20 is a 
spontaneous B-cell lymphosarcoma exhibiting the uncontrolled proliferation 
characteristic of immortalized cell lines; it is amenable to sporozoite infection 
and as TBL20 cells possess a higher proliferation rate compared to uninfected 
BL20 (Figure 3.2; unpublished supporting data kindly provided by Dr. Jane 
Kinnaird), a homogeneous parasite infected population can be obtained 
following sporozoite infection and passage in culture; utilisation of BL20 
therefore  provides an identical host cell background for comparative gene 
expression studies (Firestein and Pisetsky, 2002). Importantly, BL20 leukocytes 
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acquire characteristics of naturally infected cells. For example, TBL20 cells 
exhibit significant changes to the shape of the host leukocyte; BL20 cells possess 
a smaller more uniform shape whereas TBL20 cells display a larger, uneven 
shape with cytoplasmic projections and blebs (see Figure 3.1). Morevover, 
Theileria infection of BL20 has been shown to result in activation of NF- B  
(Heussler et al., 2002;Schmuckli-Maurer et al., 2010) and as in in vivo derived 
infected cells, NF- B is also activated in TBL20 cells via IKK signalosome 
aggregation on the surface of macroschizont surface (Schmuckli-Maurer et al., 
2010; Figure 2A). In addition preliminary experiments showed that BW720c 
treatment of TBL20 results in arrest of host cell division, whereas BL20 cells 
treated in parallel show no phenotypic effects of the treatment (Figure 3.2) 
(Oura et al., 2006). In addition, TBL20 can undergo differentiation of the 
macroschizont to generate extracellular merozoites on culture at 41ºC and 
during this event host cell proliferation subsides (Shiels and Kinnaird, 
unpublished data). Therefore, parasite infected BL20 cells have characteristics 
typical of naturally infected bovine cells and provide a useful tool to enable 
studies investigating the consequences of parasite infection on host cell 
activation. 
To fully trigger a cellular activation response in uninfected cells in a manner 
resembling activation via parasite infection, bacterial lipopolysaccharide (LPS) 
was used. LPS, which belongs to a class of pathogen-associated molecular 
patterns (PAMPs), is a potent biological response modifier and is well known to 
activate the inflammatory responses in a wide variety of cell types. Activation of 
cells, mostly macrophages, monocytes and lymphocytes results in activation of 
transcription factors, production of cytokines and other inflammatory molecules 
(Wong et al., 2007). Because of this, LPS has been used extensively by various 
Theileria research groups to stimulate monocytes/macrophages and un-infected 
BL20 cells for investigating expression of genes predicted to be under parasite 
control (Jensen et al., 2006b;Oura et al., 2006;Sager et al., 1997).  
Objectives of this study 
A major aim of the work presented in this thesis was to investigate the 
possibility that changes to host gene expression profiles associated with parasite 
infection are functionally relevant for establishment of an activated, 
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transformed leukocyte. The starting point for study of such parasite mediated 
manipulation at a global level was development of an experimental model 
allowing comparison of uninfected and Theileria infected cells under cellular 
activation conditions.  Described in this section are experiments performed to 
characterise the viability and proliferation responses of BL20 and TBL20 cells 
following LPS stimulation. In addition, assessment of NF-κB activation and the 
expression profiles of a panel of selected host genes were performed. 
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Figure 3.1:  Morphological differences of Theileria-infected and uninfected BL20 cells   
Panel A, BL20 cells stained with Giemsa showing uniform cell morphology  
Panel B, TBL20 cells stained with Giemsa showing parasite macroschizont and significant 
morphological alterations to the host cell membrane and formation of membrane blebs. Bar 
=25µm  
 
 
Figure 3.2:  Comparative growth rate analysis of Theileria-infected TBL20 and uninfected 
BL20 cells following Buparvaquone treatment 
For analysis of comparative growth rates cultures were set up in triplicate at 1.5 x 10
5
 / ml using 
fresh starter cultures and buparvaquone (BW720c) added to 50ng /ml after overnight incubation 
(15 hours). Cell numbers were estimated each day by Trypan Blue exclusion. As required, cultures 
were fed by 2 fold dilution with fresh medium and drug to maintain growing cultures in exponential 
phase. Calculation of growth rate (cell number / ml) was determined by extrapolation using the 
dilution factors. 
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3.2 Methods 
3.2.1  Cell lines and culture 
BL20, an uninfected bovine lymphosarcoma cell line (Morzaria et al., 1982;Olobo 
and Black, 1989) and TBL20, a T. annulata (Ankara strain) infected BL20 cell line 
previously derived from in vitro infection (Shiels et al., 1986), were used in the 
experimental model. Cells were cultured in standard complete medium using 
RPMI-1640 with added L-Glutamine and 25mM HEPES (Gibco), supplemented with 
20% heat-inactivated foetal bovine serum (FBS; Sigma), 8µg/ml streptomycin, 8 
units/ml penicillin, 0.6µg/ml amphotericin B and 0.05% sterile sodium 
bicarbonate. Generally the cell number of each culture was started at 2x105 /ml 
and maintained by feeding with fresh medium every two to three days at, 
usually, a 1 in 5 dilution.   
3.2.2  Stimulation of cells with lipopolysaccharide (LPS) 
Cells were cultured in tissue culture flasks (25cm2 or 75cm2) and complete 
medium at 5% CO2 and 37°C humidified atmosphere, until they reached a density 
of approximately 5×105 cells/ml (i.e. in the logarithmic phase of growth). 
Stimulation of cells was carried out in 6 well plates with the cell concentration 
adjusted to give 5×106 cells/well in a total of 5ml medium.  Cells were then 
stimulated by adding 1μg/ml final concentration of LPS (Sigma: L 2630) and 
incubated at various time points ranging from 6h-48h depending on the 
individual experimental protocol. Preliminary LPS titration experiments were 
performed to measure the minimum concentration of drug required to stimulate 
cells (based on NF- B reporter activity, see section 3.2.3) without causing rapid 
cellular cytotoxicity (data not shown). Thus, 1μg/ml of LPS was subsequently 
determined as an appropriate standard stimulation concentration. LPS was 
dissolved in dimethyl-sulfoxide (DMSO; Sigma D-8418) and non-stimulated control 
cells were incubated with the same volume of DMSO as vehicle contol.  
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3.2.3  NF- B dependent reporter assay (Dual Luciferase Assay) 
and LPS stimulation 
Estimation of NF- B activity was performed by transient co-transfection of  a 
reporter plasmid containing a promoter with an NF-B3 recognition sequence 
linked to Firefly luciferase (NF-кB-LUC) and a Renilla luciferase plasmid (phRG-
TK renilla), followed by sequential measurement of Firefly and Renilla luciferase 
activity, essentially as described by Heussler et al., (2001). 2.0μg of NF-3-Luc 
and 0.5μg of phRG-TK Renilla plasmids were mixed in an electroporation gene 
pulser cuvette (0.4cm electrode gap) with 4×106 BL20 or TBL20 cells in 300µl of 
RPMI-1640-2% FBS without antibiotics.  Electroporation was performed using a 
Gene pulser (Bio-Rad) set at 220V, 950µF. After electroporation cells were 
immediately added to 5ml of pre-warmed complete medium and incubated in six 
well plates.  
After 24h recovery, LPS (1μg/ml) or equal volume of DMSO were added for 4h. 
Cells were then harvested from each well, centrifuged at 750 × g and 4°C, for 5 
minutes. The cell pellet was then washed with 500µl of 1x PBS (phosphate buffer 
saline) and centrifuged at 925 × g for 2 min.  
A commercially available luciferase assay reagent kit (Dual Luciferase® Reporter 
Assay System; Promega) was used to assay luciferase activity, using the 
manufacturer’s protocol. Briefly, 100µl of Passive Lysis Buffer (PLB) was added 
to the cell pellet recovered from the previous step and mixed gently for 15min 
in the dark. Samples were briefly centrifuged (14000rpm) and kept on ice. 20µl 
cell extract was used per assay with 100µl of LAR (Luciferase Assay Reagent) and 
100µl of Stop & Glo reagent. A TD-20/20 luminometer (Turner Designs) was used 
for detection of luminescence. NF- B promoter activity was calculated by 
normalizing firefly luciferase activity relative to the activity of constitutive 
Renilla luciferase, the internal control for electroporation efficiency, for each 
sample. Each electroporation and luciferase assay was performed in 
quadruplicate. 
Chapter 3                                                                                                                                         78 
3.2.4  Indirect immunofluorescence analysis 
Indirect Immunofluorescence (IFA) analysis of uninfected and infected cells with 
or without LPS treatment was performed using the basic protocol described by 
Schmuckli-Maurer et al. (2010).125μl from cultures of approximately 2×106 
cells/ml were cytospun on to glass slides at 1500rpm for 5min using a Shandon 
cytospin 2 centrifuge. Different fixation protocols were performed for the 
immunodetection by each primary antibody and are detailed in 3.2.4.1 and 
3.2.4.2. Following fixation and incubation with antibodies slides were washed 
three times in 1×PBS for 3min each then incubated with secondary antibody 
(either goat anti-rabbit (Invitrogen; A-11034) or -mouse IgG (Invitrogen; A-11029) 
conjugated to Alexa 488) at 1 in 200 dilution for 1h at RT, followed by PBS 
washes as before. After the final wash, cells were counter-stained with 0.1% 
Evan’s blue for 1min, rinsed in 1× PBS and allowed to dry. Slides were then 
mounted in 10μl of mounting medium containing 50% glycerol in PBS, 4, 6-
diamindino-2-phenylindole (DAPI) at 1µg/ml and phenydiamine at 1mg/ml. 
Immunofluorescence images were examined using an Olympus BX60 microscope 
and acquired by SPOT camera and SPOTTM Advanced image software Version 
Mac: 4.6.1.26 (Diagnostic Instruments, Inc). 
3.2.4.1 Fixation protocol for anti-mouse IKKγ /NEMO  
For detection of IKKγ (NEMO) containing signalosomes, slides were dried for 
5min, fixed in 3.7% Paraformaldehyde in 1x PBS, pH 7.4 at 4oC for 30min.  Slides 
were washed three times briefly with 1x PBS then extracted in 0.2% Triton X-100 
in 1x PBS for 10min at room temperature (RT) and washed three times with 1x 
PBS. Anti-IKKγ/NEMO (BD Biosciences 611306) antibody was used at a dilution of 
1/50 in complete culture medium for 1h at RT. 
3.2.4.2 Fixation protocol for anti-p65 (NF-B sub-unit) 
For detection of the p65 sub unit of NF-B, slides were immediately fixed in ice 
cold 3.7% Paraformaldehyde-PBS, pH 7.4 for 30min. Slides were then washed 
three times briefly with 1×PBS and incubated in methanol pre-chilled to -20oC 
for 5min followed by washing three times with PBS. Anti- NF-B p65 (sc-372; 
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Santa Cruz) antibody was used at a dilution of 1/50 in complete medium for 1h 
at room temperature.  
3.2.5  Cell proliferation/viability assay 
Assessment of viable cell counts on cultures following stimulation with LPS or 
DMSO was performed using Trypan Blue exclusion. Dead or damaged cells stain 
with trypan blue, while viable cells exclude the dye. Four replicate cultures of 
BL20 and TBL20 were seeded with 2.5×105 cells/ml and incubated at 37oC for 24 
and 48h in the presence of LPS (1µg/ml) or DMSO (1µl/ml). An aliquot (50μl) of 
the cell culture was mixed with an equal volume of 0.4% (w/v) trypan blue 
solution (Gibco) and the numbers of non-viable and viable cells counted using a 
haemocytometer. Cell viability was expressed as the percentage of trypan blue 
negative cells compared to the total number of cells (Shiels et al., 1992). Viable 
and dead cells were expressed as cell number/ml for each cell culture.  
3.2.6  Cell apoptosis assay (caspase 3/7 assay) 
To assess cellular apoptosis, Caspase-3/7 activities were measured using a 
commercial Caspase-3/7 Assay kit (Promega; Madison, WI) according to the 
manufacturer's protocol. Assays were performed for four replicate cultures per 
experimental condition at designated time points (24h and 48h). In cell culture 
experiments, cells were washed three times with phosphate-buffered saline 
(PBS). 50μl Caspase-Glo reagent was added to an equal volume of cell suspension 
containing 2.0x104 cells and incubated for 1h at room temperature to lyse the 
cells. The assay utilizes a luminogenic caspase 3/7 substrate (Bayascas et al., 
2002). After caspase cleavage, a substrate (amino-luciferin) for added luciferase 
is released resulting in the generation of luminescence. In addition to an 
untreated DMSO control, a no-cell control was performed to account for baseline 
signal generated from fresh complete medium. The baseline signal was 
subtracted from the signal produced by LPS treated and untreated cells. Caspase 
3/7 activity is reported as relative fluorescence unit (RFU) of cells compared to 
DMSO-treated uninfected BL20 cells. 
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3.2.7  Statistical analysis 
Statistical analysis and generation of graphs presented were performed using 
GraphPad Prism Software version 5.0 (La Jolla, CA). Data were expressed as 
mean, ±standard error of the mean (SEM). Differences and significance between 
mean values of each experimental condition were calculated using a two-tailed 
Student's t test and p-values less than 0.05 were considered as statistically 
significant. 
3.2.8  Total RNA isolation 
Total RNA was isolated from infected and uninfected cells with TRI Reagent 
(Sigma; T9424), according to the manufacturer's instructions. Processing of RNA 
was carried out in RNase-free 14ml polypropylene tubes (Sarstedt). Cell pellets 
of approximately 6-9×106 cells were resuspended and homogenized in 3 ml of TRI 
Reagent by pipetting up and down ~15 times and left at room temperature for 
5min. Insoluble debris was removed by centrifuging at 12080 ×g for 10min at 4ºC. 
The supernatant was transferred to a fresh tube and 0.2 ml chloroform per ml of 
TRI Reagent and mixed with the lysate by vigorous shaking for 15 sec and left at 
room temperature for 5min. Following centrifugation at 12080 ×g for 15min at 
4oC the top aqueous layer containing the RNA was removed to a fresh tube. RNA 
was precipitated by adding 500μl of isopropanol per ml of original TRI Reagent, 
mixed and incubated for 10min at RT. The RNA was pelleted by centrifugation at 
12080 ×g for 10min at 4oC. The supernatant was discarded and the RNA pellet 
washed with 1ml of 75 % ethanol per ml of initial TRI Reagent and centrifuged at 
12080 ×g for 5min at 4oC. Finally, the RNA pellet was briefly dried then dissolved 
in 80μl of DEPC treated RNase free water and stored at -80oC for further 
purification and analysis. 
3.2.9  RNA processing  
3.2.9.1 Handling, storage and quantification 
RNase contamination was minimised by use of DNase/RNase-free plasticware and 
pipette tips. Total RNA samples were stored at -80oC and multiple aliquots made 
to minimise freeze/thawing. RNA samples were quantified and purity assessed by 
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UV-absorbance at 260nm and 280nm. A A260/A280 ratio of 2 or greater was 
indicative of good quality RNA. A260/A280 ratios for RNA samples obtained for 
Tri Reagent preparations ranged from 2.057 to 2.195. Quantification and 
assessment of RNA was repeated after the DNase I treatment and clean up 
protocol. 
3.2.9.2 Clean up of total RNA and removal of genomic DNA by DNase I 
treatment  
To eliminate possible contamination with genomic DNA, RNA samples to be used 
in RT-PCR analysis were treated with DNase I (Qiagen; 79254) either before 
column purification on a silica-gel membrane based RNeasy® column (Qiagen 
cat. 74104) or by an on-column DNase I treatment. DNase I treatment and 
column purification was carried on approximately 100μg RNA exactly according 
to manufacturer’s protocol. For quantification after the column purification 2μl 
of purified RNA was diluted in TE buffer (1M Tris Cl, 0.5M EDTA, ph 8.0) and 
absorbance measured as above.  A260/A280 ratios obtained for all samples fell 
in the acceptable range of 1.78-2.1. The highly purified RNA was stored in 
aliquots at -80oC.  
3.2.9.3 Assessment of RNA quality using gel electrophoresis 
To analyse the quality and integrity of the total RNA preparations gel 
electrophoresis (1.2% agarose TBE gel, with ethidium bromide, 100V, 1h) was 
performed, using the standard protocol described by Applied Biosystems 
(http://www.ambion.com/techlib/append/supp/rna_gel.html). Agarose gels 
were visualised under UV light using a FluorChem 5500 transilluminator system 
and image capturing software (Alpha Innotec; San leandvo, CA USA). The 
integrity of total RNA samples (2.0μg each) was assessed on the basis of 
visualisation of 28S and 18S ribosomal RNA subunits from the gel image as bands 
at positions 4.8 kb and 1.8 kb, respectively, as shown in Figure 3.3. The RNA 
preps were considered to show no obvious pattern of degradation if the 28S: 18S 
band ratio was estimated to be approximately 2:1. 
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Figure 3.3:  Example of RNA quality assessment by gel electrophoresis  
Gel image of total RNA samples extracted under different experimental conditions separated on 
denaturing formaldehyde agarose gel. 1μg of RNA was loaded in each well. 
3.2.10 Semi-quantitative Reverse-Transcription PCR (RT-PCR)  
Relative gene expression levels of the selected candidate genes of interest were 
analysed by semi-quantitative PCR using Superscript III-One Step RTPCR and 
standard protocols outlined by Invitrogen. 
http://tools.invitrogen.com/content/sfs/manuals/superscriptIII_onestepRTPCR_
man.pdf). 
3.2.10.1 Primers design and analysis 
All primers for standard RT-PCR were designed and tested for specificity using 
NCBI’s online program (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi) and oligonucleotide properties calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html). 
Primer sequences, GenBank accession numbers, annealing temperatures and 
product lengths for all gene-specific primers used in this study are given in Table 
3.1. Primers were synthesized and purchased from Eurofins MWG Operon 
(Ebersberg, Germany). Whenever possible, primers were designed to the 
following criteria: primers were between 18-27 bp long; the predicted product 
5 6 3 4 1 2 
1. BL20    2.  BL20-LPS 4h    3. BL20-LPS 18h 
4. TBL20  5. TBL20-LPS 4h   6. TBL20-LPS 18h 
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of the PCR was between 159-321bp; the primer spanned an intron so that only 
cDNA could be amplified or the predicted product spanned at least one intron in 
the target gene to give differentially sized genomic and cDNA products; the 
melting temperatures of both primers of each primer pair were closely matched 
to achieve a similar annealing temperature. All Primers were diluted to a stock 
concentration of 100μM and the working concentration of all primers for PCR was 
10μM. 
3.2.10.2 RT-PCR reagents and cycling conditions 
Initial PCR optimisation reactions were performed to ascertain the best 
annealing temperature (Tm), Magnesium Concentration and overall PCR 
efficiency. RT-PCR was performed in a final reaction volume of 25 μl containing: 
gene-specific primers, 12.5 ng of RNA template and 12.5μl of 2 × reaction mixes 
(SuperScript® III One-Step RT-PCR System with Platinum® Taq DNA polymerase; 
Invitrogen, Cat no. 12574-026). The thermal cycling conditions were: an initial 
cycle 50°C for 30 min, 94°C for 2 min: followed by 36 cycles of 94°C 15 sec, X°C 
for 30 sec (where X°C indicates the experimentally determined annealing 
temperature (generally Tm of primers minus 3°C) and 72°C for 1 min; a final 
extension step was performed at 72°C for 10 min. Tm of primers, product length 
and primer sequences are indicated in Table 3.1. 
3.2.10.3 Gel electrophoresis and quantification of RT-PCR products  
RT-PCR products were resolved relative to a 1kb DNA ladder molecular weight 
standard by electrophoresis through 1% (W/V) agarose gels prepared by 
dissolving powdered agarose (Sigma Aldrich) in 1 x TAE solution and ethidium 
bromide staining. Gels were cast and run in 1 x TAE buffer using horizontal 
electrophoretic tanks. Visualisation and quantitation of band intensity was 
performed using the image analysis software FluorChem 500 spot density method 
(Biosciences; Santa Clara, CA, USA). Values for each band were based on image 
pixel intensity and designated as an “integrated density value” (IDV). Image 
background values were automatically subtracted. 
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Table 3.1:  Primers used in RT-PCR for candidate gene expression profiling  
S
.N
o
 
Gene 
symbol 
Accession No  Primer sequences 
Product 
size(bp) 
Tm 
1 ZNF828 AJ817183 F 5'-AGCAGTGACCAAGAGCAGGT-3' 205 60.0 
   R 5'-TGGACCTGAGCTTTAACTACCTG-3'  59.0 
2 TLR4 NM_174198 F 5'-TTCCCGTCAGTATCAAGGTG-3' 159 59.8 
   R 5'-TTCCCGTCAGTATCAAGGTG-3'  58.5 
3 ISG15 NM_174366 F 5'-ATCGCCCAGAAGATCAATG-3' 167 58.6 
   R 5'-TTGTCGTTCCTCACCAGG-3'  58.0 
4 IL8 NM_173925 F 5'-CTGGCTGTTGCTCTCTTGG-3' 218 59.7 
   R 5'-CAGACCTCGTTTCCATTGG-3'  59.0 
5 IL10 NM_174088 F 5'-CAAGCCTTGTCGGAAATG-3' 191 57.7 
   R 5'-CTCTTCACCTTCTCCACCG-3'  58.3 
6 IFNß NM_174350 F 5'-AGGACGAAGGACATTCACTCTG-3' 201 60.6 
   R 5'-CACTCTTTAAGGCTCTGACGTTG-3'  60.4 
7 IL2RA NM_174358 F 5'-ACGGTTCATTACCAGTGCG-3' 223 59.5 
   R 5'-TGGTCCCTGCCATCCTG-3'  61.7 
8 TNF-α NM_173966 F 5'-AAGTTGCTTGTGCCTCAGC-3' 187 59.1 
   R 5'-TACCGGCTTGTTACTTGAGG-3'  57.9 
9 iNOS NM_001076799 F 5'-AAGACACGCTTCACCAGAAG-3' 222 58.0 
   R 5'-TTGTTACTGCTTCCACCCTG-3'  58.7 
10 CD14 NM_174008 F 5'-CAGTCTCCGTAACGTATCGTG-3' 221 58.3 
   R 5'-ACTTGTTCGGACAGAGAGCTG-3'  59.6 
11 IFN-α Z46508 F 5'-ACAAGAGCCTCCTGGACAAG-3' 139 59.4 
   R 5'-AAGTATTTCCTCACAGCCAGG-3'  58.3 
12 IFN-ω XM_001250228 F 5'-ACTTGTCTCCGAACCACG-3' 169 57.0 
   R 5'-AGGTTGAAGCTCTGCTGGAG-3'  59.7 
13 TLR3 NM_001008664 F 5'-GGTGTCCTTGAACTTGAAGC-3' 320 57.3 
   R 5'-GAATTTCTGGACCCAAGTGC-3'  59.5 
14 IL6 NM_173923 F 5'-AGCAAGGAGACACTGGCAG-3' 262 59.1 
   R 5'-TTGTGGCTGGAGTGGTTATTAG-3'  59.1 
ZNF828, zinc finger protein 828 (control); TLR4, toll-like receptor 4; ISG15, ISG15 
ubiquitin-like modifier; IL8, interleukin 8; IL10, interleukin 10; IFNb, interferon type b; 
IL2RA, IL-2 receptor subunit alpha; TNF-α, tumor necrosis factor a ; iNOS, inducible nitric 
oxide synthase; CD14, CD14 molecule; IFN-α, Interferon alpha ; IFN-ω, Interferon 
omega-1; TLR3, toll-like receptor 3 ; IL6, interleukin 6.  
For all semi-quantitative RT-PCR assays the expression levels of candidate genes 
were normalised to the levels obtained with primers for the gene encoding the 
zinc finger protein 828 (ZNF828), previously denoted as Chromosome 13 open 
reading frame 8. ZNF828 has been used as a normalizing gene for both 
microarray and qRT-PCR analysis, as it was assessed as a constitutively and 
moderately expressed gene in activated T. annulata infected and resting bovine 
monocytes (Jensen et al., 2008). 
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3.2.11  Western Blotting 
3.2.11.1 Sample preparation of whole cell extracts 
Total cell extracts were prepared from approximately 5x106 cells growing in 
logarithmic phase at a density of 1x106 cells/ml in a six well plate. Cells were 
either incubated with LPS or equal volume of DMSO (LPS 1μg/ml or DMSO 1µl/ml) 
for 4 h or 18. Proteasomal inhibition was achieved by adding 4μg /ml of MG132 
(Sigma-Aldrich; C2211) for 3 hours prior to harvesting the cells. Cells were 
harvested from each well and centrifuged at 4°C, 750 ×g, for 5 min. The cell 
pellet was washed twice with 3ml 1xPBS and the last traces of supernatant were 
carefully removed without disturbing the pellet. The cell pellet was resuspended 
in 100µl of 1xPBS and lysed with an equal volume of SDS sample buffer (Laemmli 
2x concentrate (Sigma; S3401). Samples were sonicated briefly to shear the DNA, 
boiled for 10 min, prior to analysis by SDS-PAGE gel electrophoresis. 
3.2.11.2 SDS gel electrophoresis and Immunoblotting 
Total proteins extracts were separated by polyacrylamide gel electrophoresis 
(SDS-PAGE) using a 12% resolving gel with a 5% stacking gel (see Section 2.2.4.7). 
After 1h of electrophoresis at 120V, proteins were electroblotted onto 0.45-µM 
nitrocellulose membrane (Protan BA 85, Whatman®) in a standard Tris-Glycine-
methanol transfer buffer (ref) for 1 h using a constant 280 milliamps current. 
Transfer of proteins to the nitrocellulose membrane and assessment of equal 
protein loading was confirmed using Ponceau S staining. Adjustments for equal 
protein loading between samples were previously estimated by SDS-PAGE and 
Coomassie Blue staining 
3.2.11.3 Immunodetection  
The membrane was washed briefly with a wash buffer (1xTris-saline with 0.1% 
Tween 20) to remove Ponceau stain and then pre-incubated with block buffer for 
1h at room temperature with gentle agitation. Blots were incubated with 
polyclonal rabbit anti-TLR4 (sc-10741, 1:1000; Santa Cruz-Biotechnology) or 
monoclonal mouse anti-Tubulin (TUB-1A2; 1:5000; Sigma T9028) diluted in fresh 
block buffer (5% Marvel skimmed milk in Tris buffered saline plus 0.1% Tween 20) 
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over night at 4°C with constant gentle agitation. The membranes were washed 
twice briefly then twice for 15min each with wash buffer. The membranes were 
incubated with appropriate secondary antibodies; goat-anti-rabbit-HRP (1:10000, 
Sigma, A6154) or anti-mouse IgG peroxidase conjugate (1:10000, Sigma, A5906) 
diluted in block buffer for 1h at room temperature. The membranes were 
washed as above with a final brief wash with 1x Tris-saline without Tween 20. 
Detection was carried out using a SuperSignal® West Pico Chemiluminescent 
Substrate kit (Pierce, supplied by Thermo Scientific, Rockford, IL). The blots 
were immediately exposed to X-ray film to capture the chemiluminescent signal. 
Several exposures were made to achieve the optimal signal for each antibody. 
The molecular weight of proteins was determined by comparison with Precision 
Plus ProteinTM Standard dual colour marker (Bio-Rad Laboratories; 161-0374). 
Complete details of reagents and buffers used in western blotting are 
described separately in chapter2. 
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3.3 Results  
3.3.1  Response of uninfected (BL20) and Theileria annulata 
infected (TBL20) cells to stimulation with LPS. 
3.3.1.1 NF-κB activation by T. annulata and LPS  
Constitutive activation of NF- B and other inflammatory associated transcription 
factors is known to be a critical component of Theileria dependent host cell 
transformation. However, the phenotypic response to activation and the 
mechanism of activation relative to uninfected cells has not been directly 
compared. To perform this type of analysis, initial experiments compared the 
cellular activation status of infected and uninfected cells following stimulation 
by bacterial lipopolysaccharide (LPS). LPS is known to be a strong inducer of NF-
B transcription factor complexes and persistent activation of NF- B can be 
achieved by exposure to soluble agonists such as LPS (Hauf et al., 1997;McKinsey 
et al., 1996;Thompson et al., 1995). Therefore, BL20 (uninfected) and TBL20 
(infected) cells were stimulated with LPS and NF- B dependent luciferase-
reporter assays performed to assess the levels of NF- B activation. The results 
represented in Figure 3.4 showed that stimulation of BL20 significantly elevated 
NF- B ctivity (P< 0.005), as a 16 fold induction of NF- B reporter activity was 
observed in LPS-stimulated BL20 cells relative to non-treated BL20 control 
cultures. In contrast, stimulation of TBL20 (infected cells) with LPS did not show 
significant induction of NF- B activity relative to the TBL20-DMSO (control) 
cultures (P> 0.05). The data also indicated that constitutive NF- B activity 
observed in TBL20 cells was significantly higher than LPS stimulated and un-
stimulated BL20 cells(P< 0.001) (Figure 3.4).  
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Figure 3.4:  NF- B dependent reporter activity in LPS stimulated BL20, TBL20 and control 
cells 
Activated levels of NF- B in Theileria annulata infected cell TBL20 & uninfected BL20 cells 
(control) following stimulation with or without LPS are shown. Cells were transiently co-transfected 
with luciferase reporter constructs. After 24h of co-transfections, cells were either stimulated with 
LPS (1µg/ml) or DMSO (1µl/ml) for 4h before luciferase assay. Cell extracts were prepared to 
measure NF- B promoter activity, which is expressed as ratio of NF- B Firefly luciferase/Renilla 
activity (mean ± S.E, n = 4). The asterisk (*) above the bars indicates the statistical significance of 
the results (Student’s t-test, *P < 0.005, **P < 0.001). Whereas, (n.s) indicates non-statistical 
difference of TBL20 LPS results relative to TBL20 cells. 
3.3.1.2 Activation of NF- B by LPS and Theileria infection are both 
associated with nuclear translocation of p65 
In an attempt to confirm that elevated reporter activity was associated with 
activation of NF- B, assessment of the level of NF- B in the nucleus of 
stimulated cells was carried out by immunofluorescence assay for the p65 sub-
unit of NF- B. The result shown in Figure 3.5 (panel 1 and 2) clearly indicated 
elevated host cell nuclear reactivity using the anti-p65 antibody in LPS 
stimulated BL20 cells relative to control cells. In addition, while the nuclear 
reactivity of p65 in TBL20 cells was greater than that detected for LPS 
stimulated BL20 cells, no significant difference in levels of p65 nuclear staining 
was detected in TBL20 when stimulated with LPS (Figure 3.5; panel 1-4) relative 
to the TBL20 DMSO control cells.  
 
** 
** 
n.s 
 
* 
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3.3.1.3 Activation of NF- B by LPS and Theileria infection are both 
associated with IKK signalosome aggregation  
Theileria dependent activation of NF- B has been shown to involve aggregation 
of IKK signalosomes complexes close to or at the surface of the macroschizont. 
Aggregation of the kinase complex results in phosphorylation of NF- B inhibitor, 
IKBα, which is then constitutively degraded, subsequently allowing the 
translocation of the previously sequestered cytoplasmic NF- B to the nucleus 
(Heussler et al., 2002). To test whether a similar mechanism operated following 
LPS stimulation in BL20 or whether LPS might alter signalosome levels in TBL20, 
IKK signalosome complexes were assessed by immunofluorescence (Figure 3.5), 
using a monoclonal antibody against IKKγ as described previously (Schmuckli-
Maurer et al., 2010). The results showed increased reactivity against IKKγ in the 
form of punctate bodies in the cytoplasm of LPS-stimulated BL20 cells relative to 
control (Figure 3.5; panel 5-6). It was concluded that these bodies were highly 
likely to represent aggregated signalosomes. Similar bodies were also detected 
in the proximity of the multinucleated schizont in parasite infected TBL20 cells 
and supporting results of previous studies (Heussler et al., 2002;Schmuckli-
Maurer et al., 2010) have indicated aggregation of signalosomes at this location. 
However, no obvious difference in the level of anti-IKKγ reactivity was obtained 
in TBL20 cells when stimulated with LPS relative to unstimulated TBL20 cells 
(Figure 3.5; panel 7-8). These results together with the results obtained from 
the NF- B reporter assay suggest LPS significantly activates NF- B in uninfected 
BL20- cells but has no effect on the infected TBL20 counterpart. 
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Figure 3.5:   mmunofluorescence analysis of activated NF- B levels in BL20 and TBL20 cells in response to LPS stimulation 
Panels1-4: Immunofluorescence analysis of activated NF- B levels using anti-p65 against BL20, LPS stimulated BL20, TBL20 and LPS stimulated TBL20 cells 
respectively. Expression and nuclear localization of anti-p65 in BL20 LPS, TBL20 and LPS stimulated TBL20 cells. 
Panels 5-8: Immunofluorescence analysis of IKK signalosomes using a mouse monoclonal anti-IKKγ against BL20, LPS stimulated BL20, TBL20 and LPS stimulated 
TBL20 cells respectively. Immunodetection of IKK signalosomes (green dots) are detected by anti-IKKγ of BL20 LPS, TBL20 and LPS stimulated TBL20 cells. Bar =   
20µm.
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3.3.2  Differential growth response of BL20 and TBL20 cells to 
stimulation by LPS 
Prolonged stimulation of cells with LPS and constitutive cellular activation of NF-
B have both been associated with a detrimental effect on cell viability (Garay-
Malpartida et al., 2011). To test whether the response of BL20 and TBL20 to LPS 
stimulation is associated with a potential detrimental outcome, cultures were 
treated with LPS and the numbers of viable and dead cells counted after 24 and 
48 hours incubation. The results showed that the growth potential of uninfected 
BL20 cells stimulated with LPS at 48h was significantly reduced, with a 1.73-fold 
reduction in cell number relative to the un-stimulated control (see Figure. 3.6). 
In addition, this loss of growth was accompanied by a significant elevation in the 
percentage of non-viable cells in the BL20-LPS cultures (Figure 3.7) at both 24 
and 48 hours. Theileria infected cells, in contrast, were found to be resistant 
to a loss of growth potential following stimulation with LPS and continued to 
proliferate at a rate comparable to untreated control cells (Figure 3.6). 
Furthermore, although an increase in the percentage of non-viable cells was 
obtained in LPS-stimulated TBL20 (2.55 fold) relative to control cells at 48 hr, 
this was significantly less than the increase in percentage cell death found for 
the LPS stimulated uninfected cells (22.5 fold).  
To determine whether the increase in non-viable cells may be linked to 
activation of programmed cell death, caspase 3/7 activity was assayed using cell 
lysates generated from cultures at both the 24h and 48h time points. A 2.5 fold 
and 5.7 fold induction in caspase 3/7 activity was detected in lysates of BL20 
cells stimulated with LPS at 24h and 48h respectively (Figure 3.8). In contrast, 
while Theileria infected TBL20 cells showed a higher baseline caspase 3/7 
activity level relative to control uninfected BL20 cells, there was no detection of 
a significant elevation in activity following stimulation of TBL20 with LPS at 
either time point (see Figure 3.8). In addition, the level of caspase activity in 
LPS stimulated TBL20 at 48 hr was shown to be significantly lower (1.86 fold) 
than LPS stimulated uninfected BL20 cells at this time point. 
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Figure 3.6:  Proliferation assays of BL20 and TBL20 cells following LPS stimulation relative 
to control cells. 
Cell viability of BL20 and TBL20 cells in cultures was assessed using Trypan blue exclusion in the 
presence of either LPS (1µg/ml) or the DMSO vehicle control (1µl/ml) at 24h and 48h post-
treatment as described previously (section 3.2.5). Results are presented as Mean ± SE, n = 4 from 
one of several independent experiments. The asterisk (*) above the data points indicates the 
statistical significance of the pair wise comparisons tested against the controls (Student’s t-test, 
*P< 0.01, **P< 0. 001). Whereas, n.s indicates non-statistical differences of the data points relative 
to controls (BL20 cells) at given conditions. 
 
Figure 3.7:  Assessment of cell death of BL20 and TBL20 cells following LPS stimulation. 
Cells were cultured in the absence or presence of LPS (1µg/ml) for 24h and 48h. Cell death was 
measured using the trypan-blue exclusion assay and is expressed as percentage of cell. Values 
are presented as Mean ± SE of four replicate cell cultures from one of several independent 
experiments. The asterisk (*) above the bars indicates the statistical significance of the pair wise 
comparisons tested against the controls (Student’s t-test, *P< 0.05, **P< 0.001). Whereas, (n.s) 
indicates non-statistical difference of TBL20 LPS results relative to TBL20 cells and control cells. 
n.s 
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Figure 3.8:  Caspase 3/7 activity assayed in TBL20 and BL20 cells following stimulation with 
LPS.  
Caspase activation was determined using a modified caspase 7 or 3-like protease substrate where 
cleavage yields a product that activates a reaction and generates a measurable fluorescence. 
Caspase 3/7 activity was determined after incubation of cells in the presence of either LPS 
(1µg/ml) or the DMSO vehicle control (1µl/ml) for 24h and 48h. Results are expressed as relative 
fluorescence units (mean, ± SEM, n = 4). The asterisk (*) above the bars indicates the statistical 
significance of the pair wise comparisons tested against the controls (Student’s t-test, *P< 0.005, 
**P< 0.00001). Whereas, (n.s) indicates non-statistical difference of TBL20 LPS results relative to 
TBL20 cells at given conditions. 
3.3.3  Comparison of candidate gene expression profiles of BL20 
and TBL20 cells stimulated with LPS 
From the results presented above, it can be concluded that the outcome of LPS 
stimulation and activation of uninfected BL20 cells relative to the infected 
TBL20 counterpart is different. A premise of this thesis was that such a 
difference would be manifest at the level of gene expression and that infection 
may manipulate the outcome of the gene expression profile associated with LPS 
stimulation. Prior to testing this hypothesis at a global level, it was decided to 
conduct a preliminary analysis using semi-quantitative RT-PCR on a panel of 
genes. This panel of genes was selected on the basis that their expression profile 
is manipulated by Theileria infection, or they were known LPS response gene 
and/or targets of activated NF- B. The panel of genes and their predicted 
expression profile with respect to infection, LPS stimulation and NF- B 
activation is shown in Table 3.2. 
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Table 3.2:  Panel of genes and their predicted expression profile with respect to infection, 
LPS stimulation and NF- B activation  
S.No 
Gene 
symbol 
Stimulus/context 
Predicted 
expression 
References 
1 TNF-α 
Theileria infection  Induced (Guergnon et al., 2003;Preston 
et al., 1993;Schnittger et al., 
2000) 
LPS stimulation  Induced (Jones et al., 2001) 
NF- B stimulation  Induced (Collart et al., 1990) 
2 iNOS 
Theileria infection Repressed (Brown et al., 1995b;Sager et 
al., 1998) 
  
LPS or NF- B 
stimulation  
Induced  (Jungi et al., 1996;Sager et al., 
1997;Xie et al., 1994) 
3 CD14 Theileria infection Repressed (Sager et al., 1997) 
  LPS stimulation  Induced (Yang et al., 1995) 
4 IFN-α 
Theileria infection No expression (Brown et al., 1995b;Sager et 
al., 1998) 
  
LPS stimulation  Induced  (Jungi et al., 1996;Sager et al., 
1998) 
5 IFN-β Theileria infection Induced  (Sager et al., 1998) 
  
LPS or NF- B 
stimulation 
Induced  (Lenardo et al., 1989;Sager et 
al., 1998;Yamamoto et al., 
2003) 
6 IFN-ω Theileria infection No expression (Sager et al., 1998) 
  LPS stimulation Induced  (Sager et al., 1998) 
7 ISG 15 Theileria infection Repressed (Oura et al., 2006) 
  
LPS or NF- B 
stimulation 
Induced (Kim et al., 2005;Malakhova et 
al., 2002;Oura et al., 2006) 
8 TLR4 Theileria infection No literature Not reported 
  
LPS  Induced  (Elner et al., 2005;Jensen et 
al., 2006b) 
9 TLR3 LPS Induced  (Hoebe et al., 2003) 
  NF- B stimulation Induced  (Alexopoulou et al., 2001) 
10 IL2R 
Theileria infection Induced  (Dobbelaere et al., 
1990;Herrmann et al., 
1989;Heussler et al., 
1992;McKeever et al., 1997) 
  NF- B stimulation Induced (Cross et al., 1989) 
11 IL6 Theileria infection Induced (Campbel and Spooner, 1999) 
  
LPS or NF- B 
stimulation 
 (Helfgott et al., 1987;Sanceau 
et al., 1989) 
12 IL-10 
Theileria infection Induced (Campbel and Spooner, 
1999;McKeever et al., 1997) 
  
LPS or NF- B 
stimulation 
 (Barsig et al., 1995;Chanteux et 
al., 2007) 
  Theileria infection Induced (Schnittger et al., 2000) 
13 IL8 LPS stimulation Induced (Jensen et al., 2006b) 
  NF- B stimulation Induced (Kunsch and Rosen, 1993) 
     
TNF-α, tumor necrosis factor a ; iNOS, inducible nitric oxide synthase; CD14, CD14 molecule; 
IFN-α, Interferon alpha; IFNb, interferon type b; IFN-ω, Interferon omega-1; ISG15, ISG15 
ubiquitin-like modifier; TLR4, toll-like receptor 4; TLR3, toll-like receptor 3 ; IL2RA, IL-2 receptor 
subunit alpha; IL6, interleukin 6; IL10, interleukin 10; IL8, interleukin 8;  
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Following RT-PCR the amplified cDNA reaction products were analysed by 
agarose gel electrophoresis. No product was obtained for primer pairs designed 
to amplify TNF-α, iNOS, CD14, IFN-α and IFN-ω. RT-PCR for these genes was 
repeated at a later date with different primer sets for each of these genes and 
validated a lack of PCR product for these genes. Products were obtained for the 
other 7 primer sets and the expression profile across the different cellular 
conditions tested for these genes, relative to the constitutive control (ZNF828). 
For one of these genes, TLR3, no observable difference in expression level across 
the range of conditions could be detected (data not shown).  
The other six genes displayed a range of modulated expression profiles. Of these 
the profile obtained for IL8 and IL2RA (CD25) appeared to be of least interest 
because although they showed evidence of elevated expression associated with 
parasite infection of BL20; i.e. clearly higher in TBL20 vs BL20, there was no 
obvious difference in the levels of expression products amplified from RNA 
representing TBL20-LPS cells vs uninfected BL20-LPS cells. In a similar manner, 
the profile for IL10 indicated that while slightly elevated expression of this gene 
was associated with parasite infection of the host cell, an increase in product 
was not detected for LPS stimulated BL20 cells (Figure 3.9). Therefore a 
conclusion that infection can modulate the expression outcome of an LPS 
responsive gene could not be made on the basis of these profiles. 
The final three genes all showed evidence for infection-associated modulation of 
an LPS stimulated response. Thus, the profiles obtained for both TLR4 (CD284) 
and IFNB1 indicated that the parasite repressed expression of these genes, 
despite evidence for induction of elevated expression following LPS stimulation 
of BL20 cells. The profile for ISG15 also showed evidence for infection associated 
repression relative to an LPS (4h) induced expression profile obtained in the 
BL20 line. In non-stimulated cells though, the level of expression was higher in 
TBL20 cells vs uninfected BL20 (Figure 3.9). This profile of ISG15 expression, 
indicative of infection associated activation but repression of higher-level 
expression, was observed previously by northern blotting (Oura et al., 2006). 
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Figure 3.9:  Semi quantitative RT-PCR expression analysis of candidate genes following 
stimulation (of BL20 and TBL20 cells) with LPS    
Differential mRNA expression levels of six candidate genes. Gel electrophoresis analysis of all RT-
PCR products showed the appropriate size on ethidium bromide stained agarose gels. The mRNA 
expressions of TLR4, ISG15, IL8, IL10, IFNB and IL2R genes normalized against ZNF828 are 
shown for TBL20 & BL20 cells (control) stimulated with LPS (1µg/ml).  
3.3.4  Theileria annulata infection of BL20 cells is associated with 
repression of TLR4 expression  
Following initial results obtained from the semi-quantitative PCR, it was of 
interest to further validate the infection associated repression profile of TLR4 
expression at the protein level. Western blotting was performed to determine 
whether decreased TLR4 mRNA expression is manifest post-translationally in 
Theileria infected cells. The western blot results showed that the TLR4 protein 
profile reflected the trend obtained at the mRNA level. Thus, a marked decrease 
in TLR4 expression was observed in TBL20 cells compared to BL20 cells (Figure 
3.10). However, unlike the RNA pattern no significant differences were noticed 
in the protein levels of TLR4 when stimulated BL20 cells were stimulated with 
LPS while infected cells continued to display evidence of repression relative to 
their uninfected counterpart. In general, the levels of Tubulin detected by 
western blotting (constitutive control) appeared to be slightly lower for the LPS 
stimulated extracts (see Figure 3.10). 
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Figure 3.10:  Imunoblot analysis of TLR4 protein expression following stimulation of BL20 
and TBL20 cells with LPS    
Expression of TLR4 was detected by western blot analysis of total cell extracts derived from 
uninfected and Theileria infected cell cultures either stimulated with LPS or unstimulated (DMSO). 
Tubulin expression was used as constitutive control. 
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3.4 Discussion 
The aim of the work presented in this chapter was to establish a cellular model 
for comparing the gene expression profiles of uninfected and Theileria infected 
cells following induction of cellular activation by an inflammatory mediator. 
Therefore, experiments were performed to assess the influence of LPS on the 
activation state of NF- B in uninfected and parasite infected host cells. 
The reporter construct data (Figure 3.4) showed that LPS stimulation of 
uninfected BL20 cells significantly induces NF- B activation. Further 
confirmatory evidence of NF- B activation was obtained by immunofluorescence 
analysis, as LPS stimulation was associated with detection of IKK signalosome 
aggregation in the cytoplasm of the uninfected BL20 cells. Such IKK complexes, 
consisting of two kinases, IKKα, IKKβ and the regulatory unit NEMO (IKKγ), have 
been shown to serve as the focal point for signalling pathways that are activated 
by numerous stimuli such as TNFα, dsRNA and LPS, all of which lead to activation 
of NF- B [reviewed in (Kanarek et al., 2010)]. 
As in the case of LPS stimulated BL20 cells, parasite infected TBL20 cells provide 
strong evidence for NF- B activation via aggregation of IKK signalosomes. In 
agreement with previous studies, TBL20 cells displayed a uniform pattern of 
parasite-associated signalosome complex over the surface of the macroschizont. 
This particular finding supports the previous model of proximity-induced IKK 
activation, where it is hypothesised that membrane parasite and/or complexed 
host proteins act as platform for the formation of parasite dependent IKK 
complex (Heussler et al., 2002). No obvious increase in the number or intensity 
of detected signalosomes was observed following LPS stimulation of TBL20 cells 
and this is supported by data indicating high levels of constitutive NF- B 
activation, which did not show significant change following stimulation by LPS 
(see Figures 3.4 and 3.5). Possible reasons for this finding may be that either 
Theileria infected cells are refractory to stimulation by LPS or activated NF- B is 
maximal in the infected cell. The latter possibility appears to be unlikely as 
Schmuckli-Maurer et al. (2010) have shown that T. annulata infected cell lines 
can show increased levels of activated NF- B following stimulation by 
cytochalasin D. 
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To investigate whether activation of the host cell by LPS is potentially associated 
with a detrimental outcome, the BL20 and TBL20 cell lines were stimulated with 
LPS and measurements made on cell viability and death. The results 
demonstrated that stimulation of uninfected BL20 cells with LPS proved to be 
detrimental and causes cell death. Similar responses have been reported in 
several studies indicating that prolonged activation with LPS induces apoptosis 
through various mechanisms such as modulation of TLR4 signalling, NF- B 
activation, activation of caspases, prolonged or excessive production of 
cytokines, production of nitric oxide and induction of apoptotic signalling 
molecules (Akgul et al., 2001;Alikhani et al., 2003;Bannerman et al., 
2002;Garay-Malpartida et al., 2011) . In contrast Theileria infected cells 
displayed no adverse effect following LPS treatment and continued to proliferate 
at the same rate as the untreated control. 
Experimental evidence of LPS induced programmed cell death of BL20 cells was 
obtained by performing caspase 3/7 activation assays. In general the caspase 
results revealed a similar trend to the data obtained for cell proliferation and 
death, with stimulation of uninfected BL20 cells generating a significantly higher 
level of caspase activation relative to the unstimulated control and its infected 
TBL20 counterpart. No significant difference was observed between un-
stimulated and control TBL20 cells (Figure 3.8), suggesting TBL20 cells are 
refractory to LPS stimulated caspase activation.  Activation of caspases is 
considered to be a hallmark of apoptosis (Porter and Janicke, 1999;Saraste and 
Pulkki, 2000) and in vitro studies have shown that LPS can induce apoptosis 
through activation of caspase 3 and 7 (Bannerman and Goldblum, 2003;Deaciuc 
et al., 1999). Thus, in the context of uninfected BL20 cells, LPS stimulation is 
associated with activation of NF- B, elevated cell death and loss of proliferation 
potential; while infected TBL20 cells show constitutive activation of NF- B that 
confers resistance to apoptosis (Heussler et al., 1999;Schmuckli-Maurer et al., 
2010), and these cells are refractory to cell death or the loss in proliferation 
potential associated with LPS stimulation of BL20 cells. This apparent Janus-like 
response to LPS stimulation and NF- B activation could be explained by the 
ability of infected cells to generate a modulated NF- B target gene expression 
profile compared to that of LPS activated BL20 cells, although it should be borne 
in mind that additional activation pathways and transcription factors such as AP-
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1 are likely to operate in establishing the distinct activation phenotypes 
associated with infection (TBL20) and inflammatory stimulation (LPS-BL20). 
To investigate whether parasite dependent control of infected host cell 
phenotype could be associated with major modulation of leukocyte gene 
expression, RNA profiling was performed using RT-PCR. Initially, investigation 
was limited to a small subset of 13 genes with expression profiles obtained for 
LPS stimulated BL20 and TBL20 cells relative to non-stimulated controls. Primer 
sets representing seven of these genes gave clear specific PCR products. While it 
cannot be discounted that the failure to obtain a PCR product for the other six 
genes was due to incorrect primer design or function, the repeated failure with 
redesigned sets of primers for each of these genes (TNF-α, iNOS, CD14, IL6, IFN-
α and IFN-ω) suggest this is unlikely. An alternative explanation is that these 
genes are expressed below the detection limit of the assay in the context of the 
tested cell types and conditions. For example as CD14 is considered to be 
primarily a monocyte and macrophage cell surface marker (Song et al., 2001), 
that plays an important role in LPS binding (Anas et al., 2010;Duchow et al., 
1993;Steinemann et al., 1994;Ulevitch and Tobias, 1995), failure to detect 
mRNA expression of CD14 could be due to the fact that the BL20 cell model 
belongs to the lymphocyte lineage. A number of studies have postulated that 
Theileria transformed bovine macrophage cells actively repress LPS inducible 
TNF, iNOS and IFN induction by modulating CD14 repression (Sager et al., 
1997;Sager et al., 1999). However, lack of CD14 in BL20 cells clearly does not 
remove LPS associated activation of NF- B or induction of other LPS associated 
response genes tested by RT-PCR (see below). It is possible that a requirement 
for a CD14, LPS interaction can be supplied by the soluble form CD14 (sCD14) 
present in fetal calf serum (FCS), or LPS activation of BL20 cells operates in a 
CD14 independent manner (Cohen et al., 1995;Lynn et al., 1993;Sauter et al., 
2007). The lack of gene expression for the 6 genes in the context of BL20 is 
supported by the array analysis performed in Chapter 4 of this thesis. 
TLR3 mRNA was shown to be constitutively expressed in both infected and 
uninfected cells and the levels did not change across the range of experimental 
conditions. This finding indicates that TLR3 mRNA is not regulated by LPS or 
parasite infection and is therefore not indicative of an infection associated 
modulation of inflammatory/ NF- B induced gene expression. 
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Of the six differentially expressed genes, IL8 and IL2RA mRNA were expressed at 
similar levels in LPS stimulated uninfected BL20 cells and infected TBL20 cells. 
However, for both of these genes the level of PCR-product was higher in non-
treated TBL20 compared to control BL20 cells.  The elevated levels of IL8 and 
IL2 receptor (IL2RA) mRNA expression observed in response to LPS stimulation 
was consistent with an earlier study where bovine peripheral blood monocyte 
(PBMC) cells were shown to exhibit high levels of induction of these genes when 
stimulated with LPS (Jensen et al., 2006b). It may not be surprising that the 
expression level of IL8 and IL2R were up-regulated in BL20 cells when stimulated 
with LPS or infected with Theileria, since both are known targets of NF- B 
(Toshchakov et al., 2002;Yoshida et al., 1998). The results suggest that these 
genes are targets for transcription factors activated by LPS treatment (BL20) and 
parasite infection and that their elevated expression is either of benefit to 
infected cells or has limited (neutral) detrimental potential. There is no 
evidence, however, that the outcome of LPS associated induction is significantly 
manipulated by infection of BL20 cells by the parasite. 
Regardless of whether TBL20 or BL20 cells were treated with LPS or left un-
stimulated, a slight induction of IL10 mRNA expression was observed in TBL20 
compared to BL20 cells. Previous studies have also shown that in vitro infection 
of bovine lymphocyte lineages with T. parva and a macrophage derived cell line 
infected with T. annulata were associated with IL-10 expression (Brown et al., 
1995b;McKeever et al., 1997). Indeed, it appears that IL-10 is universally 
expressed in T.parva and T. annulata transformed cell lines. Though NF- B has 
been proposed to be involved in the up-regulation of IL-10 expression in 
Theileria-transformed cells (Dobbelaere and Heussler, 1999), it appears to be 
unlikely in the BL20 model as LPS stimulation of BL20 cells failed to generate any 
differences in IL-10 mRNA expression levels while clearly activating NF- B. 
Interestingly phosphatidylinositol 3-kinase (PI-3K) has been reported to 
contribute toward IL-10 expression (Crawley et al., 1996). PI-3K is continuously 
activated in Theileria transformed cells (Heussler et al., 2001) and speculated to 
have an important role in cellular proliferation and survival of the parasitized 
cell via IL-10 expression (Dobbelaere and Heussler, 1999;Dobbelaere and Kuenzi, 
2004). Moreover, IL-10 serum levels have been found to correlate with tumor 
progression in murine B16 melanoma cell line (Sredni et al., 2004) and in vitro 
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studies have demonstrated that IL-10 can favour tumor growth by stimulating 
cell proliferation and inhibiting cell apoptosis (Mocellin et al., 2005). 
Stimulation of uninfected BL20 cells with LPS showed elevated expression of 
Interferon stimulated gene-15 (ISG15), IFN-beta (IFNβ) and Toll-like receptor-4 
(TLR4) but the parasite-infected TBL20 cells were clearly refractory to induction 
of ISG15 at 4h and INFβ/TLR4 at both 4 and 18 hours LPS treatment. ISG15 was 
essentially a positive control for parasite-mediated manipulation of an LPS 
activation response. Previous northern blot analysis had shown that Theileria 
infection renders TBL20 cells refractory to a high level induction of ISG15 
expression, 14h post LPS treatment. The marked elevation of ISG15 mRNA in 
BL20 LPS stimulated cells detected by both northern blotting (Oura et al., 2006) 
and RT-PCR validated an expected LPS induction response for this cell line in the 
current study. 
Like ISG15, the results presented in Figure 3.9 indicate that infection by the 
parasite modulates the LPS activation expression profile of the IFN-β1 gene, a 
member of the family of type I IFNs. Thus, upon stimulation with LPS, BL20 cells 
displayed higher levels of IFN-β relative to the untreated cells. Moreover, in the 
context of infected TBL20 the level of product remained lower than the BL20 
counterpart whether stimulated with LPS or not. This profile indicates a 
requirement of infected TBL20 to repress expression of the IFN-β1 gene and 
maintain this repression in the face of stimulation with an inflammatory mediator. 
There have been numerous citations indicating the possibility of NF- B 
involvement in IFN-β gene regulation (Lenardo et al., 1989;Megyeri et al., 1995). 
A Type I interferon (IFN-alpha/beta) response is one of the major host defence 
mechanisms against viruses and has been shown to exhibit diverse functions 
under inflammatory conditions; for instance it could act in an anti-proliferative 
and immunoregulatory manner (Dunn et al., 2006). These functions are 
considered to be of prime importance in Theileria associated infection. Studies 
pertaining to regulation of different types of IFN in Theileria-infected cells have 
shown that only T. annulata but not T. parva transformed cell lines are 
restricted to IFN-β production (Sager et al., 1998). However, T. annulata 
infected leukocytes were found to be resistant to this high level induction of 
IFNβ expression by LPS. In contrast, high level expression was induced by 
stimulation of several T. annulata infected cell lines with poly (I:C), indicating 
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subtle manipulation by parasite infection of the signal transduction pathways 
associated with regulation of IFNβ expression (Sager et al., 1998). This finding is 
in agreement with the above mentioned study indicating similarity of the BL20 
system infected with T. annulata used in the current study. 
The TLR4 (CD284) receptor complex has been identified as the major receptor 
involved in recognition and transduction of the LPS stimulated activation event 
(Beutler, 2000;Beutler, 2002;Hoshino et al., 1999;Kalis et al., 2003). TLR4 
belongs to a class of pathogen recognition receptors (PRRs) and has the ability to 
recognize a variety of microbial products bearing pathogen-associated molecular 
patterns (PAMPs) (Garay-Malpartida et al., 2011;Takeda and Akira, 2005).  
Activation via this receptor is known to operate through activation of NF- B and 
IRF3 (Kawai and Akira, 2007) and results in up-regulation of IFN-β and a range of 
inflammatory cytokines [reviewed in (Akira and Takeda, 2004;Honda et al., 
2005)] involved in triggering innate immune responses. In addition, infection of 
BL20 cells with T. annulata is associated with significant repression of TLR4 at 
both the mRNA (Figure 3.9) and protein level (Figure 3.10) relative to control 
and LPS stimulated cells. Therefore following initial results obtained from the 
semi-quantitative PCR, it was of interest to further validate the infection 
associated repression profile of TLR4 expression at the protein level. Western 
blotting was performed to determine whether decreased TLR4 mRNA expression 
is manifest post-translationally in Theileria-infected cells. The western blot 
results showed that the TLR4 protein profile reflected the trend obtained at the 
mRNA level. Thus, a marked decrease in TLR4 expression was observed in TBL20 
cells compared to BL20 cells (Figure 3.10). However, unlike the RNA pattern no 
significant differences were noticed in the protein levels of TLR4 when 
uninfected BL20 cells were stimulated with LPS while infected cells continued to 
display evidence of repression relative to their uninfected counterpart. In 
general, the levels of Tubulin detected by western blotting (constitutive control) 
appeared to be slightly lower for the LPS stimulated extracts (see Figure 3.10). 
Why should Theileria repress expression of TLR4? Simplistically this would 
appear not to be in the interest of the parasite infected cell, since it has been 
demonstrated that constitutive activation of NF- B is required for its survival 
(Heussler et al., 1999;Palmer et al., 1997). However, Heussler et al.,(2002) 
demonstrated using dominant negative mutants that signal transduction events 
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upstream of IKK signalosome aggregation are not required for NF- B activation in 
the Theileria-infected leukocyte.  Thus, the parasite bypasses a requirement for 
transduction of the NF- B activation signal from the cell membrane, potentially 
allowing down regulation of molecules involved in this event. 
The outcome of reducing the influence of TLR4 activation pathways can only be 
speculated upon, but a number of potential benefits to the infected cell can be 
postulated. Reduction of a major route of extrinsic stimulation of NF- B could 
allow the level of NF- B activation to be determined primarily by parasite 
dependent IKK signalosome aggregation. Cellular activation via the TLR4 
receptor can induce apoptosis (Haase et al., 2003;Ruckdeschel et al., 2004), 
hence repressing expression of TLR4 may therefore promote parasite 
establishment. In myeloid cells TLR4 can synergise with the TREM1 pathway 
leading to neutrophil degranulation, phagocytosis and the respiratory burst 
(TREM1 review SAB biosciences). The generation of pro-inflammatory cytokines 
via a host dependent pathway could abrogate parasite-mediated modulation of 
these effector molecules, leading to stimulation of the innate immune response 
by the infected cell. Several protozoan parasites such as Entamoeba histolytica 
(Maldonado et al., 2000), Trypanosoma spp (Ropert and Gazzinelli, 2004), 
Leishmania spp (Tuon et al., 2008), Toxoplasma gondii (Kim et al., 2004b) and 
Plasmodium falciparum (McCall et al., 2007) have been shown to actively 
modulate the expression of various TLR receptors especially TLR4 and TLR2 and 
their associated immune responses. It can be postulated therefore that the 
infected cell may down-regulate TLR4 to prevent extraneous activation via this 
receptor, allowing the activated infected cell to be under control deployed by 
the Theileria parasite to provide protection against stimulation of the immune 
response. 
Despite the evidence that T. annulata may suppress the ability of the host cell 
to respond to LPS signalling, infection of the cell generates a dichotomy, since 
transcription factors that operate in cellular activation and induce a pro-
inflammatory cytokine response (NF- B, AP1, STAT3 and ATF2) are constitutively 
activated by infection. If the outcome of parasite mediated activation is to be 
advantageous for the parasite then it can be postulated that expression of target 
genes that are beneficial would be promoted/allowed while those that are 
detrimental are suppressed. The preliminary data presented in this chapter and 
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data from previous studies (Jensen et al., 2009;Oura et al., 2006;Sager et al., 
1997) suggests that such modulation occurs. For example, IL2RA and IFNB are 
both NF- B dependent genes but Figure 3.9 shows that IFNB is repressed while 
IL2RA is elevated relative to uninfected control cells. However, the extent and 
specificity to which the parasite manipulates the expression profile of the 
activated host cell is unknown.  If detailed knowledge on the pathways that the 
parasite utilises to establish the infected cell phenotype is to be gained, a global 
analysis of the gene expression profile of TBL20 relative to uninfected activated 
BL20 cells is required. 
In summary, use of the current cellular model generated data that was both 
biologically valid as well as consistent with the past studies associated with 
Theileria infection. These findings indicated that in vitro stimulation of bovine 
leukocytes with LPS shows similarity to a typical activation of NF- B via IKK 
signalosome complex formation and represents a valuable model system for the 
study of the mechanisms of the host cellular activation state. Activation of the 
cell can be detrimental but evidence using only a limited number of genes 
indicated that T. annulata subverts the normal response of transcription factor 
activation. Apparently this may operate by blocking signal transduction pathways 
that responds to inflammatory mediator like TLR4. The results have indicated 
that the parasite manipulates the outcome of cellular events to promote the 
establishment of infected cells and prevent cell death. 
     
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Modulation of activation associated host cell gene 
expression by T. annulata
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4 Modulation of activation associated host cell 
gene expression by T. annulata 
4.1 Introduction 
Bioinformatics combined with high-throughput technologies such as microarray 
analysis and next generation sequencing have been of great use to studies 
investigating the molecular mechanisms that underlie normal and dysfunctional 
biological processes. Such methodologies provide the ability to measure the 
expression level of tens of thousands of genes simultaneously using a single RNA 
sample (Gobert et al., 2005;Manger and Relman, 2000). This property clearly has 
advantage over conventional northern blot analysis or more recent real time-
PCR-based techniques that are more applicable for expression profiling a smaller 
number of target genes. To date, several different types of microarray platforms 
have been developed to monitor the expression levels of thousands of genes, the 
basis for each methodology being essentially a glass slide or membrane spotted 
or "arrayed" with DNA fragments or oligonucleotides that represent specific gene 
regions predicted to encode mRNA and protein. Purified RNA or cDNA is then 
fluorescently labelled and hybridized to the slide/membrane. In some cases, 
hybridization is performed simultaneously with reference RNA to facilitate 
comparison of data across multiple experiments. After thorough washing, raw 
data is obtained by a laser scanning system. With the advancement of 
microarray technology, a new generation of terminology and acronyms has 
evolved and examples of these are included in Table 1.1, Appendix 1.  
Gene expression profiling has emerged as a powerful tool to investigate host 
pathogen interactions and is increasingly being used in the field of parasitology 
in general. Thus, a number of large-scale array projects have been performed to 
expression profile RNA derived from different parasites and/or their respective 
infected host cells. These include several parasites of medical and veterinary 
importance such as Trypanosma spp, Plasmodium spp., Toxoplasma, Leishmania 
spp. and Schistosoma spp. (Bahl et al., 2003;Blader et al., 2001;Bozdech et al., 
2003;Leifso et al., 2007;Minning et al., 2003;Verjovski-Almeida et al., 2003). 
Such studies include comparison of gene expression profiles obtained from, or 
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during transition of, different parasite life cycle stages. For example, Minning et 
al. (2003) utilised 4400 probes to monitor the transformation of Trypanosoma 
cruzi from the trypomastigote to the amastigote in an axenic system. Similarly, 
Le-Roch et al. (2003) also used high-density oligonucleotide array to identify 
expression profiles of both human and mosquito derived stages of the malaria 
parasite (P. falciparum) lifecycle. In this study nine different stages of the 
parasite lifecycle were examined using array of 367,226 probes. 
Recent microarray studies in apicomplexan parasites have focused on specific 
biological/cellular events including regulation of host cell gene expression 
associated with parasite infection. Significantly, these studies have highlighted 
that parasite infection can dramatically alter host cell gene expression to 
overcome immune responses directed against the parasite. For example, Blader 
et al., (2001) examined gene expression profiles generated from human foreskin 
fibroblasts (HFF) infected with Toxoplasma gondii, using a human cDNA 
microarray consisting of ~22,000 known genes and uncharacterized expressed 
sequence tags. The results revealed significant changes to expression of host 
genes encoding pro-inflammatory cytokines, MHC encoding genes involved in 
antigen presentation and genes encoding proteins that protect against apoptosis. 
Indeed, T. gondii has been shown to actively inhibit/ block IFN-gamma induced 
upregulation of MHC class II mRNA and proteins (Lang et al., 2006). Investigation 
of the ability of T. gondii to block a host cell IFN-γ response was also performed 
by Kim et al., (2007), using a microarray representing 23,228 putative human 
genes. The results demonstrated that parasite infection resulted in dysregulation 
of 65 of the 127 identified IFN-γ-inducible genes in human fibroblasts and that 
all 127 genes were refractory to IFN-γ stimulation in infected compared to 
uninfected fibroblast cells. Since 46 of the 127 IFN-gamma-responsive genes 
were already induced and 19 suppressed before infected cells were exposed to 
IFN-gamma, it was concluded that other stimuli produced during infection could 
regulate these genes. 
To date, only a limited number of studies have used microarray methodology to 
characterise parasite or host gene expression profiles of Theileria-infected 
leukocytes. Recently, Schmuckli-Maurer et al. (2009) analysed 
subtelomeric variable secreted proteins (SVSPs) expression in five different T. 
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parva-transformed cell lines established in vitro by infection of T or B-
lymphocytes.  Macroschizont transcript levels were compared using a 70-mer 
oligonucleotide microarray representing 4060 T. parva genes and included 78 of 
the 85 SVSP genes. Transcripts for 56 genes were identified and, for the 
majority, expression was found to be simultaneous and stable, with only minor 
variation in the profiles established from the different infected cell lines that 
were tested. For the small percentage of genes displaying evidence of 
differential expression, it was concluded that this is likely to be largely defined 
by the parasite genotype and not host background or cell type. 
To investigate the response of bovine macrophages to important activation 
stimuli and study early immune responses, Jensen et al., (2006b) developed a 5K 
bovine macrophage specific (BoMP) cDNA microarray. The array was developed 
to investigate gene expression in bovine myeloid cells and was generated with 
clones derived from specially created normalised bovine macrophage library: 
representative of Bos taurus and Bos indicus derived monocytes and m  subject 
to various stimuli, including infection with T. annulata. The established array 
was then used to investigate the response of bovine monocytes to stimulation 
with interferon-γ and LPS. In this study, 695 genes were identified as 
differentially expressed at 2 and 16 hours post stimulation and included a 
number of genes of immunological significance, such as interleukins, chemokine 
and TLR-4. 
The validated BoMP array was also used by Jensen et al.,(2008) to compare the 
transcriptional response induced by T. annulata infection of bovine monocytes 
derived from disease resistant (Sahiwals, Bos indicus) and susceptible (Holstein-
Friesians, Bos taurus) cattle breeds. 156 genes were identified exhibiting breed-
specific differential expression during the course of infection. 25% of these 
genes had no functional annotation, whereas of the known genes a large 
proportion (30%) encode predicted proteins expressed on the plasma membrane 
or in the extracellular space, with cellular adhesion being one of the major 
biological processes identified. The study also allowed limited discrimination 
between the breed specific response of monocytes to infection and general 
activation, with several genes (TLR10, PRNP, ICAM1 and TNFRSF18) being 
highlighted. 
Chapter 4                                                                                                                                        110    
As indicated above, previous studies demonstrate the suitability of microarray 
technology to investigate alteration of gene expression profiles following cellular 
activation or parasite infection. However, this has only been performed to a 
limited extent for T. annulata infection, as the published studies mainly focused 
on identification of breed specific differences in the response of macrophages to 
infection and activation. Moreover, the genome coverage of the BoMP array was 
limited by the available bovine genomic sequence and the number of annotated 
representative cDNA sequences derived from the constructed library. This lack 
of coverage has been resolved by completion of the bovine genome sequencing 
project and the design and generation of a new microarray platform by the 
Glasgow Theileria group. This array represents 34,315 putative or known RNA 
sequences, compiled from available transcriptomic databases of Bos taurus (Bt) 
version 4.0 (Btau_4.0) and T. annulata (Ta), a format that allows simultaneous 
analysis of parasite and host gene expression profiles. Table 4.1 summarizes 
probe-based design features included on the Bt_Ta array. 
Work in the previous chapter established that relative to uninfected BL20 cells, 
Theileria infected TBL20 showed resistance to a detrimental response induced 
by stimulation with LPS, a known major inflammatory mediator. In addition, 
while the identified down regulation of the TLR4 LPS receptor in TBL20 could 
generate the refractory behaviour of these cells to LPS, the results confirmed 
that TBL20 display high levels of constitutive activation of NF- B. Since 
activation of NF- B is a major event that transduces stimulation by LPS into a 
pro-inflammatory cellular response, it can be postulated that Theileria infection 
must modulate the outcome of cellular activation mediated by NF- B. Moreover, 
such modulation could extend to other infection activated events that prevent 
establishment of the macroschizont-infected cell. To study these possibilities 
the primary aims of the work presented in this chapter were as follows: 
1) To use the Bt_Ta microarray platform to generate differential gene 
expression profiles representative of LPS stimulated uninfected cells (BL20-
LPS) and infected TBL20 cells. 
2) Compare the expression profiles and perform bioinformatic analysis to 
screen for evidence of infection-associated modulation of LPS activated 
gene expression. 
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3) Focus on bioinformatics analysis of the NF- B pathway and genes targeted 
by activated NF- B to test postulation that Theileria infection modulates 
the outcome of this activation event. 
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4.2 Methods  
4.2.1  Microarrays experiment 
To access global expression differences among Theileria infected and LPS 
stimulated uninfected cells we utilized our previously studied model of 
uninfected bovine lymphosarcoma and Theileria infected bovine lymphosarcoma 
cell lines. The details of cell lines, cell culture protocol and stimulation of cells 
with LPS are described in section 3.2.1and 3.2.2 of Chapter 3    
4.2.1.1 Total RNA Extraction, Clean-up and Quantification  
Total RNA Extraction was performed using TRI reagent (Sigma; T9424-200ML) and 
RNeasy® Kit (Qiagen cat.74104) according to manufacture’s instructions. The 
concentration and quality of the resultant RNA was determined using a NanoDrop 
spectrophotometer (ND-1000; NanoDrop Technologies). RNA integrity was 
verified by gel electrophoresis as described previously. For all samples the 
260/280-nm ratio was >2.03 and the 260/230-nm ratio was >1.8. Detailed 
methodology of RNA extraction, DNase 1 treatment, Clean up and quantification 
is described in Chapter 3 (see Section 3.2.8 & 3.2.9). 
4.2.1.2 Microarray pilot experiment 
Total RNA Samples were prepared from three independent replicate cultures for 
each experimental condition according to the NimbelGen standards. All RNA 
Samples were submitted (30µg of total RNA per sample) to Roche NimbleGen 
Systems, Iceland for further processing. Figure 4.1 illustrates the design of the 
microarray experiment.  
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Figure 4.1:  Schematic diagram illustrating microarray experimental design and the steps 
involved  
Total RNA was isolated from uninfected and Theileria infected cells, the cells were either 
stimulated with LPS or unstimulated. Total RNA was shipped to Roche Nimblegen, Iceland for 
further processing and analysis to investigate the gene expression changes. Images courtesy of 
www.nimblegen.com   
4.2.1.3 Design & specifications of array 
The oligonucleotide microarray used in this study included all bovine RNA RefSeq 
DB available at NCBI (26751) obtained from latest Btau_4.0 (as of Oct. 4, 2007) 
assembly of the genome of Bos taurus, Hereford breed. 
(http://www.ncbi.nlm.nih.gov/RefSeq/) and a number of bovine putative RNA 
Sequences and ESTs (4730) (personal communication Kirsty Jensen, Roslin 
Institute, University of Edinburgh). This constituted of a total of 31481 bovine 
RNA sequences. In addition to these sequences the array contained 
oligonucleotide probes (3769) representing Theileria annulata genome obtained 
from GeneDB (http://www.genedb.org/Homepage/Tannulata). This array design 
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provides us an extensive platform that represents majority of the parasite and 
bovine transcriptome. Data from the Theileria probe set was not analysed during 
the course of this study. The final microarray design used in this study consisted 
of 34,315 features, making this the largest microarray available for the analysis 
of the B.taurus and T. annulata transcriptome simultaneously. The summary of 
the features present on the array is presented in Table 4.1. 
Table 4.1:  Summary of the microarray design and specifications used in the study   
 
Array format 
 
NimbleGen (similar to Affymetrix)  
Array design 
Oligonucleotide tiling array (60mers) 
max 385,000 probes set per array    
Species coverage  
Bovine (Bos taurus)  
Parasite (Theileria annulata) 
Array per slide  1    
Slide Size:  Slide Size: 1" x 3" (25 x 75mm) 
Array Size     17.4 x13mm 
Feature Size  16μm x 16μm 
Numbers of genes 
Total of 35250 gene sequences were submitted to 
NimbleGen which included all parasite ORFs (3769), 
Bovine RNA RefSeq DB at NCBI (26751) and Bovine Non-
validated RNA Seqs and ESTs (4730). The final probe 
coverage per gene on array obtained is summarised as 
follow.  
 
Probes per genes None 1 2 3 4 5 
Parasite (3769 genes) 18 6 13 2 2  3746 
Bovine  (31481genes) 351 24 10 15 10 30569 
Hybridisation 
Isothermal  
probes selected to have Tm within a set temperature 
range 
  
4.2.1.4 Microarray cDNA synthesis, fluorescent cDNA labelling, 
hybridisation and data scanning     
The process of cDNA synthesis, labeling with Cy3, hybridization to array and data 
scanning were performed by Roche NimbleGen following their standard 
operating protocol. See www.nimblegen.com. The arrays were scanned to 
extract data using NimbelScan software. The array design files, raw gene 
expression data and RMA-normalised gene expression data was obtained and 
subjected to further subsequent analysis.  
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4.2.1.5 Raw data processing and Normalisation   
The raw data (.pair file) was subjected to RMA (Robust Multi-Array Analysis) 
(Irizarry et al., 2003), quantile normalization (Bolstad et al., 2003), and 
background correction as implemented in the NimbleScan software package 
(Roche NimbleGen, Inc). Various types of data files were obtained from 
NimbelGen which contained information about the samples, arrays used, raw 
gene expression values and normalised gene expression files. Details of gene 
expression data and types of files obtained from Roche NimbleGen can be found 
in the Table 1.2, Appendix 1.  
4.2.1.6 Annotation 
An updated annotation database was assembled for the Bos taurus probesets 
(genes) present on the array. Data were sourced from Bos taurus RefSeq DB 
available at NCBI.  
4.2.2  Microarray statistical analysis  
4.2.2.1 Identification of differentially expressed genes by Rank Product 
analysis 
Differentially expressed genes were identified by using Rank Product Analysis 
(RPA). RP score obtained by RPA sorts all the genes in a dataset according to 
their expression changes and assigns statistical confidence levels to each change 
in the form of false discovery rates (FDR) (Benjamini and Hochberg, 1995). This 
method is more robust than other techniques to find differentially expressed 
genes (such as Significance of microarray (SAM)) (Breitling et al., 2004). All 
normalised hybridisation expression values were transformed to Log2 expression 
values and subjected to further analysis by RPA. The output files generated from 
RPA of various pair wise comparisons were used in the subsequent analysis steps. 
Genes with FDR cut-off of 5% and ≥ 2 fold change were considered statistically 
significant, where a 5% FDR corresponds to a p-value of 0.05. Schematic 
illustration of overall methodology and steps involved in microarray analysis in 
the current study is described in Figure 4.2. 
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Figure 4.2:  Flow chart of steps involved in the microarray data analysis  
Schematic illustration of main steps in microarray data processing involving, statistical analysis, 
and filtering approach to identify differentially expressed genes, functional analysis and validation. 
Analysis of differentially expressed genes 
Perl Script: Various pair wise comparisons by Rank Product analysis   
             e.g BL20 vs BL20 LPS 4hr/18h, BL20 vs TBL20, TBL20 vs TBL20 LPS4hr/18h 
 
Profiling of modulated dataset based on response to LPS / infection  
Validation of Microarray data 
Top candidate genes from each profile by qRT-PCR and semi quantitative RT-PCR 
 
Steps performed at Theileria Lab Steps performed at Roche NimbleGen  
                                                        
         Select all genes where LPS response is observed in BL20 (4hr+/or 18hr) 
                                                        
Discard biphasic response genes 
                                                        
        Discard genes where LPS response in BL20 (4hr+/or 18hr) is similar to infection 
response in BL20 (TBL20) 
                                                        
        Discard genes where LPS response in BL20 (4hr+/or 18hr) is similar to LPS 
response in TBL20 (4hr+/or 18hr) 
                                                        
Identification of infection modulated LPS response genes 
                                                       
 
NimbleGen design file                                             Normalized_Calls_Files 
080829_B_taurus_JK_EXP.ndf                All_norm_calls.txt 
 
NimbleGen Raw_Data_Files 
Calls_Files  and Pair_Files 
Profile 
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1 ↑ ↑↑ Up_Up         (Up in TBL20 vs BL20 LPS) 
2 ↑ ↓ Up_down     (Down in TBL20 vs BL20 LPS)  
3 ↑↑ ↑ Up_Up         (Down in TBL20 vs BL20 LPS) 
4 ↑ − Up_NC         (Down in TBL20 vs BL20 LPS) 
5 ↓ ↓↓ Down_Down (Down in TBL20 vs BL20 LPS) 
6 ↓ ↑ Down_Up     (Up in TBL20 vs BL20 LPS) 
7 ↓↓ ↓ Down_Down (Up in TBL20 vs BL20 LPS)  
8 ↓ − Down_NC     (UP in TBL20 vs BL20 LPS) 
Key: ↑,Up; ↓,down;−,No change  
 
Functional analysis of infection associated modulated dataset  
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4.2.2.2 Monte Carlo simulation and Chi square test 
In order to access the relationship and significance of the overlap between the 
differentially expressed genes identified by RPA in TBL20 and LPS stimulated 
BL20 datasets, Monte Carlo simulation was used to estimate the expected 
overlap likely to occur by chance between the results obtained from the two 
datasets (Kabakchiev et al., 2010;METROPOLIS and ULAM, 1949). Only the most 
differentially expressed genes (FDR< 0.05, FC≥2) in each dataset were 
considered for this analysis and chi-quared test was used to compare the 
expected to the observed proportion of overlap as outlined below: 
 
4.2.3  Ingenuity Pathway Analysis 
In order to identify gene expression networks which were enriched for genes 
highlighted in this study, Ingenuity Pathway Analysis V9 (Ingenuity® Systems, 
www.ingenuity.com) was utilised. Each bovine RNA sequence represented on the 
array was mapped to its corresponding gene in the Ingenuity Pathways 
Knowledge Base.  
4.2.3.1 Canonical pathway analysis 
The list of canonical pathways in the IPA system was augmented with a number 
of specific pathways, namely the NF-κB pathway, NF-κB response genes, the 
c-MYC pathway, validated targets of c-MYC transcriptional repression, validated 
targets of c-MYC transcriptional activation, AP1 target genes, ATF2 network 
genes and the WNT signalling pathway. The significance of the association 
between novel gene lists and each pathway was measured in two ways. Firstly, a 
ratio was calculated for the number of genes in a given list that map to the 
pathway divided by the total number of genes on the array that map to the same 
pathway. Secondly, Fisher's exact test was used to calculate a p value to 
Number of genes 
expected to be common 
to lists A and B 
 
Number of genes 
common to lists A and B 
Total number of genes in list A 
and B, not common to both 
lists 
Number of genes not 
expected to be common 
to lists A and B 
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determine the probability that an association between gene list and the 
canonical pathway occur by chance alone. 
4.2.3.2 Functional analysis 
Gene lists identified from RPA that met FDR cut-off of 5% and 2-fold change (up- 
and downregulated) were uploaded in Ingenuity Pathway Analysis software (IPA 
9.0; Ingenuity Systems;http://www.ingenuity.com). Fisher's exact test was used 
to calculate a p-value to determine the probability that each biological function 
assigned to that dataset can occurs by chance alone. 
4.2.4  Comparison of Microarray data with other studies 
performed in Theileria Lab at University of Glasgow  
Similar Microarray study has been conducted in Theileria Lab by Kinnaird et al 
(unpublished) to identify the gene set which are under direct control of a viable 
parasite showing reversion of TBL20 expression pattern upon treatment with 
theilericidal drug. In this experiment the parasite has been killed by 
buparvaquone (BW720c) (Datasets: BL20, TBL20 and buparvaquone treated BL20, 
TBL20). The gene set identified from BW20c experiment is of interest for 
comparison to my LPS dataset. Therefore, where necessary, this experimental 
dataset was superimposed and compared to my experimental datasets and is 
indicated in the subsequent analysis. 
4.2.5  Reverse-transcriptase polymerase chain reaction (RT- PCR)  
Microarrays evaluate thousands of genes in a single assay, but the data they 
produce may not always be reliable with respect to particular mRNAs expression, 
due to the diversity of experimental conditions and replicates involved in the 
hybridization process. Consequently an alternate methodology has to be used for 
validation of microarray results. Therefore, in this study semi-quantitative RT-
PCR and quantitative real time RT-PCR techniques were used to confirm the 
results for those genes showing greatest fold change across the experimental 
conditions. 
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4.2.5.1 Primers design and analysis 
The primers design software and methodology utilised in this study was same as 
described in chapter 3 (see section 3.2.10.1). Whenever possible, all primers 
were designed to the following criteria: Primers were all between 19-29bp long; 
the PCR product for all genes was between 159-346bp; for all genes the product 
spanned at least one intron to give differentially sized genomic and cDNA 
products. The melting temperature of the primer pairs were matched and were 
between 55 and 65ºC. Details of primer sequences, GenBank accession number, 
annealing temperature and product length for all gene-specific primers used in 
this study are listed in the Table 1.3, Appendix 1. 
4.2.5.2 House keeping genes 
In this study actin, beta (ACTβ) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were used as normalising genes. These constitutively expressed genes 
did not show significant changes on our array analysis and have been extensively 
used as normalizing genes in differential gene expression studies in bovine 
(Anstaett et al., 2010;Hruz et al., 2011;Sager et al., 1997). Amplification of 
ACTβ and GAPDH were used as positive controls for equal amounts of RNA across 
the samples.  
4.2.5.3 Total RNA samples utilised in RT-PCR assay 
Previously isolated and purified batch of total RNA samples used for the 
microarray experiment were utilised in subsequent RT-PCR assays for the 
validation of microarray results. Detailed methodology for RNA extraction and 
processing is described in chapter 3 (see section 3.2.8-9) whereas, reagents and 
kits used in the RNA extraction procedure are described separately in chapter2. 
4.2.5.4 Semi-quantitative Reverse-Transcription PCR (RT-PCR) 
Changes observed in the microarray results for differentially expressed top 
candidate genes were validated by semi-quantitative reverse-transcriptase 
polymerase chain reaction and gel electrophoresis analysis of the resultant PCR 
products. Semi-quantitative RT-PCR was conducted using Superscript III One-Step 
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RT-PCR kit from Invitrogen Corp (Cat no. 12574-026). Detailed methodology for 
semi-quantitative RT-PCR used in this study was same as outlined in chapter 3 
(see section 3.2.10.2) whereas, all PCR reagents and kits used in this study are 
described in chapter2.  
4.2.6  Quantitative Real-time Reverse-Transcription PCR (qRT-
PCR) 
With the advancement of PCR methodology, new technical developments 
refining its use have been developed. One of the powerful tools for analysing 
small scale gene expression is “real-time” PCR product quantification by 
fluorescence-kinetic detection methods. In this technique, PCR product is 
measured as it accumulates during sequential amplification cycles. The 
advantage of this method is that no post-PCR manipulation or product analysis is 
required since the quantitative measurement of the reaction product is known at 
the end of the cycling process. Therefore, in order to verify microarray results of 
differentially expressed genes in this study SYBR QRT-PCR methodology was 
utilized to quantify the mRNA expression of top candidate genes. 
4.2.6.1 SYBR Green I chemistry 
SYBR Green I is a fluorescent intercalating dye which binds to the double 
stranded DNA and generates a fluorescent signal upon binding. In qPCR, DNA 
product accumulates during amplification and fluorescent signal increases 
proportionally to the DNA concentration (Figure 4.3). When bound to double 
stranded DNA the dye absorbs light of 494nm and emits light wavelength 521nm, 
which makes it compatible with the use on any real-time thermo cycler.  
The SYBR Green methodology has several advantages, such as the ability to add 
melting point analysis to the run. This allows comparison of the melting 
temperatures of the specific product and any suspected non-specific products. 
However, there is a limitation that it detects all double stranded products, 
including primer-dimers, which may result in an overestimation of the target 
concentration, and false positive results in cases where the melting curve does 
not clearly discriminate between primer-dimer and specific amplified product. 
Therefore, several important steps were taken to ensure accurate results. cDNA 
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synthesis and qPCR were performed on purified DNase I treated RNA samples, no 
template controls and no reverse transcriptase control were always included in 
the PCR reactions for all samples. In case of primers design special care was 
taken to avoid primer-dimers formation, and secondary structures. Wherever 
possible, primers were designed to span introns to minimise the risk of potential 
contamination of genomic DNA. 
 
Figure 4.3:  Schematic diagram illustrating SYBR Green I Chemistry during PCR 
amplification 
SYBR Green I dye has a higher affinity for double-stranded DNA than single-stranded DNA or 
RNA. The SYBR Green I dye does not bind to the single-stranded RNA during denaturation and 
annealing stage and hence does not fluoresce. The cycle is repeated and the fluorescence is 
measured at the end of each extension reaction with the total amount of fluorescence being relative 
to the concentration of the amplified product. 
4.2.6.2 Two-step qRT-PCR 
In two-step qRT-PCR it is possible to store cDNA samples for later use in 
experiments at convenient conditions relative to the use of RNA for one step 
qRT-PCR. Although one-step qRT-PCR allows quantification in a single reaction 
which minimises the possibility of cross-contamination and provides a convenient 
system since less time and effort is involved. However, two-step qRT-PCR 
systems are generally considered to provide a somewhat higher sensitivity and 
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Molecules  
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to double-stranded DNA shows 
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3/ 
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specificity than one-step QRT-PCR systems (Bustin, 2000). Therefore in this study 
two step methodology of qRT-PCR was used to validate the expression of genes. 
The details protocols and steps involved are described in the following.  
4.2.6.2.1 Complementary DNA (cDNA) synthesis from total RNA 
The first step in any RT-PCR methodology is to generate cDNA by reverse 
transcription of template RNA.  First strand complementary DNA (cDNA) was 
reverse transcribed from 2.0µg of previously purified and DNase treated total 
RNA samples. cDNAs synthesis was carried out in a total volume of 20µl 
according to the manufacturer’s instructions using oligo(dT) primers provided 
with the Affinityscript QPCR cDNA synthesis kit (Stratagene, USA; Cat 
no. 600559). cDNA synthesis was carried out for 25°C for 5 min, 42°C for 25 min 
and 25°C for 5 min in a Techne thermocycler system (TC-512; Techne, UK). 
4.2.6.2.2 qRT-PCR reaction parameters 
Real-time fluorescence detection was achieved by using a Brilliant SYBR Green 
QPCR Master Mix buffer (Stratagene, 600548) which contains SYBR Green I dye, 
and Sure Start Taq DNA polymerase. The final concentration of primers was 
approximately 500nM in a total reaction volume of 25µl. Each 25µl of PCR 
reaction mix contained 10µl Nuclease-free PCR-grade water (including cDNA), 
1µl of forward primer, 1µl of reverse primer and 13µl of 2 × qPCR master mix 
buffer. Real time fluorescence detection was performed in 96-Well Semi-Skirted 
Flat Deck PCR Plates (Thermo Fisher Scientific). A Stratagene Mx3005P Real-
Time PCR System was used with the following thermal cycling parameters: 10 
min at 95°C (enzyme activation and initial denaturation); 40 cycles of 0.5min at 
95°C (denaturation), 0.5min of annealing at X °C and 0.5min at 72°C 
(extension). Fluorescence was measured at the end of the elongation phase 
(72°C) during each cycle of quantification. Where, X°C indicates corresponding 
annealing temperatures (Tm of primers minus 3°C) specific to different 
candidate genes tested. After 40 cycles of amplification, a melting curve 
analysis was carried out to verify the correct product by its specific melting 
temperature (Tm). The thermal profile for melting curve analysis consisted of an 
additional denaturation cycle for 1 min at 95°C, lowered to 55°C for 0.5min and 
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a gradient to 95°C with continuous fluorescence readings. All qPCR data was 
captured and analysed by Stratagene MxPro v4.10 software.  
Additionally, standard curves for all primer set were run over 4-fold dilutions of 
the cDNA samples from 1:10-1:1000. Where necessary, the efficiency of the 
qPCR assay was determined by generating a set of standard curves for each 
primer pair. In most of the cases primer set generated a standard curve with an 
efficiency of 85-110 and an Rsq of 0.98-1.00, over the range of experimental 
sample dilutions. Rsq value is an indicator of the quality of the fit of all data to 
the standard curve plot, where 1 corresponds to perfect alignment and the 
closer the value is to 1, the better the fit of the line. In some cases despite 
several attempts being made to optimise the PCR this was not achievable. 
However, Standard curves were assessed for all qPCR reactions and their 
efficiencies applied to the quantitation algorithm for that experiment. Every 
plate for all experimental samples contained technical replicates of each cDNA 
sample, no-template controls with PCR grade water instead of cDNA templates 
and No RT control templates.  
4.2.6.2.3 Statistical analysis 
Real-time RT-PCR data were captured and analyzed using Stratagene MxPro 
v4.10 software (Strategene). The relative quantity values were normalized to 
the house keeping gene, which was either β-actin or GAPDH and fold changes 
were calculated relative to the calibrator (DMSO-treated uninfected BL20 cells) 
using -2-∆∆Ct equation (Livak and Schmittgen, 2001). All normalised Ct values of 
the sample quantity relative to normaliser gene and log2 fold change of the 
samples relative to the calibrator calculated by MxPro software were exported 
as a text file for further analysis. Statistical analysis and generation of graphs 
presented were performed using a two-tailed Student’s t-test with GraphPad 
Prism Software version 5.0 (La Jolla, CA). The difference was considered to be 
significant if the p-value was ≤ 0.05. 
4.2.7  Indirect immunofluorescence analysis 
Indirect immunofluorescence analysis of BL20 cells and TBL20 cells was 
performed essentially using the same protocol described in chapter 3 (see 
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section 3.2.4). Following cytospin preparations, fixation protocol was carried out 
immediately in pre-chilled methanol at -20oC incubated for 10min. Slides were 
then washed briefly with 1x PBS and incubated with acetone in ice-cold (-20oC) 
for 1min and washed three times with 1x PBS for 3min each. Immunodetection of 
LMO2 was acquired by incubation of fixed cells with monoclonal anti-LMO2 (1A9-
3B11) (NB110-78626) (Novus Biologicals, USA) as primary antibody at a dilution of 
1/100 in a complete medium for 1h at room temperature (RT). Cells were then 
washed three times with PBS for 3min each. Alexa Fluor 488 goat anti-mouse IgG 
(Invitrogen; A-11029) was used as secondary antibody at a dilution of 1/200 and 
incubated for 1h at RT. Following incubation of cells with antibodies slides were 
finally washed three times in 1× PBS for 3min each. After the final wash, cells 
were counter-stained with 0.1% Evan’s blue for 1min, rinsed in 1×PBS three 
times and allowed to dry. Slides were then mounted in 10μl of mounting medium 
containing DABCO/glycerol, 4, 6-diamindino-2-phenylindole (DAPI) at 1mg/ml 
and phenydiamine at 1mg/ml and a cover slip. Immunofluorescence images were 
acquired using an Olympus BX60 microscope, a SPOT camera and SPOTTM 
Advanced image software Version Mac: 4.6.1.26 (Diagnostic Instruments, Inc). 
4.2.8  Western Blotting 
Sample preparation of whole extracts, SDS gel electrophoresis and 
immunoblotting was carried out as described previously in chapter 3 (see 
3.2.11). Following electroblotting of the sample extracts onto membrane and 
Ponceau stain assessment, immunodetection was carried out by washing the 
membrane briefly with a wash buffer (1xTris-saline with 0.1% Tween 20) and 
then pre-incubated with block buffer for 1h at room temperature with gentle 
agitation. Blots were incubated with the following antibodies/reagent:  
monoclonal mouse anti-LMO2 (LMO2 Antibody; 1:2000; Novus NB110-78626; 
Novus Biologicals, Littleton, CO, USA), monoclonal mouse anti-Tubulin (TUB-1A2; 
1:5000; Sigma T9028), polyclonal rabbit anti-VCAM1(sc- 8304, 1:1000; Santa 
Cruz-Biotechnology) were diluted in fresh block buffer (5% Marvel skimmed milk 
in Tris buffered saline plus 0.1% Tween 20) overnight at 4°C with constant gentle 
agitation. The membrane was washed twice briefly then twice for 15min each 
with wash buffer. The membranes were incubated with appropriate secondary 
antibodies; goat-anti-rabbit-HRP (1:10000, Sigma, A6154) or anti-mouse IgG 
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peroxidase conjugate (1:10000, Sigma, A5906) diluted in block buffer for 1h at 
room temperature. The membranes were washed as above with a final brief 
wash with 1x Tris-saline without Tween 20. Detection was carried out using a 
SuperSignal® West Pico Chemiluminescent Substrate kit (Pierce, supplied by 
Thermo Scientific, Rockford, IL). The blots were immediately exposed to X-ray 
film to capture the chemiluminescent signal. Several exposures were made to 
achieve the optimal signal for each antibody. The molecular weight of proteins 
was determined by comparison with Precision Plus ProteinTM Standard dual colour 
marker (Bio-Rad Laboratories; 161-0374). Complete details of reagents and 
buffers used in western blotting are described separately in chapter 2. 
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4.3 Results 
4.3.1  Microarray analysis of LPS stimulated BL20 and TBL20 cell 
lines 
Gene expression profiling was performed by employment of a microarray 
representing the entire available bovine RNA REFSEQ database (26,751 
sequences) and all T. annulata predicted mRNA open reading frames (3769 
sequences). RNA was isolated from three replicate cultures of TBL20 and BL20 
(DMSO) control cells and cultures treated with LPS for 4 hr and 18 hr. 
4.3.2  Identification of differentially expressed genes  
Following array hybridisation of each RNA sample in triplicate, differential gene 
expression on the normalised dataset provided by Roche/Nimblegen was initially 
assessed by pairwise comparisons using Ranked Product Analysis (RPA). This 
analysis allows a cut-off for significance of differential gene expression values to 
be set according to a false discovery rate (FDR) and fold change. In this study, 
differences in gene expression were taken to be statistically significant at ≥ 2 
fold change with a FDR<0.05, a standard cut off for statistical significance 
commonly applied to microarray data (Benjamini and Hochberg, 1995;Jensen et 
al., 2006b). Data analysis was also conducted using the Student’s T-test (≥ 2 
fold, F test Anova P-value <0.05) in the ArrayStar v2.1 software suite and the 
results of both analysis validated by cross comparison of the obtained datasets. 
The use of ArrayStar software also allowed enhanced visualisation of the data 
using scatter plot analysis, K-means clustering and heat maps with hierarchical 
clustering. 
4.3.2.1 Rank product analysis of various microarray comparisons 
Rank product analysis (see section 4.2.1.7.1) was used for the identification of 
genes that were up or down-regulated in Theileria infected and LPS stimulated 
uninfected cells. The descriptive statistics of this analysis is shown in Table 4.2. 
While the proportion of probe sets representing up or down-regulated genes is 
shown in Figure 4.4. Applying cut-off criteria of FC ≥ 2, FDR< 0.05, a total of 
3643 genes were altered by LPS stimulation of BL20 cells (BL20-LPS dataset). 
Chapter 4                                                                                                                                        127    
There were ~ 12.3% more up-regulated genes than down-regulated genes in LPS 
stimulated dataset. The highest fold change in hybridization value in the dataset 
of BL20-LPS up-regulated genes was recorded for myxovirus (influenza virus) 
resistance 2 (MX2) which was elevated 100 fold, while the most down-regulated 
gene was aquaporin 3 (AQP3) showing reduction of 39.3 fold. 
Table  4.2:  Descriptive statistics of microarray data analysis for all pair wise comparisons  
Comparison Largest Fold 
Change 
(Absolute) 
No of Up-
regulated 
genes 
No of Down-
regulated 
genes 
Total No 
of gene 
Up Down 
BL20 LPS  4h vs BL20 272.5 37.4 887 989 1876 
BL20 LPS 18h vs BL20 100.5 39.2 1691 1082 2773 
Composite BL20 LPS 
response vs BL20 
100.5 39.2 2045 1598 3643 
TBL20 vs BL20 618 367.6 810 2145 2955 
TBL20 LPS  4h vs TBL20 6.16 6.4 153  70 223 
TBL20 LPS 18h vs TBL20 45.9 3.1 293 31 324 
Composite TBL20 LPS 
response vs TBL20 
45.9 6.4 369 98 467 
Genes that were altered at a fold change of ≥ 2 and FDR < 0.05 across all experimental conditions 
were considered as statistically significant and were selected for further analysis. Comparisons 
highlighted in grey represent the datasets that were subsequently used in further analysis. The 
composite datasets were generated from LPS stimulated datasets at to two different time points, 
where maximal fold change was taken in account at either time points.  
 
Figure 4.4: Pie chart showing the percentage of probe sets displaying evidence of altered 
expression values on pairwise comparison of TBL20 Vs BL20 and BL20-LPS Vs BL20 
FDR<0.05 and FC ≥ 2.  
The array contained 30656 probe sets, each representing a putative bovine gene. The percentage 
of probe sets displaying evidence of elevated expression in TBL20 and BL20-LPS are denoted by 
the red slice of the pie chart, while the green slice indicates probe sets with evidence of reduced 
expression. 
5% 6% 2% 6% 
A: Infection response genes 
TBL20 Vs BL20  
A: LPS response genes 
BL20 LPS Vs BL20  
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A large number of bovine genes (2955) also showed significant alteration in 
expression levels associated with infection of BL20 cells by T. annulata (TBL20-
infection associated dataset (TBL20 vs BL20). However, in contrast to the BL20-
LPS dataset, 45% more genes were identified as down-regulated genes relative to 
those displaying evidence of up-regulation. In this dataset the highest fold 
change for an up-regulated gene was 618-fold, detected for a predicted gene 
similar to KIAA1598 protein (KIAA1598); while in the  down-regulated dataset an 
unannotated Clone (CB467496), currently matching a bovine EST sequence  
exhibited 367.6 fold drop in expression value in TBL20 relative to uninfected 
BL20. 
In a third pairwise comparison (TBL20 vs TBL20 LPS), the number of genes that 
showed evidence of significant alteration to expression following LPS stimulation 
of TBL20 cells (TBL20-LPS dataset) was obtained. Interestingly this dataset 
contained a significantly lower number of genes (467) relative to that obtained 
for uninfected BL20-LPS. This result indicates, as predicted from previous 
experiments (see Chapter 3) that infected TBL20 cells are significantly less 
responsive to stimulation by LPS, than the uninfected BL20 counterpart. 
4.3.2.2 Comparative microarray analysis of the BL20-LPS and parasite 
infection associated (TBL20) datasets 
In order to reveal the genes that are commonly regulated in parasite associated 
infection and LPS stimulated dataset, overlapping of the two datasets was 
performed by Excel based sorting and Venn diagram. A total of 2955 genes for 
parasite response genes set in TBL20 cells (dataset A) and 3,643 genes for LPS 
response genes set in BL20 (dataset B) were obtained from microarray analysis. 
Comparison of the BL20-LPS dataset and the TBL20 dataset generated an overlap 
of 1,296 genes (see Figure 4.5). To identify the statistical significance of the 
overlap, Monte Carlo (MC) simulation was used to measure the probability of the 
overlap of differentially expressed genes varying from the number expected by 
chance. In each simulation, the gene list for each condition was permutated and 
the random overlap between gene lists was recorded. From MC simulation, 369 
genes were expected to be common between the two datasets and from 
observed analysis, 1296 genes were found to be common.  
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Finally after estimating the expected random overlap from MC, the empirical P-
value was determined by Chi square analysis which estimated the probability 
that was significantly (P<0.001) greater than could have occurred by chance. The 
summary of the equation used to estimate the significance of the overlap is also 
described in Figure 4.5. 
 
Figure 4.5:  Comparison of differentially expressed gene sets using Venn diagram  
The generated lists of significant genes (FDR<5%, FC ≥ 2) from each experimental condition 
contained a modulated set of 1,296 genes common to parasite infection and LPS treatment of 
uninfected cells. The identified overlap between two datasets was found to be highly significant 
(P<0.001). Whereas summary of observations obtained from Monte Carlo simulation and chi 
square analysis are also shown. 
4.3.2.3 Identification of LPS stimulated gene expression profiles in BL20 
cells with evidence of modulation in parasite infected TBL20. 
To determine whether infection with T. annulata results in modulation of gene 
expression changes that occur in uninfected cells in response to LPS stimulation, 
the BL20-LPS and TBL20 datasets were compared. A subset of genes was 
identified representing BL20-LPS response genes that showed evidence of 
modulation by parasite infection. This subset was then reduced by removal of 
the relatively small number of genes that displayed an expression value in the 
Summary of Monte Carlo and Chi-square analysis 
 
  (P < 0.001) 
3643 
LPS response genes 
(BL20) 
2955 
Infection response 
genes (TBL20) 
Number of genes expected to be 
common to lists A and B (470) 
Number of genes common to lists A 
and B (1,296) 
Number of genes not expected to be 
common to lists A and B  (5,658) 
Total number of genes in list A and 
B, not common to both lists (4,006) 
 
Overlapping gene set n = 1,296   (p<0.001, highly significant) 
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context of TBL20-LPS that was not significantly different from BL-20-LPS (146 
genes). The final dataset (TBL20-M-LPS) representing infection associated 
modulation of BL20-LPS stimulated expression consisted of 1,959 genes (see 
Figure 4.6).  Of the 1,959 genes, 269 were found to be elevated to a greater 
level in infected TBL20 cells relative to BL20-LPS cells, while for genes repressed 
in TBL20 cells relative to BL20-LPS the number was considerably higher (1,690). 
A more detailed analysis of the modulated gene expression associated with 
infection relative to LPS stimulation was then conducted by expression profiling 
the 1,959 genes. This was achieved by sequential pairwise comparisons across all 
six cellular conditions and partitioning of genes with a similar kinetic profile 
(e.g. down in BL20-LPS Vs BL20; up in TBL20 Vs BL20-LPS and no change (NC) in 
TBL20 Vs TBL20-LPS) and representation of each profile in graphical form. In 
addition, information (obtained in an independent study; Kinnaird et al. 
unpublished) on the response of host cell gene expression following treatment of 
TBL20 with BW720c to kill the parasite was superimposed on to the profile 
datasets. This indicated whether target genes of interest were likely to be under 
direct control of parasite infection and operated in the predicted manner (i.e. 
reversed an infection-associated modulation). Eight gene clusters with distinct 
infection associated modulated BL20 LPS profiles were obtained; and for all 
eight profiles > 95% of the genes showed no significant change (NC) in expression 
in TBL20 cells stimulated with LPS. 
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Figure 4.6:  Hierarchical clustering of gene set modulated by Theileria infection   
Visualization of changes in gene expression level of 1,959 genes identified by microarray analysis, 
showing modulated expression in Theileria infection. Hierarchical clustering was performed on 
modulated dataset and the results are shown as a heat-map. Each horizontal row represents an 
individual gene, where colour is used to represent arbitrary gene expression level based on log 
intensity values (see colour scale at the bottom): blue (low), yellow (intermediate), red (high).  
Cell line     BL20        BL20        BL20         TBL20       TBL20      TBL20 
Treatment   LPS           LPS            -                 -             LPS           LPS 
Time           18h            4h                                              4h           18h 
  
  +15.2(High) 
 
 
Expression (log2) 
 
+3.8 (Low) 
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4.3.2.4 Validation of house-keeping genes for quantitative real-time PCR 
expression analysis 
To normalise qRT-PCR data it is important to select one or more reference genes 
with stable expression. Use of a valid normalising gene helps in correcting non-
specific variation, such as differences in RNA or cDNA quantity and quantity 
which can affect the efficiency of the PCR reaction. Several reports have been 
published regarding variation in apparently stable reference genes (Schmittgen 
and Zakrajsek, 2000;Selvey et al., 2001). In addition, it has been demonstrated 
that errors of up to 20-fold can be generated through normalization to a single 
house keeping gene (Vandesompele et al., 2002). Consequently, normalisation to 
a single reference gene is thought to be insufficient and it is recommended that 
potential reference genes are validated for stability across the experimental 
conditions. In this study normalisation of RT-PCR data was carried out against 
actin, beta (ACTβ) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
These constitutively expressed genes did not show significant changes on my 
array analysis and have been extensively used as a normalizing gene in 
differential gene expression studies in the bovine (Anstaett et al., 2010;Hruz et 
al., 2011;Sager et al., 1997). These genes were used to calculate a composite 
normalisation factor for analysis in qRT-PCR analysis. Figure 4.7 shows that 
mRNA expression of ACTβ was not changed when normalised against GAPDH and 
the same was true for vice versa. 
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Figure 4.7:  Microarray and qRT-PCR results of reference genes  
Consistency of the average expression levels of house keeping genes across different 
experimental conditions is shown. (A) Microarray results of mRNA expression showing average 
hybridisation values (Log2) of ACTB and GAPDH. Error bars indicate standard deviations obtained 
for six replicates from each cell lines. (B) qRT-PCR validation of changes in ACTB expression 
normalised against GAPDH. As predicted, these genes are constitutively expressed, and there was 
no significant gene expression difference between the groups for ACTB when normalised against 
GAPDH or vice versa. The lines for each bar on the graph represent the range in the relative 
expression and no statistical significance was obtained in the expression by using Student’s t-test. 
4.3.2.5 Expression profiles of genes modulated in parasite infected TBL20 
Vs LPS stimulated uninfected BL20 (BL20-LPS) 
Profile 1: Profile 1 is comprised of 44 genes whose expression was significantly 
enhanced (≥ 2 fold change, FDR < 5 %) in infected cells relative to an amplified 
uninfected BL20-LPS response (See Figure 4.8). The top 20 genes (based on 
highest fold expression difference between TBL20 Vs BL20 LPS) of the profile are 
listed in Table 4.3 and the full gene list for this profile is given in the Appendix 
2.1.1). 
A 
B 
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Figure 4.8:  Graphical display of profile 1 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
All candidate genes from profile 1 (n = 44) whose expression is elevated in both LPS stimulated 
BL20 and TBL20 cells, whereas TBL20 exhibit enhanced elevation relative to BL20-LPS. The x-
axis corresponds to the experimental conditions, the y-axis to expression values (log2) from array 
data. Each line represents an individual gene. 
Table 4.3:  Top 20 candidate genes of profile 1 showing pattern of modulated response in 
TBL20 cells relative LPS response in BL20 cells. 
 
Summary of top 20 candidate genes whose expression was significantly altered (FDR<5%, FC≥ 2) 
in Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 4h/or18) 
relative to control cells. Data is arranged in descending order of absolute fold difference between 
BL20-LPS and TBL20. Genes highlighted in light blue indicates Bw720c response previously 
identified in an independent microarray experiment (Kinnaird et al; unpublished). Gene symbols in 
bold indicate most recent annotation of the genes identified from NCBI. 
Gene 
Symbol 
Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
48h 
   
   
 
SLAMF7 Similar to 19A protein (CD319) (LOC790164) 0.000 2.8 415.38 148 – 
LRRTM4 Similar to GFHL3075, transcript variant 3 
(LOC521137) 
0.000 3.6 242.65 67.93 – 
----- CO876689 BovGen_05014 normal cattle 
brain Bos taurus cDNA clone 
0.007 2.0 114.17 55.85 – 
MMP13 Matrix metallopeptidase 13 (collagenase 3) 0.001 3.1 168.24 54.2  
XCL1 Chemokine (C motif) ligand 1 0.000 8.5 356.63 42  
WC1 Similar to BoWC1.1 (LOC783109) 0.004 2.4 93.91 39.63 – 
TP73 Similar to P73 alpha protein (LOC515105) 0.002 2.7 53.59 20.04 – 
LOC788785 Similar to ATXN1 protein 0.001 2.9 42.99 15 – 
SH3BGRL2 SH3 domain binding glutamic acid-rich 
protein like 2 
0.000 3.2 44.97 14.01 – 
IL2RB Similar to IL2RB (LOC510185) 0.000 8.3 93.15 11.16 – 
CD122 Similar to Interleukin-2 receptor subunit beta 
precursor (IL-2 receptor) (P70-75) (High 
affinity IL-2 receptor subunit beta) (CD122 
antigen) 
0.000 4.5 45.48 10.03 – 
SELL selectin L (lymphocyte adhesion molecule 1) 0.008 2.2 21.43 9.561  
LOC786204 Similar to chemokine CCL1/I-309  0.000 3.0 27.12 9.16  
MEIS3 Similar to Homeobox protein Meis3 (Meis1-
related protein 2) (LOC617311) 
0.000 8.3 71.00 8.521  
LOC785733 Similar to BoWC1.1 (LOC785733) 0.021 2.1 16.43 7.77 – 
LOC786443 Hypothetical protein  0.000 14.4 92.29 6.403 – 
ICAM1 Intercellular adhesion molecule 1(CD54) 0.000 3.8 22.81 6.029 – 
LOC788239 Similar to regulator of G-protein signaling 
16/-r 
0.025 2.0 9.63 4.743 – 
PGPEP1 Pyroglutamyl-peptidase I  0.000 4.8 22.43 4.709 – 
LOC785427 Similar to epidermis-specific serine protease-
like protein 
0.000 4.7 22.10 4.662  
 
Chapter 4                                                                                                                                        135    
For many of the genes in profile 1 the amplitude of enhanced expression 
associated with infection was considerable. Thus, mRNA expression levels of the 
SLAMF7 gene, a member of the immunoglobulin gene super family, is highly 
elevated in TBL20 cells with an absolute fold change of 148; followed by genes 
encoding MMP13, chemokine (C motif) ligand 1 and IL2RB which showed 
respective elevated responses of 54.2, 42 and 11.1 fold relative to the maximal 
BL20-LPS response (Table 4.3). A further 14 genes of this profile also displayed 
an elevation of greater than 5 fold. Of the 16 BW720c sensitive genes identified, 
10 (62.5 %) responded in a predictive manner, i.e. expression was significantly 
reduced by treatment over 48 hours. 
To determine any insight into potential biological relevance of the parasite 
associated modulation of LPS stimulated gene expression, the dataset for each 
profile was subjected to ingenuity pathway analysis software for enrichment of 
predicted molecular and cellular functions. Functional prediction (using data 
obtained from the bovine REFSEQ and NCBI databases) that may provide insight 
for the infection-associated modulation event was also utilised.  For profile 1 the 
two most significant predicted functional groups were molecules involved in 
control of cellular movement and cell-to-cell signalling and an association with 
inflammation was identified. In addition, a number of genes in profile 1 show 
similarity with alterations that have been linked to the phenotype of Theileria 
transformed leukocytes. Thus, elevated expression of a matrix metallopeptidase 
gene (MMP13), the IL2 receptor B gene (IL2RB), genes encoding cellular adhesion 
molecules (ICAM1 and SELL) and genes that regulate the cytoskeleton (SDC4 and 
CTTN) were detected. 
For profile validation, 3 to 9 genes were selected for semi-quantitative RT-PCR. 
Selection was based on amplitude of infection-associated modulation and/or 
bioinformatic functional prediction (using data obtained from the bovine REFSEQ 
and NCBI databases) that could provide possible insight for the infection-
associated modulation event. Two validated genes with a predicted function of 
interest were then selected for each profile to compare the kinetics and 
amplitude of modulation obtained by micro-array analysis relative to the results 
of qRT-PCR. Semi-quantitative RT-PCR was performed for 8 genes of profile 1, 
all of which validated the microarray profile (see Figure 4.9); the gene encoding 
the Meis3 transcription factor, for example, showed a clear elevation in PCR 
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product in LPS-stimulated uninfected BL20 cells but was significantly enhanced 
in infected TBL20, with no obvious detectable alteration of product levels 
following LPS stimulation of TBL20. Furthermore, the RT-PCR profile for these 
genes following BW720c drug treatment of TBL20 validated the microarray 
expression profile obtained independently by Dr. Jane Kinnaird. Further 
validation of profile 1 was obtained by performing qRT-PCR for the Cortactin and 
Meis homeobox 3 genes. The results showed correlation between the microarray 
and qRT-PCR data, with qRT-PCR giving a 5.98 fold elevation (log2) in expression 
level of MEIS3 in TBL20 relative to BL20-LPS compared to a difference of 3.1 fold 
(log2) generated by the array data; while correlation of the profile was even 
stronger for Cortactin gene, as qRT-PCR calculated the difference to be 1.31 fold 
(log2) relative to the 1.18 fold (log2) computed from the array data. 
 
Figure 4.9:  Validation of microarray results for profile 1 
A. Semi-quantitative RT-PCR results showing mRNA expression of 8 candidate genes (XCL1, 
MMP13, MEIS3, CTTN, IL2RB, SELL, ICAM1 and SLC6A6) in BL20 cells and TBL20 cells either 
stimulated or un-stimulated with LPS. Semi-quantitative PCR products obtained using the gene 
specific primers were resolved on 1% agarose gel, whereas ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in MEIS3 mRNA expression.  
C. Real-time qRT-PCR validation changes in CTTN mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, *P< 0.01).The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
A 
B 
C 
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Profile 2 
Profile 2 represents genes elevated by LPS stimulation of uninfected cells that 
are significantly repressed in infected TBL20, with 98 % showing no significant 
change following stimulation of TBL20 with LPS. This profile generated one of 
the larger datasets and contained 254 genes (Figure 4.10). The top 20 genes of 
the profile, absolute fold change in expression, response to BW720c and 
functional prediction are presented in Table 4.4 whereas full list of gene is 
presented in Appendix 2.1.2. 
 
Figure 4.10: Graphical display of profile 2 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 2 (n = 254) whose expression is elevated in BL20-LPS but 
significantly repressed in TBL20 cells; this repression was even greater in TBL20 when compared 
to BL20-LPS. The x-axis corresponds to the experimental conditions, the y-axis to expression 
values (log2) from array data. Each line represents an individual gene. 
Almost all of the 116 genes that were sensitive to BW720c treatment responded 
in the predicted manner (i.e. 98.2 % showed elevated expression with bpq 
treatment), indicating active repression by a viable parasite. Many genes showed 
a combined (up in BL20-LPS x down in TBL20-infection associated) absolute fold 
change >10 fold (128 genes). Genes of interest with major differences in 
expression values between TBL20 Vs BL20-LPS include MPEG1 (449.4 fold 
difference), CLU (280 fold), CD200 (132 fold), BOLA-DYA (132 fold), IL15 (107 
fold), STAP1 (43 fold), and IJG (58 fold). IPA analysis showed enrichment for 
genes predicted to function in cell to cell signalling, cell morphology, cellular 
development and cellular growth and proliferation. A significant number of 
genes were associated with cancer and included molecules associated with 
apoptosis. 
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Table 4.4:   Top 20 genes of profile 2 showing repression in TBL20 cells relative to an 
elevated LPS response in BL20 cells. 
 
20 genes from the profile whose expression was significantly altered (FDR<5%, FC ≥ 2) in 
Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 4h/or18) 
relative to control cells. Data is arranged in descending order of absolute fold difference between 
BL20-LPS and TBL20. Genes highlighted in light blue shows Bw720c response previously 
identified in an independent microarray experiment (Kinnaird et al; unpublished). Gene symbols in 
bold indicate most recent annotation of the genes identified from NCBI. 
The profile was validated for 7 genes by semi-quantitative RT-PCR (Figure 
4.11A). The gene encoding MPEG1, for example, showed an elevation in PCR 
product in LPS-stimulated uninfected BL20 cells while the relative level of 
product was clearly repressed in infected TBL20, and this repression was 
reversed upon treatment of TBL20 with BW720c. Similar results were obtained 
for STAP-1, IGJ and BOLA-DYA. Additionally, qRT-PCR validation was performed 
for the BOLA-DYA and BIRC3 genes (Figure 4.11B and C). The qRT-PCR assay 
validated the micro-array profile, giving a 11.33 fold difference (log2) in 
expression level of BOLA-DYA in TBL20 relative to BL20-LPS compared to a 
difference of 7.16 fold (log2) generated by the array data; while qRT-PCR 
calculated the difference for BIRC3 to be 7.14 fold (log2) relative to the 4.69 
fold (log2) computed from the array data. 
Gene 
Symbol 
Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
48h 
      
 
MPEG1 Macrophage expressed gene 1 0.000 79.8 -5.63 -449.4  
CLU Clusterin 0.000 8.9 -31.71 -280.7 – 
------- CO882151 BovGen_10476 normal cattle 
brain cDNA clone RZPDp1056F0925Q 5', 
mRNA sequence 
0.000 46.8 -3.98 -186.2 – 
------- Clone tghc9907 immunoglobulin gamma 1 
heavy chain constant region mRNA 
0.000 49.0 -3.62 -177.4 – 
CD200R CD200 Receptor( LOC529709) 0.000 5.2 -25.41 -132.8  
BOLA-DYA Major histocompatibility complex, class II, DY 
alpha 
0.000 27.4 -4.82 -132.1  
EPHA7 Eph receptor A7  0.000 4.6 -26.04 -120.1 – 
LOC789139 Similar to IGLV3S1 0.000 7.4 -16.30 -119.8  
SMARCA1 Hypothetical (LOC535439) 0.000 3.4 -33.93 -115.3  
IL15 Interleukin 15 0.000 5.7 -18.88 -107.3 – 
-------- N-acetylgalactosaminyltransferase A blood 
gro-like 
0.000 2.8 -35.45 -99.96 – 
------- CO894237 BovGen_22562 normal cattle 
brain cDNA clone RZPDp1056O1038Q 5' 
0.000 21.4 -4.61 -98.7 – 
-------- CO874773 BovGen_03098 normal cattle 
brain cDNA clone RZPDp1056C1255Q 3' 
0.000 8.2 -11.46 -94.19 – 
-------- CO894397 BovGen_22722 normal cattle 
brain cDNA clone RZPDp1056H2051Q 5' 
0.000 6.7 -12.71 -85.28  
BTN3A2 Butyrophilin, subfamily 3, member A2 0.000 6.5 -12.79 -82.84  
TNXB Tenascin XB 0.000 6.6 -11.85 -78.05 – 
LOC515679 Similar to putative protein product of 
HMFN0672 
0.017 2.0 -32.39 -65.13  
THBS1 Thrombospondin 1 0.000 2.5 -25.72 -65.01 – 
RGS18 Similar to regulator of G-protein signaling 13, 
transcript variant 2 (LOC613624) 
0.000 29.2 -2.16 -63.29 – 
IGJ Immunoglobulin J chain 0.001 2.9 -20.28 -58.06  
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Figure 4.11: Validation of microarray results for profile 2 
A. Semi-quantitative RT-PCR results showing mRNA expression of 7 candidate genes (CLU, IL15, 
STAP1, IGJ, MPEG1, BOLA-DYA, BIRC3) in BL20 cells and TBL20 cells either stimulated or un-
stimulated with LPS. Semi-quantitative PCR products obtained using the gene specific primers 
were resolved on 1% agarose gel, whereas; ACTB was used as an internal control. B. Real-
time qRT-PCR validation changes in BOLA-DYA mRNA expression. C. Real-time qRT-PCR 
validation changes in BIRC3 mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, * P< 0.01).The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
Profile 3 
Profile 3 represents 55 genes that are elevated by LPS stimulation of BL20 and by 
Theileria infection relative to control BL20 cells, but for these genes elevation in 
TBL20 was significantly less than BL20-LPS (Figure 4.12). No significant alteration 
occurred in TBL20-LPS for 96% of the dataset. The top 20 candidate genes of this 
profile are represented in Table 4.5, while a full list of 55 genes is presented in 
Appendix 2.1.3. An example of this profile is the gene for interferon induced 
protein 15, ISG15: elevated 121 fold in BL20-LPS but only 26 fold by infection 
(TBL20-IA) and no change in TBL20-LPS. These kinetics match the profile of 
expression previously obtained by northern blotting (Oura et al., 2006). Of the 
25 bpq responsive genes in profile 320 (80 %) were elevated upon treatment, 
indicating repression by a viable parasite. 
B 
C 
A 
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Figure 4.12: Graphical display of profile 3 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 3 (n = 55) whose expression is elevated in both LPS 
stimulated BL20 and TBL20 cells, whereas there is significant repression in TBL20 when 
compared to BL20-LPS. The x-axis corresponds to the experimental conditions, the y-axis to 
expression values (log2) from array data. Each line represents an individual gene. 
Table 4.5:  Top 20 genes of profile 3 showing repression in TBL20 cells relative to LPS 
response in BL20 cells. 
 
20 genes whose expression was significantly altered (FDR<5%, FC ≥ 2) in Theileria infected or 
LPS stimulated uninfected BL20 cells (maximal LPS response at 4h/or18) relative to control cells. 
Data is arranged in descending order of absolute fold difference between BL20-LPS and TBL20. 
Genes highlighted in light blue shows Bw720c response previously identified in an independent 
microarray experiment (Kinnaird et al; unpublished). Gene symbols in bold indicate most recent 
annotation of the genes identified from NCBI. 
Gene Symbol Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  Vs 
BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
48h 
      
 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 0.000 125.9 3.93 -32.07  
CD83 CD83 molecule  0.000 57.1 2.07 -27.51 – 
CXCL10 Chemokine (C-X-C motif) ligand 10 0.000 272.5 11.23 -24.25  
LOC789736 Hypothetical protein LOC789736  0.000 38.2 2.88 -13.27  
----- CB457261 714599 MARC 6BOV Bos taurus 
cDNA 5' 
0.000 37.1 3.35 -11.08  
RELB Similar to I-REL (LOC522670) 0.000 27.2 2.54 -10.74 – 
LOC788393 Hypothetical protein LOC788393  0.000 36.9 3.68 -10.04  
TNFAIP3 Hypothetical LOC508105 (LOC508105) 0.000 57.1 6.60 -8.649 – 
TGFBR3 Similar to transforming growth factor, beta 
receptor III (betaglycan, 300kDa)  
0.000 37.0 4.48 -8.275  
CX3CR1 Chemokine (C-X3-C motif) receptor 1  0.000 48.5 5.93 -8.182  
LOC783896 Similar to TRAF-interacting protein with a 
forkhead-associated domain  
0.000 31.9 4.09 -7.809 – 
LOC789731 Hypothetical protein LOC789731  0.000 29.1 3.91 -7.428  
TIFA Hypothetical protein LOC783855  0.000 34.8 4.96 -7.025 – 
CD69 CD69 molecule 0.000 37.7 5.75 -6.56  
ZBP1   Z-DNA binding protein 1(LOC508333) 0.000 46.3 7.38 -6.273  
DDX58 Similar to DEAD/H (Asp-Glu-Ala-Asp/His) 
box polypeptide RIG-I, transcript variant 1 
(LOC504760)  
0.000 13.9 2.23 -6.243 – 
USP18 Ubiquitin specific peptidase 18 0.000 21.5 3.74 -5.739 – 
----- AJ819856 AJ819856 KN206 Bos sp. cDNA 
clone C0006016l04 
0.000 13.9 2.45 -5.664 – 
---- DV934772 LB0308.CR_E16 GC_BGC-30 
Bos taurus cDNA clone IMAGE:8135034 5' 
0.000 39.3 7.13 -5.507 – 
BCL2L11 BCL2-like 11 (apoptosis facilitator)  0.000 14.7 2.81 -5.224  
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IPA analysis showed enrichment for genes predicted to function in protein 
modification, the antimicrobial response and the inflammatory response. 
Indeed, the top candidate gene in this profile is annotated as OAS2 (elevated 
125.9 fold in BL20-LPS Vs BL20 but only 3.93 fold up in TBL20 Vs BL20) that 
encodes an essential protein involved in the innate immune response to viral 
infection. The dataset also contains additional genes predicted to function in 
cellular defence/innate immune response (e.g. ISG15, MX2, IRF5 and IL7) and 
genes associated with transcription factors activated by Theileria infection 
(NFκB2, NFκBIZ and Jun). 
5 genes in the cluster were validated by semi quantitative RT-PCR (see (Figure 
4.13A) and showed the expected profile of lower expression in TBL20 relative to 
the peak in BL20-LPS. Similarly Figure 4.13 B and 4.13 C show the qRT-PCR 
results for the CD69 and ISG15 genes respectively, validating the micro-array 
profile. A 3.37 fold (log2) reduction in expression being computed for CD69 in 
TBL20 relative to BL20-LPS compared to a difference of 2.6 fold (log2) generated 
by the array data; while qRT-PCR calculated the modulation for ISG15 to be 2.67 
fold (log2) for TBL20 Vs BL20-LPS, compared to 2.21 fold (log2) from the array 
data.
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Figure 4.13: Validation of microarray results for profile 3 
A. Semi-quantitative RT-PCR results showing mRNA expression of 5 candidate genes (CD69, 
ISG15, CXCL10, MX2, CX3CR1) in BL20 cells and TBL20 cells either stimulated or un-stimulated 
with LPS. Semi-quantitative PCR products obtained using the gene specific primers were resolved 
on 1% agarose gel. Whereas, ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in ISG15 mRNA expression.  
C. Real-time qRT-PCR validation changes in CD69 mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, *P< 0.01). The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
Profile 4 
Profile 4 represents genes elevated by LPS stimulation of BL20 but showed no 
change on comparison of BL20 with TBL20, and 95% of the dataset showed no 
significant change following stimulation of TBL20 with LPS (Figure 4.14). The 
dataset consisted of 1,093 genes and was the largest obtained by the study. The 
top 20 candidate genes of this profile are represented in Table 4.6, while a full 
list of 1,093 genes is presented in Appendix 2.1.4.  Only a small number (16) of 
these genes were sensitive to BW720c and all of these were elevated upon 
treatment, indicating repression by the parasite. 248 genes displayed a > 5 fold 
difference between TBL20 and BL20-LPS. 
A 
B 
C 
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Figure 4.14: Graphical display of profile 4 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 4 (n = 1093) whose expression is significantly elevated in 
BL20-LPS but not changed in TBL20 cells, Furthermore this condition was associated with 
repression in TBL20 when compared to BL20-LPS. The x-axis corresponds to the experimental 
conditions, the y-axis to expression values (log2) from array data. Each line represents an 
individual gene. 
Table 4.6:  Top 20 genes of profile 4 showing elevated expression in LPS- BL20 cells, but 
no change in TBL20 Vs BL20 cells.  
 
Summary of top 20 genes whose expression was significantly altered (FDR<5%, FC ≥ 2) in 
Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 4h/or18) 
relative to control cells. Data is arranged in descending order of absolute fold difference between 
BL20-LPS and TBL20. Gene symbols in bold indicate most recent annotation of the genes 
identified from NCBI. 
Gene 
Symbol 
Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  Vs 
BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
48h 
 
 
 
 
No change   
(–)  
 
VCAM1 Vascular cell adhesion molecule 1 0.000 183.1 -1.01 -184.6 – 
TFEC Transcription factor EC 0.000 34.2 -1.38 -47.09 – 
LOC518403 Hypothetical LOC518403 0.000 30.5 -1.48 -45.13 – 
LOC613624 Similar to regulator of G-protein signaling 13, 
transcript variant 1 
0.000 27.5 -1.54 -42.28 – 
LOC511753 Similar to seven transmembrane helix 
receptor 
0.000 35.2 -1.13 -39.7 – 
LOC786647 Hypothetical protein LOC786647 0.000 26.9 -1.25 -33.52 – 
LOC784595 Similar to olfactory receptor Olfr1174  0.000 16.1 -1.67 -26.81 – 
LOC616145 Similar to ADAMTS-like protein 5 precursor 
(ADAMTSL-5) 
0.000 15.6 -1.71 -26.64 – 
LOC783981 Similar to ribonuclease 12 0.000 14.4 -1.84 -26.51 – 
LOC504861 Hypothetical LOC504861 0.000 13.5 -1.79 -24.22 – 
ITK IL2-inducible T-cell kinase 0.000 16.2 -1.39 -22.56 – 
LOC509794 Similar to TESC protein, transcript variant 1 0.000 16.5 -1.36 -22.51 – 
SYTK1 Serine/threonine/tyrosine kinase 1  0.000 23.1 1.08 -21.42 – 
VCAM1  Vascular cell adhesion molecule 1 0.000 14.4 -1.45 -20.9 – 
SRGAP1 
 
SLIT-ROBO Rho GTPase activating protein 
1 (LOC539452) 
0.000 27.7 1.32 -20.88 – 
----- AJ814580 AJ814580 KN206 Bos sp. cDNA 
clone C0005204g20 
0.000 10.4 -1.98 -20.59  
TP63 Tumor protein 63 (LOC615335) 0.000 36.2 1.90 -19.06 – 
IRAK2  Interleukin-1 receptor-associated kinase 2 0.000 9.4 -1.97 -18.5 – 
AICDA Activation-induced cytidine deaminase  0.000 16.0 -1.14 -18.26 – 
CCR8 Chemokine C-C motif receptor 8  0.000 18.2 1.03 -17.74 – 
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IPA analysis showed enrichment for genes predicted to function in cell death, 
cell function and maintenance, and cellular development. An association with 
the inflammatory response and inflammatory disease was indicated, and it was 
of interest that activation of IRF by cytosolic pattern recognition receptors and 
interferon signalling were significant top canonical pathways. In addition a 
number of these genes possess interesting predicted functions that could be 
associated with parasite infection including: VCAM1 (184.6 fold elevation in BL-
20 LPS Vs TBL20), IFIT3 (14.7 fold), IF16 (9 fold), TP63 (34 fold) CFLAR (8.6 fold) 
and RUNX2 (5.3 fold). Semi-quantitative RT-PCR results of six candidate genes 
and qRT-PCR validation results of VCAM1 and RUNX2 are shown in Figure 4.15. 
 
Figure 4.15: Validation of microarray results for profile 4 
A. Semi-quantitative RT-PCR results showing mRNA expression of 6 candidate genes (VCAM1, 
CCL4, RUNX2, IFIT3, DTX4, CFLAR) in BL20 cells and TBL20 cells either stimulated or un-
stimulated with LPS. Semi-quantitative PCR products obtained using the gene specific primers 
were resolved on 1% agarose gel. Whereas ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in VCAM1 mRNA expression.  
C. Real-time qRT-PCR validation changes in RUNX2 mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, * P< 0.01).The lines for each bar on the graph represent the range in the 
relative expression. Whereas n.s indicates statistically non-significant results in TBL20 (+/- LPS) 
relative to BL20 cells.  
 
B 
 
C 
A 
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Profile 5: Profile 5 is the reciprocal of profile 1 and represents 288 genes whose 
expression is repressed in BL20-LPS but super-repressed in TBL20 (see Figure 
4.16).  
 
Figure 4.16: Graphical display of profile 5 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 5 (n = 288) whose expression is repressed in both LPS 
stimulated BL20 and TBL20 cells, however TBL20 exhibit super-repression relative to BL20-LPS. 
The x-axis corresponds to the experimental conditions, the y-axis to expression values (log2) from 
array data. Each line represents an individual gene. 
No significant alteration occurred in > 95% of the genes in TBL20-LPS. 40 of these 
genes showed major repression (> 10 fold) in TBL20 Vs BL20 LPS. Of the 136 
genes sensitive to BW720c 99.2% responded in the predicted manner (up), 
indicating active repression by a viable parasite. The top 20 candidate genes of 
this profile are represented in Table 4.7, while a full list of 288 genes is 
presented in Appendix 2.1.5. IPA showed enrichment of genes predicted to 
function in cell death, development, growth and proliferation and cellular 
function and maintenance. An association with infectious disease, cellular 
function and maintenance was identified. Interestingly genes encoding 
membrane proteins are prominent in the dataset (91) of which 34 are predicted 
to encode membrane receptors (26 G-protein coupled and 8 transmembrane 
receptor genes). Down-regulated receptor genes included those encoding the 
IGFR1 receptor (down 85 fold in TBL20 relative to BL20-LPS), the Toll-like 
receptor 4 (down 21.4 fold), the G-protein-coupled receptor CCR6 (down 23.18 
fold), S1PR1 (down 5.8 fold) and the thrombospondin receptor (down 4.6 fold). A 
number of genes encoding transcription factors were also present in the dataset 
including LEF-1 (down 14.9 fold) and LMO2 (down 7.7 fold), both of which are 
strongly associated with leukaemia. 
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Table 4.7:  Top 20 candidate genes of profile 5 showing evidence of super repression in 
TBL20 cells relative to BL20-LPS stimulated cells. 
 
Summary of top 20 candidate genes whose expression was significantly altered (FDR<5%, FC 
≥ 2) in Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 
4h/or18) relative to control cells. Data is arranged in descending order of absolute fold 
difference between BL20-LPS and TBL20. Genes highlighted in light blue shows Bw720c 
response previously identified in an independent microarray experiment (Kinnaird et al; 
unpublished). Gene symbols in bold indicate most recent annotation of the genes identified from 
NCBI. 
Nine genes of this profile were validated by RT-PCR and agreed with the array 
profile (Figure 4.17A), although only a low level increase in the TLR4 gene PCR 
product was detected for the BW720c treated sample. qRT-PCR validation was 
performed for TLR4 and MYL4 and showed good correlation with the micro-array 
profile (see Figure 4.17 B & C), with strong evidence of super repression of gene 
expression associated with Theileria infection compared to LPS-stimulation of 
BL20. Thus for TLR4, qRT-PCR data showed that expression was repressed by 
7.08 fold in TBL20 Vs BL20, while for BL20-LPS Vs BL20 expression was only 
repressed 1.34; the corresponding array values being 6.04 and 1.63 fold 
repression, respectively. 
Gene 
Symbol 
Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
48h 
 
 
 
   
 
----- CB467496 733248 MARC 6BOV Bos 
taurus cDNA 5' 
0.000 -2.8 -367.58 -132.5 – 
LOC786899 Hypothetical protein  0.010 -2.1 -220.93 -106.5  
LOC785289 Hypothetical protein 0.004 -2.2 -203.63 -93.3  
LOC404176 T-cell receptor delta chain 0.000 -2.7 -238.33 -88  
IGF1R Insulin-like growth factor 1 receptor  0.012 -2.0 -171.47 -85.15 – 
LOC507299 Hypothetical LOC507299  0.001 -2.7 -222.27 -83.31 – 
F13A1 Similar to Coagulation factor XIII A chain 
precursor (Coagulation factor XIIIa) 
LOC617881 
0.002 -2.3 -165.61 -71.17 – 
SORCS3 Similar to Sortilin-related VPS10 domain 
containing receptor 3 (LOC531405) 
0.000 -5.4 -364.83 -67.3 – 
LOC513984 Similar to peptide transporter 3  0.002 -2.4 -158.80 -66.73  
LAIR1 Leukocyte-associated Ig-like receptor 1b 
(LOC615295) 
0.000 -3.3 -174.72 -52.82 – 
LOC786880 Hypothetical protein LOC786880  0.001 -2.4 -114.35 -47.42  
LOC786327 Hypothetical protein LOC786327 0.001 -2.5 -96.91 -39.12  
PPP1R14C Protein phosphatase 1, regulatory 
(inhibitor) subunit 14C 
0.000 -6.0 -218.98 -36.29 – 
LOC789595 Hypothetical protein LOC789595  0.000 -4.2 -148.18 -35.48  
LOC512903 Similar to carboxypeptidase A3 0.000 -3.4 -119.24 -35.17  
CD22 B-cell receptor CD22-B (LOC514582) 0.001 -2.4 -82.08 -34.81  
LOC785058 Hypothetical protein LOC785058  0.000 -7.3 -243.50 -33.54  
----- EG706640 nbm28c02.y1 Cow lens. 
Unnormalized (nbm) Bos taurus cDNA 
clone nbm28c02 5 
0.000 -3.0 -90.80 -30.1  
----- DT891920 1473102 MARC 7BOV Bos 
taurus cDNA 5 
0.004 -2.2 -62.92 -28.27 – 
FCRLA Fc receptor-like A (LOC782871) 0.000 -2.8 -80.27 -28.2  
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Figure 4.17: Validation of microarray results for profile 5 
A. Semi-quantitative RT-PCR results showing mRNA expression of 9 candidate genes (MYL4, 
CD36, CALD1, CCL3, MFAP2, LMO2, PGM5, IL18, TLR4) in BL20 cells and TBL20 cells either 
stimulated or un-stimulated with LPS. Semi-quantitative PCR products obtained using the gene 
specific primers were resolved on 1% agarose gel, whereas; ACTB was used as an internal 
control. B. Real-time qRT-PCR validation changes in TLR4 mRNA expression. 
C. Real-time qRT-PCR validation changes in MYL4 mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, * P< 0.01). The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
Profile 6: Profile 6 is the reciprocal of profile 2 and represents 71 genes that 
were repressed by LPS treatment of uninfected BL20 cells but were elevated in 
TBL20 vs BL20 cells (Figure 4.18). All 71 genes showed no significant difference 
following LPS treatment of TBL20. The combined (down in BL20-LPS, up in 
TBL20) change in expression of a number of genes in this profile was 
considerable. For example the genes encoding AHNAK, CMRF-35 and SLA were 
amplified, respectively 235.4 fold, 99 fold and 45.4 fold and a further 44 genes 
were elevated by more than 10 fold. The top 20 candidate genes of this profile 
are represented in Table 4.8, while a full list of 71 genes is presented in 
Appendix 2.1.6. 
A 
 
C 
B 
Chapter 4                                                                                                                                        148    
 
Figure 4.18: Graphical display of profile 6 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 6 (n = 71) whose expression is significantly repressed in 
BL20-LPS but elevated in TBL20 cells, Furthermore this condition was associated with enhanced 
up-regulation in TBL20 when compared to BL20-LPS. The x-axis corresponds to the experimental 
conditions, the y-axis to expression values (log2) from array data. Each line represents an 
individual gene.  
Table 4.8:  Top 20 candidate genes of profile 6 showing repression in BL20-LPS but 
elevated response in TBL20 relative to BL20 cells. 
 
Summary of top 20 candidate genes whose expression was significantly altered (FDR<5%, FC 
≥ 2) in Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 
4h/or18) relative to control cells. Data is arranged in descending order of absolute fold 
difference between BL20-LPS and TBL20. Genes highlighted in light blue shows Bw720c 
response previously identified in an independent microarray experiment (Kinnaird et al; 
unpublished). Gene symbols in bold indicate most recent annotation of the genes identified 
from NCBI. 
Gene 
Symbol 
Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
      
 
AHNAK Similar to AHNAK nucleoprotein, transcript 
variant 1 (LOC510341) 
0.007 -2.1 112.38 235.4 – 
LOC514557 Similar to OAF homolog (Drosophila)  0.000 -23.4 5.73 134.1  
CD99 CD99 molecule (LOC509230) 0.000 -5.1 22.26 113.1 – 
LOC512831 Similar to Heterogeneous nuclear 
ribonucleoproteins A2/B1 (hnRNP A2 / B1) 
0.001 -2.4 44.46 106.1  
THEM4 Thioesterase sUperfamily member 4  0.000 -19.4 5.38 104.2 – 
CD300C CD 300c molecule (LOC526163) 0.010 -2.1 47.40 99.01 – 
TMEM62 Transmembrane protein 62, transcript variant 
2 (LOC515078) 
0.000 -3.3 22.75 75.4 – 
RNASEL Ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent) 
0.000 -3.3 18.55 60.56 – 
----- AJ677254 KN224 cDNA clone KN224-
023_E12, mRNA sequence 
0.000 -7.6 7.68 58.62 – 
SPARC Secreted protein, acidic, cysteine-rich  0.000 -14.0 3.82 53.38 – 
SLA SRC-like-adaptor  0.001 -2.5 18.37 45.47 – 
NDRG1 N-myc downstream regulated gene 1 0.000 -7.9 5.52 43.42 – 
PDE4C Similar to phosphodiesterase 4C  0.001 -2.4 17.13 41.51  
ANGPT4 Angiopoietin 4 0.000 -7.5 4.88 36.45  
LOC789368 Similar to Solute carrier family 38, member 5  0.000 -9.8 3.72 36.38 – 
GALNT6 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 
0.000 -2.6 12.41 32.77 – 
LRRC6 Leucine rich repeat containing 6 0.000 -6.0 5.30 31.87 – 
RNASEL Similar to 2-5A-dependent RNase 0.002 -2.4 12.94 31.21 – 
GCET2 Germinal centre expressed transcript 2  0.000 -8.1 3.70 30.13  
LOC790449 Similar to Pcdh19 protein  0.000 -5.2 5.64 29.36  
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Interestingly, a greater proportion (60%) of the 15 BW720c sensitive genes 
responded in a non-reciprocal manner (i.e. were up regulated by BW720c). IPA 
showed enrichment of genes predicted to function in cell death, development, 
growth and proliferation and cellular function and maintenance. An association 
with infectious disease, cellular function and maintenance was identified. Of the 
51 genes that could be mapped by IPA, 21 showed association with cancer. 
Significant IPA predicted molecular functions included cell movement, cell death 
and cell growth and proliferation. Gene ontology predicted that a number of 
genes operate in signal transduction events and are associated with cancer. The 
microarray expression profile of the cluster was validated by RT-PCR for six 
genes (see Figure 4.19A).  
 
Figure 4.19: Validation of microarray results for profile 6 
A. Semi-quantitative RT-PCR results showing mRNA expression of 6 candidate genes (BCL9, 
ANGPT4, NDRG1, PAK1, RNASEL, PIK3R6) in BL20 cells and TBL20 cells either stimulated or 
un-stimulated with LPS. Semi-quantitative PCR products obtained using the gene specific primers 
were resolved on 1% agarose gel. Whereas, ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in ANGPT4 mRNA expression.  
C. Real-time qRT-PCR validation changes in NDRG1 mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, *P< 0.01).The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
A 
 
C 
 
B 
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qRT-PCR validation was performed for ANGPT4 and NDRG1 and showed good 
correlation with the micro-array profile (see Figure 4.19 B & C). For example, 
qRT-PCR estimated that NDRG1 was down regulated 1.06 fold (log2) in BL20-LPS 
Vs BL20 but up regulated 2.96 fold (log2) in TBL20 Vs BL20, while the array data 
indicated a 1.78 fold (log2) repression in BL20-LPS and a 2.49 fold (log2) up –
regulation in TBL20. 
Profile 7: Profile 7 was the reciprocal of profile 3 and represented genes that 
were repressed more significantly in BL20-LPS relative to TBL20-LPS (see Figure 
4.20).  
 
Figure 4.20: Graphical display of profile 7 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Candidate genes from profile 7 (n = 22) whose expression is repressed in both LPS stimulated 
BL20 and TBL20 cells, however TBL20 exhibit up-regulated response relative to BL20-LPS. The x-
axis corresponds to the experimental conditions, the y-axis to expression values (log2) from array 
data. Each line represents individual gene. 
This profile represented the smallest number of genes (22), and 6 out of the 7 
(85.7%) BW720c sensitive genes were elevated upon treatment. A full list of the 
22 genes of this profile is presented in Table 4.9. An enrichment of genes with 
predicted functions that could be associated with the infected cell phenotype 
was not observed, although several receptors were present in the dataset. The 
microarray expression profile of the cluster was validated by RT-PCR for 3 genes 
(see Figure 4.21). 
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Table 4.9:  Top 20 candidate genes of profile 7 showing evidence of an attenuated 
repression response in TBL20 cells relative BL20-LPS stimulated cells.  
 
Summary of top 20 candidate genes whose expression was significantly altered (FDR<5%, FC ≥ 
2) in Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 
4h/or18) relative to control cells. Data is arranged in descending order of absolute fold difference 
between BL20-LPS and TBL20. Genes highlighted in light blue shows Bw720c response 
previously identified in an independent microarray experiment (Kinnaird et al; unpublished). Gene 
symbols in bold indicate most recent annotation of the genes identified from NCBI. 
Gene Symbol Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  Vs 
BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
      
 
----- EH149305 LB01342.CR_C18 GC_BGC-
13 Bos taurus cDNA clone  
0.000 -25.8 -2.15 11.99 – 
NLRP1 NLR family, pyrin domain containing 1 
(LOC790698) 
0.000 -19.4 -3.97 4.891  
LOC781353 Similar to receptor-like tyrosine kinase  0.000 -11.3 -2.69 4.196 – 
CYP3A4 Cytochrome P450, subfamily IIIA, 
polypeptide 4  
0.000 -9.4 -2.65 3.535 – 
STXBP6 Syntaxin binding protein 6 (amisyn)  0.000 -10.3 -2.92 3.517  
CYP4F3 Cytochrome P450, family 4, subfamily F, 
polypeptide 3 
0.000 -12.4 -3.63 3.402 – 
GALNT4 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4  
0.000 -10.5 -3.21 3.279  
LOC528166 Similar to NAC-beta splice 0.000 -11.5 -3.63 3.176  
PGLYRP1 Peptidoglycan recognition protein 1  0.000 -8.4 -2.70 3.121 – 
TRAF3IP3 TRAF3 interacting protein 3  0.000 -6.8 -2.39 2.859 – 
----- DN641773 UMC-bof_0A02-012-f10 
Ovarian follicle pre-ovulatory 
0.000 -37.4 -13.58 2.751  
LOC537817 Similar to KIAA0882 protein  0.000 -5.4 -2.09 2.596 – 
LOC782612 Hypothetical protein LOC782612  0.000 -5.6 -2.27 2.469 – 
LOC789663 Similar to KIAA0882 protein  0.000 -5.3 -2.18 2.425 – 
LOC503620 VEGF-receptor 0.000 -5.1 -2.21 2.314 – 
AQP3 Aquaporin 3 (Gill blood groUp) 0.000 -39.2 -17.16 2.287  
DNTT Deoxynucleotidyltransferase, terminal  0.000 -5.7 -2.67 2.151  
----- CO893215 BovGen_21540 normal 
cattle brain Bos taurus cDNA clone 
RZPDp1056D0646Q 5' 
0.000 -8.2 -3.81 2.144 – 
CYP3A4 Cytochrome P450, family 3, subfamily 
A, polypeptide 5(LOC785314) 
0.000 -5.4 -2.56 2.13 – 
TSPAN7 Tetraspanin 7 0.000 -5.0 -2.38 2.106 – 
LOC614782   Riken cDNA 4930503b20 gene 0.00 -5.0 -2.2 2.1 --- 
--- Ee895542 a98111a FFB cDNA 
clonea9811 3' 
0.00 -4.6 -6.5 2.0 --- 
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Figure 4.21: Validation of microarray results for profile 7 
A. Semi-quantitative RT-PCR results showing mRNA expression of 3 candidate genes (AQP3, 
CYP4F3, RYK) in BL20 cells and TBL20 cells either stimulated or un-stimulated with LPS. Semi-
quantitative PCR products obtained using the gene specific primers were resolved on 1% agarose 
gel, whereas; ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in CYP4F3 mRNA expression.  
C. Real-time qRT-PCR validation changes in RYK mRNA expression.  
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, *P< 0.01).The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 LPS 
relative to TBL20 cells 
Profile 8: Profile 8 was the reciprocal of 4 and represented 132 genes that were 
down regulated in BL20-LPS but showed no change associated with infection 
(BL20 vs TBL20) (see Figure 4.22). 99% of the dataset also showed no significant 
change in TBL20-LPS. Genes sensitive to BW720c treatment were under 
represented, and of the 2 present in the dataset, one was elevated and one 
repressed. The top 20 candidate genes of this profile are represented in Table 
4.10, while the full list of 132 genes is presented in Appendix 2.1.7. 
IPA showed enrichment for genes predicted to function in cell signalling, small 
molecule biochemistry and metabolism. Genes that could be putatively 
associated with the infected cell phenotype included toll like receptor 3 (TLR3), 
a Myeloid-associated differentiation marker, a janus kinase and microtubule 
interacting protein (JAKMIP1) and NFKB activating protein-like (NKAPL).  
 
A 
 
B 
 
C 
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Figure 4.22: Graphical display of profile 8 showing the expression patterns of differentially 
expressed genes and modulated response in Theileria infection. 
Top 50 candidate genes from profile 8 (n= 132) whose expression in repressed in LPS stimulated 
BL20 but not changed in TBL20 cells, whereas there is significant elevation in TBL20 when 
compared to BL20-LPS.The x-axis corresponds to the experimental conditions, the y-axis to 
expression values (log2) from array data. Each line represents individual gene. 
Table 4.10: 20 candidate genes of profile 8 showing evidence of repression of expression 
in BL20-LPS but no change in TBL20 Vs control BL20 cells.  
 
Summary of top 20 candidate genes whose expression was significantly altered (FDR<5%, FC 
≥ 2) in Theileria infected or LPS stimulated uninfected BL20 cells (maximal LPS response at 
4h/or18) relative to control cells. Data is arranged in descending order of absolute fold 
difference between BL20-LPS and TBL20. Gene symbols in bold indicate most recent 
annotation of the genes identified from NCBI. 
Gene Symbol Annotation BL20 LPS     
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS     
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  Vs 
BL20 
 
TBL20 Vs 
BL20 LPS 
Abs:FC 
(4h/or18) 
BW720c 
Response 
 
 
 
 
No change 
(–)  
 
M6PRBP1 Mannose-6-phosphate receptor binding 
protein 1 
0.000 -9.5 1.82 17.24 – 
BCOR BCL-6 corepressor (LOC784529) 0.000 -21.0 -1.38 15.25 – 
SERPINE2 Serpin peptidase inhibitor, clade E 2  0.000 -9.2 1.63 15.05 – 
LOC505234 Similar to FYVE, RhoGEF and PH 
domain-containing protein 4 (Actin 
filament-binding protein frabin)  
0.000 -9.4 1.58 14.87 – 
C10orf132 Hypothetical protein C10orf132  0.000 -5.7 1.88 10.79 – 
CAMKV CaM kinase-like vesicle-associated  0.000 -15.7 -1.47 10.63 – 
ARMCX6 Armadillo repeat containing, X-linked 6 0.000 -15.5 -1.52 10.2 – 
LOC616063 Similar to Myeloid-associated 
differentiation marker  
0.000 -8.3 1.17 9.737 – 
----- CO891936 BovGen_20261 normal cattle 
brain  
0.000 -13.1 -1.37 9.61 – 
NID2 Nidogen 2 (osteonidogen)  0.000 -8.7 1.03 8.98 – 
LOC524078 Similar to cystine/glutamate exchanger  0.000 -9.3 -1.06 8.805 – 
PLCL1 Phospholipase C-like 1(LOC537873) 0.000 -12.5 -1.42 8.802 – 
LOC787162 Similar to Armadillo repeat containing, X-
linked 6 
0.000 -12.3 -1.46 8.47 – 
LOC540831 Similar to FLJ20273 protein, transcript 
variant 1  
0.000 -4.5 1.80 8.052 – 
IGFBP4 Insulin-like growth factor binding protein 4  0.000 -4.4 1.78 7.918 – 
----- CO871894 BovGen_00219 normal cattle 
brain Bos taurus cDNA clone 
RZPDp1056I1952Q 3'e 
0.000 -5.4 1.24 6.759 – 
TNS1 Tensin 1  0.000 -10.8 -1.65 6.559 – 
RGS1 Regulator of G-protein signalling 1, 
transcript variant 1 (LOC540836) 
0.000 -5.6 1.16 6.553 – 
SLC1A5 Solute carrier family 1 (neutral amino acid 
transporter), member 5 
0.000 -3.6 1.83 6.527 – 
PLVAP Plasmalemma vesicle associated protein 0.000 -4.3 1.53 6.517 – 
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The microarray data was validated by RT-PCR for three genes (see Figure 4.23A). 
qRT-PCR data for BCOR and RGS1 was also in agreement with the microarray 
data(Figure 4.23B-C). Thus, based on qRT-PCR, BCOR was repressed by 5.98 fold 
(log2) in BL20-LPS compared to no significant alteration in TBL20 Vs BL20, while 
the array data computed a repression of 4.36 fold (log2) for BL20-LPS and no 
change for TBL20 Vs BL20. 
 
Figure 4.23: Semi-quantitative RT-PCR confirmation of microarray results for profile 8 
A. Semi-quantitative RT-PCR results showing mRNA expression of 3 candidate genes (BCOR, 
NID2, RGS) in BL20 cells and TBL20 cells either stimulated or un-stimulated with LPS. Semi-
quantitative PCR products obtained using the gene specific primers were resolved on 1% agarose 
gel, whereas; ACTB was used as an internal control. 
B. Real-time qRT-PCR validation changes in BCOR mRNA expression.  
C. Real-time qRT-PCR validation changes in RGS1 mRNA expression. 
For microarray results the asterisk (*) above the bars indicate the statistical significance of the 
relative log fold change compared to BL20 cells (*FDR< 0.05, ± S.E.M, n = 6). For qRT-PCR data 
the asterisk denotes the statistical significance of the relative log fold change compared to BL20 
cells (Student’s t-test, *P< 0.01). The lines for each bar on the graph represent the range in the 
relative expression. Whereas, n.s indicates statistically non-significant results in TBL20 (+/- LPS) 
relative to BL20 cells. 
 
B 
 
C 
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4.3.3  Analysis of the infection associated modulated dataset by 
Ingenuity Pathway Analysis 
Following identification of genes exhibiting modulated expression in Theileria 
infected cells relative to LPS stimulation of uninfected cells, Ingenuity pathway 
analysis (IPA) was used to investigate whether the modulation event could be 
associated with important biological functions. All genes previously identified as 
modulated by infection (5% FDR and ≥ 2 fold change) were uploaded to the IPA 
programme. The analysis was conducted in two different ways: firstly, global 
analysis was performed on the entire dataset of 1052 modulated genes that 
could be mapped by IPA; secondly, analysis was performed after dividing the 
dataset into two major subsets, genes showing evidence of repression or 
elevation of expression in parasite infected cells relative to BL20-LPS. In 
addition to the functional classification, canonical pathways analysis was also 
performed to identify most relevant and significant known biological pathways 
manipulated by the parasite for a given set of genes. 
4.3.3.1 The infection modulated dataset is enriched for genes in important 
functional categories 
Analysis of the global dataset of 1052 genes provided evidence that parasite 
infection extensively modulates a wide range of biological functions and/or 
diseases. Right‐tailed Fisher’s exact test was used to calculate a P‐value 
determining the probability that each biological function and/or disease 
assigned to sets of genes enriched in the dataset could be due to chance alone. 
Genes placed in a number of important categories showed significant enrichment 
within the dataset were obtained. Thus, key categories identified included; 
Inflammatory response, Tissue morphology, Cellular movement, Cancer, Cell-to-
Cell Signaling and Interaction, Cell Death, Cell-mediated Immune Response, 
Antimicrobial Response, Cellular Assembly and Organization (See Figure 4.24). A 
full list of functional categories identified is presented in Appendix 2.2. 
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Figure 4.24: Important biological functions and diseases associated with genes significantly 
modulated by parasite infection relative to LPS response  
Biological functions associated with genes enriched in the infection-modulated dataset of 1052 
genes are shown along the y-axis with the significance of the enrichment (–log) denoted along the 
y-axis. Each bar represents –log (p-value) for the enrichment of genes in selected category. The 
orange vertical line represents the threshold for significance (p-value < 0.05). 
While enrichment for a molecular function in the infection-modulated gene list 
is informative, prediction of how altered gene expression influences the 
outcome of the function would provide greater insight into the modulation 
event. To attempt this, further enrichment analysis was undertaken. Thus, IPA 
analysis was conducted for two subsets of genes, those displaying repressed 
expression in TBL20 Vs BL20-LPS (down-regulated dataset) and those that 
showed evidence of elevated expression (up-regulated dataset). These two 
datasets obtained were then compared on the basis of genes that were enriched 
and associated with different biological process and molecular functional 
categories (P-value < 0.05), combined with the IPA prediction of whether the 
gene promoted (pro) or inhibited (anti) the designated function. The proportion 
of genes designated as pro- or anti- for each functional category was then 
directly compared for the up- and down-regulated datasets. Selection of a 
category as informative was made on the basis that the observed ratio in the 
number of pro- or anti-genes for one dataset (e.g. down) was either absent (no 
genes present) or altered in the other dataset. A number of informative 
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categories of molecular function were identified, where the ratio of the number 
of pro- and anti-effect genes for one gene-set contrasted with that of the other 
(see Appendix 2.4 for full list of comparisons). Moreover, functional categories 
highlighted by this analysis predominantly show an association with a phenotype 
that is known or could be reasonably predicted for the infected cell. Thus, genes 
placed in the metastasis of cells sub-category showed a pattern indicative of 
anti-metastasis genes being repressed by parasite infection, while those that 
promote this function were favoured in the gene set associated with elevated 
expression. Moreover, there appeared to be a bias for elevation in expression of 
genes classified as pro-cancer and pro-tumourigenesis, but repression of genes 
predicted to be anti-disease of tumor and anti-growth of tumor. In a similar 
fashion parasite infection is known to be associated with changes to cell shape 
and manipulation of the actin cytoskeleton (Schmuckli-Maurer et al., 2010). 
Enrichment of genes in categories (Cellular assembly and organisation and Cell 
morphology) associated with these alterations was obtained, with a bias towards 
pro-function for the up but not the down dataset. Additional categories 
highlighted by the analysis include the inflammatory response, cellular 
movement, cellular assembly and organisation, cellular growth and proliferation 
and cell death. A summary of the results and denotation of important genes 
within selected categories identified as modulated by infection is given below.   
While this analysis was informative it should be noted that many genes were 
simultaneously placed in multiple categories by the IPA software. This could 
indicate a diverse functional role of these genes in determining the infected cell 
phenotype but could also hinder identification of the primary role that the gene 
plays in this process. 
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Table 4.11: Important biological functions identified by Ingenuity associated with genes 
modulated by Theileria infection relative to BL20-LPS 
  Repressed by infection Enhanced by infection 
 Important functions no. Genes 
(Pro/anti) 
p-value no. Genes   
(Pro/anti) 
p-value 
      
1 Inflammatory Response 111 34 
 Immune response 100 (43,27) 2.12E-09 27 (15,7) 4.51E-04 
 Activation of leukocyte 46 (27,9) 2.67E-06 13 (9,1) 3.76E-03 
 Antimicrobial response 19 (3,1) 4.88E-05 _ _ 
 Activation of lymphocyte 31 (19,7) 9.48E-05 9 (5,1) 1.20E-02 
 Antiviral response 13 (3,1) 9.60E-05 2 (0,0) 1.17E-02 
 Inflammation 30 (12,3) 7.22E-04 12 (3,2) 6.49E-04 
 Inflamatory response 41 (17,10) 3.34E-04 16 (7,3) 2.30E-04 
2 Cancer 189 60 
 Metastasis of cells  10 (2,6 ) 3.23E-03 13 (3,1) 2.29E-03 
 Tumourigenesis 179 (26,25) 1.73E-03 60 (6,2) 1.74E-05 
 Cancer 173 (16,13) 7.55E-05 56 (3,1) 1.58E-05 
 Disease of tumor 18 (2,4) 7.29E-04 _ _ 
 Growth of tumor  20 (2,9) 1.18E-03 _ _ 
 Tumor _ _ 43 (4,2) 1.11E-04 
3 Cellular Movement 100 46 
 Movement of cells  82 (42,29) 1.67E-04 38 (19,12) 4.47E-09 
 Migration of leukocytes  36 (22,9) 1.75E-03 17(6,3) 2.49E-05 
 Invasion of eukaryotic cells _ _ 14(10,3) 5.92E-04 
 Infiltration of leukocytes 25 (8,6) 3.30E-04 14 (2,3) 1.41E-06 
 Migration of antigen presenting 
cells 
14 (7,1) 1.65E-04 _ _ 
 Influx of leukocytes  7 (4,1) 2.02E-03 _ _ 
 Chemoattraction of leukocytes 6 (6,0) 4.19E-03 _ _ 
4 Cellular Assembly and 
Organization 
21 19 
 Formation of actin filaments _ _ 8 (3,1) 1.30E-03 
 Formation of cellular protrusions _ _ 10 (4,0) 2.71E-03 
 Formation of actin cytoskeleton 4 (0,0) 1.01E-03 4 (2,0) 1.10E-02 
 Formation of filaments _ _ 9 (5,1) 4.06E-03 
 Formation of cytoskeleton 5 (0,0) 2.11E-04 _ _ 
 Elongation of plasma 
membrane projection 
7 (4,0) 3.95E-03 _ _ 
5 Cellular Growth and 
Proliferation 
140 45 
 Proliferation of normal cells  87 (43,29) 4.07E-05 29 (13,6) 1.48E-04 
 Proliferation of eukaryotic cells 111 (56,47) 7.55E-05 35 (15,9) 3.51E-04 
 Proliferation of cells  124 (72,51 3.13E-03 40 (18,13) 8.48E-04 
 Proliferation of leukocyte 50 (25,17) 1.75E-06 6 (4,0) 7.66E-03 
 Induction of leukocyte  9 (7,3) 2.23E-04 _ _ 
 Stimulation of leukocytes  11 (9,3) 2.87E-03 _ _ 
6 Cell Death 170 52 
 Cell death of cancer cells 20 (6,4) 1.15E-05 _ _ 
 Apoptosis of tumor cell line 72 (34,22) 2.34E-06 20 (12,7) 3.07E-03 
 Apoptosis 134 (70,53) 2.10E-05 42 (24,19) 1.13E-04 
 Cell death of tumor cell line 78 (38,28) 2.10E-05 24 (13,9) 9.39E-04 
 Cell death 151 (75,62) 6.59E-05 49 (26,22) 3.22E-05 
 Cytotoxicity of lymphocytes 15 (8,6) 1.65E-04 _ _ 
 Cell death of normal cell _ _ 23 (8,9) 6.77E-03 
      
The criteria applied for the selection of major biological function categories were maximum 
number of genes and the P-value of significance. P-values in the range of 2.12E-09 to 
1.10E-02 indicated statistical significance. 
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4.3.3.1.1 Modulation of inflammatory response genes 
Modulation of the inflammatory response was highlighted by IPA software and 
several subcategories showed a bias for the infection associated repressed or 
elevated gene sets. Thus genes associated with a pro antimicrobial/viral 
response are predicted to be repressed by infection. On the other hand genes 
associated with cellular activation show evidence of elevation in infected cells 
(see Table 4.11). Many of the genes in this category have been documented to 
be involved in pro-inflammatory cascades. For example, several trans-membrane 
receptors genes (IGF1R, LAIR1, CCR6, TLR4 and CD40) predicted to be pro-
inflammatory were down regulated in infected cells. Indeed, within the 
inflammation subcategory the bias was towards parasite-associated repression of 
pro inflammation genes. Interestingly a majority of the genes (CX3CR1, CXCL10, 
IL15, IRAK2, IRF8, CLU and VCAM1) enriched in the pro-inflammatory response 
category were related to TLR and NF- B signalling pathway (see Table 4.12).  In 
contrast anti-inflammatory genes upregulated (e.g. TNFRSF1BTNFR2) by parasite 
infection relative to BL20-LPS could also be identified. It should be noted 
however that a clear bias toward repression of pro-inflammatory or elevation of 
anti-inflammatory gene expression was not detected for the dataset, in general.  
4.3.3.1.2 Modulation of cancer associated genes  
Perhaps not surprisingly, a highly significant category for enrichment of genes in 
the dataset was ‘cancer’. Interestingly the percentage of genes placed in this 
functional category was higher (24%) for the up regulated relative to the down 
regulated subsets of genes (11.5%). Moreover, clear differences in the ratios for 
pro and anti function were observed when comparing the up and down datasets 
for several of the cancer related sub categories. For example, the down-
regulated dataset was enriched for anti-cancer (metastasis of cells, 
tumourigenesis and cancer) molecules relative to the up-regulated dataset, 
which was enriched for pro-cancer genes (see Table 4.11). Important genes 
identified in the down-regulated dataset included anti-cancer CD40, HTATIP2 
and IRF8, whereas the up-regulated pro-cancer genes included IL2RB, CCR7, 
TP73, ANGPT4, FOXA3, PAK1 and CTTN. Representative genes together with 
their relative fold change in gene expression and indication of a pro- or anti-
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cancer effect are shown in Table 4.12 (up regulated dataset) and 4.13 (down 
regulated dataset) respectively.  
4.3.3.1.3 Modulation of cellular movement associated genes  
IPA analysis highlighted a group of genes linked to cellular movement function, 
revealing an impact of altered gene expression on cell motility and invasiveness. 
Within the up-regulated dataset for this category, several genes were predicted 
to promote cell migration, infiltration and invasion of cells. Of particular note, is 
that significant enrichment of genes in the ‘invasion of eukaryotic cells’ category 
was only obtained for the up-regulated dataset (see Table 4.11). Furthermore, 
10 out of 14 genes (e.g. CCL1, CTTN, MMP13, ENPP2, F2R, HBEGF, PODXL, 
SLC2A1, SPARC and SPP1) in this sub category were predicted to have positive 
influence on this process. 
Genes predicted to promote ‘infiltration of leukocytes’ and ‘migration of 
leukocytes’ were also identified and included ICAM1, IL2RB, XCL2, SELL, TP73 
and NDRG1. However, as shown in Table 4.11 when the up and down datasets 
were compared for the ratio of pro and anti genes in ‘infiltration of leukocytes’ 
the indicated trend was repression of this function (elevation of anti combined 
with repression of pro). This result could be of significance as enrichment of 
genes in categories ‘migration of antigen presenting cells’, ‘influx of leukocytes’ 
and chemo-attraction of leukocytes was identified only for the down regulated 
dataset and suggested repression of pro function genes. 
4.3.3.1.4 Modulation of cellular assembly and organisation associated genes 
An interesting category distinctly altered by parasite infection was ‘cellular 
assembly and organisation’, which includes processes such as formation of actin 
filaments, formation of actin cytoskeleton and elongation of plasma membrane 
projections (podosomes, lamellipodia and filopodia). Several of these processes 
can be related to alterations in morphology and phenotype of the Theileria 
infected cell (Baumgartner, 2011b;Shiels et al., 1989;Shiels et al., 2004). 
Enrichment of genes in the majority of the associated sub-categories was 
predicted to promote these functions: i.e bias of pro-function in the parasite 
associated up-regulated dataset (see Table 4.11). Important pro-function genes 
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identified within the elevated dataset included ICAM1, F2R, PAK1, ELN and CTTN 
(see Table 4.13). In contrast, gene enrichment or information relating to pro- or 
anti effect on function was absent for most of the sub-categories in down-
regulated dataset (see Table 4.11). 
4.3.3.1.5 Modulation of cellular growth and proliferation 
Based on the comparison of up and down datasets, no clear difference was 
observed in the pro/ anti ratio of genes placed in the first three sub categories 
of ‘cellular growth and proliferation’, although the trend was to a bias in the pro 
function for up regulated genes relative to down. This bias was more pronounced 
for the sub-category ‘proliferation of leukocyte’ with 4 out of 6 genes in the up-
regulated dataset designated as pro-proliferation. In contrast, the last two sub-
categories showed evidence, relative to all other sub-categories, of a bias 
towards repression of genes that promote ‘induction of leukocytes’ and 
‘stimulation of leukocytes’. Thus, in general, genes with an anti-proliferative 
effect (e.g CD40, CD80, LAIR1 and TP53INP1) were more likely to be present in 
the repressed by parasite infection dataset (Table 4.12); while genes predicted 
to have a positive effect on proliferation were proportionally more abundant in 
the parasite associated up-regulated dataset and included: ICAM1, IL2RB, ELN 
and TP73 (Table 4.13). 
4.3.3.1.6 Modulation of cell death associated genes 
Enrichment of genes in the category ‘cell death associated’ genes which are 
known to be involved in apoptosis and pro-inflammatory processes was identified 
for both the up and down datasets, with no obvious difference in the ratio of 
pro- or anti function genes. Indeed for most sub-categories the ratio between 
the number pro-and anti was approximately the same (all <2), the only 
exception to this being the ‘cell death of normal cell’ category where there was 
an increase in the number of anti cell death genes relative to pro. Selected 
genes identified in this category, repressed by the parasite included CFLAR, 
CD40, CD80, CD69, TP53INP1, EPHA7, TP63, THBS1 and CASP4 (Table 4.12). All 
of these genes have been implicated in promoting the process of cellular death. 
Thus differential regulation of these could potentially be related to the observed 
phenotype of LPS stimulated BL20 cells. Similarly, selected genes up regulated 
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by parasite infection relative to LPS stimulation and predicted to be anti-cell 
death include CCR7, TP73, RNASEL, CD5 and ARNT2 (see Table 4.13). 
Table 4.12: Modulated genes present in the function categories significantly down-regulated 
by Theileria infection relative to BL20-LPS 
Category  Molecules with fold change 
Inflammatory Response 
(pro) 
(Immune response, Antimicrobial response) 
Transmembrane Receptor  LAIR1 (52.8), IGF1R (85.15), CCR6 (23.18), CD69 (6.56), CD40 (13.8), 
TLR4 (44.15), CD80 (37.8) 
G-protein couple receptor  CCR8 (17.7), CX3CR1 (8.18), CASR (13.15)   
Transcription Regulator ATF3 (7.27), IRF8 (8.7), EPAS1 (39.8) 
Cytokine CXCL10 (24.2), CCL4 (17.3), IL15 (107.3) 
Kinase  IRAK2 (18.49) 
Other CD207 (42.8), CD200R1 (132.8), CLU (280.7),   CD83 (27.5), VCAM1 
(184.5), CD48 (10.32)  
  
Cancer (anti) (Tumor, transformation of cells, growth of tumor) 
Transmembrane Receptor  CD40 (13.8) 
Transcription Regulator HTATIP2 (27.86), IRF8 (8.77) 
Other COL18A1 (19.5), NFKB1A (13.01), THBSI (65.01)  
  
Cellular Movement (Pro) Migration of antigen presenting cells, Influx of leukocytes, 
Chemoattraction of leukocytes 
Transmembrane Receptor  CD40 (13.8), TLR4 (44.15), IL6R (4.82) 
Transcription Regulator IRF4 (3.36) 
Cytokine CCL4 (17.3), IL15 (107.3), CSF1 (5.13), IL12B (2.69), IL18 (2.43), SPP1 
(9.74), C5 (3.15)  
  
Cell Death (pro) (Apoptosis, apoptosis of cancer cells, apoptosis of leukocyte) 
Transmembrane Receptor  CD40 (13.8), CD69 (6.56), CD80 (37.8), IGF1R (85.15), ITGB3 (6.29), 
LAIR1 (52.8), TLR4 (44.15)   
G-protein couple receptor  CASR (13.15) 
Transcription Regulator ATF3 (7.27), HTATIP2 (27.86),IRF8 (8.77), LEF1 (14.9), TP63 (19.06)  
Enzyme  IFIH1 (7.27), OAS1 (6.9)  
Cytokine CCL4 (17.3), IL15 (107.3) 
Kinase  CDK5R1 (11.75), EPHA7 (120.1), IKBKE (6.47), MAP3K8 (5.2), SGK1 
(9.92), TGFBR3 (8.2)    
Growth Factor BMP4 (12.38) 
Other CD48 (10.32), CFLAR (8.57), CLU (280.74), COL18A1 (19.5), KNG1 
(8.43), THBS1 (65.01), TP53INP1 (18.93), TRAF4 (8.07), UBD (22.80) 
  
Cellular assembly and 
organisation (anti) 
(Organization of cytoskeleton, formation of actin cytoskeleton) 
---------------------- ----------------------------------------------------------------------------------- 
  
Cellular growth and 
proliferation (anti) 
(Proliferation of leukocyte, growth of leukocyte) 
Transmembrane Receptor  CD40 (13.8), CD80 (37.8), LAIR1 (52.8), TLR4 (21.37), 
G-protein couple receptor  CASR (13.15) 
Transcription Regulator IRF8 (8.77), 
Cytokine CCL4 (17.3), IL15 (107.3), CXCL10 (24.2), 
Growth Factor BMP4 (12.38) 
Other CD83 (27.5), COL18A1 (19.5), TP53INP1 (18.93), CLU (280.74), NFKB1A 
(13.01) 
The given table represents the most relevant biological process categories and key molecules 
from each category that can be linked to parasite infection and LPS stimulation of BL20 cells. 
Similarly, the prediction of whether the molecules promoted (pro) or inhibited (anti) the 
designated functional category by IPA is also indicated. The absolute fold change for each 
molecule is given in brackets. 
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Table 4.13: Modulated genes present in the function categories significantly up-regulated by 
Theileria infection relative to BL20-LPS 
Category  Molecules with fold change 
  
Inflammatory Response 
(anti) 
(Immune response, Antimicrobial response) 
Transmembrane Receptor  TNFRSF1B (5.85) 
Other RGS1 (6.55),  
 
Cancer (pro) 
 
(Tumor, transformation of cells, growth of tumor) 
Transmembrane Receptor  IL2RB (11.15),  
G-protein couple receptor  F2R (5.97), CCR7 (17.9) 
Transcription Regulator TP73 (20.04), FOXA3 (10.84),  
Enzyme  ENPP2 (10.02), PDE4C (41.5) 
Kinase  PAK1 (22.33), NDRG1 (43.4) 
Peptidase MMP13 (54.20), EPHX1 (10.25), GZMA (24.8),  
Growth Factor ANGPT4 (36.45),  
Transporter AP3M2 (10.35) 
Other CTTN (4.47), FGD4 (14.8), PLIN3 (17.23) 
 
Cellular Movement (pro) 
 
Infiltration, Invasion of cells, Migration of cells 
Transmembrane Receptor  ICAM1 (12.02), IL2RB (11.15) 
G-protein couple receptor  CCR7 (17.94) 
Transcription Regulator TP73 (20.04), ETV5 (6.22) 
Enzyme  ENPP2 (10.02) 
Cytokine CCL1 (9.16), XCL2 (42) 
Kinase  PAK1 (22.33), NDRG1 (43.4) 
Peptidase MMP13 (54.20)  
Other CTTN (4.47), ELN (3.216), SELL (9.50), SEMAF3 (5.09), SPARC (53.3), 
TNS1 (6.55) 
 
Cell Death (anti) 
 
(Apoptosis, apoptosis of cancer cells, apoptosis of leukocyte) 
Transmembrane Receptor  CD5 (4.8) 
G-protein couple receptor  CCR7 (17.94) 
Transcription Regulator TP73 (20.04), ARNT2 (4.26),  
Enzyme  RNASEL (60.5) 
Kinase  HCK (6.3), MLLT3 (13.94), PAK1 (22.33), SEMAF3 (5.09), SERPINE2 
(15.05) 
Transporter SLC7A11 (8.80) 
Other ANTXR2 (5.39), NLRP1 (4.89), SPARC (53.3), 
 
Cellular assembly and 
organisation (pro) 
 
(Organization of cytoskeleton, formation of actin 
cytoskeleton) 
Transmembrane Receptor  ICAM1 (12.02, 
G-protein couple receptor  F2R (5.97), 
Kinase  PAK1 (22.33), 
Other SDC4 (2.6), ELN (3.2), CTTN (4.47),  
 
Cellular growth and 
proliferation (pro) 
 
(Proliferation of leukocyte, growth of leukocyte)  
Transmembrane Receptor  ICAM1 (12.02), IL2RB (11.15), FCGR2B (5.4), TNFSRSF1B (5.85) 
G-protein couple receptor  F2R (5.97), 
Transcription Regulator TP73 (20.04) 
Kinase  HCK (6.3) 
Other ELN (3.2), MLLT3 (13.9), LAMC1 (4.2), SUMO3 (6.03),  
  
The given table represents the most relevant biological process categories and key 
molecules from each category that can be linked to the phenotype of parasite infection and 
LPS stimulation of BL20 cells. Similarly, prediction of whether the molecules promoted (pro) 
or inhibited (anti) the designated functional category identified by IPA is also indicated. The 
absolute fold change for each molecule is given in brackets.  
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4.3.3.2 Canonical pathway analysis 
IPA analysis of the infection modulated date set identified several important 
canonical pathways as being manipulated by the parasite infection relative to 
LPS stimulation of BL20 cells. Significant pathways were identified by screening 
for enrichment of genes placed within canonical pathways available in the IPA 
library. The most significant canonical pathways identified are shown in Figure 
4.25, while the full list of pathways can be view in Appendix 2.3. Not 
surprisingly, identified pathways included signalling pathways associated with 
the inflammatory and anti-microbial response including NF- B and PI3K 
signalling pathways known to be manipulated by parasite infection. In addition, 
other pathways relevant to stimulation of the inflammatory response that 
showed evidence of modulation by parasite infection were  ‘activation of IRF by 
cytosolic pattern recognition receptor’, ‘TNFR2 signalling’, ‘role of pattern 
recognition receptors in recognition of bacteria and viruses’, ‘CD40 signalling’, 
‘LPS-stimulated MAPK signalling’, ‘G-protein coupled receptor signalling’, ‘Toll-
like receptor signalling’ and interferon (IFN) signalling. Enrichment of genes that 
operate in pathways associated with induction of cell death/apoptosis (‘death 
receptor signalling’, ‘p53 signalling’) were also identified by IPA.  
 
Figure 4.25: Identification of top canonical pathways in infection associated modulation 
dataset  
Bar chart shows important canonical pathways enriched for genes significantly modulated by 
Theileria infection compared to LPS stimulation of BL20 cells. Each bar represents –log (p-value) 
for over representation of genes in the selected pathway. Threshold (orange line) denotes P = 
0.05. 
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Detailed exploration of the canonical NF- B signalling pathway showed a number 
of interesting infection associated modulations relative to the LPS stimulated 
response. These can be divided into two general categories: repression of genes 
encoding receptors that perceive a signal that activates NF- B, and partial up-
regulation of components of the pathway downstream of the IKK signalosome 
(p100/p52, RelB). Two additional modulations of note were found: (a) levels of 
the IkB inhibitors (NFKBIA, NFKBIE and NFKBIZ) were repressed in TBL20 relative 
to LPS-stimulated BL20 and (b) two PI3K regulatory subunits (PIK3R5 and PIK3R6) 
were predicted to be elevated in TBL20 but repressed in BL20-LPS. Similarly, 
several molecules upstream of the IKK signalosomes (TRAF2, PKR and TNFAIP3 
A20/MAD6) were also predicted to be repressed in TBL20 but elevated in BL20-LPS 
(see Figure 4.26). 
4.3.3.3 Custom pathway analysis 
Infection of bovine leukocytes with T. annulata or T. parva is known to result in 
constitutive activation of transcription factors associated with the inflammatory 
response. To investigate whether the outcomes of transcription factor/signalling 
pathway activation were being effectively modulated, sets of known target 
genes were uploaded to IPA using the custom pathways feature and screened for 
evidence of significant enrichment of genes within infection-modulated dataset. 
Pathways were selected on the basis of a known association with the Theileria 
transformed cells and generated using available lists of known and predicted NF-
B0(http://www.bu.edu/nf-kb/gene-resources/target-genes/),0C-myc 
(http://www.ncbi.nlm.nih.gov/biosystems/169353)0and0TGFb 
(http://www.netpath.org) response/target genes. As shown in Figure 4.27, 
significant enrichment in targets of NF- B and cMYC repression targets was 
observed, together with a particular enrichment of genes known to be regulated 
in response to TGFb signalling.  
Interestingly, 75 percent (46) of the 61 NF- B target genes identified as 
modulated by infection showed a down-regulated response relative to LPS 
stimulated BL20 cells. Whereas a lower number of the NF- B target genes (15) 
were up-regulated in TBL20 relative to BL20 LPS. For the 46 genes in the 
repressed dataset, enrichment was found in several IPA categories that could 
influence establishment of the parasite infected leukocyte and included: 
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activation of leukocytes (with a strong bias in genes designated as pro-function), 
differentiation of leukocytes (pro); apoptosis (pro and anti); immune response 
(pro) and inflammatory response (pro). Genes belonging to several members of 
NF- B activation cascade and regulatory subunits were also present in the 
repressed dataset. 
 
Figure 4.26: Modulation of NF- B pathway in infection associated modulated dataset  
NF- B signaling pathway was the most significant (P< 0.001) canonical pathway modulated by 
parasite infection relative to LPS response. Modulated dataset was clustered into canonical 
pathway using IPA. The genes which are coloured are differentially expressed in TBL Vs BL (red = 
up in TBL, green = down in TBL). The arrows are beside those genes which are on the LPS 
modulated list (1,053/1,959). Green and red arrows indicate down and up-regulation response 
respectively. Whereas arrow signs before vertical bar (│) indicates LPS response and after bar 
indicates parasite response. For example ↑↑│↑ = super-up, up and ↑- means up, no change. The 
data for IL-1R/TLR and growth factor receptor are exploded in two boxes. 
© 2000-2011 Ingenuity Systems, Inc. all rights reserved 
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Figure 4.27: Custom pathway analysis of infection associated modulated dataset   
Bar chart shows customised pathway analysis, performed by enrichment of modulated gene set 
against literature based compiled gene lists of selected pathways. Each bar represents –log (p-
value) for over representation of the modulated genes in the selected pathway. Threshold (orange 
line) denotes the P= 0.05 level. 
Thus, genes encoding NF- B inhibitor proteins (NFKBIA/IkBα, NFKBE/IkBε and 
NFKBIZ), responsible for the sequestration of NF- B in the cytoplasm, and 2 NF-
B subunits (REL-B and NFKB2/p52) were identified (see Figure 4.28). The number 
of target genes up-regulated by parasite infection was too small to screen for 
enrichment but up-regulation of several of these NF- B targets (e.g. ICAM-1 and 
SPARC) could be predicted to strongly influence the phenotype of the infected 
cell. Secreted Protein Acid and Rich in Cystein (SPARC), for example, has been 
implicated in apoptosis, differentiation, metastasis and regulation of immune 
cell response. Moreover recent studies have indicated that SPARC can be pro-
tumorigenic via inactivation of the p53 tumour suppressor (Fenouille et al., 
2011a). 
Modulated NF- B target genes included several chemokines and cytokines 
predicted to be involved in pro- or anti-inflammatory response: IL15, CXCL10, 
CCL4, and IL12B were significantly suppressed by the parasite infection; whereas 
CCL1, CCR7 and XCL2 were significantly up-regulated in infected cells. 
Additional molecular function categories designated to modulated NF- B target 
genes belonged to transcription regulation (down regulated), protein binding 
activity (predominantly down), cell adhesion (up and down regulated), 
immunoreceptors (down regulated) and regulators of apoptosis (down regulated, 
Table 4.12). 
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Figure 4.28: Expression profile of NF- B response genes identified in infection associated 
modulated dataset 
Data are presented in visualized expression of hybridization values as a heat map. The rows 
represent individual genes and columns represent each experimental condition. The red and blue 
colours reflect high and low expression (log2-transformed scale) levels, respectively, as indicated in 
the scale bar.  
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Table 4.14: Molecular function or biological process categories of NF- B target 
genes modulated by Theileria infection relative to BL20-LPS 
Gene 
Symbol 
Modulation 
(Fold change) 
Gene 
Symbol 
Modulation 
(Fold change) 
Gene 
Symbol 
Modulation 
(Fold change) 
Cytokines/ Chemokines Immunoreceptors Enzymes 
CCL1 15.60 PGLYRP1 3.12 APOD −8.69 
CCR7 17.94 CD80 −37.89 ADAM19 −19.78 
XCL2 54.23 CD83 −27.51 BMP4 −12.38 
IL15 −107.32 PIGR −16.02 CSF1 −5.14 
CXCL10 −24.25 TNFRSF5 −13.83 KCNK5 −4.77 
CCL4 −17.31 CD48 −10.33 GCNT1 −4.44 
IL12B −2.69   LYZ −3.83 
Regulators of apoptosis Transcription regulation   Protein binding activity 
WNT10B −42.63 TFEC −47.09 SLC6A6 8.48 
CFLAR −8.58 LEF1 −21.21 SERPINE2 15.05 
TRAF1 −7.23 NFKBIA −13.01 NDRG1 43.42 
CASP4 −2.74 RELB −10.74 SPARC 53.38 
Others SNAI1 −7.28 THBS1 −65.01 
SDC4 12.29 NFKB2 −4.0 LCN2 −18.46 
NRN1 11.84 NFKBIE −3.38 AICDA −18.26 
PRF1 8.94 NFKBIZ −3.59 TNFAIP3 −8.65 
TNFRSF1B 5.86 NR4A2 −3.51 TIFA −7.02 
SPP1 −9.74 NF-EM5 −3.37 FABP6 −6.41 
IER2 −3.07 ANKRD1 2.72 MYLK −4.21 
IFI44L −5.62 JUNB −2.72 B2M −2.48 
KLRA1 −2.7 Cell adhesion molecules RIPK2 −2.91 
  ICAM1 12.03 CDKN1A −2.64 
  VCAM1 −20.9   
Modulated NF- B response genes are described as those whose expression was 
altered in TBL20 relative to BL20-LPS cells, making a simple designation of either up- 
or down-regulated response. Fold change of individual gene is shown, and minus 
indicates down-regulated expression in parasite infection. 
Investigation of genes classified as cMyc validated repression genes indicated 
that the majority, 7 out of 10, have an expression profile consistent with 
maintenance of repression associated with infection. The NDRG1 gene, however, 
showed a contrasting pattern from the rest of the dataset, as the RNA level for 
this gene was found to be elevated in infected TBL20 cells but repressed in LPS 
stimulated BL20 cells. 7 of the 10 genes in this pathway were designated as 
located to the nucleus with a predicted function as a regulator of transcription 
or a kinase.  
Evidence for modulation of TGF target genes was also obtained, as the 
predicted response to stimulation could not be identified: roughly equivalent 
numbers of target genes that are up- or down-regulated by TGFβ were identified 
within the ‘parasite-repressed’ gene list, with a similar finding for the ‘parasite-
enhanced’ gene list. TGFβ targets modulated by the parasite were categorised in 
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cancer, cell death, cellular growth and development. Of particular note was that 
inflammatory response TGFβ target genes were generally associated with 
repression of expression by parasite infection. These results may be explained, 
in part, by the observation that expression of genes encoding TGFB2, TGFB3 and 
the TGFBR3 are slightly elevated in parasite infection of BL20 cells, while TGFB1 
is slightly reduced. The TGF signalling pathway has been implicated as a 
determinant of pathogenicity and metastatic activity in tropical theileriosis. 
Reduced TGF2 expression and lower virulence was measured for infected cells 
derived from an attenuated vaccine line and disease resistant Sahiwal (Bos 
indicus) cattle (Chaussepied et al., 2010). Differential expression of TGF target 
genes was also identified for the attenuated vaccine cell line, with elevated as 
well as repressed expression detected. Thus, modulation of TGFB signalling and 
the respective target genes appears to be a common event associated with T. 
annulata infected leukocytes. 
4.3.4  Proteomic validation of microarray results 
In addition to validation of modulation of Toll-like receptor 4 at the protein level 
(see Chapter 3) a further two proteins were validated for differential expression 
in Theileria infected and uninfected cells before and following LPS stimulation. 
These proteins were selected on the basis of high fold-change, interesting 
biological functions and availability of commercial antibodies suitable for 
western blot or immunofluorescence analysis. 
The first gene of interest investigated was LIM domain only 2 (LMO2), which 
encodes a cysteine-rich, two LIM-domain protein that has a central and crucial 
role in hematopoietic development. Immunoblot analysis of LMO2 detected a 
~24 kDa protein that was expressed in BL20 cells at a high level, with repression 
in LPS stimulated BL20, but associated with significant repression in Theileria 
infected control and LPS stimulated TBL20 cells (see Figure 4.29A). Thus, the 
protein data agreed with the RNA data indicating super repression associated 
with infection (profile 6). The expression pattern of LMO2 was also assessed by 
immunofluorescence analysis (IFA) of LPS stimulated and un-stimulated BL20 and 
TBL20 cells (see Figure. 4.29B). The results clearly showed high-level reactivity 
against LMO2 in BL20 relative to a virtually complete lack of staining in TBL20 
cells (see Figure. 4.29B: panel 1 Vs panel 2). Moreover, as predicted from its 
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function as a regulator of gene expression, the IFA clearly demonstrated that the 
protein was located to the nucleus of BL20 cells. A significant reduction in 
staining by IFAT was not evident for LPS-stimulated BL20 cells. (Figure 4.29B: 
panel 1 Vs panel 3).  
The second gene tested encoded Vascular cell adhesion molecule 1 (VCAM1), a 
member of the Ig superfamily which encodes a cell surface sialoglycoprotein and 
mediates leukocyte cell adhesion and signal transduction. As predicted VCAM1 
protein was detected at 110 kDa, and was only detected in extracts derived from 
LPS stimulated BL20 cells (see Figure 4.29A). Consistent with the microarray and 
RT-PCR results, No band of predicted size (110 kDa) was observed in un-
stimulated BL20, TBL20 and LPS stimulated TBL20 cells. Furthermore with 
respect to LPS stimulation of BL20 cells, VCAM1 was detected at a higher level at 
18h relative to 4h post LPS stimulation. It was concluded that the strong band 
detected just below 110 kDa was due, most likely, to non-specific recognition of 
a protein by the poly-specific anti-VCAM1 serum. 
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Figure 4.29: Validation of proteomic expression profile of candidate genes  
A. Shows validation of the protein expression of 3 candidate genes by Immunoblotting. Expression 
of LMO2 and VCAM1 was detected by western blot analysis of total cell extracts derived from 
uninfected and Theileria infected cell cultures either stimulated with LPS (4h/18h) or unstimulated 
(DMSO). Equal protein loading was assessed by immunodetection of the Tubulin expression using 
a monoclonal anti-actin antibody (TUB-1A2). 
B. Immunofluorescence analysis of LMO2 expression in un-infected BL20 and Theileria infected 
TBL20 cells. Panel 1 and 2, anti-LMO2 reactivity in BL20 and TBL20 cells respectively. Bar = 
20µm. Panel 3 and 4, anti-LMO2 reactivity in LPS stimulated BL20 and TBL20 cells respectively. 
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4.4  Discussion 
The aim of the work presented in this chapter was to investigate the postulation 
that infection of the bovine cell modulates the outcome of a cellular activation 
event at the global level. This was performed using an oligonucleotide 
microarray platform designed by the Glasgow Theileria group that represented 
the largest number of genes, at the time, for putative or known bovine RNA 
features (31,481). The Glasgow microarray therefore provided a considerable 
increase in the number of represented bovine genes compared to the cDNA 
(BoMP) array generated by Jensen et al., 2006 and 2008, and limited gene 
expression studies performed by other co-workers (Jensen et al., 2009;Oura et 
al., 2006;Sager et al., 1997). Moreover, studies using the BoMP array were 
aimed, primarily, at comparing the response of cells from different cattle breeds 
infected with T. annulata or stimulated with LPS. Therefore, the results 
described are the most comprehensive analysis to date of gene expression 
changes that occur following activation of uninfected cells compared to changes 
in gene expression associated with infection.  
4.4.1 Interpretation of microarray data 
It is clear form the results that both infection and LPS stimulation result in 
alteration in expression to a large number of bovine genes (approximately 3000 
genes, 10% of array features). These numbers, although high, are supported by 
the earlier study of Jensen et al., 2008 that reported 695 altered genes 
associated with LPS & IFN stimulated macrophages and 1000 differentially 
expressed genes associated with parasite infection (unpublished data in Jensen 
et al., 2008) using the smaller BoMP array. Of the 3634 BL20 LPS response genes 
12.3% more showed evidence of elevated expression, while in contrast, 45% 
more of the infection altered genes showed evidence of repression. While this 
result may indicate that parasite infection is more associated with repression 
than elevation of host cell gene expression, it is possible that the large excess in 
repressed genes is caused by an unknown skew in the normalised dataset that 
increases the probability of a down regulated gene being scored as significant. 
However such a skew, if present, is unlikely to influence generation of the 
infection modulated dataset (1959 genes) as this represents genes scored as 
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significant by ranked product analysis (FDR < 0.05, fold change ≥ 2) in the BL20 
dataset and a ≥ 2 fold difference between the expression value in TBL20 and LPS 
stimulated BL20.  
Rank product analysis  (Breitling et al., 2004) has now been widely adopted to 
study differential gene expression due to its robust nature and has been utilised 
by several recent studies performed to identify differentially expressed genes 
(Leifso et al., 2007;Morrison et al., 2010;Veitch et al., 2010). Gene expression 
analysis was also performed using a Student’s T test (≥2 fold, F test Anova P-
value <0.05) in the ArrayStar software suite and the results of both analyses 
were validated by cross comparison of the obtained datasets.  
Comparison of the infection (TBL20) Vs the LPS (BL20) response datasets and 
Chi-square analysis demonstrated that a significant number of genes (1296) 
showed an altered expression response associated with both parasite infection 
and LPS stimulation of BL20 cells (see Figure 4.5). This result is important as it 
clearly demonstrates that the gene expression profile of the parasite-infected 
cell is related to an activated state induced by a classical inflammatory 
mediator. Indeed IPA analysis of the LPS BL20 dataset showed that enrichment 
for inflammatory response genes was of greatest significance (Figure 4.24). 
Thus, as indicated from previous studies it is likely that the parasite infection 
results in constitutive activation of transcription factors that are also activated 
by inflammatory mediators such as LPS. What is not clear from this analysis, 
however, is the degree of variability in the outcome of the activation event in 
these two cellular states and whether a difference in outcome could be 
predicted to influence the establishment of the parasite infected cell.  
Initial analysis of the array results also showed that TBL20 cells were refractory 
to major LPS-induced global expression changes, as only a small subset of genes 
(1.5%) showed altered expression following stimulation of TBL20 with LPS. These 
results clearly indicated that parasite is a dominant suppressor of 
lipopolysaccharide (LPS) inducible gene expression. One way in which the 
parasite infected TBL20 cell may be able to achieve this relative non-
responsiveness is via down regulation of the major LPS receptor TLR4 (see 
chapter 3). Consistent with the results obtained in the previous chapter, 
microarray and real time RT-PCR confirmed repression of 21-fold in TBL20 cells 
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relative to BL20-LPS. Furthermore, analysis of the TBL20 VS BL20 array data 
(Kinnaird et al., un-published) indicated that other genes encoding LPS receptors 
(integrin, alpha L (CD11a) and platelet-activating factor receptor (PTAFR)) are 
also down regulated by infection. Therefore the mechanism that leads to altered 
expression of the 1.5% genes of TBL20 that were stimulated by LPS may involve 
alternative surface molecules able to bind to LPS. For example, low-affinity 
lipopolysaccharide receptors P and L-selectin, which are exclusively expressed in 
parasite infection or HSP90/70 and class B scavenger receptor molecules 
(SCARB1 and SCARB2) are expressed at equal levels in BL20/TBL20 cells (non-LPS 
response genes identified in microarray analysis of Kinnaird et al; unpublished), 
each of which have been reported to bind LPS in various cell types (Bocharov et 
al., 2004;Malhotra et al., 1998;Malhotra and Bird, 1997a;Malhotra and Bird, 
1997b;Pearson, 1996;Triantafilou and Triantafilou, 2004). Therefore, it is likely 
that the minor subset of LPS-inducible response genes associated with parasite 
infection is mediated via TLR-4 independent signalling.  
The BL20 Vs TBL20 model was chosen for this study because it provided a cell 
culture system that would provide a reproducible response to simulation and 
infection. Moreover, TBL cells have been used in a number of previous studies to 
investigate infection-associated phenotypes (Baylis et al., 1995;Dando and 
Shiels, 1997;Oura et al., 2006) and it has been demonstrated that TBL cells are 
dependent on a viable parasite and undergo apoptosis when the schizont is killed 
by BW720c (see chapter 3). The results of the array data in general support the 
use of the TBL20 model to investigate parasite control of the infected cell 
phenotype. Thus, differential expression of a number of genes (for example, 
CCR1, ICAM1, TLR 10, ITGB7, ISG15) previously reported as altered in the 
context of infection was found (Jensen et al., 2008;Jensen et al., 2009;Oura et 
al., 2006) . In addition, a significant number of genes show a change in 
expression pattern when TBL20 was treated with BW720C over a short time 
period (48h). Some of these changes are non-reciprocal and indicate that on 
removal of the parasite the cell does not simply revert to the uninfected BL20 
state but instead progresses towards cell death. It has been concluded from the 
parallel study of Kinnaird et al., that infection of the cell promotes a major 
alteration to the profile of host transcription factors resulting in a 
reconfiguration of gene expression networks that is not reversible following 
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removal of the parasite encoded signal(s) that control the infected cell 
phenotype. Irreversible reconfiguration of gene networks associated with 
cellular differentiation is increasingly proposed for stem cell systems 
(Chickarmane et al., 2006;Wang et al., 2010).   
4.4.2 Interpretation of modulated expression profiles 
The results presented in this chapter provide strong evidence that infection of 
BL20 cells with T. annulata is associated with modulation of gene expression 
changes induced by LPS. 8 profiles of modulated expression were obtained by 
comparison of expression data across all 6 cellular conditions.  Two of these 
profiles (profile 1 and 5) represented an enhancement of the expression change 
induced by LPS (e.g. elevated expression of an LPS stimulated up regulated 
gene; repression of an LPS repressed gene) and it could be argued that these 
patterns of expression are caused by a greater activation status in the infected 
BL20 cell relative to the LPS stimulated counterpart. For example, the level of 
NF- B reporter activity is significantly higher in TBL20 compared to LPS 
stimulated BL20 (see Figure. 3.4, Chapter 3). Therefore, if expression levels of 
the target genes were directly linked to quantitative changes in the level of an 
activated regulator, these enhanced expression profiles would be generated. 
This postulation is probably over simplistic and is also unlikely to account for the 
other 6 modulation profiles where infection is associated with either: a reversal 
of the change induced by LPS (profile 2 and 6); an attenuated response of the 
LPS induced alteration (profile 3 and 7); and no infection associated change in 
expression, compared to an LPS induced response (profile 4 and 8). This last 
modulation event (profile 4 and 8) could be explained in part by proposing that 
the infected cell simply does not respond to LPS stimulation. As stated above, 
infection down regulates receptors required for transduction of the LPS signal. 
For this mechanism to operate factors that control target gene expression in 
response to LPS stimulation of BL20 would not be activated by parasite 
infection. The observation that the largest number of genes were recorded for 
profile 4, and that the vast majority showed no response to BW720c, supports a 
lack of response mechanism, although in some cases this model may not be 
appropriate. VCAM1 for example is a classical NF- B dependent gene but shows 
no change in expression associated with infection, and it is conceivable that 
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infection is modulating expression (repressing) of this gene in a more direct 
manner. 
Direct modulation of host gene expression can be postulated where expression is 
reversed or attenuated by infection (and may also operate for enhanced 
expression e.g. profile 1). Where expression is reversed (profile 2 and 6), it can 
be postulated that the infected cell requires the gene to be strongly repressed 
or elevated and interestingly IPA analysis of the genes in profile 6 (elevated by 
infection) showed an associated with cancer, while IPA analysis of profile 2 
(repressed by infection) showed an enrichment for genes in a range of 
categories, including cancer and apoptosis. Relative to LPS stimulation, 
repression of genes placed in profile 2 can be high (over 50 fold). These include 
repression of genes encoding the macrophage expressed MPEG1, the 
inflammatory cytokine IL15, and the major histocompatibility complex class II DY 
alpha. Repression of these genes could be predicted to be advantageous to the 
parasite infected cell by manipulating the immune response and promoting 
macrophage dedifferentiation. 
A significant number of genes in these two profiles were sensitive to BW720c, 
also indicating direct modulation by infection. How this operates requires 
further investigation but could involve parasite-encoded molecules or a 
qualitative change in bovine regulators of gene expression induced by an 
infection dependent alteration of host cell status. Previous studies have 
concluded that the differentiation state of the host cell is under control of the 
T. annulata parasite (Sager et al., 1997) and that this involves changes in 
expression regulators that regulate myeloid development (Jensen et al., 2009). 
Microarray data generated in my study and the parallel study of Kinnaird et al 
showed significant changes to the expression levels of genes encoding regulators 
of developmental gene expression. 
Like profiles 2 and 6 it can be proposed that infection promotes high level 
expression of genes in profile 1 and repression of genes in profile 5 because they 
are likely to be advantageous or detrimental to the infected cell, respectively. 
This supposition is supported by identification of gene classes in profile 1, in 
particular, previously identified as being markers for the macroschizont infected 
cell phenotype (e.g. IL2R, MMP13, ICAM1). Other potentially significant genes in 
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this profile include the lymphocyte adhesion molecule selectin L gene, the 
homeobox protein Meis 3 gene and the gene encoding cortactin. Profile 5 
represents super repressed genes and indicates a requirement for the parasite-
infected cell to down-regulate their expression. Genes encoding membrane 
proteins, including a number of important receptors are prominent in this 
profile. The data from this profile and others strongly suggests that the parasite 
significantly modulates the infected cell surface to influence interaction of the 
infected cell with a range of ligands, inflammatory mediators and cells of the 
bovine immune system. 
A prediction that the modulations represented by profiles 3 and 7 are beneficial 
by repressing or elevating target gene expression is more difficult, since they 
represent attenuation of the LPS response. Thus, elevation of a target gene 
(profile 3) could be beneficial but does not occur at the same level as BL20 cells 
stimulated by LPS (e.g. the Jun proto oncogene). On the other hand it is 
possible, as postulated previously, that high-level expression of cellular defence 
genes, such as ISG15, that occur via activation of the cell are repressed by the 
parasite infection, as they are potentially detrimental. The enrichment of 
important genes (OAS2, ISG15, MX2, IRF5 and IL7) was associated with the 
interferon/innate immune/cellular defence response (Gessner et al., 
1993;Hovanessian and Justesen, 2007;Jin et al., 1999;Lu et al., 2006;Pitha-Rowe 
and Pitha, 2007;Sieling et al., 1995). Furthermore, expression of 80% of the 
BW720c sensitive genes in profile 3 was elevated upon treatment, indicating a 
requirement for active repression by the parasite. IPA analysis for profile 7 
showed enrichment for genes predicted to have a function in cellular 
metabolism. Metabolism genes were also enriched in profile 8 and since these 
two profiles could be taken as evidence for elevation in gene expression relative 
to the LPS response, it is possible they reflect a requirement for maintenance of 
cellular metabolism pathways in the infected cell.  
4.4.3 Interpretation of qRT-PCR data 
In addition to validation of genes representing each of the 8 profiles by semi-
quantitative PCR analysis, sixteen genes candidate genes were also validated by 
real-time RT-PCR using relative quantification (∆∆Ct) methodology. Real time 
Chapter 4                                                                                                                                        179    
PCR has advantages over semi-quantitative methodology, being quicker to 
perform and relatively more sensitive, allowing quantification of lesser fold 
changes in RNA levels (Ponchel et al., 2003;Wong and Medrano, 2005). In the 
current study, the use of ACTβ or GAPDH as reference genes proved to be a good 
choice: they were validated as being equally expressed across all experimental 
conditions in both the microarray and RT-PCR experiments. These genes have 
previously been used as reference genes in several studies using RT-PCR (Habibi 
et al., 2009;Lizundia et al., 2006;Sager et al., 1997) as they allow normalisation 
of candidate genes expression against potential variation in the amount of cDNA 
used in the reaction. In addition they allowed demonstration that PCR 
efficiencies of the target genes were in the acceptable range for comparative 
analysis. This is an essential standard for ∆∆Ct equation, where the efficiencies 
of the control and target genes need to be approximately equal (Livak and 
Schmittgen, 2001). The results obtained from qRT-PCR were consistent with the 
microarray analysis and the trends in the expression pattern obtained were 
similar for all genes tested across the different expression profiles. However, 
qRT-PCR showed higher magnitudes of expression level alteration, presumably 
because qRT-PCR is a more sensitive technique than microarray (Bruder et al., 
2007). 
4.4.4 Interpretation of IPA analysis of the infection modulated LPS 
dataset 
In addition to performing analysis for predicted gene function on genes placed 
within the 8 profiles, IPA was performed on the 1052 genes of the complete 
infection modulated LPS dataset that could be mapped. This was carried out to 
give a more global assessment of the most important molecular functions, 
diseases and pathways manipulated by infection. Reassuringly, the most 
significant category mapped for the dataset was the inflammatory response, 
with many other categories that could be linked to the infected cell phenotype 
highlighted e.g. tissue morphology, cancer, cell death, antimicrobial response 
and cell signalling. Furthermore, enrichment of genes in the dataset that 
mapped to biological pathways highlighted modulation of signalling pathways 
associated with the inflammatory response and included the NF- B, TNFR2 and 
interferon signalling pathways. Thus, it can be concluded that the infected cell 
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is significantly modulating pathways and a large number of target genes that 
regulate and execute the inflammatory response and cellular transformation. 
Also, the dataset is rich for mining infection associated candidate genes that 
operate in these processes. 
Attempts were made using IPA to make the output of the analysis more 
predictive. This was performed utilising the designated pro or anti function of a 
given molecule and screening two lists representing genes displaying infection 
associated elevated or repressed expression for a change in the pro/anti bias 
across different functional categories. The power of the prediction is based on 
the number of genes enriched for each category, confidence of the IPA 
designation (accurate and unequivocal) and, preferably, an equal number of 
designated pro and anti genes. Unfortunately the gene number was often small, 
the designation equivocal and throughout the dataset a bias in pro-function was 
observed. These characteristics may, for example, have made it difficult to 
observe for the apoptosis category any obvious bias in upregulation of anti- 
together with down regulation of pro-apoptotic genes. Moreover genes 
functioning in apoptosis commonly switch from a pro to anti function depending 
on cellular context (Fannjiang et al., 2003;Hess et al., 2004b) and without 
knowledge of the context, a prediction of overall outcome would be impossible. 
Despite these caveats a number of interesting predicted outcomes were 
obtained that fit with known phenotypes displayed by Theileria infected cells 
(pro-metastasis and pro alteration of cell shape, for example). Mining functional 
categories highlighted by this analysis should provide candidate novel pathways 
and genes that operate in establishment of the infected cell. Two example 
categories are given below. 
Cancer: This category showed significant enrichment for genes in the infection 
modulated LPS-dataset. Using the IPA knowledgebase, 60 genes (24%) were 
placed in the cancer category with high statistical significance (p-value, 1.56E-
05 –1.57E-02). These include, for example, pro cancer genes MMP13, SPARC, 
NDRG1, PAK1, ICAM1, ANGPT4, IL2RB, RGS1, SELL, SERPINE2, CCR7, CTTN, 
LTB4R, SLC2A1 and TP73 which are expressed at significantly higher levels in 
parasite infection relative to BL20-LPS and are known to be involved in 
carcinoma, metastasis, tumourigenesis and malignant tumor conditions 
[reviewed in (Dummler et al., 2009;Rosette et al., 2005;Tai and Tang, 
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2008;Yamaguchi and Condeelis, 2007) and (Balbin et al., 1999;Buchholz et al., 
2003;Elnemr et al., 2003;Jiang et al., 2010;Mannori et al., 1995;Stiewe and 
Putzer, 2002)]. Interestingly the majority of these pro cancer genes and a 
significant proportion of cancer genes identified (21) were grouped in a distinct 
expression profile (profile 6; see Figure 4.18). Since this profile shows significant 
elevation of expression associated with infection but repression of expression 
associated with LPS stimulation of BL20, it can be postulated that they are likely 
to be involved in establishing the transformed infected TBL20 cell phenotype 
and possibly the loss of proliferation potential displayed by LPS stimulated BL20. 
An example of an identified pro cancer gene is MMP13, which was found to be 
robustly up-regulated (54-fold) in TBL20 cells relative to BL20 LPS. MMP13 is a 
member of the matrix metalloproteinases (MMPs), a large group of secreted 
proteinases. MMPs have been reported to be involved in a variety of 
physiological and pathological processes including tissue remodelling, 
angiogenesis, cell proliferation and regulation of tumor progression, tumor cell 
invasion and metastasis (Deryugina and Quigley, 2006;Folgueras et al., 
2004;Sounni and Noel, 2005). Furthermore, altered expression of MMPs at the 
protein and mRNA levels has been strongly correlated to poor disease prognosis 
in various human cancer studies (Kondratiev et al., 2008). 
Previous studies have reported induction of other types of MMPs (MMP9 and 
MMP2) as important mediators of the metastatic phenotype of Theileria infected 
leukocytes via in vitro or in vivo model systems (Adamson and Hall, 
1997;Adamson and Hall, 1996;Baylis et al., 1992;Somerville et al., 1998a). 
Evidence of involvement of MMPs in the metastatic potential of Theileria 
annulata infected has also been provided in initial studies where T. annulata 
infected attenuated vaccine cell lines were found to exhibit reduced MMP9 with 
a concomitant reduction in metastatic potential (Adamson et al., 2000;Hall et 
al., 1999). An association of high MMP13 production in low passage Theileria 
infected cell lines has been recently reported (Habibi et al., 2009). 
Intercellular adhesion molecule-1 (ICAM-1/CD54) is another gene whose 
expression is elevated at higher levels (12-fold) in TBL20 cells relative to BL20-
LPS. ICAM-1 is a transmembrane glycoprotein and a member of the 
immunoglobulin supergene family. Although ICAM1 is known to play an important 
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role in the immune response (Yockell-Lelievre et al., 2009), it has also been 
implicated to play a role in cancer metastasis and can illustrate tumor prognosis 
and progression in several types of cancer (Huang et al., 2004;Li et al., 1997;Lin 
et al., 2006). It has been known for some time that infection and transformation 
of bovine cells with T. annulata generates alteration at the infected cell surface 
including the appearance and loss of specific polypeptides (Shiels et al., 1989). A 
study on altered surface marker expression in T. annulata was performed where 
attempts were made to characterise a novel surface glycoprotein of 125 kDa. 
Peptide sequencing results indicated sequence homology with human ICAM-
1(Dando, 1997). 
Recently Jensen et al., (2008) have also shown that mRNA expression level of 
ICAM-1 is up-regulated following infection of monocytes with T. annulata 
infected cells. In addition it was shown that while the level of ICAM1 mRNA was 
similar in infected monocytes derived from disease susceptible (Holstein) and 
disease resistant (Sahiwal) breeds at 2 h post infection the level of mRNA was 
significantly reduced in Sahiwal-derived monocytes at 72 h post infection. 
Expression of the ICAM-1 gene is regulated by NF- B (Chen et al., 
2001;Voraberger et al., 1991), and IPA canonical and custom pathway analysis 
identified ICAM1 as an infection modulated NF- B signaling response genes. 
Therefore it is possible that modulated ICAM-1 in different breeds could be due 
to differences in the level of NF- B activation or a qualitative difference in a 
parasite dependent mechanism that modulates the expression of NF- B target 
genes. Interestingly NF- B regulated expression of ICAM-1 has also been shown in 
other apicomplexan parasite system, Plasmodium falciparum; elevated 
expression of ICAM1 occurring in human brain microvascular endothelial cells in 
response to exposure to Plasmodium falciparum-infected erythrocytes (Tripathi 
et al., 2006). 
Expression of ICAM-1 is known to have crucial role in cell–cell contact and cell–
matrix adhesion and is associated with contact-mediated immune responses 
(Boyd et al., 1988). The significance of ICAM-1 expression in the pathogenesis of 
Theileria infection is not clear. However, studies on T. parva have shown that 
continuous proliferation requires surface stimulation mediated via cell-cell 
contact (Dobbelaere et al., 1991a) and it is possible that ICAM-1 plays a role in 
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this process (Boyd et al., 1988) as well as recruitment of and interaction with 
cells of the immune response. Further investigations are required to characterise 
the role ICAM-1 expression in determining establishment and virulence of the T. 
annulata infected cell. 
Secreted protein acidic and rich in cysteine (SPARC/Osteonectin/BM-40) is 
another interesting gene found to be up-regulated by 53-fold in Theileria 
infected cells relative to BL20-LPS (placed in profile 6). SPARC is a matricellular 
protein that influences cell-matrix interactions and has been reported to have 
multiple functions playing a role in immune evasion, inflammatory processes cell 
morphology, Inhibition of cell cycle progression and synthesis of the 
extracellular matrix (Bradshaw and Sage, 2001;Rempel et al., 2001;Rittling and 
Chambers, 2004). In addition to its normal physiological role, SPARC has been 
correlated with cancer progression, as many cancer types exhibit increased 
SPARC levels upon invasion or metastasis (Massi et al., 1999;Podhajcer et al., 
2008;Yamashita et al., 2003). Furthermore, SPARC is well established to have 
pro-invasive activity and is known to alter the process of transformation related 
to tumor-host interaction (Fenouille et al., 2011c). 
Recent studies have implicated an interesting connection between expression of 
SPARC and the tumour suppressor p53 in melanoma cells (Fenouille et al., 
2011b).  Essentially these studies showed that SPARC can act as an anti-stress 
factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to 
promote melanoma cell survival. SPARC, PI3K/AKT has also been shown to be a 
potent pro-survival pathway that contributes to the malignancy of gliomas and in 
this system SPARC may mediate survival through increased AKT and decreased 
caspase 3/7 activity (Shi et al., 2004). Whether SPARC could play a related role 
in Theileria infected cells is unclear, but worthy of consideration. The 
acquisition of a survival pathway promoting resistance to apoptosis is a 
characteristic feature of Theileria infected cells and has been linked to 
constitutive activation of both NF- B and PI3-K/AKT pathways (Baumgartner et 
al., 2000;Heussler et al., 2001). The prediction from the findings of Fenouille et 
al. would be that if SPARC operated in a similar manner in Theileria infected 
cells, p53 protein levels would be reduced due to elevated degradation 
promoted by MDM2. Interestingly findings by the Glasgow group indicate that 
while levels of p53 mRNA are high, protein levels are virtually undetectable in T. 
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annulata infected cells (Shiels and McKellar unpublished) and similar results 
implicating a role for MDM2 and constitutive degradation of p53 have been 
obtained by Yashida et al (personal communication). p53 has been implicated in 
repression of SPARC expression via tumor protein 53 induced nuclear protein 1, 
TP53INP1 (Seux et al., 2011). TP53INP1 expression is down regulated in Theileria 
infected cells relative to LPS stimulated BL20 (profile 2). Moreover SPARC is 
identified in my study as an elevated NF- B response gene (see Figure 4.28) and 
has previously described as a c-Jun-responsive target gene (Briggs et al., 2002). 
Thus, it would appear that the infected cell promotes expression of SPARC and 
further investigation of the role of this oncogenic protein in establishment of the 
transformed phenotype is warranted. 
Additional genes that could promote a cancer phenotype of the T. annulata 
infected cell include NDRG1, ANGPT4, CCR7, XCL2 and CCL1. These genes have 
not been previously associated with the infected cell but were expressed at 
significantly higher fold differences relative to uninfected BL20-LPS. 
Overexpression of NDRG1 has been reported in different human prostate, breast 
and colon cancers and renal cell carcinomas (Cangul, 2004;Caruso et al., 
2004;Nishie et al., 2001). Similarly, ANGPT4 has been implicated in promoting 
tumor cell progression by enhancing viability and angiogenesis in human 
glioblastoma (Brunckhorst et al., 2010). In summary, the microarray results 
strongly suggest an association of parasite infection in acquiring a cancer like 
cell phenotype. Identification of novel candidate genes and potential pathways 
will help to provide more detailed understanding of how the parasite 
manipulates the infected cell to achieve this state. 
Cellular assembly and organisation: IPA significantly identified 17 genes in the 
infection-modulated dataset categorised as involved in cellular assembly and 
organisation. Genes belonging to this functional category were found to be 
distinctly up-regulated by parasite infection. Interesting genes include CTTN, 
SDC4, ICAM1, PAK1, ELN, SPARC, SORBS1, TNS1 and F2R that encode proteins 
involved in the formation of actin filaments and cellular protrusions, 
reorganisation of cytoskeleton, assembly of focal adhesion, size of lamellipodia 
and formation of podosomes (Barker et al., 2005;Cosen-Binker and Kapus, 
2006;Illes et al., 2006;Longley et al., 1999;Papakonstanti and Stournaras, 
2002;Robinet et al., 2005;Webb et al., 2005;Webb et al., 2006;Yang et al., 
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2006). Theileria infection is known to alter the morphology of the infected host 
cell (Baumgartner, 2011b;Schneider et al., 2007;Shiels et al., 2004) and it has 
been postulated that changes to the cytoskeleton impact on parasite dependent 
host cell activation and transformation status (Schmuckli-Maurer et al., 2010). 
However the mechanisms and molecules underlying these changes are not 
understood completely. 
Recent elegant studies performed by Baumgartner (2011b) have shown that 
parasite dependent polarisation of actin based structures are critical for both 
attachment to substrates and motility [reviewed by (Baumgartner, 2011a)]. Thus 
Baumgartner (2011b) showed that T. annulata infection promotes alterations to 
the actin cytoskeleton of macrophage to regulate adherence and cell motility via 
enhanced podosomes and lamellipodia formation. Cell movement involves a 
sequential process that requires cell protrusions at the leading edge and 
retraction at the trailing edge of the cell, and the actin cytoskeleton plays a 
critical role in both processes. Furthermore polarised infected cell morphology is 
characterised by the formation of actin-rich single lamellipodium and cortactin-
rich podosome type-adhesions (PTAs). Modulation of host cell actin dynamics has 
also been linked to the virulent host cell phenotype (Chaussepied et al., 2010) 
by demonstration of a difference in the TGF-b2 dependent invasive potential of 
Theileria-transformed cells derived from disease resistant and susceptible 
cattle, and a cell line with an attenuated virulence profile. Thus, Theileria 
infected disease susceptible macrophages were found to exhibit increased actin 
dynamics in their lamellipodia and podosomal adhesion structures and develop 
more membrane blebs. Molecules thought to function in regulation of these 
structures include the Src kinase, Hck; the Rho kinase, ROCK, cortactin and ERM 
proteins [Reviewed by Baumgartner, 2011a). 
The finding that expression of the cortactin (CTTN, also known as EMS1) and Hck 
genes are up-regulated at higher levels (4.4-fold and 6.3 fold, respectively) in 
TBL20 cells relative to BL20-LPS (profile 1) is, based on the above studies, likely 
to be of importance to regulation of cell shape. This difference for cortactin was 
even higher (25-fold) in TBL20 when compared to BL20 cells. CTTN has been 
shown to enhance lamellipodial persistence and the rate of adhesion formation 
in lamellipodia, consistent with an important function in regulation of directed 
cell motility (Bryce et al., 2005). Modulation of cell motility and cell adhesion is 
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also believed to be an essential phenomenon for metastasis and arises as a result 
of changes in the cytoskeletal architecture (Yamaguchi et al., 2005). Over 
expression of cortactin has been reported to promote contact and 
communication between the cell and the extracellular environment by 
modulating the clustering of ICAM1 and selectin receptors on endothelial cells in 
order to promote adherence of leukocytes at the site of inflammation (Barreiro 
and Sanchez-Madrid, 2009;Tilghman and Hoover, 2002). All of these molecules 
(CTTN, ICAM1 and SELL) were expressed at an elevated level in infected cells in 
my study (all profiled 1, enhanced elevation), and RT-PCR results successfully 
validated the microarray data (see Figure 4.9). Interestingly in line with previous 
findings in other cellular models (Barker et al., 2005;Longley et al., 
1999;Robinet et al., 2005), the array data identified additional up-regulated 
genes SDC4, PAK1, ELN and SAPRC that have potential roles in altering host cell 
cytoskeletal dynamics in the Theileria infected cell. 
The gene "PAK1" encoding the p21 protein (Cdc42/Rac)-activated kinase 1 
(family member of serine/threonine p21-activating kinases) was significantly up-
regulated (>22 fold) in Theileria infection compared to BL20-LPS (profile 6) the 
elevation profile being confirmed by semi-quantitative RT-PCR (see Figure 4.19). 
Pak1 has been reported to have a number of functions including cell survival and 
motility, proliferation, and has been implicated in cell transformation and tumor 
progression (Huynh et al., 2010). Furthermore, the role of Pak1 in coordinating 
the dynamics of the actin and microtubule cytoskeletons during directional 
motility of cells, cell-cell contact [reviewed by (Bokoch, 2003)] and formation of 
lamellipodias and filopodias (Crespin et al., 2009) has been reported. It is also 
well known that cell-cell contact of Theileria infected T cells increases their 
proliferation (Chaussepied et al., 2006;Dobbelaere et al., 1991b) and the 
formation of actin-rich single lamellipodium and cortactin-rich podosome type-
adhesions has been reported recently (Baumgartner, 2011b). Due to the function 
of Pak1 as a key molecule in the regulation of actin dynamics further studies are 
required to investigate the consequence of up-regulating this gene on the 
transformed phenotype of the Theileria infected cell. For example PAK plays a 
crucial role in formation of podosomes and membrane ruffles and can 
phosphorylate cortactin to regulate the dynamics of branched actin filaments 
(Webb et al., 2006). More intriguingly, PAKs have been reported to activate 
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transcription factors associated with the Theileria infected cell: ATF2, c-Jun and 
NF- B (Neumann et al., 2006). Furthermore PAK1 also mediates signals through 
PI3K and Akt to sustain cell transformation. 
Cellular defence and inflammatory response genes: A number genes associated 
with host cell defence responses against invading pathogens and the immune 
responses were identified in analysis of the microarray data. Many of the genes 
identified within this category are regulated by NF- B, encoding proteins 
involved in signaling and regulation of transcription, as well as immune 
responses and defence mechanism pathways. Among these genes several 
cytokine and chemokine receptor genes were differentially expressed in TBL20 
and BL20-LPS cells. These included genes encoding anti-inflammatory proteins 
(CCR7, CCL1 and XCL2) whose expression was associated with 15- to -54-fold 
enhancement in parasite infection versus LPS stimulated BL20. Modulated 
expression of the chemokine receptor CCR7 and other chemokines has also been 
reported during the early stage of infection with Leishmania major parasite in 
human dendritic cells in vitro (Steigerwald and Moll, 2005). Expression of CCL1 
and XCL2 has been implicated as key players in cancer (Arya et al., 2003). Genes 
encoding pro-inflammatory cytokines and chemokines whose expression was 
significantly down regulated by infection compared to LPS included CXCL10, 
CCL4 and IL15. CXCL10/IP-10 for example is a member of the chemokine family 
of cytokines and is induced in a variety of cell types in response to interferon 
gamma and lipopolysaccharide administration (Ohmori and Hamilton, 
1990;Ohmori and Hamilton, 1995). Elevated expression of CXCL10 has been 
reported to inhibit the process of angiogenesis (Angiolillo et al., 1995) and 
reduced tumour angiogenesis (Sgadari et al., 1996). Additionally, it has been 
reported that over expression of CXCL10 is involved in inhibition of proliferation 
process in variety of cell types including endothelial and melanoma cells 
(Feldman et al., 2002;Luster et al., 1995;Nagpal et al., 2004;Romagnani et al., 
1999). Manipulation of chemokines/chemokine receptor expression is certainly 
an exciting area of research in the field of host-parasite interaction as 
expression of these factors can be used to either enhance or limit various 
cellular responses to infection. It is clear that the parasite interacts with and 
manipulates the immune and innate cellular defence responses. Further 
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investigation of the genes identified will provide greater insight into how the 
parasite avoids host defence mechanisms and stimulates them to cause disease. 
4.4.5 Interpretation of pathways analysis and modulation of 
pathway response genes  
The most significant pathways modulated by parasite infection were TNFR2, 
pattern recognition receptors, CD40, NF- B, PI3K, LPS stimulated MAPK and 
interferon signaling pathways. Detailed exploration of individual pathways 
revealed that many of the transcripts identified were commonly associated with 
other pathways. Moreover, an event that is common to many of these pathways 
is the activation of NF- B and the general implication is that the parasite 
infection of BL20 modulates signalling pathways associated with the 
inflammatory response relative to LPS stimulated BL20. Indeed the results of the 
study demonstrate that the Theileria parasite modulates the NF- B at multiple 
levels. Firstly the parasite constitutively activates NF- B by sequestration and 
activation of the IKK signalosome to its surface (Heussler et al., 2002). This 
event may be aided by manipulation of the host actin cytoskelelton (Schmuckli-
Maurer et al., 2010) and involve elevation of PAK1 pathway genes (see above). 
Interestingly the microarray data generated little evidence for repression of the 
signalling pathway below the level of the activated signalosome: the repression 
of the IkB inhibitor (relative to LPS) would promote NF- B activation. Secondly 
the parasite infected cell clearly represses expression of the gene encoding the 
TLR4, a major receptor that recognises extrinsic signals that activate NF- B, 
(see chapter 3). Thirdly results from the custom pathway analysis indicate that 
infection relative to LPS stimulation modulates the response of NF- B activation 
by either repression or elevating target gene expression. Thus a major premise 
of this study that the parasite infection modulates the outcome of activation is 
supported by the pathway analysis. The postulation that this modulation event is 
likely to be beneficial to the establishment of the infected cell is also indicated. 
For example, NF- B response genes repressed in parasite infected cells showed 
enrichment by IPA for pro inflammatory response genes and pro differentiation 
of leukocytes. 
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Two genes included in the modulated dataset of NF- B target encode  molecules 
(ICAM-1 and VCAM-1) that have important functional roles in cellular adhesion 
and immune responses (Van and Mallard, 2001). Both genes were up regulated by 
LPS in uninfected BL20 and are known be regulated by immunomodulators, such 
as LPS and PMA and cytokines, including TNF-α (Bevilacqua, 1993;Carluccio et 
al., 2007;Fakler et al., 2000). Additionally, these molecules are known to 
contain sequences consistent with NF- B and AP-1 binding sites (Dhawan et al., 
1997;Iademarco et al., 1992;Lindner and Collins, 1996;Roebuck and Finnegan, 
1999). Despite NF- B being activated in both systems (TBL20/BL20-LPS), parasite 
infection was found to be associated with down-regulation VCAM-1(184-fold) but 
up-regulation of ICAM-1 (12-fold) when compared to BL20-LPS. At present it is 
not clear why parasite infection selectively modulates the expression of these 
two molecules. However, it is possible that activation of NF- B alone is not 
responsible for the expression of these adhesion molecules. In fact, NF- B-
independent induction of VCAM-1 has also been reported in endothelial cells 
(Wolle et al., 1996). Similarly differential expression of other host cell or 
parasite associated factor(s) could influence selective expression of these genes. 
Repressed NF- B target genes also included regulators of apoptosis. Several of 
these genes, CFLAR, CASP4, TRAF1 and WnT10B, up-regulated in BL20-LPS 
(repressed by parasite) are known to be involved in multiple biological effects on 
cells such as cell proliferation, cytokine production and cellular death response 
(Chang et al., 2002;Henkler et al., 2003;Mao et al., 2010;Speiser et al., 
1997;Yoshikawa et al., 2007;Zaitseva et al., 2011) and include caspase gene 
family members CASP4 and CFLAR that are regulators of apoptosis (see table 
4.12). The number of up regulated NF- B response genes was too small for 
enrichment analysis, but did provide some interesting candidate genes e.g. 
SPARC (see above), ICAM1 and NDRG1. 
NDRG1 was also mapped by the custom pathway analysis as a repression target 
of c-MYC. Constitutive activation of cMYC is known to occur in Theileria infected 
leukocytes and the data obtained in the present studies indicate a requirement 
for the parasite to maintain repression of these target genes. These include 
CFLAR, interferon regulatory factor 8(IRF8) and two inhibitors of the cell cycle 
(CDKN1A and CDKN2B) (Cazzalini et al., 2010;Fournier et al., 2004;Park and Lee, 
2003;Satyanarayana et al., 2008). In marked contrast to these genes, the N-myc 
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downstream regulated 1 (NDRG1) gene shows a significant elevation associated 
with parasite infection (profile 6), indicating a requirement for elevation of this 
cMYC repressed target. While NDRG1 has been associated with carcinogenesis 
(see above) elevation by the parasite infected cell is potentially 
counterintuitive. Thus NDRG1 has been proposed to be a suppressor of 
metastasis (Liu et al., 2011) and has been found to operate as an attenuator of 
NF- B activation (Hosoi et al., 2009). However the function of NDRG1 can be 
strongly influenced by cellular context and has been linked to p53 dependent 
apotosis by some studies, while others have attributed pro-survival and anti-
apototic functions [reviewed by (Kitowska and Pawelczyk, 2010)]. Interestingly, 
a role for NDRG1 at the spindle check-point of mitosis has been shown and it is 
thought to be important for maintaining correct microtubule functioning (Kim et 
al., 2004a) and spindle formation. Recent work by the group of Dobbelare have 
shown an intricate relationship between the Theileria schizont and host cell 
mitotic and central spindles, dependent on recruitment and catalytic activity of 
host cell Polo-like kinase (von et al., 2010). Further work investigating the role 
of NDRG1 in the relationship between parasite and host cell spindle would be of 
interest. 
A further relevant pathway identified within the modulated dataset was 
PI3K/AKT. Of particular note, two cytosolic effectors or regulatory subunit 
(PIK3R5, and PIK3R6) of PI3K were identified to be up-regulated in parasite 
infection. PI3K/AKT is implicated in the process of proliferation and cell survival 
[reviewed in (Fresno Vara et al., 2004;Hennessy et al., 2005;Osaki et al., 2004)]. 
Acquisition of survival pathways in promoting resistance to apoptosis is a 
characteristic feature of Theileria infected cells and has been linked to 
constitutive activation of the PI3-K/AKTpathway (Baumgartner et al., 
2000;Heussler et al., 2001). 
In summary, analysis of the microarray data presented in this chapter 
demonstrate that although the gene expression profiles of LPS stimulated 
uninfected BL20 and infected TBL20 cells significantly overlap, parasite infection 
promotes a major reorganisation of gene expression associated with cellular 
activation. Moreover, the findings indicate that parasite infection can modulate 
the outcome of a host cellular activation state in a manner that is predicted to 
Chapter 4                                                                                                                                        191    
be beneficial for establishment and survival of the proliferating transformed 
cell. 
Further work is needed to examine alteration of host gene expression at the 
proteomic level as well as test for predicted functional implication of altered 
expression. Investigations are also required to identify the mechanisms that the 
parasite utilises to manipulate the outcome of cellular activation. This is likely 
to involve a major reorganisation of host factors and chromatin states that 
regulate gene expression, as identified in a parallel microarray study conducted 
by Kinnaird et al., (unpublished).  However the export of polypeptides from the 
parasite that have the potential to manipulate gene expression could also be 
involved (Shiels et al., 2004). Parasite encoded AT-hook DNA-binding proteins of 
the TashAT family have been implicated in altering gene expression in 
transfected uninfected bovine macrophage cells (Oura et al., 2006). In addition, 
Theileria AT hook DNA binding protein SuAT1 (Shiels et al., 2004) and secreted 
Theileria protein (TaSE) (Schneider et al., 2007) has been identified as possible 
parasite regulators of host cell morphology. The work in the next chapter set out 
to investigate whether a TashAT2 gene could alter bovine gene expression in a 
related manner to parasite infection and manipulate the outcome of stimulation 
with inflammatory mediators. 
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5 Global identification of modulated gene 
expression in a bovine macrophage (BoMac) 
cell line stably transfected with the T. annulata 
TashAT2 gene 
5.1 Introduction 
In the previous chapter, it was established using a comparative microarray 
analysis approach that T. annulata infection imposes a remarkable level of 
control over host cell gene expression by modulating the outcome of a 
classical cellular activation response that is typically stimulated by 
inflammatory mediators such as LPS. An important question is how might the 
Theileria macroschizont stage achieve this degree of control over host cell 
gene expression? Increasingly, evidence points to multiple mechanisms that 
converge to promote a modulated activation status required for 
establishment, proliferation and dissemination of the parasite infected cell. 
It is highly probable that significant modulation of host gene expression by 
apicomplexan parasites occurs via secretion of regulatory molecules into the 
host cell compartment. Within the Apicomplexa, predominantly in 
Toxoplasma, Plasmodium and Theileria, a number of proteins synthesised by 
the parasite have been located in the host cell (Luder et al., 2009;Plattner 
and Soldati-Favre, 2008;Ravindran and Boothroyd, 2008;Saeij et al., 2007) 
and data indicates that some interfere with the host cell signal transduction 
pathways. Theileria parasites are unique in that, unlike Plasmodium and 
Toxoplasma, they do not develop within a parasitophorous vacuole following 
invasion and the macroschizont membrane is in direct contact with the host 
cell cytoplasm (Shaw, 2003). It has been proposed that because of this 
fundamental difference in transport, control mechanisms engendered by 
apicomplexan secreted molecules are unlikely to be highly conserved 
(Ravindran and Boothroyd, 2008). In T. gondii infection it has been shown 
that parasite actively subverts host defence responses and co-opts various 
host cell processes. These processes have been shown to involve various 
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candidate parasite proteins secreted via the surface or from secretory 
organelles such as rhoptries, micronemes and dense granules into the host 
cell compartment during invasion process. Secreted molecules include protein 
phosphatase 2C (PP2C-hn) and rhoptry protein 16 (ROP16) both of which have 
been located to the host nucleus (Gilbert et al., 2007;Ong et al., 2010). 
Additionally, ROP16 has been reported to influence the activation of host 
signal transducer and activator of transcription (STAT) signalling pathways 
and expression of STAT target genes such as interleukin (IL)-12 (Saeij et al., 
2007). Since Theileria macroschizonts do not possess rhoptries, an orthologue 
of ROP16 could be considered unlikely to play role in maintaining the 
transformed host leukocyte. 
Activation of NF- B is central to the establishment of the Theileria 
transformed leukocyte and has been implicated in modulation of the host cell 
apoptosis and survival pathways in both Toxoplasma gondii and Plasmodium 
[reviewed in (Leiriao et al., 2004) and (Nash et al., 1998;Payne et al., 2003)]. 
In Theileria, NF- B is activated via aggregation of IKK complexes on the 
surface of the macroschizont (Heussler et al., 1999;Heussler et al., 2002) but 
evidence for this event was not obtained for Toxoplasma (Molestina et al., 
2003;Molestina and Sinai, 2005). Recently, a parasite derived protein; TpSCOP 
has been shown to be involved in the activation of NF- B in T. parva-infected 
lymphocytes (Hayashida et al., 2010), but the parasite molecule responsible 
for aggregation of the IKK signalosome at the parasite membrane is still 
unknown (Schmuckli-Maurer et al., 2010). 
Results obtained from chapter 4 showed a range of NF- B target genes 
associated with cellular activation were differentially regulated in parasite 
infected cells. In T.annulata there is evidence that modulation of gene 
expression in the infected cell occurs by secretion of parasite encoded 
regulatory molecules that have the ability to localise to the host cell nucleus. 
T. annulata genome sequence data has identified a number of parasite genes 
that could function to manipulate the phenotype of infected cells (Pain et 
al., 2005). Parasite polypeptides have been identified that are likely to be 
expressed on the surface of parasite or secreted into the host cell 
compartment. Some of these polypeptides have been described as potential 
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candidates for manipulators of gene expression and are known to possess 
signal peptides, nuclear localisation signals and DNA binding motifs. These are 
encoded by members of the TashAT and SuAT gene families (Shiels et al., 
2004;Swan et al., 1999;Swan et al., 2001;Swan et al., 2003). Transfection of 
a construct expressing the T. annulata TashAT2 protein in uninfected bovine 
macrophages resulted in identification of a number of differentially expressed 
host genes by proteomic and RNA display analysis (Oura et al., 2006). 
Although relatively small-scale, this analysis served to underpin the potential 
importance of parasite encoded TashAT proteins in manipulation of host cell 
gene expression. 
The TashAT cluster of T. annulata contains seventeen contiguous genes, 
twelve of which encode proteins that are predicted to localise to the host 
nucleus (Pain et al., 2005). Recent studies using comparative genomic 
analysis have also revealed that the TashAT and related T. parva TpHN gene 
clusters are probably specific to Theileria species that transform the 
leukocytes (Shiels et al., 2006;Weir et al., 2009). Experimental data obtained 
to date confirms that five TashAT parasite proteins are detected in the 
nucleus of infected leukocyte. In addition to localising to the host nucleus, 
members of TashAT family (TashAT1/3, TashAT2, and SuAT1) possess domains 
containing AT hook motifs that suggest the ability to bind DNA (Shiels et al., 
2004;Swan et al., 1999) and TashAT1 and 2 have been experimentally shown 
to bind to AT-rich DNA sequences (Shiels et al., 2004;Swan et al., 1999;Swan 
et al., 2001). 
AT hooks are DNA binding motifs that show conservation in arrangement and 
sequence across multiple alleles of SuAT1, TashAT2 and TashAT3, implying 
they confer functional and target specificity (Swan et al., 2001;Weir et al., 
2010). Interestingly AT hook motifs are also found in a range of DNA binding 
proteins including the mammalian High Mobility Group A (HMGA) family 
(Reeves, 2010). HMG proteins act as architectural elements by modulating 
chromatin structure and, therefore, regulating expression of large numbers of 
genes that control cell fate (Cleynen and Van de Ven, 2008;Reeves, 
2001;Reeves, 2010). The majority of the HMG proteins are highly mobile, bind 
transiently to chromatin and compete with histone H1 for nucleosome binding 
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sites, thus loosening the nucleosomal structure to enable access of 
transcriptional regulators (Catez et al., 2004;Garcia-Heras et al., 2009). 
Furthermore, HMGA proteins can physically interact with a large number of 
proteins, including transcription factors such as NF- B (p50/65), AP-1, ATF-2, 
IRF1, c-Jun, Oct-1, Oct-2A, PU.1 and NF-AT (Lewis et al., 2001;Reeves, 
2001;Thomas and Travers, 2001). Recently, other important molecular 
partners have also been discovered that suggest involvement of HMGA 
proteins in a variety of functions such as DNA replication and processing of 
RNA, as well as structural organisation and re-modelling of chromatin (Sgarra 
et al., 2005). Over-expression of HMGA1 proteins has also been associated 
with certain types of malignant neoplasia and benign tumours (Catez et al., 
2004;Fedele et al., 2001;Flohr et al., 2003;Sarhadi et al., 2006;Wood et al., 
2000;Wunderlich and Bottger, 1997) and may be a central event in 
oncogenesis (Resar, 2010;Wood et al., 2000). 
HMGA1/2 potentially controls expression of a wide range of target genes, 
including those encoding inflammatory mediators and cytokines (John et al., 
1995;Lin, 2006;Martinez et al., 2004). Interestingly, TashAT2 bears three AT 
hook DNA binding motifs whose arrangement shows significant similarity to 
that in HMGA1 (Weir et al., 2010), which is known as a co-regulator of 
inflammatory response genes including those targeted by NF- B (Amiri et al., 
2006;Collins et al., 1995a;Takamiya et al., 2008;Yie et al., 1997). The 
majority of these genes are positively regulated and their promoter regions 
contain multiple stretches of AT-rich sequence. Transcriptional activation 
may involve formation of ‘enhancesosomes’ which are multi-protein 
complexes containing HMGA/transcription factors. Likewise negative 
regulation of gene transcription by AT hook proteins may occur via inhibition 
of enhancesosome formation, possibly by preventing functional binding of 
critical transcription factors to their recognition sites in gene promoters 
(Reeves, 2001). 
To date, functional analysis has shown that parasite polypeptides TashAT2 
and SuAT1 can alter the morphology of transfected bovine cells. A small 
number of candidate response genes whose RNA and protein expression may 
altered in a similar way to that observed in parasite infected leukocytes have 
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been identified (Oura et al., 2006;Shiels et al., 2004). This small-scale 
analysis confirmed that members of the TashAT family should be considered 
prime candidates as modulators of infected host cell phenotype. 
In summary, taking together the conclusive evidence of extensive modulation 
of inflammatory response gene expression, including targets of NF- B in 
parasite infected cells presented in Chapter 4, and the evidence from 
previous studies where the functional role of TashAT2 protein was partly 
characterised, it was highly relevant to undertake a global analysis to identify 
the potential of TashAT proteins to alter bovine gene expression. Given the 
structural similarity to HMGA proteins, it was of particular interest to 
determine whether any of the differentially expressed genes might also be 
targeted by NF- B or other transcription factors. The primary aims of the 
work presented in this chapter were as follows. 
Objectives of this study 
1. To use the available bovine microarray platform to perform a second 
microarray experiment to test the ability of a single member of the TashAT 
family, TashAT2, to function as a modulator of bovine gene expression, 
using a bovine cell line stably transfected with the TashAT2 plasmid. 
2. To compare any TashAT2-altered dataset with the infection-modulated 
datasets (TBL/LPS-BL20 datasets) obtained in the previous chapter, to 
reveal host genes that may be manipulated by TashAT2 in the context of T. 
annulata infection. 
3. To test the ability of TashAT2 to modulate altered gene expression induced 
by stimulation with an inflammatory mediator and compare any obtained 
dataset with the dataset representing infection-associated modulation of 
LPS induced gene expression obtained in the previous chapter. 
4. To identify transcription factor (s) target genes, in particular NF- B that 
may exhibit altered expression levels associated with to TashAT2 
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expression, and compare with the NF- B target genes identified in 
infection associated datasets. 
5. To perform Ingenuity Pathway Analysis of the TashAT2 manipulated dataset 
and compare with the results derived from the infection-associated 
datasets. 
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5.2 Methods  
5.2.1  Cell lines and culture 
Cell lines, BoMac-TashAT2 and BoMac-pCAGGS, used in this study were 
previously derived (Oura et al., 2006) by transfection of an SV40 transformed 
bovine macrophage (BoMac) cell line (Stabel and Stabel, 1995). BoMac-
pCAGGS contains a control plasmid (pCAGGS) and BoMac-TashAT2, the same 
pCAGGS plasmid expressing the TashAT2 gene.  
Also used in this study were stably transfected BL20_TashAT2, BL20_pCAGGS, 
D7-TashAT2 and D7-pCAGGS,  cell lines which were previously generated in 
this laboratory (Shiels et al.,  unpublished) using the plasmids as described 
above. BL20 is the previously described uninfected bovine lymphosarcoma 
(BL20) cell line (Chapters 2 and 3), and D7 is a T. annulata (Ankara) infected 
cloned cell line (Swan et al., 2003). Transfected BL20 and D7 cell lines were 
cultured as described in Chapter 2, except that the medium was 
supplemented with 250 µg/ml of Geneticin (Gibco; 1013-019). Transfected 
BoMac cells were cultured under similar conditions, except that 10% heat-
inactivated foetal calf serum was used with 500 µg/ml of Geneticin. BoMac 
cell lines were maintained by trypsinisation followed by dilution into fresh 
medium twice per week. 
5.2.1.1 pCAGGS-TashAT2 construct  
Generation of the pCAGGS-TashAT2 construct, transfection protocol and 
selection of lines was carried out previously and fully described (Oura et al., 
2006) Briefly, the TashAT2 coding sequence with a V5 epitope tag was cloned 
into the vector pCAGGS-Bstx1 IRES Bgeo (pCAGGS), which contains an internal 
ribosomal entry site (IRES) immediately downstream of the gene of interest, 
followed by the neomycin resistance gene. Thus the TashAT2 gene and the 
neomycin gene are transcribed as one long mRNA from a single chicken β-
actin promoter with a human cytomegalovirus (CMV) immediate early 
enhancer. This construct was called pCAGGS-TashAT2 and guarantees 
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expression of the TashAT2 transgene following successful selection of a stably 
transfected cell line. 
5.2.2  Stimulation of cells with inflammatory mediators 
Cells in logarithmic phase (approximately 5×105 cells/ml) were stimulated 
either by adding LPS (Sigma; L2630) to a final concentration of 1μg/ml for 4h 
or phorbol myristate acid (PMA) (Sigma; P8139) at 10ng/ml for 6h. Following 
stimulation, cells were harvested for luciferase assays, immunofluorescence 
assay or total RNA isolation. Prolonged stimulation (24-72h) was also 
performed where necessary for cell viability and caspase assays. 
5.2.3  Treatment of pCAGGS-TashAT2 transfected Theileria 
infected (D7) cells with BW720c 
Buparvaquone treatment of D7-TashAT2 cells was carried out as described 
(Oura et al., 2006). Cells at 1×105 /ml were incubated in the presence of 50 
ng/ml of BW720c for either 48 or 72h, followed by immunofluorescence 
assays or isolation of RNA for RT PCR.     
5.2.4  NF-B dependent reporter assay (Dual Luciferase Assay) 
and PMA stimulation 
The NF- B dependent reporter assay was essentially performed as described 
previously in Chapter 3, section 3.2.3 except that following transfection of 
the reporter constructs, BoMac cells were cultured in 75cm2 flasks and 
stimulated with PMA for 6h. 
5.2.5  Indirect immunofluorescence analysis 
Cytospin preparation of cells and indirect immunofluorescence analysis (IFA) 
of TashAT2-transfected BoMac or BL20 cells was performed using the basic 
protocol described by Oura et al (2006). Approximately 2-3 x 105 cells were 
used per cytospin preparation and centrifuged at 1500rpm for 5 minutes 
(Shandon cytospin 2).  
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For detection of the anti-V5 tag, cytospin slides were immediately fixed in 
pre-chilled methanol at -20°C for 10 min followed by acetone for 1 min. 
Detection was achieved using monoclonal anti-V5 (Sigma; V8012) primary 
antibody at 1/500 dilution in complete medium for 1h at room temperature 
(RT). The Lim Domain Only 2 (LMO2) protein was detected by IFAT using fixed 
cells as above and monoclonal anti-LMO2 (1A9-3B11) (NB110-78626) 
(Novus Biologicals, USA) at a 1/100 dilution. Slides were then washed three 
times with PBS for 3min each. Alexa Fluor 488 goat anti-mouse IgG 
(Invitrogen; A-11029) was used as secondary antibody at 1/200 dilution and 
incubated for 1h at RT followed by washing in 1× PBS. After the final wash, 
cells were counter-stained with 0.1% Evan’s blue for 1min, rinsed in 1× PBS 
and allowed to dry. Slides were then mounted in 10μl of mounting medium 
containing 50% glycerol in PBS, 4, 6-diamindino-2-phenylindole (DAPI) at 
1µg/ml and phenylenediamine at 1mg/ml. 
5.2.6  Giemsa stain analysis 
Morphological assessment of TashAT2 transfected BoMac cells following PMA 
stimulation was carried out on Giemsa stained samples. Cells were grown in 
standard culture conditions on a sterile slide in a Petri dish. 24 or 48h post-
PMA incubation, slides were air dried at room temperature for 10 min, fixed 
in absolute methanol for 20 min, dried at room temperature for 20min and 
stained in 4% Giemsa solution for 30 min. Finally the slides were rinsed in tap 
water for 5 min; air dried and examined using an Olympus BX60 microscope. 
Images were acquired by a SPOT camera and SPOTTM Advanced image 
software Version Mac: 4.6.1.26 (Diagnostic Instruments, Inc).     
5.2.7  Cell proliferation, viability and caspase 3/7 assay   
Estimation of cell numbers and viability following stimulation with PMA or 
DMSO was performed using Trypan Blue exclusion as described previously in 
chapter 3 (see section3.2.5). Each experimental condition: 24, 48 and 72h 
incubation with PMA (10 ng/ml) or DMSO (1µl/ml) as unstimulated control, 
was carried out in quadruplicate. Cell viability and caspase 3/7 activity were 
then measured as described previously in section 3.2.6 of chapter 3. Caspase 
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3/7 was measured as relative fluorescence unit (RFU) of PMA stimulated cells 
compared to DMSO-treated control cells in either pCAGGS-TashAT2 or pCAGGS 
transfected BoMacs. 
5.2.8  Comparative microarray analysis of Gene expression in 
BoMac-TashAT2 and BoMac-pCAGGS cell lines 
5.2.8.1 Total RNA Extraction, Clean-up and Quantification  
Detailed methodology of RNA extraction, DNase 1 treatment, clean up and 
quantification is described in Chapter 3 (see Section 3.2.8 & 3.2.9).  
5.2.8.2 Hybridisation and Analysis of Data 
In order to globally identify expression changes in host genes due to the 
influence of TashAT2, RNA was prepared from BoMac-TashAT2 and BoMac-
pCAGGS with and without PMA stimulation, as described in section 5.2.1-2. 
Total RNA Samples were prepared from three independent replicate cultures 
for each experimental condition. 30µg from each RNA preparation was 
submitted to Roche NimbleGen Systems for cDNA synthesis and hybridisation. 
Figure 5.1 illustrates the design of the microarray experiment and steps 
involved in the analysis of microarray data. Details of the microarray, 
hybridisation, processing of raw data, statistical analysis, Ingenuity Pathway 
Analysis and Monte Carlo simulation are described in section 4.2.  
5.2.9   Validation by semi-quantitative Reverse-Transcription 
PCR (RT-PCR) 
Gene expression changes observed in the microarray analysis were validated 
for selected genes by semi-quantitative RT-PCR followed by gel 
electrophoresis analysis of the PCR products. RT-PCR validation was 
performed using the same RNA samples prepared for microarray analysis. 
Methodology for semi-quantitative RT-PCR used was similar to that outlined in 
chapter 3. Details of gene specific primer sequences, GenBank accession 
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numbers, annealing temperature and length of predicted product are listed in 
Table 1.3, Appendix 1. 
 
Figure 5.1:  Schematic diagram illustrating microarray experimental design and the steps 
involved in data analysis 
Total RNA was isolated from BoMac cells transfected with control (pCAGGS) or pCAGGS-
TashAT2 construct; the cells were either stimulated with PMA or unstimulated.  
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5.3 Results 
5.3.1  Validation of TashAT2 expression in BL20 and BoMac 
transfected cell lines  
The gene expression analysis by microarray presented in the previous chapter 
was based on a comparison between the bovine lymphoid cell line BL20, with 
its T. annulata infected counterpart TBL20, under conditions of LPS 
stimulation. Experimental evidence has shown that TashAT2, a member of a 
parasite encoded family of DNA-binding proteins exported to the host cell, is 
involved in modulation of host cell gene expression. A BL20 cell line (BL20-
TashAT2) stably transfected with the plasmid pCAGGS –V5_TashAT2 was 
available in the laboratory and was tested as to its suitability for use in a 
global microarray analysis. Unfortunately, immunofluorescence analysis using 
a monoclonal antibody to the V5 tag showed extremely weak fluorescence in 
the nucleus of the TashAT2-transfected BL20 cells (Figure 5.1 panels A & B).  
 
Figure 5.2:  Expression levels of V5 tagged TashAT2 in the stable cell lines, BL20-
TashAT2 and BoMac-TashAT2  
TashAT2 expression was detected by immunofluorescence analysis using an anti-V5 
monoclonal antibody. (A) BL20 transfected with pCAGGS (control) (B) BL20 transfected with 
pCAGGS-V5_TashAT2 construct. (C). pCAGGS transfected BoMacs (control) (D) pCAGGS-
V5_TashAT2 transfected BoMacs 
A B 
C D 
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In contrast the previously reported (Oura et al., 2006) transfected bovine 
macrophage cell line (BoMac-TashAT2) exhibited evidence of strong 
expression of V5 tagged TashAT2 in the nucleus (Figure 5.1 panels C and D) 
compared to a control cell line transfected with plasmid vector and was used 
for the remainder of the experimental work presented in this chapter. 
5.3.2  Response of pCAGGS-TashAT2 transfected BoMac cells 
to cellular activation  
In chapter three of the current study I compared the response of uninfected 
(BL20) cells and Theileria-infected (TBL20) cells under activated cellular 
conditions. The results clearly demonstrated that stimulation of uninfected 
cells with LPS was detrimental, resulting in cell death whereas Theileria-
infected cells were refractory to LPS stimulation and continued to proliferate 
at the same rate as the unstimulated control. As an aim of the work 
performed in this chapter was to characterise the response of BoMac-TashAT2 
cell line to cellular activation by microarray analysis, preliminary experiments 
were performed to assess the influence of inflammatory mediators (LPS and 
PMA) on TashAT2 transfected and control BoMac cell lines.  
5.3.2.1 Influence of TashAT2 expression on NF- B reporter activity in 
response to LPS and PMA stimulation 
Activation of the transcription factor NF- B is a central event in Theileria-
infection of lymphoid cells. It was of major interest, therefore, to investigate 
the ability of TashAT2 to influence NF- B activity. NF- B dependent 
luciferase-reporter assays were performed to compare the levels of NF- B 
activity between BoMac-pCAGGS (control) and BoMac-TashAT2 cell lines and 
following activation with either LPS or PMA. No difference in NF- B reporter 
activity was found in non-stimulated BoMac cells expressing TashAT2 
compared to the control (Figure. 5.3). In addition, when exposed to LPS, both 
control and TashAT2-transfected BoMac cell lines exhibited no significant 
increase in NF- B reporter activity indicating that both cell lines were 
insensitive to stimulation by LPS. In contrast, significant elevation in NF- B 
reporter activity was obtained for both control and TashAT2-expressing BoMac 
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cells when Phorbol myristate acid (PMA) was used for stimulation. 
Furthermore, PMA stimulation of BoMac-TashAT2 cells resulted in a much 
greater increase in NF- B reporter activity compared to the control line. 
Therefore PMA stimulation was used to induce a cellular (NF- B) activation 
state in all further experiments. 
 
Figure 5.3:  NF- B-dependent reporter assays on BoMac cells expressing TashAT2 and 
control cells without treatment and following LPS or PMA stimulation.  
Cells were either non-stimulated (DMSO) or stimulated with LPS (4h) or PMA (6h). NF- B 
promoter activity was measured as the ratio of NF- B Firefly luciferase/renilla activity (Mean ± 
S.E, n = 4). The asterisk (*) above the bars indicates the statistical significance of the results 
(Student’s t-test, *P< 0.05, **P< 0.01) relative to control cells, whereas (n.s) indicates non-
statistical difference of TashAT2 relative to pCAGGS controls in stimulated or non-stimulated 
conditions.  
5.3.2.2 Differential growth response in pCAGGS and pCAGGS-TashAT2 
transfected BoMac cells following PMA stimulation 
Data presented in Chapter 3 demonstrated that stimulation of uninfected 
BL20 cells with LPS and constitutive activation of NF- B, led to a loss in 
viability. Theileria-infected (TBL20) cells, despite having high NF- B activity, 
were refractory to LPS induced cell death. To test whether expression of 
TashAT2 could influence the cellular activation response, the viability and 
proliferation of BoMac-TashAT2 cells compared to control cells was studied 
following PMA exposure for 24, 48, 72 hours. The results showed that growth 
potential of control cells stimulated with PMA at 24h was significantly 
* 
n.s 
** 
n.s 
n.s 
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reduced, by 1.32-fold, relative to the unstimulated control (see Figure 5.4). 
This reduction in growth rate was even more pronounced (1.9-fold) by 72h of 
PMA stimulation. In contrast, TashAT2 transfected BoMac cells displayed no 
adverse effect when stimulated with PMA and continued to proliferate at the 
same rate as the untreated control (see Figure 5.4). 
 
Figure 5.4:  Proliferation assays of pCAGGS and pCAGGS-TashAT2 transfected BoMac 
cells following PMA stimulation relative to control cells.  
Numbers of viable cells in control and BoMac-TashAT2 cultures growing in the presence of 
either PMA (10ng/ml) or the DMSO vehicle control (1µl/ml) were assessed using Trypan Blue 
exclusion at 24h, 48h and 72h exposure as described previously (3.2.5). Values are presented 
as Mean ± SE of four replicate cell cultures. The asterisk (*) sign associated with the data 
points indicate the statistical significance of the results (Student’s t-test, *P< 0.05, **P< 0.01) 
of the data points relative to controls at given conditions. 
In addition, this loss of growth was accompanied by a significant elevation in 
percentage of dead cells in the PMA stimulated control cells (see Figure 5.5) 
at 24h, 48 and 72 hours which was not seen in PMA- treated BoMAc-TashAT2 
cells. A slight increase in the percentage of dead cells at 48 and 72 h was 
obtained in all cell lines but differences between controls and BoMac-TashAT2 
PMA-treated cultures were not statistically significant and were considerably 
less than the level of cell death found for the PMA stimulated pCAGGS-
transfected BoMac cells. 
 
** * 
 
 
** 
n.s 
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Figure 5.5:  Estimation of cell death in pCAGGS and pCAGGS-TashAT2 transfected 
BoMac cells following PMA stimulation relative to untreated control cells.  
Cells were cultured in the absence (DMSO) or presence of PMA (10ng/ml) for 24h, 48h and 
72h. Cell death was measured using the Trypan Blue exclusion assay and is expressed as 
percentage of the total cell number for each culture. Values are presented as Mean ± SE of four 
replicate cell cultures. The asterisk (*) above the bars indicates the statistical significance of the 
pair wise comparisons tested against the controls (Student’s t-test, *P< 0.01) cells at given 
conditions. Whereas, n.s indicates statistically non-significant results in BoMac-pCAGGS 
TashAT2 (+/- PMA) relative to BoMac-pCAGGS (control) cells. 
To confirm that TashAT2 expressing cells were resistant to cell death caspase 
3/7 activity, a marker of apoptosis, was assayed using cell lysates obtained 
from the same cultures at 24, 48 and 72 hours. Significantly higher levels of 
caspase 3/7 activity was observed at all time points in BoMac-pCAGGS cells 
treated with PMA than in any of the other cultures (5.2, 3.8 and 2.4-fold 
increase compared to the untreated control at 24,48 and 72h respectively) 
(see Figure 5.6). This confirmed activation of the caspase cascade and 
initiation of apoptosis on stimulation with PMA in BoMac-pCAGGS cells and 
also that BoMac cells expressing TashAT2 were resistant to induction of 
apoptosis following exposure to PMA. 
  
 
  *  
* 
 * 
n.s 
n.s  n.s 
n.s n.s 
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Figure 5.6:  Caspase 3/7 activity assayed in BoMac-pCAGGS and BoMac-
pCAGGSTashAT2 cells following PMA stimulation relative to unstimulated control cells. 
Caspase 3/7 activity was determined after incubation of cells in the presence of either PMA 
(10ng/ml) or the DMSO vehicle control (1µl/ml) for 24h, 48h and 72h. Results are expressed as 
relative fluorescence units (Mean ± SE, n = 4). The asterisk (*) above the bars indicates the 
statistical significance of the pair wise comparisons (treated and untreated) tested against the 
controls (Student’s t-test, *P< 0.05, **P< 0.01) cells at given conditions. Whereas, n.s indicates 
statistically non-significant results in BoMac-pCAGGS TashAT2 (+/- PMA) relative to BoMac-
pCAGGS (control) cells. 
5.3.2.3 Morphological assessment of BoMac-TashAT2 cells compared 
to BoMac-pCAGGS control cells following PMA stimulation 
It was observed by Oura et al., (2006) that the overall morphology of the 
BoMac-TashAT2 cell line was different from the control cell line; TashAT2 
expressing cells tended to be slightly larger and more uniformly spread out 
with fewer cytoplasmic processes relative to pCAGGS control cells (see 
Figure.5.7, C and D). In this study, changes in the morphology were examined 
following exposure to PMA. Interestingly, Giemsa stain analysis of BoMac-
pCAGGS cells when stimulated with PMA had typical morphological changes 
associated with apoptosis. These included cell shrinkage, reduction in cell 
volume, formation of cytoplasmic blebs and change from a rounded cell shape 
to a more elongated shape with extended cytoplasmic processes (see Figure 
5.7, E) (Benjamin et al., 1984;Hsu et al., 1998;Malide et al., 1998). In 
contrast, as shown in Figure 5.7, F TashAT2 expressing cells displayed little 
change in morphology when treated with PMA. Additionally, these results 
 
n.s 
 ** 
 
 ** 
 
 
  ** 
 
n.s 
 
n.s 
 * 
 
 
n.s 
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suggest that the PMA-induced morphological alterations in the pCAGGS 
control cell line are associated with the detrimental outcome of cellular 
activation i.e. cell death. 
 
Figure 5.7:  Morphological analysis of BoMac-pCAGGS (control) and BoMac-TashAT2 
following PMA stimulation.  
Immunofluorescence analysis with anti-V5 monoclonal antibody of pCAGGS-transfected 
BoMacs (A) and pCAGGS-TashAT2-transfected BoMacs (B) confirming expression of 
TashAT2: Bar = 25 µm; Giemsa stain of BoMac-pCAGGS (control) cells (C), BoMac-TashAT2- 
cells (D) growing under normal culture conditions; Bar = 25 µm. Giemsa staining of control 
cells stimulated with PMA (E) and the TashAT2 expressing BoMac cell line stimulated with 
PMA (F): panel A-B, 60x and panel C-F 20x.  
A B 
C D 
E F 
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5.3.3  Microarray analysis to identify the influence of TashAT2 
on BoMac gene expression 
Microarray analysis was performed in order to test the ability of TashAT2 to 
function as modulator of bovine gene expression. RNA was prepared in 
triplicate from cultures of unstimulated BoMac-pCAGGS and BoMac-TashAT2 
cell lines and also following PMA stimulation for six hours. Array hybridisation 
and normalisation of the dataset was performed by Roche-NimbleGen as 
described in Chapter 4 and similar statistical analysis approaches were 
adopted as described in chapter four (see section 4.2.1.7.1). A number of 
pair-wise comparisons were undertaken: BoMac-pCAGGS Vs BoMac-TashAT2; 
BoMac-pCAGGS_PMA vs BoMac-TashAT2_PMA; BoMac-pCAGGS Vs BoMac-
pCAGGS_PMA. Differentially expressed genes were identified using Rank 
Product analysis applying the criteria of a fold change > 2, and FDR < 0.05. 
5.3.3.1 Differentially expressed genes identified from pair-wise 
comparisons 
The summary data from the various pairwise comparisons obtained from this 
Rank Product analysis are shown in Table 5.1. In the first pair wise 
comparison, BoMac-pCAGGS (control) vs pCAGGS-TashAT2, a total of 3,734 
genes were differentially expressed and similar numbers of up-regulated and 
down-regulated genes were identified. The highest fold changes observed 
amongst the up-regulated genes was for cadherin 2 (CDH2) which showed a 
fold change of 598 and for down-regulated genes, matrix metallopeptidase 14 
(MMP14) showed a -366 fold change. 
Similarly a large number of genes (3,927) were altered in the BoMac- TashAT2 
line relative to the control when both cell lines were treated with PMA. As in 
the non-PMA treated dataset, the highest up-regulated fold change observed 
in TashAT2 PMA-treated dataset was also that of cadherin 2 (CDH2) showing 
785-fold difference. In the gene set that was down-regulated in PMA-treated 
TashAT2 cells, the greatest fold change was observed for the transcription 
factor ERG; v-ets erythroblastosis virus E26 oncogene homolog (avian) which 
exhibited a massive -511 fold change in expression level. 
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In the third pairwise comparison, PMA response genes were identified in 
BoMac cells by comparing unstimulated BoMac-pCAGGS cells with the same 
cells under PMA stimulation. A total of 1,177 PMA response genes were 
identified in BoMac cells and of these 690 genes were up-regulated and 487 
genes were down-regulated (see Table 5.1). Here, the gene showing the 
greatest down-regulation (-19 fold) was chemokine (C-X3-C motif) ligand 1 
(CX3CL1) while the gene showing the greatest up-regulation (109 fold) was an 
un-annotated bovine clone (CO884224) representing an identified bovine EST 
(Jensen et al., 2006a) sequence.  
Table 5.1:  Summary statistics for all the pair wise comparisons undertaken in this 
microarray analysis  
Comparison 
Largest Fold 
Change 
(Absolute) 
No of Up-
regulated 
genes 
No of Down-
regulated 
genes 
Total no 
of gene 
Up Down 
1.  BoMacs pCAGGS-TashAT2 
vs BoMacs pCAGGS 
598 -366 1884 1850 3734 
2.  BoMacs pCAGGS-TashAT2 PMA  
vs BoMacs pCAGGS PMA 
785 -511 2001 1926 3927 
3.  BoMacs pCAGGS PMA vs 
BoMacs pCAGGS 
108.8 -19 690 487 1177 
Differentially expressed genes identified using Rank Product Analysis (≥ 2 fold change and 
FDR < 0.05) and selected for further analysis.  
The pCAGGS (control) vs pCAGGS-TashAT2 dataset was compared with the 
dataset of the same cell lines stimulated with PMA revealing a large number 
of commonly altered genes (n = 2,804) (Figure 5.8). These results indicate 
that a large proportion of genes (40 %) altered in BoMac-TashAT2 cells were 
also differentially regulated in the pCAGGS control BoMac response to PMA. In 
contrast, 60 % of the genes differentially expressed in BoMac-TashAT2 cells 
were also altered in TashAT2 expressing BoMac cells treated with PMA vs the 
PMA treated control. Overall, this suggests that while BoMac-TashAT2 cells 
have the ability to respond to PMA, many genes are already altered by 
expression of TashAT2. In addition, over 800 genes exhibited altered 
expression in BoMac-TashAT2 cells in response to PMA that are not normally 
sensitive to PMA stimulation. Although the majority of these were close to the 
threshold for statistical significance (755 genes), the remaining 128 showed 
large differences in fold change of expression in TashAT-PMA stimulated cells 
relative to all other cellular conditions. 
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Figure 5.8:  Commonly altered genes across experimental conditions  
Total number of genes showing altered expression levels identified by pair-wise comparisons 
is shown by Venn diagram illustration. Numbers of genes for individual and intersecting 
datasets are shown in the table. 
5.3.3.2 Identification of TashAT2 as manipulator of bovine gene 
expression 
In order to identify putative TashAT2 target genes that are also modulated by 
infection, the gene set altered by TashAT2 expression in BoMac cells was 
compared with a combined TBL20-LPS modulated and TBL20 altered gene list 
(individual lists identified previously, see Chapter 3) to generate a global list 
of 4,280 parasite infection-LPS modulated candidate genes. In an attempt to 
identify TashAT2 modulated genes, all genes obtained for dataset 1 (see 
Figure 5.8) plus a further 1,123 (883 + 240) TashAT2 modulated genes unique 
to dataset 2 (Figure 5.8) were combined for a global list of 4,857 genes 
putatively altered by TashAT2 in the absence or presence of PMA. Comparison 
of the two datasets identified an overlapping subset of 1,206 genes 
(Figure 5.9). Using Monte Carlo simulation and Chi square analysis, it was 
determined that the size of the overlap was significantly greater than would 
be expected by chance (p < 0.001). A summary of the analysis used to 
estimate the significance of the overlap is shown in Figure 5.9. 
Datasets  
Number of 
differentially 
expressed genes 
1 3734 
2 3927 
3 1177 
1 only 779 
2 only 883 
3 only 473 
1 & 2 2804 
2 & 3 553 
1 & 3 464 
1 & 2 & 3 313 
1 & 2 only 2491 
2 & 3 only 240 
1 & 3 only 151 
 
Dataset 1 
 TashAT2 Vs pCAGGS 
Dataset 2  
TashAT2 PMA Vs pCAGGS PMA  Analysis key  
Dataset 3 
pCAGGS Vs pCAGGS PMA  
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Additional filtration was performed on the overlapping dataset of 1,206 genes 
to identify those that were altered by TashAT2 expression and by infection in 
a predictable manner (i.e. up in TashAT2 and up in parasite infection or vice 
versa). This process identified a subset of 466 genes which are listed in 
Appendix 3.1.  
 
Figure 5.9:  Comparison of differentially expressed gene sets  
The lists of differentially expressed genes from the two global experimental datasets 
contained a set of 1,206 genes common to parasite infection and TashAT2-expressing 
BoMac cells. This overlap was found to be significantly larger than expected by chance 
alone (p < 0.001). A summary of the observations obtained from Monte Carlo simulation 
and Chi square analysis are also shown. 
5.3.3.3 TashAT2 modulates gene expression profiles associated with 
Theileria infection 
In the filtered dataset of 466 genes, expression of 353 genes was significantly 
repressed and 113 significantly elevated both by TashAT2 and parasite 
infection and are listed in Appendix 3.1.1 and 3.1.2, respectively. In the 
repressed gene set, 41 showed greater than ten-fold down-regulation in 
BoMac-TashAT2 when compared to pCAGGS control and also exhibited 
repression in infected (TBL20) compared to the uninfected (BL20) control. 
The 15 most down-regulated genes, ranked on expression difference between 
Number of genes expected to be 
common to lists A and B (903) 
Number of genes common to lists A 
and B (1,206) 
Number of genes not expected to be 
common to lists A and B  (7,331) 
Total number of genes in list A and 
B, not common to both lists (6,725) 
 
Overlapping gene set n = 1,206   p<0.001, highly significant 
Summary of Monte Carlo and Chi-square analysis 
4280 
Total no of genes significantly 
altered in infection-LPS modulated 
data set 
 
 
4857 
Total no of genes significantly 
altered in BoMac-TashAT2 under 
PMA stimulated and non-stimulated 
conditions 
3074 1206 3651 
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BoMac-TashAT2 and BoMac-pCAGGS are listed in Table 5.2. For example, 
expression of the Microfibrillar-associated protein 2 (MFAP2) gene is highly 
repressed in BoMac-TashAT2 cells (fold change, -52.9); and also repressed by -
22.5 fold in TBL20 cells relative to BL20 controls. 
Table 5.2:  Top 15 genes showing repression in BoMac-TashAT2 cells together with 
repression in TBL20 cells relative to BL20 cells or to the BL20 LPS response. 
 
15 genes from the filtered overlap gene set of 353 that showed the greatest level of repression 
in BoMac-TashAT2 cells where the Theileria-infected BL20 cellular model showed a parallel 
profile. Data is arranged in descending order of absolute fold difference between BoMac-
TashAT2 compared to BoMac pCAGGS. Bw720c indicates the direction of a buparvaquone 
response where present. Where expression was validated by semi-quantitative RT-PCR 
genes are highlighted in light blue. 
Two other genes of note were identified in this group. Runt-related 
transcription factor 2 (RUNX2) and tumour protein p63 (TP63) were 
significantly repressed by 11.6 and 11.4 fold respectively in Bomac-TashAT2 
relative to the control. Both also exhibited a significant degree of repression 
in parasite infection compared to control when stimulated by LPS. 
The expression profiles of six genes MFAP2, RAB15, RUNX2, TP63, C1QTNF1 
and IL18, from this group were validated by semi-quantitative RT-PCR. Thus, 
  TashAT2 transfected 
BoMac array results 
Infection associated 
TBL20 array results 
Gene 
Symbol 
Annotation TashAT2  
vs 
PCAGGS 
control 
Abs: FC 
TashAT2 
PMA vs 
Control PMA 
 
Abs: FC  
TBL20 
vs  
BL20 
 
TBL20 
LPS vs 
BL20 LPS  
Abs:FC 
(4h/or18) 
BW720c 
Response 
       
       
MFAP2 Microfibrillar-associated protein 2 -52.9 -68.4 -22.5 -8.6  
FAM20A family with sequence similarity 20, 
member A 
-31.3 -18.1 -21.3 -18.3 – 
RAB15 RAB15, member RAS onocogene 
family 
-17.5 -7.6 1.7 -5.0 – 
KIF1A Kinesin family member 1A -11.9 -14.2 -23.7 -18.0 
 
RUNX2 PREDICTED: runt-related 
transcription factor 2 
-11.6 -2.9 1.2 -5.7 – 
TP63 tumor protein p63 -11.4 -3.6 1.9 -36.7 – 
ANK1 Ankyrin 1, erythrocytic (ANK1), mRNA -11.3 -10.1 -93.6 -82.9 
 
ANGPTL1 Angiopoietin-like 1 -9.6 -3.8 -8.7 -10.4 
 
MYOM1 Myomesin 1, 185kDa -9.3 -2.9 -9.7 -8.3 
 
C1QTNF1 C1q and tumor necrosis factor related 
protein 1 
-7.4 -8.5 -150.3 -69.5 
 
LOC520070 PREDICTED: Tumor endothelial 
marker 1, 
-6.9 -6.0 -22.0 -13.9 – 
IL18 interleukin 18 (interferon-gamma-
inducing factor) 
-6.7 -3.7 -10.4 -4.3 
 
LOC515697 Apolipoprotein L, 3-like (LOC515697), 
mRNA 
-6.2 -9.4 -15.0 -11.8 
 
RASGEF1A RasGEF domain family, member 1A -5.5 -5.4 -6.2 -11.7 
 
BOLA-DOB Major histocompatibility complex, 
class II, DO beta 
-4.4 -3.7 -11.6 -27.6 
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for example, the gene encoding MFAP2 showed positive correlation of the RT-
PCR results with the microarray profile, showing strong repression both in 
TashAT2 expressing cells and in Theileria infection relative to their 
corresponding controls. Similar supporting results were obtained for RUNX2 
and TP63 mRNA where the RT-PCR analysis showed repression in Bomac-
TashAT2 cells and in Theileria infected cells relative to their corresponding 
control cell lines (BL20_LPS for TP63) (see Figure 5.10). 
 
Figure 5.10: Semi-quantitative RT-PCR validation of microarray results for selected 
repressed genes in BoMac-TashAT2 cells compared to their profiles in the BL20-
TBL20_LPS model 
The RT-PCR expression pattern of MFAP2, TP63, RUNX2, C1QTNF1, IL-18 and RAB15 genes 
in BoMac-TashAT2 cells is shown in the left panel. The panel on the right represents RT-PCR 
results for the corresponding genes in TBL20 and BL20 cells (LPS +/-). ACTB was used as a 
constitutive standard. 
113 genes had significantly elevated expression in BoMac-TashAT2 relative to 
the pCAGGS control and also showed elevated expression in Theileria infected 
cells when compared to BL20 cells either without or in the presence of LPS 
(LPS +/-) (see Appendix 3.1.2). 19 genes in this group showed an elevation 
greater than 10 fold and the top 15 are shown in Table 5.3. These included 
Von willebrand factor a domain containing 5a (VWA5A) elevated by 116 fold, 
Melanoma associated antigen (mutated) 1-like 1 (MUM1L1), 91 fold, Collagen 
type viii, alpha 1 (COL8A1), 74 fold, Thymocyte selection-associated high 
mobility group box (TOX), 64 fold and RasGEF domain family, member 1B 
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(RASGEF1B) by 5.8 fold. Furthermore, these genes also showed elevated 
expression in TBL20 relative to BL20 (LPS+/-) cells (Table 5.3). 
Table 5.3:  Top 15 genes showing elevation in BoMac-TashAT2 cells together with 
elevation in TBL20 cells relative to BL20 cells or to the BL20 LPS response. 
 
The top 15 genes whose expression is significantly elevated in BoMac-TashAT2 and in the 
Theileria-infected BL20 cellular model are shown. Data is arranged in descending order of 
absolute fold difference between BoMac-TashAT compared to the BoMac-pCAGGS (control). 
Bw720c indicates the direction of a buparvaquone response where present. Where 
expression was validated by semi-quantitative RT-PCR genes are highlighted in light blue. 
Six members from this elevated group were validated by RT-PCR, and the 
results gave good correlation with the profile obtained by microarray. For 
example, genes encoding VWA5A, COL8A1, MUML and ALDH1A1 showed a 
clear elevation in the amount of PCR product in BoMac-TashAT2 cells relative 
to BoMac-pCAGGS control cells. A pattern of elevated expression was also 
observed for these genes in TBL20 cells when compared to BL20 (LPS+/-) cells 
(see Figure 5.11). 
  TashAT2 transfected 
BoMac array results 
Infection associated 
TBL20 array results 
Gene 
Symbol 
Annotation TashAT2  
vs 
PCAGGS 
control 
abs: FC 
TahAT2 PMA 
vs control 
PMA 
 
abs: FC  
TBL20 
vs  
BL20 
 
abs: FC 
TBL20LPS 
vs BL20 
LPS  
abs:FC 
(4h/or18) 
BW720c 
Response 
       
       
VWA5A Von willebrand factor a domain 
containing 5a 
116.3 199.8 31.5 33.2 – 
MUM1L1 Melanoma associated antigen 
(mutated) 1-like 1 
91.4 85.2 28.8 25.8 – 
COL8A1 Collagen, type viii, alpha 1 74.9 100.6 5.0 3.2  
TOX Thymocyte selection-associated 
high mobility group box 
64.2 32.8 8.1 3.5 – 
TMEM62 Transmembrane protein 62 61.8 50.9 22.8 65.5 – 
PRSS23 protease, serine, 23 16.7 31.2 23.3 30.6 – 
INPP4B Inositol polyphosphate-4-
phosphatase, type II, 105kDa 
14.8 23.2 4.0 2.1  
ALDH1A1 Aldehyde dehydrogenase 1 family, 
member A1 
10.5 112.8 14.0 64.4  
PDE3B Phosphodiesterase 3B, cGMP-
inhibited 
9.1 11.7 3.0 2.3 – 
SORL1 Sortilin-related receptor, L(DLR 
class) A repeats containing 
8.9 6.5 4.1 18.5  
ZBTB20 Zinc finger and BTB domain 
containing 20 
7.0 5.7 6.7 16.1 – 
RASGEF1B RasGEF domain family, member 1B 5.8 9.4 32.9 2.14 – 
SERPINE1 Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
Inhibitor type 1), member 1 
4.3 3.2 67.6 43.6  
RNASEL Ribonuclease L (2',5'-
oligoisoadenylate synthetase-
dependent) 
2.6 3.1 18.6 72.8 – 
SLC6A6 Solute carrier family 6, member 6 2.4 2.3 55.6 8.3  
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Figure 5.11: Validation of microarray results for selected up-regulated genes in BoMac-
TashAT2 cells compared to their profiles in the BL20-TBL20_LPS model.  
Semi-quantitative RT-PCR results showing the expression pattern of genes elevated in 
TashAT2-BoMacs and in Theileria infected TBL20 cells, relative to their respective controls. 
Panel on the left shows RT-PCR results of mRNA expression pattern of vWA5A, COL8A1, 
MUM1L1, SERPINE1, SLC6A6 and ALDH1A1 in BoMac-TashAT2 and BoMac-pCAGGS cell 
lines. Panel on the right shows RT-PCR results for the corresponding genes for TBL20 and 
BL20 (LPS +/-) cells. ACTB was used as a constitutive standard. 
5.3.3.4 Ingenuity Pathway Analysis of the overlapping gene set 
identified for TashAT2 transfected BoMacs and Theileria 
infection. 
Following identification of the common set of differentially expressed genes 
between the TashAT2 and infection-modulated global datasets, Ingenuity 
Pathway Analysis (IPA) was performed to identify potentially important 
biological functions and disease categories that could be associated with 
modulation of host gene expression by TashAT2/parasite infection. Thus, the 
dataset of 1,206 genes was uploaded to IPA software suite and analysis was 
performed to identify significant biological functions and disease categories, 
canonical and custom pathways, and target genes of selected known 
infection-associated transcription factors. 
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5.3.3.5 TashAT2 modulates set of genes enriched for important 
functional categories associated with Theileria infection. 
Functional analysis of the dataset identified significant enrichment of genes 
for important biological function and disease categories. The statistical 
analysis used by IPA for determining the p-value for each functional category 
is discussed previously in Section 4.3.3.1. Important categories identified 
include; Cancer, Cell Death, Inflammatory Disease, Cellular movement, 
immunological disease, Cellular Growth and Proliferation, Cell-Cell-Signaling 
and Interaction, and Cell morphology (See Figure 5.12). The complete list of 
molecular functions and disease categories identified in TashAT2/infection 
modulated dataset is presented in Appendix 3.4. 
 
Figure 5.12: Selected key biological functions and diseases categories identified as 
significantly enriched by IPA in the TashAT2-modulated dataset  
Biological functions associated with genes in the TashAT2-altered overlapping dataset of 1,206 
genes are shown along the y-axis with the significance of the enrichment (–log transformed) 
denoted along the x-axis. Each bar represents –log (p-value) for the enrichment of genes in a 
category. The orange vertical line represents the threshold for significance (p-value = 0.05). 
Interestingly most of the functional categories highlighted were also 
indentified in the IPA performed in Chapter 4 on the parasite modulated LPS 
dataset (TBL20-M-LPS). However, the significance of the enrichment for 
different categories differed between the two analysis with Cancer 
highlighted as most significantly enriched followed by inflammatory disease 
and Cell death for the TashAT2 IPA, while for the infection modulated LPS 
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dataset IPA order of significance was ‘Inflammatory Response’, ‘Tissue 
Morphology’, ‘Celular Development’, ‘Cellular Movement’, ‘Cell Death’, 
‘Inflammatory Diseases’, ‘Cancer’ and so on (see Appendix 2.2 for the 
sequence of full analysis). 
IPA was also performed on the subset of 466 TashAT2-modulated genes that 
show the same directional change of expression in response to parasite 
infection of BL20. The functional categories obtained by IPA for this subset 
was then compared to the analysis performed on the complete 
TashAT2/infection overlapping dataset of 1,206 genes, with the proportion of 
genes altered in each category being computed. Thus, it appeared that a 
greater percentage of genes were altered for the categories of Cancer 
(26.6%), Immune response (12%) and Cell morphology (12.2%) in the subset of 
genes relative to complete dataset (20.8%, 7.6% and 6.9% genes altered in 
these categories, respectively). A summary of the results is presented in 
Appendix 3.4. Many of the genes identified were placed in multiple categories 
within the IPA knowledge database. While this indicates a possible diverse 
functional role of these genes, it may hinder identification of the primary role 
that they may play in determining the phenotype of the TashAT2-transfected 
BoMac or parasite-infected TBL20 cell. 
As highlighted above, the number of genes enriched in the category ‘Cancer’ 
was highly significant for the TashAT2-modulated and infection-modulated 
datasets. Important genes in this category included Aldehyde dehydrogenase 
1 family, member A1 (ALDH1A1), Angiopoietin-like 1 (ANGPTL1), 
Apolipoprotein D (APOD), Bone marrow stromal cell antigen 2 (BST2), CD3g 
molecule, gamma (CD3G), Insulin-like growth factor binding protein 6 
(IGFBP6), LIM domain only 2 (LMO2), Melanoma associated antigen (mutated) 
1-like 1 (MUM1L1), Ribonuclease L (2',5'-oligoisoadenylate synthetase-
dependent) (RNASEL), sphingosine-1-phosphate receptor 1 (S1PR1), Serpin 
peptidase inhibitor, clade E, member 1 (SERPINE1), Tumour protein 63 (TP63) 
and von Willebrand factor A domain containing 5A (VWA5A) (see Appendix 
3.6).  
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Another interesting category modulated by TashAT2 and infection was 
‘Inflammatory response’ which included genes placed in relevant sub-
categories such as ‘immune response’,’inflammation’, ‘phagocytosis of cell’, 
and ‘adhesion of phagocytes’. Important genes identified within this category 
included Interleukin 18 (IL18), Interferon regulatory factor 8 (IRF8), Inhibitor 
of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE), 
Interferon (alpha, beta and omega) receptor 2 (IFNAR2), Immediate early 
response 3 (IER3), Sphingosine-1-phosphate receptor 1 (S1PR1), Vascular cell 
adhesion molecule 1 (VCAM1) and Serpin peptidase inhibitor, clade E, 
member 1 (SERPINE1). 
Enrichment of genes in the category ‘Cell morphology’ was also identified for 
TashAT2/infection-modulated dataset with a marked increase in enrichment 
for the subset of 446, where TashAT2-induced and infection-associated 
expression agree. Sub-categories identified were ‘shape changes’, 
‘morphology of cells’, ‘reorganisation of cytoskeleton’ and ‘ruffling’. Genes 
of particular interest are presented in Appendix 3.6 and included Cdc42 
guanine nucleotide exchange factor (ARHGEF9), BAI1-associated protein 2 
(BAIAP2), CD3g molecule, gamma (CD3G), chimerin 1(CHN1), LIM domain only 
2 (LMO2), Nerve growth factor receptor (NGFR), Phosphodiesterase 3B, cGMP-
inhibited (PDE3B) and Serpin peptidase inhibitor, clade E, member 1 
(SERPINE1). 
5.3.3.6 TashAT2 and Theileria infection modulate expression of genes 
in important canonical and custom pathways. 
IPA analysis of the TashAT2/infection modulated common dataset also 
indicated enrichment of genes in important canonical and custom pathways. 
Important top ranking canonical pathways identified by IPA are shown in 
Figure 5.13; the full list of pathways along their –log (p-value) is presented in 
Appendix 3.5. Interestingly, identified pathways included ‘Production of nitric 
oxide and reactive oxygen species in macrophages’, ‘Role of tissue factor in 
Cancer’, ‘G-Protein Coupled Receptor Signaling’, ‘TNFR2/1 Signaling’, ‘NF-κB 
Signaling’, ‘CD40 Signaling’, ‘NF-κB Activation by Viruses’, ‘PI3K Signaling in B 
Lymphocytes’, ‘LPS-stimulated MAPK Signaling’ and ‘apoptosis signalling’. 
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Figure 5.13: Identification of top canonical pathways in TashAT2 modulated / infection-
associated dataset  
Bar chart shows selected important canonical pathways enriched for genes modulated both by 
TashAT2 transfection and Theileria infection compared to LPS stimulation of BL20 cells. Each 
bar represents –log (p-value) for the enrichment of genes in a category. The orange vertical line 
represents the threshold for significance (p-value = 0.05). 
To investigate whether TashAT2 could modulate the expression of genes that 
are targets of transcription factors known to be associated with Theileria 
infection, IPA was performed using a custom pathway library of known 
transcription factors targets. Interestingly, significant enrichment of gene 
targets of NF- B (33 genes), AP-1 (06 genes), ATF-2 (05genes) and cMYC (03 
genes) was obtained. Expression levels of 12 of the 33 NF- B target genes 
were modulated by TashAT2 in a similar manner to the alteration associated 
with parasite infection (see Table 5.4). Functional categories associated with 
these NF- B targets genes included chemokines (CCL5 and IL-8) predicted to 
be prime mediators of the inflammatory response; enzymes (TNFAIP3 and 
TGM2); growth factors (BMP and HGF); peptidases (MMP9 and ADAM19), 
transcription regulators (FOS and JUNB) and transmembrane receptors (CD3G, 
IL2R and TNFRSF1B). 
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Table 5.4:  NF- B target genes set commonly altered/ modulated in TashAT2 transfected 
BoMacs and Theileria infection 
Gene    
Symbol 
Annotation  TashAT2 
altered/ 
modulated 
response  
Infection 
altered/ 
modulated 
response  
                            
                           Cytokines/ Chemokines 
 
1 CCL5 Chemokine (C-C motif) ligand 5    
2 IL8 Interleukin 8   
  Enzyme   
3 GBP1 Guanylate binding protein 1, interferon-inducible   
4 TGM2 Transglutaminase 2     
5 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3    
  G-protein coupled receptor   
6 CCR7 Chemokine (C-C motif) receptor 7    
  Growth Factor   
7 BMP4 Bone morphogenetic protein 4   
8 HGF Hepatocyte growth factor    
9 MDK Midkine (neurite growth-promoting factor 2)   
  Ligand-dependent nuclear receptor   
10 NR4A2 Nuclear receptor subfamily 4, group A, member 2   
  Peptidase 
  
11 ADAM19 ADAM metallopeptidase domain 19   
12 MMP9 matrix metallopeptidase 9    
13 PLAU plasminogen activator, urokinase   
  Phosphatase   
14 PTPN13 protein tyrosine phosphatase, non-receptor type 
13 
   
  Transcription regulator   
15 FOS FBJ murine osteosarcoma viral oncogene homolog 
  
16 JUNB Jun B proto-oncogene   
  Transmembrane receptor   
17 CD3G CD3g molecule, gamma (CD3-TCR complex)   
18 FAS Fas (TNF receptor superfamily, member 6) 
  
19 IL2RA Interleukin 2 receptor, alpha    
20 TLR2 Toll-like receptor 2    
21 TNFRSF1B Tumor necrosis factor receptor superfamily, 
member 1B 
   
  Transporter   
22 ABCB1 ATP-binding cassette, sub-family B, member 1    
23 APOD Apolipoprotein D   
24 SLC6A6 Solute carrier family 6, member 6 
  
  Other   
25 BCL2A1 Bcl2-related protein A1    
26 CD274 CD274 molecule    
27 FCER2 Fc fragment of IgE, low affinity II (CD23)   
28 IER3 Immediate early response 3 
  
29 TIFA TRAF-interacting protein with forkhead-associated 
domain 
  
30 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2    
31 TRAF1 TNF receptor-associated factor 1   
32 VCAM1 Vascular cell adhesion molecule 1   
33 WNT10B Wingless-type MMTV integration site family, 
member 10B 
  
NF- B response genes are shown whose expression was modulated in BoMac-TashAT2 and 
in Theileria-infected cells relative to control or uninfected counterparts. Gene expression 
patterns are indicated by either red (up-regulated) or green (down-regulated) arrows. Genes 
highlighted in grey are modulated in a similar direction. 
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Genes classified in the ‘other’ category by IPA includes those encoding 
products predicted to be involved in protein binding (FCER2, IER3, TIFA and 
TRAF1) and cell adhesion molecule binding (VCAM1), and the expression 
profile of all five of these genes showed a similar alteration associated with 
TashAT2 and infection (see Table 5.4). 
Other transcription factor target genes identified in TashAT2/infection 
modulated dataset included AP-1 and ATF2. Detailed exploration of the AP-1 
target gene list identified six genes in the common dataset (IL8, JUNB, MMP9, 
PLAU, NFATC1 and PLAUR) and several of these genes (IL8, JUNB, MMP, and 
PLAU) are also known to be targets of NF- B (see Table 5.4). Similarly, five 
ATF2 target genes were identified (IL8, JUNB, PLAU, HES1 and CSRP2) with 
IL8, JUNB and PLAU also identified as NF- B and AP-1 targets. 
5.3.4  TashAT2 modulates the expression profile of genes 
stimulated by PMA 
To investigate whether transfecting BoMac cells with TashAT2 would result in 
modulation of gene expression changes associated with PMA stimulation of 
BoMac-pCAGGS (control) cells, the BoMac pCAGGS-PMA and pCAGGS-TashAT2 
PMA datasets were compared and a subset of 553 genes identified 
representing a PMA response in pCAGGS with evidence of modulated 
expression in pCAGGS-TashAT2-PMA. Further analysis revealed 342 genes 
whose expression was up-regulated by PMA stimulation of BoMac control cells. 
From the pair-wise comparisons, three distinct patterns of expression could 
be obtained and these are graphically represented in Figure 5.14 while the 
full list of 342 genes is presented in Appendix 3.2. The first profile consisted 
of subset of 52 genes whose elevated expression in pCAGGS-PMA was 
amplified in pCAGGS-TashAT2-PMA. Based on fold change, the top 15 genes 
from this profile are listed in tabulated form (see Figure 5.14, profile1). Many 
of these genes showed a considerable level of amplified expression in 
TashAT2-PMA relative to pCAGGS (control)-PMA. Important genes identified 
include a kinase (TRIB2, 13.3 f.c.), peptidases (AQPEP, 9.5 f.c. and MMP1, 3.4 
f.c.), transcription regulators (SMAD7, 3.4 f.c.; TGIF1, 2.8 f.c. and JUNB, 2.1 
f.c.) and chemokines such as IL24 with a fold change of 2.4. 
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Figure 5.14: Expression profiles of PMA responsive up-regulated genes showing 
modulated expression in TashAT2-PMA BoMac cells.  
A summary of the absolute fold difference in BoMac pCAGGS-PMA and TashAT2-PMA relative 
to pCAGGS (control) cells is shown for top 15 representative genes of each profile.  Trend of 
the profile is highlighted in red. Expression of genes highlighted in blue has been validated by 
semi-quantitative RT-PCR. 
Profile 2: n=220 
Profile 1: n=52 
Gene Symbol Annotation 
BoMac PMA 
vs       
BoMac 
TahAT2 PMA 
vs        
BoMac PMA  
 
 
     
TRIB2 Tribbles homolog 2 2.7 13.3 
AQPEP Laeverin  5.0 9.5 
PECAM1 platelet/endothelial cell adhesion 
molecule (CD31 antigen)  
2.4 5.0 
VASN Vasorin 2.4 4.0 
SMAD7 SMAD-family member 7   2.5 3.4 
MMP1 Preprocollagenase  2.4 3.4 
MT2A Metallothionein-2  4.5 3.3 
PLCXD2 Phosphatidylinositol-specific 
phospholipase C, X domain 
containing 2 
2.1 3.2 
TGIF1 TG-interacting factor  5.3 2.8 
JHDM1D KIAA1718 protein  4.3 2.6 
IL24 Interleukin 24 37.6 2.4 
JUNB Jun B proto-oncogene  2.1 2.1 
SEMA3C Sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted,  
2.4 6.3 
FAM117B Family with sequence similarity 
117, member B 
2.0 3.4 
INHBA Inhibin, beta A 3.1 2.2 
 
 
  
     
TNFRSF11B TNFR superfamily, member 11b 9.96 -16.3 
PGLYRP2 Peptidoglycan recognition protein2 9.73 -10.8 
SELP Selectin P 5.51 -7.92 
SELE Selectin E  6.92 -3.85 
CCL5 Chemokine (C-C motif) ligand 5 5.49 -7.53 
LY6G6E Lymphocyte antigen 6 complex, 
locus G6E 2.43 -3.99 
PLAU Plasminogen activator, urokinase 6.38 -3.87 
LYST Lysosomal trafficking regulator 2.09 -3.76 
BIk1 BCL2-interacting killer 7.37 -3.49 
FGF21 Fibroblast growth factor 21 3.11 -3.05 
NFATC1 Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 1 3.45 -2.99 
CYP3A4 Cytochrome P450, family 3, 
subfamily A, polypeptide 4 14.16 -2.37 
TNFAIP3 TNF, alpha-induced protein 3 22.30 -2.36 
ADAMTS6 ADAM metallopeptidase with 
thrombospondin type 1 motif, 6 7.27 -2.32 
PTK2B Protein tyrosine kinase 2 beta 2.07 -2.03 
  
  
  
   
OAF OAF homolog (Drosophila) 2.46 -223 
LGALS9 Lectin, galactoside-binding, 
soluble, 9 
2.03 -146 
CEACAM8 Carcinoembryonic antigen-related 
cell adhesion molecule 8 
2.72 -39.6 
CLMP Cxadr-like membrane protein 2.76 -33.8 
LMO2 LIM domain only 2  3.25 -30.1 
CEACAM5 Carcinoembryonic antigen-related 
cell adhesion molecule 1 
2.75 -21.3 
ASGR2 asialoglycoprotein receptor 2 2.76 -20.2 
LAMA3 Alpha3a chain laminin-like 4.02 -25.5 
S1PR1 sphingosine-1-phosphate 
receptor1 
12.56 -64.5 
GPR110 G protein-coupled receptor 110 3.32 -13.5 
CCL2 Chemokine (C-C motif) ligand 2 40.23 -105 
SLC6A3 Solute carrier family 6 
(neurotransmitter transporter, 
dopamine), member 3 
3.08 -7.81 
TRAF1 TNF receptor-associated factor1 2.38 -5.87 
MERTK C-mer proto-oncogene tyrosine 
kinase 
3.75 -8.57 
VCAM1 Vascular cell adhesion molecule 1 11.81 -24.7 
 
Profile 3: n=70 
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The second profile consisted of 220 genes, whose expression was elevated in 
BoMac-pCAGGS control cells when stimulated with PMA but showed slightly 
repressed expression in pCAGGS-TashAT2-PMA compared to pCAGGS-PMA (i.e. 
repression level was less than or equal to pCAGGS-PMA elevation, see Figure 
5.14). Genes identified in this profile included those genes encoding BCL2-
interacting killer (BIK1), Selectin P (SELP), Selectin E (SELE) and TNF, alpha-
induced protein 3 (TNFAIP3) whose fold changes are given in Figure 5.14, 
Profile 2.  
The third profile consisted of genes whose expression was elevated in BoMac-
pCAGGS-PMA but highly repressed in pCAGGS-TashAT-PMA compared to 
pCAGGS-PMA (i.e. elevation associated with PMA significantly reversed in 
BoMac-TashAT2 cells, see Figure 5.14). The profile consisted of 70 genes; 
interesting genes with evidence of major repression of a PMA response 
associated with TashAT expression include OAF homolog (-223-fold), CEACAM8 
(-39.6), LMO2 (-30.1), VCAM1 (-24.7), S1PR1 (-64.5) and TRAF1 (-5.9). IPA 
exploration of the profile gene list showed enrichment for genes in the 
categories of ‘immune response’, ‘cell death’, ‘cancer’, ‘gene expression’ 
and ‘cell signalling’. The microarray expression pattern of four genes from 
profile 3 was validated using semi-quantitative RT-PCR (see Figure 5.15). For 
example, VCAM1 and LMO2 showed clear elevation of PCR product in pCAGGS 
compared to pCAGGS-PMA BoMacs, while the relative level of product was 
clearly lower in TashAT2 and TashAT2-PMA. Additionally, the expression level 
of these genes in Theileria infected cells was also determined and showed a 
related profile of repression associated with infection (Figure 5.15). Similar 
results were obtained for CEACAM8 and TRAF1 whose expression was reduced 
in TashAT2-PMA cells. 
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Figure 5.15: Semi-quantitative RT-PCR validation of microarray results of TashAT2 
modulated PMA response genes  
Panel on the left represents the mRNA expression of 6 genes (VCAM1, LMO2, SEPP1, PGM5, 
CEACAM8 and TRAF1) in BoMac cells. The panel on the right represents RT-PCR results of 
the corresponding genes set in TBL20 and BL20 (LPS +/-) cells. ACTB was used as a 
constitutive standard. 
Profiling of a second subset of 211 down-regulated PMA responsive genes also 
revealed three distinct patterns of modulated expression associated with 
TashAT2-PMA cells that were the reciprocal of the three profiles described 
above. Thus, profile 4 represented 91 genes whose expression is repressed by 
PMA stimulation in BoMac-pCAGGS but highly-repressed in BoMac-TashAT2 
cells when stimulated with PMA (see Figure 5.16, profile 4). 14 of these genes 
showed a major repression (> 10-fold), see table in Appendix 3.3 for a full list 
of genes in the profile). IPA showed enrichment for genes predicted to 
function in cell death, cellular development, cellular growth and proliferation 
and cancer. Interestingly, genes encoding enzymes (PGM5 and PTER), 
transcription regulators (HES1, HLF and TRERF1) and transporters such as 
AQP1, SLC23A1 and TRAF5 were included in this profile. Two of the genes in 
this profile (SEPP1 and PGM5) were validated by RT-PCR. The RT-PCR results 
were in agreement with the expression profile generated from microarray 
expression values and demonstrated super-repression associated with TashAT 
and TBL20 (see Figure 5.15). 
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Figure 5.16: Expression profiles of PMA responsive down-regulated genes showing 
modulated expression in TashAT2-PMA BoMac cells.  
A summary of the absolute fold difference in BoMac pCAGGS-PMA and TashAT2-PMA relative 
to pCAGGS (control)cells is shown for top 15 representative genes of each profile.  Trend of the 
profile is highlighted in red. Expression of genes highlighted in blue has been validated by semi-
quantitative RT-PCR. 
Gene Symbol Annotation 
BoMac PMA 
vs  
BoMac 
TahAT2 PMA 
vs  
BoMac PMA  
  
    
KBTBD6 Kelch repeat and BTB (POZ) 
domain containing 6 
-9.03 -23.7 
SEPP1 Selenoprotein P, plasma, 1 -2.11 -20.7 
PTER Phosphotriesterase related -2.80 -13.8 
HLF Hepatic leukemia factor -2.18 -12.1 
HVCN1 Hydrogen voltage-gated channel 1 -2.09 -8.6 
PKNOX2 PBX/knotted 1 homeobox 2 -2.87 -7.6 
JAKMIP3 Janus kinase and microtubule 
interacting protein 3 
-3.21 -5.9 
PNPLA3 Patatin-like phospholipase domain 
containing 3 
-2.04 -4.8 
LMOD1 Leiomodin 1 -5.94 -4.5 
TRERF1 Transcriptional regulating factor 1 -2.72 -3.3 
MYOM1 Myomesin 1, 185kDa -3.37 -2.9 
ZFP3 Zinc finger protein 3 homolog -9.04 -2.7 
PDE7B Phosphodiesterase 7B -6.29 -2.7 
PGM5 Phosphoglucomutase 5 -2.12 -2.4 
PTPN6 Protein tyrosine phosphatase, non-
receptor type 6 
-2.05 -2.2 
      
GADD45B Growth arrest and DNA-damage-
inducible, beta 
-2.54 4.3 
INSIG1 Insulin induced gene 1 -3.78 4.3 
DNAJB5 DnaJ, subfamily B, member 5 -2.02 3.9 
CRISPLD2 Cysteine-rich secretory protein 
LCCL domain containing 2 
-2.02 3.9 
PIK3R3 Phosphoinositide-3-kinase, 
regulatory subunit 3 (gamma) 
-2.48 3.7 
RNF150 Ring finger protein 150 -3.29 3.7 
BST2 Bone marrow stromal cell antigen2 -2.72 3.4 
ENPP5  Ectonucleotide pyrophosphatase/ 
phosphodiesterase 5 
-2.09 3.3 
OAS1 2',5'-oligoadenylate synthetase 1, 
40/46kDa 
-3.44 3.2 
RASL11B RAS-like, family 11, member B -7.62 2.5 
ARMCX6 Armadillo repeat containing, X-
linked 6 
-2.27 2.3 
DDIT4L DNA-damage-inducible transcript 
4-like 
-2.68 2.2 
GPR137C G protein-coupled receptor 137C -3.20 2.2 
TCEAL1 Transcription elongation factor A 
(SII)-like 1 
-2.30 2.1 
FBXL4 F-box and leucine-rich repeat 
protein 4 
-2.28 2.0 
   
 
    
LRRTM4 Leucine rich repeat 
transmembrane neuronal 4 
-11.59 47.50 
EFEMP1 EGF containing fibulin-like 
extracellular matrix protein 1 
-2.18 32.81 
PDE4B Phosphodiesterase 4B, cAMP-
specific 
-2.06 20.13 
AMIGO2 Adhesion molecule with Ig-like 
domain 2 
-2.94 14.81 
JAKMIP2 Janus kinase and microtubule 
interacting protein 2 
-2.17 10.61 
VEPH1 Ventricular zone expressed PH 
domain homolog 1 (zebrafish) 
-2.67 8.66 
DAAM2 Dishevelled associated activator 
of morphogenesis 2 
-2.11 7.59 
PPAP2B phosphatidic acid phosphatase 
type 2B 
-2.24 6.73 
ITGB8 Integrin, beta 8 -2.17 6.66 
PCDHGA2 Protocadherin γ subfamily A, 2 -2.15 6.58 
C5orf13 Chromosome 5 open reading 
frame 13 
-2.28 6.52 
MBNL3 Muscleblind-like 3 (Drosophila) -2.24 5.49 
TANC2 Tetratricopeptide repeat, ankyrin 
repeat and coiled-coil containing 2 
-2.09 5.41 
PLCH1 Phospholipase C, eta 1 -2.22 4.52 
NTRK2 Neurotrophic tyrosine kinase, 
receptor, type 2 
-2.02 4.41 
 
Profile 5: n=91 
Profile 6: n=29 
Profile 4: n=91 
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Profile 5 is the reciprocal of profile 2 and represents 91 genes that are 
repressed by PMA treatment in BoMac-pCAGGS cells but showed slight 
elevation in TashAT2-PMA compared to pCAGGS-PMA. The top 15 genes of this 
profile are listed in Figure 5.16 profile 5, while the full list of 91 genes is 
presented in Appendix 3.3. IPA showed enrichment for genes predicted to 
function in cell cycle, cell morphology, cellular growth, proliferation and 
cancer. 
Profile 6 consisted of 29 genes whose expression was repressed slightly in 
pCAGGS upon PMA stimulation but significantly-elevated in TashAT2 under 
PMA stimulation (i.e. PMA response significantly reversed in BoMac-TashAT2 
cells). A full list of the 29 genes of this profile is presented in Appendix 3.3, 
and the top ranking 15 genes are listed in Figure 5.16, profile 6. Important 
genes identified in this profile included genes encoding Leucine rich repeat 
(LRRTM4), EGF containing fibulin-like extracellular matrix protein 1 (EFBMP1) 
and Janus kinase and microtubule interacting protein 2 (JAKMIP2), which are 
predicted to have a functional role in protein binding. 
5.3.5  Comparison of the TashAT2-modulated PMA and 
infection-modulated LPS datasets 
To identify genes that are commonly altered in the TashAT2-modulated PMA 
response (552 genes) and the infection-modulated LPS response (1,995 
genes), the two datasets were compared to identify common genes and the 
results are illustrated in a Venn diagram (Figure 5.17). The comparison 
revealed 86 common genes, which was a significantly larger number 
(p < 0.001) than expected to occur by chance, as MC simulation suggested 
only 48 genes would be expected to be common between the two datasets. 
The summary of the calculation used to estimate the significance of the 
overlap is described in Figure 5.17. 
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Figure 5.17: Comparison of TashAT2 modulated PMA response genes and Infection 
modulated LPS response genes sets 
Comparison of the two lists of differentially expressed genes identified 86 common genes. 
This overlap was found to be significantly larger than expected by chance alone (p< 
0.001). A summary of the observations obtained from Monte Carlo simulation and Chi 
square analysis are also shown. 
Pathway analysis of the dataset of 86 common genes identified five NF-κB 
target genes. These included vascular cell adhesion molecule (VCAM1), 
chemokine (c-c motif) receptor 7 (CCR7), Jun B proto-oncogene (JUNB), TNF 
alpha-induced protein 3 (TNFAIP3) and TNF receptor-associated factor 1 
(TRAF1). These genes were predicted to function in ‘Cell-To-Cell Signaling 
and infection’, ‘Inflammatory Response’, ‘Cancer’ and ‘Cell death’. IPA 
analysis also identified enrichment for non NF-κB target genes in molecular 
function and disease categories of ‘Cell-to Cell Signaling’ (e.g. IRF8, BIRC3 
and NFATC1), ‘Inflammatory response’ (IL24, IL2RB, LTB4R, S1PR1, IRF8, OAS1 
and VCAM1), ‘Cancer’ (CCR7, LMO2, IL2RB and CYP3A4) and ‘Cell death’ 
(IRF8, TNFAIP3, CYP34A4 and IL24). These categories could be reasonably 
predicted to be associated with the known phenotype of the parasite-infected 
cell. 
  
 
Summary of MC and Chi-square analysis 
TashAT2 modulated dataset of PMA 
response genes 
(553) 
Number of genes expected to be 
common to lists A and B (48) 
Number of genes common to lists A 
and B (86) 
Number of genes not expected to be 
common to lists A and B  (2415) 
Total number of genes in list A and 
B, not common to both lists (2340) 
 
Overlapping gene set n= 86   p<0.001, highly significant 
467 
 
86 1873 
Infection associated modulated 
dataset of LPS response genes  
(1959) 
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5.3.6  RT-PCR analysis of candidate gene expression in a 
TashAT2 transfected T. annulata infected D7 cell lines. 
The results above indicate expression of TashAT2 can modulate the outcome 
of bovine genes whose expression is altered in the context of Theileria 
infection of the host cell. To investigate this further, Theileria infected D7 
cell lines stably transfected with pCAGGS-TashAT2 or pCAGGS (control) 
constructs were utilised. D7-pCAGGS-TashAT2 were capable of expressing 
both endogenous TashAT2 produced by the parasite and experimentally 
induced exogenous TashAT2, with expression of exogenous TashAT2 validated 
by immunofluorescence analysis using an anti-V5 monoclonal antibody (see 
Figure 5.18, panel 1). Endogenous TashAT2 expression was confirmed with 
DE39 antisera (capable of reacting with both forms of TashAT2) but as 
expected the cell line transfected with the pCAGSS-TashAT2 construct 
generated a higher level of reactivity in the host cell nucleus but not the 
parasite (see Figure 5.18, panel 3 and 6). pCAGGS-TashAT2, D7-transfected 
cells were treated with buparvaquone (BW720c) for 48 and 72 hours in order 
to kill the parasite. Following BW720c treatment expression of endogenous 
and exogenous TashAT2 was tested using anti-V5 and DE39 antisera. The 
results showed reduced but persistent expression of TashAT2 (see Figure 5.18, 
panels 7 and 9) in the drug treated cells. 
Semi-quantitative RT-PCR analysis was performed on the RNA samples 
isolated from TashAT2-transfectd and pCAGGS-transfected D7 cells (BW720c 
+/-). Of the previously PCR validated genes (see Figures 5.10-11 and 5.15) 
two, VWA5A and LMO2, showed a similar pattern of modulation in TashAT2-
transfected D7 cells as that obtained for TashAT2 transfected BoMac. Thus for 
VWA5A, the level of PCR product was clearly higher in cells over expressing 
exogenous TashAT2 and this elevated expression was maintained in the 
presence of drug (BW720c) (see Figure 5.19). This result may not be 
surprising, because although a small increase in product was observed in the 
pCAGGS control cells treated with drug, an independent analysis (Kinnaird et 
al; unpublished) did not show any significant difference in the level of VWA5A 
RNA in TBL20 cells following buparvaquone treatment.  
  
Figure 5.18: Immunofluorescence analysis of D7 cells transfected with pCAGGS and pCAGGS-TashAT2 using anti-V5 antibody and DE39 antisera  
Panels 1-3: pCAGGS (control) transfected D7 cells. Panels 4-6: pCAGGS-TashAT2 transfected D7 cells. Panels 7-9: pCAGGS-TashAT2 transfected D7 
cells incubated with 50ng/ml buparvaquone (BW720c) for 48h. Panels 1, 4 and 7 were analysed using anti-V5 antibody and their respective DAPI-stained 
images are shown in panels 2, 5 and 8. Cells shown in panels 3, 6 and 9 were analysed using rabbit antisera DE39 raised against recombinant TashAT2 
(Swan et al., 1999). P/white arrows denote the schizont/parasite nuclei: Bar = 20µm. 
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Figure 5.19: Semi-quantitative RT-PCR analysis of TashAT2 modulated genes in TashAT2 
transfected and T. annulata infected D7 cell line.  
RT-PCR results showing the modulated expression pattern of genes in TashAT2 transfected D7 
cells relative to their controls. ACTβ and GAPDH were used as an internal control. Panel on the top 
represents the mRNA expression of VWA5A and LMO2 in D7-pcaggs and D7-TashAT2 cells 
following buparvaquone treatment for 72h. 
The LMO2 expression pattern in D7-transfected cells was in agreement with 
previous array and RT-PCR expression profiles, as the data indicated that a 
viable parasite was required to maintain repression of this gene in the D7 cell 
line, because the PCR product was clearly elevated following treatment with 
BW720c to kill the parasite (see Figure 5.15 for evidence of repression by 
TashAT2 in BoMac and in TBL20 compared to BL20). Moreover, over-expression of 
TashAT2 in D7 appeared to be associated with maintenance of partial repression 
in the presence of BW720C (see Figure 5.19 top panel lane 3 vs 4 for LMO2 
product). A further experiment was conducted to test if the level of maintained 
repression of the LMO2 gene might be sensitive to the level of exogenous 
TashAT2.To attempt this TashAT2 transfected cells were grown in the absence of 
the drug used for selection of stable transfectants (Geneticin), as it had been 
shown previously that this procedure resulted in a reduction of transgene 
expression (Shiels et al., 2004). The RT-PCR results from RNA derived from these 
samples are shown in the bottom panel of Figure 5.19. The mRNA product 
obtained was significantly lower in D7-TashAT2 relative to D7-pCAGGS in both 
conditions (with or without Geneticin) but with an increase in the level of 
product in TashAT2 transfected cells cultured in the absence of Geneticin 
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compared to cells grown in the drug (compare lane 2 and 4). However, the LMO2 
expression level was also relatively higher in RNA derived from the PCAGGS 
control transfected cell line grown in the absence of Geneticin.  A definitive 
conclusion on the effect of altering the level of TashAT2 production (with or 
without geneticin) on LIMO2 levels could, therefore, not be made. 
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5.4 Discussion 
Work presented in the previous chapter of this thesis provided conclusive 
evidence that the parasite extensively modulates the host cell gene expression 
profile to influence the outcome of cellular activation. The aim of the work 
presented in the current chapter was to investigate the ability of a candidate 
parasite protein, TashAT2 (TashAT family member), to function as a modulator 
of bovine gene expression at a global level. 
Use of experimental model and modulation of phenotypic responses  
To establish the suitability of TashAT transfected uninfected cell lines for 
further study IFAT was performed using a monoclonal anti-V5-tag. The result 
indicated that BL20-TashAT2 cells displayed an extremely low level reactivity in 
the nucleus. In contrast bovine macrophage cell line (BoMac-TashAT2) showed 
evidence of strong expression of V5-tagged TashAT2 in the nucleus compared to 
a control cell line transfected with plasmid vector alone (Figure 5.2). The reason 
for low expression in the BL20 line is unclear and was unfortunate as it 
prevented a direct comparison against the same host cell background used in the 
previous study.  As, BoMac cells provided expression levels of TashAT2 
comparable to the level detected in Theileria  infected cells, it was decided to 
utilise this cell line. While utilisation of this model may make comparison with 
changes associated with infection more difficult, it could be argue that any 
overlap in modulation of genes between TashAT2 transfected BoMacs and 
infected cells may be less expected and therefore considered more significant. 
NF- B, reporter assays were performed on TashAT2 transfected BoMac and 
control cell lines following stimulation with either LPS or PMA. No difference in 
NF-κB reporter activity was found comparing non-stimulated cell lines or cell 
lines stimulated with LPS, confirming previous studies indicating that BoMacs are 
refractory to LPS stimulation (Oura et al., 2006). However, TashAT2 transfected 
BoMacs showed a significantly greater increase in NF-κB reporter activity 
compared to the control line when stimulated with phorbol-12-myristate-13-
acetate, PMA (see Figure 5.3). To test if this may be due to elevated activation 
of NF- B IFAT was undertaken. Unfortunately, a firm difference between the 
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p65 nuclear reactivity of pCAGGS-PMA and TashAT2-PMA (data not shown) was 
not observed and the level of p65 nuclear reactivity appeared to be same. 
However, given the fact that no difference in reporter activity level was 
detected in non-stimulated TashAT2 and control cells, the most likely 
explanation is that elevated reporter values in TashAT2-PMA cells are due to an 
enhancement in NF- B transcriptional activity rather than an increase in the 
amount of activated NF- B. Further investigations are required to confirm these 
findings by performing more sensitive experimental methodology such as 
electrophoretic mobility shift analysis (EMSA) and gel-shift western blotting. 
Chromatin immunoprecipitation (ChIP) PCR using primers against the NF- B 
reporter would also be of interest. 
Experiments performed to assess whether prolonged activation of BoMac cells by 
PMA is potentially associated with detrimental outcome provided evidence that 
TashAT2 protects BoMac cells against a PMA induced activation response and cell 
death. Prolonged treatment of cells with the phorbol ester (PMA) has been 
reported to trigger apoptosis in several cellular models, via distinct mechanisms 
including NF- B activation, activation of caspases, activation of protein kinase C 
(PKC) and associated pro-apoptotic genes (Chung and Kim, 1988;Day et al., 
1994;Gunji et al., 1992;Hida et al., 2000;Lai et al., 2003). BoMac-TashAT2 cells 
were refractory to detrimental outcome of cellular death and continued to 
proliferate at the same rate as the untreated control. Giemsa staining and 
microscopic examination of PMA stimulated BoMac cells showed they displayed 
profound morphological alterations characteristically related to programmed cell 
death. This included obvious cytoplasmic blebbing, elongated cell shape, cell 
shrinkage and darkly stained apoptotic cells (see Figure 5.7). Conversely, BoMac-
TashAT2 cells were refractory to these morphological changes when stimulated 
with PMA. Numerous studies have shown that PMA can induce such morphological 
changes that are typically related to apoptosis (Benjamin et al., 1984;Hsu et al., 
1998;Malide et al., 1998). 
Confirmation of PMA induced cellular apoptosis of BoMac-pCAGGS cells was 
obtained by performing caspase 3/7 activation assays; higher caspase activation 
levels were obtained in PMA stimulated pCAGGS cells relative to unstimulated 
control confirming activation of the caspase cascade and initiation of apoptosis. 
In contrast, the activity of caspase 3/7 remained unchanged for PMA stimulated 
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TashAT2 transfected cell line. Numerous studies have shown that PMA can 
induce caspase 3/7 activity in a variety of cellular models (Busuttil et al., 
2002;Hida et al., 2000;Varghese et al., 2003). It can be concluded from these 
results that a BoMac cell line expressing TashAT2 showed greater levels of NF- B 
activity but reduced levels of alterations associated with apoptosis when 
stimulated by PMA. 
Interpretation of microarray analysis and gene expression profiles modulated 
by TashAT2 in BoMacs cells 
Comparison of global datasets obtained from microarray analysis (BoMac: 
control/TashAT2/TashAT2_PMA vs TBL20/TBL20_LPS) demonstrated a large 
number of modulated genes (1,206) that were common to both TashAT2-
transfected BoMac and parasite-infected cells. This overlap was significantly 
greater than expected to occur by chance (P < 0.01). IPA of this common gene 
set ascribed important biological functions and diseases categories identified for 
the infection-modulated LPS dataset, although the order of significance 
observed was different. While these results are not surprising they indicate 
TashAT2 transfected cells show similar modulations to infected cells and support 
TashAT2 as a potential modulator of gene expression in a parasite infected cell. 
Differences in the order of significance and the direction and size of any 
modulation may be explained by differences in the additional factor(s) that are 
highly likely to be present in parasite infected cells compared to BoMac cells. In 
addition to host cell factors the detected differences could also be influenced by 
presence of other parasite molecules that are candidate modulators of the host 
phenotype, including a number of other proteins encoded by the TashAT cluster 
(Shiels et al., 2006). 
Interestingly, the most significant enrichment in TashAT2-modulated dataset was 
found for genes placed in the categories of ‘Cancer’, followed by ‘Inflammatory 
disease’ and ‘Cell death’. One postulation from this result is that TashAT2 may 
operate together with NF- B and be a key manipulator of cancer cell phenotype 
in the context of the infected cell. DNA binding AT hook motifs with a similar 
arrangement to that of TashAT2 are also found in mammalian HMGA family 
proteins that have been found to play major roles  in Cancer [reviewed in (Fusco 
and Fedele, 2007;Pierantoni et al., 2003)]. Enrichment of genes in ‘Cancer’ by 
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IPA was also found in the complete dataset of genes altered in TashAT2 
transfected BoMac cells (data not shown). Further investigation of TashAT2 in 
disregulation of genes associated with cancer is required. 
Excel based sorting of the common modulated dataset (1,206) generated a sub 
set of 466 genes that displayed the same directional change in expression level 
associated with TashAT2 and infection of BL20 cells with T. annulata. IPA mining 
of the down-regulated genes (353), revealed enrichment of genes biased towards 
anti-cancer and anti-tumor (i.e. IL18, IFR8, NGFR, PLAU and TP63), pro-cell 
death genes (i.e. CDKN2C, IL18, Il24, KIF1A, MAP3K1, IKBKE, IRF8, and TP63), 
and pro-inflammatory immune response genes (CD3G, FCER2, IL18, IRF8, S1PR1 
and VCAM1). IPA exploration of up-regulated genes set (113) indicated 
enrichment of genes biased towards elevation of pro-tumourigenesis (FOS, IER3, 
NAUPR1, PLAUR) and cellular growth and proliferation (SMAD7, SERPINE1, IER3 
and PLAUR). Six representative genes from each profile were analysed by semi-
quantitative RT-PCR and the results obtained were consistent with the 
microarray analysis (see Figures 5.10-11). These results provide further evidence 
that expression of TashAT2 may be involved in manipulating expression of host 
cell genes that could play an important role in determining establishment of 
infected-transformed cells. 
IPA also highlighted important canonical pathways: production of Nitric Oxide 
and Reactive Oxygen species in macrophages (NO & ROS), G-Protein Coupled 
Receptor Signaling, TNFR2, NF- B and CD40 Signaling as being altered in 
TashAT2 BoMac cells. Activation of the ROS pathway is generally associated with 
strong inflammatory conditions (Bulua et al., 2011;Hakim, 1993;Johar et al., 
2004) and implicated in the induction of apoptosis and antimicrobial defence 
mechanisms via activation of NADPH oxidase, also known as oxidative respiratory 
burst (Bjorkman et al., 2008;Smith, 1994). Increasingly, it is proposed that 
activation of ROS plays a key role in human cancer development by causing 
structural damage to DNA (Feig et al., 1994;Jackson and Loeb, 2001;Routledge 
et al., 1994;Waris and Ahsan, 2006). Of the 20 genes identified in this pathway, 
fifteen were found to be down-regulated in the TashAT2-modulated dataset and 
included Cytochrome-b245, alpha polypeptide (CYBA), inhibitor of kappa light 
polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE), protein 
phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A) and Tumor necrosis 
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factor receptor superfamily, member 11b (TNFRSF11b). These results are of 
interest and are indicative of involvement of TashAT2 in protecting the cell from 
stress induced DNA damage. Of the other important pathways, NF- B was of 
particular interest with 17 genes identified, whereas Custom pathway indicated 
33 NF- B target genes modulated in TashAT2 BoMac and infected TBL20 cells 
(Table 5.4). The majority of the mapped NF- B target genes showed enrichment 
for the pro-inflammatory response, and genes related to cancer. It would 
appear, therefore, that the majority of genes altered in TashAT2-BoMacs are not 
recognised targets of activated NF- B. Such a result is potentially possible as AT 
hook mammalian genes have a wide range of gene targets, in addition to known 
NF- B targets (Hommura et al., 2004;Ogram and Reeves, 1995;Reeves and 
Beckerbauer, 2001). 
Interpretation of TashAT2-modulated gene expression profiles and genes 
associated with inflammatory inducers 
A second set of analysis of the TashAT2 dataset was performed to identify a 
subset of genes that showed a PMA response that is significantly modulated in 
TashAT2 expressing BoMac cells. Six profiles of modulated expression were 
obtained. These profiles clearly demonstrated distinct prototypes of 
manipulation of gene expression in TashAT2-PMA when compared to pCAGGS-
PMA. 
Profile 1 represented a subset of genes that showed super elevated expression in 
TashAT2-PMA relative to pCAGGS-PMA (see Figure 5.14). It is possible that such a 
profile is related to greater NF- B reporter activity detected in TashAT2 BoMacs. 
In addition, since it is likely that genes that are not NF- B targets are being up 
regulated in the context of PMA it is plausible to propose that TashAT2 generates 
enhancement of transcriptional activity for a number of factors activated by this 
phorbol ester. HMGA proteins bearing DNA binding AT hook motifs identical to 
TashAT2 have been shown to promote formation of the enhanceosome that 
results from combinatorial binding of transcription factors at target gene 
promoters resulting in efficient recruitment of core complexes that initiate 
efficient transcription (Mantovani et al., 1998;Thanos et al., 1993;Thanos and 
Maniatis, 1995). Interestingly these HMGA proteins operate together with several 
transcription factors (p50/p65 NF- B heterodimer, ATF2 and c-Jun) that are 
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activated in Theileria infected cells to induce synergistic transcription from 
target promoters (Du et al., 1993;Du and Maniatis, 1994;Mantovani et al., 
1998;Thanos et al., 1993;Thanos and Maniatis, 1995). It is not unreasonable to 
propose that similar events are occurring in PMA stimulated BoMac cells and that 
TashAT2 acts as an analogue of HMGA architectural proteins to promote 
enhanceosome formation at promoters of genes represented by profile 1. 
Genes indentified in profile 1 that show the same type of modulation in infected 
cells include SMAD7, MT2A, JHDM1D and JUNB, which are predicted to have a 
functional role in protein binding. SMAD7 and JHDM1D and JUNB are also 
predicted to have roles in transcription regulatory region DNA binding or 
chromatin modification. Metallothionein-2A (MT2A) belongs to the 
metallothionein gene family that encodes proteins involved in protein binding, 
cell proliferation, essential metal homeostasis and protection against several 
types of cell damage (Lazo and Pitt, 1995;Reinecke et al., 2006;Yamasaki et al., 
2007). Over expression of MT2A is frequently observed in invasive human breast 
tumours and promotes cell invasion by up-regulating MMP-9 via AP-1 and NF-
κB activation (Kim et al., 2011). Elevated MMP-9 expression is known to be 
induced by infection of the leukocyte by T. annulata (Adamson and Hall, 1996). 
JunB, is a member of Jun protein family and together with Fos proteins  give rise 
to a large variety of either homodimers or heterodimers constituting the AP-1 
transcription factor complex (Foletta et al., 1998). A protective role for JunB 
against stress-mediated apoptosis (Gurzov et al., 2008;Son et al., 2010) has been 
proposed.  However, the exact role of JunB in stress response signaling is still 
not clear. Moreover JUN family proteins have janus like properties and can be 
pro- and anti-apoptotic depending on the context of cell type and stress 
conditions (Shaulian and Karin, 2002). Increased AP-1 activity occurs in HMGA-
expressing fully transformed rat thyroid cells and was found to be fully 
dependent on HMGA over expression (Vallone et al., 1997). Vallone et al., (1997) 
also demonstrated that cell lines expressing HMGA1 and HMGA2 display 
remarkable induction levels of JUNB and the FRA1 gene (FOSL1) proteins. FRA1 is 
required for mitotic progression at G1/G2 phase transition, (Casalino et al., 
2007;Jochum et al., 2001), and is recruited to the promoter of cyclin A. 
Theileria  transformed lymphocytes have been shown to express activated AP-1 
components at varying levels that are dependent on viable parasite (Chaussepied 
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et al., 1998). The possibility that TashAT2 acts like HMGA to elevate expression 
of components of the AP1 complex in transfected BoMac cells and in parasite-
infected cells requires further investigation. 
Evidence of modulation of the BoMac PMA response in TashAT2 BoMac is also 
indicated by profile 2 and 3. Genes were either slightly or highly repressed in 
BoMac-TashAT2-PMA relative to the response identified for PMA stimulated 
BoMac-pCAGGS control cells (see Figure 5.14 profile 2-3). IPA analysis of these 
two profiles showed enrichment for genes in various categories: including 
Cellular Movement, Cellular Growth and Proliferation, Cancer, Tissue 
Morphology and Inflammatory Response and Cell Death. Repression of genes 
indentified in profile 3 showed  high fold differences (maximum -511-fold) with 
42 genes repressed (over 10 fold) in TashAT2-PMA. Genes encoding cell adhesion 
molecules VCAM1, P-selectin (SELP) and E-selectin (SELE), carcinoembryonic 
antigen-related cell adhesion molecules (CEACAM8/5) that are predicted to play 
critical role in inflammatory and immune responses were prominent. Expression 
of candidate genes in profile3 was validated by RT-PCR, confirming repression in 
TashAT2-BoMac. 
VCAM1 has been implicated in a variety of inflammatory processes and immune 
cell interactions (Huo et al., 2000;Neish et al., 1995;Ou et al., 2008;Ren et al., 
2010). Although resting cells do not express VCAM-1 message, exposure to pro-
inflammatory mediators or cytokines (PMA, LPS and TNF-α) cause a rapid 
induction (Kawai et al., 2001;Lee et al., 2006;Marui et al., 1993;Valentin et al., 
1997). Transcription of VCAM1 is regulated by several inflammatory transcription 
factors including NF- B and Ap-1 (Ahmad et al., 1998;Collins et al., 1995b;Neish 
et al., 1995;Shu et al., 1993). VCAM1 regulation at the promoter level is a 
complex process and involves interaction of various transcription factors 
including NF- B, IRF-1, Sp1, and DNA binding factors such as HMGA1 (Harris et 
al., 2008;Neish et al., 1995). 
An increasing number of studies over the past few years have shown a major role 
for the HMGA proteins in controlling gene transcription of a large number of 
genes including IFN-β, IL2, IL-2Rα.. In addition to binding to DNA, HMGA proteins 
physically interact with large number of proteins, most of which are 
transcription factors, including NF- B, c-Jun, Oct-2, ATF2, NFAT, and Elf-1 
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(Arlotta et al., 1997;Boise et al., 1993;Jain et al., 1992;Jain et al., 1995;Panne 
et al., 2004;Rao et al., 1997). Several models of interaction(s) between HMGAs, 
transcription factors and promoter elements have been proposed that influence 
positive or negative transcription of genes (Chuvpilo et al., 1993;Shannon et al., 
1998). These include direct interaction of HMGA alone at the promoter; 
modification of DNA structure to influence binding of TFs and direct interactions 
with TFs that may or may not require the presence of DNA. Importantly, a high 
concentration of HMGA protein has been shown to inhibit the binding of certain 
transcription factors to promoter targets. For example, inhibition of AP-1 
binding to NFIL-2A, NFAT binding to CD28RR and the IL-4 promoter has been 
proposed to operate (Bustin and Reeves, 1996;Chuvpilo et al., 1993;Shang et al., 
1999). Based on the known ability of HMGA proteins to repress the expression of 
genes that are targeted by transcription factors activated by LPS, PMA and 
Theileria-infection, it is tempting to speculate that TashAT2 and other members 
of the TashAT cluster perform a similar role. The finding that TashAT2 
expressing BoMac cells markedly repress VCAM1 induction by PMA supports this 
possibility. However it is also possible that a more indirect mechanism of 
repression is in operation. Further experiments are required to confirm the 
structural interactions of parasite secreted TashAT2 proteins (bearing AT hook 
motifs) and transcription factor bindings in the regulation of VCAM1. 
 LIM domain only 2 (LMO2), a member of the LIM-only class proteins and formerly 
termed as rhombotin-2 (rbtn-2 or Ttg-2) has been reported to play a critical role 
in normal hematopoietic stem cell development and differentiation (Boehm et 
al., 1991;Hansson et al., 2007;McGuire et al., 1989;Yamada et al., 1998). 
TashAT2-transfected BoMac cells hardly express LMO2 relative to control cells. 
Furthermore, marked repression was observed for Theileria-infected cells and 
elevated expression of LMO2 was observed following buparvaquone (BW720c) 
treatment (Figure 4.17). A role for TashAT2 as a repressor of LMO2 expression 
was supported by the result showing that in D7 transfected cells over expressing 
TashAT2 the increase of LMO2 PCR product in response to BW720 treatment was 
inhibited. Two explanations are possible: either LMO2 expression is sensitive to 
stress responses induced by drug treatment and cells over-expressing TashAT2 
are protected against this event, or TashAT2 directly/indirectly alters the 
transcription factor complexes required for LM02 transcription. 
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Proximal and distal promoters have been described for LMO2 gene (Hammond et 
al., 2005;Royer-Pokora et al., 1995). The proximal promoter region of LMO2 has 
been shown to contain positive regulatory elements (3 conserved Ets factor 
binding sites) that mainly facilitate binding of the Ets transcription family. While 
the distal promoter of LMO2 has been demonstrated to repress transcriptional 
activity via the presence of tissue specific upstream negative regulatory 
elements, predicted to have functional role in leukaemia (Hammond et al., 
2005). Furthermore, Hammond et al., (2005) have suggested the tissue-specific 
repressor activity could occur via a specific factor binding to negative promoter 
elements, or to a ubiquitous factor working in combination with tissue-restricted 
proteins interacting at the LMO2 promoter. Interestingly Tsunoda et al., (2010) 
reported that the ZFAT factor is important for transcriptional regulation of LM02 
and binds to the proximal promoter. ZFAT contains an AT hook as well as a zinc 
finger and conserved nucleotides within the proximal promoter region of LMO2 
bear similarity to AT hook DNA binding motifs (Landry et al., 2005). 
PMA stimulation of TashAT2-transfected BoMac also provided reciprocal profiles 
to those described above. Thus, profile 4 represented 91 genes whose expression 
was down-regulated in BoMac-PMA and associated with greater repression in 
TashAT2-PMA. Candidate genes indentified in this profile included genes like 
SEPP1 and PGM5 whose expression is reported to be down-regulated in variety of 
cancers (Gresner et al., 2009;Magee et al., 2001). RT-PCR analysis validated the 
repression of these genes in BoMac and Theileria-infected cells (see Figure 
5.15). IPA exploration of genes in this profile showed enrichment in Cell Death 
(SFRP2, PDE7B, PTPN6 and HLF), inflammatory response (PTPN6) and Cancer 
(SFRP2, LMOD1, HLF, PGM5 and SEPP1) categories. Repression of some genes was 
found to be high and included secreted frizzled-related protein 2 (SFRP2; over 
159), kelch repeat and BTB (POZ) domain containing 6 (KBTBD6; 23 fold) and 
hydrogen voltage-gated channel 1 (HVCN; over 8 fold). Like SEPP1, HVCN 1 was 
also repressed in parasite-infected cells and these proteins are predicted to play 
a role in protein binding and the oxidative stress response (Burk and Hill, 
2009;Capasso et al., 2010;Gonzalez-Moreno et al., 2011). 
An extreme pattern of modulation was observed in profile 6 with a similar trend 
in profile 5: genes down-regulated in BoMacs in PMA response to PMA were up 
regulated in TashAT2-BoMac in BoMac cells. These profiles contained a smaller 
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number of genes relative to their reciprocal profiles (2 and 3). In general a lower 
number of PMA responsive genes were elevated than repressed in TashAT2-
BoMacs, indicating TashAT2 is more likely to act as a repressor of PMA 
stimulated gene expression. Combined IPA analysis of profile 5 and 6 highlighted 
genes in the categories of cancer (ITGB8, PPAP2B, PDE4B, EFEMp1 and BST2) and 
cell cycle (GADD45B). 
In addition to these results, analysis of the TashAT2-modulated_PMA dataset also 
identified 24 NF- B target genes, with 14 NF- B target genes not highlighted in 
my previous analysis. The implication is that TashAT2 can manipulate the 
outcome of expression of genes targeted by NF- B, which is perhaps not 
surprising given the result showing enhanced NF- B reporter activity in TashAT2 
expressing BoMacs stimulated with PMA. However, given the large number of NF-
B transcription factor sites identified in whole genome ChIP analysis, it is 
probable that the NF- B target gene list utilised in my study is not fully 
representative and the number of putative TashAT2/NF- B targets are 
underestimated. 
Interpretation of Common genes altered in ‘TashAT2 modulated PMA’ and 
infection modulated LPS datasets 
A global comparison of the TashAT2 and Theileria-modulated datasets generated 
by stimulation with by LPS or PMA was performed to assess if there was a 
significant degree of overlap in gene expression changes representing these 
cellular states. Thus, results obtained showed significant association by Monte 
Carlo simulation, providing a dataset of 86 common genes that was greater than 
the number of common genes expected to occur by chance. This dataset 
included genes encoding VCAM1, LMO2, TRAF1, IRF8 and PGM5. It can be 
concluded that both TashAT2 and infection manipulate the outcome of cellular 
activation induced by two distinct inflammatory mediators in a related but 
distinct cellular context. This was unlikely to have occurred by chance and 
provides evidence that a parasite-encoded gene is able to promote a cellular 
outcome related to that displayed by Theileria-infected leukocytes. These 
results and the recent findings that TashAT/TpHN gene families are expanded 
and highly conserved in transforming Theileria species (Hyashida et al., 
unpublished; Weir et al., 2009) add further support to the hypothesis that, 
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together with activation of key host transcription factors, TashATs are likely to 
play a role in the regulatory circuits that define the gene expression networks of 
T. annulata infected leukocytes. 
Conclusions and future directions 
Results presented in the previous chapter provided evidence of a parasite 
dependent global reprogramming of gene expression networks in Theileria 
infected leukocytes. This is likely to occur via activation of host transcription 
factors, induction of a dedifferentiation event and transportation of parasite 
factors into the host cell compartment. Consistent with these models, results 
presented in this chapter provide further evidence that TashAT2 gene family 
proteins are involved in this process. Based on the available bioinformatic and 
experimental data it is likely that TashAT2 proteins bind to the promoter regions 
of host genes or influence the formation of complexes that operate as co-
repressors or activators of transcription. TashAT2 expressing cells have 
demonstrated modulation of a number of functional activities that are also 
modulated by infection (resistance to apoptosis, control of cell shape, and 
repression of cellular defence genes). However it is also possible that TashATs 
mediate their effects in an indirect manner or operate in a regulatory cascade, 
and so genes identified by the microarray analysis may not be direct targets of 
TashAT2. Therefore it is important to validate the ability of TashAT2 to bind to 
the promoters of identified genes. Demonstration that TashATs are directly 
responsible for altered phenotypes following their expression is also required. 
Work that could be conducted to confirm these roles is outlined below. 
1. Global bioinformatic screening of putative target genes: Based on the 
datasets identified in my study screening for known DNA binding motifs of 
TashAT2 and activated host transcription factors could be performed.  
Bioinformatic tools such as Multiple EM for Motif Elicitation (MEME), weight 
matrix-based tool (MatchTM) and TRANSFAC® for searching putative 
transcription factor binding sites in DNA sequences are available (Bailey et 
al., 2006;Kel et al., 2003;Matys et al., 2006). 
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2. Validation of TashAT2 targets for binding to host cell promoters: 
Confirmation of physical interaction or binding of TashAT2 should be 
performed by ChIP-sequencing (ChIP-seq) methodology. This methodology 
involves chromatin immunoprecipitation (ChIP) followed by massively 
parallel sequence analysis to identify putative DNA targets sites at more 
global scale (Robertson et al., 2007). Identification of mammalian DNA 
sequences bound by transcription factor(s) and/or TashAT2 across the host 
genome should be possible, including observations of changes to binding 
patterns associated with infection, inflammatory activation and expression 
of TashAT factors. My data indicates there is good probability that NF- B and 
TashAT2 recognise common gene promoters. Affinity purified antibody 
specific to TashAT2 or Antibody specific to tagged versions of TashAT2 and 
commercial antibodies against NF- B subunits are available for use in 
standard Chip-Seq protocols 
(http://www.illumina.com/Documents/products/datasheets/datasheet_chip
_sequence.pdf). More precise investigations could then be undertaken by 
electrophoretic mobility shift analysis (EMSA), gel-shift western blotting, and 
DNA site mutated reporter constructs. 
3. Reversal of TashAT2 dependent altered phenotype: attempts to reverse 
the phenotypes attributed to could be attempted by employing siRNA to 
knock out expression in BoMac cells. Alternatively cell lines expressing 
mutant generating TashAT2-truncated cell line (minus AT hook motifs) could 
be used. Experiments using a novel class of DNA minor groove binding (MGB) 
drugs such as Distamycin A that compete with HMGA proteins for binding in 
the minor groove of AT-rich DNA sequences (Baron et al., 2010;Chiang et al., 
1994;Ghersa et al., 1997;Smith and Buchmueller, 2011) may also be 
informative if performed on TashAT2 transfected or parasite infected cells. 
It is possible however that TashAT expression promotes an irreversible 
change in regulatory networks and if so knock out experiments would prove 
un-rewarding. 
4. Characterisation of TashAT2 as modulators of the attenuated cell 
phenotype: It is of additional interest to investigate whether TashAT 
proteins are involved in generation of the attenuated cell phenotype that 
occurs during prolonged culture/cloning in vitro. Theileria  lab (Glasgow) 
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has already established a cellular model system of two cloned infected cell 
lines (D7 and D7B12) that encounter marked differences in cell phenotype: 
attenuation of parasite differentiation, resistance to cell death, cell shape 
and expression of TashAT family genes (TashAT2 and TashHN) and a 
significant difference in activated levels of NF- B (Schmuckli-Maurer et al., 
2010). An independent microarray analysis has been performed to study 
profile changes to host and parasite gene expression associated with altered 
phenotype (D7 vs D7B12). Preliminary results obtained from this analysis 
have already highlighted differential modulation in expression of NF- B 
target genes and cytoskeleton signalling (unpublished data). Comparison of 
this dataset with my dataset may provide further information regarding the 
role of TashATs to modulate host cell gene expression and influence the 
phenotype and virulence of different T. annulata infected cell lines. 
The results of this study provide evidence that the T. annulata infected cell 
controls and modulates the outcome of constitutive activation of NF- B. 
Evidence is also provided that members of the TAshAT family are involved in this 
modulation event. In general, IPA indicates that these changes are beneficial to 
establishment of the infected cell. Additional pathways/transcription factors 
that operate in the inflammatory response and are associated with 
carcinogenesis are also manipulated e.g. TNF, TGFβ and cMYC, supporting 
previous findings (Chaussepied et al., 2010;Dessauge et al., 2005a;Guergnon et 
al., 2003).It can be postulated that a major reorganisation of networks that 
regulate signal transduction pathways and gene expression occur following 
infection of the host leukocyte by T. annulata. Studies on Toxoplama gondii 
have identified parasite rhoptry and dense granular proteins that modulate 
inflammatory gene networks by activating transcription factors, including NF- B 
(Rosowski et al., 2011;Saeij et al., 2007). Parasite dependent modification of 
histone H3 can also prevent transcription factors binding to host cell 
inflammatory gene promoters (Leng and Denkers, 2009) and it has been proposed 
that this mechanism accounts for the large-scale down-regulation of pro-
inflammatory genes by T. gondii (Leng et al., 2009). It is possible that Theileria 
parasites deploy similar mechanisms to manipulate gene expression on a wide 
scale and evidence of an alteration in the gene encoding a host histone 
deacetylase has been generated (Kinnaird et al., unpublished data). However, 
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my results suggest additional alterations are involved. This is indicated by the 
pairs of reciprocal modulated expression profiles (Figures 5.14 and 5.16) 
associated with infection and TashAT2 expression; the indication that infection 
and TashAT2 can reverse gene expression changes induced by LPS and PMA and 
the non-reversible and non-reciprocal nature of a large number of host gene 
expression changes when the parasite is killed by drug (Kinnaird et al., 
unpublished). Such changes could be generated by an irreversible 
reconfiguration of transcription factor networks associated with differentiation 
events, as increasingly proposed for stem cell systems (Chickarmane et al., 
2006;Chickarmane et al., 2009;Wang et al., 2010). Whether this reorganisation 
can be brought about by activation of one or several host factors in combination 
with deployment of TashAT family proteins to the host nucleus is not clear. 
Other studies have found evidence for additional events such as activation of 
host polo like kinase (von et al., 2010) and other parasite proteins secreted into 
the host cell compartment (MacHugh et al., 2011;Schmuckli-Maurer et al., 
2009). Given the propensity of Theileria parasites to control gene expression 
networks associated with inflammatory disease and cancer, further study of the 
mechanisms deployed and the outcomes they promote is warranted. 
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Appendix 1: 
1.1 Table showing important microarray terminologies 
Array 
 
Refers to the physical substrate to which bio-sequence reporters are 
attached to create features. 
Array Design An array design is conceptual it is the layout or blueprint of one or 
more arrays. 
Background/ 
Background noise 
 
Background is the measured signal outside of a feature on an array. 
In many gene expression analysis methods, background subtraction is 
performed to correct measured signals for observed local and/or 
global background. 
Channel 
 
A channel is an intensity-based portion of an expression dataset that 
consists of the set of signal measurements across all features on an 
array for a particular labelled preparation used in hybridization. In 
some cases, such as Cy3/Cy5 array hybridizations, multiple channels 
(one for each label used) may be combined in a single expression 
profile to create ratios. 
Chip The physical medium of many arrays used in gene expression. 
contig 
 
A contig, an abbreviation for “contiguous sequence” is a group of 
clones representing overlapping regions of a genome. 
Control The reference for comparison when determining the effect of some 
procedure or treatment. (Deletion, mismatch, positive, negative). 
Error Model 
 
An error model is an algorithm that computes quality statistics such as 
p-values and error bars for each gene expression measurement. 
Expression The conversion of the genetic instructions present in a DNA sequence 
into a unit of biological function in a living cell. Typically involves the 
process of transcription of a DNA sequence into an RNA sequence 
followed by translation of the mRNA into protein 
Feature A feature refers to a specific instance of a position upon an array. 
Commonly referred to as a spot in a microarray experiment. 
Feature Extraction Quantitative analysis of an array image or scan to measure the 
expression values. 
Filter/ed A mathematical algorithm applied to image/array data for the purpose 
of enhancing image quality/defining expression analysis 
Fluor/ Fluorophore/ 
Fluorescent label 
A fluorescent tag bound to mRNA or cDNA extracted from a sample. 
When properly excited the fluor gives off measurable fluorescence 
which is the observable in an experiment. 
Hybridization Treating an array with one or more labelled preparations under a 
specified set of conditions. 
Label Label refers to fluorescent labels, for example, Cy3 and Cy5, 
commonly used to distinguish baseline and experimental preparations 
in gene expression microarray hybridizations. 
Normalisation Normalisation is the procedure by which signal intensities from two or 
more expression profiles (or channels) are made directly comparable 
through application of an appropriate algorithm. 
Oligo / 
Oligonucleotide 
Usually short strings of DNA or RNA to be used as probes (features) or 
spots. These short stretches of sequence are often chemically 
synthesised. 
Probe In some organisations, probe is used as a synonym for feature. 
Ratio Also referred to as “fold change”. A ratio refers to a normalised signal 
intensity generated in a feature given channel divided by a normalised 
signal intensity generated by the same feature in another channel. 
The channels compared are typically baseline versus experimental, for 
example normal versus diseased or untreated vs. treated. 
Target Material that may hybridize to the probe, usually containing all of the 
mRNA (cDNA or cRNA) or gDNA of the subject organism. 
 
Adapted from Rosetta BioSoftWare: 
http://www.rosettabio.com/tech/geml/omg/lsr_ge_glossary.doc’. 
 1.2 Table showing details of raw data file types obtained from Roche NimbleGen 
Directory  Subdirectory  File  Description  
Design_Files  design.ndf1 Contained the complete information about the probes, including sequences, target 
genes, and location in the array. 
  design.ngd1 Contained information on the target genes, including database source, gene name, 
gene accession number, and gene ID. 
  DesignNotes.txt1 Contained information about the design of the array, including the number of 
target genes, number of probes, and number of probe replicates. 
Documentation  NimbleGen_data_formats.pdf2 Contained detailed information on various data formats provided by Roche 
NimbleGen. 
Processed_Data_Files  Contained subdirectories whose files list probe level and gene level expression 
values. Expression values are generated using quantile normalization (Bolstad et 
al., 2003, Bioinformatics, 19:185), and Robust Multichip Average (RMA) algorithm 
(Irizarry et al., 2003, Nucleic Acids Res. 31: e15 and Irizarry et al., 2003, 
Biostatistics 4:249).  
 Normalized_Calls_Files arrayID_532_RMA_calls.txt1 Contained normalized gene expression summary value for each gene in each array. 
  All_norm_calls.txt1 Contained normalized gene expression summary value and information for each 
gene in all arrays in this order. 
 Normalized_Pair_Files arrayID_532_norm_RMA_ 
pair.txt1 
Contained normalized gene expression value for each probe in each array. 
  All_norm_pair.txt1 Contained normalized gene expression value for each probe in all arrays in this 
order. 
Raw_Data_Files   Contained subdirectories whose files list un-normalized probe level and gene level 
expression values. For best results, use normalized data provided in the 
Normalized_Calls_Files directory, described above. 
 Calls_Files  arrayID_532 _calls.txt1 Contained un-normalized gene expression summary value for each gene in each 
array. 
  All_ calls.txt1 Contained un-normalized gene expression value and information for each gene in 
all arrays in this order 
 Pair_Files arrayI D_532 _pair.txt1 Contained un-normalized gene expression value for each probe in each array.  
  All_ pair.txt1 Contained un-normalized gene expression value and target gene information for 
each probe in all arrays in this order.  
root directory  SampleKey.txt1 Contained information about the samples and arrays used in this order. 
1 Open with a text editor, such as Microsoft WordPad, or spreadsheet software, such as Microsoft Excel.  
2 Open with Adobe Acrobat Reader. 
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 1.3 Table showing details of primers used for semi-quantitative RT-PCR and real-time quantitative RT-
PCR 
Gene 
symbol 
GenBank 
accession 
number 
F/R 
  
Primer sequences (5' → 3')  Length 
(bp) 
Product 
length 
(bp) 
Tm 
(°C) 
  
Gene name 
        
ACTB NM_173979 F CTCTCTTCCAGCCTTCCTTCCTGG 24 240 58.21 Actin, beta 
   R ACACGGAGTACTTGCGCTCAGG 22  58.92 
ALDH1A1 NM_174239 F TGCTGTTGAATTTGCACACCAAGGAG 26 334 58.71 Aldehyde dehydrogenase 1 family, member A1 
   R GGCAATGCGCATATCATCAGTAACATC 27  57.24 
ANGPT4 NM_001076483 F ACAATGACAACTGCCTCTGCAAGTGC 26 214 60.39 Angiopoietin 4 
   R GCTGCCCCTTAGATGCCCGAG 21  59.31 
AQP3 NM_001079794 F TACCCCTCTGGACACTTGGACATGG 25 242 59.42 Aquaporin 3 (Gill blood groUp) 
   R CCGGCGATGGCGGTGAAAAGG 21  60.96 
BCL9  XR_028680 F TACCCCTAAAGCACTCCCTGGCC 23 214 59.67 B-cell CLL/lymphoma 9 
   R CGAGTGTGGTGTGTGCTGGGAATC 24  60 
BCOR NM_001191544 F AGGTGTGCAAATTCAGCCCCACTG 24 244 59.88 Similar to BCL-6 corepressor  
    R ATGTCTGGGGTGACCTGGTCGG 22  59.92 
BIRC3 NM_001035293 F GGATGATGCTATGTCAGAACACCTGAG 27 255 57.24 Baculoviral IAP repeat-containing 3 
   R TCCCAACACCTCAGTCCACCATC 23  58 
BOLA-DYA     NM_001012678 F CTTGGGTGCTGCCTCCAGACGT 22  61.01 BOLA-DYA major histocompatibility complex, class II, DY alpha 
   R TGGAAGGAGCTCTGTGATGAAGTGG 25 248 58.23 
CALD1 NM_174258 F CCTACCAGCGGAATGACGATGACG 24 230 59.49 Caldesmon 1  
   R CCGAGCCAGTCGCTCCAGG 19  59.17 
CCL4 NM_001075147 F CCTTCTGTTCTCCAGCGCTCTCAG 24 192 59.08 Chemokine (C-C motif) ligand 4 
   R GCTCACTGGGGTTGGCGCAG 20  60.59 
CCL3 NM_174511 F AGCAAGCACCGAGTCCCACCTC 22 244 60.75 chemokine (C-C motif) ligand 3 
   R CTTGGAGCACTGGCTGCTGGTC 22  59.99 
CD36 NM_174010 F TGTGCAGAATCCAGATGAAGTGACAG 26 225 57.18 CD36 molecule (thrombospondin receptor)  
   R GCTGCTACAGCCAGGTTGAGAATG 24  58.08 
CD69 NM_174014 F ACTGTAGGTTGGCTCCACGTGG 22 288 58.51 CD69 molecule 
   R TGGTGGCGCTGATGATGCATATTG 24  58.19 
CEACAM8 NM_205788 F TCACAGAGGGACACAGCAGACAGC 24 203 60.41 Carcinoembryonic antigen-related cell adhesion molecule 8  
   R CGTTGTGGGCAAGCAGAAGAACATC 25  59.07 
CFLAR NM_001012281 F CTGTCTTCTGTGAGCTTGGCTGAGC 25 237 59.78 CASP8 and FADD-like apoptosis regulator 
   R ATCCTTGGCTATCTTGCTTCGACCCG 26  60.61 
C1QTNF1 NM_001083409 F CTGCTTCTCGGTGCCTCCGCTG 22 273 61.98 C1q and tumor necrosis factor related protein 1 
   R CGTTGCTGTGCAGGGGCTTCTTCC 24  62.48 
CLU NM_173902 F CTCCAGTCCTACCAGCAGAAGATGC 25 279 58.65 Clusterin  
   R CAGTGCTTTCTCTGCCACATTCTCC 25  58.1 
COL8A1  NM_001101176 F AAGTGGAGCAGCATCTGAAGAGACG 25 217 58.83 Collagen, type VIII, alpha 1 
   R GGTAGCGGCTTGATCCCATAGTAG 24  56.48 
CTTN NM_001075287 F TTGTGAGCGTCTCGCATCTGCACG 24 224 62.04 Cortactin 
   R AACACATTCTCCCGCAGCTTGTGG 24  59.94 
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 CXCL10 NM_001046551 F TGCAAGTCAATCCTGCCCACGTG 23 203 59.93 Chemokine (C-X-C motif) ligand 10 
   R GAGGTAGCTTCTCTCTGGTCCATCC 25  57.67 
CX3CR1 NM_001102558 F AGGAAGACTGACGGGCACATCG 22 243 58.66 Chemokine (C-X3-C motif) receptor 1  
   R TTGATGAGGGCAAACACCACCAGC 24  59.88 
CYP4F3 NM_001046391 F AGCACTCGTCTGGACATGTTTGAAC 25 202 57.77 Cytochrome P450, family 4, subfamily F, polypeptide 3 
   R CATCGCGGGTGAGGTAGTACAGG 23  58.61 
DTX4 XM_606934 F GCAGTGTCCGACCTGTAAGACC 22 216 57.03 Deltex homolog 2 
   R AGGTAACAATGTCGAGGGAAGCCAC 25  58.76 
GAPDH NM_001034034 F CAGCGACACTCACTCTTCTACCTTC 25 194 56.95 Glyceraldehyde-3-phosphate dehydrogenase 
   R GAACTCTTCCTCTCGTGCTCCTG 23  56.67 
ICAM1 NM_174348 F TGGCCCTGCTCGGGACTCTG 20 191 60.25 ICAM1 intercellular adhesion molecule 1 
   R AACCTTCCAGTTGTCCCCACGG 22  58.69 
IFIT3 NM_001075414 F GGCAGGCAAACAGCCATCATGAG 23 239 58.78 Interferon-induced protein with tetratricopeptide repeats 3 
   R CGCAAGCATTCCAGGGCTGC 20  59.22 
IGJ NM_175773 F TCCTAGTCAAGACATTGTGGAGAG 24 227 53.57 Iimmunoglobulin J chain  
   R TGTCATAGGTGTAACAGGTCTCAG 24  53.58 
IL2RB XM_587301 F ACTCACTCCAGGTCGTCCGCATAG 24 217 59.82 Interleukin 2 receptor, beta 
   R ACCTGAAGCTCATATTCCGTGCCTG 25  58.87 
IL15 NM_174090 F GAGAAGTACTTCCATCCAGTGCTAC 25 255 54.76 Interleukin 15  
   R AGGAGAAAGCACTGCATCGCTG 22  57.59 
IL18 NM_174091 F GGAATCAGATCACTTTGGCAAACTTGAACC 30 202 58.99 Interleukin 18 
   R GATGGTTACGGCCAGACCTCTAGTG 25  58.43 
ISG15 NM_174366 F TGCAGAGAGCCTGGCACCAGAAC 23 268 60.97 ISG15 ubiquitin-like modifier 
   R GATGCAGTTCTGCACCACCAGC 22  58.67 
LMO2 NM_001076352 F CTACTACAAGCTGGGCCGGAAGC 23 217 59.33 LIM domain only 2 (rhombotin-like 1) 
   R CACGATGTCGGAGTTGATGAGGAGG 25  58.95 
MFAP2 NM_174388 F TGGGAGCAGAAGCGGCCGTG 20 221 61.77 Microfibrillar-associated protein 2  
   R CTGCTCGCTGTAGTGGGTATACTGC 25  59.01 
MFAP2** NM_174388 F CCGCGTCTACGTCGTCAATAAGG 23 169 57.71 Microfibrillar-associated protein 2  
   R GCAGCCCCCACAGCTCCTG 19  59.67 
MEIS3 NM_001193152 F CGCTGCTAGCCCTGGTCTTTGAG 23 232 59.57 MEIS3 similar to Meis1, myeloid ecotropic viral integration site 1 
homolog 3     R AGGTGGAAGCGGAGCACTTGAATG 24  59.47 
MMP13 NM_174389 F TGGTGACTTCTACCCATTTGATGG 24 275 54.56 Matrix metallopeptidase 13 (collagenase 3)  
   R ACTGAATCCCTTGGACATCATCATC 25  54.66 
MPEG1 NM_001046464 F AAGGATCAAGCTGTAACTACCCAGG 25 243 56.03 Macrophage expressed gene 1  
   R CCTGATGTGGTCCTCCTGAATGAG 24  56.5 
MUM1L1 XM_586767 F CTAGCCACACAGTCAGAGGTCAG 23 228 56.34 Hypothetical LOC539380 (MUM1L1) 
   R CTTTGGTAAGTCTCCTTCTCCTTCGTG 27  57.1 
MX2 NM_173941 F CAAGAGGCACACTCAGACTTCCACT 25 256 58.42 Myxovirus (influenza virus) resistance 2 (mouse) 
   R CCGCACCTTCTCCTCATACTTTCTG 25  57.2 
MYL4 NM_001075149 F ATGCCGAGGTGCTGCGTGTCC 21 208 62.01 Myosin, light chain 4, alkali; 
   R GCAAGGACGTGGCGAAGCTCAG 22  60.61 
NDRG1 NM_001035009 F AGCAGGACATTGAGACTTTGCATGGC 26 222 60.01 N-myc downstream regulated 1  
   R TGGGGAAGGACGCAGCGCC 19  61.85 
NID2 NM_001102065 F CACTCCCACCCACGCCTTTCTG 22 261 59.67 Nidogen 2 (osteonidogen)  
   R CTATTCAGGTCATCAACCTCTCCTCGG 27  58.12 
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 PAK1 NM_001076898 F CGACAGAAACCGCAGGCAGAGATG 24 249 60.12 p21 protein (Cdc42/Rac)-activated kinase 1 
   R CAGGTAAGATGGCTCGGTAAAATCGG 26  57.64 
PGM5 NM_001102335 F TGCCCAACTTCATCCAGAGCGTGC 24 295 61.75 Phosphoglucomutase 5 
   R GCAACATTAAACTTCACTCCAAACTCTCC 29  57.07 
PIK3R6 NM_001102028 F ACTCTAATGTACGTGCTCACTAAGGC 26 205 56.6 phosphoinositide-3-kinase, regulatory subunit 6  
   R CACTCGTCAGGTTCTGCTCGG 21  57.25 
RAB15 NM_001046538 F AGCAGAAACGGCAGGTGGGAAGAG 24 214 60.94 RAB15,member RAS onocogene family 
   R TCATCCTCCTCCAGCTCTGCCAAG 24  59.76 
RGS1 NM_001199063 F GTGAGGAGAATATTGAGTTCTGGCTGG 27 321 57.18 Similar to regulator of G-protein signalling 1, 
   R AGCCAGGAGCCAGTCACTTTAGAC 24  58.16 
RNASEL NM_001098165 F GACTGAGGACGAGGCATCTACG 22 243 56.42 Ribonuclease L 
   R GGGTTGTTATGGCTCTCAGTCTCC 24  56.75 
Runx-2 XM_002684501 F GACAGAAGCTTGATGACTCTAAACCTAG 28 224 55.33 Runt-related transcription factor 2 
   R CGAGGGATAGGACTGGTCATAGG 23  55.17 
RYK XM_001249766 F CCAGACACCCTACGTGGACATCG 23 238 58.79 Similar to receptor-like tyrosine kinase  
   R TCCTGACGCTGTGAGACTGTGAC 23  58.36 
SELL NM_174182 F ATGCAGCGGCCATGGACAATGTG 23 211 60.6 Selectin L 
   R AATCATGTCTGTTCCCTTGGAGCAG 25  57.03 
SEPP1 NM_174459.3 F CCGCCTTGTATATCATCTTGGTTTGCC 27 331 58.4 Selenoprotein P, plasma, 1 
   R AGGGGTATCTGGTGTGTCTGGTTTTG 26  58.46 
SERPINE1 NM_174137 F ATGTCTCCGGTCTTTGCCTGCCTC 24 346 60.76 Serpin peptidase inhibitor, clade E member 1  
   R CGGCTGTGCTGATCTCATCCTTGTTC 26  59.91 
SLC6A6 NM_174610 F CGTACCCCTGACCTACAACAAAGTCTAC 28 266 58.51 Solute carrier family 6 (neurotransmitter transporter, taurine), 
member 6    R CAATGATGTGCGTGGGTTTCCTGAG 25  58.62 
STAP1 NM_001077868 F ACTGCTCTACCCTTGTACTTTGAAG 25 177 54.53 Signal transducing adaptor family member 1  
   R CTGATCAGTAAGGCATGTAAGGTC 24  53.07 
TLR4 NM_174198 F TGGACCTGAGCTTTAACTACCTG 23 159 59.39 Toll-like receptor 4  
   R TTCCCGTCAGTATCAAGGTG 20  58.8 
TRAF1 XM_002689959 F AGAGGGGAGTATGATGCTCTGCTGC 25 251 59.89 TNF receptor-associated factor 1 
   R TCCACGACGCACTTGACGAACATG 24  60 
TP63 NM_001191337 F CTCGATGCAGTCTCAGTCTTCCTACG 26 258 58.58 Tumor protein p63 
   R CAGTGGGAGGTGGATGGCATGG 22  59.21 
VCAM1 NM_174484 F CAGGCACCTTCAGGAGGGACAG 22 226 58.57 Vascular cell adhesion molecule 1 
   R CAGCCTGTTGTGCTGCAAGTCAGTG 25  60.89 
VWA5A XM_002699100 F GTTAGCATGGAGTGTGGAGTCATAAGC 27 248 57.67 Von Willebrand factor A domain containing 5A  
   R GGCTTCTCAAGACGGGCCTCTG 22  59.23 
XCL1 NM_175716 F TCAGCCTCTTACTGCACAGCTCAG 24 264 58.48 Chemokine (C motif) ligand 1 
   R CAGGCAGCTTGAGGATCAGCACAG 24  59.83 
 
Xxxxxxxxxxxxxxxxxxxxxx 
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Appendix 2: Microarray results of chapter 4 
2.1 Complete lists of infection associated modulated 1959 genes 
2.1.1 Full list of genes in profile 1(n = 44) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name  
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
 
          
1 gi_119889107 XM_001256711 SLAMF7 Slam family member 7 0.00 2.8 415.4 148.0 --- 
2 gi_119903692 XM_871827 LRRTM4 Leucine rich repeat transmembrane neuronal 4 0.00 3.6 242.6 67.9 --- 
3 gi_51806603 --- --- Co876689 bovgen_05014 normal cattle brain cDNA clone 
rzpdp1056k1259q 5' 
0.01 2.0 114.2 55.8 --- 
4 gi_31342133 NM_174389 MMP13 Matrix metallopeptidase 13 (collagenase 3) 0.00 3.1 168.2 54.2  
5 gi_31342239 NM_175716 XCL2 Chemokine (c motif) ligand 1 (xcl1) 0.00 8.5 356.6 42.0  
6 gi_119891855 XM_001250312 LOC783109 Similar to bowc1.1 0.00 2.4 93.9 39.6 --- 
7 gi_119927959 XM_593064 TP73 Tumor protein p73 0.00 2.7 53.6 20.0 --- 
8 gi_119915824 XM_001255734 LOC788785 Similar to atxn1 protein  0.00 2.9 43.0 15.0 --- 
9 gi_139948768 NM_001083791 SH3BGRL2 Sh3 domain binding glutamic acid-rich protein like 2 0.00 3.2 45.0 14.0 --- 
10 gi_119894051 XM_587301 IL2RB Interleukin 2 receptor, beta 0.00 8.3 93.1 11.2 --- 
11 gi_119892822 XM_001250337 CD122 Interleukin-2 receptor subunit beta precursor (IL-2 receptor) 
(p70-75)  
0.00 4.5 45.5 10.0 --- 
12 gi_27901800 NM_174182 SELL Selectin l 0.01 2.2 21.4 9.6  
13 gi_119911540 XM_001253061 CCL1 Chemokine (c-c motif) ligand 1 0.00 3.0 27.1 9.2  
14 gi_119910732 XM_869544 MEIS3 Meis homeobox 3 0.00 8.3 71.0 8.5  
15 gi_119893066 XM_001252456 LOC785733 Similar to bowc1.1 0.02 2.1 16.4 7.8 --- 
16 gi_119896248 XM_001254114 LOC786443 Hypothetical protein (LOC786443) 0.00 14.4 92.3 6.4 --- 
17 gi_31342240 NM_174348 ICAM1 Intercellular adhesion molecule 1 0.00 3.8 22.8 6.0 --- 
18 gi_119913829 XR_028628 LOC788239 Similar to regulator of g-protein signaling 16/-r 0.02 2.0 9.6 4.7 --- 
19 gi_158341675 NM_001109983 PGPEP1 Pyroglutamyl-peptidase i 0.00 4.8 22.4 4.7 --- 
20 gi_119908880 XM_001253453 LOC785427 Similar to epidermis-specific serine protease-like protein  0.00 4.7 22.1 4.7  
21 gi_119900312 XM_612930 BNC2 Basonuclin 2 0.00 4.9 22.6 4.6 --- 
22 gi_114051048 NM_001046491 MOBKL2B Mob1, mps one binder kinase activator-like 2b (yeast) 0.01 2.1 8.6 4.1 --- 
23 gi_31341516 NM_174619 STXBP1 Syntaxin binding protein 1 0.00 2.9 11.2 3.9 --- 
24 gi_119916814 XR_028239 LOC785278 Similar to regulator of g-protein signaling 16/-r  0.00 2.6 9.8 3.7 --- 
25 gi_119891399 XM_599768 JHDM1D Jumonji c domain containing histone demethylase 1 homolog 
d (s. Cerevisiae) 
0.00 2.7 9.9 3.7 --- 
26 gi_119915826 XM_868412 ATXN1 Ataxin 1 0.00 3.5 12.8 3.6 --- 
27 gi_119891397 XM_001249623 LOC781418 Hypothetical protein (LOC781418) 0.01 2.1 7.4 3.5 --- 
28 gi_119903194 XM_001255518 IL18RAP Interleukin 18 receptor accessory protein  0.00 4.1 14.3 3.5  
29 gi_119914616 XM_597868 LOC519644 Similar to voltage-gated calcium channel alpha(2)delta-3 
subunit 
0.01 2.1 7.3 3.4  
30* gi_115495042 NM_001075961 RTP4 Receptor (chemosensory) transporter protein 4 0.00 4.5 14.9 3.3  
31 gi_31341539 NM_174610 SLC6A6 Solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 
0.00 17.0 55.6 3.3  
32 gi_28461172 NM_175772 ELN Elastin 0.00 3.2 10.2 3.2  
33 gi_119887104 XM_587930 ABCG1 Atp-binding cassette, sub-family g (white), member 1 0.00 3.5 9.6 2.7  
34 gi_31341556 NM_174602 SLC2A1 Solute carrier family 2 (facilitated glucose transporter), 
member 1 
0.00 2.3 6.2 2.7  
35 gi_77735634 NM_001034341 --- Four and a half lim domains 1 (FHL1), transcript variant 3 0.00 2.8 7.7 2.7  
36 gi_119906041 XM_584869 SDC4 Syndecan 4 0.00 5.6 14.9 2.7 --- 
37 gi_60722467 --- --- Dn512277 1248296 marc 7bov cDNA 3' 0.00 4.4 11.4 2.6 --- 
38 gi_119890101 XM_616138 CACHD1 Cache domain containing 1 0.00 2.3 5.7 2.5 --- 
39* gi_119932755 XR_028507 RTP4 Receptor (chemosensory) transporter protein 4 0.00 4.4 11.0 2.5  
40 gi_114051635 NM_001046438 NRN1 Neuritin 1 0.00 12.3 29.4 2.4 --- 
41 gi_78369225 NM_001035273 SSBP4 Single stranded dna binding protein 4 0.00 5.6 13.3 2.4 --- 
42 gi_115497085 NM_001075287 CTTN Cortactin 0.00 11.0 25.0 2.3  
43 gi_155372054 NM_001101164 EGLN3 Egl nine homolog 3 (c. Elegans) 0.00 2.6 5.8 2.2 --- 
44 gi_119919443 XM_588001 TNFRSF26 Tumor necrosis factor receptor serfamily, member 26 0.01 2.2 4.8 2.2 --- 
          
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset     
 
2.1.2 Full list of genes in profile 2 (n = 254) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
          
1 gi_114050822 NM_001046464 MPEG1 Macrophage expressed 1 0.00 79.8 -5.6 -449.4  
2 gi_31343308 NM_173902 CLU Clusterin 0.00 8.9 -31.7 -280.7 --- 
3 gi_51812080 --- --- Co882151 bovgen_10476 normal cattle brain cDNA clone 
rzpdp1056f0925q 5' 
0.00 46.8 -4.0 -186.2 --- 
4 gi_91982958 --- --- Clone tghc9907 immunoglobulin gamma 1 heavy chain 
constant region, mRNA 
0.00 49.0 -3.6 -177.4 --- 
5* gi_119879490 XR_027375 CD200R1 Cd200 receptor 1 0.00 5.2 -25.4 -132.8  
6 gi_60592981 NM_001012678 BOLA-DYA Major histocompatibility complex, class ii, dy alpha (bola-dya) 0.00 27.4 -4.8 -132.1  
7 gi_119901378 XM_611161 EPHA7 Eph receptor a7 0.00 4.6 -26.0 -120.1 --- 
8 gi_119909596 XM_001255981 LOC789139 Similar to iglv3s1 (LOC789139) 0.00 7.4 -16.3 -119.8  
9 gi_119919728 XR_028639 LOC535439 Hypothetical (LOC535439) 0.00 3.4 -33.9 -115.3  
10 gi_41386773 NM_174090 IL15 Interleukin 15 0.00 5.7 -18.9 -107.3 --- 
11 gi_119904381 XM_001256288 ABO Abo blood group (transferase a, alpha 1-3-n-
acetylgalactosaminyltransferase) 
0.00 2.8 -35.5 -100.0 --- 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Appendices  297 
12 gi_51824544 --- --- Co894237 bovgen_22562 normal cattle brain cDNA clone 
rzpdp1056o1038q 5' 
0.00 21.4 -4.6 -98.7 --- 
13 gi_51804673 --- --- Co874773 bovgen_03098 normal cattle brain cDNA clone 
rzpdp1056c1255q 3' 
0.00 8.2 -11.5 -94.2 --- 
14 gi_51824705 --- --- Co894397 bovgen_22722 normal cattle brain cDNA clone 
rzpdp1056h2051q 5' 
0.00 6.7 -12.7 -85.3  
15 gi_119915695 XR_028435 LOC786760 Similar to BTN3A2 (LOC786760) 0.00 6.5 -12.8 -82.8  
16 gi_31340694 NM_174703 TNXB Tenascin Xb 0.00 6.6 -11.8 -78.0 --- 
17 gi_119896111 XM_593744 C8orf80 Chromosome 8 open reading frame 80 0.02 2.0 -32.4 -65.1  
18 gi_41386684 NM_174196 THBS1 Thrombospondin 1 0.00 2.5 -25.7 -65.0 --- 
19* gi_119908116 XM_864590 RGS18 Regulator of g-protein signaling 18 0.00 29.2 -2.2 -63.3 --- 
20 gi_75832075 NM_175773 IGJ Immunoglobulin j polypeptide 0.00 2.9 -20.3 -58.1  
21 gi_119891985 XM_596354 PLXNC1 Plexin C1 0.00 2.6 -19.4 -50.5  
22 gi_112210002 --- --- Ee349629 lb02756.cr_b03 gc_bgc-27 cDNA clone 
image:8630885 
0.00 11.8 -4.1 -47.9  
23 gi_78369299 NM_001035404 SAMSN1 Sam domain, sh3 domain and nuclear localization signals 1 0.00 4.5 -10.2 -46.2  
24 gi_119910850 XM_869691 RASIP1 Ras interacting protein 1 0.00 5.4 -8.5 -46.0  
25 gi_115497721 NM_001075231 PDGFA Platelet-derived growth factor alpha polypeptide 0.00 18.0 -2.5 -44.7 --- 
26 gi_118150845 NM_001077868 STAP1 Signal transducing adaptor family member 1 0.02 2.1 -21.2 -43.8  
27 gi_76628966 XM_588243 CD207 CD207 molecule, Langerin 0.00 3.8 -11.3 -42.9  
28 gi_45469784 --- --- Ck955404 4095662 barc 10bov cDNA clone 10bov34_k13 5' 0.00 16.5 -2.6 -42.8  
29 gi_119892202 XM_586498 WNT10B Similar to wingless-type mmtv integration site family, 
member 10b, transcript variant 1 (LOC539337) 
0.00 10.3 -4.2 -42.6  
30 gi_119905622 XM_001256257 LOC789517 Similar to neurotensin receptor (LOC789517) 0.00 10.5 -4.0 -42.3 --- 
31 gi_62751708 NM_001015520 LASS4 Lag1 homolog, ceramide synthase 4 0.00 9.2 -4.3 -39.9  
32* gi_68319996  AM018804.1 EPAS1 Endothelial pas domain protein 1 0.00 12.3 -3.3 -39.9  
33 gi_51827054 --- --- Co896734 bovgen_25059 normal cattle brain cDNA clone 
rzpdp1056g181q 5' 
0.00 16.3 -2.3 -38.1 --- 
34 gi_119879508 XM_617543 CD80 Cd80 molecule 0.00 13.4 -2.8 -37.9  
35 gi_51809329 --- --- Co879405 bovgen_07732 normal cattle brain cDNA clone 
rzpdp1056g089q 5' 
0.00 3.3 -10.9 -36.2  
36* gi_31340626 NM_174725 EPAS1 Endothelial pas domain protein 1 0.00 12.0 -2.9 -35.2  
37 gi_119930249 XM_001251416 LOC782773 Hypothetical protein (LOC782773) 0.00 4.1 -8.4 -34.8  
38* gi_150247135 NM_001099374 CD200R1 Cd200 receptor 1 0.00 8.3 -4.2 -34.6 --- 
39 gi_76668819 XM_864611 SIM1 Single-minded homolog 1 (drosophila) 0.00 6.7 -4.9 -33.2  
40 gi_115494923 NM_001075952 ASGR2 Asialoglycoprotein receptor 2 0.00 3.4 -9.7 -32.7  
41 gi_119894218 XM_608086 LOC529634 Similar to mist (LOC529634) 0.00 3.4 -9.5 -32.2  
42* gi_119914332 XM_001250255 MOBP Myelin-associated oligodendrocyte basic protein 0.00 14.3 -2.2 -32.0 --- 
43 gi_119904441 XM_580490 KBTBD6 Kelch repeat and btb (poz) domain containing 6 0.00 10.3 -3.0 -30.4 --- 
44 gi_119930251 XM_001251461 LOC782810 Hypothetical protein (LOC782810) 0.00 3.4 -8.5 -28.9  
45 gi_119916402 XM_580886 CCDC68 Coiled-coil domain containing 68 0.00 5.7 -5.0 -28.1  
46 gi_94966920 NM_001040563 HTATIP2 Hiv-1 tat interactive protein 2, 30kda 0.00 6.5 -4.3 -27.9 --- 
47 gi_149642680 NM_001098991 FGR Gardner-rasheed feline sarcoma viral (v-fgr) oncogene homolog 0.00 3.9 -7.1 -27.6  
48* gi_119889877 XM_591946 GBP2 Guanylate binding protein 2, interferon-inducible 0.00 3.8 -7.3 -27.4  
49 gi_78369443 NM_001035293 BIRC3 Baculoviral iap repeat containing 3 0.00 5.8 -4.5 -26.1 --- 
50 gi_119910918 XM_869891 SIGLEC10 Sialic acid binding ig-like lectin 10 0.00 2.7 -9.4 -25.4 --- 
51 gi_51813369 --- --- Co883435 bovgen_11760 normal cattle brain cDNA clone 
rzpdp1056h1817q 5' 
0.00 4.2 -5.9 -24.9  
52 gi_77736010 NM_001034532 PYROXD2 Pyridine nucleotide-disulphide oxidoreductase domain 2 0.00 7.2 -3.2 -23.4 --- 
53* gi_119915684 XM_863936 UBD Ubiquitin d 0.00 9.6 -2.4 -22.8  
54 gi_51811530 --- --- Co881601 bovgen_09926 normal cattle brain cDNA clone 
rzpdp1056j0915q 5' 
0.00 2.3 -9.8 -22.7  
55 gi_89886136 NM_001014870 TMEM106A Transmembrane protein 106a 0.00 2.1 -10.5 -22.2  
56 gi_119934649 XM_001256269 LOC789535 Similar to vasoactive intestinal peptide receptor 2  0.00 2.4 -8.9 -21.5 --- 
57 gi_119901653 XM_604128 PLEKHG1 Pleckstrin homology domain containing, family g (with 
RHOGEF domain) member 1 
0.00 2.1 -10.3 -21.5 --- 
58 gi_41386777 NM_174115 MUC1 Mucin 1, cell surface associated 0.00 10.2 -2.1 -21.2 --- 
59 gi_119922733 XM_001249941 LOC781780 Hypothetical protein (LOC781780) 0.00 4.1 -5.1 -21.0  
60 gi_119903737 XM_596854 PLEK Pleckstrin 0.00 5.6 -3.7 -20.3  
61 gi_51887667 --- --- Aj820191 aj820191 kn206 bos sp. CDNA clone c0006017l10 0.00 4.4 -4.6 -20.2 --- 
62 gi_162287249 NM_001075475 ADAM19 Adam metallopeptidase domain 19 0.00 3.0 -6.6 -19.8 --- 
63 gi_119890722 XM_592017 SAMD9 Sterile alpha motif domain containing 9 0.00 7.2 -2.8 -19.8  
64 gi_119904782 XM_868438 KCTD12 Potassium channel tetramerisation domain containing 12 0.00 5.7 -3.4 -19.5  
65 gi_119927147 XM_001253465 LOC785445 Similar to guanylate binding protein 4 (LOC785445) 0.00 5.5 -3.5 -19.2  
66 gi_119906769 XM_001250623 TP53INP1 Tumor protein p53 inducible nuclear protein 1 0.00 2.3 -8.3 -18.9  
67 gi_119887080 XM_584543 ICOSLG Inducible t-cell co-stimulator ligand 0.00 3.8 -4.9 -18.9  
68 gi_119905627 XM_606839 NTSR1 Neurotensin receptor 1 (high affinity) 0.00 6.6 -2.8 -18.1 --- 
69 gi_29184272 --- --- Cb419326 592181 marc 6bov cDNA 5' 0.00 3.8 -4.7 -17.9  
70 gi_156120748 NM_001102051 TXLNB Taxilin beta 0.00 8.5 -2.0 -17.3 --- 
71 gi_119906824 XM_001251675 LOC784120 Hypothetical protein, transcript variant 1 (LOC784120) 0.00 3.5 -4.9 -17.3  
72 gi_119920140 XM_001251153 LOC782514 Hypothetical protein (LOC782514) 0.00 8.3 -2.1 -17.1 --- 
73 gi_119918514 XM_001250260 LOC781983 Similar to proteoglycan 1 precursor-like (LOC781983) 0.00 5.6 -3.0 -16.8  
74 gi_77735736 NM_001034391 LRRC33 Leucine rich repeat containing 33 0.00 2.2 -7.7 -16.7  
75 gi_119906373 XM_594631 KLHL38 Kelch-like 38 (drosophila) 0.00 4.5 -3.7 -16.7  
76 gi_139948810 NM_001083735 TRIM2 Tripartite motif containing 2 0.00 5.6 -3.0 -16.6 --- 
77 gi_119909414 XM_590469 RASAL1 Ras protein activator like 1 (gap1 like) 0.00 8.1 -2.0 -16.5 --- 
78 gi_119918508 XR_027379 MYPN Myopalladin 0.00 3.5 -4.7 -16.4 --- 
79 gi_119887502 XR_027685 LOC540561 Similar to titin (connectin) 0.02 2.1 -7.6 -16.2  
80 gi_119893129 XM_867752 PRMT8 Protein arginine methyltransferase 8 0.00 6.7 -2.4 -16.1 --- 
81 gi_119887408 XR_028509 LOC787276 Hypothetical protein (LOC787276) 0.00 2.4 -6.6 -15.9 --- 
82 gi_60592983 NM_001012679 BOLA-DYB Major histocompatibility complex, class ii, dy beta (bola-dyb) 0.00 5.9 -2.7 -15.7 --- 
83 gi_51815496 --- --- Co885211 bovgen_13536 normal cattle brain cDNA clone 
rzpdp1056j083q 5' 
0.00 4.1 -3.8 -15.6 --- 
84 gi_116004198 NM_001076987 PLAC8 Placenta-specific 8 0.00 3.4 -4.5 -15.3  
85 gi_51811539 --- --- Co881610 bovgen_09935 normal cattle brain cDNA clone 
rzpdp1056k0421q 5' 
0.01 2.1 -7.1 -14.8  
86 gi_119900630 XM_001249758 LOC781261 Similar to clusterin precursor (Glycoprotein iii) (GPIII) 0.00 4.1 -3.6 -14.7 --- 
87* gi_119879546 XM_001251104 PARP14 Poly (adp-ribose) polymerase family, member 14 0.00 3.2 -4.6 -14.6  
88 gi_148236122 NM_001098043 CLMP Cxadr-like membrane protein 0.00 4.5 -3.2 -14.5 --- 
89 gi_119922735 XM_001251182 LOC782552 Hypothetical protein (LOC782552) 0.00 3.4 -4.1 -14.2  
90 gi_114050810 NM_001046507 EAF2 Ell associated factor 2 0.00 3.7 -3.8 -14.1 --- 
91 gi_51808399  CO878479.1 CEBPA CCAAT/enhancer binding protein (c/ebp), alpha 0.00 2.7 -5.2 -14.0  
92 gi_51885959 --- --- Aj818483 kn206 bos sp. CDNA clone c0006012g21 0.00 6.0 -2.3 -13.9 --- 
93 gi_119936478 XM_001257128 LOC790729 Similar to osbp-related protein 6; orp6 (LOC790729) 0.01 2.3 -6.0 -13.8 --- 
94* gi_119914330 XM_001250204 MOBP Myelin-associated oligodendrocyte basic protein 0.00 6.0 -2.3 -13.8 --- 
95 gi_119927163 XM_001249585 LOC783074 Hypothetical protein (LOC783074) 0.00 3.8 -3.6 -13.7  
96* gi_156121166 NM_001102261 GBP4 Guanylate binding protein 4 0.00 2.8 -4.8 -13.5  
97 gi_125991949 NM_001081581 ABAT 4-aminobutyrate aminotransferase 0.00 6.3 -2.1 -13.5 --- 
98 gi_119904527 XM_597949 CAB39L Calcium binding protein 39-like 0.00 4.0 -3.2 -13.0  
99* gi_119879548 XM_613140 PARP14 Poly (adp-ribose) polymerase family, member 14 0.00 3.2 -3.9 -12.6  
100* gi_119923113 XM_001250460 FRMD6 Ferm domain containing 6 0.00 6.1 -2.0 -12.4 --- 
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101 gi_114052742 NM_001045877 BMP4 Bone morphogenetic protein 4 0.00 3.0 -4.2 -12.4 --- 
102* gi_119927149 XM_872465 GBP4 Guanylate binding protein 4 0.01 2.3 -5.4 -12.3  
103 gi_119910364 XM_583222 KIRREL2 Kin of irre like 2 (drosophila) 0.00 3.4 -3.4 -11.9 --- 
104 gi_119907584 XM_867197 FCHSD2 Fch and double sh3 domains 2 0.00 2.9 -4.1 -11.8  
105 gi_51885704 --- --- Aj818228 kn206 bos sp. CDNA clone c0006011j16 0.00 2.3 -5.1 -11.8 --- 
106 gi_84370132 NM_001038554 ADPRH Adp-ribosylarginine hydrolase 0.00 2.1 -5.6 -11.8  
107 gi_76642926 XM_600064 SLFN11 Schlafen family member 11 0.00 2.9 -4.0 -11.8  
108 gi_51883657 --- --- Aj816181 kn206 bos sp. CDNA clone c0005210o22 0.00 3.7 -3.2 -11.7  
109 gi_156121204 NM_001102280 GAS7 Growth arrest-specific 7 0.00 2.1 -5.6 -11.6 --- 
110 gi_15776290 --- --- Bi775313 467737 marc 2bov cDNA 5' 0.00 2.7 -4.3 -11.6  
111 gi_157279976 NM_001105034 GIMAP7 Gtpase, imap family member 7 0.00 4.4 -2.6 -11.4 --- 
112 gi_119913163 XM_001253420 LOC785366 Similar to embigin homolog (mouse) (LOC785366) 0.01 2.2 -5.2 -11.3  
113 gi_51887200 --- --- Aj819724 kn206 bos sp. CDNA clone c0006016e15 0.00 4.0 -2.8 -11.2 --- 
114 gi_119917968 XM_866446 JAKMIP3 Janus kinase and microtubule interacting protein 3 0.02 2.1 -5.3 -10.8  
115 gi_62751902 NM_001015610 PLA1A Phospholipase a1 member a 0.00 5.1 -2.1 -10.7 --- 
116 gi_75832127 NM_001025326 SRGN Serglycin (srgn) 0.00 4.6 -2.3 -10.6 --- 
117 gi_45430044 NM_205812 PKIG Protein kinase (camp-dependent, catalytic) inhibitor gamma 0.00 4.2 -2.5 -10.6 --- 
118* gi_115496411 NM_001075349 CHN1 Chimerin (chimaerin) 1 0.00 3.2 -3.3 -10.6  
119 gi_119923438 XM_615898 VAV3 Vav 3 protein, transcript variant 1 (LOC521961) 0.02 2.0 -5.2 -10.5 --- 
120 gi_155371902 NM_001101086 CPD Carboxypeptidase d 0.00 3.8 -2.8 -10.5 --- 
121* gi_119921604 XM_001250189 GBP2 Guanylate binding protein 2, interferon-inducible 0.01 2.1 -5.1 -10.5  
122 gi_31341685 NM_174553 IFNAR2 Interferon (alpha, beta and omega) receptor 2 0.00 4.6 -2.3 -10.5 --- 
123 gi_114050846 NM_001046461 TRIM34 Trim6-trim34 readthrough (TRIM6-TRIM34) 0.00 2.1 -4.9 -10.4  
124 gi_119911048 XM_602125 PRKCG Protein kinase c, gamma 0.00 2.9 -3.6 -10.4 --- 
125 gi_114050784 NM_001046002 CD48 CD48 molecule 0.00 4.2 -2.5 -10.3  
126 gi_51880943 --- --- Aj813467 kn206 bos sp. CDNA clone c0005207e23 0.02 2.0 -5.1 -10.3  
127 gi_156523137 NM_001102513 PCDHGB4 Protocadherin gamma subfamily b, 4 0.03 2.0 -5.1 -10.2  
128 gi_61870087 XM_588576 PCDHGA5 Protocadherin gamma subfamily a, 5 0.01 2.2 -4.7 -10.1  
129 gi_156120712 NM_001102033 SGK1 Serum/glucocorticoid regulated kinase 1 0.00 4.3 -2.3 -9.9 --- 
130 gi_115496777 NM_001076371 SEPT5 Septin 5 0.00 2.6 -3.9 -9.9  
131 gi_119911648 XM_001251943 LOC783305 Similar to tnf receptor-associated factor 4 (LOC783305) 0.00 3.7 -2.6 -9.8 --- 
132 gi_119922622 XM_001255033 LOC787761 Similar to g protein coupled receptor 133 (LOC787761) 0.00 2.3 -4.2 -9.8 --- 
133 gi_119894894 XM_600015 TNFSF9 Tumor necrosis factor (ligand) superfamily, member 9 0.00 2.3 -4.1 -9.7 --- 
134 gi_119888895 XM_581276 UBXN10 Ubx domain protein 10 0.00 2.5 -3.9 -9.6 --- 
135 gi_156120916 NM_001102135 LAMP3 Lysosomal-associated membrane protein 3 0.00 2.8 -3.4 -9.4  
136 gi_119914719 XM_001254179 CDHR4 Cadherin-related family member 4 0.00 2.4 -3.8 -9.3 --- 
137 gi_51812298 --- --- Co882366 bovgen_10691 normal cattle brain cDNA clone 
rzpdp1056h213q 5' 
0.00 2.7 -3.4 -9.2 --- 
138 gi_31342628 NM_174190 SVIL Supervillin 0.00 4.1 -2.3 -9.2 --- 
139 gi_29234175 --- --- Cb444296 695445 marc 6bov cDNA 3' 0.01 2.3 -3.9 -8.8  
140 gi_9600749 --- --- Be481216 166577 barc 5bov cDNA 5' 0.00 3.5 -2.5 -8.8 --- 
141 gi_139949110 NM_001083769 IRF8 Interferon regulatory factor 8 0.00 2.4 -3.7 -8.8  
142 gi_119925221 XM_001254480  Similar to zinc finger protein 75 (LOC614260) 0.00 3.1 -2.8 -8.7 --- 
143 gi_119889702 XM_001254448 LOC786893 Similar to vav 3 oncogene (LOC786893) 0.01 2.1 -4.2 -8.7 --- 
144 gi_31343026 NM_174020 LYST Lysosomal trafficking regulator 0.00 2.2 -3.8 -8.6 --- 
145 gi_164450480 NM_001113277 KNG1 Kininogen 1 0.01 2.1 -4.1 -8.4  
146 gi_115495496 NM_001076276 MARCKS Myristoylated alanine-rich protein kinase c substrate 0.00 3.8 -2.2 -8.3 --- 
147 gi_119889728 XM_001254754 LOC787315 Similar to vav 3 oncogene (LOC787315) 0.00 2.3 -3.6 -8.3 --- 
148 gi_119915696 XM_870260 BTN2A2 Butyrophilin, subfamily 2, member a2 0.00 3.2 -2.5 -8.2 --- 
149 gi_156120442 NM_001101897 KIAA0226 Kiaa0226 0.00 3.0 -2.7 -8.2 --- 
150 gi_49409176 --- --- Aj676886 kn224 cDNA clone kn224-022_e21 0.01 2.0 -4.1 -8.2  
151 gi_10025444  BE665170.1 PNRC1 Proline-rich nuclear receptor coactivator 1 0.00 3.4 -2.4 -8.1  
152 gi_51823891 --- --- Co893586 bovgen_21911 normal cattle brain cDNA clone 
rzpdp1056p2234q 5' 
0.00 2.9 -2.8 -8.1 --- 
153 gi_119909598 XM_001256017 LOC789191 Similar to mgc127066 protein (LOC789191) 0.00 3.6 -2.2 -8.0 --- 
154 gi_116004060 NM_001076918 TLR10 Toll-like receptor 10 0.00 3.5 -2.3 -8.0 --- 
155 gi_119891152 XM_594668 MYO1G Myosin ig 0.00 2.6 -3.0 -8.0 --- 
156 gi_51820108 --- --- Co889821 bovgen_18146 normal cattle brain cDNA clone 
rzpdp1056o0331q 5' 
0.00 3.5 -2.2 -7.9 --- 
157 gi_119895312 XM_866364 OR2G3 Olfactory receptor, family 2, subfamily g, member 3 0.00 3.5 -2.2 -7.8 --- 
158 gi_119921600 XM_001249998 LOC781557 Hypothetical protein (LOC781557) 0.00 2.3 -3.3 -7.7 --- 
159 gi_119907376 XM_001255273 LOC788122 Similar to tripartite motif protein trim5 (LOC788122) 0.00 3.2 -2.4 -7.7 --- 
160 gi_76678805 XM_586049 LOC509148 Similar to clll7 protein (LOC509148) 0.00 3.1 -2.5 -7.7 --- 
161 gi_115496207 NM_001075746 GBP5 Guanylate binding protein 5 0.00 3.4 -2.2 -7.6 --- 
162 gi_119910891 XM_870599 LOC618268 Similar to CD33L1 (LOC618268) 0.00 2.3 -3.3 -7.5 --- 
163* gi_62751495 NM_001015680 NAPEPLD N-acyl phosphatidylethanolamine phospholipase d 0.00 2.6 -2.9 -7.5  
164 gi_115495090 NM_001075392 ANKRD37 Ankyrin repeat domain 37 0.00 2.5 -3.0 -7.5 --- 
165 gi_119923988 XR_028027 LOC784083 Similar to lar-interacting protein 1a (LOC784083) 0.01 2.4 -3.1 -7.5 --- 
166 gi_58765354 --- --- Cx951827 umc-bemiv_0a02-017-h02 nuclear-transfer derived 
blastocysts d8 bemiv cDNA 3' 
0.00 3.1 -2.4 -7.5  
167 gi_119922554 XM_001254319 LOC786718 Hypothetical protein loc786718 (LOC786718) 0.01 2.3 -3.2 -7.4  
168 gi_51827041 --- --- Co896721 bovgen_25046 normal cattle brain cDNA clone 
rzpdp1056i111q 5' 
0.01 2.2 -3.4 -7.4  
169 gi_6955562_ --- --- Aw427615 63840 marc 3bov cDNA 5' 0.00 2.8 -2.6 -7.4 --- 
170 gi_51881820 --- --- Aj814344 aj814344 kn206 bos sp. CDNA clone c0005200k24 0.00 3.0 -2.4 -7.3  
171 gi_114052650 NM_001046309 BAMBI Bmp and activin membrane-bound inhibitor homolog 
(xenopus laevis) 
0.00 3.5 -2.1 -7.2 --- 
172 gi_51883270 --- --- Aj815794 kn206 bos sp. cDNA clone c0005198a15 0.02 2.1 -3.4 -7.2 --- 
173 gi_119912293 XM_586229 GSDMB Gasdermin b 0.00 2.7 -2.6 -7.1 --- 
174 gi_119907378 XM_864679 LOC516599 Similar to tripartite motif protein trim5, transcript variant 2  0.01 2.2 -3.2 -7.1  
175 gi_51887143 --- --- Aj819667 kn206 bos sp. cDNA clone c0006016b24 0.00 3.2 -2.2 -7.0 --- 
176 gi_51887526 --- --- Aj820050 kn206 bos sp. cDNA clone c0006017e07 0.00 2.9 -2.4 -7.0  
177* gi_61011750 DN547960.1 AP1M2 Adaptor-related protein complex 1, mu 2 subunit 0.02 2.1 -3.3 -7.0  
178 gi_119919105 XM_001254753 GPR44 G protein-coupled receptor 44 0.02 2.0 -3.4 -6.9 --- 
179* gi_51824596   AP1M2 Adaptor-related protein complex 1, mu 2 subunit 0.00 2.4 -2.9 -6.9  
180 gi_115496154 NM_001075480 C11H2orf50 Chromosome 2 open reading frame 50 ortholog  0.00 2.6 -2.6 -6.9 --- 
181 gi_119888565 XM_001252890 LOC785844 Hypothetical protein (LOC785844) 0.00 2.5 -2.7 -6.8  
182 gi_155371870 NM_001101070 FAM117A Family with sequence similarity 117, member a 0.00 2.2 -3.1 -6.8 --- 
183 gi_31343630 NM_177523 SOCS2 Suppressor of cytokine signaling 2 0.00 2.5 -2.7 -6.8 --- 
184 gi_116003948 NM_001076862 SNX29 Sorting nexin 29 0.00 3.3 -2.1 -6.7 --- 
185 gi_156121170 NM_001102263 GRAMD4 Gram domain containing 4 (gramd4) 0.00 3.2 -2.1 -6.7 --- 
186 gi_119924029 XM_618019 LOC537832 Similar to IL1RAPL1 protein (LOC537832) 0.00 2.6 -2.6 -6.7  
187 gi_71034621 DR749281.1  --- Dr749281 ng010006a12h05 ng01 rearrayed soares 
normalized bovine placenta cDNA clone bp230018a10b10 3' 
0.00 2.2 -3.0 -6.6  
188 gi_51809011  CO879087.1  --- Co879087 bovgen_07412 normal cattle brain cDNA clone 
rzpdp1056e1615q 5' 
0.01 2.0 -3.3 -6.6  
189 gi_118150825 NM_001077856 LY6G6C Lymphocyte antigen 6 complex, locus g6c 0.01 2.1 -3.2 -6.6 --- 
190 gi_51884088 AJ816612.1 --- Aj816612 kn206 bos sp. cDNA clone c0005209j9 0.01 2.1 -3.1 -6.6  
191 gi_51887654 AJ820178.1 --- Aj820178 kn206 bos sp. cDNA clone c0006017k17 0.00 3.2 -2.0 -6.5 --- 
192 gi_114052363 NM_001046345 IKBKE Inhibitor of kappa light polypeptide gene enhancer in b-cells, 
kinase epsilon 
0.01 2.1 -3.1 -6.5 --- 
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193 gi_164518975 NM_001113301 SERF1B Small edrk-rich factor 1b (centromeric) (serf1b) 0.00 2.5 -2.6 -6.5 --- 
194 gi_126722664 NM_001082452 PARP11 Poly (adp-ribose) polymerase family, member 11 0.00 2.5 -2.6 -6.4  
195 gi_119879516 XM_593520 ARHGAP31 Rho gtpase activating protein 31 0.00 2.3 -2.8 -6.4 --- 
196 gi_51883432 Aj815956   Aj815956 kn206 bos sp. cDNA clone c0005202f3 0.02 2.0 -3.2 -6.4  
197 gi_119927292 XM_001255388 SPRR4 Small proline-rich protein 4 0.00 3.0 -2.1 -6.4 --- 
198 gi_115496919 NM_001075675 FABP6 Fatty acid binding protein 6, ileal 0.00 2.5 -2.6 -6.4 --- 
199 gi_119893047 XM_613380 CD163 CD163 molecule 0.01 2.1 -3.0 -6.4  
200 gi_114053094 NM_001046256 MTMR9  Myotubularin related protein 9 (mtmr9) 0.00 2.4 -2.7 -6.3  
201 gi_119912528 XM_616376 ITGB3 Integrin, beta 3 (platelet glycoprotein iiia, antigen CD61) 0.00 2.6 -2.5 -6.3  
202 gi_119937182 XM_001255975 LOC789130 Similar to zinc finger protein 567 (LOC789130) 0.00 2.3 -2.7 -6.2 --- 
203 gi_51824234  Co893927 --- Co893927 bovgen_22252 normal cattle brain cDNA clone 
rzpdp1056j2443q 5' 
0.00 2.4 -2.6 -6.2  
204 gi_51826163  Co895846 --- Co895846 bovgen_24171 normal cattle brain cDNA clone 
rzpdp1056n1538q 5' 
0.00 2.5 -2.5 -6.2  
205 gi_119889555 XM_001250648 LOC782071 Similar to LFA-3 (LOC782071) 0.00 2.8 -2.2 -6.1 --- 
206 gi_119908832 XR_027675 LOC531974 Similar to mkiaa1151 protein (LOC531974) 0.01 2.2 -2.8 -6.1 --- 
207 gi_76659540 XM_864058 LOC613370 Similar to hmgb3 protein (LOC613370) 0.00 3.0 -2.0 -6.0 --- 
208 gi_115495920 NM_001075138 RTN4  Reticulon 4 (RTN4), transcript variant 1 0.00 3.0 -2.0 -6.0  
209 gi_119934667 XM_001256326 LOC789628 Hypothetical protein (LOC789628) 0.00 2.8 -2.1 -6.0 --- 
210 gi_119915594 XM_606763 LOC528343 Similar to olfactory receptor mor256-5 (LOC528343) 0.00 2.5 -2.4 -6.0  
211 gi_111087524 EE226389.1 --- Ee226389 lb0188.cr_p05 gc_bgc-18 cDNA clone 
image:8288503 
0.01 2.0 -2.9 -6.0 --- 
212 gi_155722980 NM_001101042 SLC2A5 Solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5 
0.00 2.2 -2.7 -5.9  
213 gi_166159169 NM_001114080 --- Protocadherin gamma subfamily c, 3 (pcdhgc3), transcript 
variant 1 
0.02 2.0 -2.9 -5.9  
214 gi_46418898 Cn439634 --- Cn439634 be04020a1c06 be04 normalized and subtracted 
bovine embryonic and extraembryonic tissue cDNA clone 
be04020a1c06 5' 
0.00 2.4 -2.4 -5.8 --- 
215 gi_119901056 XM_610591 LOC532081 Hypothetical (LOC532081) 0.00 2.4 -2.4 -5.8  
216 gi_119915604 XM_589001 LOC511626 Similar to olfactory receptor, family 2, subfamily j, member 3 0.00 2.5 -2.3 -5.8  
217 gi_77735772 NM_001034409 EEPD1 Endonuclease/exonuclease/phosphatase family domain 
containing 1 
0.00 2.3 -2.5 -5.8 --- 
218 gi_119924891 XM_001254602 LOC787107 Similar to steerin3 protein (LOC787107) 0.01 2.2 -2.6 -5.8 --- 
219* gi_119915602 XM_001253092 Olfr129 Olfactory receptor 129 0.01 2.4 -2.4 -5.7  
220 gi_119895959 XM_613847 RGMB Rgm domain family, member b 0.00 2.1 -2.7 -5.6 --- 
221 gi_119889872 XM_591383 GBP7 Guanylate binding protein 7 0.00 2.7 -2.1 -5.6 --- 
222 gi_119905278 XM_601498 CUBN Cubilin (intrinsic factor-cobalamin receptor) 0.00 2.7 -2.0 -5.5 --- 
223 gi_51826533 Co896216 --- Co896216 bovgen_24541 normal cattle brain cDNA clone 
rzpdp1056c0748q 5' 
0.00 2.7 -2.0 -5.5 --- 
224 gi_61946435 DN641034 --- Dn641034 umc-bend_0b02-031-a05 day 16 uterus from a 
non-pregnant animal bend cDNA 3' 
0.01 2.1 -2.7 -5.5 --- 
225 gi_125991875 NM_001081602 STK38 Serine/threonine kinase 38 0.02 2.0 -2.7 -5.5 --- 
226 gi_119889385 XM_590074 RFX5 Regulatory factor x, 5 (influences hla class ii expression) 0.00 2.1 -2.5 -5.4 --- 
227* gi_51811774   NAPEPLD N-acyl phosphatidylethanolamine phospholipase d 0.02 2.0 -2.6 -5.3  
228 gi_119895611 XM_870459 LOC618132 Similar to protocadherin gamma a9 short form protein  0.01 2.3 -2.3 -5.3  
229 gi_119909826 XM_869529 LOC617296 Similar to plcg2 protein (LOC617296) 0.00 2.4 -2.2 -5.3 --- 
230 gi_51887569 Aj820093 --- Aj820093 kn206 bos sp. cDNA clone c0006017g15 0.00 2.4 -2.2 -5.3 --- 
231 gi_119879413 XM_001251003 LOC782355 Hypothetical protein (LOC782355) 0.01 2.3 -2.3 -5.3 --- 
232 gi_77736300 NM_001034678 HES1 Hairy and enhancer of split 1, (drosophila) 0.00 2.1 -2.5 -5.2  
233 gi_166157485 NM_001113762 ICAM5 Intercellular adhesion molecule 5, telencephalin 0.00 2.5 -2.1 -5.2 --- 
234 gi_119933354 XM_001256838 LOC790336 Hypothetical protein (LOC790336) 0.00 2.6 -2.0 -5.2  
235 gi_51886086 Aj818610 --- Aj818610 kn206 bos sp. cDNA clone c0006012n11 0.01 2.2 -2.4 -5.2 --- 
236 gi_119903011 XM_580522 RPS6KA5 Ribosomal protein s6 kinase, 90kda, polypeptide 5 0.01 2.0 -2.6 -5.2 --- 
237* gi_119902242 XM_001253748 Olfr49 Olfactory receptor 49 0.02 2.1 -2.5 -5.2 --- 
238 gi_49354162 Aj669708 --- Aj669708 kn224 cDNA clone kn224-001_h03 0.01 2.2 -2.4 -5.1 --- 
239 gi_119910901 XM_870570 LOC618240 Hypothetical (LOC618240) 0.02 2.1 -2.4 -5.1  
240 gi_51887345 Aj819869 ---  Aj819869 kn206 bos sp. cDNA clone c0006016l19 0.03 2.0 -2.5 -5.1  
241 gi_51881051 Aj813575 --- Aj813575 kn206 bos sp. cDNA clone c0005207e7 0.00 2.4 -2.1 -5.1  
242 gi_60443178 DN274568 --- Dn274568 1153592 marc 7bov cDNA 3' 0.00 2.5 -2.1 -5.1 --- 
243 gi_119934357 XM_001254441 LOC786885 Similar to glucose transporter 5 (LOC786885) 0.00 2.3 -2.2 -5.1  
244 gi_119934023 XM_001257056 LOC790637 Hypothetical protein (LOC790637) 0.00 2.3 -2.2 -5.1 --- 
245 gi_156121152 NM_001102254 NCOA7 Nuclear receptor coactivator 7 0.00 2.1 -2.4 -5.0 --- 
246 gi_157073983 NM_001103231 MEF2B Myocyte enhancer factor 2b 0.01 2.0 -2.5 -5.0 --- 
247 gi_115497499 NM_001075894 CDKN2B Cyclin-dependent kinase inhibitor 2b (p15, inhibits cdk4) 0.01 2.1 -2.3 -4.9 --- 
248 gi_119893623 XM_595689 LOC517517 Hypothetical protein (LOC517517) 0.01 2.3 -2.1 -4.7 --- 
249 gi_119902502 XM_601785 MYO1E Myosin 1E 0.01 2.1 -2.2 -4.7 --- 
250 gi_119911605 XM_610844 NEK8 Nima (never in mitosis gene a)- related kinase 8 0.01 2.1 -2.1 -4.5 --- 
251 gi_119930554 XR_028682 LOC788758 Hypothetical protein (LOC788758) 0.02 2.1 -2.2 -4.5 --- 
252 gi_78369187 NM_001035478 SSBP2 Single-stranded dna binding protein 2 0.01 2.1 -2.2 -4.5 --- 
253 gi_119915568 XM_607721 LOC529277 Similar to homeostatic thymus hormone alpha (LOC529277) 0.03 2.1 -2.1 -4.4  
254 gi_51881606 Aj814130 --- Aj814130 kn206 bos sp. cDNA clone c0005198k15 0.02 2.0 -2.1 -4.2  
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
     
          
          
2.1.3 Full list of genes in profile 3 (n = 55) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
          
1 gi_66792905 NM_001024557 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kda 0.00 125.9 3.9 -32.1  
2 gi_114051539 NM_001046590 CD83 CD83 molecule 0.00 57.1 2.1 -27.5 --- 
3 gi_114052748 NM_001046551 CXCL10 Chemokine (c-x-c motif) ligand 10 0.00 272.5 11.2 -24.3  
4 gi_119910571 XM_001256399 LOC789736 Hypothetical protein (LOC789736) 0.00 38.2 2.9 -13.3  
5 gi_29263643 Cb457261  --- Cb457261 714599 marc 6bov cDNA 5' 0.00 37.1 3.4 -11.1  
6 gi_119910676 XM_600955 RELB V-rel reticuloendotheliosis viral oncogene homolog b 0.00 27.2 2.5 -10.7 --- 
7 gi_119910534 XM_001254854 LOC788393 Hypothetical protein (LOC788393) 0.00 36.9 3.7 -10.0  
8 gi_119901537 XM_584832 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 0.00 57.1 6.6 -8.6 --- 
9 gi_119889854 XM_001253071 TGFBR3 Transforming growth factor, beta receptor iii 0.00 37.0 4.5 -8.3  
10 gi_156523227 NM_001102558 CX3CR1 Chemokine (C-x3-C motif) receptor 1 0.00 48.5 5.9 -8.2  
11 gi_119893517 XM_001252348 LOC783896 Similar to TRAF-interacting protein with a forkhead-
associated domain (LOC783896) 
0.00 31.9 4.1 -7.8 --- 
12 gi_119910569 XM_001256395 LOC789731 Hypothetical protein (LOC789731) 0.00 29.1 3.9 -7.4  
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13 gi_125991933 NM_001081621 TIFA Traf-interacting protein with forkhead-associated domain 0.00 34.8 5.0 -7.0 --- 
14 gi_31343037 NM_174014 CD69 CD69 molecule 0.00 37.7 5.7 -6.6  
15 gi_119905687 XM_585095 ZBP1 Similar to putative tumor stroma and activated macrophage 
protein dlm-1 (LOC508333) 
0.00 46.3 7.4 -6.3  
16 gi_119896106 XM_580928 DDX58 Dead (asp-glu-ala-asp) box polypeptide 58 0.00 13.9 2.2 -6.2 --- 
17 gi_62988293 NM_001017940 USP18 Ubiquitin specific peptidase 18 (usp18) 0.00 21.5 3.7 -5.7 --- 
18 gi_51887332 Aj819856 --- Aj819856 kn206 bos sp. cDNA clone c0006016l04 0.00 13.9 2.5 -5.7 --- 
19 gi_82991961 DV934772 --- Dv934772 lb0308.cr_e16 gc_bgc-30 cDNA clone 
image:8135034 5' 
0.00 39.3 7.1 -5.5 --- 
20 gi_115496813 NM_001075310 BCL2L11 BCL2-like 11 (apoptosis facilitator) (BCL2L11) 0.00 14.7 2.8 -5.2  
21 gi_31343249 NM_173924 IL7 Interleukin 7 0.00 10.3 2.1 -5.0  
22 gi_27805954 NM_174366 ISG15 ISG15 ubiquitin-like modifier 0.00 120.9 25.8 -4.7 --- 
23* gi_71067099 NM_001029846 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda 0.00 13.1 2.9 -4.5  
24* gi_94967003 NM_001040606 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda 0.00 34.5 8.1 -4.3  
25 gi_62751388 NM_001015545 LGP2  Rna helicase LGP2  0.00 20.0 4.8 -4.2  
26 gi_156120848 NM_001102101 NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in b-
cells 2 (p49/p100) 
0.00 28.3 7.1 -4.0 --- 
27 gi_115494987 NM_001075771 PARM1 Prostate androgen-regulated mucin-like protein 1 0.00 8.5 2.3 -3.7 --- 
28 gi_119894560 XM_584000 BST2 Bone marrow stromal cell antigen 2 0.00 17.6 4.8 -3.7 --- 
29 gi_119917771 XM_583612 LOC507061 Similar to dual specificity phosphatase 5 (LOC507061) 0.00 11.9 3.3 -3.6 --- 
30 gi_158341671 NM_001109981 ITGA6 Integrin, alpha 6 0.00 43.2 11.9 -3.6 --- 
31 gi_41386700 NM_174726 NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in b-
cells inhibitor, zeta 
0.00 14.3 4.0 -3.6 --- 
32 gi_119913076 XM_587229 PLK2 Polo-like kinase 2 0.00 7.4 2.2 -3.4 --- 
33 gi_118150773 NM_001077827 JUN Jun proto-oncogene 0.00 7.0 2.2 -3.1 --- 
34* gi_31342215 NM_174364 INPP1 Inositol polyphosphate-1-phosphatase 0.00 6.0 2.0 -3.0 --- 
35 gi_119923683 XR_027350 LOC781857 Similar to interferon-induced protein 44 (antigen p44) (non-a 
non-b hepatitis-associated microtubular aggregates protein)  
0.00 9.0 3.1 -2.8  
36 gi_119908035 XM_589248 LOC511831 Similar to renin (LOC511831) 0.00 9.4 3.3 -2.8  
37 gi_51814407 Co884407 ---  Co884407 bovgen_12732 normal cattle brain cDNA clone 
rzpdp1056m1612q 5' 
0.00 26.0 9.2 -2.8  
38 gi_78365288 NM_001035465 IRF5 Interferon regulatory factor 5 0.00 5.9 2.1 -2.8  
39 gi_119901919 XM_593090 SMAD3 Smad family member 3 0.00 10.7 4.0 -2.7 --- 
40 gi_157074115 NM_001103300 MAFF V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
f (avian) 
0.00 6.7 2.6 -2.6  
41 gi_119879663 XR_027887 LOC525407 Hypothetical loc525407 (LOC525407) 0.00 10.9 4.3 -2.6  
42 gi_31343213 NM_173941 MX2 Myxovirus (influenza virus) resistance 2 (mouse) 0.00 100.5 39.9 -2.5  
43 gi_119925448 XM_001251333 MYO10 Myosin x 0.00 5.4 2.2 -2.4 --- 
44 gi_119889992 XM_872122 IFI44 Interferon-induced protein 44 0.00 7.4 3.1 -2.4  
45* gi_118601803 NM_001079603 CBLN3 Cerebellin 3 precursor 0.00 9.3 3.9 -2.4  
46 gi_51826112 Co895796 --- Co895796 bovgen_24121 normal cattle brain cDNA clone 
rzpdp1056b1744q 5' 
0.00 15.3 6.6 -2.3  
47 gi_119927124 XM_001252928 LOC784693 Similar to dipeptidyl peptidase iv (LOC784693) 0.00 5.1 2.3 -2.2 --- 
48 gi_147902261 NM_001098095 EXT1 Exostosin 1 0.00 4.5 2.1 -2.2 --- 
49 gi_119922761 XM_001252258 LOC783754 Similar to mkiaa1108 protein (LOC783754) 0.00 4.4 2.0 -2.2 --- 
50* gi_62988287 NM_001017937 BAIAP2 Bai1-associated protein 2 0.00 16.4 7.6 -2.2 --- 
51 gi_51821917 Co891619 --- Co891619 bovgen_19944 normal cattle brain cDNA clone 
rzpdp1056b0838q 5' 
0.00 4.3 2.0 -2.1 --- 
52 gi_58764282 Cx950755 --- Cx950755 umc-bcl_0b02-030-d06 day 14 cl from a pregnant 
animal bcl cDNA 3' 
0.00 5.1 2.4 -2.1 --- 
53 gi_112219499 EE358869 --- Ee358869 lb02964.cr_k02 gc_bgc-29 cDNA clone 
image:8476732 
0.00 4.7 2.2 -2.1 --- 
54 gi_78045237 NM_001034502 ACTA2 Actin, alpha 2, smooth muscle, aorta 0.00 11.8 5.7 -2.1 --- 
55 gi_51818119 Co887834  --- Co887834 bovgen_16159 normal cattle brain cDNA clone 
rzpdp1056p0114q 5' 
0.00 4.9 2.4 -2.0 --- 
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
     
 
2.1.4 Full list of genes in profile 4 (n = 1093) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
       
No 
Change  
 
1* gi_41386706 NM_174484 VCAM1 Vascular cell adhesion molecule 1 (VCAM1) 0.00 183.1 1.0 -184.6 --- 
2 gi_139947562 NM_001083739 TFEC Transcription factor ec 0.00 34.2 -1.4 -47.1 --- 
3 gi_119913384 XM_596594 ANKRD33B Ankyrin repeat domain 33b 0.00 30.5 -1.5 -45.1 --- 
4* gi_119908118 XM_001252844 RGS18 Regulator of g-protein signaling 18 0.00 27.5 -1.5 -42.3 --- 
5 gi_119924697 XM_589150 LOC511753 Similar to seven transmembrane helix receptor (LOC511753) 0.00 35.2 -1.1 -39.7 --- 
6 gi_119906810 XM_001254274 OSGIN2 Oxidative stress induced growth inhibitor family member 2 0.00 26.9 -1.2 -33.5 --- 
7 gi_119922152 XM_001252866 LOC784595 Similar to olfactory receptor olfr1174 (LOC784595) 0.00 16.1 -1.7 -26.8 --- 
8 gi_119930245 XM_868109 ADAMTSL5 Adamts-like 5 0.00 15.6 -1.7 -26.6 --- 
9 gi_119902166 XM_001251339 LOC783981 Similar to ribonuclease 12 (LOC783981) 0.00 14.4 -1.8 -26.5 --- 
10 gi_119911031 XM_581045 AU018091 Expressed sequence AU018091 0.00 13.5 -1.8 -24.2 --- 
11 gi_157427901 NM_001105388 ITK Il2-inducible t-cell kinase 0.00 16.2 -1.4 -22.6 --- 
12 gi_119925538 XM_586833 LOC509794 Similar to tesc protein, transcript variant 1 (LOC509794) 0.00 16.5 -1.4 -22.5 --- 
13 gi_119892989 XM_591681 STYK1 Serine/threonine/tyrosine kinase 1 0.00 23.1 1.1 -21.4 --- 
14* gi_155372040 NM_001101158 VCAM1 Vascular cell adhesion molecule 1 0.00 14.4 -1.5 -20.9 --- 
15 gi_119892383 XM_587244 SRGAP1 Slit-robo rho gtpase activating protein 1 0.00 27.7 1.3 -20.9 --- 
16 gi_51882056 Aj814580 --- Aj814580 kn206 bos sp. CDNA clone c0005204g20 0.00 10.4 -2.0 -20.6  
17 gi_119879695 XM_867115 TP63 Tumor protein p63 0.00 36.2 1.9 -19.1 --- 
18 gi_115496711 NM_001075696 IRAK2 Interleukin-1 receptor-associated kinase 2 0.00 9.4 -2.0 -18.5 --- 
19 gi_84579864 NM_001038682 AICDA Activation-induced cytidine deaminase 0.00 16.0 -1.1 -18.3 --- 
20 gi_119914336 XM_871109 CCR8 Chemokine (c-c motif) receptor 8 0.00 18.2 1.0 -17.7 --- 
21 gi_119934789 XM_001256599 LOC790001 Similar to transmembrane protein 17 (LOC790001) 0.00 11.0 -1.6 -17.3 --- 
22 gi_115496259 NM_001075147 CCL4 Chemokine (c-c motif) ligand 4 0.00 13.4 -1.3 -17.3 --- 
23 gi_119901659 XM_001253771 LOC785913 Hypothetical protein (LOC785913) 0.00 10.8 -1.6 -16.9 --- 
24 gi_114052247 NM_001045923 PLS3 Plastin 3 0.00 23.5 1.4 -16.5 --- 
25 gi_84000076 NM_001038050 IFI27 Interferon, alpha-inducible protein 27 0.00 14.2 -1.2 -16.5 --- 
26 gi_51808298 --- --- Co878378 bovgen_06703 normal cattle brain cDNA clone 
rzpdp1056o0112q 5' 
0.00 12.3 -1.3 -16.1 --- 
27 gi_119927221 XM_586292 FAM111B Family with sequence similarity 111, member b 0.00 9.8 -1.6 -15.4 --- 
28 gi_119906812 XM_001254290 LOC786676 Hypothetical protein (LOC786676) 0.00 13.2 -1.2 -15.2 --- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendices  301 
29 gi_115495364 NM_001075414 IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 0.00 10.4 -1.4 -14.7 --- 
30 gi_149944702 NM_001099086 BLOC1S3 Biogenesis of lysosomal organelles complex-1, subunit 3 0.00 8.2 -1.7 -14.3 --- 
31 gi_149642684 NM_001098935 OSTN Osteocrin 0.00 10.5 -1.4 -14.2 --- 
32 gi_51802498 --- --- Co872658 bovgen_00983 normal cattle brain cDNA clone 
rzpdp1056g1055q 3' 
0.00 10.5 -1.3 -14.1  
33 gi_119906018 XM_581509 CD40 CD40 molecule, tnf receptor superfamily member 5 0.00 10.7 -1.3 -13.8 --- 
34 gi_115497163 NM_001075120 LPL Lipoprotein lipase 0.00 7.2 -1.9 -13.8 --- 
35 gi_31343065 NM_174002 CASR Calcium-sensing receptor 0.00 7.8 -1.7 -13.2 --- 
36 gi_114052816 NM_001045868 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in b-
cells inhibitor, alpha 
0.00 6.6 -2.0 -13.0 --- 
37 gi_119927839 XM_001250816 LOC785902 Hypothetical protein (LOC785902) 0.00 8.8 -1.4 -12.7  
38* gi_118150869 NM_001077879 MOBP Myelin-associated oligodendrocyte basic protein 0.00 8.4 -1.5 -12.5 --- 
39 gi_119908270 XR_027843 LOC515996 Similar to kynurenine 3-monooxygenase (LOC515996) 0.00 9.8 -1.3 -12.3 --- 
40 gi_119921259 XR_027535 LOC781932 Similar to seven transmembrane helix receptor (LOC781932) 0.00 7.9 -1.5 -12.2 --- 
41 gi_119918849 XM_586751 ODZ4 Odz, odd oz/ten-m homolog 4 (drosophila) 0.00 6.9 -1.8 -12.1 --- 
42 gi_116004430 NM_001077106 MGC140080 Hypothetical protein mgc140080 (MGC140080) 0.00 8.0 -1.5 -12.0 --- 
43* gi_28151981 --- CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 0.00 6.4 -1.8 -11.6 --- 
44 gi_68317327 --- --- Am016135 kn-252-liver, cDNA clone c0007420b02 5' 0.00 8.1 -1.4 -11.4 --- 
45 gi_119939076 XM_001257154 LOC790762 Similar to trace amine associated receptor 7a (LOC790762) 0.00 7.8 -1.5 -11.4 --- 
46 gi_119890779 XM_864659 AGMO Alkylglycerol monooxygenase 0.00 5.9 -1.9 -11.2 --- 
47 gi_119907990 XM_606934 LOC528508 Similar to DTX4 protein (LOC528508) 0.00 9.2 -1.2 -11.0 --- 
48 gi_119927812 XM_001255631 LOC788631 Similar to t-cell receptor delta chain trdv2-2 (LOC788631) 0.00 6.2 -1.7 -10.9 --- 
49 gi_78045490 NM_001035045 FSCN1 Fascin homolog 1, actin-bundling protein (strongylocentrotus 
purpuratus) 
0.00 5.5 -2.0 -10.9 --- 
50 gi_84000092 NM_001038063 TMCC3 Transmembrane and coiled-coil domain family 3 0.00 16.0 1.5 -10.8 --- 
51 gi_119895319 XM_001254960 LOC787618 Similar to olfactory receptor mor104-2 (LOC787618) 0.00 8.0 -1.4 -10.8 --- 
52 gi_119921165 XM_001254986 LOC787665 Similar to cfolf4 (LOC787665) 0.00 5.6 -1.9 -10.7 --- 
53 gi_119932608 XM_001252260 LOC783756 Similar to olfactory receptor olr1533 (LOC783756) 0.00 8.8 -1.2 -10.6 --- 
54 gi_119926791 XM_001250097 LOC781642 Similar to olfactory receptor mor8-2 (LOC781642) 0.00 8.7 -1.2 -10.6 --- 
55 gi_156120634 NM_001101994 SLC6A12 Solute carrier family 6 (neurotransmitter transporter, 
betaine/gaba), member 12 (SLC6A12) 
0.00 9.2 -1.1 -10.4 --- 
56 gi_119648604 --- --- Eh177212 lb01742.cr_c23 gc_bgc-17 cDNA clone 
image:8565649 5' 
0.00 5.2 -2.0 -10.4 --- 
57 gi_51813662 --- --- Co883718 bovgen_12043 normal cattle brain cDNA clone 
rzpdp1056f2013q 5' 
0.00 6.6 -1.6 -10.3 --- 
58 gi_119935010 XM_001256813 LOC790300 Similar to deltex1 (LOC790300) 0.00 9.8 -1.0 -10.2 --- 
59* gi_119924440 XM_868840 TAAR6 Trace amine associated receptor 6 0.00 7.3 -1.4 -10.1 --- 
60* gi_119922656 XM_001256081 OR5W2 Olfactory receptor, family 5, subfamily w, member 2 0.00 7.4 -1.4 -10.1 --- 
61 gi_119910036 XR_027515 LOC539231 Hypothetical loc539231 (LOC539231) 0.00 11.1 1.1 -9.9 --- 
62 gi_119903170 XM_864858 TBC1D8 Tbc1 domain family, member 8 (with gram domain) 0.00 6.2 -1.6 -9.9 --- 
63 gi_31340697 NM_178572 CA2 Carbonic anhydrase ii 0.00 6.6 -1.5 -9.8 --- 
64* gi_31342632 NM_174187 SPP1 Secreted phosphoprotein 1 0.00 12.0 1.2 -9.7 --- 
65 gi_139948963 NM_001083752 C3AR1 Complement component 3a receptor 1 0.00 19.4 2.0 -9.7 --- 
66 gi_119311853 --- --- Ee975255 q56911a fnm cDNA clone q5691 3' 0.00 14.2 1.5 -9.7 --- 
67* gi_156120912 NM_001102133 FRMD6 Ferm domain containing 6 0.00 5.3 -1.8 -9.6 --- 
68 gi_119939697 XM_582730 LOC506303 Similar to h factor 1 (complement) (loc506303) 0.00 9.0 -1.1 -9.5 --- 
69 gi_59676571 NM_001012284 UBA7 Ubiquitin-like modifier activating enzyme 7 0.00 6.3 -1.5 -9.4 --- 
70 gi_29258721 --- --- Cb452339 707195 marc 6bov cDNA 3' 0.00 12.3 1.3 -9.2 --- 
71 gi_119933162 XM_001256684 LOC790127 Similar to killer cell immunoglobulin-like receptor kir3dl1  0.00 4.9 -1.8 -9.0  
72 gi_119926098 XM_001254787 LOC787369 Similar to olfactory receptor Olfr1174 (LOC787369) 0.00 7.4 -1.2 -8.9 --- 
73 gi_119902553 XR_027333 LOC781271 Similar to gag-pro-pol-env protein (LOC781271) 0.00 5.5 -1.6 -8.7 --- 
74 gi_115496899 NM_001075588 IFI6 Interferon, alpha-inducible protein 6 0.00 10.5 1.2 -8.7 --- 
75 gi_119928263 XM_001250225 LOC783841 Hypothetical protein loc783841 (LOC783841) 0.00 8.1 -1.1 -8.7 --- 
76 gi_61827360 XM_586955 OR5M9 Olfactory receptor, family 5, subfamily m, member 9 0.00 8.1 -1.1 -8.7 --- 
77 gi_61826046 XM_610803 Olfr1390 Olfactory receptor 1390 0.00 6.4 -1.4 -8.6 --- 
78 gi_76686226 XM_866296 LOC614709 Similar to protein alo17 (alk lymphoma oligomerization 
partner on chromosome 17) 
0.00 7.0 -1.2 -8.6 --- 
79 gi_30794323 NM_181017 TAC3 Tachykinin 3 0.00 4.8 -1.8 -8.6 --- 
80 gi_59676558 NM_001012281 CFLAR Casp8 and fadd-like apoptosis regulator 0.00 5.5 -1.6 -8.6 --- 
81 gi_119902180 XM_001252672 LOC784332 Similar to olfactory receptor, family 11, subfamily h, member 1 0.00 7.2 -1.2 -8.5 --- 
82 gi_119922313 XM_601384 Olr53 Olfactory receptor 53 0.00 7.2 -1.2 -8.5 --- 
83 gi_76681522 XM_593553 OR5D18 Olfactory receptor, family 5, subfamily d, member 18 0.00 6.3 -1.4 -8.5 --- 
84 gi_119903950 XM_866254 Adam1a A disintegrin and metallopeptidase domain 1a 0.00 5.5 -1.5 -8.4 --- 
85* gi_119892557 XM_001255374 Olr1012 Olfactory receptor 1012 0.00 8.5 1.0 -8.3 --- 
86 gi_157427871 NM_001105373 TMEM140 Transmembrane protein 140 0.00 5.3 -1.6 -8.3 --- 
87 gi_10029506   Be668915 159342 marc 4bov cDNA 5' 0.00 5.1 -1.6 -8.3 --- 
88 gi_119895328 XM_001255032 LOC787758 Similar to olfactory receptor mor277-1 (LOC787758) 0.00 7.8 -1.0 -8.2 --- 
89 gi_119920466 XM_001249777 LOC781369 Hypothetical protein (LOC781369) 0.00 5.3 -1.6 -8.2 --- 
90 gi_51882465   Aj814989 kn206 bos sp. CDNA clone c0005203m2 0.00 4.4 -1.9 -8.1 --- 
91 gi_119927666 XM_587987 LOC510786 Similar to olfactory receptor olfr1034 (LOC510786) 0.00 6.9 -1.2 -8.1 --- 
92 gi_155372274 NM_001101280 TRAF4 TNF receptor-associated factor 4 0.00 4.3 -1.9 -8.1 --- 
93 gi_47950914 --- --- Cn822845 oa_splbn_02g02_m13reverse sheep spleen\brain 
psport1 library ovis aries cDNA clone oa_splbn_02g02 5' 
0.00 4.1 -1.9 -8.0 --- 
94 gi_119914298 XR_028825 LOC509859 Similar to kiaa0342 protein (LOC509859) 0.00 4.8 -1.7 -8.0 --- 
95 gi_76718610 XM_871454 LOC619135 Hypothetical (LOC619135) 0.00 6.8 -1.2 -8.0 --- 
96 gi_76686224 XM_608422 LOC529960 Similar to KIAA1618 protein (LOC529960) 0.00 6.6 -1.2 -7.9 --- 
97 gi_31341586 NM_174593 RASSF2 Ras association (ralgds/af-6) domain family member 2  0.00 4.7 -1.7 -7.9 --- 
98 gi_119892545 XM_001255291 OR6C3 Olfactory receptor, family 6, subfamily c, member 3 0.00 6.3 -1.2 -7.8 --- 
99 gi_119921041 XM_001252382 LOC783934 Similar to olfactory receptor mor17-2 (LOC783934) 0.00 6.3 -1.2 -7.8 --- 
100 gi_119931104 XM_001256850 LOC790355 Similar to olfactory receptor mor17-2 (LOC790355) 0.00 6.8 -1.1 -7.6 --- 
101 gi_119901479 XM_001250862 LOC783380 Similar to trace amine receptor 8 (LOC783380) 0.00 6.9 -1.1 -7.5 --- 
102 gi_119927907 XM_001256066 LOC789270 Similar to t-cell receptor delta chain trdv2-2 (LOC789270) 0.00 5.6 -1.3 -7.5 --- 
103 gi_119924695 XM_605606 Olfr827 Olfactory receptor 827 0.00 5.7 -1.3 -7.5 --- 
104 gi_119921949 XM_001252233 LOC783706 Similar to t-cell receptor delta chain trdv2 (LOC783706) 0.00 5.6 -1.3 -7.5 --- 
105 gi_119879545 XM_592997 DTX3L Deltex 3-like (drosophila) 0.00 4.4 -1.7 -7.5 --- 
106 gi_119923001 XM_001252136 LOC783560 Similar to estrogen receptor-beta (LOC783560) 0.00 3.7 -2.0 -7.4 --- 
107 gi_56136763 --- --- Cv976042 umc-bcl_0b01-015-f02 day 14 cl +8h prostaglandin 
f2-alpha bcl cDNA 3' 
0.00 8.3 1.1 -7.4 --- 
108 gi_76688849 XM_589845 LOC512340 Similar to olfactory receptor mor210-5 (LOC512340) 0.00 4.7 -1.5 -7.3 --- 
109 gi_166157489 NM_001113764 TYK2 Tyrosine kinase 2 0.00 3.8 -1.9 -7.3 --- 
110* gi_119921250 XM_587900 OR4A47 Olfactory receptor, family 4, subfamily a, member 47 0.00 7.3 1.0 -7.3 --- 
111 gi_119921722 XM_001255525 LOC788476 Similar to olfactory receptor olfr1174 (LOC788476) 0.00 6.4 -1.1 -7.3 --- 
112 gi_162951886 NM_001112708 SNAI1 Snail homolog 1 (drosophila) 0.00 3.8 -1.9 -7.3 --- 
113 gi_114051256 NM_001046193 ATF3 Activating transcription factor 3 0.00 3.7 -2.0 -7.3 --- 
114 gi_119887633 XM_615590 IFIH1 Interferon induced with helicase c domain 1 0.00 11.4 1.6 -7.3 --- 
115 gi_119910857 XM_587935 PLEKHA4 Pleckstrin homology domain containing, family a 
(phosphoinositide binding specific) member 4 
0.00 7.4 1.0 -7.3 --- 
116 gi_31341381 NM_176668 AOX1 Aldehyde oxidase 1 0.00 4.1 -1.7 -7.2 --- 
117 gi_119901000 XM_613776 TRAF1 Tnf receptor-associated factor 1 0.00 3.9 -1.8 -7.2 --- 
118 gi_119918771 XM_001254971 LOC787636 Hypothetical protein (LOC787636) 0.00 6.6 -1.1 -7.2 --- 
119 gi_119914622 XM_876930 CACNA1D Calcium channel, voltage-dependent, l type, alpha 1d subunit 0.00 5.0 -1.5 -7.2 --- 
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120 gi_114051859 NM_001045963 Chn2 Chimerin (chimaerin) 2 0.00 5.3 -1.4 -7.2 --- 
121 gi_119928126 XM_001249637 LOC782278 Hypothetical protein loc782278 (LOC782278) 0.00 6.3 -1.1 -7.1 --- 
122 gi_78369427 NM_001035317 MVP Major vault protein 0.00 3.6 -2.0 -7.1 --- 
123 gi_76633796 XM_585978 C20orf123 Chromosome 20 open reading frame 123 0.00 3.8 -1.9 -7.1 --- 
124* gi_119910956 XM_001254693 Vmn1r233 Similar to pheromone receptor (LOC787233) 0.00 5.3 -1.3 -7.0 --- 
125* gi_119895348 XM_001255168 OR2L3 Olfactory receptor, family 2, subfamily l, member 3 0.00 6.6 -1.1 -7.0 --- 
126 gi_119930502 XM_001255446 LOC788363 Hypothetical protein (LOC788363) 0.00 5.8 -1.2 -7.0 --- 
127* gi_76670425 XM_588413 TAAR6 Trace amine associated receptor 6 0.00 6.0 -1.2 -7.0 --- 
128* gi_31342492 NM_178108 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda 0.00 11.2 1.6 -6.9 --- 
129* gi_119922211 XM_611011 Olfr1199 Olfactory receptor 1199 0.00 5.2 -1.3 -6.9 --- 
130 gi_119891154 XM_863839 ZMIZ2 Similar to zmiz2 protein, transcript variant 2 (LOC537266) 0.00 5.2 -1.3 -6.8 --- 
131 gi_119905685 XM_001252041 LOC783430 Hypothetical protein loc783430 (LOC783430) 0.00 10.3 1.5 -6.8 --- 
132 gi_76619274 XM_597187 OVCH1 Ovochymase 1 0.00 5.2 -1.3 -6.8 --- 
133 gi_76670295 XM_865067 RNF213 Ring finger protein 213 0.00 6.8 1.0 -6.8 --- 
134 gi_29257333 CB450951 --- Cb450951 705652 marc 6bov cDNA 5' 0.00 7.2 1.1 -6.7 --- 
135 gi_51884136 Aj816660 --- Aj816660 kn206 bos sp. CDNA clone c0005209h3 0.00 10.3 1.5 -6.7 --- 
136 gi_119926169 XM_001255294 LOC788146 Similar to olfactory receptor olfr723 (LOC788146) 0.00 6.2 -1.1 -6.7 --- 
137 gi_119904826 XM_001249505 SLITRK6 Slit and ntrk-like family, member 6 0.00 6.1 -1.1 -6.6 --- 
138 gi_119879459 XM_865244 C3orf52 Chromosome 3 open reading frame 52 0.00 6.6 1.0 -6.6 --- 
139 gi_118150959 NM_001077930 ERRFI1 Erbb receptor feedback inhibitor 1 0.00 6.3 1.0 -6.6 --- 
140 gi_119906065 XM_589621 ZNFX1 Similar to kiaa1404 protein (LOC539807) 0.00 5.0 -1.3 -6.5 --- 
141 gi_114051699 NM_001046522 TMEM100 Transmembrane protein 100 0.00 7.5 1.1 -6.5 --- 
142 gi_87196509 NM_001010995 TPM2 Tropomyosin 2 (Beta) 0.00 4.1 -1.6 -6.5 --- 
143 gi_115497773 NM_001075226 RILPL1 Rab interacting lysosomal protein-like 1 0.00 4.1 -1.6 -6.4 --- 
144 gi_68321769 --- --- Am020577 kn-252-liver, cDNA clone c0007416o07 5' 0.00 4.5 -1.4 -6.4 --- 
145 gi_119894058 XM_605463 ENAM Enamelin 0.00 4.5 -1.4 -6.4 --- 
146 gi_119894556 XM_593682 LOC515629 Similar to b-cell novel protein isoform 1; bcnp1 (LOC515629) 0.00 3.9 -1.7 -6.4 --- 
147 gi_119921254 XM_609448 OR9G1 Olfactory receptor, family 9, subfamily g, member 1 0.00 5.4 -1.2 -6.4 --- 
148 gi_119925075 XM_001249670 LOC781503 Similar to trace amine receptor 8 (LOC781503) 0.00 5.5 -1.2 -6.4 --- 
149 gi_119908943 XM_001255263 LOC788108 Similar to interspersed repeat antigen, putative (LOC788108) 0.00 5.2 -1.2 -6.3 --- 
150* gi_119902162 XM_001252369 OR11G2 Olfactory receptor, family 11, subfamily g, member 2 0.00 5.2 -1.2 -6.3 --- 
151 gi_118151335 NM_001078135 LOC768323  Hypothetical protein (LOC768323) 0.00 6.7 1.1 -6.2 --- 
152* gi_119930898 XM_001256701 OR4A47 Olfactory receptor, family 4, subfamily a, member 47 0.00 6.2 1.0 -6.2 --- 
153* gi_119889733 XM_001253222 COL11A1 Collagen, type xi, alpha 1 0.00 5.2 -1.2 -6.2 --- 
154* gi_119924512 XM_001253583 Olfr1303 Olfactory receptor 1303 0.00 4.5 -1.4 -6.1  
155 gi_51886798 AJ819322 --- Aj819322 kn206 bos sp. CDNA clone c0006015a02 0.00 4.8 -1.3 -6.1 --- 
156 gi_31342122 NM_174395 MYO1A Myosin 1A 0.00 3.5 -1.8 -6.1 --- 
157 gi_119925028 XM_001251240 LOC786308 Hypothetical protein (LOC786308) 0.00 5.5 -1.1 -6.1 --- 
158 gi_76683585 XM_592773 Olr1159 Olfactory receptor 1159 0.00 4.2 -1.4 -6.0 --- 
159 gi_164451473 NM_001024530 SIDT2 Sid1 transmembrane family, member 2 0.00 5.6 -1.1 -6.0 --- 
160 gi_119924832 XM_001253774 LOC785917 Similar to olfactory receptor olr87 (LOC785917) 0.00 4.9 -1.2 -6.0 --- 
161 gi_119923684 XR_027801 LOC782879 Similar to interferon-induced protein 44-like (LOC782879) 0.00 6.0 1.0 -6.0 --- 
162 gi_119875306 XM_877339 LOC614436 Hypothetical (LOC614436) 0.00 4.6 -1.3 -6.0 --- 
163 gi_51803217 --- --- Co873377 bovgen_01702 normal cattle brain cDNA clone 
rzpdp1056j1858q 3' 
0.00 6.3 1.0 -6.0 --- 
164 gi_119889924 XM_001252509 LOC785006 Similar to spi-c transcription factor (spi-1/pu.1 related) 0.00 5.9 1.0 -6.0 --- 
165 gi_70778941 NM_001025332 FABP2 Fatty acid binding protein 2, intestinal 0.00 3.2 -1.9 -5.9  
166 gi_119932901 XM_001255986 LOC789146 Hypothetical protein (LOC789146) 0.00 3.8 -1.6 -5.9 --- 
167 gi_119915708 XM_870237 LOC617905 Similar to histone h4 (LOC617905) 0.00 4.0 -1.5 -5.9 --- 
168* gi_119922797 XM_001253297 Olfr591 Olfactory receptor 591 0.00 5.2 -1.1 -5.9 --- 
169 gi_119915700 XM_592049 OR2M2 Olfactory receptor, family 2, subfamily m, member 2 0.00 4.6 -1.3 -5.9 --- 
170* gi_119923762 XM_001253761 OR5AN1 Olfactory receptor, family 5, subfamily an, member 1 0.00 3.7 -1.6 -5.9 --- 
171 gi_119917459 XM_580537 SLC16A12 Solute carrier family 16, member 12 (monocarboxylic acid 
transporter 12) 
0.00 4.3 -1.4 -5.8 --- 
172 gi_119921747 XM_001255714 LOC788750 Similar to olfr586 protein (LOC788750) 0.00 5.7 1.0 -5.8 --- 
173* gi_119923766 XM_580276 OR5AN1 Olfactory receptor, family 5, subfamily an, member 1 0.00 3.9 -1.5 -5.8 --- 
174 gi_51823012 --- --- Co892712 bovgen_21037 normal cattle brain cDNA clone 
rzpdp1056a2248q 5' 
0.00 3.8 -1.5 -5.7 --- 
175 gi_119887639 XM_587821 TANK Traf family member-associated nfkb activator 0.00 4.5 -1.3 -5.7 --- 
176 gi_76688756 XM_587788 LOC510625 Similar to olf4 (LOC510625) 0.00 4.9 -1.2 -5.7 --- 
177 gi_115497925 NM_001076102 EPS8 Epidermal growth factor receptor pathway substrate 8 0.00 6.0 1.1 -5.7 --- 
178 gi_119910567 XM_001256373 LOC789703 Hypothetical protein (LOC789703) 0.00 6.0 1.1 -5.7 --- 
179* gi_119907935 XM_001253806 OR4A47 Olfactory receptor, family 4, subfamily a, member 47 0.00 4.8 -1.2 -5.7 --- 
180 gi_119914992 XM_583261 TXNRD3 Thioredoxin reductase 3 0.00 3.0 -1.9 -5.7 --- 
181 gi_119924693 XM_001255886 LOC788998 Similar to olfactory receptor mor210-5 (LOC788998) 0.00 4.8 -1.2 -5.7 --- 
182* gi_119892513 XM_001254983 Olfr802 Olfactory receptor 802 0.00 4.3 -1.3 -5.7 --- 
183 gi_10026167 --- --- Be665576 154662 marc 4bov cDNA 5' 0.00 3.1 -1.8 -5.7 --- 
184 gi_119903539 XM_607432 LOC528994 Hypothetical loc528994 (LOC528994) 0.00 4.8 -1.2 -5.7 --- 
185 gi_119889996 XR_028184 LOC508347 Similar to interferon-induced protein 44-like (LOC508347) 0.00 5.5 1.0 -5.6 --- 
186 gi_119921019 XM_001251884 LOC783244 Similar to olfactory receptor mor17-2 (LOC783244) 0.00 4.7 -1.2 -5.6 --- 
187 gi_119901657 XM_595033 IPCEF1 Interaction protein for cytohesin exchange factors 1 0.00 5.0 -1.1 -5.6 --- 
188 gi_82617557 NM_205774 LOC404073 Riken cDNA 1700024p04 gene 0.00 5.0 -1.1 -5.6 --- 
189* gi_119892567 XM_001255454 OR6C74 Olfactory receptor, family 6, subfamily c, member 74 0.00 5.2 -1.1 -5.6 --- 
190 gi_31442874 NM_174655 SLC24A1 Solute carrier family 24 (Na/K/Ca exchanger), member 1 0.00 3.6 -1.5 -5.6 --- 
191 gi_119922456 XM_868862 OR8G1 Olfactory receptor, family 8, subfamily g, member 1 0.00 4.0 -1.4 -5.5 --- 
192 gi_28311321 --- --- Bp109033 orcs bovine utero-placenta cDNA cDNA clone 
orcs12720 3' 
0.00 3.5 -1.6 -5.5 --- 
193 gi_51881771 --- --- Aj814295 kn206 bos sp. CDNA clone c0005204n18 0.00 2.9 -1.9 -5.5 --- 
194 gi_119922789 XM_001253117 LOC784956 Hypothetical protein (LOC784956) 0.00 5.3 1.0 -5.5 --- 
195 gi_119938335 XM_001257058 LOC790639 Similar to pol; truncated polymerase (LOC790639) 0.00 4.3 -1.3 -5.5 --- 
196 gi_119644144 --- --- Eh173005 lb01647.cr_h07 gc_bgc-16 cDNA clone 
image:8383353 5' 
0.00 7.7 1.4 -5.4 --- 
197 gi_119937909 XM_001256935 LOC790478 Hypothetical protein (LOC790478) 0.00 5.3 1.0 -5.4 --- 
198 gi_119903166 XM_001254926 LOC787570 Hypothetical protein (LOC787570) 0.00 2.9 -1.9 -5.4 --- 
199 gi_119927273 XM_001255295 LOC788147 Similar to atp-binding cassette protein c4 splice (LOC788147) 0.00 3.7 -1.5 -5.4 --- 
200* gi_119892561 XM_001255399 OR6C74 Olfactory receptor, family 6, subfamily c, member 74 0.00 5.3 1.0 -5.4 --- 
201 gi_51826239 --- --- Co895922 bovgen_24247 normal cattle brain cDNA clone 
rzpdp1056i2437q 5' 
0.00 3.0 -1.8 -5.4 --- 
202 gi_76685850 XM_599512 Olfr1178 Olfactory receptor 1178 0.00 5.1 -1.1 -5.4 --- 
203 gi_119926161 XM_589549 OR4L1 Olfactory receptor, family 4, subfamily l, member 1 0.00 4.6 -1.2 -5.4 --- 
204 gi_51881604 --- --- Aj814128 kn206 bos sp. cDNA clone c0005205b18 0.00 2.8 -1.9 -5.4  
205 gi_61877384 XM_591641 LOC513884 Similar to seven transmembrane helix receptor (LOC513884) 0.00 3.9 -1.4 -5.4 --- 
206 gi_119908105 XM_001256258 LOC789518 Hypothetical protein (LOC789518) 0.00 2.8 -1.9 -5.4 --- 
207 gi_119893024 XM_001253563 LOC785584 Similar to natural killer cell receptor protein 1 (LOC785584) 0.00 6.9 1.3 -5.4 --- 
208 gi_148233351 NM_001098001 FAP Fibroblast activation protein, alpha 0.00 4.8 -1.1 -5.4 --- 
209 gi_119915305 XR_028046 RUNX2 Similar to runt-related transcription factor 2 (LOC536911) 0.00 6.3 1.2 -5.4 --- 
210 gi_31340693 NM_174701 HSD17B14 Hydroxysteroid (17-beta) dehydrogenase 14 0.00 3.0 -1.8 -5.3 --- 
211 gi_119917348 XM_583388 GPR146 G protein-coupled receptor 146 0.00 2.9 -1.9 -5.3 --- 
212* gi_119913160 XM_001251499 PARP8 Poly (adp-ribose) polymerase family, member 8 0.00 4.7 -1.1 -5.3 --- 
213 gi_118151305 NM_001078119 FBXO16  F-box protein 16 (FBXO16) 0.00 3.2 -1.6 -5.3 --- 
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214 gi_119895380 XM_001255445 OR2T4 Olfactory receptor, family 2, subfamily t, member 4 0.00 4.5 -1.2 -5.3 --- 
215 gi_149642672 NM_001099071 MAP3K8 Mitogen-activated protein kinase kinase kinase 8 0.00 5.5 1.0 -5.3 --- 
216 gi_76657295 XM_869298 Olfr890 Olfactory receptor 890 0.00 4.1 -1.3 -5.3  
217 gi_51824369 --- LCAT Lecithin-cholesterol acyltransferase 0.00 5.0 -1.0 -5.3 --- 
218 gi_119907451 XM_868602 LOC616556 Similar to npas3 protein (LOC616556) 0.00 3.4 -1.5 -5.2 --- 
219 gi_119918950 XM_865914 LOC614419 Similar to odorant receptor k13 (LOC614419) 0.00 4.5 -1.2 -5.2 --- 
220 gi_51819191 --- --- Co888906 bovgen_17231 normal cattle brain cDNA clone 
rzpdp1056e2246q 5' 
0.00 4.8 -1.1 -5.2 --- 
221 gi_157279948 NM_001105020 KRTAP9L3 Keratin associated protein 9-1 0.00 3.6 -1.5 -5.2 --- 
222 gi_51881277 --- --- Aj813801 kn206 bos sp. CDNA clone c0005205i9 0.00 6.1 1.2 -5.2 --- 
223 gi_76678008 XM_584199 OR10A3 Olfactory receptor, family 10, subfamily a, member 3 0.00 4.8 -1.1 -5.2 --- 
224 gi_119910279 XM_600249 DPY19L3 Dpy-19-like 3 (c. Elegans) 0.00 3.8 -1.4 -5.2 --- 
225 gi_46417924 --- --- Cn438660 be04 normalized and subtracted bovine embryonic 
and extraembryonic tissue cDNA clone be04016b2f01 5' 
0.00 2.9 -1.8 -5.2 --- 
226 gi_119879609 XM_606096 LOC527699 Similar to Kalirin, RHOGEF kinase (LOC527699) 0.00 2.7 -1.9 -5.2 --- 
227 gi_119922019 XM_868429 OR8U8 Olfactory receptor, family 8, subfamily u, member 8 0.00 4.5 -1.1 -5.2 --- 
228 gi_119906638 XM_001251005 LOC782357 Similar to inositol polyphosphate 1-phosphatase (LOC782357) 0.00 5.9 1.1 -5.2 --- 
229 gi_119902030 XR_028230 REC8 REC8 homolog (yeast) 0.00 3.5 -1.5 -5.2 --- 
230* gi_119931138 XM_597087 OR8G2 Olfactory receptor, family 8, subfamily g, member 2 0.00 4.9 -1.0 -5.2 --- 
231 gi_119889564 XM_001250774 CD58 CD58 molecule 0.00 2.6 -2.0 -5.2 --- 
232 gi_47686978 --- --- Cn790998 4125657 barc 8bov cDNA clone 8bov_38b16 5' 0.00 10.2 2.0 -5.1 --- 
233 gi_119892967 XM_870975 DUSP16 Dual specificity phosphatase 16 0.00 6.0 1.2 -5.1 --- 
234 gi_27806678 NM_174026 CSF1 Colony stimulating factor 1 (macrophage) 0.00 5.0 1.0 -5.1 --- 
235 gi_119915547 XM_601579 LOC523283 Similar to olfactory receptor olfr1365 (LOC523283) 0.00 4.2 -1.2 -5.1 --- 
236 gi_68425684 --- --- Am026861 kn-252-lymph, cDNA clone c0007393i02 3' 0.00 3.2 -1.6 -5.1 --- 
237 gi_119937889 XM_001256927 LOC790466 Similar to endothelial pas domain protein 1/hypoxia-inducible 
factor-2 alpha (LOC790466) 
0.00 3.0 -1.7 -5.1 --- 
238 gi_119918606 XM_868011 Dusp13 (rat) Dual specificity phosphatase 13 0.00 3.8 -1.3 -5.1 --- 
239 gi_119925451 XM_001251376 LOC782733 Hypothetical protein (LOC782733) 0.00 3.7 -1.4 -5.1 --- 
240 gi_119927681 XM_001254405 LOC786840 Similar to cfolf4 (LOC786840) 0.00 4.7 -1.1 -5.1 --- 
241 gi_119906190 XM_588232 PARP10 Poly (adp-ribose) polymerase family, member 10 0.00 2.9 -1.7 -5.0 --- 
242* gi_119892577 XM_001255552 Olr1070 Olfactory receptor 1070 0.00 4.9 1.0 -5.0 --- 
243 gi_119892500 XM_001254798 LOC787380 Similar to integrin alpha-7 (LOC787380) 0.00 2.5 -2.0 -5.0 --- 
244* gi_119915596 XM_001253001 Olfr129 Olfactory receptor 129 0.00 3.1 -1.6 -5.0 --- 
245 gi_149642646 NM_001099168 RBM43 Rna binding motif protein 43 0.00 3.8 -1.3 -5.0 --- 
246* gi_51821409 --- OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda 0.00 9.1 1.8 -5.0 --- 
247 gi_119905168 XM_001253613 LOC785665 Hypothetical protein (LOC785665) 0.00 3.0 -1.7 -5.0 --- 
248 gi_119923556 XM_001254131 LOC786468 Hypothetical protein (LOC786468) 0.00 5.0 1.0 -5.0 --- 
249 gi_119235075 --- --- Ee898501 b14051a ffb cDNA clone b1405 3' 0.00 3.5 -1.4 -5.0 --- 
250 gi_119928883 XM_581609 LOC505334 Hypothetical (LOC505334) 0.00 2.5 -2.0 -5.0  
251 gi_166157493 NM_001113766 TMC2 Transmembrane channel-like 2 0.00 3.2 -1.6 -5.0 --- 
252 gi_119915598 XM_588373 LOC511103 Similar to olfactory receptor, family 2, subfamily j, member 3  0.00 2.9 -1.7 -4.9 --- 
253 gi_51808686 --- --- Co878762 bovgen_07087 normal cattle brain cDNA clone 
rzpdp1056k234q 5' 
0.00 2.8 -1.8 -4.9 --- 
254 gi_119891937 XM_588753 ALX1 Alx homeobox 1 0.00 5.1 1.0 -4.9 --- 
255 gi_156120432 NM_001101892 C1orf109 Chromosome 1 open reading frame 109 0.00 4.3 -1.1 -4.9 --- 
256 gi_157427785 NM_001105329 CSNK1G3 Casein kinase 1, gamma 3 (CSNK1G3) 0.00 3.6 -1.4 -4.9 --- 
257 gi_51811834 --- --- Co881905 bovgen_10230 normal cattle brain cDNA clone 
rzpdp1056k2414q 5' 
0.00 3.3 -1.5 -4.9 --- 
258 gi_119893524 XM_001250407  Similar to n-deacetylase/n-sulfotransferase (heparan 
glucosaminyl) 3 (MGC142329) 
0.00 2.9 -1.7 -4.9 --- 
259 gi_76670917 XM_605163 LOC526789 Similar to histone h4 (LOC526789) 0.00 3.1 -1.6 -4.8 --- 
260 gi_119901513 XM_001253901 LOC786117 Hypothetical protein (LOC786117) 0.00 2.5 -1.9 -4.8 --- 
261 gi_162287311 NM_001080908 CA5B Carbonic anhydrase vb, mitochondrial 0.00 4.1 -1.2 -4.8 --- 
262 gi_119901493 XR_028228 LOC785236 Hypothetical protein (LOC785236) 0.00 4.6 -1.1 -4.8 --- 
263 gi_160707930 NM_001110785 IL6R Interleukin 6 receptor 0.00 2.9 -1.7 -4.8 --- 
264 gi_51886630 --- --- Aj819154 kn206 bos sp. CDNA clone c0006014h18 0.00 3.6 -1.3 -4.8 --- 
265 gi_119889431 XM_585905 C1orf51 Chromosome 1 open reading frame 51 0.00 3.4 -1.4 -4.8 --- 
266 gi_119923401 XM_001249461 SHISA3 Shisa homolog 3 (xenopus laevis) 0.00 4.4 -1.1 -4.8 --- 
267 gi_119892314 XM_582025 PTPRB Protein tyrosine phosphatase, receptor type, b 0.00 4.6 -1.0 -4.8 --- 
268 gi_119912777 XM_586217 LOC509283 Similar to chromosome 17 open reading frame 27 0.00 6.4 1.3 -4.8 --- 
269 gi_119909812 XM_582583 LOC506171 Similar to phospholipase c, gamma 2 (LOC506171) 0.00 2.8 -1.7 -4.8 --- 
270 gi_119915205 XM_001250256 KCNK5 Potassium channel, subfamily k, member 5 0.00 3.1 -1.5 -4.8 --- 
271 gi_119917845 XR_027657 LOC539889 Hypothetical (LOC539889) 0.00 3.4 -1.4 -4.8 --- 
272* gi_119929609 XM_611004 OR4A47 Olfactory receptor, family 4, subfamily a, member 47 0.00 4.8 1.0 -4.8 --- 
273 gi_51801949 --- --- Co872113 bovgen_00438 normal cattle brain cDNA clone 
rzpdp1056e1858q 3' 
0.00 2.5 -1.9 -4.8 --- 
274 gi_119879472 XM_589632 ZDHHC23 Similar to membrane-associated dhhc23 zinc finger protein 
(LOC512177) 
0.00 5.5 1.2 -4.7 --- 
275 gi_139948994 NM_001083697 MGC157405  Pregnancy-associated glycoprotein (MGC157405) 0.00 4.0 -1.2 -4.7 --- 
276 gi_51885893 --- --- Aj818417 kn206 bos sp. CDNA clone c0006012d21 0.00 2.7 -1.7 -4.7 --- 
277 gi_51809527 --- --- Co879603 bovgen_07930 normal cattle brain cDNA clone 
rzpdp1056b2216q 5' 
0.00 2.5 -1.9 -4.7 --- 
278 gi_119926223 XM_588414 OR2J2 Olfactory receptor, family 2, subfamily j, member 2 0.00 2.9 -1.6 -4.7  
279* gi_148539985 NM_174512 CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 0.00 2.6 -1.8 -4.7 --- 
280 gi_116003876 NM_001076828 PARP9 Poly (adp-ribose) polymerase family, member 9 0.00 4.2 -1.1 -4.7 --- 
281 gi_119920747 XM_001251180 LOC782548 Similar to was protein family, member 1 (LOC782548) 0.00 4.3 -1.1 -4.7 --- 
282 gi_157427889 NM_001105382 Prune2 (rat) Prune homolog 2 (drosophila) 0.00 7.8 1.7 -4.7 --- 
283 gi_76662019 XM_877625 LOC614527 Hypothetical (LOC614527) 0.00 3.1 -1.5 -4.7 --- 
284* gi_119930582 XM_001255843 Olfr591 Olfactory receptor 591 0.00 4.5 1.0 -4.7 --- 
285* gi_119925715 XM_001255793 OR5F1 Olfactory receptor, family 5, subfamily f, member 1 0.00 3.7 -1.3 -4.6 --- 
286 gi_118151377 NM_001077829 LYZ1 Lysozyme 1 0.00 5.0 1.1 -4.6 --- 
287* gi_119892521 XM_001255098 Olr1012 Olfactory receptor 1012 0.00 4.5 1.0 -4.6 --- 
288 gi_119909824 XM_608473 LOC530011 Similar to plcg2 protein (LOC530011) 0.00 2.6 -1.8 -4.6 --- 
289 gi_51819056 --- --- Co888771 bovgen_17096 normal cattle brain cDNA clone 
rzpdp1056e1232q 5' 
0.00 2.7 -1.7 -4.6 --- 
290 gi_119924090 XM_001251040 SERPINB4 Serpin peptidase inhibitor, clade b (ovalbumin), member 4 0.00 2.9 -1.6 -4.6 --- 
291 gi_119916743 XM_864316 SOCS1 Suppressor of cytokine signaling 1 0.00 8.9 2.0 -4.6  
292* gi_119922658 XM_001256086 OR5W2 Olfactory receptor, family 5, subfamily w, member 2 0.00 3.6 -1.3 -4.6 --- 
293 gi_119923483 XM_001252794 LOC784514 Similar to olfr586 protein (LOC784514) 0.00 4.7 1.0 -4.5 --- 
294 gi_114051785 NM_001046630 Tas2r122 Taste receptor, type 2, member 122 0.00 4.5 1.0 -4.5 --- 
295 gi_119925570 XM_001254515 CXorf66 Chromosome x open reading frame 66 0.00 4.1 -1.1 -4.5 --- 
296 gi_119895839 XR_028142 LOC535967 Similar to kiaa0715 protein (LOC535967) 0.00 4.3 -1.0 -4.5 --- 
297 gi_119909965 XM_589041 LOC511659 Similar to phospholipase c, gamma 2 (LOC511659) 0.00 2.8 -1.6 -4.5 --- 
298 gi_119931741 XR_028812 LOC789877 Similar to pol protein (LOC789877) 0.00 2.8 -1.6 -4.5 --- 
299 gi_119892689 XM_001251716 LOC783379 Similar to kiaa1033 protein (LOC783379) 0.00 2.3 -2.0 -4.5 --- 
300 gi_115496313 NM_001075738 Gstt3 Glutathione s-transferase, theta 3 0.00 3.7 -1.2 -4.5 --- 
301* gi_119915666 XM_580689 UBD Ubiquitin D 0.00 3.3 -1.4 -4.5 --- 
302 gi_119895897 XM_001249627 LOC781380 Hypothetical protein (LOC781380) 0.00 2.4 -1.8 -4.5  
303 gi_119892596 XM_867721 ITGA7 Integrin, alpha 7 0.00 3.8 -1.2 -4.5 --- 
304 gi_119900588 XM_588491 LZTS1 Leucine zipper, putative tumor suppressor 1 0.00 2.9 -1.5 -4.5 --- 
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305 gi_51815582 --- --- Co885297 bovgen_13622 normal cattle brain cDNA clone 
rzpdp1056d0515q 5' 
0.00 3.7 -1.2 -4.4 --- 
306 gi_31343556 NM_177510 GCNT1 Glucosaminyl (n-acetyl) transferase 1, core 2 0.00 5.1 1.1 -4.4 --- 
307 gi_51808339 --- --- Co878419 bovgen_06744 normal cattle brain cDNA clone 
rzpdp1056f1228q 5' 
0.00 5.1 1.1 -4.4 --- 
308 gi_119901485 XM_001253189 LOC785047 Similar to trace amine receptor 8 (LOC785047) 0.00 3.7 -1.2 -4.4 --- 
309 gi_119902191 XM_609796 Olfr731 Olfactory receptor 731 0.00 4.5 1.0 -4.4 --- 
310 gi_119901577 XM_614057 GPR126 G protein-coupled receptor 126 0.00 3.3 -1.3 -4.4 --- 
311 gi_119931076 XM_001256837 LOC790332 Similar to enterocytin (LOC790332) 0.00 4.3 1.0 -4.4 --- 
312* gi_119932269 XM_001256929 NXF3 Nuclear rna export factor 3 0.00 2.4 -1.8 -4.4 --- 
313 gi_119924949 XM_001255225 LOC788043 Similar to kiaa0966 protein (LOC788043) 0.00 3.0 -1.5 -4.4 --- 
314 gi_119924379 XM_001254841 OR5T1 Olfactory receptor, family 5, subfamily t, member 1 0.00 4.0 -1.1 -4.4 --- 
315* gi_119922460 XM_001250569 OR8G2 Olfactory receptor, family 8, subfamily g, member 2 0.00 3.9 -1.1 -4.4 --- 
316 gi_122692322 NM_001080336 LOC781146 Lysozyme (LOC781146) 0.00 3.5 -1.3 -4.4 --- 
317 gi_76679710 XM_606544 PRAMEF12 Prame family member 12 0.00 3.9 -1.1 -4.4 --- 
318 gi_119904820 XM_001250391 LOC782559 Hypothetical protein (LOC782559) 0.00 3.2 -1.4 -4.4 --- 
319 gi_119922154 XM_001252905 LOC784661 Hypothetical protein (LOC784661) 0.01 2.3 -1.9 -4.4 --- 
320 gi_119926726 XM_599805 NUP210 Nucleoporin 210kda 0.00 4.3 1.0 -4.4 --- 
321 gi_119921161 XM_001254952 LOC787604 Similar to olfactory receptor olr1075 (LOC787604) 0.00 2.8 -1.5 -4.4 --- 
322 gi_119874947 XM_604589 LOC526226 Similar to histone h4 (LOC526226) 0.00 2.8 -1.5 -4.4 --- 
323* gi_119895356 XM_001255247 OR2L3 Olfactory receptor, family 2, subfamily l, member 3 0.00 3.8 -1.2 -4.4 --- 
324 gi_51815204 --- --- Co884919 bovgen_13244 normal cattle brain cDNA clone 
rzpdp1056k2317q 5' 
0.00 3.0 -1.5 -4.4 --- 
325* gi_76716222 XM_871383 Olfr49 Olfactory receptor 49 0.00 3.0 -1.4 -4.4 --- 
326 gi_116003864 NM_001076823 TAGAP T-cell activation rhogtpase activating protein 0.00 7.0 1.6 -4.3 --- 
327 gi_119918717 XM_599400 Olfr214 Olfactory receptor 214 0.00 3.4 -1.3 -4.3 --- 
328 gi_51888157 --- --- Aj820681 kn206 bos sp. cDNA clone c0006020e19 0.01 2.3 -1.9 -4.3  
329* gi_119895410 XM_001255686 Olfr30 Olfactory receptor 30 0.00 3.7 -1.2 -4.3 --- 
330 gi_119923773 XM_001250268  Hypothetical protein, transcript variant 2 (LOC783422) 0.00 3.2 -1.4 -4.3 --- 
331 gi_119922799 XM_001253315 LOC785238 Similar to olfactory receptor olr87 (LOC785238) 0.00 4.5 1.0 -4.3 --- 
332 gi_114050926 NM_001046126 ELL3 Elongation factor rna polymerase ii-like 3 0.00 5.8 1.3 -4.3 --- 
333* gi_119933344 XM_001256835 Olr94 Olfactory receptor 94 0.00 3.7 -1.2 -4.3 --- 
334 gi_119879605 XM_865427 OSBPL11 Oxysterol binding protein-like 11 0.00 3.1 -1.4 -4.3 --- 
335 gi_119930790 XM_001256547 LOC789934 Similar to LOC407199 protein (LOC789934) 0.00 2.5 -1.7 -4.3 --- 
336 gi_119921720 XM_001255420 LOC788326 Similar to protein tyrosine phosphatase, receptor type, f 
polypeptide (ptprf), interacting protein (liprin), alpha 1 
0.01 2.4 -1.8 -4.3 --- 
337 gi_115497767 NM_001075224 PPP1R13L Protein phosphatase 1, regulatory (inhibitor) subunit 13 like 0.00 2.3 -1.9 -4.3 --- 
338 gi_51816596 --- --- Co886311 bovgen_14636 normal cattle brain cDNA clone 
rzpdp1056i2111q 5' 
0.01 2.3 -1.9 -4.3 --- 
339 gi_51821587 --- --- Co891292 bovgen_19617 normal cattle brain cDNA clone 
rzpdp1056g1039q 5' 
0.01 2.2 -1.9 -4.3 --- 
340 gi_66792729 NM_001024506 IRF9 Interferon regulatory factor 9 0.00 4.0 -1.1 -4.3 --- 
341 gi_119894006 XM_612336 UGT2B4 Udp glucuronosyltransferase 2 family, polypeptide b4 0.00 2.8 -1.5 -4.3 --- 
342 gi_119895080 XM_001256277 LOC789548 Hypothetical protein (LOC789548) 0.00 2.9 -1.5 -4.3 --- 
343 gi_119902087 XM_605073 LOC526700 Similar to olfactory receptor mor118-1 (LOC526700) 0.00 3.1 -1.4 -4.3 --- 
344 gi_119917902 XM_614294 LOC534506 Similar to kiaa0598 protein, transcript variant 1 (LOC534506) 0.00 2.9 -1.5 -4.3 --- 
345 gi_119929450 XM_001256653 LOC790079 Hypothetical protein (LOC790079) 0.00 2.9 -1.5 -4.3 --- 
346 gi_119902917 XM_869926 BATF Basic leucine zipper transcription factor, atf-like 0.00 3.3 -1.3 -4.3 --- 
347 gi_115497501 NM_001075911 NR4A1 Nuclear receptor subfamily 4, group a, member 1 0.00 2.7 -1.6 -4.3 --- 
348 gi_51817299 --- --- Co887014 bovgen_15339 normal cattle brain cDNA clone 
rzpdp1056h1010q 5' 
0.00 3.2 -1.3 -4.3 --- 
349 gi_114052379 NM_001046538 RAB15 Rab15, member ras onocogene family 0.00 2.5 -1.7 -4.3 --- 
350 gi_139949042 NM_001083711 TNFAIP8 Tumor necrosis factor, alpha-induced protein 8 0.00 2.4 -1.7 -4.2 --- 
351 gi_119923777 XM_001250364 LOC783509 Similar to l antigen family, member 3 (LOC783509) 0.00 2.5 -1.7 -4.2 --- 
352 gi_119911353 XR_028864 LOC790331 Similar to eukaryotic translation initiation factor 4b 0.00 3.2 -1.3 -4.2 --- 
353* gi_119924442 XM_001251569 TAAR8 Trace amine associated receptor 8 0.00 3.9 -1.1 -4.2 --- 
354 gi_51804806 --- --- Co874906 bovgen_03231 normal cattle brain cDNA clone 
rzpdp1056k0255q 3' 
0.00 2.4 -1.7 -4.2 --- 
355 gi_119935266 XM_001256915 LOC790450 Similar to rna helicase ii/gu protein (LOC790450) 0.00 2.7 -1.6 -4.2 --- 
356 gi_119894724 XM_599736 ANGPTL6 Angiopoietin-like 6 0.00 2.7 -1.5 -4.2 --- 
357 gi_51880934 --- --- Aj813458 kn206 bos sp. cDNA clone c0005201m9 0.00 2.4 -1.7 -4.2 --- 
358 gi_51887964 --- --- Aj820488 kn206 bos sp. cDNA clone c0006020o03 0.00 3.4 -1.2 -4.2 --- 
359* gi_76657212 XM_610318 Olfr921 Olfactory receptor 921 0.00 3.5 -1.2 -4.2 --- 
360 gi_119904452 XM_617702 DGKH Diacylglycerol kinase, eta 0.01 2.3 -1.9 -4.2 --- 
361 gi_119879589 XM_590786 MYLK Myosin, light polypeptide kinase (mylk) 0.00 2.6 -1.6 -4.2 --- 
362* gi_119920960 XM_001249726 OR52A5 Olfactory receptor, family 52, subfamily a, member 5 0.00 4.2 1.0 -4.2 --- 
363 gi_119894644 XM_001256245 LOC789504 Similar to bc85395_3 (LOC789504) 0.00 3.7 -1.1 -4.2 --- 
364 gi_51885341 --- --- Aj817865 kn206 bos sp. cDNA clone c0006005b13 0.00 3.5 -1.2 -4.2 --- 
365 gi_164518983 NM_001113297 ACBD7 Acyl-coa binding domain containing 7 0.00 2.5 -1.7 -4.2 --- 
366 gi_119900621 XM_607313 LOC528877 Similar to neuron-derived orphan receptor-1 alfa (LOC528877) 0.00 6.4 1.5 -4.2 --- 
367 gi_119931764 XM_001256548 LOC789935 Similar to mkiaa1301 protein (LOC789935) 0.00 2.6 -1.6 -4.2 --- 
368 gi_119902066 XM_589218 ZFHX2 Zinc finger homeobox 2 (LOC100505) 0.00 2.4 -1.7 -4.2 --- 
369 gi_119925108 XM_590561 LOC512948 Similar to olf4 (LOC512948) 0.00 4.0 -1.0 -4.2 --- 
370 gi_51822356 --- --- Co892055 bovgen_20380 normal cattle brain cDNA clone 
rzpdp1056j1631q 5' 
0.00 2.3 -1.8 -4.2 --- 
371 gi_51882334 --- --- Aj814858 kn206 bos sp. cDNA clone c0005200e16 0.01 2.1 -2.0 -4.2 --- 
372 gi_119935945 XM_001257083 LOC790672 Hypothetical protein (LOC790672) 0.00 2.7 -1.5 -4.2 --- 
373* gi_119902240 XM_605072 Olfr49 Olfactory receptor 49 0.01 2.3 -1.8 -4.2 --- 
374 gi_56145168 --- --- Cv984447 umc-bov_0b01-006-f09 day 0 oviduct post-lh surge 
bov cDNA 3' 
0.00 2.5 -1.6 -4.2 --- 
375 gi_119922646 XM_867468 LOC615605 Similar to olfactory receptor mor231-1 (LOC615605) 0.00 3.5 -1.2 -4.1 --- 
376 gi_119921941 XM_871152 LOC618831 Similar to t cell receptor delta chain (LOC618831) 0.00 3.2 -1.3 -4.1 --- 
377* gi_119895407 XM_001253323 Olfr30 Olfactory receptor 30 0.00 2.7 -1.5 -4.1 --- 
378 gi_115497413 NM_001076421 SPIC Spi-c transcription factor (Spi-1/pu.1 related) 0.00 4.5 1.1 -4.1 --- 
379 gi_119921939 XM_001251837 LOC783209 Hypothetical protein loc783209 (LOC783209) 0.00 2.5 -1.6 -4.1 --- 
380 gi_119920986 XM_591949 LOC514146 Similar to olfactory receptor mor30-1 (LOC514146) 0.00 3.0 -1.4 -4.1 --- 
381 gi_156121338 NM_001102348 ARL4C Adp-ribosylation factor-like 4c 0.00 5.6 1.4 -4.1 --- 
382 gi_119922122 XM_584568 Olfr513 Olfactory receptor 513 0.00 4.0 1.0 -4.1 --- 
383* gi_119921755 XM_001255762 OR51T1 Olfactory receptor, family 51, subfamily t, member 1 0.00 2.9 -1.4 -4.1 --- 
384 gi_119901491 XM_865063 LOC613867 Similar to trace amine receptor 8 (LOC613867) 0.00 3.7 -1.1 -4.1 --- 
385 gi_119914770 XM_001255129 LOC787910 Hypothetical protein (LOC787910) 0.01 2.1 -2.0 -4.1 --- 
386 gi_51832764 --- --- Co875536 bovgen_03861 normal cattle brain cDNA clone 
rzpdp1056k0353q 3' 
0.00 3.3 -1.3 -4.1 --- 
387 gi_29229162 --- --- Cb441787 692297 marc 6bov cDNA 3' 0.00 3.3 -1.2 -4.1 --- 
388 gi_119889614 XM_001251548 CTTNBP2NL Cttnbp2 n-terminal like 0.00 2.3 -1.8 -4.1 --- 
389 gi_119889139 XM_592982 OR10K1 Olfactory receptor, family 10, subfamily k, member 1 0.00 3.4 -1.2 -4.1 --- 
390 gi_119921658 XM_001254417 LOC786859 Similar to trav20 protein (LOC786859) 0.01 2.1 -1.9 -4.1 --- 
391 gi_119919114 XM_870538 LOC618211 Similar to histone H4 (LOC618211) 0.00 2.6 -1.6 -4.1 --- 
392 gi_51818847 --- --- Co888562 bovgen_16887 normal cattle brain cDNA clone 
rzpdp1056i1050q 5' 
0.00 4.3 1.1 -4.0 --- 
393 gi_119919246 XM_001254190 LOC788447 Hypothetical protein (LOC788447) 0.00 3.6 -1.1 -4.0 --- 
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394 gi_48374082 NM_001001440 ANXA4 Annexin a4 0.00 2.4 -1.7 -4.0 --- 
395 gi_119924438 XM_001251459 LOC782807 Similar to trace amine receptor 8 (LOC782807) 0.00 3.2 -1.3 -4.0 --- 
396 gi_119890020 XM_606535 WLS Hypothetical (LOC528123) 0.00 3.4 -1.2 -4.0 --- 
397 gi_139948327 NM_001083728 MAPK10 Mitogen-activated protein kinase 10 0.00 3.1 -1.3 -4.0 --- 
398 gi_119929037 XM_001250178 LOC783299 Similar to b7 olfactory receptor (LOC783299) 0.00 4.6 1.1 -4.0 --- 
399 gi_119892563 XM_001255417 OR6C70 Olfactory receptor, family 6, subfamily c, member 70 0.00 3.7 -1.1 -4.0 --- 
400 gi_119907486 XM_580632 OR2D2 Olfactory receptor, family 2, subfamily d, member 2 0.01 2.3 -1.8 -4.0 --- 
401 gi_119935923 XM_001257082 LOC790671 Similar to interphotoreceptor matrix proteoglycan 200  0.02 2.1 -1.9 -4.0 --- 
402 gi_51827229 --- --- Co896907 bovgen_25232 normal cattle brain cDNA clone 
rzpdp1056k201q 5' 
0.00 2.1 -1.9 -4.0 --- 
403 gi_119912471 XM_584593 LOC539069 Similar to copper amine oxidase (LOC539069) 0.00 3.9 1.0 -4.0 --- 
404 gi_119907337 XM_001254939 Olfr676 Olfactory receptor 676 0.00 3.0 -1.3 -4.0 --- 
405 gi_119924385 XM_583364 OR5I1 Olfactory receptor, family 5, subfamily i, member 1 0.00 4.3 1.1 -4.0 --- 
406 gi_119901487 XM_001253215 LOC785080 Similar to trace amine associated receptor 6 (loc785080) 0.00 3.2 -1.2 -4.0 --- 
407 gi_119926100 XR_028522 LOC787388 Similar to olfactory receptor olfr1174 (LOC787388) 0.00 3.1 -1.3 -4.0 --- 
408 gi_76662924 XM_882063 LOC616766 Hypothetical (LOC616766) 0.01 2.4 -1.7 -4.0 --- 
409 gi_10870122 BF076357 --- BF076357 225899 marc 2bov cDNA 5' 0.00 3.4 -1.2 -4.0 --- 
410 gi_119875275 XM_609842 BACH1 Btb and cnc homology 1, basic leucine zipper transcription 
factor 1 
0.00 2.3 -1.7 -4.0 --- 
411 gi_119914325 XM_616073 SCN11A Sodium channel, voltage-gated, type xi, alpha subunit 0.00 3.7 -1.1 -4.0 --- 
412 gi_51812273 --- --- Co882341 bovgen_10666 normal cattle brain cDNA clone 
rzpdp1056l1824q 5' 
0.00 2.6 -1.5 -4.0 --- 
413 gi_119916460 XM_001250160 LOC782394 Hypothetical protein (LOC782394) 0.00 2.4 -1.6 -4.0 --- 
414 gi_119902193 XM_001252966 OR4K2 Olfactory receptor, family 4, subfamily k, member 2 0.00 4.3 1.1 -4.0 --- 
415* gi_119923020 XM_001253097 Olfr1303 Olfactory receptor 1303 0.00 4.1 1.0 -4.0 --- 
416 gi_119926936 XM_001251377 Olfr630 Olfactory receptor 630 0.00 3.7 -1.1 -4.0 --- 
417 gi_115496034 NM_001076311 SNX24 Sorting nexin 24 0.00 6.4 1.6 -4.0 --- 
418 gi_119923523 XM_001253504 LOC785507 Similar to sp alpha (LOC785507) 0.00 2.9 -1.4 -3.9 --- 
419 gi_119907606 XM_590174 Olr36 Olfactory receptor 36 0.00 3.2 -1.2 -3.9 --- 
420 gi_119901591 XM_590527 STX11 Syntaxin 11 0.00 4.5 1.1 -3.9 --- 
421 gi_51888463 AJ820987 --- Aj820987 kn206 bos sp. CDNA clone c0006019g01 0.01 2.3 -1.7 -3.9 --- 
422 gi_119894463 XM_597995 PBX4 Pre-b-cell leukemia homeobox 4 0.00 2.7 -1.4 -3.9 --- 
423 gi_51881154 AJ813678 --- Aj813678 kn206 bos sp. CDNA clone c0005205l4 0.01 2.3 -1.7 -3.9 --- 
424 gi_119890208 XM_588670 CC2D1B Coiled-coil and c2 domain containing 1b 0.00 2.9 -1.3 -3.9 --- 
425 gi_51883784 AJ816308 --- Aj816308 kn206 bos sp. CDNA clone c0005210i19 0.00 2.5 -1.6 -3.9 --- 
426 gi_119921000 XM_001251294 LOC782658 Similar to olfr586 protein (LOC782658) 0.00 3.9 1.0 -3.9 --- 
427 gi_119896062 XR_027676 LOC782371 Hypothetical protein (LOC782371) 0.00 3.5 -1.1 -3.9 --- 
428 gi_119922219 XM_585077 LOC508315 Similar to olfactory receptor mor232-3 (LOC508315) 0.00 3.0 -1.3 -3.9 --- 
429* gi_119921045 XM_593866 OR52A1 Olfactory receptor, family 52, subfamily a, member 1 0.00 3.4 -1.1 -3.9 --- 
430 gi_32189319 NM_181033 LPHN3 Latrophilin 3 0.00 3.6 -1.1 -3.9 --- 
431 gi_119921882 XM_001256453 LOC789812 Similar to olfactory receptor mor262-6 (LOC789812) 0.00 3.9 1.0 -3.9 --- 
432 gi_119909828 XM_586270 LOC509331 Similar to plcg2 protein (LOC509331) 0.00 2.6 -1.5 -3.9 --- 
433 gi_136256478 NM_001077899 NFE2L3 Nuclear factor (erythroid-derived 2)-like 3 0.00 4.8 1.2 -3.9 --- 
434 gi_119889279 XM_001253716 NUP210L Nucleoporin 210kda-like 0.00 2.6 -1.5 -3.9 --- 
435 gi_51814505 --- --- Co884486 bovgen_12811 normal cattle brain cDNA clone 
rzpdp1056b079q 5' 
0.00 2.9 -1.3 -3.9 --- 
436 gi_119921953 XM_001252278 LOC783789 Similar to t-cell receptor alpha chain (LOC783789) 0.00 3.1 -1.2 -3.9 --- 
437 gi_51815687 --- --- Co885402 bovgen_13727 normal cattle brain cDNA clone 
rzpdp1056l1615q 5' 
0.00 3.3 -1.2 -3.9 --- 
438 gi_119892579 XM_001255560 LOC788524 Similar to cor9k3 olfactory receptor family 9 subfamily k-like 0.00 4.1 1.1 -3.9 --- 
439 gi_119906802 XM_869405 SLC26A7 Solute carrier family 26, member 7 0.01 2.1 -1.8 -3.9 --- 
440 gi_51809307 --- --- Co879383 bovgen_07710 normal cattle brain cDNA clone 
rzpdp1056c1320q 5' 
0.00 3.3 -1.2 -3.9 --- 
441 gi_119892535 XM_001255202 OR6C1 Olfactory receptor, family 6, subfamily c, member 1 0.00 3.7 -1.1 -3.9 --- 
442 gi_119877636 XM_001252430 LOC783994 Hypothetical protein loc783994 (LOC783994) 0.00 2.4 -1.6 -3.9 --- 
443 gi_119903343 XM_609234 SULT6B1 Sulfotransferase family, cytosolic, 6b, member 1 0.00 3.1 -1.3 -3.9 --- 
444 gi_76690438 XM_583591 LOC538910 Similar to protocadherin gamma a4 (LOC538910) 0.01 2.2 -1.8 -3.9 --- 
445* gi_119910954 XM_001254677 Vmn1r233 Similar to pheromone receptor (LOC787211) 0.00 3.0 -1.3 -3.9 --- 
446 gi_119931962 XM_587211 GPCRLTM7 Putative olfactory receptor GPCRLTM7 0.00 4.2 1.1 -3.9 --- 
447 gi_119905969 XM_604955 TTPAL Tocopherol (alpha) transfer protein-like 0.00 2.3 -1.7 -3.8 --- 
448 gi_119907359 XM_001255071 Olfr661 Olfactory receptor 661 0.00 3.9 1.0 -3.8 --- 
449 gi_118151441 NM_001078159 LYZ Lysozyme 0.01 2.2 -1.7 -3.8 --- 
450 gi_119922109 XM_001250343 LOC781841 Hypothetical protein (LOC781841) 0.00 2.4 -1.6 -3.8 --- 
451 gi_77736454 NM_001034755 MOBKL2C Mob1, mps one binder kinase activator-like 2c (yeast) 0.00 2.6 -1.5 -3.8 --- 
452 gi_126723003 NM_001082454 CCRN4L Ccr4 carbon catabolite repression 4-like (s. Cerevisiae) 0.00 4.6 1.2 -3.8 --- 
453 gi_67691040 --- --- Dr116230 1431370 marc 7bov cDNA 3' 0.02 2.0 -1.9 -3.8 --- 
454* gi_76670422 XM_581219 TAAR8 Trace amine associated receptor 8 0.00 3.8 1.0 -3.8 --- 
455 gi_119906354 XM_001254631 LOC787152 Hypothetical protein (LOC787152) 0.01 2.2 -1.8 -3.8 --- 
456 gi_119923783 XM_001250507 LOC783650 Hypothetical protein (LOC783650) 0.00 2.6 -1.5 -3.8 --- 
457 gi_119930466 XM_001255198 LOC788004 Similar to f-box only protein 16 (LOC788004) 0.00 3.3 -1.2 -3.8 --- 
458 gi_119921039 XM_001252349 LOC783898 Similar to mor 3beta4 (LOC783898) 0.00 3.7 1.0 -3.8 --- 
459 gi_119923151 XM_001255840 LOC788936 Hypothetical protein loc788936 (LOC788936) 0.01 2.1 -1.8 -3.8  
460 gi_119925825 XM_001251152 Olfr1351 Olfactory receptor 1351 0.00 2.7 -1.4 -3.8 --- 
461 gi_119895944 XM_001250359 ELL2 Elongation factor, rna polymerase ii, 2 0.00 3.9 1.0 -3.8 --- 
462 gi_119887309 XM_585327 NIPA1 Non imprinted in prader-willi/angelman syndrome 1 0.00 2.4 -1.6 -3.8 --- 
463 gi_119901496 XM_001253352 LOC785282 Similar to trace amine receptor 8 (LOC785282) 0.00 3.0 -1.2 -3.8 --- 
464 gi_119915592 XM_001252942 OR2J3 Olfactory receptor, family 2, subfamily j, member 3 0.00 2.9 -1.3 -3.8 --- 
465 gi_119916182 XM_866291 PSMA8 Proteasome (prosome, macropain) subunit, alpha type, 8 0.00 3.4 -1.1 -3.8 --- 
466* gi_76674338 XM_865987 OR7D4 Olfactory receptor, family 7, subfamily d, member 4 0.00 3.3 -1.1 -3.8 --- 
467* gi_119925321 XM_001255568 Olfr921 Olfactory receptor 921 0.00 3.0 -1.3 -3.8 --- 
468 gi_114052944 NM_001046095 CXCL16 Chemokine (c-x-c motif) ligand 16 0.00 2.3 -1.6 -3.8 --- 
469 gi_70829482 --- --- Dr713179 lb0054.cr_n13 gc_bgc-05 cDNA clone image:7963695 5' 0.00 2.5 -1.5 -3.7 --- 
470 gi_119925385 XM_866146 LOC614592 Similar to olfactory receptor olr1414 (LOC614592) 0.00 2.7 -1.4 -3.7 --- 
471 gi_119922177 XM_001253330 LOC785259 Hypothetical protein (LOC785259) 0.00 3.0 -1.3 -3.7 --- 
472 gi_51826609 --- --- Co896292 bovgen_24617 normal cattle brain cDNA clone 
rzpdp1056l1135q 5' 
0.00 2.4 -1.6 -3.7 --- 
473 gi_119907937 XM_591624 OR4C13 Olfactory receptor, family 4, subfamily c, member 13 0.00 3.6 -1.1 -3.7 --- 
474 gi_119902201 XM_001253086 OR4K14 Olfactory receptor, family 4, subfamily k, member 14 0.00 3.3 -1.1 -3.7 --- 
475 gi_77404220 NM_001034056 MS4A8B Membrane-spanning 4-domains, subfamily a, member 8b 0.00 2.3 -1.6 -3.7 --- 
476 gi_68427075 --- --- Am027990 am027990 kn-252-lymph, bos indicus bos indicus 
cDNA clone c0007394c04 3' 
0.00 2.6 -1.4 -3.7 --- 
477 gi_29262527 --- --- Cb456145 713366 marc 6bov cDNA 3' 0.01 2.3 -1.6 -3.7 --- 
478 gi_119931163 XM_001256873 LOC790391 Hypothetical protein (LOC790391) 0.00 4.5 1.2 -3.7 --- 
479 gi_119925806 XM_001250000 LOC781561 Hypothetical protein (LOC781561) 0.02 2.2 -1.7 -3.7 --- 
480 gi_119888322 XM_001253419 LOC785365 Hypothetical protein (LOC785365) 0.01 2.3 -1.6 -3.7 --- 
481 gi_119884978 XM_001253176 GPR87 G protein-coupled receptor 87 0.00 3.6 1.0 -3.7 --- 
482 gi_119890516 XM_868290 KCNJ13 Potassium inwardly-rectifying channel, subfamily j, member 13 0.02 2.1 -1.8 -3.7 --- 
483 gi_119926154 XM_001255113 LOC787886 Hypothetical protein (LOC787886) 0.02 2.1 -1.8 -3.7 --- 
484 gi_119894665 XM_583975 LOC507378 Similar to Cfolf4 (LOC507378) 0.00 3.1 -1.2 -3.7 --- 
485 gi_119922149 XM_870554 LOC618225 Similar to olfactory receptor olfr1177 (LOC618225) 0.00 2.9 -1.3 -3.7 --- 
486 gi_119923034 XM_001253258 LOC785145 Similar to seven transmembrane helix receptor (LOC785145) 0.00 2.3 -1.6 -3.7 --- 
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487 gi_119901527 XR_028449 EYA4 Eyes absent homolog 4 (drosophila) 0.00 2.6 -1.4 -3.7 --- 
488 gi_51822791 --- --- Co892491 bovgen_20816 normal cattle brain cDNA clone 
rzpdp1056i2133q 5' 
0.00 2.6 -1.4 -3.7 --- 
489* gi_119895352 XM_591451 OR2T8 Olfactory receptor, family 2, subfamily t, member 8 0.00 3.5 -1.1 -3.7 --- 
490 gi_119908082 XM_001256153 OR5L1 Olfactory receptor, family 5, subfamily l, member 1 0.00 2.6 -1.4 -3.7 --- 
491 gi_45498818 --- --- Ck980838 4112836 barc 9bov cDNA clone 9bov42_g03 3' 0.01 2.5 -1.5 -3.7 --- 
492 gi_119915994 XM_001256549 LOC789936 Similar to olfactory receptor 1160 (LOC789936) 0.00 2.5 -1.5 -3.7 --- 
493 gi_51824423 --- --- Co894116 bovgen_22441 normal cattle brain cDNA clone 
rzpdp1056h2334q 5' 
0.00 3.5 -1.0 -3.7 --- 
494 gi_119907040 XM_590126 ZC3H12C Similar to kiaa1726 protein, transcript variant 1 (LOC512586) 0.00 5.1 1.4 -3.6 --- 
495 gi_119910056 XM_001250846 NLRC5 Nlr family, card domain containing 5 0.00 4.3 1.2 -3.6 --- 
496 gi_119902654 XR_028233 LOC785249 Similar to loc767881 protein (LOC785249) 0.00 3.2 -1.1 -3.6 --- 
497 gi_119910346 XM_001253667 ZBTB32 Similar to testis zinc finger protein (LOC785741) 0.00 2.3 -1.6 -3.6 --- 
498 gi_45060035 --- --- Ck832605 4056810 barc 8bov cDNA clone 8bov_17p20 5' 0.01 2.4 -1.5 -3.6 --- 
499 gi_119924558 XM_867000 LOC615243 Similar to t-cell receptor delta (LOC615243) 0.01 2.3 -1.6 -3.6 --- 
500 gi_76674021 XM_604240 LOC525881 Similar to EPA6 (LOC525881) 0.00 2.9 -1.3 -3.6 --- 
501 gi_51888300 AJ820824 --- Aj820824 kn206 bos sp. CDNA clone c0006019n24 0.00 2.4 -1.5 -3.6 --- 
502 gi_119929386 XM_001256545 LOC789931 Hypothetical protein (LOC789931) 0.00 2.6 -1.4 -3.6 --- 
503 gi_119893667 XM_001249425 NAP1L5 Nucleosome assembly protein 1-like 5 0.01 2.3 -1.6 -3.6 --- 
504 gi_114703724 NM_174509 CACNB3 Calcium channel, voltage-dependent, beta 3 subunit 0.00 2.7 -1.3 -3.6 --- 
505 gi_156121078 NM_001102216 ZNF565  Zinc finger protein 565 0.00 2.4 -1.5 -3.6 --- 
506 gi_51820694 --- --- Co890406 bovgen_18731 normal cattle brain cDNA clone 
rzpdp1056g0160q 5' 
0.00 2.9 -1.2 -3.6 --- 
507 gi_119924710 XM_001249554 LOC781173 Similar to guanine nucleotide release/exchange factor 0.00 2.5 -1.4 -3.6 --- 
508* gi_119924436 XM_001251414 TAAR8 Trace amine associated receptor 8 0.00 3.4 -1.1 -3.6 --- 
509 gi_119924775 XM_587889 LOC510712 Similar to olf4 (LOC510712) 0.00 3.4 -1.1 -3.6 --- 
510 gi_51824784 --- --- Co894476 bovgen_22801 normal cattle brain cDNA clone 
rzpdp1056e0641q 5' 
0.00 3.0 -1.2 -3.6 --- 
511 gi_119903689 XM_872068 LOC613399 Similar to kiaa0903-like protein, transcript variant 2 0.00 2.5 -1.4 -3.6 --- 
512 gi_31342998 NM_174030 CTGF Connective tissue growth factor 0.00 2.6 -1.4 -3.6 --- 
513 gi_87278868 --- --- Dy465743 1606324 marc 11bov cDNA 3' 0.00 2.9 -1.2 -3.6 --- 
514 gi_27881411 NM_174294 CSN3 Casein kappa 0.00 2.5 -1.4 -3.6 --- 
515 gi_119921576 XM_583518 KIAA1147 KIAA1147 0.00 4.8 1.3 -3.6 --- 
516 gi_119921932 XM_871139 Olfr768 Olfactory receptor 768 0.00 2.9 -1.2 -3.6 --- 
517 gi_119936421 XM_001257122 LOC790723 Similar to connector enhancer of KSR2A (LOC790723) 0.00 3.2 -1.1 -3.6 --- 
518 gi_119934261 XM_001252663 LOC784317 Similar to wd repeat endosomal protein (LOC784317) 0.01 2.2 -1.6 -3.6 --- 
519 gi_134085668 NM_001083451 RORC Rar-related orphan receptor c 0.02 2.0 -1.8 -3.6 --- 
520 gi_51886917 AJ819441 --- Aj819441 kn206 bos sp. CDNA clone c0006015g04 0.02 2.1 -1.7 -3.6 --- 
521 gi_21681585 AU278275 --- Au278275 cloned bovine placenta cDNA cDNA clone 
placenta0318 3' 
0.00 4.2 1.2 -3.6 --- 
522 gi_119923914 XM_001255594 OR4A5 Olfactory receptor, family 4, subfamily a, member 5 0.00 3.1 -1.2 -3.6 --- 
523 gi_119934405 XM_001254935 LOC787580 Similar to chain a, structure of human neutral endopeptidase 
complexed with phosphoramidon (LOC787580) 
0.02 2.0 -1.7 -3.6 --- 
524 gi_119912384 XM_586375 CCDC103 Coiled-coil domain containing 103 0.01 2.0 -1.8 -3.6 --- 
525 gi_119922290 XR_027641 LOC522586 Hypothetical (LOC522586) 0.00 2.5 -1.4 -3.6 --- 
526 gi_156120686 NM_001102020 CLIP4 Cap-gly domain containing linker protein family, member 4 0.00 2.4 -1.5 -3.6 --- 
527 gi_119905750 XM_001253180 C20orf112 Chromosome 20 open reading frame 112 0.00 2.7 -1.3 -3.6 --- 
528 gi_119935000 XM_001256810 LOC790297 Similar to protein kinase (LOC790297) 0.01 2.0 -1.8 -3.6 --- 
529 gi_119892451 XM_588270 STAT2 Signal transducer and activator of transcription 2, 113kda 0.00 2.9 -1.2 -3.5 --- 
530 gi_119925143 XM_001252882 LOC784626 Similar to neuron-derived orphan receptor-1 alfa (LOC784626) 0.00 3.6 1.0 -3.5 --- 
531 gi_119889480 XM_868112 LOC616149 Hypothetical (LOC616149) 0.01 2.3 -1.6 -3.5 --- 
532 gi_119936114 XM_001257101 LOC790695 Similar to t-cell receptor alpha chain (LOC790695) 0.00 2.6 -1.3 -3.5 --- 
533 gi_51802822 --- --- Co872982 bovgen_01307 normal cattle brain cDNA clone 
rzpdp1056m2256q 3' 
0.00 2.4 -1.5 -3.5 --- 
534* gi_119925918 XM_609712 Olfr921 Olfactory receptor 921 0.00 3.4 1.0 -3.5 --- 
535 gi_119921163 XM_869117 LOC616964 Similar to cfolf4 (LOC616964) 0.00 2.6 -1.4 -3.5 --- 
536 gi_119906071 XM_586129 B4GALT5 Udp-gal:betaglcnac beta 1,4- galactosyltransferase, 
polypeptide 5 
0.00 6.8 1.9 -3.5 --- 
537 gi_60958168 --- --- Dn519419 1260254 marc 7bov cDNA 3' 0.00 2.4 -1.5 -3.5 --- 
538 gi_110347578 NM_174257 S100G S100 calcium binding protein g 0.01 2.1 -1.7 -3.5 --- 
539 gi_115496050 NM_001076208 NR4A2 Nuclear receptor subfamily 4, group a, member 2 0.00 3.4 1.0 -3.5 --- 
540 gi_119921695 XM_001254784 CFH Complement factor h 0.00 3.1 -1.1 -3.5 --- 
541 gi_119927361 XM_589643 CDADC1 Cytidine and dcmp deaminase domain containing 1 0.00 2.1 -1.6 -3.5 --- 
542 gi_119906900 XM_001254050  Glutamate receptor, ionotrophic, ampa 4 (gria4) 0.00 2.9 -1.2 -3.5 --- 
543 gi_156071442 NM_001101661 DEFB119 Defensin, beta 119 0.00 3.0 -1.1 -3.5 --- 
544 gi_119914146 XM_868259 RAGE Renal tumor antigen 0.00 2.6 -1.3 -3.5 --- 
545 gi_119918504 XM_001250186 LOC781705 Hypothetical protein (LOC781705) 0.01 2.3 -1.5 -3.5 --- 
546 gi_76679265 XM_591472 OR7A10 Olfactory receptor, family 7, subfamily a, member 10 0.00 2.9 -1.2 -3.5 --- 
547 gi_119877840 XM_616959 ROBO1 Roundabout, axon guidance receptor, homolog 1 (drosophila) 0.00 2.9 -1.2 -3.5 --- 
548 gi_119877632 XM_603300 NRIP1 Nuclear receptor interacting protein 1 0.00 2.1 -1.7 -3.5 --- 
549* gi_119920994 XM_001251099 OR51T1 Olfactory receptor, family 51, subfamily t, member 1 0.00 3.5 1.0 -3.5 --- 
550 gi_51812540 --- --- Co882608 bovgen_10933 normal cattle brain cDNA clone 
rzpdp1056l087q 5' 
0.00 3.7 1.1 -3.5 --- 
551 gi_158819086 NM_001110183 MGC134232 Hypothetical loc618600 (MGC134232) 0.03 2.0 -1.7 -3.5 --- 
552 gi_164448591 NM_001113258 FHL1 Four and a half lim domains 1 (fhl1), transcript variant 1 0.00 2.5 -1.4 -3.5 --- 
553 gi_119910391 XM_001254872 LOC787495 Hypothetical protein loc787495 (LOC787495) 0.00 2.9 -1.2 -3.5 --- 
554 gi_119913871 XM_617995 AKAP6 A kinase (prka) anchor protein 6 0.00 2.9 -1.2 -3.5 --- 
555 gi_119902298 XM_601356 LOC523062 Similar to seven transmembrane helix receptor (LOC523062) 0.00 3.3 -1.1 -3.5 --- 
556 gi_119556585 --- --- Eh157580 lb01364.cr_c04 gc_bgc-13 cDNA clone 
image:8441982 5' 
0.00 2.5 -1.4 -3.5 --- 
557 gi_119910344 XM_001253642 LOC785707 Hypothetical protein (LOC785707) 0.00 2.5 -1.4 -3.5 --- 
558 gi_76683775 XM_586650 LOC509641 Similar to olf4 (LOC509641) 0.01 2.2 -1.6 -3.5 --- 
559 gi_68422126 --- --- Am023811 kn-252-lymph, cDNA clone c0007400i17 5' 0.00 3.2 -1.1 -3.5 --- 
560 gi_119919833 XM_001254041 LOC786332 Similar to transmembrane protein with egf-like and two 
follistatin-like domains 1 (LOC786332) 
0.00 2.8 -1.3 -3.5 --- 
561 gi_119929117 XM_589033 OR4A15 Olfactory receptor, family 4, subfamily a, member 15 0.00 4.0 1.2 -3.5 --- 
562 gi_115496747 NM_001075692 MTUS1  Mitochondrial tumor suppressor 1 (mtus1), nuclear gene 
encoding mitochondrial protein 
0.00 2.3 -1.5 -3.4 --- 
563 gi_51816378 --- --- Co886093 bovgen_14418 normal cattle brain cDNA clone 
rzpdp1056o0525q 5' 
0.00 3.8 1.1 -3.4 --- 
564* gi_118151067 NM_001077987 SNX13 Sorting nexin 13 0.00 3.6 1.0 -3.4 --- 
565 gi_119927808 XM_001255617 LOC788608 Similar to t-cell receptor alpha chain (LOC788608) 0.00 2.4 -1.4 -3.4 --- 
566 gi_119918970 XM_581982 OR8G5 Olfactory receptor, family 8, subfamily g, member 5 0.01 2.4 -1.5 -3.4 --- 
567* gi_119891767 XM_001249363 INSIG1 Insulin induced gene 1 0.00 2.3 -1.5 -3.4 --- 
568 gi_119920756 XM_001251412 LOC782764 Similar to mitochondrial cytochrome c oxidase subunit vb 0.00 2.6 -1.3 -3.4 --- 
569 gi_119892519 XM_001255059 OR6C76 Olfactory receptor, family 6, subfamily c, member 76 0.00 3.2 -1.1 -3.4 --- 
570 gi_51810873 --- --- Co880944 bovgen_09269 normal cattle brain cDNA clone 
rzpdp1056b0414q 5' 
0.00 2.5 -1.4 -3.4 --- 
571 gi_51808688 --- --- Co878764 bovgen_07089 normal cattle brain cDNA clone 
rzpdp1056h0526q 5' 
0.00 2.6 -1.3 -3.4 --- 
572 gi_119939528 XM_001257172 LOC790784 Similar to p63 (processed form) (LOC790784) 0.01 2.0 -1.7 -3.4 --- 
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573 gi_51883450 AJ815974 --- Aj815974 kn206 bos sp. cDNA clone c0005202f17 0.01 2.1 -1.6 -3.4 --- 
574* gi_119892525 XM_001255131 Olfr802 Olfactory receptor 802 0.00 3.2 -1.1 -3.4 --- 
575 gi_119918285 XM_001253310 LOC785230 Hypothetical protein (LOC785230) 0.01 2.0 -1.7 -3.4 --- 
576 gi_119923452 XM_001249761 LOC781734 Similar to g antigen, family d, 1 (LOC781734) 0.00 2.9 -1.2 -3.4 --- 
577 gi_119889486 XM_867242 NOTCH2 NOTCH 2 0.00 2.2 -1.5 -3.4 --- 
578* gi_119892978 XM_001251585 KLRC1 Killer cell lectin-like receptor subfamily c, member 1 0.00 3.6 1.1 -3.4 --- 
579 gi_119922699 XM_868317 LOC616322 Hypothetical (LOC616322) 0.00 2.8 -1.2 -3.4 --- 
580 gi_119915359 XM_583214 NFKBIE Nuclear factor of kappa light polypeptide gene enhancer in b-
cells inhibitor, epsilon 
0.00 3.9 1.2 -3.4 --- 
581 gi_119920307 XR_028058 LOC785658 Similar to spi-c transcription factor (spi-1/pu.1 related) 0.00 4.0 1.2 -3.4 --- 
582 gi_119910944 XM_001254581 Vmn1r67 Similar to pheromone receptor (LOC787075) 0.00 2.8 -1.2 -3.4 --- 
583 gi_119901769 XM_581038 MLLT4 Myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, drosophila); translocated to, 4 
0.00 2.9 -1.2 -3.4 --- 
584 gi_119915909 XM_865312 IRF4 Interferon regulatory factor 4 0.00 4.7 1.4 -3.4 --- 
585 gi_51880653 AJ813177 --- Aj813177 kn206 bos sp. CDNA clone c0005207e19 0.01 2.3 -1.5 -3.4 --- 
586 gi_119921525 XM_001254038 LOC786324 Similar to enterocytin (LOC786324) 0.00 3.2 -1.1 -3.4 --- 
587 gi_119915588 XM_001252901 OR2B3 Olfactory receptor, family 2, subfamily b, member 3 0.02 2.1 -1.6 -3.4 --- 
588 gi_51815409 --- --- Co885124 bovgen_13449 normal cattle brain cDNA clone 
rzpdp1056c1211q 5' 
0.00 2.9 -1.2 -3.3 --- 
589* gi_119902016 XM_001252771 CBLN3 Cerebellin 3 precursor 0.00 5.2 1.5 -3.3  
590* gi_119920962 XM_581965 OR52A1 Olfactory receptor, family 52, subfamily a, member 1 0.00 3.3 1.0 -3.3 --- 
591 gi_119903302 XM_588244 CLEC4F C-type lectin domain family 4, member f 0.01 2.1 -1.6 -3.3 --- 
592* gi_119892583 XM_001255583 Olr1070 Olfactory receptor 1070 0.00 2.6 -1.3 -3.3 --- 
593 gi_119938116 XM_599621 LOC521360 Hypothetical (LOC521360) 0.00 2.6 -1.3 -3.3 --- 
594 gi_116004282 NM_001077032 CXorf65 Chromosome x open reading frame 65 0.01 2.2 -1.5 -3.3 --- 
595* gi_119887366 XM_001254094 INPP1 Inositol polyphosphate-1-phosphatase 0.00 5.9 1.8 -3.3 --- 
596 gi_31343166 NM_173964 TEK Tek tyrosine kinase, endothelial 0.00 2.3 -1.4 -3.3 --- 
597 gi_51882655 AJ815179 --- Aj815179 kn206 bos sp. CDNA clone c0005203i11 0.01 2.1 -1.6 -3.3 --- 
598 gi_119940726 XM_001257205 LOC790830 Hypothetical protein (LOC790830) 0.00 2.6 -1.3 -3.3 --- 
599 gi_119908232 XM_618596 CDC42BPA Cdc42 binding protein kinase alpha (dmpk-like) 0.00 2.4 -1.4 -3.3 --- 
600 gi_115496687 NM_001075698 IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 0.00 4.1 1.2 -3.3 --- 
601 gi_66792745 NM_001024493 TRPV2 Transient receptor potential cation channel, subfamily v, 
member 2 
0.01 2.2 -1.5 -3.3 --- 
602 gi_119910478 XM_580597 RINL Ras and rab interactor-like 0.00 3.2 1.0 -3.3 --- 
603 gi_119912581 XR_027582 PITPNC1 Phosphatidylinositol transfer protein, cytoplasmic 1 0.00 2.3 -1.4 -3.3 --- 
604 gi_51882625 --- --- Aj815149 kn206 bos sp. cDNA clone c0005200a24 0.01 2.1 -1.6 -3.3 --- 
605 gi_119922265 XM_001254653 LOC787179 Similar to t cell receptor alpha chain (LOC787179) 0.00 3.4 1.0 -3.3 --- 
606 gi_78369353 NM_001035367 LOC527068 Aldo-keto reductase family 1 member c3 -like (LOC527068) 0.01 2.2 -1.5 -3.3 --- 
607 gi_119932114 XM_001256880 LOC790399 Similar to seven transmembrane helix receptor (LOC790399) 0.00 2.7 -1.2 -3.3 --- 
608* gi_119928286 XM_001255475 OR13F1 Olfactory receptor, family 13, subfamily f, member 1 0.00 3.3 1.0 -3.3 --- 
609 gi_119913798 XM_588916 SNX33 Sorting nexin 33 0.00 2.2 -1.5 -3.3 --- 
610 gi_84000234 NM_001038135 REEP6 Receptor accessory protein 6 0.00 3.3 1.0 -3.3 --- 
611 gi_119889482 XM_611707 LOC532585 Hypothetical (LOC532585) 0.01 2.3 -1.4 -3.3  
612 gi_16186852 --- --- Bi898780 480531 marc 2bov cDNA 5' 0.02 2.1 -1.6 -3.3 --- 
613 gi_76625185 XM_603327 LOC524985 Similar to olfactory receptor mor222-1 (LOC524985) 0.00 3.0 -1.1 -3.3 --- 
614 gi_119920877 XM_001257254 NOVA1 Neuro-oncological ventral antigen 1 0.00 2.8 -1.2 -3.3 --- 
615 gi_119889147 XM_585637 LOC508806 Similar to seven transmembrane helix receptor (LOC508806) 0.00 2.5 -1.3 -3.3 --- 
616 gi_51884171 Aj816695 --- Aj816695 kn206 bos sp. cDNA clone c0005209g15 0.00 2.5 -1.3 -3.3 --- 
617 gi_119916331 XM_608193 TNIP2 Tnfaip3 interacting protein 2 0.00 2.9 -1.1 -3.3 --- 
618 gi_114051342 NM_001046143 CDKN2AIP Cdkn2a interacting protein) 0.00 2.1 -1.5 -3.3 --- 
619* gi_119925417 XM_613566 NUB1 Negative regulator of ubiquitin-like proteins 1 0.00 4.9 1.5 -3.3 --- 
620 gi_76670427 XM_604131 LOC525775 Similar to trace amine receptor 8 (LOC525775) 0.01 2.3 -1.4 -3.3 --- 
621* gi_124249271 NM_001080906 NUB1 Negative regulator of ubiquitin-like proteins 1 0.00 5.7 1.7 -3.3 --- 
622 gi_119925658 XM_001255387 LOC788279 Similar to olf4 (LOC788279) 0.00 3.3 1.0 -3.3 --- 
623 gi_119926964 XM_594793 Olfr6 Olfactory receptor 6 0.00 3.4 1.0 -3.3 --- 
624 gi_119893520 XM_001249301 LOC780970 Hypothetical protein (LOC780970) 0.00 2.7 -1.2 -3.3 --- 
625 gi_110626110 NM_001013593 BCAT2 Branched chain amino-acid transaminase 2, mitochondrial 0.00 2.3 -1.4 -3.3 --- 
626 gi_119934846 XM_001250325 LOC785695 Hypothetical protein (LOC785695) 0.00 3.8 1.2 -3.3 --- 
627 gi_62116764 --- --- Dn740589 1403150 marc 7bov cDNA 3' 0.00 3.2 1.0 -3.3 --- 
628 gi_51826686 --- --- Co896369 bovgen_24694 normal cattle brain cDNA clone 
rzpdp1056d0543q 5' 
0.03 2.0 -1.6 -3.3 --- 
629 gi_119915432 XM_869123 MUC21 Mucin 21, cell surface associated 0.01 2.1 -1.5 -3.2 --- 
630 gi_119892555 XM_001255364 Olfr820 Olfactory receptor 820 0.00 2.7 -1.2 -3.2 --- 
631 gi_119908569 XR_028737 LOC789222 Similar to zinc finger protein riz (LOC789222) 0.00 2.3 -1.4 -3.2 --- 
632 gi_51815757 --- --- Co885472 bovgen_13797 normal cattle brain cDNA clone 
rzpdp1056c199q 5' 
0.00 2.9 -1.1 -3.2 --- 
633 gi_119914504 XM_001251656 LOC783001 Similar to chromosome 12 open reading frame 2 (LOC783001) 0.00 2.4 -1.4 -3.2 --- 
634* gi_119923954 XM_595420 Olfr1276 Olfactory receptor 1276 0.00 3.1 -1.1 -3.2 --- 
635 gi_119314652 --- --- Ee978054 p34501a fnm cDNA clone p3450 3' 0.01 2.1 -1.5 -3.2 --- 
636* gi_119919022 XM_001251836 OR8A1 Olfactory receptor, family 8, subfamily a, member 1 0.00 2.4 -1.3 -3.2 --- 
637 gi_119892575 XM_001255503 LOC788438 Similar to olfactory receptor mor210-4 (LOC788438) 0.00 3.0 -1.1 -3.2 --- 
638 gi_51881897 --- --- Aj814421 aj814421 kn206 bos sp. CDNA clone c0005204k1 0.00 2.6 -1.3 -3.2 --- 
639 gi_119875296 XM_001252915 LOC784671 Hypothetical protein (LOC784671) 0.01 2.3 -1.4 -3.2 --- 
640 gi_156120584 NM_001101968 STYXL1 Serine/threonine/tyrosine interacting-like 1 0.01 2.2 -1.4 -3.2 --- 
641 gi_119922882 XM_600016 LOC521749 Similar to olfactory receptor mor245-4 (LOC521749) 0.00 3.5 1.1 -3.2 --- 
642 gi_51815212 --- --- Co884927 bovgen_13252 normal cattle brain cDNA clone 
rzpdp1056i0316q 5' 
0.00 2.8 -1.2 -3.2 --- 
643 gi_51821644 --- --- Co891349 bovgen_19674 normal cattle brain cDNA clone 
rzpdp1056p0648q 5' 
0.00 2.6 -1.2 -3.2 --- 
644* gi_119913158 XM_588962 PARP8 Poly (adp-ribose) polymerase family, member 8 0.00 3.2 1.0 -3.2 --- 
645 gi_51811180 --- --- Co881251 bovgen_09576 normal cattle brain cDNA clone 
rzpdp1056i093q 5' 
0.00 2.3 -1.4 -3.2 --- 
646 gi_114050764 NM_001046472 GPR183 G protein-coupled receptor 183 0.01 2.2 -1.4 -3.2 --- 
647 gi_77736288 NM_001034672 TSPAN33 Tetraspanin 33 0.00 4.4 1.4 -3.2 --- 
648 gi_76686154 XM_590795 OR4C12 Olfactory receptor, family 4, subfamily c, member 12 0.00 3.0 -1.1 -3.2 --- 
649 gi_119921693 XM_587804 LOC510640 Similar to h factor 1 (complement), transcript variant 2 0.00 2.6 -1.2 -3.2 --- 
650 gi_27807288 NM_174716 ANXA2 Annexin a2 0.00 3.2 1.0 -3.2 --- 
651 gi_119921731 XM_001255638 LOC788640 Similar to olfactory receptor olr87 (LOC788640) 0.00 3.3 1.0 -3.2 --- 
652 gi_51884776 --- --- Aj817300 kn206 bos sp. CDNA clone c0006006n10 0.00 2.3 -1.4 -3.2 --- 
653* gi_119921037 XM_604679 Olfr622 Olfactory receptor 622 0.00 2.5 -1.3 -3.2 --- 
654 gi_51818716 --- --- Co888431 bovgen_16756 normal cattle brain cDNA clone 
rzpdp1056n1319q 5' 
0.00 3.1 1.0 -3.2 --- 
655 gi_119902174 XM_605040 LOC526667 Similar to olfactory receptor mor106-5 (LOC526667) 0.01 2.3 -1.4 -3.2 --- 
656 gi_119902413 XM_617674 MDGA2 Mam domain containing glycosylphosphatidylinositol anchor 2 0.00 2.9 -1.1 -3.2 --- 
657 gi_119895360 XM_586131 LOC509217 Similar to seven transmembrane helix receptor (LOC509217) 0.00 2.7 -1.2 -3.2 --- 
658 gi_119893497 XM_607704 NDST4 N-deacetylase/n-sulfotransferase (heparan glucosaminyl) 4 0.00 2.7 -1.2 -3.2 --- 
659 gi_156121044 NM_001102199 MYO1B Myosin ib 0.00 2.4 -1.3 -3.2 --- 
660* gi_134085656 NM_001083422 STK17A Serine/threonine kinase 17a 0.00 2.3 -1.4 -3.2 --- 
661 gi_119915895 XM_001250447 LOC782393 Similar to eukaryotic translation elongation factor 1 epsilon 1 0.00 2.1 -1.5 -3.2 --- 
662 gi_119909922 XM_001256073 LOC789278 Hypothetical protein (LOC789278) 0.01 2.2 -1.4 -3.2 --- 
663 gi_119888596 XR_028504 SP110 Sp110 nuclear body protein 0.00 2.3 -1.4 -3.2 --- 
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664 gi_119901002 XM_589483 C5 Complement component 5 0.00 2.4 -1.3 -3.2 --- 
665 gi_51808026 --- --- Co878110 bovgen_06435 normal cattle brain cDNA clone 
rzpdp1056a1417q 5' 
0.00 4.4 1.4 -3.2 --- 
666 gi_119886996 XM_001249828 LCA5L Leber congenital amaurosis 5-like 0.00 2.6 -1.2 -3.1 --- 
667 gi_119892507 XM_001254890 Olfr770 Olfactory receptor 770 0.00 2.9 -1.1 -3.1 --- 
668 gi_119924514 XM_001253602 Olfr1293 Olfactory receptor 1293 0.00 3.0 -1.1 -3.1 --- 
669 gi_134085676 NM_001083530 S100A3  S100 calcium binding protein a3 (s100a3) 0.00 4.0 1.3 -3.1 --- 
670 gi_119926165 XM_001255258 LOC788100 Similar to seven transmembrane helix receptor (LOC788100) 0.01 2.2 -1.4 -3.1 --- 
671 gi_68312483 --- --- Am011292 am011292 kn-252-bone-marrow, cDNA clone 
c0007384f18 5' 
0.00 2.5 -1.3 -3.1 --- 
672 gi_157279990 NM_001105041 RUSC1 Run and sh3 domain containing 1 0.00 4.2 1.3 -3.1 --- 
673* gi_61812675 XM_598133 Olfr622 Olfactory receptor 622 0.00 2.5 -1.3 -3.1 --- 
674* gi_119929138 XM_001255607 OR51T1 Olfactory receptor, family 51, subfamily t, member 1 0.00 3.1 1.0 -3.1 --- 
675 gi_119937175 XM_001255947 LOC789094 Similar to ampa type glutamate receptor (LOC789094) 0.01 2.2 -1.4 -3.1 --- 
676 gi_116734828 NM_001075320 TIMD4 T-cell immunoglobulin and mucin domain containing 4 0.00 2.5 -1.2 -3.1 --- 
677 gi_51880414 --- --- Aj812938 kn206 bos sp. CDNA clone c0005208a14 0.01 2.2 -1.4 -3.1 --- 
678 gi_119892607 XM_001249868 LOC781440 Similar to olfactory receptor mor114-1 (LOC781440) 0.00 3.0 1.0 -3.1 --- 
679* gi_119895405 XM_001253303 Olfr30 Olfactory receptor 30 0.00 2.5 -1.3 -3.1 --- 
680 gi_31341720 NM_174541 GABRA2 Gamma-aminobutyric acid (gaba) a receptor, alpha 2 0.00 2.5 -1.3 -3.1 --- 
681 gi_119892357 XM_592833 DYRK2 Dual-specificity tyrosine-(y)-phosphorylation regulated kinase 2 0.01 2.2 -1.4 -3.1 --- 
682 gi_119926000 XM_001250683 CA1 Carbonic anhydrase i 0.00 2.9 -1.1 -3.1 --- 
683 gi_119926757 XM_001256213 LOC789465 Hypothetical protein (LOC789465) 0.00 4.1 1.3 -3.1 --- 
684 gi_119923232 XM_612459 LOC533149 Hypothetical (LOC533149) 0.00 2.3 -1.4 -3.1 --- 
685 gi_119910251 XM_001250104 FTSJD1 Ftsj methyltransferase domain containing 1 0.00 5.1 1.6 -3.1 --- 
686 gi_119920696 XM_608251 CRLF2 Cytokine receptor-like factor 2 0.00 4.0 1.3 -3.1 --- 
687 gi_51809237 --- --- Co879313 bovgen_07640 normal cattle brain cDNA clone 
rzpdp1056d0127q 5' 
0.00 2.5 -1.2 -3.1 --- 
688 gi_119893783 XM_001250975 LOC782331 Hypothetical protein (LOC782331) 0.00 3.0 1.0 -3.1 --- 
689* gi_119907426 XM_001255664 OR52A1 Olfactory receptor, family 52, subfamily a, member 1 0.00 3.4 1.1 -3.1 --- 
690 gi_119902080 XM_588656 BVd1.18 T cell receptor delta chain variable region (bvd1.18) 0.00 2.6 -1.2 -3.1 --- 
691 gi_119888478 XM_587645 CPS1 Carbamoyl-phosphate synthase 1, mitochondrial 0.02 2.0 -1.5 -3.1 --- 
692* gi_119892543 XM_001255277 Olfr802 Olfactory receptor 802 0.00 2.9 -1.1 -3.1 --- 
693 gi_60453989 --- --- Dn285379 1235238 marc 7bov cDNA 3' 0.00 4.6 1.5 -3.1 --- 
694* gi_119920966 XM_001249871 OR52A1 Olfactory receptor, family 52, subfamily a, member 1 0.00 3.4 1.1 -3.1 --- 
695 gi_119884953 XM_591264 PLCH1 Phospholipase c, eta 1 0.00 5.0 1.6 -3.1 --- 
696 gi_51809759 --- --- Co879836 bovgen_08161 normal cattle brain cDNA clone 
rzpdp1056d159q 5' 
0.01 2.2 -1.4 -3.1 --- 
697 gi_51882102 --- --- Aj814626 kn206 bos sp. CDNA clone c0005200h11 0.00 2.9 -1.1 -3.1 --- 
698 gi_119924516 XM_001253624 LOC785683 Similar to olfactory receptor olr758 (LOC785683) 0.00 2.5 -1.2 -3.1 --- 
699 gi_119927331 XM_586485 LOC509509 Similar to t-cell receptor alpha chain (LOC509509) 0.01 2.2 -1.4 -3.1 --- 
700 gi_119889928 XM_609742 COL24A1 Collagen, type xxiv, alpha 1 0.00 3.1 1.0 -3.1 --- 
701 gi_119889322 XM_001254388 LOC786817 Hypothetical protein (LOC786817) 0.01 2.2 -1.4 -3.1 --- 
702 gi_51887120 --- --- Aj819644 aj819644 kn206 bos sp. CDNA clone c0006016a22 0.01 2.3 -1.3 -3.1 --- 
703 gi_119921654 XM_870882 LOC618552 Similar to t-cell receptor alpha chain (LOC618552) 0.00 2.7 -1.1 -3.1 --- 
704 gi_115497951 NM_001075871 IER2 Immediate early response 2 0.00 4.0 1.3 -3.1 --- 
705 gi_119915866 XM_607555 HIVEP1 Human immunodeficiency virus type i enhancer binding 
protein 1 
0.00 3.8 1.2 -3.1 --- 
706 gi_51817518 --- --- Co887233 bovgen_15558 normal cattle brain cDNA clone 
rzpdp1056j1016q 5' 
0.00 2.6 -1.2 -3.1 --- 
707 gi_119911171 XM_609549 ZNF584 Similar to zinc finger protein 420 (LOC531064) 0.01 2.1 -1.5 -3.1 --- 
708 gi_119920543 XM_868002 MAP7D2 Map7 domain containing 2 0.00 3.1 1.0 -3.1 --- 
709 gi_119893022 XM_587046 Clec2e C-type lectin domain family 2, member e 0.00 2.5 -1.2 -3.1 --- 
710 gi_119921415 XM_001249872 LOC781446 Similar to olfactory receptor olr1108 (LOC781446) 0.00 2.9 -1.0 -3.0 --- 
711 gi_119929786 XM_001255691 LOC788715 Similar to low-density lipoprotein receptor-related protein 1b 
precursor lrp-dit) (LOC788715) 
0.00 2.6 -1.2 -3.0 --- 
712 gi_51814035 --- --- Co884088 bovgen_12413 normal cattle brain cDNA clone 
rzpdp1056m0216q 5' 
0.00 2.3 -1.3 -3.0 --- 
713 gi_119901510 XM_001253691 TAAR1 Trace amine associated receptor 1 0.00 3.0 1.0 -3.0 --- 
714 gi_119923060 XM_001253760 LOC785898 Similar to olfactory receptor (LOC785898) 0.00 2.7 -1.1 -3.0 --- 
715 gi_119891945 XM_001249702 MGAT4C Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-n-
acetylglucosaminyltransferase, isozyme c (putative) 
0.00 3.1 1.0 -3.0 --- 
716 gi_119923045 XM_001253400 LOC785338 Hypothetical protein (LOC785338) 0.00 2.4 -1.2 -3.0 --- 
717 gi_119938379 XM_001257069 LOC790653 Similar to mll5 (LOC790653) 0.01 2.3 -1.3 -3.0 --- 
718 gi_156120930 NM_001102142 SP7 Sp7 transcription factor 0.00 2.5 -1.2 -3.0 --- 
719 gi_164448597 NM_001035271 KLF6 Kruppel-like factor 6 0.00 2.1 -1.4 -3.0 --- 
720* gi_51815648 --- BAIAP2 Bai1-associated protein 2 0.00 4.1 1.4 -3.0 --- 
721 gi_119901506 XM_001253621 Taar3 Trace amine-associated receptor 3 0.00 2.4 -1.2 -3.0 --- 
722 gi_119895362 XM_868904 OR2M4 Olfactory receptor, family 2, subfamily m, member 4 0.00 2.8 -1.1 -3.0 --- 
723 gi_119929817 XM_593643 Olfr1086 Olfactory receptor 1086 0.00 2.5 -1.2 -3.0 --- 
724 gi_51820553 --- --- Co890265 bovgen_18590 normal cattle brain cDNA clone 
rzpdp1056j0134q 5' 
0.00 2.2 -1.4 -3.0 --- 
725 gi_119889478 XM_608618 Olfr1402 Olfactory receptor 1402 0.00 2.8 -1.1 -3.0 --- 
726 gi_119915614 XM_001253184 LOC785040 Similar to seven transmembrane helix receptor (LOC785040) 0.00 2.9 -1.1 -3.0 --- 
727 gi_119902205 XM_001253130 LOC784974 Similar to olfactory receptor MOR242-1 (LOC784974) 0.00 3.1 1.0 -3.0 --- 
728 gi_119894688 XM_001249956 ZSWIM4 Similar to flj00044 protein (LOC781514) 0.00 2.5 -1.2 -3.0 --- 
729 gi_51884045 --- --- Aj816569 aj816569 kn206 bos sp. CDNA clone c0005209l7 0.00 2.4 -1.3 -3.0 --- 
730 gi_119877213 XM_614756 ROBO2 Roundabout, axon guidance receptor, homolog 2 (drosophila) 0.01 2.2 -1.4 -3.0 --- 
731 gi_119916408 XM_616601 WDR7 Similar to rabconnectin-3 beta (loc536469) 0.00 2.2 -1.4 -3.0 --- 
732 gi_119906499 XM_588521 VCPIP1 Similar to kiaa1850 protein, transcript variant 1 (LOC539643) 0.01 2.0 -1.5 -3.0 --- 
733 gi_51884568 --- --- Aj817092 kn206 bos sp. cDNA clone c0006007h13 0.00 2.9 -1.0 -3.0 --- 
734 gi_119922419 XM_001254973 Olfr1132 Olfactory receptor 1132 0.00 2.8 -1.1 -3.0 --- 
735 gi_119930323 XM_001253262 LOC785149 Similar to olfactory receptor olr1414 (LOC785149) 0.01 2.2 -1.4 -3.0 --- 
736 gi_119928129 XM_001253316 LOC785240 Hypothetical protein (LOC785240) 0.00 2.3 -1.3 -3.0 --- 
737 gi_119916443 XM_881561 LOC616344 Hypothetical loc616344 (LOC616344) 0.00 3.5 1.2 -3.0 --- 
738 gi_119920998 XM_001251219 LOC782589 Similar to seven transmembrane helix receptor (LOC782589) 0.00 2.6 -1.1 -3.0 --- 
739 gi_119923950 XM_001250244 LOC781758 Similar to olfactory receptor olr753 (LOC781758) 0.02 2.2 -1.4 -3.0 --- 
740 gi_119889472 XM_001255499 LOC788724 Similar to hist2h2aa1 protein (LOC788724) 0.00 2.5 -1.2 -3.0 --- 
741 gi_76662928 XM_588102 OR2M3 Olfactory receptor, family 2, subfamily m, member 3 0.00 2.9 1.0 -3.0 --- 
742* gi_119902300 XM_001254661 Olfr1276 Olfactory receptor 1276 0.00 3.0 1.0 -3.0 --- 
743 gi_119924838 XM_001253851 LOC786035 Similar to seven transmembrane helix receptor (LOC786035) 0.00 2.7 -1.1 -3.0 --- 
744* gi_119895332 XM_001255076 OR2T8 Olfactory receptor, family 2, subfamily t, member 8 0.00 2.8 -1.1 -3.0 --- 
745 gi_116003900 NM_001076841 H2-T24 Histocompatibility 2, t region locus 24 0.00 3.1 1.0 -3.0 --- 
746 gi_51824355 --- --- Co894048 bovgen_22373 normal cattle brain cDNA clone 
rzpdp1056j0944q 5' 
0.00 2.5 -1.2 -3.0 --- 
747 gi_51822391 --- --- Co892090 bovgen_20415 normal cattle brain cDNA clone 
rzpdp1056l2144q 5' 
0.00 2.5 -1.2 -3.0 --- 
748 gi_119924939 XM_001255062 LOC787802 Similar to t cell receptor alpha chain (LOC787802) 0.01 2.2 -1.4 -3.0 --- 
749 gi_77735876 NM_001034463 C21orf33 Chromosome 21 open reading frame 33 0.00 2.6 -1.1 -3.0 --- 
750 gi_51884353 --- --- Aj816877 kn206 bos sp. CDNA clone c0005208n17 0.00 4.5 1.5 -3.0 --- 
751 gi_119923948 XM_001250190 Olfr1280 Olfactory receptor 1280 0.00 2.7 -1.1 -3.0 --- 
752 gi_119921644 XM_001254228 LOC786593 Similar to t-cell receptor alpha chain (LOC786593) 0.00 3.0 1.0 -3.0 --- 
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753 gi_119881228 XM_001251762 DVL3 Dishevelled, dsh homolog 3 (drosophila) 0.00 2.3 -1.3 -3.0 --- 
754 gi_119895593 XR_028187 LOC510849 Similar to protocadherin gamma b6 (LOC510849) 0.01 2.2 -1.3 -3.0 --- 
755 gi_119894394 XM_585315 BOD1L Biorientation of chromosomes in cell division 1-like 0.00 2.1 -1.4 -3.0 --- 
756 gi_51882386 --- --- Aj814910 kn206 bos sp. cDNA clone c0005203o21 0.01 2.3 -1.3 -3.0 --- 
757 gi_51812990 --- --- Co883056 bovgen_11381 normal cattle brain cDNA clone 
rzpdp1056b034q 5' 
0.00 2.4 -1.2 -3.0 --- 
758 gi_119935071 XM_001256856 LOC790362 Similar to myst histone acetyltransferase (monocytic 
leukemia) 4 (LOC790362) 
0.01 2.2 -1.3 -3.0 --- 
759 gi_51883172 --- --- Aj815696 kn206 bos sp. cDNA clone c0005202l4 0.00 2.2 -1.3 -3.0 --- 
760 gi_119915680 XM_001253103 LOC786846 Similar to olfactory receptor 9, rat orthologue of mouse 
mor156-2a, transcript variant 1 (LOC786846) 
0.01 2.2 -1.3 -3.0 --- 
761 gi_119907926 XM_869607 OR8H3 Olfactory receptor, family 8, subfamily h, member 3 0.00 2.6 -1.1 -3.0 --- 
762 gi_119922650 XM_601354 Olfr1239 Olfactory receptor 1239 0.01 2.3 -1.3 -3.0 --- 
763 gi_51807744 --- --- Co877828 bovgen_06153 normal cattle brain cDNA clone 
rzpdp1056a1220q 5' 
0.00 2.5 -1.2 -3.0 --- 
764 gi_119895350 XM_001255203 LOC788011 Similar to olfactory receptor olr1566 (LOC788011) 0.00 2.4 -1.2 -3.0 --- 
765 gi_119923779 XM_001250462 LOC783543 Similar to l antigen family, member 3, transcript variant 2 0.00 2.4 -1.2 -3.0 --- 
766 gi_119879601 XM_612607 KALRN Kalirin, rhogef kinase 0.01 2.2 -1.4 -3.0 --- 
767 gi_51827036 --- --- Co896716 bovgen_25041 normal cattle brain cDNA clone 
rzpdp1056c101q 5' 
0.01 2.2 -1.3 -2.9 --- 
768 gi_119922048 XM_001254493 NCKAP5 Nck-associated protein 5 0.01 2.1 -1.4 -2.9 --- 
769 gi_31341372 NM_176674 COX7A1 Cytochrome c oxidase subunit viia polypeptide 1 (muscle) 0.01 2.0 -1.4 -2.9 --- 
770 gi_75864894 --- --- Dt884531 1437726 marc 7bov cDNA 5' 0.00 2.8 -1.0 -2.9 --- 
771 gi_117935050 NM_178109 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 0.00 2.9 1.0 -2.9 --- 
772 gi_119921111 XM_001253992 LOC786246 Similar to t-cell receptor alpha chain (LOC786246) 0.00 2.9 1.0 -2.9 --- 
773* gi_119921043 XM_001252468 OR52A5 Olfactory receptor, family 52, subfamily a, member 5 0.00 2.8 -1.0 -2.9 --- 
774 gi_51881271   Aj813795 kn206 bos sp. CDNA clone c0005205j12 0.00 2.7 -1.1 -2.9 --- 
775 gi_139949155 NM_001083740 GPT Glutamic-pyruvate transaminase (alanine aminotransferase) 0.00 2.4 -1.2 -2.9 --- 
776 gi_119929446 XM_001256647 LOC790072 Hypothetical protein (LOC790072) 0.00 3.4 1.2 -2.9 --- 
777 gi_148226500 NM_001098047 GPR21 G protein-coupled receptor 21 0.01 2.4 -1.2 -2.9 --- 
778 gi_119925030 XM_001251274 LOC786338 Hypothetical protein (LOC786338) 0.00 2.9 1.0 -2.9 --- 
779 gi_77736166 NM_001034610 RIPK2 Receptor-interacting serine-threonine kinase 2 0.00 2.6 -1.1 -2.9 --- 
780 gi_51818876 --- --- Co888591 bovgen_16916 normal cattle brain cDNA clone 
rzpdp1056l0443q 5' 
0.01 2.2 -1.3 -2.9 --- 
781 gi_51818604 --- --- Co888319 bovgen_16644 normal cattle brain cDNA clone 
rzpdp1056e045q 5' 
0.01 2.2 -1.3 -2.9 --- 
782 gi_119924682 XM_581926 LOC538674 Similar to protocadherin (LOC538674) 0.01 2.2 -1.3 -2.9 --- 
783 gi_68427045 --- --- Am027970 am027970 kn-252-lymph, bos indicus bos indicus 
cDNA clone c0007393m15 3' 
0.00 3.2 1.1 -2.9 --- 
784 gi_119892509 XM_001254905 Olfr794 Olfactory receptor 794 0.01 2.2 -1.3 -2.9 --- 
785 gi_119895309 XM_601243 OR2C3 Olfactory receptor, family 2, subfamily c, member 3 0.00 2.7 -1.1 -2.9 --- 
786* gi_119920034 XM_001251323 LOC784096 Riken cDNA 1700014n06 gene 0.00 2.5 -1.2 -2.9 --- 
787* gi_119928444 XM_001256165 OR52A1 Olfactory receptor, family 52, subfamily a, member 1 0.00 2.8 -1.0 -2.9 --- 
788 gi_51819323 --- --- Co889038 bovgen_17363 normal cattle brain cDNA clone 
rzpdp1056g0341q 5' 
0.00 2.1 -1.4 -2.9 --- 
789 gi_119902109 XM_001251139 LOC782490 Hypothetical protein (LOC782490) 0.01 2.3 -1.2 -2.9 --- 
790* gi_119892559 XM_001255392 OR6C6 Olfactory receptor, family 6, subfamily c, member 6 0.00 2.7 -1.1 -2.9 --- 
791 gi_119924200 XM_614803 GLRA3 Glycine receptor, alpha 3 0.00 2.7 -1.0 -2.9 --- 
792 gi_119921093 XM_869126 LOC616970 Similar to t-cell receptor delta (LOC616970) 0.00 2.6 -1.1 -2.9 --- 
793* gi_119931641 XM_613045 STK17A Serine/threonine kinase 17a 0.00 2.5 -1.1 -2.9 --- 
794 gi_119934383 XM_001254673 LOC787205 Hypothetical protein (LOC787205) 0.01 2.1 -1.4 -2.9 --- 
795 gi_76662918 XM_868812 OR2L2 Olfactory receptor, family 2, subfamily l, member 2 0.01 2.3 -1.3 -2.9 --- 
796 gi_50872142 NM_001002890 KLRD1 Killer cell lectin-like receptor subfamily d, member 1 0.01 2.2 -1.3 -2.9 --- 
797 gi_51813436 --- --- Co883502 bovgen_11827 normal cattle brain cDNA clone 
rzpdp1056i048q 5' 
0.02 2.1 -1.3 -2.9 --- 
798 gi_119925323 XM_001255584 Olfr905 Olfactory receptor 905 0.00 2.5 -1.2 -2.9 --- 
799 gi_119927767 XM_868179 OR5M3 Olfactory receptor, family 5, subfamily m, member 3 0.00 2.6 -1.1 -2.9 --- 
800 gi_51813625 --- --- Co883682 bovgen_12007 normal cattle brain cDNA clone 
rzpdp1056b1620q 5' 
0.01 2.3 -1.2 -2.9 --- 
801 gi_139947537 NM_001083736 JAM2 Junctional adhesion molecule 2 0.00 4.4 1.5 -2.9 --- 
802 gi_116004236 NM_001077009 P2RY14 Purinergic receptor p2y, g-protein coupled, 14 0.00 2.7 -1.1 -2.9 --- 
803 gi_119915421 XM_584616 LOC507917 MHC class i heavy chain (LOC507917) 0.00 2.6 -1.1 -2.9 --- 
804* gi_76677494 XM_587133 OR6C4 Olfactory receptor, family 6, subfamily c, member 4 0.01 2.2 -1.3 -2.9 --- 
805 gi_51820271 --- --- Co889984 bovgen_18309 normal cattle brain cDNA clone 
rzpdp1056c0838q 5' 
0.00 2.9 1.0 -2.9 --- 
806 gi_119916333 XM_001250672 LOC782780 Hypothetical protein (LOC782780) 0.00 2.6 -1.1 -2.9 --- 
807 gi_119894667 XM_001256348 LOC789667 Similar to olf4 (LOC789667) 0.00 3.1 1.1 -2.9 --- 
808 gi_157427975 NM_001105426 RNASE13 Ribonuclease, rnase a family, 13 (non-active) 0.00 3.5 1.2 -2.9 --- 
809* gi_76635921 XM_596754 Olfr561 Olfactory receptor 561 0.01 2.3 -1.3 -2.9 --- 
810 gi_119906418 XM_001250149 LOC782051 Similar to alpha 2 actin (LOC782051) 0.00 2.7 -1.0 -2.9 --- 
811 gi_119892569 XM_001255472 LOC788396 Similar to olfactory receptor mor265-1 (LOC788396) 0.00 3.1 1.1 -2.8 --- 
812 gi_51809379 --- --- Co879455 bovgen_07782 normal cattle brain cDNA clone 
rzpdp1056l0127q 5' 
0.03 2.0 -1.4 -2.8 --- 
813 gi_119918790 XM_001255453 LOC788371 Hypothetical protein (LOC788371) 0.02 2.0 -1.4 -2.8 --- 
814 gi_51885865 --- --- Aj818389 kn206 bos sp. CDNA clone c0006012c16 0.01 2.2 -1.3 -2.8 --- 
815 gi_119921256 XM_001249957 OR5M10 Olfactory receptor, family 5, subfamily m, member 10 0.02 2.0 -1.4 -2.8 --- 
816 gi_119922015 XM_001253993 OR8J1 Olfactory receptor, family 8, subfamily j, member 1 0.01 2.5 -1.2 -2.8 --- 
817 gi_31341996 NM_174439 TMPRSS15 Transmembrane protease, serine 15 0.01 2.3 -1.2 -2.8 --- 
818 gi_51821972 --- --- Co891674 bovgen_19999 normal cattle brain cDNA clone 
rzpdp1056a0534q 5' 
0.00 2.5 -1.1 -2.8 --- 
819 gi_118151099 NM_001078004 PELI1 Pellino homolog 1 (drosophila) 0.00 3.8 1.3 -2.8 --- 
820 gi_119902376 XM_001253943 VPS39 Similar to vps39/vam6-like protein (LOC520990) 0.01 2.2 -1.3 -2.8 --- 
821 gi_119920980 XM_001250243 OR51F2 Olfactory receptor, family 51, subfamily f, member 2 0.00 2.4 -1.2 -2.8 --- 
822 gi_119917386 XM_001253094 LOC784919 Similar to olfactory receptor olr507 (LOC784919) 0.01 2.4 -1.2 -2.8 --- 
823 gi_119921914 XM_001250926 LOC782296 Similar to olfactory receptor mor114-3 (LOC782296) 0.00 2.7 -1.0 -2.8 --- 
824 gi_51817560 --- --- Co887275 bovgen_15600 normal cattle brain cDNA clone 
rzpdp1056k1923q 5' 
0.00 2.5 -1.1 -2.8 --- 
825 gi_119909160 XR_028423 LOC615031 Hypothetical (LOC615031) 0.00 2.6 -1.1 -2.8 --- 
826 gi_149642782 NM_001098895 SLC25A30 Solute carrier family 25, member 30 0.00 2.2 -1.3 -2.8 --- 
827* gi_119902302 XM_001254703 Olfr1276 Olfactory receptor 1276 0.01 2.2 -1.3 -2.8 --- 
828* gi_119895412 XM_600845 Olfr30 Olfactory receptor 30 0.00 2.5 -1.1 -2.8 --- 
829 gi_119903309 XM_605410 SRD5A2 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 
alpha-steroid delta 4-dehydrogenase alpha 2) 
0.01 2.1 -1.3 -2.8 --- 
830 gi_51886476 --- --- Aj819000 kn206 bos sp. cDNA clone c0006014a01 0.00 2.3 -1.2 -2.8 --- 
831 gi_119922890 XM_001255730 Olfr1316 Olfactory receptor 1316 0.00 2.5 -1.1 -2.8 --- 
832 gi_76684604 XM_870419 Olr468 Olfactory receptor 468 0.01 2.3 -1.2 -2.8 --- 
833 gi_119907381 XM_593669 OR52H1 Olfactory receptor, family 52, subfamily h, member 1 0.01 2.3 -1.2 -2.8 --- 
834 gi_119911558 XM_588697 TNFAIP1 Tumor necrosis factor, alpha-induced protein 1 (endothelial) 0.00 2.7 -1.0 -2.8 --- 
835 gi_119892515 XM_584195 LOC507560 Similar to olfactory receptor olr920 (LOC507560) 0.01 2.4 -1.2 -2.8 --- 
836 gi_119910989 XR_028595 LOC788051 Similar to zinc finger protein 616 (LOC788051) 0.03 2.0 -1.4 -2.8 --- 
837 gi_119908142 XM_001249329 LOC780987 Hypothetical protein (LOC780987) 0.00 2.2 -1.3 -2.8 --- 
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838 gi_119926167 XM_001255280 LOC788129 Similar to seven transmembrane helix receptor (LOC788129) 0.01 2.3 -1.2 -2.8 --- 
839 gi_27805856 NM_174285 CREB1 Camp responsive element binding protein 1 0.00 2.1 -1.3 -2.8 --- 
840 gi_119920625 XM_001250573 LOC782015 Similar to melanoma antigen family b, 4 (LOC782015) 0.00 2.4 -1.2 -2.8 --- 
841 gi_119887404 XM_589101 FSIP2 Fibrous sheath interacting protein 2 0.00 2.4 -1.2 -2.8 --- 
842 gi_119931421 XM_001254549 LOC787028 Similar to olfactory receptor mor111-1 (LOC787028) 0.00 2.8 1.0 -2.8 --- 
843 gi_119893030 XM_584745 LOC508026 Similar to pregnancy-zone protein (LOC508026) 0.03 2.0 -1.4 -2.8 --- 
844 gi_119894646 XM_590569 LOC512956 Similar to olfactory receptor (LOC512956) 0.00 2.6 -1.1 -2.8 --- 
845 gi_119921997 XM_001253442 LOC785406 Similar to olfactory receptor mor185-5 (LOC785406) 0.00 2.8 1.0 -2.8 --- 
846* gi_119892531 XM_001255188 Olr1012 Olfactory receptor 1012 0.01 2.3 -1.2 -2.8 --- 
847 gi_119903385 XM_599529 Ttc39d Tetratricopeptide repeat domain 39d 0.00 2.5 -1.1 -2.8 --- 
848 gi_119922520 XM_001252579 LOC784191 Similar to seven transmembrane helix receptor (LOC784191) 0.00 2.5 -1.1 -2.8 --- 
849 gi_149643056 NM_001099198 MGC165685 Hypothetical protein loc786491 (MGC165685) 0.01 2.2 -1.3 -2.8 --- 
850 gi_119892549 XM_001255334 LOC788199 Similar to olfactory receptor mor113-4 (LOC788199) 0.01 2.2 -1.2 -2.8 --- 
851* gi_119922221 XM_001254166 Olfr1199 Olfactory receptor 1199 0.00 2.7 1.0 -2.8 --- 
852 gi_119892152 XM_001250287 LOC781800 Similar to ubie-yghl1 fusion protein (LOC781800) 0.02 2.1 -1.3 -2.8 --- 
853 gi_119912466 XM_001255693 LOC789252 Similar to copper containing amine oxidase 3 (LOC789252) 0.01 2.2 -1.3 -2.8 --- 
854 gi_51882753 --- --- Aj815277 aj815277 kn206 bos sp. CDNA clone c0005203f3 0.01 2.2 -1.2 -2.8 --- 
855 gi_119909126 XM_001252899 LOC784650 Similar to guanylate cyclase 70 kda subunit (LOC784650) 0.01 2.3 -1.2 -2.8 --- 
856 gi_119925348 XM_001250814 LOC785762 Similar to prostaglandin f synthase-like1 protein (LOC785762) 0.00 2.7 1.0 -2.8 --- 
857 gi_119922591 XM_001254813 LOC787405 Similar to t cell receptor delta chain (LOC787405) 0.00 3.4 1.2 -2.8 --- 
858 gi_51809994 --- --- Co880069 bovgen_08394 normal cattle brain cDNA clone 
rzpdp1056f1825q 5' 
0.00 2.4 -1.2 -2.8 --- 
859 gi_119922293 XM_610277 Gm4911 Predicted pseudogene 4911 0.00 2.6 -1.1 -2.8 --- 
860 gi_119902304 XM_001254746 Olfr1277 Olfactory receptor 1277 0.00 2.5 -1.1 -2.8 --- 
861 gi_119910745 XM_870804 GNG8 Guanine nucleotide binding protein (G protein), gamma 8 0.00 2.4 -1.1 -2.8 --- 
862 gi_116004418 NM_001077100 MGC137454 Hypothetical protein (MGC137454) 0.00 2.5 -1.1 -2.7 --- 
863 gi_119921172 XM_001255156 LOC787947 Similar to Cfolf4 (LOC787947) 0.01 2.3 -1.2 -2.7 --- 
864 gi_119924969 XM_590908 OR52N5 Olfactory receptor, family 52, subfamily n, member 5 0.00 2.5 -1.1 -2.7 --- 
865 gi_119924106 XM_001254827 LOC787427 Similar to serpinb3 (LOC787427) 0.01 2.4 -1.2 -2.7 --- 
866 gi_119903698 XM_001253179 LOC785033 Similar to olfactory receptor mor245-12 (LOC785033) 0.01 2.3 -1.2 -2.7 --- 
867 gi_88319945 NM_176638 CASP4 Caspase 4, apoptosis-related cysteine peptidase 0.00 3.2 1.2 -2.7 --- 
868 gi_119894615 XM_868476 OR10H3 Olfactory receptor, family 10, subfamily h, member 3 0.00 2.5 -1.1 -2.7 --- 
869 gi_163915356 NM_001113173 CXCL11 Chemokine (c-x-c motif) ligand 11 (CXCL11) 0.01 2.4 -1.1 -2.7 --- 
870 gi_119645494 --- --- Eh174267 lb01651.cr_a21 gc_bgc-16 cDNA clone 
image:8384735 5' 
0.00 4.9 1.8 -2.7 --- 
871 gi_119914158 XM_001255194 LOC787999 Hypothetical protein (LOC787999) 0.00 2.6 -1.0 -2.7 --- 
872 gi_119907422 XM_592902 LOC514976 Similar to olfactory receptor hpfh1or (LOC514976) 0.02 2.1 -1.3 -2.7 --- 
873 gi_119935565 XM_001257018 LOC790589 Similar to olfactory receptor olr726 (LOC790589) 0.00 2.5 -1.1 -2.7 --- 
874 gi_119893818 XM_612659 LOC533295 Similar to y53f4b.4a (LOC533295) 0.01 2.4 -1.1 -2.7 --- 
875 gi_115497081 NM_001075656 JUNB Jun b proto-oncogene 0.00 3.9 1.4 -2.7 --- 
876 gi_116003880 NM_001076831 COL3A1 Collagen, type iii, alpha 1 0.00 2.7 1.0 -2.7 --- 
877 gi_119929284 XM_001250912 LOC785874 Hypothetical protein (LOC785874) 0.01 2.4 -1.2 -2.7 --- 
878 gi_119927416 XM_001256048 LOC789240 Similar to testis derived transcript (LOC789240) 0.01 2.2 -1.2 -2.7 --- 
879 gi_119902188 XM_586246 OR4M1 Olfactory receptor, family 4, subfamily m, member 1 0.02 2.1 -1.3 -2.7 --- 
880 gi_51822925 --- --- Co892625 bovgen_20950 normal cattle brain cDNA clone 
rzpdp1056k1533q 5' 
0.00 2.2 -1.2 -2.7 --- 
881 gi_119902105 XM_001250965 LOC782316 Similar to t cell receptor alpha chain (LOC782316) 0.00 3.3 1.2 -2.7 --- 
882 gi_29394713 --- --- Cb531727 754593 marc 6bov cDNA 3' 0.00 2.4 -1.1 -2.7 --- 
883 gi_76686152 XM_593724 OR4C46 Olfactory receptor, family 4, subfamily c, member 46 0.00 2.3 -1.2 -2.7 --- 
884* gi_119920037 XR_027774 LOC784212 Riken cDNA 1700014n06 gene 0.02 2.0 -1.3 -2.7 --- 
885 gi_76677166 XM_598492 OR6Y1 Olfactory receptor, family 6, subfamily y, member 1 0.00 2.4 -1.1 -2.7 --- 
886* gi_119902168 XM_001252434 OR11G2 Olfactory receptor, family 11, subfamily g, member 2 0.00 2.5 -1.1 -2.7 --- 
887 gi_31342172 NM_174376 KLRA1 Killer cell lectin-like receptor subfamily a pseudogene 1 0.00 3.2 1.2 -2.7 --- 
888 gi_119901504 XM_600290 Taar4 Trace amine-associated receptor 4 0.00 2.5 -1.1 -2.7 --- 
889 gi_119887587 XM_001252615 SCN9A Sodium channel, voltage-gated, type ix, alpha subunit 0.01 2.2 -1.2 -2.7 --- 
890 gi_41386789 NM_174356 IL12B Interleukin 12b (natural killer cell stimulatory factor 2, 
cytotoxic lymphocyte maturation factor 2, p40) 
0.00 2.3 -1.2 -2.7 --- 
891 gi_119916421 XM_001249415 LOC781345 Hypothetical protein (LOC781345) 0.01 2.1 -1.3 -2.7 --- 
892 gi_119884883 XM_606901 PRKCI Protein kinase c, iota 0.00 2.6 -1.0 -2.7 --- 
893 gi_119928081 XM_001251993 LOC783368 Similar to Attractin (LOC783368) 0.01 2.2 -1.2 -2.7 --- 
894 gi_7056080_ --- --- Aw485974 69107 marc 4bov cDNA 5' 0.01 2.1 -1.3 -2.7 --- 
895 gi_115497291 NM_001075634 TCIRG1 T-cell, immune regulator 1, atpase, h+ transporting, lysosomal 
v0 subunit a3 
0.00 2.1 -1.3 -2.7 --- 
896 gi_31341616 NM_174579 POU1F1 Pou class 1 homeobox 1 0.01 2.2 -1.2 -2.7 --- 
897 gi_119925795 XM_586018 OR9G4 Olfactory receptor, family 9, subfamily g, member 4 0.01 2.4 -1.1 -2.7 --- 
898 gi_119928284 XM_580340 OR13C9 Olfactory receptor, family 13, subfamily c, member 9 0.00 2.6 1.0 -2.7 --- 
899 gi_119915640 XM_592285 Olr1768 Olfactory receptor 1768 0.01 2.4 -1.1 -2.7 --- 
900 gi_119926136 XM_599438 PM20D2 Peptidase m20 domain containing 2 0.00 4.2 1.6 -2.7 --- 
901 gi_134085852 NM_001083407 SPATA20 Spermatogenesis associated 20 0.00 2.4 -1.1 -2.7 --- 
902 gi_119901508 XM_001253652 TAAR2 Trace amine associated receptor 2 0.00 2.4 -1.1 -2.7 --- 
903 gi_61808422 XM_586491 OR4C6 Olfactory receptor, family 4, subfamily c, member 6 0.01 2.2 -1.2 -2.7 --- 
904 gi_51883358 --- --- Aj815882 kn206 bos sp. CDNA clone c0005202h22 0.02 2.1 -1.3 -2.7 --- 
905 gi_76680252 XM_870182 LOC521256 Similar to olfactory receptor olfr566 (LOC521256) 0.01 2.2 -1.2 -2.7 --- 
906 gi_119906377 XR_028594 LOC515601 Similar to hyaluronan synthase type 2 (LOC515601) 0.01 2.3 -1.2 -2.7 --- 
907 gi_51809708 --- --- Co879785 bovgen_08110 normal cattle brain cDNA clone 
rzpdp1056k1413q 5' 
0.00 2.5 -1.1 -2.7 --- 
908 gi_119908080 XM_001256129 LOC789351 Hypothetical protein (LOC789351) 0.00 2.4 -1.1 -2.7 --- 
909 gi_77404247 NM_001034041 SNCA Synuclein, alpha (non a4 component of amyloid precursor) 0.00 2.5 -1.1 -2.7 --- 
910 gi_119903002 XM_867514 TTC8 Tetratricopeptide repeat domain 8 0.00 2.3 -1.2 -2.7 --- 
911 gi_119909243 XM_614458 CLIP1 Cap-gly domain containing linker protein 1 0.00 2.2 -1.2 -2.6 --- 
912 gi_119924434 XM_001251222 LOC782594 Similar to trace amine receptor 4 (LOC782594) 0.01 2.2 -1.2 -2.6 --- 
913 gi_119926744 XM_001251442 LOC787053 Hypothetical protein (LOC787053) 0.00 3.7 1.4 -2.6 --- 
914 gi_119907881 XM_001251517 LOC782866 Similar to olfactory receptor olfr987 (LOC782866) 0.01 2.3 -1.2 -2.6 --- 
915 gi_119913890 XM_001249357 LOC781017 Hypothetical protein (LOC781017) 0.01 2.2 -1.2 -2.6 --- 
916 gi_119924826 XM_001253694 LOC785794 Similar to g antigen, family d, 1 (LOC785794) 0.03 2.0 -1.3 -2.6 --- 
917 gi_149643100 NM_001098958 CDKN1A Cyclin-dependent kinase inhibitor 1a (p21, cip1) 0.00 2.2 -1.2 -2.6 --- 
918 gi_51824812 --- --- Co894504 bovgen_22829 normal cattle brain cDNA clone 
rzpdp1056i0644q 5' 
0.01 2.2 -1.2 -2.6 --- 
919 gi_119924383 XM_001254912 Olfr1124 Olfactory receptor 1124 0.00 2.5 -1.1 -2.6 --- 
920 gi_51888409 --- --- Aj820933 kn206 bos sp. CDNA clone c0006019i15 0.01 2.3 -1.2 -2.6 --- 
921 gi_51880814 --- --- Aj813338 kn206 bos sp. CDNA clone c0005206l14 0.01 2.2 -1.2 -2.6 --- 
922 gi_119920952 XM_870254 LOC617921 Similar to olfactory receptor mor14-2 (LOC617921) 0.01 2.2 -1.2 -2.6 --- 
923 gi_119907885 XM_001251593 LOC782933 Similar to olfactory receptor olfr987 (LOC782933) 0.03 2.0 -1.3 -2.6 --- 
924 gi_31342685 NM_174169 RGS7 Regulator of g-protein signaling 7 0.01 2.3 -1.2 -2.6 --- 
925 gi_31342076 NM_174411 PAG1B Pregnancy-associated glycoprotein 1 (pag1b) 0.02 2.1 -1.3 -2.6 --- 
926 gi_119917416 XM_001250496 LOC782888 Hypothetical protein (LOC782888) 0.00 2.6 1.0 -2.6 --- 
927 gi_119902589 XR_027721 DMXL2 Dmx-like 2 0.00 2.4 -1.1 -2.6 --- 
928 gi_78050076 NM_001035055 CLDN11 Claudin 11 0.01 2.4 -1.1 -2.6 --- 
929 gi_158519826 NM_001110096 BEX4 Brain expressed, x-linked 4 0.02 2.2 -1.2 -2.6 --- 
930 gi_119931487 XM_001255207 LOC788017 Similar to Ser/Thr protein kinase par-1balpha (LOC788017) 0.01 2.1 -1.2 -2.6 --- 
931 gi_119921691 XM_001249303 LOC781004 Hypothetical protein (LOC781004) 0.00 2.5 1.0 -2.6 --- 
Appendices  311 
932* gi_119921055 XM_001252743 Olr94 Olfactory receptor 94 0.01 2.3 -1.2 -2.6 --- 
933 gi_75832085 NM_177432 IRF1 Interferon regulatory factor 1 (irf1) 0.00 4.4 1.7 -2.6 --- 
934 gi_119889562 XM_001250696 LOC782107 Similar to kiaa0466 protein (LOC782107) 0.00 2.1 -1.2 -2.6 --- 
935 gi_119911429 XR_027573 LOC783256 Similar to brca1-binding helicase-like protein bach1 0.00 2.5 -1.1 -2.6 --- 
936 gi_119890257 XR_027905 LOC784417 Similar to cytochrome p450, family 4,subfamily a,polypeptide 11 0.02 2.0 -1.3 -2.6 --- 
937 gi_119915977 XM_588519 NFATC1 Nuclear factor of activated t-cells, cytoplasmic, calcineurin-
dependent 1 
0.00 2.5 1.0 -2.6 --- 
938 gi_119922217 XM_593873 Olfr1257 Olfactory receptor 1257 0.00 2.5 1.0 -2.6 --- 
939* gi_119925767 XM_868453 LOC616431 Riken cDNA 1700014n06 gene 0.00 2.4 -1.1 -2.6 --- 
940 gi_119923068 XM_001253958 LOC786202 Similar to olfactory receptor (LOC786202) 0.02 2.2 -1.2 -2.6 --- 
941 gi_115495730 NM_001076164 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3c 0.03 2.0 -1.3 -2.6 --- 
942 gi_164452934 NM_001080297 SWAP70 Swap-70 protein (swap70) 0.00 2.1 -1.2 -2.6 --- 
943 gi_51885968 --- --- Aj818492 kn206 bos sp. cDNA clone c0006012h09 0.01 2.3 -1.1 -2.6 --- 
944 gi_51885590 --- --- Aj818114 kn206 bos sp. cDNA clone c0006011d09 0.00 3.4 1.3 -2.6 --- 
945* gi_119929994 XM_001256551 OR13F1 Olfactory receptor, family 13, subfamily f, member 1 0.00 2.6 1.0 -2.6 --- 
946 gi_119905975 XM_602010 NCOA3 Nuclear receptor coactivator 3 0.01 2.2 -1.2 -2.6 --- 
947 gi_116004376 NM_001077079 C1orf185 Chromosome 1 open reading frame 185 0.02 2.1 -1.2 -2.6 --- 
948 gi_27806988 NM_174545 GABRG2 Gamma-aminobutyric acid (gaba) a receptor, gamma 2 0.00 2.4 -1.1 -2.6 --- 
949 gi_119910565 XM_001256367 LOC789693 Hypothetical protein (LOC789693) 0.00 2.2 -1.2 -2.6 --- 
950 gi_119887145 XR_028592 SIK1 Salt-inducible kinase 1 0.00 2.1 -1.2 -2.6 --- 
951 gi_157428069 NM_001105473 STOM Stomatin 0.00 4.0 1.6 -2.6 --- 
952 gi_116004410 NM_001077096 TNFRSF19 Tumor necrosis factor receptor superfamily, member 19 0.00 2.2 -1.1 -2.6 --- 
953 gi_119902141 XM_001252038 RNASE11 Ribonuclease, rnase a family, 11 (non-active) 0.02 2.1 -1.2 -2.5 --- 
954 gi_119905174 XR_028303 LOC505099 Hypothetical (LOC505099) 0.01 2.2 -1.2 -2.5 --- 
955 gi_68425682 --- --- Am026859 kn-252-lymph, cDNA clone c0007393h11 3' 0.01 2.3 -1.1 -2.5 --- 
956 gi_119922207 XM_001253994 LOC786248 Similar to c4bp alpha chain (LOC786248) 0.03 2.0 -1.3 -2.5 --- 
957 gi_28603729 NM_176626 PAG18 Pregnancy-associated glycoprotein 18 (PAG18) 0.00 2.4 -1.0 -2.5 --- 
958 gi_119912262 XM_001254120 KRTAP4-6 Keratin associated protein 4-6 0.02 2.1 -1.2 -2.5 --- 
959 gi_51814500 --- --- Co884481 bovgen_12806 normal cattle brain cDNA clone 
rzpdp1056g0217q 5' 
0.01 2.2 -1.1 -2.5 --- 
960 gi_115497393 NM_001076097 SULT1C4 Sulfotransferase family, cytosolic, 1c, member 4 (SULT1C4) 0.03 2.0 -1.3 -2.5 --- 
961 gi_119927333 XM_001255661 LOC788676 Similar to t-cell receptor alpha chain (LOC788676) 0.01 2.2 -1.1 -2.5 --- 
962 gi_94966908 NM_001040554 HLA-A Major histocompatibility complex, class i, a 0.00 4.0 1.6 -2.5 --- 
963* gi_119929795 XM_581848 OR8A1 Olfactory receptor, family 8, subfamily a, member 1 0.01 2.2 -1.2 -2.5 --- 
964 gi_119928966 XM_001253584 LOC785624 Similar to olf4 (LOC785624) 0.01 2.2 -1.1 -2.5 --- 
965 gi_119922291 XM_001251181 MAGEB17 Melanoma antigen family b, 17 0.02 2.0 -1.2 -2.5 --- 
966 gi_51887303 --- --- Aj819827 aj819827 kn206 bos sp. CDNA clone c0006016j19 0.01 2.1 -1.2 -2.5 --- 
967* gi_119907553 XM_870343 Olfr561 Olfactory receptor 561 0.01 2.2 -1.1 -2.5 --- 
968 gi_119901893 XM_001251257 DENND4A Denn/madd domain containing 4a 0.00 2.1 -1.2 -2.5 --- 
969 gi_119922801 XM_589238 Olfr594 Olfactory receptor 594 0.01 2.3 -1.1 -2.5 --- 
970* gi_119924375 XM_001254801 OR5F1 Olfactory receptor, family 5, subfamily f, member 1 0.01 2.3 -1.1 -2.5 --- 
971 gi_76651124 XM_870382 Olfr124 Olfactory receptor 124 0.01 2.2 -1.2 -2.5 --- 
972 gi_119927729 XM_001254998 Olfr143 Olfactory receptor 143 0.01 2.2 -1.1 -2.5 --- 
973 gi_134085628 NM_001083391 ELMO2 Engulfment and cell motility 2 0.00 2.3 -1.1 -2.5 --- 
974 gi_115496269 NM_001075993 ODF2L Outer dense fiber of sperm tails 2-like 0.02 2.0 -1.2 -2.5 --- 
975 gi_119903020 XM_001251107 B2M Beta-2-microglobulin 0.00 2.2 -1.2 -2.5 --- 
976 gi_119920001 XM_001250962 LOC783475 Hypothetical protein (LOC783475) 0.01 2.3 -1.1 -2.5 --- 
977 gi_119888344 XM_001252286 LOC784637 Similar to bicaudal d homolog 1 (drosophila) (LOC784637) 0.02 2.0 -1.2 -2.5 --- 
978 gi_119930598 XM_001255904 LOC789026 Hypothetical protein (LOC789026) 0.01 2.4 1.0 -2.5 --- 
979* gi_119891769 XM_001249423 INSIG1 Insulin induced gene 1 0.00 2.4 1.0 -2.5 --- 
980 gi_119937584 XM_871051 LOC618728 Similar to neural cell adhesion protein (LOC618728) 0.02 2.1 -1.2 -2.5 --- 
981 gi_119915423 XR_028666 LOC788634 Similar to non-classical mhc class i antigen (LOC788634) 0.01 2.1 -1.2 -2.5 --- 
982 gi_119889249 XM_581374 ADAR Adenosine deaminase, RNA-specific 0.00 4.0 1.6 -2.5 --- 
983 gi_119921920 XM_001251100 LOC782474 Similar to olfactory receptor mor112-1 (LOC782474) 0.02 2.2 -1.1 -2.5 --- 
984* gi_119892609 XM_867045 OR6C4 Olfactory receptor, family 6, subfamily c, member 4 0.01 2.2 -1.1 -2.5 --- 
985 gi_76616267 XM_870706 TRIM69 Tripartite motif containing 69 0.01 2.2 -1.1 -2.5 --- 
986* gi_119889739 XM_001253287 COL11A1 Collagen, type xi, alpha 1 0.00 2.4 1.0 -2.4 --- 
987 gi_118151015 NM_001077961 NDST3 N-deacetylase/n-sulfotransferase (heparan glucosaminyl) 3 0.00 2.3 -1.1 -2.4 --- 
988 gi_119915551 XM_871334 Olfr1535 Olfactory receptor 1535 0.01 2.2 -1.1 -2.4 --- 
989 gi_154152200 NM_001100309 TDRD7 Tudor domain containing 7 0.00 4.4 1.8 -2.4 --- 
990 gi_119921007 XM_001251527 LOC782875 Similar to olfactory receptor olr88 (LOC782875) 0.01 2.2 -1.1 -2.4 --- 
991 gi_119933559 XM_001256916 LOC790451 Hypothetical protein (LOC790451) 0.00 2.4 1.0 -2.4 --- 
992 gi_119904810 XM_001253713 LOC785828 Similar to replication protein a2, 32kda (LOC785828) 0.03 2.1 -1.2 -2.4 --- 
993* gi_119894398 XM_001253396 OR5W2 Olfactory receptor, family 5, subfamily w, member 2 0.01 2.4 1.0 -2.4 --- 
994 gi_149643024 NM_001099037 ABCD2 ATP-binding cassette, sub-family d (ald), member 2 (ABCD2) 0.02 2.1 -1.2 -2.4 --- 
995 gi_119895358 XM_582424 OR2L13 Olfactory receptor, family 2, subfamily l, member 13 0.01 2.2 -1.1 -2.4 --- 
996 gi_119912322 XM_618105 KRT39 Keratin 39 0.01 2.3 -1.0 -2.4 --- 
997* gi_119927679 XM_001254322 OR7D4 Olfactory receptor, family 7, subfamily d, member 4 0.01 2.3 -1.1 -2.4 --- 
998 gi_119879617 XM_001254174 LOC786513 Similar to leishmanolysin-like (metallopeptidase m8 family) 0.02 2.0 -1.2 -2.4 --- 
999 gi_119922011 XM_001253957 OR8K1 Olfactory receptor, family 8, subfamily k, member 1 0.02 2.1 -1.2 -2.4 --- 
1000 gi_76253719 NM_001002892 ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 0.00 2.4 1.0 -2.4 --- 
1001 gi_149642586 NM_001098900 SLC44A3 Solute carrier family 44, member 3 0.01 2.2 -1.1 -2.4 --- 
1002 gi_157074077 NM_001103280 TRDN Triadin 0.01 2.2 -1.1 -2.4 --- 
1003 gi_119912444 XM_001255546 LOC789125 Similar to alpha-n-acetylglucosaminidase (LOC789125) 0.00 2.2 -1.1 -2.4 --- 
1004 gi_119921413 XM_583529 LOC506992 Similar to olfactory receptor mor160-5 (LOC506992) 0.01 2.3 -1.0 -2.4 --- 
1005 gi_119908975 XM_594035 SETD7 Set domain containing (lysine methyltransferase) 7 0.00 2.1 -1.1 -2.4 --- 
1006 gi_51883259 --- --- Aj815783 kn206 bos sp. CDNA clone c0005202j4 0.02 2.1 -1.1 -2.4 --- 
1007 gi_56119115 NM_001007819 DDX4 Dead (asp-glu-ala-asp) box polypeptide 4 0.00 2.4 1.0 -2.4 --- 
1008 gi_115495458 NM_001075504 NLGN3 Neuroligin 3 0.01 2.1 -1.1 -2.4 --- 
1009 gi_45469018 --- --- Ck954638 4094593 barc 10bov cDNA clone 10bov33_n24 3' 0.00 2.4 1.0 -2.4 --- 
1010 gi_155372024 NM_001101150 NOVA1 Neuro-oncological ventral antigen 1 (nova1) 0.01 2.1 -1.1 -2.4 --- 
1011 gi_119895374 XM_001255418 LOC788323 Similar to olfactory receptor 2t29 (LOC788323) 0.00 2.4 1.0 -2.4 --- 
1012 gi_119921664 XM_587190 LOC616123 Similar to t cell receptor delta (LOC616123) 0.02 2.0 -1.2 -2.4 --- 
1013 gi_119902186 XM_869270 LOC617084 Similar to seven transmembrane helix receptor (LOC617084) 0.01 2.3 1.0 -2.4 --- 
1014 gi_119893491 XM_614586 LOC541108 Similar to hist2h2aa1 protein (LOC541108) 0.01 2.0 -1.2 -2.4 --- 
1015 gi_119930158 XM_869637 Olfr284 Olfactory receptor 284 0.01 2.3 1.0 -2.4 --- 
1016 gi_51818470 --- HEY1 Hairy/enhancer-of-split related with yrpw motif 1 0.02 2.1 -1.1 -2.4 --- 
1017 gi_84000380 NM_001038200 PRP8 Prolactin-related protein viii (PRP8) 0.01 2.2 -1.1 -2.4 --- 
1018 gi_31341292 NM_176643 DDHD1 Ddhd domain containing 1 0.00 2.2 -1.1 -2.4 --- 
1019 gi_119921234 XM_597790 RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 0.02 2.0 -1.2 -2.4 --- 
1020 gi_119892869 XM_871851 CAPRIN2 Caprin family member 2 0.00 2.3 -1.0 -2.4 --- 
1021 gi_51880611 --- --- Aj813135 aj813135 kn206 bos sp. cDNA clone c0005206g15 0.01 2.0 -1.2 -2.3 --- 
1022 gi_115496829 NM_001075309 GPM6A Glycoprotein m6a 0.01 2.3 1.0 -2.3 --- 
1023 gi_119895074 XM_001255309 LOC789216 Similar to interferon regulatory factor 1 (LOC789216) 0.00 4.5 1.9 -2.3 --- 
1024 gi_51817930 --- --- Co887645 bovgen_15970 normal cattle brain cDNA clone 
rzpdp1056l1213q 5' 
0.03 2.1 -1.1 -2.3 --- 
1025 gi_149642938 NM_001098988 NEK6 Nima (never in mitosis gene a)-related kinase 6 0.00 3.5 1.5 -2.3 --- 
1026 gi_119893961 XM_598333 RASSF6 Ras association (ralgds/af-6) domain family member 6 0.02 2.1 -1.1 -2.3 --- 
1027 gi_31341715 NM_174543 GABRA4 Gamma-aminobutyric acid (gaba) a receptor, alpha 4 0.01 2.3 1.0 -2.3 --- 
1028 gi_119923620 XM_609508 LOC531024 Similar to olfactory receptor olfr1197 (LOC531024) 0.01 2.3 1.0 -2.3 --- 
1029 gi_154385465 --- --- Ev628744 lb02244.cr_a21 gc_bgc-22 cDNA clone 0.01 2.1 -1.1 -2.3 --- 
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1030 gi_51884285 --- --- Aj816809 kn206 bos sp. CDNA clone c0005209a1 0.01 2.1 -1.1 -2.3 --- 
1031 gi_119908469 XM_001252162 DVL1 Dishevelled, dsh homolog 1 (drosophila) 0.01 2.0 -1.1 -2.3 --- 
1032 gi_62751672 NM_001015586 DSTN Destrin (actin depolymerizing factor) 0.01 2.2 -1.1 -2.3 --- 
1033 gi_119914058 XM_001249413 C14orf129 Chromosome 14 open reading frame 129 0.01 2.2 1.0 -2.3 --- 
1034 gi_147900717 NM_001098141 GYPA Glycophorin a  0.01 2.2 -1.0 -2.3 --- 
1035 gi_119912260 XM_001254106 LOC787090 Similar to hair keratin cysteine rich protein (LOC787090) 0.02 2.1 -1.1 -2.3 --- 
1036 gi_119875947 XM_615721 NCAM2 Neural cell adhesion molecule 2 0.02 2.1 -1.1 -2.3 --- 
1037 gi_119924389 XR_027626 LOC784129 Hypothetical protein (LOC784129) 0.03 2.0 -1.1 -2.3 --- 
1038 gi_119879088 XM_001252292 OR5H1 Olfactory receptor, family 5, subfamily h, member 1 0.01 2.1 -1.1 -2.3 --- 
1039 gi_119894037 XM_001251291 LOC782655 Hypothetical protein (LOC782655) 0.01 2.3 1.0 -2.3 --- 
1040 gi_29263084 --- --- Cb456702 713982 marc 6bov cDNA 3' 0.01 2.1 -1.1 -2.3 --- 
1041 gi_119924185 XM_001255673 OR4D1 Olfactory receptor, family 4, subfamily d, member 1 0.01 2.1 -1.1 -2.3 --- 
1042* gi_119892551 XM_001255346 OR6C74 Olfactory receptor, family 6, subfamily c, member 74 0.01 2.2 -1.0 -2.3 --- 
1043 gi_114053296 NM_001046390 TES Testis derived transcript (3 lim domains) 0.01 2.1 -1.1 -2.3 --- 
1044* gi_119892565 XM_001255442 OR6C6 Olfactory receptor, family 6, subfamily c, member 6 0.01 2.2 1.0 -2.3 --- 
1045* gi_119890804 XM_001252604 SNX13 Sorting nexin 13 0.01 2.1 -1.1 -2.3 --- 
1046 gi_119892287 XM_001252824 LOC785803 Similar to lysozyme (LOC785803) 0.01 2.3 1.0 -2.3 --- 
1047 gi_76627174 XM_867591 LOC615713 Hypothetical (LOC615713) 0.01 2.2 -1.1 -2.3 --- 
1048 gi_119878574 XM_595936 CADM2 Cell adhesion molecule 2 0.01 2.1 -1.1 -2.3 --- 
1049 gi_51810612 --- --- Co880683 bovgen_09008 normal cattle brain cDNA clone 
rzpdp1056e1113q 5' 
0.01 2.1 -1.1 -2.3 --- 
1050 gi_119921417 XM_586484 Olfr282 Olfactory receptor 282 0.01 2.1 -1.1 -2.3 --- 
1051 gi_157279882 NM_001104987 MCTP1 Multiple c2 domains, transmembrane 1 0.01 2.2 -1.0 -2.3 --- 
1052 gi_51810298 --- --- Co880369 bovgen_08694 normal cattle brain cDNA clone 
rzpdp1056f177q 5' 
0.01 2.2 1.0 -2.3 --- 
1053 gi_51887857 --- --- Aj820381 kn206 bos sp. CDNA clone c0006018e07 0.01 2.2 1.0 -2.3 --- 
1054 gi_76623803 XM_586022 LOC509128 Similar to olfactory receptor, family 11, subfamily h, member 1 0.01 2.2 1.0 -2.3 --- 
1055 gi_119928697 XM_593499 OR4K15 Olfactory receptor, family 4, subfamily k, member 15 0.01 2.1 -1.1 -2.3 --- 
1056 gi_75832089 NM_181012 IDH1 Isocitrate dehydrogenase 1 (nadp+), soluble 0.02 2.0 -1.1 -2.3 --- 
1057 gi_119306996 --- --- Ee970422 q25371a FNM cDNA clone q2537 3' 0.01 2.1 -1.1 -2.3 --- 
1058 gi_119902074 XM_593013 LOC515064 Similar to TCR delta (LOC515064) 0.01 2.2 1.0 -2.3 --- 
1059* gi_119895354 XM_001255231 OR2L3 Olfactory receptor, family 2, subfamily l, member 3 0.01 2.1 -1.1 -2.3 --- 
1060 gi_119887420 XM_001254873 NCKAP1 Nck-associated protein 1 0.01 2.2 -1.0 -2.3 --- 
1061 gi_119922263 XM_001254600 LOC787105 Similar to t-cell receptor alpha chain (LOC787105) 0.01 2.1 -1.1 -2.2 --- 
1062 gi_119921087 XM_001253675 LOC785752 Hypothetical protein (LOC785752) 0.02 2.2 1.0 -2.2 --- 
1063 gi_119906534 XM_612068 PI15 Peptidase inhibitor 15 0.01 2.1 -1.0 -2.2 --- 
1064 gi_51887457 --- --- Aj819981 kn206 bos sp. CDNA clone c0006017a22 0.03 2.0 -1.1 -2.2 --- 
1065* gi_119892977 XM_591626 KLRC1 Killer cell lectin-like receptor subfamily c, member 1 0.01 2.2 1.0 -2.2 --- 
1066 gi_90991697 NM_001012285 LEPR Leptin receptor 0.03 2.0 -1.1 -2.2 --- 
1067 gi_119914208 XM_580659 LOC538493 Similar to chromosome 14 open reading frame 173 0.00 2.2 1.0 -2.2 --- 
1068 gi_119922421 XM_602604 Olfr1134 Olfactory receptor 1134 0.02 2.1 -1.1 -2.2 --- 
1069 gi_31342589 NM_174209 UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats 0.01 2.2 1.0 -2.2 --- 
1070 gi_119892851 XM_608933 METTL20 Methyltransferase like 20 0.01 2.2 1.0 -2.2 --- 
1071 gi_119901594 XM_600433 PHACTR2 Phosphatase and actin regulator 2 0.01 2.2 1.0 -2.2 --- 
1072 gi_119891943 XM_001249912 LRRIQ1 Leucine-rich repeats and iq motif containing 1 0.01 2.1 -1.0 -2.2 --- 
1073 gi_119922783 XM_001252792 SLC30A9 Solute carrier family 30 (zinc transporter), member 9 0.01 2.0 -1.1 -2.2 --- 
1074 gi_119918958 XM_583490 LOC506960 Similar to seven transmembrane helix receptor (LOC506960) 0.02 2.1 1.0 -2.2 --- 
1075 gi_119902535 XM_613448 PRTG Protogenin 0.02 2.1 -1.0 -2.2 --- 
1076 gi_119902733 XM_617753 LOC537580 Hypothetical (LOC537580) 0.02 2.1 1.0 -2.2 --- 
1077 gi_119921109 XM_001253971 LOC786219 Similar to t-cell receptor alpha chain (LOC786219) 0.01 2.2 1.0 -2.2 --- 
1078 gi_119921057 XM_001252809 LOC784539 Similar to olfactory receptor olfr598 (LOC784539) 0.03 2.0 -1.1 -2.2 --- 
1079 gi_119928796 XR_028820 LOC789937 Similar to wd and tetratricopeptide repeats protein 1  0.00 2.1 1.0 -2.1 --- 
1080 gi_119907383 XM_610954 LOC532436 Similar to olfactory receptor mor31-7 (LOC532436) 0.02 2.0 -1.0 -2.1 --- 
1081 gi_157074135 NM_001103310 LOC789977 Hypothetical (LOC789977) 0.02 2.1 1.0 -2.1 --- 
1082 gi_51808439 --- --- Co878519 bovgen_06844 normal cattle brain cDNA clone 
rzpdp1056n0811q 5' 
0.02 2.1 1.0 -2.1 --- 
1083 gi_119913333 XM_614947 CDH9 Cadherin 9, type 2 (T1-cadherin) 0.02 2.1 -1.0 -2.1 --- 
1084 gi_119892713 XR_028263 LOC505479 Similar to grp94 neighboring nucleotidase (LOC505479) 0.02 2.1 1.0 -2.1 --- 
1085 gi_76669664 XM_864501 OR6C75 Olfactory receptor, family 6, subfamily c, member 75 0.02 2.1 1.0 -2.1 --- 
1086* gi_164420765 NM_001113247 CHN1 Chimerin (chimaerin) 1 0.03 2.0 -1.1 -2.1 --- 
1087 gi_119915801 XM_001254745 LOC788718 Hypothetical protein (LOC788718) 0.00 3.9 1.8 -2.1 --- 
1088 gi_148229657 NM_181002 AOC3 Amine oxidase,copper containing 3(vascular adhesion protein 1) 0.02 2.0 -1.0 -2.1 --- 
1089 gi_119919308 XM_600752 BATF2 Basic leucine zipper transcription factor, atf-like 2 0.01 2.0 1.0 -2.1 --- 
1090 gi_51820855 --- --- Co890567 bovgen_18892 normal cattle brain cDNA clone 
rzpdp1056j1149q 5' 
0.01 2.0 1.0 -2.1 --- 
1091 gi_119889551 XM_001250479 LOC781930 Hypothetical protein (LOC781930) 0.01 2.0 -1.0 -2.1 --- 
1092 gi_119900577 XM_617223 LOC537068 Similar to piwi-like 2 (drosophila) (LOC537068) 0.02 2.1 1.0 -2.1 --- 
1093 gi_77735964 NM_001034509 LOC515736 Caspase-15 (LOC515736) 0.02 2.0 1.0 -2.1 --- 
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
     
 
2.1.5 Full list of genes in profile 5 (n = 288) 
S.No 
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1 gi_29273881 --- --- Cb467496 733248 marc 6bov cDNA 5' 0.00 -2.8 -367.6 -132.5 --- 
2 gi_119922045 XM_001254453 LOC786899 Hypothetical protein (LOC786899) 0.01 -2.1 -220.9 -106.5  
3 gi_119930329 XM_001253356 LOC785289 Hypothetical protein (LOC785289) 0.00 -2.2 -203.6 -93.3  
4 gi_119902260 XM_603355 LOC404176 T-cell receptor delta chain (LOC404176) 0.00 -2.7 -238.3 -88.0  
5 gi_119913552 XM_606794 IGF1R Insulin-like growth factor 1 receptor 0.01 -2.0 -171.5 -85.2 --- 
6 gi_119925613 XM_583887 GXYLT2 Glucoside xylosyltransferase 2 0.00 -2.7 -222.3 -83.3 --- 
7 gi_119915839 XM_588122 F13A1 Coagulation factor xiii, a1 polypeptide 0.00 -2.3 -165.6 -71.2 --- 
8 gi_119917736 XM_609898 SORCS3 Sortilin-related vps10 domain containing receptor 3 0.00 -5.4 -364.8 -67.3 --- 
9 gi_119919107 XM_591760 SLC15A3 Solute carrier family 15, member 3 0.00 -2.4 -158.8 -66.7  
10 gi_119911249 XM_867060 LAIR1 Leukocyte-associated immunoglobulin-like receptor 1 0.00 -3.3 -174.7 -52.8 --- 
11 gi_119922043 XM_001254436 LOC786880 Hypothetical protein (LOC786880) 0.00 -2.4 -114.4 -47.4  
12 gi_119923075 XM_001254039 LOC786327 Hypothetical protein (LOC786327) 0.00 -2.5 -96.9 -39.1  
13* gi_118151215 NM_001078068 PPP1R14C Protein phosphatase 1, regulatory (inhibitor) subunit 14c 0.00 -6.0 -219.0 -36.3 --- 
14 gi_119918053 XM_001256302 LOC789595 Hypothetical protein (LOC789595) 0.00 -4.2 -148.2 -35.5  
15 gi_119891326 XM_590508 CPA4 Carboxypeptidase a4 0.00 -3.4 -119.2 -35.2  
16 gi_119910462 XM_592455 LOC514582 Similar to b-cell receptor CD22-b (LOC514582) 0.00 -2.4 -82.1 -34.8  
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17 gi_119911490 XM_001252357 LOC785058 Hypothetical protein (LOC785058) 0.00 -7.3 -243.5 -33.5  
18 gi_117377406 --- --- Eg706640 nbm28c02.y1 cow lens. Unnormalized (NBM) cDNA 
clone nbm28c02 5' 
0.00 -3.0 -90.8 -30.1  
19 gi_75872327 --- --- Dt891920 1473102 marc 7bov cDNA 5' 0.00 -2.2 -62.9 -28.3 --- 
20 gi_119889163 XM_001251523 FCRLA Fc receptor-like a 0.00 -2.8 -80.3 -28.2  
21 gi_134085858 NM_001083409 C1QTNF1 C1q and tumor necrosis factor related protein 1 0.00 -5.4 -150.3 -27.7  
22 gi_119922040 XR_028437 LOC786767 Hypothetical protein (LOC786767) 0.01 -2.1 -50.0 -23.8  
23 gi_7055130_ --- --- Aw485024 63440 marc 3bov cDNA 5' 0.00 -3.1 -71.7 -23.3  
24 gi_76660614 XM_597941 CCR6 Chemokine (c-c motif) receptor 6 0.00 -3.1 -71.6 -23.2  
25 gi_126723186 NM_174198 TLR4 Toll-like receptor 4 0.00 -2.9 -61.4 -21.4  
26 gi_134085612 NM_001083388 COL18A1 Collagen, type xviii, alpha 1 0.00 -3.7 -72.5 -19.6 --- 
27* gi_119895038 XM_001256059 ZNF77 Similar to zinc finger protein 77 (LOC789258) 0.00 -2.3 -42.3 -18.2 --- 
28* gi_119914433 XM_585399 ZNF77 Similar to zinc finger protein 77 (LOC508603) 0.00 -2.3 -39.6 -17.2 --- 
29 gi_68422364 --- --- Am024035 kn-252-lymph, cDNA clone c0007392c13 3' 0.00 -3.8 -60.5 -16.0  
30 gi_119893570 XM_615475 LEF1 Lymphoid enhancer-binding factor 1 0.00 -3.5 -52.4 -15.0  
31* gi_119906950 XM_001251159 PPP1R14C Protein phosphatase 1, regulatory (inhibitor) subunit 14c 0.00 -6.3 -92.1 -14.7 --- 
32 gi_119900339 XM_614789 KANK1 Kn motif and ankyrin repeat domains 1 0.00 -3.0 -43.9 -14.6  
33 gi_119895702 XM_616288 SH3TC2 Sh3 domain and tetratricopeptide repeats 2 0.01 -2.0 -26.6 -13.1  
34 gi_119925247 XM_001254851 LOC787461 Similar to retina-derived pou-domain factor-1 (LOC787461) 0.00 -3.5 -45.4 -13.1 --- 
35 gi_119909284 XM_868620 HVCN1 Hydrogen voltage-gated channel 1 0.00 -2.3 -30.4 -13.0  
36 gi_149642838 NM_001099200 PNPLA1 Patatin-like phospholipase domain containing 1 0.00 -7.5 -93.7 -12.5 --- 
37 gi_119910899 XM_001254077 LOC786386 Hypothetical protein (LOC786386) 0.00 -2.4 -28.7 -12.0 --- 
38 gi_119911051 XM_599883 CACNG6 Calcium channel, voltage-dependent, gamma subunit 6 0.00 -2.6 -27.8 -10.6 --- 
39 gi_119912992 XM_001252543 LOC784141 Hypothetical protein (LOC784141) 0.00 -3.4 -35.1 -10.2  
40 gi_119904678 XM_869633 LOC617384 Similar to atpase, aminophospholipid transporter-like, class i, 
type 8a, member 2 (LOC617384) 
0.00 -7.8 -77.8 -10.0 --- 
41 gi_51822678 --- --- Co892378 bovgen_20703 normal cattle brain cDNA clone 
rzpdp1056m2034q 5' 
0.00 -3.6 -36.1 -9.9 --- 
42 gi_51809258 --- --- Co879334 bovgen_07661 normal cattle brain cDNA clone 
rzpdp1056j1530q 5' 
0.01 -2.1 -20.5 -9.7 --- 
43 gi_119919031 XM_869090 VSIG2 Similar to v-set and immunoglobulin domain containing 2  0.00 -2.3 -21.9 -9.3 --- 
44 gi_51812473 --- --- Co882541 bovgen_10866 normal cattle brain cDNA clone 
rzpdp1056j2225q 5' 
0.00 -2.3 -21.3 -9.3 --- 
45 gi_119916419 XM_587341 ALPK2 Alpha-kinase 2 0.00 -11.3 -104.0 -9.2 --- 
46 gi_119920608 XM_001249720 LOC781352 Hypothetical protein (LOC781352) 0.01 -2.1 -19.1 -9.2 --- 
47 gi_51826329  ---  --- Co896012 bovgen_24337 normal cattle brain cDNA clone 
rzpdp1056e0933q 5' 
0.00 -3.0 -26.4 -8.9  
48 gi_119911988 XM_582998 SPECC1 Sperm antigen with calponin homology and coiled-coil domains1 0.00 -2.8 -24.4 -8.8  
49 gi_119920594 XM_001249399 LOC781057 Hypothetical protein (LOC781057) 0.01 -2.1 -18.2 -8.7 --- 
50 gi_51821293 --- --- Co891000 bovgen_19325 normal cattle brain cDNA clone 
rzpdp1056e0735q 5' 
0.00 -2.2 -19.5 -8.7 --- 
51 gi_119920600 XM_001249543 LOC781191 Hypothetical protein (LOC781191) 0.01 -2.0 -17.7 -8.7  
52* gi_119902292 XM_001253121 RASGRP1 Ras guanyl releasing protein 1 (calcium and dag-regulated) 0.00 -2.8 -23.8 -8.6  
53 gi_115496172 NM_001075149 MYL4 Myosin, light chain 4, alkali; atrial, embryonic 0.00 -6.9 -58.7 -8.6  
54 gi_156120728 NM_001102041 C13orf18 Chromosome 13 open reading frame 18 0.01 -2.1 -17.8 -8.6  
55 gi_119913257 XM_616682 SPEF2 Sperm flagellar 2 0.00 -2.5 -20.8 -8.2 --- 
56 gi_119920598 XM_001249501 LOC781114 Hypothetical protein (LOC781114) 0.02 -2.0 -16.3 -8.2 --- 
57 gi_119933176 XM_001256699 LOC790148 Similar to mgc127009 protein (LOC790148) 0.01 -2.0 -15.8 -7.9  
58 gi_31341796 NM_174511 CCL3 Chemokine (c-c motif) ligand 3  0.00 -3.7 -29.2 -7.8  
59 gi_119889183 XR_028030 LOC517126 Similar to fc receptor-like 5 (LOC517126) 0.00 -3.9 -30.0 -7.8 --- 
60 gi_76672950 XM_607792 GAB2 Grb2-associated binding protein 2 0.00 -2.6 -20.1 -7.8  
61 gi_119906188 XM_001253797 LOC786946 Hypothetical protein loc786946 (LOC786946) 0.00 -2.3 -18.1 -7.7 --- 
62 gi_115496605 NM_001076352 LMO2 Lim domain only 2 (rhombotin-like 1) 0.01 -2.0 -15.7 -7.7  
63 gi_119912910 XM_599356 FAM20A Family with sequence similarity 20, member a 0.00 -2.8 -21.3 -7.7 --- 
64* gi_156120738 NM_001102046 POU6F2 Pou class 6 homeobox 2 0.00 -2.9 -22.4 -7.7 --- 
65 gi_119918583 XR_027958 LOC531034 Similar to synaptopodin 2-like (LOC531034) 0.00 -2.3 -17.6 -7.6  
66 gi_119905537 XM_001253283 LOC785870 Similar to prodynorphin (LOC785870) 0.00 -2.8 -20.3 -7.3 --- 
67* gi_119902290 XM_612430 RASGRP1 RAS guanyl releasing protein 1 (calcium and dag-regulated) 0.00 -2.8 -20.3 -7.3  
68 gi_51810356  ---  --- Co880427 bovgen_08752 normal cattle brain cDNA clone 
rzpdp1056k019q 5' 
0.00 -2.4 -17.0 -7.1  
69 gi_156523111 NM_001102500 MMRN1 Multimerin 1 0.00 -3.1 -21.8 -7.0  
70 gi_31342484 NM_174258 Cald1 Caldesmon 1 0.00 -4.6 -31.7 -6.9 --- 
71 gi_119910079 XM_592529 LPCAT2 Lysophosphatidylcholine acyltransferase 2 0.01 -2.2 -14.7 -6.8  
72 gi_78050050 NM_001035070 ASB14 Ankyrin repeat and socs box-containing 14 0.00 -2.2 -14.8 -6.8  
73 gi_119924763 XM_601339 PSD2 Pleckstrin and sec7 domain containing 2 0.00 -5.6 -37.8 -6.8 --- 
74 gi_119891244 XR_028414 C7orf58 Chromosome 7 open reading frame 58 0.00 -3.2 -21.5 -6.8  
75 gi_119919341 XR_027385 LOC520070 Similar to tumor endothelial marker 1, (LOC520070) 0.00 -3.2 -22.0 -6.8 --- 
76 gi_119893188 XM_608437 LOC529975 Hypothetical (LOC529975) 0.00 -2.6 -17.0 -6.6 --- 
77 gi_115495262 NM_001075943 PEX5L Peroxisomal biogenesis factor 5-like 0.00 -2.3 -15.2 -6.5 --- 
78 gi_119909623 XM_871314 LOC404062 Immunoglobin light chain vj region (LOC404062) 0.00 -4.8 -30.8 -6.4 --- 
79 gi_118150919 NM_001077905 CPA5 Carboxypeptidase a5  0.00 -4.6 -28.2 -6.1 --- 
80* gi_119920009 XM_601830 NXF3 Nuclear rna export factor 3 0.00 -27.3 -166.5 -6.1 --- 
81 gi_156121314 NM_001102335 PGM5 Phosphoglucomutase 5 0.00 -8.5 -50.8 -6.0  
82 gi_115496048 NM_001075977 GMPR Guanosine monophosphate reductase 0.00 -3.0 -17.7 -6.0 --- 
83 gi_49411022 --- --- Aj678437 kn224 cDNA clone kn224-026_h03 0.00 -2.7 -16.0 -6.0 --- 
84 gi_32189337 NM_174143 PIGR Polymeric immunoglobulin receptor 0.00 -6.4 -38.3 -5.9  
85* gi_119902288 XM_001253077 RASGRP1 Ras guanyl releasing protein 1 (calcium and dag-regulated) 0.00 -2.4 -14.3 -5.9  
86 gi_119900832 XM_001249686 LOC781282 Similar to polydom (LOC781282) 0.00 -3.2 -19.1 -5.9 --- 
87 gi_148238272 NM_001098016 ITIH2 Inter-alpha (globulin) inhibitor h2 0.00 -5.3 -30.8 -5.9  
88 gi_89886135 NM_001013585 S1PR1 Sphingosine-1-phosphate receptor 1 0.00 -9.4 -54.6 -5.8  
89 gi_51826409 --- --- Co896092 bovgen_24417 normal cattle brain cDNA clone 
rzpdp1056a0831q 5' 
0.00 -11.9 -67.5 -5.7 --- 
90* gi_119889658 XM_001252361 KIAA1324 Kiaa1324 0.00 -3.3 -18.6 -5.6 --- 
91 gi_77404230 NM_001034043 Gulo Gulonolactone (l-) oxidase 0.00 -4.9 -27.5 -5.6 --- 
92 gi_51887072 --- --- Aj819596 kn206 bos sp. CDNA clone c0006015o15 0.01 -2.1 -11.4 -5.3 --- 
93 gi_122692374 NM_001080353 MGC148792 Similar to elafin (mgc148792) 0.00 -3.6 -19.0 -5.3 --- 
94 gi_31341725 NM_174538 FCGR1A Fc fragment of igg, high affinity ia, receptor (CD64) 0.00 -2.5 -12.8 -5.2  
95 gi_155372098 NM_001101188 ASB16 Ankyrin repeat and socs box containing 16 0.00 -5.1 -25.2 -5.0 --- 
96 gi_156523197 NM_001102543 DUSP27 Dual specificity phosphatase 27 (putative) 0.00 -4.6 -22.7 -5.0  
97 gi_119940186 XM_607283 LOC528849 Similar to mer receptor tyrosine kinase (LOC528849) 0.00 -3.7 -18.1 -4.9 --- 
98 gi_119927744 XM_869472 bTrappin-5 Trappin 5 (btrappin-5) 0.00 -5.5 -26.9 -4.9 --- 
99 gi_158519866 NM_001110070 CTSW Cathepsin W  0.00 -9.0 -43.6 -4.8 --- 
100 gi_156120752 NM_001102053 KANK4 Kn motif and ankyrin repeat domains 4 0.00 -2.8 -13.6 -4.8 --- 
101 gi_119910848 XM_581838 LOC505540 Hypothetical (LOC505540) 0.00 -5.7 -27.2 -4.8 --- 
102 gi_164414434 NM_001113227 ELMO1 Engulfment and cell motility 1 (elmo1), transcript variant 1 0.00 -2.3 -10.8 -4.8  
103 gi_119894347 XM_602917 DOK7 Docking protein 7 0.00 -2.6 -12.6 -4.8 --- 
104 gi_119891299 XM_607870 LOC529423 Similar to family with sequence similarity 40, member b 0.00 -4.4 -21.0 -4.7  
105 gi_118151371 NM_001078149 GSTA3 Glutathione s-transferase alpha 3 0.00 -10.0 -46.9 -4.7 --- 
106 gi_119891361 XM_001251678 LOC784524 Similar to cytosolic carboxypeptidase 3 (LOC784524) 0.00 -2.5 -11.5 -4.7  
107 gi_150247093 NM_001099397 GAPT Grb2-binding adaptor protein, transmembrane 0.00 -2.5 -11.5 -4.7  
108 gi_31343049 NM_174010 CD36 CD36 molecule (thrombospondin receptor) 0.00 -24.3 -111.0 -4.6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices  314 
109 gi_76674996 XM_603316 XKRX Similar to membrane protein xplac (LOC524975) 0.00 -5.9 -26.7 -4.6 --- 
110 gi_119941394 XM_001257213 LOC790840 Hypothetical protein (LOC790840) 0.00 -2.8 -12.8 -4.6 --- 
111 gi_155372256 NM_001101271 FAM176B Family with sequence similarity 176, member b 0.00 -6.6 -30.0 -4.5  
112 gi_115495674 NM_001076228 PTPRG Protein tyrosine phosphatase, receptor type, g 0.00 -2.5 -11.4 -4.5  
113 gi_51816005 --- --- Co885720 bovgen_14045 normal cattle brain cDNA clone 
rzpdp1056m074q 5' 
0.00 -4.9 -22.5 -4.5  
114 gi_51809242 --- --- Co879318 bovgen_07645 normal cattle brain cDNA clone 
rzpdp1056g2111q 5' 
0.00 -2.6 -11.5 -4.5  
115 gi_84370178 NM_001038568 GPR84 G protein-coupled receptor 84 0.00 -4.1 -18.1 -4.5  
116 gi_119903128 XM_580552 MERTK C-mer proto-oncogene tyrosine kinase 0.00 -4.5 -20.0 -4.4 --- 
117 gi_119888204 XM_595958 DNAH7 Dynein, axonemal, heavy chain 7 0.00 -2.8 -11.9 -4.3 --- 
118 gi_156120860 NM_001102107 CALCRL Calcitonin receptor-like 0.00 -5.4 -23.2 -4.3 --- 
119 gi_115496321 NM_001075915 POU2AF1 Pou class 2 associating factor 1 0.00 -2.4 -10.1 -4.3 --- 
120 gi_119927740 XM_001250419 PI3 Protease inhibitor 3, skin-derived (skalp) (pi3) 0.00 -4.2 -17.8 -4.2 --- 
121 gi_119904117 XM_605012 LCN2 Lipocalin 2 0.00 -6.1 -25.6 -4.2 --- 
122 gi_51823209 --- --- Co892909 bovgen_21234 normal cattle brain cDNA clone 
rzpdp1056d1644q 5' 
0.01 -2.2 -8.8 -4.1 --- 
123 gi_119895212 XM_001251719 LOC783028 Similar to prr16 protein (LOC783028) 0.01 -2.1 -8.4 -4.0 --- 
124 gi_119904406 XR_028798 LOC536255 Hypothetical (LOC536255) 0.00 -2.5 -10.1 -4.0  
125 gi_70793607 --- --- Am038299 kn-252-spleen, cDNA clone c0007409k18 3' 0.00 -2.8 -11.2 -4.0  
126 gi_119920899 XM_001253921 LOC786146 Hypothetical protein loc786146 (LOC786146) 0.00 -2.9 -11.5 -3.9 --- 
127 gi_119904676 XM_594814 LOC516657 Similar to atpase, aminophospholipid transporter-like, class i, 
type 8a, member 2 (LOC516657) 
0.00 -3.1 -12.2 -3.9 --- 
128 gi_148540299 NM_001098474 EG667604 Predicted gene 8721 0.01 -2.2 -8.7 -3.9  
129 gi_119887556 XM_001254330 LOC786733 Hypothetical protein (LOC786733) 0.01 -2.1 -7.7 -3.8 --- 
130 gi_51811404 --- --- Co881475 bovgen_09800 normal cattle brain cDNA clone 
rzpdp1056h1915q 5' 
0.00 -2.2 -8.4 -3.7  
131 gi_126723450 NM_001082467 C6orf26 Chromosome 6 open reading frame 26 0.00 -2.7 -9.9 -3.7 --- 
132 gi_139948854 NM_001083706 PDGFD Platelet derived growth factor d 0.00 -2.6 -9.5 -3.7  
133* gi_51827365 --- RPSA Ribosomal protein sa 0.00 -2.6 -9.6 -3.7  
134 gi_114050912 NM_001046512 TSPAN12 Tetraspanin 12 0.00 -8.2 -29.9 -3.6  
135 gi_119918570 XM_001252944 CDH23 Cadherin-related 23 0.00 -7.8 -28.3 -3.6 --- 
136 gi_115494983 NM_001076301 APOD Apolipoprotein d 0.00 -2.8 -10.1 -3.6  
137 gi_119902084 XR_027480 LOC613744 Hypothetical (LOC613744) 0.01 -2.0 -7.3 -3.6  
138 gi_119894846 XM_611456 ARHGEF18 Rho/rac guanine nucleotide exchange factor (GEF) 18 0.00 -3.1 -11.2 -3.6  
139 gi_119925656 XM_001255377 LOC788264 Similar to rap guanine nucleotide exchange factor (LOC788264) 0.00 -2.7 -9.5 -3.5 --- 
140 gi_157428139 NM_001105511 RNASE2 Ribonuclease, rnase a family, 2 (liver, eosinophil-derived 
neurotoxin) (RNase2) 
0.00 -10.0 -34.8 -3.5 --- 
141 gi_157074113 NM_001103299 PLS1 Plastin 1 0.00 -2.8 -9.9 -3.5 --- 
142 gi_118151317 NM_001078121 LOC768255 Hypothetical protein (LOC768255) 0.00 -2.2 -7.7 -3.4  
143* gi_119925245 XM_618000 POU6F2 Pou class 6 homeobox 2 0.00 -2.8 -9.7 -3.4 --- 
144 gi_114051470 NM_001046060 GIMAP4 GTPase, imap family member 4 0.00 -2.7 -9.2 -3.3  
145 gi_119904673 XM_869410 LOC617199 Similar to atpase, aminophospholipid transporter-like, class i, 
type 8a, member 2 (LOC617199) 
0.00 -10.3 -34.1 -3.3 --- 
146 gi_119904699 XM_872272 LOC505426 Similar to mflj00298 protein, transcript variant 2 (LOC505426) 0.00 -2.9 -9.8 -3.3 --- 
147 gi_119893582 XM_599206 SGMS2 Sphingomyelin synthase 2 0.00 -2.9 -9.7 -3.3  
148 gi_119920329 XM_586812 CACNA1F Calcium channel, voltage-dependent, l type, alpha 1f subunit 0.00 -3.2 -10.4 -3.3  
149 gi_61888881 NM_001013600 BOLA-DOB Major histocompatibility complex, class ii, do beta  0.00 -3.5 -11.6 -3.3  
150 gi_149642786 NM_001099152 LBH Limb bud and heart development homolog (mouse) 0.00 -2.9 -9.6 -3.3  
151 gi_119240719 --- --- Ee904145 b46270a ffb cDNA clone b4627 5' 0.00 -3.2 -10.3 -3.3 --- 
152* gi_51810577 --- RPSA Ribosomal protein sa 0.00 -2.8 -9.1 -3.3  
153 gi_156120434 NM_001101893 ZNF423 Zinc finger protein 423  0.01 -2.2 -7.0 -3.2 --- 
154 gi_61946762 --- --- Dn641361 umc-bof_0a01-016-a04 ovarian follicle bof cDNA 3' 0.00 -3.0 -9.7 -3.2  
155 gi_119934258 XM_001252637 LOC784284 Similar to receptor-like protein tyrosine phosphatase gamma 
a-type 
0.01 -2.0 -6.5 -3.2 --- 
156 gi_119906110 XM_001252909 LOC785384 Hypothetical protein (LOC785384) 0.01 -2.1 -6.6 -3.2 --- 
157 gi_110347592 NM_001024505 --- Engulfment and cell motility 1 (ELMO1), transcript variant 2 0.01 -2.1 -6.9 -3.2 --- 
158 gi_119912932 XM_001249520 LOC781143 Hypothetical protein (LOC781143) 0.00 -2.7 -8.5 -3.2  
159 gi_119917116 XM_870165 SH2B2 Sh2b adaptor protein 2 0.01 -2.0 -6.5 -3.2 --- 
160 gi_31342006 NM_174436 Prkg1 Protein kinase, cgmp-dependent, type 1 0.00 -4.3 -13.7 -3.2 --- 
161 gi_119927948 XM_001256226 LOC789480 Similar to breast cancer antiestrogen resistance 3 (LOC789480) 0.00 -5.7 -17.8 -3.1  
162 gi_119917849 XM_607507 PPAPDC1A Phosphatidic acid phosphatase type 2 domain containing 1a 0.00 -2.9 -9.1 -3.1  
163 gi_119907018 XM_866023 C11orf52 Chromosome 11 open reading frame 52 0.00 -11.5 -35.9 -3.1  
164 gi_115496130 NM_001076499 LOC390213 Double c2-like domains, gamma, pseudogene 0.01 -2.1 -6.6 -3.1  
165 gi_119912938 XR_028796 LOC615883 Similar to slit3 (LOC615883) 0.00 -4.8 -14.9 -3.1 --- 
166 gi_51815966 --- --- Co885681 bovgen_14006 normal cattle brain cDNA clone 
rzpdp1056g0625q 5' 
0.01 -2.2 -6.6 -3.1 --- 
167 gi_119912710 XR_028608 LOC788092 Similar to beta heavy chain of outer-arm axonemal dynein 
atpase (LOC788092) 
0.00 -2.4 -7.3 -3.1 --- 
168 gi_118151127 NM_001078018 SEZ6 Seizure related 6 homolog (mouse) 0.00 -3.1 -9.5 -3.0 --- 
169 gi_119895258 XR_028366 LOC514894 Hypothetical (LOC514894) 0.01 -2.0 -6.1 -3.0  
170 gi_156121258 NM_001102307 RGNEF 190 kda guanine nucleotide exchange factor 0.00 -5.9 -17.5 -2.9 --- 
171 gi_119932453 XM_001256991 LOC790552 Similar to multidrug resistance-associated protein 0.00 -2.6 -7.6 -2.9 --- 
172 gi_31342140 NM_174388 MFAP2 Microfibrillar-associated protein 2 0.00 -7.7 -22.5 -2.9  
173 gi_62751568 NM_001015669 DBC1 Deleted in bladder cancer 1 0.00 -2.2 -6.4 -2.9  
174* gi_78370166 NM_001035285 SERINC2 Serine incorporator 2 0.00 -2.5 -7.2 -2.9  
175 gi_119924426 XR_027552 LOC782012 Similar to deubiquitinating enzyme dub2 (LOC782012) 0.01 -2.5 -7.3 -2.9  
176 gi_119912178 XM_612461 ABCC3 Atp-binding cassette, sub-family c (cftr/mrp), member 3 0.00 -2.3 -6.8 -2.9  
177 gi_9751160 --- --- Av615490 adipocyte cell line cDNA clone e1ad012c06 5' 0.00 -2.5 -7.2 -2.9  
178 gi_119895794 XM_001253881 LOC786092 Hypothetical protein (LOC786092) 0.00 -4.7 -13.6 -2.9 --- 
179 gi_119924746 XM_001251460 LOC782808 Similar to rap guanine nucleotide exchange factor (LOC782808) 0.00 -2.4 -6.9 -2.9 --- 
180 gi_51817133 --- --- Co886848 bovgen_15173 normal cattle brain cDNA clone 
rzpdp1056k2113q 5' 
0.00 -2.3 -6.5 -2.9 --- 
181 gi_76638859 XM_582510 GPR81 G protein-coupled receptor 81 0.00 -9.5 -27.3 -2.9 --- 
182 gi_119909533 XM_001254956 LOC787612 Hypothetical protein loc787612 (LOC787612) 0.00 -2.8 -7.9 -2.9  
183 gi_110347586 NM_001014879 PPP2R2B Protein phosphatase 2, regulatory subunit b, beta 0.00 -5.2 -14.9 -2.8 --- 
184 gi_60972164 --- --- Dn526932 1271740 marc 7bov cDNA 5' 0.00 -2.4 -6.9 -2.8  
185 gi_119895769 XM_617891 EBF1 Early b-cell factor 1 0.00 -3.4 -9.5 -2.8 --- 
186 gi_51810857 --- --- Co880928 bovgen_09253 normal cattle brain cDNA clone 
rzpdp1056n2313q 5' 
0.00 -8.2 -23.1 -2.8 --- 
187 gi_119893677 XM_001249755 LOC781459 Hypothetical protein (LOC781459) 0.01 -2.1 -5.7 -2.8  
188 gi_119894965 XM_870596 GIPC3 Gipc pdz domain containing family, member 3 0.00 -5.0 -14.1 -2.8 --- 
189 gi_119913498 XM_582218 ZO1 Tight junction protein 1  0.00 -4.2 -11.6 -2.8 --- 
190 gi_51818387 --- --- Co888102 bovgen_16427 normal cattle brain cDNA clone 
rzpdp1056g1725q 5' 
0.01 -2.0 -5.5 -2.8  
191 gi_51822808 --- --- Co892508 bovgen_20833 normal cattle brain cDNA clone 
rzpdp1056n1649q 5' 
0.00 -3.4 -9.3 -2.8  
192 gi_51823236 --- --- Co892936 bovgen_21261 normal cattle brain cDNA clone 
rzpdp1056h0445q 5' 
0.00 -2.4 -6.7 -2.8 --- 
193 gi_119915518 XM_608214 LOC529757 Similar to lymphotoxin-beta, transcript variant 1 (LOC529757) 0.00 -6.8 -18.6 -2.7 Down 
194 gi_111104592 --- --- Ee243456 lb02230.cr_g22 gc_bgc-22 cDNA clone 0.01 -2.0 -5.5 -2.7  
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195 gi_76638411 XM_612023 MBNL3 Muscleblind-like 3 (drosophila) 0.01 -2.1 -5.6 -2.7  
196 gi_119908015 XM_604649 IL24 Interleukin 24 0.00 -2.4 -6.6 -2.7 --- 
197 gi_156121118 NM_001102237 TMEM132A Transmembrane protein 132a 0.00 -2.2 -5.9 -2.7 --- 
198 gi_119910909 XM_870781 KLK12 Kallikrein-related peptidase 12 0.00 -2.7 -7.2 -2.7 --- 
199 gi_119895214 XM_867687 PRR16 Proline rich 16 0.00 -2.6 -6.9 -2.7 --- 
200 gi_51817522 --- --- Co887237 bovgen_15562 normal cattle brain cDNA clone 
rzpdp1056a203q 5' 
0.00 -2.4 -6.2 -2.6 --- 
201 gi_66792889 NM_001024553 KCND1 Potassium voltage-gated channel, shal-related subfamily, 
member 1 
0.00 -2.3 -6.1 -2.6  
202 gi_51886061 --- --- Aj818585 kn206 bos sp. cDNA clone c0006012m03 0.00 -2.9 -7.6 -2.6  
203 gi_119890531 XM_001254797 LOC787378 Similar to iq motif containing with aaa domain (LOC787378) 0.00 -3.5 -9.1 -2.6 --- 
204* gi_119889656 XM_001252338 KIAA1324 Kiaa1324 0.00 -2.3 -5.9 -2.6 --- 
205 gi_119893792 XM_001251250 LOC782618 Hypothetical protein (LOC782618) 0.01 -2.0 -5.3 -2.6 --- 
206 gi_31342494 NM_174254 CABP1 Calcium binding protein 1 0.00 -2.3 -6.0 -2.6 --- 
207 gi_51885046 --- --- Aj817570 kn206 bos sp. cDNA clone c0006006a15 0.00 -2.7 -7.0 -2.6  
208 gi_62460475 NM_001014892 C16orf5 Chromosome 16 open reading frame 5 0.01 -2.1 -5.4 -2.5 --- 
209 gi_119891365 XM_605871 AGBL3 Atp/gtp binding protein-like 3 0.01 -2.2 -5.5 -2.5  
210 gi_119914793 XM_001255342 NBEAL2 Neurobeachin-like 2 0.01 -2.1 -5.3 -2.5 --- 
211* gi_119931673 XM_001249309 SERINC2 Serine incorporator 2 0.00 -2.2 -5.5 -2.5  
212 gi_70788841 --- --- Am033533 am033533 kn-252-spleen, cDNA clone 
c0007407m24 3' 
0.00 -2.8 -7.1 -2.5  
213 gi_119895089 XM_001256303 RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 0.00 -3.2 -7.9 -2.5 --- 
214 gi_51810688 --- RPS3A Ribosomal protein s3a 0.00 -3.2 -8.0 -2.5  
215 gi_51810363 --- --- Co880434 bovgen_08759 normal cattle brain cDNA clone 
rzpdp1056d0510q 5' 
0.00 -19.2 -47.8 -2.5 --- 
216 gi_119917978 XM_591917 C10orf92 Chromosome 10 open reading frame 92 0.00 -2.5 -6.2 -2.5 --- 
217 gi_119893204 XM_001255230 LOC788054 Similar to bcl-rambo (LOC788054) 0.00 -2.4 -5.9 -2.5  
218 gi_51888365 --- --- Aj820889 kn206 bos sp. cDNA clone c0006019k19 0.00 -5.0 -12.2 -2.5 --- 
219 gi_119903859 XM_613774 DTNB Dystrobrevin, beta 0.01 -2.1 -5.2 -2.5  
220 gi_119906935 XM_586071 TRPC6 Transient receptor potential cation channel, subfamily c, 
member 6 
0.00 -2.9 -7.0 -2.5 --- 
221 gi_119891011 XM_588627 LRRN3 Leucine rich repeat neuronal 3 0.00 -4.3 -10.7 -2.5 --- 
222 gi_119913675 XM_864691 CPEB1 Cytoplasmic polyadenylation element binding protein 1 0.00 -2.2 -5.5 -2.4 --- 
223 gi_51821936 --- --- Co891638 bovgen_19963 normal cattle brain cDNA clone 
rzpdp1056h0138q 5' 
0.01 -2.2 -5.3 -2.4 --- 
224 gi_31342868 NM_174091 IL18 Interleukin 18 (interferon-gamma-inducing factor) 0.00 -4.3 -10.4 -2.4  
225 gi_119927615 XM_001253466 LOC785446 Similar to ob-cadherin-1 (LOC785446) 0.00 -23.5 -57.1 -2.4 --- 
226 gi_61675701 NM_001013402 SGCA Sarcoglycan, alpha (50kda dystrophin-associated glycoprotein) 0.00 -3.1 -7.4 -2.4  
227 gi_51826740 --- --- Co896423 bovgen_24748 normal cattle brain cDNA clone 
rzpdp1056o0232q 5' 
0.01 -2.0 -4.9 -2.4  
228 gi_119908963 XM_866831 RNF150 Ring finger protein 150 0.00 -2.9 -7.0 -2.4  
229 gi_156121234 NM_001102295 TM6SF1 Transmembrane 6 superfamily member 1 0.00 -2.2 -5.3 -2.4 --- 
230 gi_119894870 XM_612193 MYO1F Myosin if 0.00 -3.6 -8.5 -2.4  
231 gi_77736358 NM_001034707 RGS5 Regulator of g-protein signaling 5 0.00 -3.6 -8.5 -2.4 --- 
232 gi_119894939 XM_582663 TBXA2R Thromboxane a2 receptor 0.00 -5.8 -13.7 -2.4  
233 gi_156120626 NM_001101989 TMEM144 Transmembrane protein 144 0.00 -5.7 -13.5 -2.4  
234 gi_156120736 NM_001102045 FCRL1 Fc receptor-like 1 0.00 -2.4 -5.5 -2.3  
235 gi_119912092 XM_595012 IGF2BP1 Insulin-like growth factor 2 mrna binding protein 1 0.01 -2.1 -5.0 -2.3 --- 
236 gi_119914721 XM_601010 LOC522724 Similar to bassoon protein (LOC522724) 0.01 -2.1 -4.9 -2.3  
237 gi_115495806 NM_001076172 MARCKSL1 Marcks-like 1 0.00 -3.3 -7.5 -2.3 --- 
238 gi_119935543 XM_001257014 LOC790584 Hypothetical protein (LOC790584) 0.01 -2.1 -4.8 -2.3  
239 gi_119917956 XR_028155 LOC616097 Hypothetical loc616097 (LOC616097) 0.00 -2.4 -5.5 -2.3 --- 
240* gi_119932781 XM_581475 ABCG2 Atp-binding cassette, sub-family g (white), member 2 0.00 -2.8 -6.4 -2.3  
241 gi_119893202 XM_870126 CECR1 Cat eye syndrome chromosome region, candidate 1 0.00 -2.7 -6.2 -2.3  
242 gi_119920461 XM_615546 LOC541298 Similar to interleukin 1 receptor accessory protein-like 1 0.01 -2.0 -4.7 -2.3  
243 gi_119886199 XM_590382 DZIP1L Daz interacting protein 1-like 0.00 -3.9 -8.9 -2.3 --- 
244 gi_119934220 XM_001251698 LOC783056 Hypothetical protein (LOC783056) 0.00 -2.5 -5.7 -2.3 --- 
245 gi_76681354 XM_876891 LOC510087 Similar to loc508140, transcript variant 2 (LOC510087) 0.01 -2.1 -4.7 -2.2 --- 
246 gi_119912116 XM_584605 NGFR Nerve growth factor receptor 0.00 -25.0 -55.6 -2.2 --- 
247 gi_119891420 XM_597033 SVOPL Svop-like 0.00 -9.8 -21.7 -2.2 --- 
248 gi_119901319 XM_001254544 LOC787023 Hypothetical protein (LOC787023) 0.00 -3.2 -7.0 -2.2 --- 
249 gi_119909629 XM_867430 GGT1 Gamma-glutamyltransferase 1 0.00 -2.8 -6.1 -2.2 --- 
250 gi_156120476 NM_001101914 NINJ2 Ninjurin 2 0.00 -4.0 -8.7 -2.2 --- 
251 gi_119912285 XM_870899 RAPGEFL1 Rap guanine nucleotide exchange factor (gef)-like 1 0.00 -2.4 -5.2 -2.2 --- 
252 gi_51819194 --- --- Co888909 bovgen_17234 normal cattle brain cDNA clone 
rzpdp1056g0746q 5' 
0.00 -2.2 -4.7 -2.2 --- 
253 gi_51816309 --- --- Co886024 bovgen_14349 normal cattle brain cDNA clone 
rzpdp1056p1219q 5' 
0.00 -4.4 -9.6 -2.2 --- 
254 gi_119890374 XM_594566 KLF17 Kruppel-like factor 17 0.00 -2.9 -6.4 -2.2 --- 
255 gi_51884658 --- --- Aj817182 aj817182 kn206 bos sp. cDNA clone c0006007d06 0.00 -3.1 -6.7 -2.2  
256 gi_99028972 NM_174195 TCN2 Transcobalamin ii 0.01 -2.1 -4.6 -2.2  
257 gi_62460541 NM_001014923 NFE2 Nuclear factor (erythroid-derived 2), 45kda 0.00 -20.7 -44.5 -2.2 --- 
258 gi_118150847 NM_001077867 OSTBETA Organic solute transporter beta 0.00 -6.9 -14.8 -2.1  
259 gi_51816466 --- MRPL49 Mitochondrial ribosomal protein l49 0.01 -2.0 -4.4 -2.1 --- 
260 gi_110626118 NM_001040495 IGFBP6 Insulin-like growth factor binding protein 6 0.00 -2.9 -6.2 -2.1 --- 
261 gi_77735824 NM_001034435 CTSK Cathepsin k 0.00 -3.7 -7.9 -2.1  
262 gi_119889381 XM_001254920 LOC787557 Hypothetical protein (LOC787557) 0.00 -2.6 -5.5 -2.1  
263 gi_115495086 NM_001075767 ATP2A1 Atpase, ca++ transporting, cardiac muscle, fast twitch 1 0.00 -2.4 -5.1 -2.1 --- 
264 gi_119888991 XM_001249302 LOC780966 Hypothetical protein (LOC780966) 0.01 -2.1 -4.4 -2.1 --- 
265 gi_122692514 NM_001080250 AMICA1 Adhesion molecule, interacts with cxadr antigen 1 0.00 -2.2 -4.7 -2.1  
266 gi_119919496 XM_001256184 LOC789424 Hypothetical protein (LOC789424) 0.00 -2.4 -5.1 -2.1  
267 gi_119904297 XM_001255213 LOC788022 Hypothetical protein (LOC788022) 0.00 -3.1 -6.4 -2.1  
268 gi_164448627 NM_001015642 CPXM Carboxypeptidase x (CPXM) 0.00 -4.8 -10.1 -2.1 --- 
269 gi_154152128 NM_001100334 AFAP1L1 Actin filament associated protein 1-like 1 0.00 -3.0 -6.3 -2.1 --- 
270 gi_115496685 NM_001075325 FOLR2 Folate receptor 2 (fetal) 0.00 -2.9 -6.1 -2.1  
271 gi_155371954 NM_001101113 GPX7 Glutathione peroxidase 7 0.01 -2.1 -4.4 -2.1 --- 
272 gi_149642888 NM_001099151 LHFPL2 Lipoma hmgic fusion partner-like 2 0.00 -2.5 -5.1 -2.0  
273* gi_112817614 NM_001037478 ABCG2 ATP-binding cassette, sub-family g (white), member 2 0.00 -2.9 -6.0 -2.0  
274 gi_119910592 XM_583110 LOC506634 Hypothetical (LOC506634) 0.00 -2.7 -5.5 -2.0  
275 gi_115495372 NM_001076284 PCBP3 Poly(rc) binding protein 3 0.00 -2.7 -5.4 -2.0 --- 
276 gi_119891765 XR_028844 LOC790134 Similar to deubiquitinating enzyme dub1 (LOC790134) 0.00 -2.5 -5.1 -2.0  
277 gi_119895827 XM_001250068 ADRA1B Adrenergic, alpha-1b-, receptor 0.00 -2.6 -5.4 -2.0  
278 gi_134085895 NM_001083469 TMEM156 Transmembrane protein 156 0.00 -4.5 -9.2 -2.0  
279 gi_119912559 XM_586841 LOC509801 Similar to ig-beta, (LOC509801) 0.00 -2.3 -4.6 -2.0 --- 
280 gi_119916122 XM_001249390 LOC781041 Hypothetical protein (LOC781041) 0.00 -26.5 -53.9 -2.0 --- 
281 gi_119915523 XM_868666 LOC615744 Similar to lst-1 gene product, transcript variant 1 (LOC615744) 0.00 -4.9 -9.8 -2.0  
282 gi_155371996 NM_001101135 PAQR8 Progestin and adipoq receptor family member viii 0.00 -2.5 -5.1 -2.0 --- 
283 gi_28849942 NM_174776 TAP Tracheal antimicrobial peptide  0.01 -2.0 -4.1 -2.0 --- 
284 gi_86204308 --- --- Dy059203 001016bemn049454ht bemn cDNA 0.00 -9.1 -18.2 -2.0 --- 
285 gi_148356245 NM_001098380 HSPB2 Heat shock 27kda protein 2 0.01 -2.1 -4.2 -2.0 --- 
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286 gi_119922978 XM_001251667 LOC783012 Hypothetical protein (LOC783012) 0.00 -2.7 -5.4 -2.0  
287 gi_157279838 NM_001104964 ART5 Adp-ribosyltransferase 5 0.00 -7.6 -15.2 -2.0  
288 gi_10169687 --- --- Be755695 209602 marc 2bov cDNA 5' 0.00 -2.3 -4.5 -2.0  
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
     
2.1.6 Full list of genes in profile 6 (n = 71) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
         
 
1 gi_119919150 XM_587468 AHNAK AHNAK nucleoprotein 0.01 -2.1 112.4 235.4 --- 
2 gi_119907136 XM_592427 OAF Oaf homolog (drosophila) 0.00 -23.4 5.7 134.1  
3 gi_119920686 XM_586146 LOC509230 Hypothetical (LOC509230) 0.00 -5.1 22.3 113.1 --- 
4 gi_119895006 XM_590414 LOC512831 Similar to heterogeneous nuclear ribonucleoproteins a2/b1 
(HNRNP a2 / HNRNP b1) (LOC512831) 
0.00 -2.4 44.5 106.1  
5 gi_122692346 NM_001080368 THEM4 Thioesterase superfamily member 4 0.00 -19.4 5.4 104.2 --- 
6 gi_119912853 XM_604523 LOC526163 Similar to cmrf-35 antigen (LOC526163) 0.01 -2.1 47.4 99.0 --- 
7 gi_119902404 XM_869291 TMEM62 Transmembrane protein 62 0.00 -3.3 22.8 75.4 --- 
8* gi_148233315 NM_001098165 RNASEL Ribonuclease l (2',5'-oligoisoadenylate synthetase-dependent) 0.00 -3.3 18.6 60.6 --- 
9 gi_49409620 --- --- Aj677254 kn224 cDNA clone kn224-023_e12 0.00 -7.6 7.7 58.6 --- 
10 gi_31341924 NM_174464 SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 0.00 -14.0 3.8 53.4 --- 
11 gi_164451483 NM_001024533 SLA Src-like-adaptor 0.00 -2.5 18.4 45.5 --- 
12 gi_78042479 NM_001035009 NDRG1 N-myc downstream regulated 1 0.00 -7.9 5.5 43.4 --- 
13 gi_119894531 XM_602953 PDE4C Phosphodiesterase 4c, camp-specific 0.00 -2.4 17.1 41.5  
14 gi_115497115 NM_001076483 ANGPT4 Angiopoietin 4 0.00 -7.5 4.9 36.5  
15 gi_119937227 XM_001256143 LOC789368 Similar to solute carrier family 38, member 5 (LOC789368) 0.00 -9.8 3.7 36.4 --- 
16 gi_62751481 NM_001015534 GALNT6 Udp-n-acetyl-alpha-d-galactosamine:polypeptide n-
acetylgalactosaminyltransferase 6 (galnac-t6) 
0.00 -2.6 12.4 32.8 --- 
17 gi_115495710 NM_001075904 LRRC6 Leucine rich repeat containing 6 0.00 -6.0 5.3 31.9 --- 
18* gi_119908657 XR_027398 RNASEL Ribonuclease l (2',5'-oligoisoadenylate synthetase-dependent) 0.00 -2.4 12.9 31.2 --- 
19 gi_119879461 XM_001253104 GCET2 Germinal center expressed transcript 2 0.00 -8.1 3.7 30.1  
20 gi_119933556 XM_001256914 LOC790449 Similar to PCDH19 protein (LOC790449) 0.00 -5.2 5.6 29.4  
21 gi_119915783 XM_617171 CMAH Cytidine monophosphate-n-acetylneuraminic acid 
hydroxylase (cmp-n-acetylneuraminate monooxygenase) 
pseudogene 
0.00 -11.0 2.5 27.7 --- 
22 gi_51809852 --- --- Co879927 bovgen_08252 normal cattle brain cDNA clone 
rzpdp1056n145q 5' 
0.00 -3.5 7.6 26.3 --- 
23 gi_157279936 NM_001105014 TRIM44 Tripartite motif containing 44 0.00 -4.1 6.1 25.1  
24 gi_154707907 NM_001099095 GZMA Granzyme a (granzyme 1, cytotoxic t-lymphocyte-associated 
serine esterase 3) 
0.00 -4.1 6.1 24.8 --- 
25 gi_116004014 NM_001076898 PAK1 P21 protein (cdc42/rac)-activated kinase 1 0.00 -3.7 6.1 22.3  
26 gi_119888157 XM_580320 STEAP3 STEAP family member 3 0.01 -2.0 10.9 21.9 --- 
27 gi_119889474 XR_028680 LOC788729 Similar to B-cell cll/Lymphoma 9 (LOC788729) 0.00 -3.2 6.6 21.1 --- 
28 gi_119913792 XM_866155 PSTPIP1 Proline-serine-threonine phosphatase interacting protein 1 0.00 -6.4 3.2 20.7 --- 
29 gi_119889467 XM_871861 LOC613322 Hypothetical (LOC613322) 0.00 -3.0 6.9 20.6  
30 gi_61316456 NM_001013003 NEIL2 Nei endonuclease viii-like 2 (e. Coli) 0.00 -2.8 7.1 20.1 --- 
31 gi_119913787 XM_616041 TBC1D2B Tbc1 domain family, member 2b 0.00 -2.7 7.4 19.6 --- 
32 gi_119901593 XM_593801 FUCA2 Fucosidase, alpha-l- 2, plasma 0.00 -2.9 6.4 18.5  
33 gi_119910039 XM_587049 GPR114 G protein-coupled receptor 114 0.01 -2.1 8.5 18.2 --- 
34 gi_117935052 NM_001024930 CCR7 Chemokine (c-c motif) receptor 7 0.00 -8.9 2.0 17.9 --- 
35 gi_31341731 NM_174536 ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1 0.00 -2.3 7.6 17.1 --- 
36 gi_62751350 NM_001015580 SLC38A5 Solute carrier family 38, member 5 0.00 -5.1 3.2 16.1 --- 
37 gi_119879477 XM_585702 ZBTB20 Similar to btb/poz zinc finger protein DPZF (LOC508864) 0.00 -2.3 6.7 15.1 --- 
38 gi_119896213 XM_600235 MLLT3 Myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, drosophila); translocated to, 3 
0.00 -3.3 4.2 13.9 --- 
39 gi_77736587 NM_001034795 GALM Galactose mutarotase (aldose 1-epimerase) 0.00 -6.9 2.0 13.9 --- 
40 gi_119911895 XM_866482 PIK3R5 Phosphoinositide-3-kinase, regulatory subunit 5 0.00 -2.3 6.0 13.5 --- 
41 gi_51822883 --- --- Co892583 bovgen_20908 normal cattle brain cDNA clone 
rzpdp1056b0260q 5' 
0.00 -5.6 2.4 13.5 --- 
42 gi_51802721 --- --- Co872881 bovgen_01206 normal cattle brain cDNA clone 
rzpdp1056n0454q 3' 
0.00 -2.3 4.9 11.2 --- 
43 gi_95147677 NM_001033119 FOXA3 Forkhead box a3 0.00 -2.5 4.3 10.8 --- 
44 gi_119930210 XM_001249776 LOC781367 Similar to ep2 receptor (LOC781367) 0.01 -2.1 5.0 10.7 --- 
45 gi_119918268 XM_877825 AP3M2 Adaptor-related protein complex 3, mu 2 subunit 0.00 -2.5 4.1 10.4 --- 
46 gi_77736204 NM_001034629 EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) 0.00 -2.3 4.4 10.3  
47 gi_122692482 NM_001080293 ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 0.00 -3.4 3.0 10.0 --- 
48 gi_119906384 XM_601798 MTSS1 Metastasis suppressor 1 0.00 -2.5 3.8 9.3  
49 gi_119928343 XM_001255819 LOC788911 Similar to ectonucleotide pyrophosphatase/phosphodiesterase 
2 (autotaxin) (LOC788911) 
0.00 -3.2 2.8 9.1  
50 gi_119918529 XM_585583 PRF1 Perforin 1 (pore forming protein) 0.01 -2.0 4.4 8.9 --- 
51 gi_115496985 NM_001076382 MGST2 Microsomal glutathione s-transferase 2 0.00 -3.1 2.7 8.2 --- 
52 gi_119879750 XM_596716 DGKG Diacylglycerol kinase, gamma 90kda 0.00 -3.4 2.4 8.1 --- 
53 gi_51817761 --- --- Co887476 bovgen_15801 normal cattle brain cDNA clone 
rzpdp1056l1719q 5' 
0.00 -2.3 3.5 8.1 --- 
54 gi_29398540 --- --- Cb533633 761630 marc 6bov cDNA 3' 0.00 -3.8 2.1 8.0 --- 
55 gi_156120702 NM_001102028 PIK3R6 Phosphoinositide-3-kinase, regulatory subunit 6 0.01 -2.0 3.8 7.8  
56 gi_134085680 NM_001083454 ABI3 ABI family, member 3 0.00 -3.0 2.5 7.6 --- 
57 gi_156121270 NM_001102313 HRC Histidine rich calcium binding protein 0.01 -2.2 3.3 7.1 --- 
58 gi_154152162 NM_001100375 BBS12 Bardet-biedl syndrome 12 0.01 -2.1 3.3 7.0 --- 
59 gi_158937245 NM_001110194 HCK Hemopoietic cell kinase 0.00 -2.7 2.3 6.3 --- 
60* gi_119907280 XM_001252306 SUMO3 SMT3 suppressor of mif two 3 homolog 3 (s. Cerevisiae) 0.00 -2.6 2.3 6.0 --- 
61* gi_115497781 NM_001076449 SUMO3 SMT3 suppressor of mif two 3 homolog 3 (s. Cerevisiae) 0.01 -2.1 2.8 5.9 --- 
62 gi_94966784 NM_001040490 TNFRSF1B Tumor necrosis factor receptor superfamily, member 1b 0.01 -2.1 2.8 5.9 --- 
63 gi_155372272 NM_001101279 LOC781494 Similar to myeloid-associated differentiation marker 0.01 -2.1 2.7 5.7  
64 gi_119893596 XM_584935 SLC39A8 Solute carrier family 39 (zinc transporter), member 8 0.01 -2.1 2.6 5.5 --- 
65 gi_119915318 XR_028520 LOC512304 Similar to enpp5 (LOC512304) 0.00 -2.5 2.2 5.5 --- 
66 gi_125991861 NM_001081619 MGC151839 Similar to calpain (MGC151839) 0.01 -2.0 2.7 5.4 --- 
67 gi_116003874 NM_001076826 ANTXR2 Anthrax toxin receptor 2 0.01 -2.1 2.6 5.4 --- 
68 gi_119914706 XM_609627 SEMA3F SEMA domain, immunoglobulin domain (ig), short basic 
domain, secreted, (semaphorin) 3f 
0.00 -2.5 2.0 5.1 --- 
69 gi_119913706 XM_001250647 LOC782068 Hypothetical protein (LOC782068) 0.01 -2.1 2.2 4.6 --- 
70 gi_49357521 --- --- Aj671973 kn224 cDNA clone kn224-007_o17 0.01 -2.0 2.2 4.4 --- 
71 gi_119908660 XM_611689 LAMC1 Laminin, gamma 1 (formerly lamb2) 0.01 -2.0 2.1 4.2 --- 
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Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
     
 
2.1.7 Full list of genes in profile 8 (n = 132) 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
BL20 LPS 
Vs BL20 
FDR 
(4h/or18) 
BL20 LPS 
Vs BL20 
Abs: FC 
(4h/or18) 
TBL20  
Vs BL20 
Abs: FC 
TBL20 Vs 
BL20 LPS 
Abs: FC 
(4h/or18) 
BW720c 
Response 
       
No 
change  
 
1 gi_116004314 NM_001077046 PLIN3 Perilipin 3 0.00 -9.5 1.8 17.2 --- 
2 gi_119920411 XM_001252291 BCOR Bcl6 corepressor 0.00 -21.0 -1.4 15.2 --- 
3 gi_31340780 NM_174669 SERPINE2 Serpin peptidase inhibitor, clade e (nexin, plasminogen 
activator inhibitor type 1), member 2 
0.00 -9.2 1.6 15.0 --- 
4 gi_119892844 XM_581489 FGD4 Fyve, rhogef and ph domain containing 4 0.00 -9.4 1.6 14.9 --- 
5 gi_116004122 NM_001076954 GOLGA7B Golgin a7 family, member b 0.00 -5.7 1.9 10.8 --- 
6 gi_115495426 NM_001075876 CAMKV Cam kinase-like vesicle-associated 0.00 -15.7 -1.5 10.6 --- 
7* gi_118151321 NM_001078125 ARMCX6 Armadillo repeat containing, x-linked 6 0.00 -15.5 -1.5 10.2 --- 
8 gi_119913698 XM_868029 LOC616063 Similar to myeloid-associated differentiation marker  0.00 -8.3 1.2 9.7 --- 
9 gi_51822234 --- --- Co891936 bovgen_20261 normal cattle brain cdna clone 
rzpdp1056m1641q 5' 
0.00 -13.1 -1.4 9.6 --- 
10 gi_156120776 NM_001102065 NID2 Nidogen 2 (osteonidogen)  0.00 -8.7 1.0 9.0 --- 
11 gi_119908995 XM_602397 SLC7A11 Solute carrier family 7, (cationic amino acid transporter, y+ 
system) member 11 
0.00 -9.3 -1.1 8.8 --- 
12 gi_119888246 XR_027752 PLCL1 Phospholipase c-like 1 0.00 -12.5 -1.4 8.8 --- 
13* gi_119922570 XM_001254638 ARMCX6 Armadillo repeat containing, x-linked 6 0.00 -12.3 -1.5 8.5 --- 
14 gi_119893809 XM_613340 RBM47 Rna binding motif protein 47 0.00 -4.5 1.8 8.1 --- 
15 gi_148230339 NM_174557 IGFBP4 Insulin-like growth factor binding protein 4 0.00 -4.4 1.8 7.9 --- 
16 gi_51801726 --- --- Co871894 bovgen_00219 normal cattle brain cdna clone 
rzpdp1056i1952q 3' 
0.00 -5.4 1.2 6.8 --- 
17 gi_31340894 NM_174766 TNS1 Tensin 1 0.00 -10.8 -1.6 6.6 --- 
18* gi_119908122 XM_001252887 RGS1 Regulator of g-protein signaling 1 0.00 -5.6 1.2 6.6 --- 
19 gi_31341563 NM_174601 SLC1A5 Solute carrier family 1 (neutral amino acid transporter), 
member 5 
0.00 -3.6 1.8 6.5 --- 
20 gi_78369387 NM_001035353 PLVAP Plasmalemma vesicle associated protein 0.00 -4.3 1.5 6.5 --- 
21 gi_150247056 NM_001099366 SPRY1 Sprouty homolog 1, antagonist of FGF signaling (drosophila) 0.00 -5.0 1.3 6.5 --- 
22 gi_154152126 NM_001100354 OLFML2B Olfactomedin-like 2b 0.00 -3.9 1.6 6.4 --- 
23 gi_156120814 NM_001102084 NELL2 Nel-like 2 (chicken) 0.00 -4.9 1.3 6.4 --- 
24 gi_51826539   Co896222 bovgen_24547 normal cattle brain cdna clone 
rzpdp1056g0845q 5' 
0.00 -4.8 1.3 6.3 --- 
25 gi_115497431 NM_001075560 NUDT16 Nudix (nucleoside diphosphate linked moiety x)-type motif 16 0.00 -6.2 1.0 6.3 --- 
26 gi_119879733 XM_614853 ETV5 ETS variant 5 0.00 -4.4 1.4 6.2 --- 
27 gi_119230367 --- --- Ee893793 a88211a ffb cdna clone a8821 3' 0.00 -4.8 1.3 6.2 --- 
28 gi_156718123 NM_001103097 F2R Coagulation factor ii (thrombin) receptor 0.00 -4.8 1.2 6.0 --- 
29* gi_119908120 XM_613370 RGS1 Regulator of g-protein signaling 1 0.00 -4.5 1.3 5.8 --- 
30 gi_115494955 NM_001075853 PDK2 Pyruvate dehydrogenase kinase, isozyme 2 0.00 -4.4 1.3 5.8 --- 
31 gi_112218025   Ee357395 lb02958.cr_p24 gc_bgc-29 cdna clone 
image:8474570 
0.00 -3.5 1.6 5.7 --- 
32 gi_119918344 XM_001256392 LOC789727 Hypothetical protein (LOC789727) 0.00 -2.8 2.0 5.6  
33 gi_157954058 NM_001109806 FCGR2B Fc fragment of igg, low affinity iib, receptor (CD32) 0.00 -5.1 1.1 5.4 --- 
34 gi_134085719 NM_001083488 FAM107A Family with sequence similarity 107, member a 0.00 -2.9 1.8 5.2 --- 
35 gi_157074119 NM_001103302 LOC618633 Similar to myeloid-associated differentiation marker  0.00 -2.8 1.8 5.1 --- 
36 gi_116004140 NM_001076960 ARMCX2 Armadillo repeat containing, x-linked 2 0.00 -3.5 1.5 5.1 --- 
37 gi_51812106 --- --- Co882174 bovgen_10499 normal cattle brain cdna clone 
rzpdp1056d2128q 5' 
0.00 -4.3 1.2 5.0 --- 
38 gi_77736420 NM_001034738 LTB4R Leukotriene b4 receptor 0.00 -3.2 1.6 5.0 --- 
39 gi_31343314 NM_173899 CD5 CD5 molecule 0.00 -4.9 1.0 4.8 --- 
40 gi_148237174 NM_001098148 KIAA1383 KIAA1383 0.00 -2.6 1.8 4.8 --- 
41 gi_119930243 XM_585571 PCSK4 Proprotein convertase subtilisin/kexin type 4 0.00 -2.9 1.6 4.7 --- 
42 gi_76657936 XM_597134 LGALS12 Lectin, galactoside-binding, soluble, 12 0.00 -5.5 -1.2 4.6 --- 
43 gi_51820532 --- --- Co890244 bovgen_18569 normal cattle brain cdna clone 
rzpdp1056p2248q 5' 
0.00 -3.3 1.4 4.6 --- 
44 gi_119906547 XR_027912 LOC535166 Similar to sulfatase 1 (LOC535166) 0.00 -2.6 1.7 4.6 --- 
45 gi_119903494 XM_595079 EML6 Echinoderm microtubule associated protein like 6 0.00 -6.3 -1.4 4.5 --- 
46 gi_150247133 NM_001099371 HPDL 4-hydroxyphenylpyruvate dioxygenase-like 0.00 -3.2 1.4 4.5 --- 
47 gi_119887452 XM_874476 GPR155 G protein-coupled receptor 155 0.00 -4.0 1.1 4.5 --- 
48 gi_119904602 XM_582091 STARD13 Star-related lipid transfer (start) domain containing 13 0.00 -4.5 -1.0 4.4 --- 
49 gi_119913769 XM_612854 ARNT2 Aryl-hydrocarbon receptor nuclear translocator 2 0.00 -2.3 1.8 4.3 --- 
50 gi_51819829 --- --- Co889544 bovgen_17869 normal cattle brain cdna clone 
rzpdp1056p2346q 5' 
0.00 -3.4 1.2 4.2 --- 
51 gi_114052243 NM_001046358 CMTM8 Cklf-like marvel transmembrane domain containing 8 0.01 -2.1 2.0 4.2  
52 gi_31343172 NM_173962 SV2A Synaptic vesicle glycoprotein 2a 0.00 -5.5 -1.3 4.2 --- 
53 gi_126158902 NM_001081577 SLC1A4 Solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
0.00 -3.2 1.3 4.2 --- 
54 gi_119910001 XR_028045 LOC786252 Similar to armadillo repeat containing 2 (LOC786252) 0.00 -3.6 1.1 4.1 --- 
55 gi_119912114 XM_614523 NXPH3 Neurexophilin 3 0.00 -3.3 1.2 4.1 --- 
56 gi_148238184 NM_001098020 TLE1 Transducin-like enhancer of split 1 (e(sp1) homolog, 
drosophila) (tle1) 
0.00 -2.2 1.9 4.1 --- 
57 gi_61016342 --- --- DN550204 1408544 marc 7bov cdna 5' 0.00 -5.0 -1.2 4.1 --- 
58 gi_119901706 XM_596626 SYNJ2 Synaptojanin 2 0.01 -2.1 1.9 4.0 --- 
59 gi_119913067 XM_001252617 PDE4D Phosphodiesterase 4d, camp-specific 0.00 -5.2 -1.3 3.9 --- 
60 gi_156121146 NM_001102251 Jakmip1 Janus kinase and microtubule interacting protein 1 0.00 -3.2 1.2 3.8 --- 
61 gi_119891341 XM_868371 PODXL Podocalyxin-like 0.00 -4.7 -1.3 3.8 --- 
62 gi_149642966 NM_001099031 POC1B Poc1 centriolar protein homolog b (chlamydomonas) 0.00 -5.2 -1.4 3.8 --- 
63 gi_51803202 --- --- Co873362 bovgen_01687 normal cattle brain cdna clone 
rzpdp1056h1957q 3' 
0.00 -4.2 -1.1 3.7 --- 
64* gi_51804582 --- SPP1 Secreted phosphoprotein 1 0.00 -4.1 -1.1 3.7 --- 
65 gi_156120560 NM_001101956 MGC152278 Similar to myeloid-associated differentiation marker 0.00 -3.3 1.1 3.7 --- 
66 gi_119895490 XM_601210 HBEGF Heparin-binding egf-like growth factor 0.00 -2.6 1.4 3.6 --- 
67 gi_119892809 XM_615197 CARD10 Caspase recruitment domain family, member 10 0.00 -4.2 -1.2 3.6 --- 
68 gi_114051791 NM_001045971 SPINT2 Serine peptidase inhibitor, kunitz type, 2 0.00 -2.5 1.4 3.6 --- 
69 gi_114051388 NM_001046175 MAP1LC3A Microtubule-associated protein 1 light chain 3 alpha 0.01 -2.1 1.7 3.5 --- 
70 gi_119887600 XM_615555 GALNT3 Udp-n-acetyl-alpha-d-galactosamine:polypeptide n-
acetylgalactosaminyltransferase 3 (GALNAC-t3) 
0.01 -2.2 1.6 3.5 --- 
71 gi_119927446 XM_868985 LOC616864 Similar to proton/amino acid transporter 4 (LOC616864) 0.01 -2.1 1.7 3.5 --- 
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72 gi_119920662 XM_586585 FRMPD4 Ferm and pdz domain containing 4 0.00 -2.6 1.3 3.5 --- 
73 gi_82675971 --- --- Dv815778 lb01717.cr_l17 gc_bgc-17 cdna clone 
image:8094211 5' 
0.01 -2.0 1.7 3.5 --- 
74 gi_114050922 NM_001046448 TSPAN14 Tetraspanin 14 0.00 -2.9 1.2 3.5 --- 
75 gi_31342305 NM_174331 GRK5 G protein-coupled receptor kinase 5 0.00 -3.4 1.0 3.5 --- 
76 gi_15378372 --- --- Bi537262 396963 marc 4bov cdna 5' 0.00 -2.2 1.6 3.4 --- 
77 gi_62460585 NM_001014947 MAPK13 Mitogen-activated protein kinase 13 0.00 -4.5 -1.3 3.4 --- 
78 gi_76665844 XM_609088 AADACL3 Arylacetamide deacetylase-like 3 0.00 -5.7 -1.7 3.4 --- 
79 gi_115497717 NM_001075593 PLEKHA1 Pleckstrin homology domain containing, family a 
(phosphoinositide binding specific) member 1 (plekha1) 
0.01 -2.1 1.6 3.4 --- 
80 gi_116004188 NM_001076984 GLIPR1 Gli pathogenesis-related 1 0.00 -4.3 -1.3 3.4 --- 
81 gi_51803037 --- --- Co873197 bovgen_01522 normal cattle brain cdna clone 
rzpdp1056e1355q 3' 
0.00 -2.3 1.4 3.4 --- 
82 gi_51814093 --- --- Co884145 bovgen_12470 normal cattle brain cdna clone 
rzpdp1056m1024q 5' 
0.00 -2.5 1.4 3.4 --- 
83 gi_115495864 NM_001075533 ST6GALNAC2 ST6 (alpha-n-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-n-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
0.00 -3.3 1.0 3.4 --- 
84 gi_115495270 NM_001075169 SORBS1 Sorbin and sh3 domain containing 1 0.00 -2.8 1.2 3.4 --- 
85 gi_51818199 --- --- Co887914 bovgen_16239 normal cattle brain cdna clone 
rzpdp1056i127q 5' 
0.00 -2.8 1.2 3.3 --- 
86 gi_119932478 XM_001256999 LOC790565 Similar to KIAA0882 protein (LOC790565) 0.00 -5.7 -1.7 3.3 --- 
87 gi_126723520 NM_001082439 IGSF8 Immunoglobulin superfamily, member 8 0.02 -2.0 1.6 3.3 --- 
88 gi_31342040 NM_174422 PDE6H Phosphodiesterase 6h, cgmp-specific, cone, gamma 0.01 -2.2 1.5 3.2 --- 
89 gi_119929752 XM_872864 ARRB2 Arrestin, beta 2 0.00 -3.4 -1.1 3.2 --- 
90* gi_116686101 NM_001077402 FCGR3A Fc fragment of igg, low affinity iiia, receptor (CD16A) 0.00 -2.7 1.2 3.2 --- 
91 gi_51814346 --- DNAJC6 DNAj (hsp40) homolog, subfamily c, member 6 0.01 -2.2 1.5 3.2 --- 
92 gi_119930626 XM_870478 TLE2 Transducin-like enhancer of split 2 (e(sp1) homolog, drosophila) 0.00 -3.1 1.0 3.2 --- 
93 gi_31342110 NM_174398 NCALD Neurocalcin delta 0.00 -3.1 1.0 3.2 --- 
94 gi_157785606 NM_001105637 MAF V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
0.00 -2.4 1.3 3.1 --- 
95 gi_76611568 XM_869196 E2F2 E2f transcription factor 2 0.01 -2.1 1.5 3.1 --- 
96 gi_115495180 NM_001076537 TRIM9 Tripartite motif containing 9 0.00 -3.2 1.0 3.1 --- 
97 gi_78365245 NM_001035418 ARHGEF9 Cdc42 guanine nucleotide exchange factor (Gef) 9 0.00 -3.0 1.0 3.1 --- 
98 gi_156121042 NM_001102198 SLC19A3 Solute carrier family 19 (sodium/hydrogen exchanger), 
member 3 
0.01 -2.1 1.5 3.1 --- 
99 gi_51810610 --- --- Co880681 bovgen_09006 normal cattle brain cdna clone 
rzpdp1056l159q 5' 
0.00 -3.0 1.0 3.1 --- 
100 gi_119909968 XM_870732 GPT2 Glutamic pyruvate transaminase (alanine aminotransferase) 2 0.00 -2.8 1.1 3.0 --- 
101 gi_119909938 XR_028750 SPIRE2 Spire homolog 2 (drosophila) 0.00 -2.4 1.2 3.0 --- 
102 gi_51814374 --- --- Co884380 bovgen_12705 normal cattle brain cdna clone 
rzpdp1056f1329q 5' 
0.00 -2.4 1.3 3.0 --- 
103 gi_115497811 NM_001076453 SLC19A1 Solute carrier family 19 (folate transporter), member 1 0.00 -2.4 1.2 3.0 --- 
104 gi_154152082 NM_001100341 C1orf74 Chromosome 1 open reading frame 74 0.00 -4.4 -1.5 3.0 --- 
105 gi_155371832 NM_001101051 MFNG Mfng o-fucosylpeptide 3-beta-n-
acetylglucosaminyltransferase 
0.00 -3.1 -1.1 2.9 --- 
106 gi_51812300 --- --- Co882368 bovgen_10693 normal cattle brain cdna clone 
rzpdp1056o0813q 5' 
0.00 -2.2 1.3 2.9 --- 
107 gi_115496721 NM_001075152 TMC4 Transmembrane channel-like 4 0.01 -2.2 1.3 2.9 --- 
108 gi_82812588 --- --- Dv878359 lb0261.cr_k19 gc_bgc-26 cdna clone 
image:8279949 5' 
0.01 -2.0 1.4 2.9 --- 
109 gi_123858767 NM_001080366 PJA1 Praja ring finger 1 0.00 -2.7 1.1 2.9 --- 
110 gi_119911133 XM_001256455 C19orf51 Chromosome 19 open reading frame 51 0.00 -2.6 1.1 2.9 --- 
111 gi_156523107 NM_001102498 NKAPL NFkB activating protein-like  0.00 -2.5 1.1 2.9 --- 
112* gi_31342344 NM_174317 FCGR3A Fc fragment of igg, low affinity iiia, receptor (CD16A) 0.00 -2.4 1.2 2.8 --- 
113 gi_41386781 NM_174231 ADRB2 Adrenergic, beta-2-, receptor, surface 0.00 -2.5 1.1 2.8 --- 
114 gi_119915572 XM_588389 ZKSCAN4 Similar to zinc finger protein 307, transcript variant 1 
(LOC539620) 
0.00 -3.2 -1.1 2.8 --- 
115 gi_119912967 XM_596546 SH3PXD2B Sh3 and px domains 2b 0.00 -2.8 1.0 2.8 --- 
116* gi_164420752 NM_001113245 TRAF3IP3 TRAF3 interacting protein 3 0.00 -4.6 -1.7 2.8 --- 
117 gi_94966796 NM_001040496 ART3 Adp-ribosyltransferase 3 0.01 -2.1 1.3 2.8 --- 
118 gi_119896289 XM_867351 KIAA1797 Kiaa1797 0.00 -2.4 1.1 2.7 --- 
119 gi_51804553 --- ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) 0.00 -2.4 1.1 2.7 --- 
120 gi_51816423 --- --- Co886138 bovgen_14463 normal cattle brain cDNA clone 
rzpdp1056k1213q 5' 
0.00 -2.5 1.1 2.6 --- 
121 gi_51823084 --- --- Co892784 bovgen_21109 normal cattle brain cDNA clone 
rzpdp1056l2445q 5' 
0.00 -2.3 1.1 2.6 --- 
122 gi_119914579 XM_001250879 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 0.00 -4.7 -1.8 2.6 --- 
123 gi_119912784 XM_001253301 MXRA7 Matrix-remodelling associated 7 0.00 -2.2 1.2 2.6 --- 
124 gi_115496251 NM_001075741 GPRC5B G protein-coupled receptor, family c, group 5, member b 0.00 -2.4 1.0 2.5 --- 
125 gi_82691756 --- --- Dv831563 lb01919.cr_p18 gc_bgc-19 cdna clone 
image:8116580 5' 
0.00 -2.3 1.1 2.5 --- 
126 gi_56710322 NM_001008664 TLR3 Toll-like receptor 3 0.00 -4.8 -2.0 2.4 --- 
127 gi_118150831 NM_001077858 CTPS CTP synthase 0.00 -2.2 1.1 2.4 --- 
128 gi_119887519 XM_607085 PDK1 Pyruvate dehydrogenase kinase, isozyme 1 0.01 -2.1 1.1 2.4 --- 
129 gi_78042497 NM_001035017 PHGDH Phosphoglycerate dehydrogenase 0.00 -2.3 1.0 2.3 --- 
130 gi_119918586 XM_586457 FUT11 Fucosyltransferase 11 (alpha (1,3) fucosyltransferase) 0.01 -2.0 1.1 2.2 --- 
131 gi_119907072 XR_028456 LOC614237 Similar to apolipoprotein c-iii (LOC614237) 0.00 -4.0 -1.9 2.1 --- 
132 gi_157954050 NM_001109796 CARD11 Caspase recruitment domain family, member 11 0.01 -2.0 1.0 2.1 --- 
Asterisk (*) beside the serial no indicates duplicate probe present in the modulated dataset 
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2.2 Complete list of ‘biological function and disease’ categories 
identified by IPA in modulated gene list (1959 genes) 
 Category  p-value 
   
1 Inflammatory Response 8.22E-17-8.68E-04 
2 Hematological System Development and Function 1.46E-12-7.67E-04 
3 Tissue Morphology 1.46E-12-4.88E-04 
4 Cellular Development 6.01E-12-6.08E-04 
5 Hematopoiesis 6.01E-12-7.39E-04 
6 Nervous System Development and Function 6.74E-12-6.74E-12 
7 Cell-To-Cell Signaling and Interaction 7.36E-12-8.63E-04 
8 Cellular Movement 1E-11-7.87E-04 
9 Cell Death 4.79E-11-7.39E-04 
10 Inflammatory Disease 4.99E-11-7.75E-04 
11 Cancer 1.08E-10-6.92E-04 
12 Cell-mediated Immune Response 1.11E-10-7.39E-04 
13 Cellular Function and Maintenance 1.11E-10-6.93E-04 
14 Renal and Urological Disease 6.21E-10-9.19E-05 
15 Dermatological Diseases and Conditions 9.06E-10-8.03E-04 
16 Immune Cell Trafficking 1.11E-09-7.39E-04 
17 Immunological Disease 1.39E-09-7.66E-04 
18 Infectious Disease 1.52E-09-6.93E-04 
19 Cellular Growth and Proliferation 2.48E-09-8.39E-04 
20 Tissue Development 7.22E-09-5.07E-04 
21 Respiratory Disease 3.79E-08-6.93E-04 
22 Gastrointestinal Disease 4.86E-08-5.07E-04 
23 Hepatic System Disease 1.94E-07-5.07E-04 
24 Antimicrobial Response 2.33E-07-6.33E-04 
25 Organismal Survival 3.14E-07-2.07E-06 
26 Reproductive System Disease 5.54E-07-6E-05 
27 Connective Tissue Disorders 6.16E-07-7.75E-04 
28 Skeletal and Muscular Disorders 6.16E-07-7.75E-04 
29 Organismal Injury and Abnormalities 1.2E-06-8E-04 
30 Humoral Immune Response 2.03E-06-4.43E-04 
31 Antigen Presentation 5.62E-06-6.48E-04 
32 Cell Signaling 5.72E-06-2.56E-04 
33 Molecular Transport 5.72E-06-3.7E-04 
34 Vitamin and Mineral Metabolism 5.72E-06-1.24E-04 
35 Hematological Disease 7.29E-06-7.69E-04 
36 Neurological Disease 7.9E-06-7.97E-04 
37 Gene Expression 7.99E-06-2.72E-04 
38 Genetic Disorder 8.81E-06-7.75E-04 
39 Infection Mechanism 1.16E-05-4.76E-04 
40 Metabolic Disease 1.27E-05-6.2E-04 
41 Cardiovascular System Development and Function 1.32E-05-5.18E-04 
42 Organismal Development 1.32E-05-5.18E-04 
43 Cell Morphology 1.85E-05-6.93E-04 
44 Lymphoid Tissue Structure and Development 1.89E-05-8.39E-04 
45 Endocrine System Disorders 2.1E-05-6.07E-04 
46 Small Molecule Biochemistry 2.12E-05-3.7E-04 
47 DNA Replication, Recombination, and Repair 2.42E-05-2.42E-05 
48 Embryonic Development 5.1E-05-1.58E-04 
49 Organismal Functions 5.35E-05-5.35E-05 
50 Cellular Assembly and Organization 1.39E-04-8.63E-04 
51 Cardiovascular Disease 1.42E-04-6.25E-04 
52 Skeletal and Muscular System Development and Function 1.43E-04-4.69E-04 
53 Hair and Skin Development and Function 1.58E-04-5.69E-04 
54 Renal and Urological System Development and Function 1.58E-04-1.58E-04 
55 Cellular Compromise 1.74E-04-3.29E-04 
56 Tumor Morphology 1.74E-04-3.67E-04 
57 Post-Translational Modification 2.14E-04-2.14E-04 
58 Connective Tissue Development and Function 2.2E-04-2.2E-04 
59 Amino Acid Metabolism 3.7E-04-3.7E-04 
60 Carbohydrate Metabolism 4.27E-04-4.27E-04 
61 Free Radical Scavenging 4.67E-04-4.67E-04 
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2.3 Full list of ‘canonical pathways’ identified by IPA in modulated 
gene list (1959 genes) 
 Ingenuity Canonical Pathways -log(p-value) Ratio 
1 
 
Dendritic Cell Maturation 1.27E+01 1.81E-01 
2 Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 7.19E+00 1.14E-01 
3 Activation of IRF by Cytosolic Pattern Recognition Receptors 6.63E+00 2.08E-01 
4 Hepatic Fibrosis / Hepatic Stellate Cell Activation 6.59E+00 1.56E-01 
5 Crosstalk between Dendritic Cells and Natural Killer Cells 6.52E+00 1.86E-01 
6 TNFR2 Signaling 6.23E+00 2.94E-01 
7 Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 6.09E+00 1.84E-01 
8 CD40 Signaling 5.84E+00 2.00E-01 
9 NF-kB Signaling 5.23E+00 1.31E-01 
10 LPS-stimulated MAPK Signaling 5.04E+00 1.71E-01 
11 G-Protein Coupled Receptor Signaling 4.38E+00 8.70E-02 
12 4-1BB Signaling in T Lymphocytes 4.29E+00 2.35E-01 
13 Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 4.25E+00 1.07E-01 
14 April Mediated Signaling 4.19E+00 2.09E-01 
15 IL-12 Signaling and Production in Macrophages 4.15E+00 1.21E-01 
16 B Cell Activating Factor Signaling 4.00E+00 2.00E-01 
17 Communication between Innate and Adaptive Immune Cells 3.93E+00 1.28E-01 
18 Atherosclerosis Signaling 3.83E+00 1.31E-01 
19 PI3K Signaling in B Lymphocytes 3.70E+00 1.19E-01 
20 IL-17A Signaling in Fibroblasts 3.67E+00 2.00E-01 
21 VDR/RXR Activation 3.45E+00 1.48E-01 
22 Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 3.38E+00 9.58E-02 
23 TNFR1 Signaling 3.36E+00 1.70E-01 
24 Type II Diabetes Mellitus Signaling 3.36E+00 9.38E-02 
25 Toll-like Receptor Signaling 3.29E+00 1.64E-01 
26 Role of PKR in Interferon Induction and Antiviral Response 3.24E+00 1.74E-01 
27 IL-6 Signaling 3.23E+00 1.30E-01 
28 iCOS-iCOSL Signaling in T Helper Cells 3.23E+00 1.15E-01 
29 NF-kB Activation by Viruses 3.13E+00 1.34E-01 
30 Type I Diabetes Mellitus Signaling 3.10E+00 1.16E-01 
31 Role of Tissue Factor in Cancer 3.10E+00 1.23E-01 
32 Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 3.06E+00 1.30E-01 
33 RANK Signaling in Osteoclasts 3.01E+00 1.26E-01 
34 Interferon Signaling 2.98E+00 1.94E-01 
35 TREM1 Signaling 2.98E+00 1.36E-01 
36 Lymphotoxin Î² Receptor Signaling 2.98E+00 1.48E-01 
37 Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes 2.84E+00 1.24E-01 
38 B Cell Receptor Signaling 2.78E+00 1.03E-01 
39 GÎ±12/13 Signaling 2.73E+00 1.09E-01 
40 Death Receptor Signaling 2.70E+00 1.38E-01 
41 Induction of Apoptosis by HIV1 2.64E+00 1.36E-01 
42 Hepatic Cholestasis 2.57E+00 8.67E-02 
43 IL-17A Signaling in Airway Cells 2.50E+00 1.25E-01 
44 LXR/RXR Activation 2.45E+00 1.08E-01 
45 Angiopoietin Signaling 2.40E+00 1.22E-01 
46 CD28 Signaling in T Helper Cells 2.39E+00 9.85E-02 
47 Role of IL-17A in Arthritis 2.37E+00 1.27E-01 
48 Role of IL-17F in Allergic Inflammatory Airway Diseases 2.37E+00 1.52E-01 
49 Reelin Signaling in Neurons 2.32E+00 1.22E-01 
50 Erythropoietin Signaling 2.31E+00 1.15E-01 
51 Role of RIG1-like Receptors in Antiviral Innate Immunity 2.31E+00 1.43E-01 
52 Role of JAK1, JAK2 and TYK2 in Interferon Signaling 2.28E+00 1.85E-01 
53 FcÎ³ Receptor-mediated Phagocytosis in Macrophages and Monocytes 2.28E+00 1.08E-01 
54 TWEAK Signaling 2.27E+00 1.54E-01 
55 IL-10 Signaling 2.27E+00 1.15E-01 
56 Agrin Interactions at Neuromuscular Junction 2.27E+00 1.30E-01 
57 Growth Hormone Signaling 2.27E+00 1.20E-01 
58 Macropinocytosis Signaling 2.27E+00 1.18E-01 
59 HMGB1 Signaling 2.24E+00 1.10E-01 
60 T Helper Cell Differentiation 2.23E+00 1.25E-01 
61 PPAR Signaling 2.21E+00 1.04E-01 
62 Role of JAK family kinases in IL-6-type Cytokine Signaling 2.20E+00 1.85E-01 
63 Small Cell Lung Cancer Signaling 2.15E+00 1.01E-01 
64 Systemic Lupus Erythematosus Signaling 2.15E+00 8.48E-02 
65 T Cell Receptor Signaling 2.14E+00 1.01E-01 
66 PKCÎ¸ Signaling in T Lymphocytes 2.00E+00 8.45E-02 
67 O-Glycan Biosynthesis 1.99E+00 1.16E-01 
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68 CD27 Signaling in Lymphocytes 1.96E+00 1.23E-01 
69 Natural Killer Cell Signaling 1.95E+00 1.00E-01 
70 Role of JAK1 and JAK3 in Î³c Cytokine Signaling 1.93E+00 1.16E-01 
71 ATM Signaling 1.91E+00 1.30E-01 
72 MIF Regulation of Innate Immunity 1.87E+00 1.20E-01 
73 Pancreatic Adenocarcinoma Signaling 1.86E+00 9.24E-02 
74 Molecular Mechanisms of Cancer 1.86E+00 6.90E-02 
75 Glioma Signaling 1.78E+00 8.93E-02 
76 Glucocorticoid Receptor Signaling 1.77E+00 7.12E-02 
77 ILK Signaling 1.74E+00 8.29E-02 
78 Role of NFAT in Regulation of the Immune Response 1.67E+00 7.50E-02 
79 IGF-1 Signaling 1.66E+00 9.35E-02 
80 Leukocyte Extravasation Signaling 1.64E+00 8.04E-02 
81 MSP-RON Signaling Pathway 1.64E+00 1.18E-01 
82 Inhibition of Angiogenesis by TSP1 1.64E+00 1.28E-01 
83 Estrogen-Dependent Breast Cancer Signaling 1.59E+00 1.00E-01 
84 JAK/Stat Signaling 1.56E+00 1.09E-01 
85 Nitrogen Metabolism 1.54E+00 4.13E-02 
86 PI3K/AKT Signaling 1.53E+00 7.86E-02 
87 IL-15 Signaling 1.52E+00 1.03E-01 
88 Virus Entry via Endocytic Pathways 1.52E+00 9.00E-02 
89 NRF2-mediated Oxidative Stress Response 1.52E+00 7.77E-02 
90 IL-17A Signaling in Gastric Cells 1.51E+00 1.60E-01 
91 Acute Phase Response Signaling 1.49E+00 7.87E-02 
92 Ceramide Signaling 1.46E+00 9.20E-02 
93 p53 Signaling 1.44E+00 9.38E-02 
94 Cdc42 Signaling 1.38E+00 7.47E-02 
95 Prostate Cancer Signaling 1.37E+00 8.25E-02 
96 OX40 Signaling Pathway 1.37E+00 8.89E-02 
97 IL-15 Production 1.35E+00 1.25E-01 
98 Thrombopoietin Signaling 1.31E+00 9.52E-02 
99 HGF Signaling 1.29E+00 8.57E-02 
100 Nicotinate and Nicotinamide Metabolism 1.29E+00 6.67E-02 
101 Renal Cell Carcinoma Signaling 1.28E+00 9.46E-02 
102 Parkinson's Signaling 1.27E+00 1.67E-01 
103 14-3-3-mediated Signaling 1.26E+00 8.33E-02 
104 Intrinsic Prothrombin Activation Pathway 1.26E+00 1.18E-01 
105 IL-3 Signaling 1.25E+00 9.46E-02 
106 PDGF Signaling 1.25E+00 8.86E-02 
107 Human Embryonic Stem Cell Pluripotency 1.25E+00 7.14E-02 
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2.4 Full list of important biological functions identified by Ingenuity 
associated with genes modulated by Theileria infection relative to 
BL20-LPS 
  Repressed by parasite  Enhanced by parasite 
 Important functions no. Genes 
(Pro/anti) 
p-value no. Genes   
(Pro/anti) 
p-value 
      
1 Inflammatory Response 111 34 
 Immune response 100 (43,27) 2.12E-09 27 (15,7) 4.51E-04 
 Activation of leukocyte 46 (27,9) 2.67E-06 13 (9,1) 3.76E-03 
 Antimicrobial response 19 (3,1) 4.88E-05 _ _ 
 Activation of lymphocyte 31 (19,7) 9.48E-05 9 (5,1) 1.20E-02 
 Antiviral response 13 (3,1) 9.60E-05 2 (0,0) 1.17E-02 
 Inflammation 30 (12,3) 7.22E-04 12 (3,2) 6.49E-04 
 Inflamatory response 41 (17,10) 3.34E-04 16 (7,3) 2.30E-04 
2 Cellular Development 146 31 
 Development of cells  84 (34,21) 3.74E-04 30 (14,4) 8.94E-05 
 Development of leukocytes  54 (20,14) 4.18E-07 18 (9,2) 2.54E-03 
 Differentiation of cancer cells 7 (3,1) 1.68E-04 _ _ 
 Differentiation of cells  94 (45,32) 6.55E-04 _ _ 
3 Hematological System 
Development and Function 
120 40 
 Activation of leukocyte  46 (27,9) 2.67E-06 13 (9,1) 3.76E-03 
 Adhesion of leukocyte  21 (10,1) 2.78E-04 7 (3,1) 7.24E-03 
 Cell movement of leukocyte  37 (16,10) 1.15E-03 20(6,7) 4.46E-07 
 Development of leukocytes  54 (20,14) 4.18E-07 _ _ 
 Development of lymphocytes  51 (19,12) 1.74E-06 17(7,2) 1.97E-04 
 Proliferation of lymphocytes 49 (24,16) 7.80E-07 14 (7,3) 2.07E-03 
 Differentiation of leukocytes 36 (20,10) 1.65E-03 _ _ 
 Hematological process 72 (31,18) 1.37E-07 20 (8,4) 1.26E-03 
4 Cell-To-Cell Signaling and 
Interaction 
126 38 
 Activation of leukocyte  46 (27,9) 2.67E-06 13 (9,1) 3.76E-03 
 Adhesion of cells 59 (23,11) 2.75E-06 10 (5,2) 3.20E-03 
 Response of cell  36 (9,8) 4.32E-05 _ _ 
 Binding of eukaryotic cell  36 (14,10) 1.08E-04 12(5,2) 2.25E-03 
 Stimulation of eukaryotic cells 15 (12,1) 2.83E-03 7 (3,0) 1.38E-03 
5 Tissue Morphology 77 26 
 Quantity of leukocyte 47 (11,8) 7.47E-07 15 (1,0) 3.79E-04 
 Quantity of antigen presenting 
cell  
14 (5,0) 3.46E-03 _ _ 
 Quantity of phagocytes 20 (5,1) 1.02E-03 7 (1,0) 8.40E-03 
6 Cellular Growth and 
Proliferation 
140 45 
 Proliferation of cells  124 (72,51 3.13E-03 40 (18,13) 8.48E-04 
 Proliferation of leukocyte 50 (25,17) 1.75E-06 6 (4,0) 7.66E-03 
 Induction of leukocyte  9 (7,3) 2.23E-04 _ _ 
 Stimulation of leukocytes  11 (9,3) 2.87E-03 _ _ 
7 Immunological Disease 150 52 
 Immunological disorder 150 (6,5) 1.37E-03 52 (0,2) 1.50E-05 
8 Cell Death 170 52 
 Cell death of cancer cells 20 (6,4) 1.15E-05 _ _ 
 Apoptosis of tumor cell line 72 (34,22) 2.34E-06 20 (12,7) 3.07E-03 
 Apoptosis 134 (70,53) 2.10E-05 42 (24,19) 1.13E-04 
 Cell death of tumor cell line 78 (38,28) 2.10E-05 24 (13,9) 9.39E-04 
 Cell death 151 (75,62) 6.59E-05 49 (26,22) 3.22E-05 
 Cytotoxicity of lymphocytes 15 (8,6) 1.65E-04 _ _ 
 Cell death of normal cell _ _ 23 (8,9) 6.77E-03 
9 Cell-mediated Immune 
Response 
57 18 
 Adhesion of T lymphocytes 10 (5,0) 8.50E-04 _ _ 
 Differentiation of T lymphocytes 24 (9,1) 1.45E-03 _ _ 
 Induction of T lymphocytes 6 (3,0) 2.50E-03 _ _ 
 T cell development _ _ 16 (7,2) 2.60E-04 
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10 Cellular Function and 
Maintenance 
67 28 
 Differentiation of T lymphocytes 24 (9,1) 1.45E-03 _ _ 
11 Tissue Development 74 29 
 Adhesion of cells  59 (23,11) 2.75E-06 10 (5,2) 2.30E-03 
 Generation of lymphocytes 11 (5,2) 5.69E-04 _ _ 
12 Cellular Movement 100 46 
 Movement of cells  82 (42,29) 1.67E-04 38 (19,12)  4.47E-09 
 Migration of leukocytes  36 (22,9) 1.75E-03 17(6,3) 2.49E-05 
 Invasion of eukaryotic cells _ _ 14(10,3) 5.92E-04 
 Infiltration of leukocytes 25 (8,6) 3.30E-04 14 (2,3) 1.41E-06 
 Migration of antigen presenting 
cells 
14 (7,1) 1.65E-04 _ _ 
 Influx of leukocytes  7 (4,1) 2.02E-03 _ _ 
 Chemoattraction of leukocytes 6 (6,0) 4.19E-03 _ _ 
13 Antimicrobial Response 19 19 
 Antimicrobial Response 19 (3,1) 4.88E-05 _ _ 
 Antiviral response  13 (3,1) 9.60E-05 2 (0,0) 1.17E-02 
14 Cancer 189 60 
 Metastasis of cells  10 (2,6 ) 3.23E-03 13 (3,1) 2.29E-03 
 Tumourigenesis 179 (26,25) 1.73E-03 60 (6,2) 1.74E-05 
 Cancer 173 (16,13) 7.55E-05 56 (3,1) 1.58E-05 
 Disease of tumor 18 (2,4) 7.29E-04 _ _ 
 Growth of tumor  20 (2,9) 1.18E-03 _ _ 
 Tumor _ _ 43 (4,2) 1.11E-04 
15 Antigen Presentation 45 16 
 Differentiation of macrophages 10 (7,2) 4.76E-03 _ _ 
 Chemoattraction of antigen 
presenting cells 
4(4,1) 3.73E-03 _ _ 
 Activation of monocytes 8(7,1) 2.37E-03 _ _ 
16 Cell Signaling 46 35 
 Activation of cells  61 (35,15) 2.85E-06 20 (12,2) 6.10E-05 
 Activation of leukocytes 46 (27,9) 2.67E-06 13 (9,1) 3.76E-03 
 Adhesion of cells  59 (23,11) 2.75E-06 10 (5,2) 3.20E-03 
 Activation of lymphocyte 31 (19,17) 9.48E-05 9 (5,1) 1.20E-02 
 Production of nitric oxide 17(8,2) 1.65E-04 _ _ 
 Binding of eukaryotic cell  36 (14,10) 1.08E-04 12 (5,2) 2.25E-03 
17 Cellular Assembly and 
Organization 
21 19 
 Formation of actin filaments _ _ 8 (3,1) 1.30E-03 
 Formation of cellular protrusions _ _ 10 (4,0) 2.71E-03 
 Formation of actin cytoskeleton 4 (0,0) 1.01E-03 4 (2,0) 1.10E-02 
 Formation of filaments _ _ 9 (5,1) 4.06E-03 
 Formation of cytoskeleton 5 (0,0) 2.11E-04 _ _ 
 Elongation of plasma 
membrane projection 
7 (4,0) 3.95E-03 _ _ 
18 Organismal Injury and 
Abnormalities 
29 20 
 Angiogenesis 32 (13,8) 2.64E-04 _ _ 
19 Cell Morphology 53 17 
 Shape changes of eukaryotic 
cells 
_ _ 11 (6,3) 6.12E-04 
 Shape changes _ _ 13 (7,4) 3.65E-03 
20 DNA Replication, 
Recombination, and Repair 
26 13 
 Synthesis of DNA  26 (9,13) 3.67E-03 10 (4,3) 3.77E-03 
21 Gene expression 61 1 
 Expression of synthetic 
promotor 
31 (23,9) 1.00E-03 _ _ 
 Transcription of synthetic 
promotor 
28 (21,8) 1.38E-03 _ _ 
 Activation of NF-kB binding site 10 (6,2) 2.08E-03 _ _ 
 Transactivation 41 (27,14) 2.15E-03 _ _ 
 
 
    
The criteria applied for the selection of major biological function categories were maximum number of 
genes and the P-value of significance. P-values in the range of 2.12E-09 to 1.10E-02 indicated 
statistical significance
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Appendix 3: Microarray results of chapter 5  
3.1 Complete lists of TashAT2 modulated 466 genes showing similar 
response in parasite infection 
3.1.1 Full list of TashAT2 modulated repressed genes (n = 353) showing 
similar response in parasite infection 
     
TashAT2 transfected BoMac 
array results 
Infection associated 
TBL20 array results 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
TashAT2 
vs 
PCAGGS 
control 
FDR  
TashAT2  
vs 
PCAGGS 
control 
abs: FC 
TahAT2 
PMA vs 
control 
PMA 
abs: FC  
TBL20  
vs BL20   
 
 
abs: FC 
TBL20 LPS 
vs BL20 LPS 
 
abs:FC 
(4h/or18) 
B
W
7
2
0
c 
R
es
p
o
n
se
 
       /-- /-- /--  
1 gi_119904441 XM_580490 KBTBD6 Kelch repeat and btb (poz) domain containing 6 0.000 -193.13 -23.66 -3.0 -26.96 -- 
2 gi_51827054 CO896734 – – - Co896734 bovgen_25059 normal cattle brain cDNA clone 
rzpdp1056g181q 5' sequence 
0.000 -148.50 -10.67 -2.3 -39.82 -- 
3 gi_119893539 XM_597721 C4orf31 Chromosome 4 open reading frame 31 0.000 -95.97 -161.26 -4.2 -2.21 -- 
4 * gi_118601863 NM_001079634 S100A14 S100 calcium binding protein a14 0.000 -73.91 -81.80 -2.8 -4.04 -- 
5 * gi_113204619 NM_001015570 LGALS9 Lectin, galactoside-binding, soluble, 9 0.000 -55.55 -146.46 -4.0 -2.42  
6 gi_31342140 NM_174388 MFAP2 Microfibrillar-associated protein 2 0.000 -52.90 -68.35 -22.5 -8.57  
7 gi_155372278 NM_001101282 PTER Phosphotriesterase related 0.000 -46.06 -13.84 -3.0 -2.29 -- 
8 * gi_115496411 NM_001075349 CHN1 Chimerin 1 0.000 -35.99 -22.44 -3.3 -11.21  
9 gi_156631000 NM_174459 SEPP1 Selenoprotein p, plasma, 1 0.000 -31.85 -20.75 -18.1 -32.12  
10 gi_119912910 XM_599356 FAM20A Family with sequence similarity 20, member a 0.000 -31.30 -18.06 -21.3 -18.36 -- 
11 gi_119917968 XM_866446 JAKMIP3 Janus kinase and microtubule interacting protein 3 0.000 -29.29 -5.88 -5.3 -16.13  
12 gi_119891852 XM_001253861 LOC786058 Similar to neuron navigator 3 (LOC786058) 0.000 -23.15 -1.76 -3.7 -2.99  
13 gi_119647255 EH175940 – – - Eh175940 lb01656.cr_a03 gc_bgc-16cDNA clone 
image:8386637 5' sequence 
0.000 -22.95 -20.23 -3.3 -3.40 -- 
14 gi_51809236 CO879312 – – - Co879312 bovgen_07639 normal cattle brain cDNA clone 
rzpdp1056h0111q 5' sequence 
0.000 -22.50 -1.90 -3.3 -2.50  
15 gi_51887303 AJ819827 – – - Aj819827 kn206 bos sp. cDNA clone c0006016j19  Seq 0.000 -19.98 -7.75 -1.2 -2.25 -- 
16 gi_148236122 NM_001098043 CLMP CXADR-like membrane protein 0.000 -19.47 -33.85 -3.2 -12.63 -- 
17 gi_112203941 EE344148 – – - Ee344148 lb02547.cr_a22 gc_bgc-25cDNA clone 
image:8617440 sequence 
0.000 -18.59 -1.78 -3.4 -3.07  
18 gi_49410464 AJ677881 – – - Aj677881 kn224cDNA clone kn224-024_p02 sequence 0.000 -18.55 -29.00 -5.4 -3.52 -- 
19 gi_89886135 NM_001013585 S1PR1 Sphingosine-1-phosphate receptor 1 0.000 -17.70 -64.46 -54.6 -15.19  
20 gi_119891847 XM_607306 NAV3 Neuron navigator 3 0.000 -17.61 -1.57 -3.7 -2.72  
21 gi_114052379 NM_001046538 RAB15 Rab15, member ras onocogene family 0.000 -17.52 -7.59 -1.7 -4.76 -- 
22 gi_78369427 NM_001035317 MVP Major vault protein 0.000 -17.27 -23.91 -2.0 -9.94 -- 
23 gi_45430004 NM_205788 CEACAM8 Carcinoembryonic antigen-related cell adhesion molecule 8 0.000 -17.26 -39.63 -6.0 -9.41  
24 gi_119916193 XM_612197 LOC532965 Similar to alpha3a chain laminin (LOC532965) 0.000 -16.92 -25.49 -4.2 -2.41 -- 
25 gi_119887265 XM_587548 PLCL2 Phospholipase c-like 2 0.000 -15.51 -10.53 -5.0 -4.30  
26 gi_119909284 XM_868620 HVCN1 Hydrogen voltage-gated channel 1 0.000 -15.22 -8.63 -30.4 -24.83  
27 gi_51880943 AJ813467 – – - Aj813467 kn206 bos sp. cDNA clone c0005207e23 seq 0.000 -15.12 -14.90 -5.1 -10.63  
28 gi_119935010 XM_001256813 LOC790300 Similar to deltex1 (loc790300) 0.000 -14.61 -12.26 -1.0 -12.21 -- 
29 gi_10870122 BF076357 – – - BF076357 225899 marc 2bov cDNA 5' seq 0.000 -13.97 -4.30 -1.2 -3.33 -- 
30 gi_119888854 XM_866713 MAN1C1 Mannosidase, alpha, class 1c, member 1 0.000 -13.33 -8.32 -4.3 -3.83 -- 
31 gi_119940186 XM_607283 LOC528849 Similar to mer receptor tyrosine kinase (LOC528849) 0.000 -12.50 -13.10 -18.1 -11.92 -- 
32 gi_115496605 NM_001076352 LMO2 Lim domain only 2 (rhombotin-like 1) 0.000 -12.25 -30.10 -15.7 -10.54  
33 gi_119919045 XM_869718 PKNOX2 Pbx/knotted 1 homeobox 2 0.000 -12.02 -7.59 -3.7 -4.63 -- 
34 gi_119890631 XM_606290 KIF1A Kinesin family member 1A 0.000 -11.86 -14.21 -23.7 -18.01  
35 gi_119925613 XM_583887 GXYLT2 Glucoside xylosyltransferase 2 0.000 -11.69 -9.28 -222.3 -87.74 -- 
36 gi_51809634 CO879711 – – - Co879711 bovgen_08036 normal cattle brain cDNA clone 
rzpdp1056j1411q 5' sequence 
0.000 -11.62 -9.69 -2.7 -2.85  
37 gi_119915305 XR_028046 RUNX2 Similar to runt-related transcription factor 2 (LOC536911) 0.000 -11.58 -2.93 1.2 -5.73 -- 
38 gi_119879695 XM_867115 TP63 Tumor protein p63 0.000 -11.42 -3.62 1.9 -36.69 -- 
39 gi_157279834 NM_001104962 ANK1 Ankyrin 1, erythrocytic 0.000 -11.29 -10.10 -93.6 -82.95  
40 gi_61870087 XM_588576 PCDHGA5 Protocadherin gamma subfamily A, 5 0.000 -10.70 -10.47 -4.7 -7.65  
41 gi_156120752 NM_001102053 KANK4 KN motif and ankyrin repeat domains 4 0.000 -10.50 -2.65 -13.6 -9.45 -- 
42 gi_119893961 XM_598333 RASSF6 Ras association (ralgds/af-6) domain family member 6 0.000 -9.90 -8.91 -1.1 -1.97 -- 
43 gi_51825172 CO894862 – – - Co894862 bovgen_23187 normal cattle brain cDNA clone 
rzpdp1056i0635q 5' sequence 
0.000 -9.87 -1.73 -3.2 1.07  
44 gi_156120844 NM_001102099 FRMD4B Ferm domain containing 4b 0.000 -9.67 -14.93 -4.3 -7.29  
45 gi_115495518 NM_001075426 ANGPTL1 Angiopoietin-like 1 0.000 -9.59 -3.79 -8.7 -10.42  
46 gi_119909544 XM_865632 NEFH Neurofilament, heavy polypeptide 0.000 -9.57 -9.91 -3.5 -1.46 -- 
47 gi_119916232 XM_618609 MYOM1 Myomesin 1, 185kda 0.000 -9.28 -2.87 -9.7 -8.35  
48 gi_157427975 NM_001105426 RNASE13 Ribonuclease, rnase a family, 13 (non-active) 0.000 -9.12 -2.90 1.2 -2.22 -- 
49 gi_119906362 XM_605757 FER1L6 Fer-1-like 6 (c. Elegans) 0.000 -8.87 -10.14 -2.8 -1.73 -- 
50 gi_119916293 XM_588401 IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 0.000 -8.46 -8.13 -4.9 -6.05 -- 
51 gi_116003880 NM_001076831 COL3A1 Collagen, type iii, alpha 1 0.000 -8.46 -9.27 1.0 -2.22 -- 
52 gi_157427889 NM_001105382 Prune2 (rat) Prune homolog 2 (drosophila) 0.000 -8.44 -7.17 1.7 -3.85 -- 
53 gi_119905157 XM_866719 IL15RA Interleukin 15 receptor, alpha 0.000 -8.16 -7.24 -2.7 2.17 -- 
54 gi_119908399 XM_580673 PIK3CD Phosphoinositide-3-kinase, catalytic, delta polypeptide 0.000 -7.75 -5.62 -2.7 -1.44 -- 
55 gi_31342993 NM_174034 CYBA Cytochrome b-245, alpha polypeptide 0.000 -7.73 -8.56 -5.5 -4.84  
56 gi_115494923 NM_001075952 ASGR2 Asialoglycoprotein receptor 2 0.000 -7.62 -20.22 -9.7 -27.15  
57 gi_51815966 CO885681 – – - Co885681 bovgen_14006 normal cattle brain cDNA clone 
rzpdp1056g0625q 5' sequence 
0.000 -7.54 -4.59 -6.6 -6.60 -- 
58 gi_134085858 NM_001083409 C1QTNF1 C1q and tumor necrosis factor related protein 1 0.000 -7.41 -8.49 -150.3 -69.48  
59 gi_62751653 NM_001015673 MPZL2 Myelin protein zero-like 2 0.000 -7.38 -4.54 -3.0 -2.41 -- 
60 gi_51818194 CO887909 – – - Co887909 bovgen_16234 normal cattle brain cDNA clone 
rzpdp1056n1629q 5' sequence 
0.000 -7.32 -3.87 -3.1 -3.33  
61 gi_119895036 XM_588822 LOC511478 Hypothetical loc511478 (loc511478) 0.000 -7.29 -5.85 -3.2 -2.57 -- 
62 gi_119910630 XM_001256469 LOC789828 Similar to carcinoembryonic antigen-related cell adhesion 
molecule 1 isoform 3l 
0.000 -7.14 -21.31 -5.9 -9.42  
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63 * gi_119892099 XM_585454 KRT6A Keratin 6a 0.000 -7.06 -5.20 -3.2 -2.28 -- 
64 gi_60979607 DN532330 – – - Dn532330 1360359 marc 7bovcDNA 5' sequence 0.000 -6.88 -3.93 -2.7 -2.91 -- 
65 gi_119919341 XR_027385 LOC520070 Similar to tumor endothelial marker 1, (LOC520070) 0.000 -6.87 -6.02 -22.0 -13.88 -- 
66 gi_156120782 NM_001102068 PDE7B Phosphodiesterase 7b 0.000 -6.78 -2.66 -3.3 -4.79 -- 
67 gi_31342868 NM_174091 IL18 Interleukin 18 (interferon-gamma-inducing factor) 0.000 -6.66 -3.73 -10.4 -4.28  
68 gi_110626118 NM_001040495 IGFBP6 Insulin-like growth factor binding protein 6 0.000 -6.65 -6.28 -6.2 -3.20 -- 
69 gi_119895570 XM_581784 SLC23A1 Solute carrier family 23(nucleobase transporters), member1 0.000 -6.52 -3.92 -3.6 -1.89 -- 
70 gi_149642786 NM_001099152 LBH Limb bud and heart development homolog (mouse) 0.000 -6.31 -1.87 -9.6 -6.51  
71 gi_119916443 XM_881561 LOC616344 Hypothetical (LOC616344) 0.000 -6.29 -9.13 1.2 -3.03 -- 
72 gi_156120706 NM_001102030 LOC515697 Apolipoprotein l, 3-like (LOC515697) 0.000 -6.18 -9.42 -15.0 -11.85  
73 gi_122692576 NM_001080280 SLC20A2 Solute carrier family 20 (phosphate transporter), member 2 0.000 -6.11 -5.14 -2.7 -2.03  
74 gi_78042515 NM_001035027 PLTP Phospholipid transfer protein 0.000 -6.10 -4.00 -3.1 -2.23 -- 
75 gi_119916419 XM_587341 ALPK2 Alpha-kinase 2 0.000 -6.01 -1.56 -104.0 -12.42 -- 
76 * gi_119907773 XM_001251746 CD82 CD82 molecule 0.000 -5.94 -4.62 -2.7 -4.47 -- 
77 * gi_119874935 XM_001249464 ITSN1 Intersectin 1 (SH3 domain protein) 0.000 -5.77 -3.43 -3.7 -3.80 -- 
78 gi_125991897 NM_001081594 RASD2 Rasd family, member 2 0.000 -5.72 -8.14 -4.3 -1.59 -- 
79 gi_119937889 XM_001256927 LOC790466 Similar to endothelial pas domain protein 1/hypoxia-
inducible factor-2 alpha (LOC790466) 
0.000 -5.70 -3.57 -1.7 -4.16 -- 
80 gi_119905554 XR_028664 SLC4A11 Solute carrier family 4, sodium borate transporter, 
member 11 
0.000 -5.67 -6.08 -3.0 1.37 -- 
81 gi_119895756 XM_580665 GM2A GM2 ganglioside activator 0.000 -5.64 -3.16 -2.8 -2.77 -- 
82 gi_51822678 CO892378 – – - Co892378 bovgen_20703 normal cattle brain cDNA clone 
rzpdp1056m2034q 5' sequence 
0.000 -5.59 -3.66 -36.1 -24.70 -- 
83 * gi_62752830 NM_001015601 RASGEF1A Rasgef domain family, member 1a 0.000 -5.53 -5.41 -6.2 -11.68  
84 * gi_119932781 XM_581475 ABCG2 ATP-binding cassette, sub-family g (white), member 2 0.000 -5.51 -4.51 -6.4 -2.77  
85 gi_119892308 XM_598691 KCNMB4 Potassium large conductance calcium-activated channel, 
subfamily m, beta member 4 
0.000 -5.51 -4.06 -3.9 -5.18 -- 
86 * gi_119915471 XM_001249886 LY6G6C Lymphocyte antigen 6 complex, locus g6c 0.000 -5.44 -5.58 -3.6 -6.94 -- 
87 * gi_51826800 CO896484 RASGEF1A Rasgef domain family, member 1a 0.000 -5.43 -5.32 -6.5 -11.91  
88 gi_31341755 NM_174526 CRYBB1 Crystallin, beta b1 0.000 -5.37 -9.49 -4.6 -11.41 -- 
89 * gi_118150825 NM_001077856 LY6G6C Lymphocyte antigen 6 complex, locus g6c 0.000 -5.28 -5.32 -3.2 -6.81 -- 
90 * gi_118151127 NM_001078018 SEZ6 Seizure related 6 homolog (mouse) 0.000 -5.27 -3.22 -9.5 -3.96 -- 
91 gi_119910121 XM_615431 LOC535363 Similar to ob-cadherin-1, transcript variant 1 (LOC535363) 0.000 -5.18 -4.49 -41.6 -2.94 -- 
92 gi_119915324 XM_590184 GPR110 G protein-coupled receptor 110 0.000 -5.18 -13.45 -10.4 -5.72 -- 
93 gi_139948280 NM_001083751 SYNPO2 Synaptopodin 2 0.000 -5.12 -1.33 -17.0 -9.86 -- 
94 * gi_51818470 CO888185 HEY1 Hairy/enhancer-of-split related with yrpw motif 1 0.000 -5.07 -3.96 -1.1 -2.53 -- 
95 gi_119909414 XM_590469 RASAL1 Ras protein activator like 1 (GAP1 like) 0.000 -4.98 -5.99 -2.0 -19.73 -- 
96 gi_155371958 NM_001101115 SPOCK2 Sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 2 
0.000 -4.97 -3.93 -5.4 -8.79  
97 gi_119927615 XM_001253466 LOC785446 Similar to ob-cadherin-1 (LOC785446) 0.000 -4.94 -4.08 -57.1 -4.09 -- 
98 gi_119892785 XM_610055 LOC531557 Similar to apolipoprotein l, 3 (LOC531557) 0.000 -4.91 -3.87 -4.2 -4.11  
99 gi_51812540 CO882608 – – - Co882608 bovgen_10933 normal cattle brain cDNA clone 
rzpdp1056l087q 5' sequence 
0.000 -4.88 -4.30 1.1 -3.21 -- 
100 gi_51811539 CO881610 – – - Co881610 bovgen_09935 normal cattle brain cDNA clone 
rzpdp1056k0421q 5' sequence 
0.000 -4.78 -18.80 -7.1 -17.89  
101 gi_51808554 CO878630 – – - Co878630 bovgen_06955 normal cattle brain cDNA clone 
rzpdp1056e225q 5' sequence 
0.000 -4.75 -2.23 -9.6 -9.78  
102 gi_156120634 NM_001101994 SLC6A12 Solute carrier family 6 (neurotransmitter transporter, 
betaine/gaba), member 12  
0.000 -4.74 -12.11 -1.1 -12.83 -- 
103 gi_119904529 XM_590570 EBPL Emopamil binding protein-like 0.000 -4.71 -4.82 -3.0 -3.40 -- 
104 * gi_119895038 XM_001256059 ZNF77 Zinc finger protein 77 0.000 -4.70 -3.57 -42.3 -21.36 -- 
105 gi_119891326 XM_590508 CPA4 Carboxypeptidase a4 0.000 -4.70 -2.26 -119.2 -114.07  
106 * gi_119914433 XM_585399 ZNF77 Zinc finger protein 77 0.000 -4.65 -3.56 -39.6 -20.92 -- 
107 gi_49411022 AJ678437 – – - Aj678437 kn224cDNA clone kn224-026_h03 sequence 0.000 -4.60 -3.22 -16.0 -9.53 -- 
108 gi_115497925 NM_001076102 EPS8 Epidermal growth factor receptor pathway substrate 8 0.000 -4.59 -4.37 1.1 -4.81 -- 
109 gi_51824780 CO894472 – – - Co894472 bovgen_22797 normal cattle brain cDNA clone 
rzpdp1056c2346q 5' sequence 
0.000 -4.57 -2.78 -3.0 -3.06 -- 
110 gi_119903128 XM_580552 MERTK C-mer proto-oncogene tyrosine kinase 0.000 -4.55 -8.57 -20.0 -13.51 -- 
111 * gi_112817614 NM_001037478 ABCG2 ATP-binding cassette, sub-family g (white), member 2 0.000 -4.52 -4.78 -6.0 -2.33  
112 * gi_31340626 NM_174725 EPAS1 Endothelial pas domain protein 1 0.000 -4.46 -3.45 -2.9 -33.05  
113 * gi_88319943 NM_001001172 HEY1 Hairy/enhancer-of-split related with yrpw motif 1 0.000 -4.44 -3.60 -3.1 -2.01 -- 
114 gi_149642784 NM_001099025 NTNG2 Netrin g2 0.000 -4.44 -4.89 -3.3 -4.01 -- 
115 gi_61888881 NM_001013600 BOLA-DOB Major histocompatibility complex, class ii, do beta 0.000 -4.43 -3.68 -11.6 -27.61  
116 gi_119895617 XM_588575 LOC539652 Similar to protocadherin gamma b3 short form protein 0.000 -4.38 -5.49 -3.9 -7.41  
117 gi_119919496 XM_001256184 LOC789424 Hypothetical protein (LOC789424) 0.000 -4.37 -4.53 -5.1 -2.41  
118 gi_51820161 CO889874 – – - Co889874 bovgen_18199 normal cattle brain cDNA clone 
rzpdp1056c0845q 5' sequence 
0.000 -4.22 -2.49 -8.4 -6.70  
119 gi_119933246 XM_001256766 LOC790239 Hypothetical protein (LOC790239) 0.000 -4.06 -3.66 -2.8 -2.84 -- 
120 gi_119908049 XM_611589 LOC515828 Hypothetical (LOC515828) 0.000 -3.98 -3.07 -236.9 -222.75 -- 
121 gi_119912389 XM_597900 C1QL1 Complement component 1, q subcomponent-like 1 0.000 -3.91 -3.53 -3.2 1.29 -- 
122 gi_77735752 NM_001034399 FXYD6 Fxyd domain containing ion transport regulator 6 0.000 -3.86 -2.90 -3.6 1.24  
123 * gi_68319996 AM018804 EPAS1 Endothelial pas domain protein 1 0.000 -3.85 -2.89 -3.3 -47.56  
124 gi_122692514 NM_001080250 AMICA1 Adhesion molecule, interacts with cxadr antigen 1 0.000 -3.83 -2.79 -4.7 -2.58  
125 gi_51807407 CO877491 – – - Co877491 bovgen_05816 normal cattle brain cDNA clone 
rzpdp1056a2459q 3' sequence 
0.000 -3.83 -2.91 -3.3 -3.09  
126 gi_139949110 NM_001083769 IRF8 Interferon regulatory factor 8 0.000 -3.82 -2.43 -3.7 -7.05  
127 gi_31343103 NM_173985 AIF1 Allograft inflammatory factor 1 0.000 -3.81 -2.65 -3.6 -2.13  
128 gi_29257333 CB450951 – – - Cb450951 705652 marc 6bovcDNA 5' sequence 0.000 -3.78 -2.28 1.1 -6.82 -- 
129 gi_118150959 NM_001077930 ERRFI1 ERBB receptor feedback inhibitor 1 0.000 -3.75 -2.64 1.0 -7.81 -- 
130 gi_84000076 NM_001038050 IFI27 Interferon, alpha-inducible protein 27 0.000 -3.72 -3.80 -1.2 -20.13 -- 
131 gi_51825034 CO894726 – – - Co894726 bovgen_23051 normal cattle brain cDNA clone 
rzpdp1056a0148q 5' sequence 
0.000 -3.71 -3.42 -4.7 -8.54  
132 gi_51821293 CO891000 – – - Co891000 bovgen_19325 normal cattle brain cDNA clone 
rzpdp1056e0735q 5' sequence 
0.000 -3.70 -1.32 -19.5 -8.66 -- 
133 * gi_156121314 NM_001102335 PGM5 Phosphoglucomutase 5 0.000 -3.70 -2.36 -50.8 -14.70  
134 gi_119932747 XM_001254656 LOC787184 Similar to interleukin 7 receptor (LOC787184) 0.000 -3.67 -2.77 -7.1 -12.58 -- 
135 gi_119915240 XM_865759 TRERF1 Transcriptional regulating factor 1 0.000 -3.66 -3.25 -2.7 -2.53 -- 
136 gi_115495364 NM_001075414 IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 0.000 -3.66 -5.57 -1.4 -11.41 -- 
137 * gi_119918758 XM_865363 C11orf75 Chromosome 11 open reading frame 75 0.000 -3.66 -3.72 -2.7 -2.14 -- 
138 gi_76690438 XM_583591 LOC538910 Similar to protocadherin gamma a4 (LOC538910) 0.000 -3.63 -3.97 -1.8 -4.15 -- 
139 gi_51813585 CO883646 – – - Co883646 bovgen_11971 normal cattle brain cDNA clone 
rzpdp1056m0315q 5' sequence 
0.000 -3.61 -3.97 -3.2 -2.86 -- 
140 gi_158519860 NM_001110076 C8G Complement component 8, gamma polypeptide 0.000 -3.60 -2.15 -3.0 -3.57 -- 
141 gi_156120978 NM_001102166 RAB40B Rab40b, member ras oncogene family 0.000 -3.58 -3.25 -3.5 -2.59 -- 
142 gi_51819167 CO888882 – – - Co888882 bovgen_17207 normal cattle brain cDNA clone 
rzpdp1056k0539q 5' sequence 
0.000 -3.56 -7.41 -6.0 -4.62 -- 
143 gi_114051615 NM_001045985 SORBS3 Sorbin and SH3 domain containing 3 0.000 -3.54 -3.49 -3.1 -5.72  
144 gi_31341685 NM_174553 IFNAR2 Interferon (alpha, beta and omega) receptor 2 0.000 -3.52 -2.88 -2.3 -10.28 -- 
145 gi_31342479 NM_174260 CAPN3 Calpain 3, (p94) 0.000 -3.51 -2.37 -3.9 -2.28  
146 gi_119913259 XM_599818 IL7R Interleukin 7 receptor 0.000 -3.51 -2.53 -4.9 -9.02 -- 
147 gi_119907033 XM_615064 DIXDC1 DIX domain containing 1 0.000 -3.50 -3.13 -3.1 -1.95 -- 
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148 gi_119925538 XM_586833 LOC509794 Similar to tesc protein, transcript variant 1 (LOC509794) 0.001 -3.44 -5.25 -1.4 -23.27 -- 
149 gi_95147663 NM_001040472 CD3G CD3G molecule, gamma (CD3-TCR complex) 0.000 -3.43 -3.92 -5.7 -7.19  
150 gi_119919833 XM_001254041 LOC786332 Similar to transmembrane protein with egf-like and two 
follistatin-like domains 1 
0.000 -3.42 -3.44 -1.3 -2.30 -- 
151 gi_119905465 XM_867900 AKR1E2 Aldo-keto reductase family 1, member e2 0.001 -3.41 -3.28 -3.1 -3.97  
152 gi_119922048 XM_001254493 NCKAP5 NCK-associated protein 5 0.000 -3.40 -2.08 -1.4 -2.32 -- 
153 gi_6955562b AW427615 – – - Aw427615 63840 marc 3bovcDNA 5' sequence 0.000 -3.39 -1.89 -2.6 -12.17 -- 
154 * gi_164420765 NM_001113247 CHN1 Chimerin 1 0.000 -3.35 -3.10 -1.1 -1.60 -- 
155 gi_51813747 CO883803 – – - Co883803 bovgen_12128 normal cattle brain cDNA clone 
rzpdp1056e214q 5' sequence 
0.000 -3.35 -4.70 -3.2 -2.30 -- 
156 gi_119920038 XM_001254134 LOC786473 Similar to zinc finger, cchc domain containing 12 0.000 -3.35 -1.99 -2.9 -5.37 -- 
157 gi_31343627 NM_177520 MGAT4A Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-n-
acetylglucosaminyltransferase, isozyme a 
0.000 -3.34 -3.15 -3.4 -4.99 -- 
158 gi_119907990 XM_606934 LOC528508 Similar to DTX4 protein (LOC528508) 0.001 -3.34 -8.47 -1.2 -13.20 -- 
159 gi_51825868 CO895554 – – - Co895554 bovgen_23879 normal cattle brain cDNA clone 
rzpdp1056f1749q 5' sequence 
0.000 -3.33 -3.59 -3.7 -6.70 -- 
160 gi_89886136 NM_001014870 TMEM106A Transmembrane protein 106a 0.000 -3.32 -1.99 -10.5 -15.32  
161 gi_114050810 NM_001046507 EAF2 Ell associated factor 2 0.001 -3.30 -3.24 -3.8 -17.34 -- 
162 gi_51886086 AJ818610 – – - Aj818610 kn206 bos sp. cDNA clone c0006012n11 seq 0.001 -3.27 -1.74 -2.4 -9.43 -- 
163 * gi_122692344 NM_001080363 PNPLA4 Patatin-like phospholipase domain containing 4 0.001 -3.23 -3.77 -2.6 -3.24 -- 
164 gi_119905276 XM_865369 C1QL3 Complement component 1, q subcomponent-like 3 0.001 -3.22 -1.45 -5.3 -4.44 -- 
165 * gi_119918577 XM_001252006 VCL Vinculin 0.001 -3.21 -2.53 -3.7 -3.84 -- 
166 gi_51807418 CO877502 – – - Co877502 bovgen_05827 normal cattle brain cDNA clone 
rzpdp1056a1958q 3' sequence 
0.001 -3.20 -4.42 -7.2 -17.10  
167 gi_166159169 NM_001114080 – – - Protocadherin gamma subfamily c, 3 (PCDHGC3), 
transcript variant 1 
0.001 -3.19 -2.84 -2.9 -6.35  
168 gi_119925772 XM_001256054 LOC789248 Similar to zinc finger, cchc domain containing 12 0.001 -3.18 -2.20 -3.0 -6.11 -- 
169 gi_119919463 XM_001252801 LOC785604 Hypothetical protein (LOC785604), transcript variant 1 0.001 -3.18 -3.69 -4.3 -2.12  
170 gi_119891871 XM_591008 GNB3 Guanine nucleotide binding protein (g protein), beta 
polypeptide 3 
0.001 -3.11 -1.87 -2.7 -1.68 -- 
171 gi_119894463 XM_597995 PBX4 Pre-b-cell leukemia homeobox 4 0.001 -3.11 -2.97 -1.4 -3.64 -- 
172 gi_119909727 XR_028833 LOC526847 Hypothetical (LOC526847) 0.001 -3.09 -3.71 -3.3 -6.29 -- 
173 gi_125991759 NM_173976 TPPP Tubulin polymerization promoting protein 0.001 -3.09 -2.29 -5.0 -4.29 -- 
174 gi_119895615 XM_588574 LOC511274 Similar to protocadherin gamma a6 (LOC511274) 0.001 -3.09 -5.03 -3.9 -7.02  
175 gi_119907265 XR_027897 AMPD3 Adenosine monophosphate deaminase 3 0.001 -3.07 -1.79 -40.4 -42.52  
176 gi_157427855 NM_001105365 ITGB7 Integrin, beta 7 0.001 -3.06 -2.81 -12.3 -2.49  
177 gi_114052363 NM_001046345 IKBKE Inhibitor of kappa light polypeptide gene enhancer in b-
cells, kinase epsilon 
0.001 -3.05 -4.14 -3.1 -5.55 -- 
178 gi_155371838 NM_001101054 CDKN2C Cyclin-dependent kinase inhibitor 2c (p18, inhibits cdk4) 0.001 -3.04 -1.65 -2.7 -3.08 -- 
179 gi_119925997 XM_869237 LOC617055 Similar to bank (LOC617055) 0.001 -3.04 -1.28 -10.5 -18.34 -- 
180 gi_119895636 XM_596806 PCDHB13 Protocadherin beta 13 0.001 -3.03 -2.66 -5.3 -5.61  
181 gi_76253719 NM_001002892 ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 0.001 -3.03 -1.75 1.0 -2.30 -- 
182 gi_31340697 NM_178572 CA2 Carbonic anhydrase ii 0.001 -3.02 -7.35 -1.5 -11.30 -- 
183 gi_119916460 XM_001250160 LOC782394 Hypothetical protein (LOC782394) 0.001 -3.00 -4.12 -1.6 -4.13 -- 
184 gi_148237208 NM_001098017 PTPN6 Protein tyrosine phosphatase, non-receptor type 6 0.001 -3.00 -2.21 -31.9 -43.83  
185 gi_148229657 NM_181002 AOC3 Amine oxidase, copper containing 3 (vascular adhesion 
protein 1) 
0.001 -2.99 -1.90 -1.0 -2.31 -- 
186 gi_114052323 NM_001046535 Rbpms Rna binding protein gene with multiple splicing 0.001 -2.97 -2.05 -6.4 -4.90  
187 gi_119894365 XM_870556 LOC618227 Hypothetical (LOC618227) 0.001 -2.97 -2.33 -5.6 -5.28 -- 
188 * gi_139948327 NM_001083728 MAPK10 Mitogen-activated protein kinase 10 0.001 -2.96 -2.82 -1.3 -3.39 -- 
189 gi_77404220 NM_001034056 MS4A8B Membrane-spanning 4-domains, subfamily a, member 8b 0.001 -2.96 -3.05 -1.6 -3.94 -- 
190 gi_119904873 XM_864748 LOC613706 Similar to atp-binding cassette protein c4 splice 0.001 -2.92 -5.02 -2.9 -3.09 -- 
191 gi_119909946 XM_593446 CPNE7 Copine 7 0.001 -2.90 -1.54 -2.8 -2.04 -- 
192 gi_51884658 AJ817182 – – - Aj817182 kn206 bos sp. cDNA clone c0006007d06 
sequence 
0.001 -2.89 -2.57 -6.7 -5.89  
193 gi_156120860 NM_001102107 CALCRL Calcitonin receptor-like 0.001 -2.89 -2.36 -23.2 -4.80 -- 
194 gi_115494983 NM_001076301 APOD Apolipoprotein d 0.001 -2.89 -1.07 -10.1 -11.85  
195 gi_30794323 NM_181017 TAC3 Tachykinin 3 0.001 -2.89 -2.36 -1.8 -7.66 -- 
196 gi_51886061 AJ818585 – – - Aj818585 kn206 bos sp. cDNA clone c0006012m03 
sequence 
0.001 -2.88 -2.70 -7.6 -5.34  
197 gi_114053244 NM_001046251 VRK3 Vaccinia related kinase 3 0.001 -2.88 -2.41 -2.8 -2.68 -- 
198 gi_51885046 AJ817570 – – - Aj817570 kn206 bos sp. cDNA clone c0006006a15 seq 0.001 -2.88 -2.56 -7.0 -4.93  
199 gi_115495650 NM_001075552 PIK3IP1 Phosphoinositide-3-kinase interacting protein 1 0.001 -2.87 -2.07 -2.8 -3.61 -- 
200 gi_119895619 XM_870861 LOC618528 Similar to protocadherin gamma b2 short form protein 0.001 -2.87 -2.80 -4.3 -5.71  
201 * gi_119920668 XM_590366 PNPLA4 Patatin-like phospholipase domain containing 4 0.001 -2.85 -2.81 -2.8 -2.92 -- 
202 gi_155371902 NM_001101086 CPD Carboxypeptidase d 0.001 -2.85 -1.54 -2.8 -16.69 -- 
203 gi_119912361 XM_875498 LOC514744 Hypothetical loc514744, transcript variant 4 (LOC514744) 0.001 -2.84 -5.52 -8.3 1.42  
204 gi_119921169 XR_028574 LOC787851 Similar to RBP-Ms/type 3 (LOC787851) 0.001 -2.84 -2.42 -5.2 -4.34 -- 
205 gi_139948709 NM_001083767 C12orf53 Chromosome 12 open reading frame 53 0.001 -2.81 -2.28 -6.2 -6.22  
206 gi_119892759 XR_028120 LOC518495 Hypothetical loc518495 (LOC518495) 0.001 -2.81 -4.53 -13.7 -10.35  
207 gi_157074179 NM_001103334 PCDHGC3 Protocadherin gamma subfamily c, 3, transcript variant 2 0.001 -2.79 -2.45 -4.3 -3.45  
208 gi_164448611 NM_001075425 CLSTN3 Calsyntenin 3 0.001 -2.78 -2.52 -6.0 -1.62 -- 
209 gi_51814009 CO884065 – – - Co884065 bovgen_12390 normal cattle brain cDNA clone 
rzpdp1056o085q 5' sequence 
0.001 -2.76 -2.84 -3.0 -3.55 -- 
210 * gi_119919887 XM_580464 ATP2B3 ATPase, ca++ transporting, plasma membrane 3 0.001 -2.75 -1.41 -3.1 -1.64 -- 
211 gi_119894347 XM_602917 DOK7 Docking protein 7 0.001 -2.74 -2.28 -12.6 -5.94 -- 
212 gi_31341586 NM_174593 RASSF2 Ras association (RALGDS/Af-6) domain family member 2 0.001 -2.71 -1.82 -1.7 -5.53 -- 
213 gi_119919492 XM_001256176 LOC789415 Hypothetical protein (LOC789415) 0.001 -2.71 -3.41 -4.0 -2.65  
214 gi_115497713 NM_001076440 SPA17 Sperm autoantigenic protein 17 0.001 -2.71 -2.39 -2.8 -5.99 -- 
215 gi_119889938 XM_001250562 LOC781999 Similar to amp deaminase (LOC781999) 0.001 -2.70 -1.45 -12.1 -17.45 -- 
216 gi_115497719 NM_001076119 TSPAN5 Tetraspanin 5 0.001 -2.67 -1.87 -4.0 -3.76 -- 
217 gi_77736300 NM_001034678 HES1 Hairy and enhancer of split 1, (drosophila) 0.001 -2.66 -2.30 -2.5 -6.72  
218 gi_51825504 CO895190 – – - Co895190 bovgen_23515 normal cattle brain cDNA clone 
rzpdp1056a1147q 5' sequence 
0.001 -2.65 -2.20 -7.7 -6.00  
219 gi_119908832 XR_027675 LOC531974 Similar to mkiaa1151 protein (LOC531974) 0.001 -2.64 -2.83 -2.8 -6.34 -- 
220 gi_51887072 AJ819596 – – - Aj819596 kn206 bos sp. cDNA clone c0006015o15 seq 0.001 -2.63 -2.44 -11.4 -8.00 -- 
221 gi_45465357 CK950977 – – - Ck950977 4090253 barc 10bovcDNA clone 10bov27_j04 
5' sequence 
0.001 -2.63 -1.80 -4.2 -3.99 -- 
222 gi_114050926 NM_001046126 ELL3 Elongation factor rna polymerase ii-like 3 0.002 -2.62 -2.43 1.3 -3.73 -- 
223 gi_148540319 NM_001098473 B3GNT3 Udp-glcnac:betagal beta-1,3-n-
acetylglucosaminyltransferase 3 
0.002 -2.62 -1.54 -4.3 -4.33  
224 gi_70778797 NM_001025333 OSTalpha Organic solute transporter alpha 0.001 -2.62 -3.69 -3.6 -2.27 -- 
225 * gi_119904381 XM_001256288 ABO Abo blood group (transferase a, alpha 1-3-n-
acetylgalactosaminyltransferase; transferase b, alpha 1-3-
galactosyltransferase) 
0.002 -2.62 -2.66 -35.5 -77.46 -- 
226 gi_119893382 XM_603482 WNT7B Wingless-type mmtv integration site family, member 7b 0.001 -2.61 -2.87 -3.0 -2.30 -- 
227 gi_157074155 NM_001103321 GALNT4 Udp-n-acetyl-alpha-d-galactosamine:polypeptide n-
acetylgalactosaminyltransferase 4 (GALNAC-t4) 
0.001 -2.61 -2.24 -3.2 5.27  
228 gi_119895759 XM_608339 CCDC69 Coiled-coil domain containing 69 0.002 -2.60 -2.19 -2.8 -2.06 -- 
229 gi_51813662 CO883718 – – - Co883718 bovgen_12043 normal cattle brain cDNA clone 
rzpdp1056f2013q 5' sequence 
0.003 -2.60 -8.06 -1.6 -12.94 -- 
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230 gi_119921194 XR_028648 LOC788414 Hypothetical protein (LOC788414) 0.002 -2.60 -1.61 -2.7 -4.16  
231 gi_51880396 AJ812920 – – - AJ812920 kn206 bos sp. cDNA clone c0005201f5 seq 0.002 -2.60 -2.91 -3.4 -2.69  
232 gi_111104592 EE243456 – – - Ee243456 lb02230.cr_g22 gc_bgc-22cDNA clone 
image:8261424 sequence 
0.001 -2.59 -2.06 -5.5 -5.33  
233 gi_115496313 NM_001075738 Gstt3 Glutathione s-transferase, theta 3 0.002 -2.58 -2.59 -1.2 -5.55 -- 
234 gi_31342246 NM_175717 CA11 Carbonic anhydrase xi 0.001 -2.58 -2.01 -8.7 -9.73  
235 gi_119927167 XM_868813 LOC616717 Hypothetical (LOC616717) 0.001 -2.57 -1.98 -4.0 -4.02  
236 gi_157279990 NM_001105041 RUSC1 Run and SH3 domain containing 1 0.001 -2.57 -2.39 1.3 -2.53 -- 
237 gi_119913108 XM_600430 IL6ST Interleukin 6 signal transducer(gp130,oncostatin m receptor) 0.001 -2.56 -2.47 -3.1 -2.55 -- 
238 * gi_118150779 NM_001077833 PRKCZ Protein kinase c, zeta 0.002 -2.53 -2.54 -3.9 -2.00 -- 
239 gi_31341450 NM_174647 PPP1R1B Protein phosphatase 1, regulatory (inhibitor) subunit 1b 0.002 -2.52 -2.11 -3.1 -3.71 -- 
240 gi_119892433 XM_584663 ARHGAP9 Rho gtpase activating protein 9 0.002 -2.51 -3.01 -4.0 -2.79  
241 gi_119895613 XM_001254336 LOC786740 Similar to protocadherin gamma a7 precursor (pcdh-
gamma-a7) 
0.003 -2.51 -2.59 -2.9 -5.97  
242 gi_164518983 NM_001113297 ACBD7 Acyl-coa binding domain containing 7 0.003 -2.50 -1.84 -1.7 -4.97 -- 
243 gi_31342621 NM_174191 SYN1 Synapsin i 0.003 -2.50 -2.91 -2.8 -3.30 -- 
244 gi_148229444 NM_001098093 ST5 Suppression of tumorigenicity 5 0.002 -2.49 -3.76 -13.4 -1.66 -- 
245 gi_48374082 NM_001001440 ANXA4 Annexin a4 0.002 -2.49 -2.33 -1.7 -3.79 -- 
246 gi_119934023 XM_001257056 LOC790637 Hypothetical protein (LOC790637) 0.002 -2.49 -2.67 -2.2 -5.29 -- 
247 gi_115495730 NM_001076164 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3c 0.002 -2.49 -1.59 -1.3 -2.69 -- 
248 * gi_51808399 CO878479 CEBPA CCAAT/enhancer binding protein (c/ebp), alpha 0.002 -2.48 -2.47 -5.2 -13.96  
249 gi_62460541 NM_001014923 NFE2 Nuclear factor (erythroid-derived 2), 45kda 0.003 -2.47 -2.04 -44.5 -6.40 -- 
250 gi_119936811 XM_001250386 LOC781880 Similar to multidrug resistance-associated protein(mrp)-
like protein-2 (mlp-2)  
0.003 -2.46 -2.53 -3.7 -3.86  
251 gi_157427775 NM_001105322 KRT17 Keratin 17 0.003 -2.45 -5.07 -3.6 1.23 -- 
252 gi_51823975 CO893670 – – - Co893670 bovgen_21995 normal cattle brain cDNA clone 
rzpdp1056i0938q 5' sequence 
0.003 -2.44 -2.42 -3.4 -4.02  
253 gi_76678805 XM_586049 LOC509148 Similar to CLLL7 protein (LOC509148) 0.004 -2.43 -2.20 -2.5 -7.51 -- 
254 gi_119919548 XM_879446 LOC540854 Hypothetical, transcript variant 3 (LOC540854) 0.003 -2.42 -3.38 -3.5 -2.48  
255 gi_119902226 XR_027935 LOC535046 Similar to cadherin-24 (LOC535046) 0.003 -2.42 -1.35 -3.6 -6.10  
256 gi_119901197 XM_608490 MAN1A1 Mannosidase, alpha, class 1a, member 1 0.003 -2.42 -1.77 -3.5 -1.50 -- 
257 gi_51888625 AJ821149 – – - Aj821149 aj821149 kn206 bos sp. cDNA clone 
c0006018o05 sequence 
0.004 -2.42 -1.96 -2.7 -3.29  
258 gi_119900520 XM_589465 SIT1 Signaling threshold regulating transmembrane adaptor 1 0.005 -2.40 -2.38 -8.2 -8.12  
259 gi_31342739 NM_174147 PLAU Plasminogen activator, urokinase 0.003 -2.40 -3.87 -5.5 2.39 -- 
260 gi_119895598 XM_865017 PCDHB14 Protocadherin beta 14 0.004 -2.40 -1.94 -3.0 -4.42  
261 gi_29267700 CB461316 – – - Cb461316 721270 marc 6bovcDNA 3' sequence 0.006 -2.38 -1.82 -27.9 -21.64  
262 * gi_119908469 XM_001252162 DVL1 Dishevelled, dsh homolog 1 (drosophila) 0.005 -2.38 -3.73 -1.1 -2.64 -- 
263 * gi_119907771 XM_001251709 CD82 CD82 molecule 0.005 -2.37 -3.13 -3.4 -3.36  
264 gi_122692362 NM_001080360 KCTD1 Potassium channel tetramerisation domain containing 1  0.004 -2.36 -2.82 -4.3 -6.98  
265 * gi_41386706 NM_174484 VCAM1 Vascular cell adhesion molecule 1 0.005 -2.36 -24.67 1.0 -224.00 -- 
266 gi_148236812 NM_001098118 MRAS Muscle ras oncogene homolog 0.004 -2.36 -3.66 -5.2 -6.05  
267 * gi_51815648 CO885363 BAIAP2 Bai1-associated protein 2 0.005 -2.36 -2.01 1.4 -2.45 -- 
268 gi_68422588 AM024227 – – - Am024227 kn-252-lymph,bos taurus cDNA clone 
c0007396p19 3' sequence 
0.005 -2.35 -2.52 -4.7 -5.23  
269 gi_119912178 XM_612461 ABCC3 ATP-binding cassette, sub-family c (cftr/mrp), member 3 0.004 -2.35 -2.26 -6.8 -5.76  
270 gi_51591896 NM_001004024 JUP Junction plakoglobin 0.005 -2.34 -2.39 -3.3 -4.58 -- 
271 gi_51885704 AJ818228 – – - Aj818228 kn206 bos sp. cDNA clone c0006011j16 sequence 0.005 -2.32 -2.00 -5.1 -13.50 -- 
272 gi_115495988 NM_001075518 ALDH3B1 Aldehyde dehydrogenase 3 family, member b1 0.005 -2.32 -2.63 -2.9 1.20 -- 
273 gi_115496555 NM_001075713 MYL6B Myosin, light chain 6b, alkali, smooth muscle and non-
muscle 
0.005 -2.31 -2.41 -2.6 -3.85 -- 
274 gi_119930931 XM_001256733 LOC790194 Similar to cgmp-specific phosphodiesterase (LOC790194) 0.005 -2.31 -1.65 -3.2 -4.27  
275 gi_119919465 XM_001252823 – – - Hypothetical protein, transcript variant 2 (LOC785604) 0.005 -2.30 -2.63 -4.0 -3.12  
276 gi_51816295 CO886010 – – - Co886010 bovgen_14335 normal cattle brain cDNA clone 
rzpdp1056c249q 5' sequence 
0.007 -2.30 -1.51 -2.8 -2.18 -- 
277 gi_51823984 CO893679 – – - Co893679 bovgen_22004 normal cattle brain cDNA clone 
rzpdp1056b1442q 5' sequence 
0.005 -2.30 -4.28 -3.6 -3.06  
278 gi_119919467 XM_001257253 LOC790877 Hypothetical protein, transcript variant 3 (LOC790877) 0.005 -2.30 -3.09 -4.4 -2.84  
279 gi_76638883 XM_591410 P2RX7 Purinergic receptor p2x, ligand-gated ion channel, 7 0.006 -2.29 -4.20 -3.2 -2.70 -- 
280 gi_119908015 XM_604649 IL24 Interleukin 24 0.007 -2.29 2.41 -6.6 -4.40 -- 
281 gi_119915955 XM_001256057 LOC789256 Hypothetical protein (LOC789256) 0.007 -2.29 -1.77 -3.1 -1.89 -- 
282 gi_51818847 CO888562 – – - Co888562 bovgen_16887 normal cattle brain cDNA clone 
rzpdp1056i1050q 5' sequence 
0.005 -2.28 -2.20 1.1 -4.20 -- 
283 gi_119903838 XM_582962 PLB1 Phospholipase b1 0.010 -2.26 -1.79 -3.7 -4.85  
284 gi_119910850 XM_869691 RASIP1 Ras interacting protein 1 0.006 -2.26 -2.24 -8.5 -47.33  
285 gi_87196509 NM_001010995 TPM2 Tropomyosin 2 (beta) 0.007 -2.26 -1.55 -1.6 -5.04 -- 
286 gi_119901064 XM_597850 OGFRL1 Opioid growth factor receptor-like 1 0.006 -2.25 -1.65 -4.2 -5.90 -- 
287 gi_118151237 NM_001078081 C6orf25 Chromosome 6 open reading frame 25 (c6orf25) 0.007 -2.24 -2.21 -3.8 -4.49 -- 
288 gi_119925143 XM_001252882 LOC784626 Similar to neuron-derived orphan receptor-1 alfa 0.007 -2.24 -1.40 1.0 -5.41 -- 
289 gi_119930624 XM_001249903 LOC783914 Hypothetical protein (LOC783914) 0.007 -2.23 -2.07 -2.7 -3.51 -- 
290 gi_125991949 NM_001081581 ABAT 4-aminobutyrate aminotransferase 0.007 -2.23 -1.78 -2.1 -20.75 -- 
291 * gi_119909004 XM_870711 MDK Midkine (neurite growth-promoting factor 2) 0.007 -2.22 -2.11 -4.2 -8.20 -- 
292 gi_87271067 DY457942 – – - Dy457942 1585752 marc 11bovcDNA 3' sequence 0.007 -2.22 -1.82 -2.9 -1.87 -- 
293 gi_119907581 XM_592504 STARD10 Star-related lipid transfer (start) domain containing 10 0.007 -2.22 -1.89 -5.8 -3.88 -- 
294 gi_119927352 XM_001250999 LOC785349 Similar to DTFT5783 (LOC785349) 0.009 -2.21 -3.25 -4.4 -6.84  
295 gi_41386767 NM_174009 CD34 CD34 molecule 0.008 -2.21 -2.07 -12.6 -18.20 -- 
296 gi_51816347 CO886062 – – - Co886062 bovgen_14387 normal cattle brain cDNA clone 
rzpdp1056i1418q 5' sequence 
0.008 -2.20 -2.26 -4.3 -1.48  
297 gi_51884851 AJ817375 – – - Aj817375 kn206 bos sp. cDNA clone c0006006j21 seq 0.007 -2.20 -1.46 -3.6 -4.24  
298 gi_119901000 XM_613776 TRAF1 TNF receptor-associated factor 1 0.009 -2.20 -5.87 -1.8 -10.95 -- 
299 gi_119923417 XM_001250290 LOC781803 Similar to osbp related protein 10 (LOC781803) 0.009 -2.20 -2.17 -4.9 -4.54  
300 gi_61888849 NM_001013582 AK1 Adenylate kinase 1 0.007 -2.19 -1.83 -2.9 -1.81  
301 gi_119909629 XM_867430 GGT1 Gamma-glutamyltransferase 1 0.009 -2.19 -1.93 -6.1 -3.96 -- 
302 gi_119909828 XM_586270 LOC509331 Similar to plcg2 protein (LOC509331) 0.008 -2.19 -2.31 -1.5 -3.95 -- 
303 gi_51818911 CO888626 – – - Co888626 bovgen_16951 normal cattle brain cDNA clone 
rzpdp1056m2243q 5' sequence 
0.010 -2.18 -1.53 -3.3 -3.73  
304 gi_7055130b AW485024 – – - Aw485024 63440 marc 3bovcDNA 5' sequence 0.008 -2.18 -4.18 -71.7 -33.36  
305 gi_119937909 XM_001256935 LOC790478 Hypothetical protein (LOC790478) 0.009 -2.18 -2.12 1.0 -4.13 -- 
306 gi_119901882 XM_580814 SERINC5 Serine incorporator 5 0.008 -2.18 -1.37 -2.8 -1.52 -- 
307 gi_119909826 XM_869529 LOC617296 Similar to PLCG2 protein (LOC617296) 0.008 -2.18 -2.82 -2.2 -4.69 -- 
308 gi_60453989 DN285379 – – - DN285379 1235238 marc 7bov cDNA 3' sequence 0.008 -2.17 -1.66 1.5 -3.10 -- 
309 gi_114053334 NM_001046099 ECSCR Endothelial cell-specific chemotaxis regulator 0.013 -2.17 -1.91 -2.6 -3.21 -- 
310 gi_119904995 XM_581907 MCF2L Mcf.2 cell line derived transforming sequence-like 0.010 -2.16 -1.05 -25.0 -32.70  
311 gi_115496553 NM_001076491 ATP8B3 Atpase, class i, type 8b, member 3 0.012 -2.15 -1.63 -2.9 -1.97 -- 
312 gi_51811313 CO881384 – – - Co881384 bovgen_09709 normal cattle brain cDNA clone 
rzpdp1056o179q 5' sequence 
0.010 -2.15 -4.92 -26.4 -33.63 -- 
313 gi_119930598 XM_001255904 LOC789026 Hypothetical protein (LOC789026) 0.010 -2.15 1.30 1.0 -2.38 -- 
314 gi_156121054 NM_001102204 RIN2 Ras and rab interactor 2 0.009 -2.15 -2.48 -7.4 -3.55  
315 gi_51884304 AJ816828 – – - Aj816828 kn206 bos sp. cDNA clone c0005208p21 seq 0.010 -2.13 -1.69 -3.1 -2.88  
316 gi_47952192 CN824123 – – - Cn824123 oa_splbn_07g03_m13reverse sheep 
spleen\brain psport1 library ovis aries cDNA clone 
0.013 -2.13 -1.62 -2.7 -3.34  
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oa_splbn_07g03 5' sequence 
317 gi_119913104 XM_602275 MAP3K1 Mitogen-activated protein kinase kinase kinase 1 0.010 -2.12 -1.72 -6.2 -3.92 -- 
318 gi_119901259 XM_001253056 LOC784866 Hypothetical protein (LOC784866) 0.012 -2.12 -2.02 -3.1 -2.98 -- 
319 gi_51824423 CO894116 – – - Co894116 bovgen_22441 normal cattle brain cDNA clone 
rzpdp1056h2334q 5' sequence 
0.011 -2.12 -1.88 -1.0 -3.45 -- 
320 gi_119929731 XM_869028 LOC616895 Retinoic acid receptor beta (LOC616895) 0.017 -2.11 -1.23 -3.7 -1.50 -- 
321 gi_51821577 CO891282 – – - Co891282 bovgen_19607 normal cattle brain cDNA clone 
rzpdp1056m1045q 5' sequence 
0.013 -2.11 -1.39 -12.9 -33.01  
322 gi_119911632 XM_604237 EFCAB5 EF-hand calcium binding domain 5 0.016 -2.11 -2.57 -4.6 -2.78 -- 
323 gi_76668819 XM_864611 SIM1 Single-minded homolog 1 (drosophila) 0.015 -2.10 -1.83 -4.9 -19.31  
324 * gi_119892012 XM_611497 ZNF385A Zinc finger protein 385A 0.012 -2.10 -1.38 -7.0 -2.24  
325 * gi_75832046 NM_173935 MDK Midkine (neurite growth-promoting factor 2) 0.013 -2.09 -2.23 -4.0 -7.18 -- 
326 gi_156121204 NM_001102280 GAS7 Growth arrest-specific 7 0.013 -2.09 -1.75 -5.6 -13.79 -- 
327 * gi_119890150 XM_867937 FAM151A Family with sequence similarity 151, member a 0.018 -2.09 -2.41 -3.2 1.25  
328 gi_51801600 CO871768 – – - Co871768 bovgen_00093 normal cattle brain cDNA clone 
rzpdp1056l1557q 3' sequence 
0.013 -2.08 -4.32 -2.8 -2.45 -- 
329 * gi_119909631 XM_001253630 GGT5 Gamma-glutamyltransferase 5 0.017 -2.08 -1.97 -9.1 -8.98  
330 gi_51815582 CO885297 – – - Co885297 bovgen_13622 normal cattle brain cDNA clone 
rzpdp1056d0515q 5' sequence 
0.013 -2.08 -2.30 -1.2 -3.85 -- 
331 gi_119907061 XM_582232 SCN2B Sodium channel, voltage-gated, type ii, beta 0.015 -2.08 -1.24 -2.9 -1.59 -- 
332 gi_119894838 XM_592551 FCER2 Fc fragment of ige, low affinity ii, receptor for (CD23) 0.014 -2.08 -2.30 -3.0 -3.37 -- 
333 gi_160333826 NM_001110441 TMEM145 Transmembrane protein 145 0.014 -2.07 -2.12 -4.6 -5.69 -- 
334 gi_51812559 CO882627 – – - Co882627 bovgen_10952 normal cattle brain cDNA clone 
rzpdp1056b2211q 5' sequence 
0.015 -2.07 -2.40 -3.0 -3.41 -- 
335 gi_119912471 XM_584593 LOC539069 Similar to copper amine oxidase (LOC539069) 0.017 -2.07 -1.32 1.0 -3.09 -- 
336 gi_119891937 XM_588753 ALX1 ALX homeobox 1 0.014 -2.06 -1.38 1.0 -3.44 -- 
337 gi_116003924 NM_001076850 UGCG Udp-glucose ceramide glucosyltransferase 0.014 -2.06 -2.02 -8.9 -8.94 -- 
338 gi_155722980 NM_001101042 SLC2A5 Solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5 
0.021 -2.06 -1.48 -2.7 -7.55  
339 gi_119919471 XM_001257252 – – - Hypothetical protein, transcript variant 2 (LOC790877) 0.015 -2.04 -2.28 -4.4 -2.78 -- 
340 gi_29275040 CB468655 – – - Cb468655 734502 marc 6bovcDNA 5' sequence 0.015 -2.04 -1.40 -3.4 -4.55  
341 gi_71034621 DR749281 – – - Dr749281 ng010006a12h05 ng01 rearrayed soares 
normalized bovine placenta cDNA clone bp230018a10b10 
3' sequence 
0.017 -2.04 -3.25 -3.0 -7.10  
342 gi_82660204 DV800011 – – - Dv800011 lb01310.cr_o08 gc_bgc-13cDNA clone 
image:8183650 5' sequence 
0.015 -2.04 -2.04 -10.6 -9.77 -- 
343 gi_77736348 NM_001034702 ENO3 Enolase 3 (beta, muscle) 0.017 -2.03 -2.19 -6.5 -8.31  
344 gi_119895593 XR_028187 LOC510849 Similar to protocadherin gamma b6 (LOC510849) 0.018 -2.03 -1.89 -1.3 -2.48  
345 gi_119908895 XM_616231 DCLK2 Doublecortin-like kinase 2 0.019 -2.03 -2.07 -3.1 -3.37 -- 
346 gi_119934004 XM_586352 LOC509406 Hypothetical (LOC509406) 0.018 -2.03 -4.27 -5.4 -7.41  
347 gi_134085863 NM_001083514 LASS1 Lag1 homolog, ceramide synthase 1 0.018 -2.03 -1.59 -3.8 -4.48 -- 
348 gi_119892869 XM_871851 CAPRIN2 Caprin family member 2 0.018 -2.02 -1.71 -1.0 -1.58 -- 
349 * gi_119892014 XM_872514 ZNF385A Zinc finger protein 385a 0.018 -2.02 -1.20 -6.2 -2.05  
350 * gi_78369652 NM_001035494 RPH3AL Rabphilin 3a-like (without c2 domains) 0.019 -2.02 -2.46 -6.9 1.24 -- 
351 gi_119901199 XM_001250567 LOC782005 Similar to man9-mannosidase (LOC782005) 0.018 -2.01 -1.54 -3.0 1.02 -- 
352 gi_119912116 XM_584605 NGFR Nerve growth factor receptor 0.021 -2.01 -1.71 -55.6 -2.40 -- 
353 * gi_119908232 XM_618596 CDC42BPA Cdc42 binding protein kinase alpha (DMPK-like) 0.019 -2.00 -2.02 -1.4 -1.83 -- 
           
           
 
3.1.2 Full list of TashAT2 modulated up-regulated genes (n = 113) 
showing similar response in parasite infection 
     
TashAT2 transfected BoMac 
array results 
Infection associated 
TBL20 array results 
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene 
symbol 
Gene Name 
TashAT2 
vs 
PCAGGS 
control 
FDR  
TashAT2  
vs 
PCAGGS 
control 
abs: FC 
TahAT2 
PMA vs 
control 
PMA 
abs: FC  
TBL20  
vs BL20   
 
 
abs: FC 
TBL20 LPS 
vs BL20 LPS 
 
abs:FC 
(4h/or18) 
B
W
7
20
c 
R
es
p
o
n
se
 
       /-- /-- /--  
1 gi_61016342 DN550204 – – - DN550204 1408544 marc 7bovcDNA 5' sequence 0.000 397.2 417.78 -1.2 5.37 -- 
2 gi_156120814 NM_001102084 NELL2 Nel-like 2 (chicken) 0.000 265.1 322.08 1.3 7.53 -- 
3 gi_60997329 DN540953 – – - Dn540953 marc 7bov cDNA 3' sequence 0.000 144.3 198.00 45.9 33.94 -- 
4 gi_119918977 XM_600048 VWA5A Von willebrand factor a domain containing 5a 0.000 116.3 199.83 31.5 33.23 -- 
5 gi_119923735 XM_586767 MUM1L1 Melanoma associated antigen (mutated) 1-like 1 0.000 91.4 85.15 28.8 25.85 -- 
6 gi_155372078 NM_001101176 COL8A1 Collagen, type viii, alpha 1 0.000 74.9 100.62 5.0 3.23  
7 gi_156120838 NM_001102096 TOX Thymocyte selection-associated high mobility group box 0.000 64.2 32.82 8.1 3.54 -- 
8 gi_119902404 XM_869291 TMEM62 Transmembrane protein 62 0.000 61.8 50.92 22.8 65.56 -- 
9 gi_119889179 XM_001252441 LOC784007 Similar to LOC496253 protein 0.000 46.3 56.68 96.3 74.79 -- 
10 gi_115494987 NM_001075771 PARM1 Prostate androgen-regulated mucin-like protein 1 0.000 44.3 45.93 2.3 -3.47 -- 
11* gi_78365245 NM_001035418 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 0.000 42.2 44.42 1.0 1.84 -- 
12 gi_51827110 CO896790 – – - Co896790 bovgen_25115 normal cattle brain cDNA clone 
rzpdp1056m161q 5' sequence 
0.000 34.4 22.39 6.7 5.39 -- 
13 gi_114051791 NM_001045971 SPINT2 Serine peptidase inhibitor, kunitz type, 2 0.000 33.9 41.81 1.4 3.19 -- 
14 gi_119918691 XM_001252439 C10orf72 Chromosome 10 open reading frame 72 0.000 18.4 7.76 2.0 3.36 -- 
15 gi_122692456 NM_001080306 PRSS23 Protease, serine, 23 0.000 16.7 31.18 23.3 30.66 -- 
16 gi_119908954 XM_614680 INPP4B Inositol polyphosphate-4-phosphatase, type ii, 105kda 0.000 14.8 23.19 4.0 2.15  
17 gi_68427085 AM027998 – – - Am027998 kn-252-lymph, bos indicus bos indicus cDNA 
clone c0007394g06 3' sequence 
0.000 11.6 2.69 2.8 1.92 -- 
18 gi_31342530 NM_174239 ALDH1A1 Aldehyde dehydrogenase 1 family, member a1 0.000 10.5 112.82 14.0 64.46  
19 gi_41386781 NM_174231 ADRB2 Adrenergic, beta-2-, receptor, surface 0.000 10.0 15.62 1.1 3.94 -- 
20 gi_119907228 XM_618666 PDE3B Phosphodiesterase 3b, cgmp-inhibited 0.000 9.1 11.73 3.0 2.34 -- 
21 gi_119903692 XM_871827 LRRTM4 Leucine rich repeat transmembrane neuronal 4 0.000 9.0 47.50 242.6 219.67 -- 
22 gi_119907150 XM_612483 SORL1 Sortilin-related receptor, l(dlr class) a repeats containing 0.000 8.9 6.49 4.1 18.50  
23 gi_112219499 EE358869 – – - EE358869 lb02964.cr_k02 gc_bgc-29 cDNA clone 
image:8476732 sequence 
0.000 8.5 11.63 2.2 -2.79 -- 
24 gi_78042501 NM_001035019 SMPDL3A Sphingomyelin phosphodiesterase, acid-like 3a 0.000 7.4 6.70 2.2 -2.03 -- 
25 gi_119879477 XM_585702 ZBTB20 Zinc finger and btb domain containing 20 0.000 7.0 5.73 6.7 16.12 -- 
26* gi_119923900 XM_001251680 Gm41 Melanoma antigen, family b, 4 pseudogene 0.000 6.9 5.63 2.2 3.62  
27 gi_119910070 XM_586929 MT2A Metallothionein 2a 0.000 6.1 3.30 4.5 4.87 -- 
28 gi_119900406 XR_028276 LOC785532 Similar to dap-1 alpha (LOC785532) 0.000 6.1 6.44 4.4 4.80 -- 
29 gi_139948748 NM_001083764 MYL12B Myosin, light chain 12b, regulatory 0.000 6.0 8.63 3.6 6.81 -- 
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30* gi_158937245 NM_001110194 HCK Hemopoietic cell kinase 0.000 5.9 6.11 2.3 6.33 -- 
31 gi_31341534 NM_174613 SLC7A5 Solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 5 
0.000 5.9 -1.42 2.9 4.61  
32 gi_119901194 XM_001250525 LOC781963 Similar to sphingomyelin phosphodiesterase, acid-like 3a  0.000 5.8 6.35 2.0 -2.21 -- 
33 gi_139948480 NM_001083649 RASGEF1B RASGEF domain family, member 1b 0.000 5.8 9.35 32.9 -2.15 -- 
34 gi_51802721 CO872881 – – - Co872881 bovgen_01206 normal cattle brain cDNA clone 
rzpdp1056n0454q 3' sequence 
0.000 5.4 4.41 4.9 10.22 -- 
35* gi_119935095 XM_585695 Gm41 Melanoma antigen, family b, 4 pseudogene 0.000 5.4 4.60 3.0 4.14  
36 gi_136256366 NM_174035 CYBB Cytochrome b-245, beta polypeptide 0.000 5.2 4.20 2.2 2.13 -- 
37 gi_119908995 XM_602397 SLC7A11 Solute carrier family 7, (cationic amino acid transporter, 
y+ system) member 11 
0.000 5.2 -2.31 -1.1 17.30 -- 
38* gi_119905669 XM_001249927 PMEPA1 Prostate transmembrane protein, androgen induced 1 0.000 5.0 4.94 2.7 2.07 -- 
39* gi_118150817 NM_001077850 BCAS1 Breast carcinoma amplified sequence 1 0.000 5.0 5.69 2.2 3.36 -- 
40* gi_119927606 XM_001253379 CYP3A4 Cytochrome p450, family 3, subfamily a, polypeptide 4 0.000 4.9 -2.21 -2.6 1.91 -- 
41 gi_156718111 NM_001103091 LTBP1 Latent transforming growth factor beta binding protein 1 0.000 4.8 9.68 2.4 1.74  
42 gi_119889181 XM_001252489 LOC784072 Similar to cd84-h1 (loc784072) 0.000 4.4 2.93 13.1 13.31 -- 
43 gi_119884823 XM_587050 SERPINI1 Serpin peptidase inhibitor, clade i (neuroserpin), member 1 0.000 4.4 4.31 9.2 5.38 -- 
44 gi_51822234 CO891936 – – - Co891936 bovgen_20261 normal cattle brain cDNA clone 
rzpdp1056m1641q 5' sequence 
0.000 4.3 -2.07 -1.4 10.39 -- 
45 gi_31342766 NM_174137 SERPINE1 Serpin peptidase inhibitor, clade e (nexin, plasminogen 
activator inhibitor type 1), member 1 
0.000 4.3 3.17 67.6 43.63  
46* gi_150247128 NM_001099368 PCDHGA2 Protocadherin gamma subfamily a, 2 0.000 4.2 6.58 2.4 1.69 -- 
47 gi_119933556 XM_001256914 LOC790449 Similar to PCDH19 protein (LOC790449) 0.000 3.9 3.57 5.6 38.82  
48 gi_119879733 XM_614853 ETV5 ETS variant 5 0.000 3.9 1.55 1.4 5.52 -- 
49* gi_190360732 NM_001128499 TGIF1 TGFB-induced factor homeobox 1 0.000 3.9 2.31 2.0 2.09 -- 
50 gi_119916372 XM_616030 SMAD7 Smad family member 7 0.000 3.8 3.43 2.1 1.11 -- 
51* gi_119895626 XR_028461 PCDHGA2 Protocadherin gamma subfamily a, 2 0.000 3.8 5.05 2.1 3.04 -- 
52 gi_119890101 XM_616138 CACHD1 Cache domain containing 1 0.000 3.7 3.77 5.7 3.27 -- 
53 gi_31342041 NM_174423 PLAUR Plasminogen activator, urokinase receptor 0.000 3.7 1.15 3.6 2.10 -- 
54 gi_77735810 NM_001034432 CREB3L3 Camp responsive element binding protein 3-like 3 0.000 3.7 3.44 5.7 6.69  
55* gi_119923957 XM_001250482 Gm41 Melanoma antigen, family b, 4 pseudogene 0.000 3.6 2.47 2.2 3.40  
56 gi_115496251 NM_001075741 GPRC5B G protein-coupled receptor, family c, group 5, member b 0.000 3.5 4.65 1.0 1.72 -- 
57 gi_119891399 XM_599768 JHDM1D Jumonji c domain containing histone demethylase 1 
homolog d (s. Cerevisiae) 
0.000 3.5 2.62 9.9 9.27 -- 
58 gi_51815450 CO885165 – – - Co885165 bovgen_13490 normal cattle brain cDNA clone 
rzpdp1056e197q 5' sequence 
0.000 3.5 3.02 14.9 12.66 -- 
59 gi_139948893 NM_001083648 CHST1 Carbohydrate (keratan sulfate gal-6) sulfotransferase 1 0.000 3.4 2.31 4.9 -1.68 -- 
60 gi_60722467 DN512277 – – - Dn512277 1248296 marc 7bov cDNA 3' sequence 0.000 3.3 3.38 11.4 3.90 -- 
61 gi_119906547 XR_027912 LOC535166 Similar to sulfatase 1 (LOC535166) 0.001 3.1 1.76 1.7 4.37 -- 
62 gi_119923683 XR_027350 LOC781857 Similar to interferon-induced protein 44 (antigen p44) 0.001 3.1 1.48 3.1 -4.30  
63* gi_119894560 XM_584000 BST2 Bone marrow stromal cell antigen 2 0.001 3.0 3.41 4.8 -4.02 -- 
64 gi_119889540 XM_596143 LOC517961 Hypothetical (LOC517961) 0.001 3.0 3.15 2.5 1.39  
65* gi_119922382 XM_001254377 Gm41 Melanoma antigen, family b, 4 pseudogene 0.001 2.9 2.10 3.2 5.13  
66 gi_84000564 NM_001034457 WBSCR22 Williams beuren syndrome chromosome region 22 0.001 2.9 2.48 2.9 2.76 -- 
67 gi_119917674 XM_589432 ELOVL3 Elongation of very long chain fatty acids (fen1/elo2, 
sur4/elo3, yeast)-like 3 
0.001 2.8 3.58 3.6 3.65  
68 gi_119901328 XM_618588 PRDM1 Pr domain containing 1, with znf domain 0.001 2.8 2.41 3.9 10.91 -- 
69 gi_115495710 NM_001075904 LRRC6 Leucine rich repeat containing 6 0.001 2.7 3.37 5.3 21.15 -- 
70 gi_149643068 NM_001098866 ACPP Acid phosphatase, prostate 0.001 2.7 3.65 4.5 3.36 -- 
71 gi_110347584 NM_182786 FOS FBJ murine osteosarcoma viral oncogene homolog 0.001 2.7 -1.85 3.8 4.48 -- 
72 gi_119889992 XM_872122 IFI44 Interferon-induced protein 44 0.001 2.7 2.39 3.1 -4.50  
73 gi_46559375 NM_206971 SEC16B Sec16 homolog b (s. Cerevisiae) 0.001 2.7 1.86 4.2 4.63 -- 
74* gi_51814346 CO884356 DNAJC6 DNAj (hsp40) homolog, subfamily c, member 6 0.002 2.6 7.23 1.5 -3.30 -- 
75* gi_148233315 NM_001098165 RNASEL Ribonuclease l (2',5'-oligoisoadenylate synthetase-
dependent) 
0.001 2.6 3.07 18.6 72.89 -- 
76* gi_118150929 NM_001077912 TPST1 Tyrosylprotein sulfotransferase 1 0.001 2.6 3.07 2.7 1.60 -- 
77 gi_119917796 XM_604643 CASP7 Caspase 7, apoptosis-related cysteine peptidase 0.001 2.6 3.26 6.2 5.40 -- 
78 gi_116004140 NM_001076960 ARMCX2 Armadillo repeat containing, x-linked 2 0.001 2.6 3.84 1.5 3.27 -- 
79 gi_157074115 NM_001103300 MAFF V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog f (avian) 
0.002 2.5 1.43 2.6 -4.11  
80 gi_119917033 XM_001250581 LOC782311 Similar to tyrosylprotein sulfotransferase 1, transcript 
variant 2 (LOC782311) 
0.002 2.4 2.81 2.1 1.73 -- 
81 gi_119910001 XR_028045 LOC786252 Similar to armadillo repeat containing 2 (LOC786252) 0.003 2.4 2.73 1.1 3.05 -- 
82 gi_155372230 NM_001101257 FAM89A Family with sequence similarity 89, member a 0.003 2.4 2.92 4.5 2.67 -- 
83* gi_119929648 XM_864342 Gm41 Melanoma antigen, family b, 4 pseudogene 0.003 2.4 2.19 3.1 4.29  
84 gi_31341539 NM_174610 SLC6A6 Solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 
0.003 2.4 2.31 55.6 8.36  
85 gi_150247056 NM_001099366 SPRY1 Sprouty homolog 1, antagonist of fgf signaling (drosophila) 0.003 2.4 2.38 1.3 5.40 -- 
86 gi_58764282 CX950755 – – - Cx950755 umc-bcl_0b02-030-d06 day 14 cl from a 
pregnant animal bclcDNA 3' sequence 
0.005 2.4 2.52 2.4 -3.36 -- 
87 gi_147899351 NM_001098072 NRAP Nebulin-related anchoring protein 0.005 2.4 3.01 8.4 3.06 -- 
88 gi_119889474 XR_028680 LOC788729 Similar to b-cell cll/lymphoma 9 (LOC788729) 0.003 2.4 1.75 6.6 22.61 -- 
89 gi_125991933 NM_001081621 TIFA TRAF-interacting protein with forkhead-associated domain 0.004 2.3 3.33 5.0 -10.34 -- 
90 gi_119916277 XM_616212 PTPRM Protein tyrosine phosphatase, receptor type, m 0.004 2.3 2.17 6.8 10.65 -- 
91* gi_115495042 NM_001075961 RTP4 Receptor (chemosensory) transporter protein 4 0.004 2.3 1.86 14.9 4.69  
92 gi_119915345 XM_001255058 LOC787796 Hypothetical protein (LOC787796) 0.006 2.3 1.24 8.4 7.17 -- 
93* gi_119888383 XM_586318 NINJ1 Ninjurin 1 0.005 2.3 1.77 3.0 4.29 -- 
94 gi_119903215 XM_865470 LOC614107 Similar to hexokinase ii (loc614107) 0.005 2.3 1.58 2.3 3.33 -- 
95 gi_119889467 XM_871861 LOC613322 Hypothetical loc613322 (loc613322) 0.005 2.2 2.44 6.9 27.21  
96* gi_119901428 XM_001251458 Gm41 Melanoma antigen, family b, 4 pseudogene 0.006 2.2 1.41 2.5 5.16  
97 gi_119893596 XM_584935 SLC39A8 Solute carrier family 39 (zinc transporter), member 8 0.007 2.2 2.72 2.6 4.23 -- 
98 gi_119888157 XM_580320 STEAP3 Steap family member 3 0.006 2.2 1.88 10.9 21.37 -- 
99 gi_119910534 XM_001254854 LOC788393 Hypothetical protein loc788393 (loc788393) 0.006 2.2 -1.36 3.7 -7.87  
100 gi_119893517 XM_001252348 LOC783896 Similar to TRAF-interacting protein with a forkhead-
associated domain (LOC783896) 
0.007 2.2 2.86 4.1 -11.74 -- 
101 gi_119903224 XM_001255831 HK2 Hexokinase 2 0.007 2.2 1.53 2.0 2.81 -- 
102* gi_118150987 NM_001077947 GPR77 G protein-coupled receptor 77 0.009 2.2 1.98 2.3 5.57 -- 
103 gi_51816841 CO886556 – – - Co886556 bovgen_14881 normal cattle brain cDNA clone 
rzpdp1056n2423q 5' sequence 
0.008 2.1 2.01 2.3 2.46 -- 
104 gi_115497873 NM_001075202 IER3 Immediate early response 3 0.008 2.1 1.11 14.3 20.10 -- 
105 gi_31340867 NM_174758 NPC1 Niemann-pick disease, type c1 0.009 2.1 1.10 2.8 2.25 -- 
106 gi_164420718 NM_001075214 GSTO1 Glutathione s-transferase omega 1  0.011 2.1 1.94 3.3 2.63 -- 
107 gi_78045548 NM_001035075 XAF1 Xiap associated factor 1 0.014 2.1 2.24 3.0 -1.61  
108 gi_119915318 XR_028520 LOC512304 Similar to enpp5 (LOC512304) 0.011 2.1 3.31 2.2 5.57 -- 
109 gi_31343172 NM_173962 SV2A Synaptic vesicle glycoprotein 2a 0.011 2.1 2.88 -1.3 2.31 -- 
110 gi_134085833 NM_001083490 HOXC13 Homeobox c13 0.012 2.1 1.39 10.1 11.48  
111 gi_31340793 NM_174662 FAS Fas (TNF receptor superfamily, member 6) 0.012 2.1 1.04 4.0 1.52 -- 
112 gi_84000334 NM_001038183 CSRP2 Cysteine and glycine-rich protein 2 0.013 2.0 2.23 2.2 3.06 -- 
113* gi_167583505 NM_001114515 NUPR1 Nuclear protein, transcriptional regulator, 1 0.013 2.0 -1.64 4.3 3.69  
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3.2 List of PMA induced up-regulated genes (n = 342) showing 
modulated expression profiles in TashAT2  
Profile 1 n = 52   
  
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene symbol 
Gene Name 
BoMac PMA 
vs BoMac 
Abs FC: 
TashAT2 PMA  vs 
PCAGGS PMA  
Abs: FC 
       
1 gi_136256085 NM_001038533 F2RL2 Coagulation factor II (thrombin) receptor-like 2 2.54 16.52 
2 gi_58332431 NM_178317 TRIB2 Tribbles homolog 2 (Drosophila) 2.68 13.30 
3 gi_31342775 NM_174132 OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 8.42 11.36 
4 gi_119901828 XM_604049 AQPEP Laeverin 4.97 9.51 
5 gi_76642509 XM_871034 LOC618709 Hypothetical (LOC618709) 2.53 8.26 
6 gi_155371894 NM_001101082 SEMA3C Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C 2.36 6.32 
7 gi_119893972 XM_596732 LOC518539 Similar to epiregulin (LOC518539) 5.40 6.18 
8 gi_119889047 XM_592485 SLAMF8 SLAM family member 8 2.34 6.09 
9 gi_58764139 CX950612 – – - CX950612 UMC-bcl_0B02-028-b07 Day 14 CL from a pregnant animal bclcdna 3' sequence 3.89 6.01 
10 gi_119901966 XM_605853 PAQR5 Progestin and adipoq receptor family member V 2.98 5.88 
11 gi_76642926 XM_600064 SLFN11 Schlafen family member 11 2.14 5.57 
12 gi_51815461 CO885176 – – - CO885176 bovgen_13501 normal cattle brain cdna clone rzpdp1056b2017q 5' sequence 2.50 5.39 
13 gi_31341636 NM_174571 PECAM1 Platelet/endothelial cell adhesion molecule 2.37 4.99 
14 gi_119928196 XM_001254362 LOC786779 Similar to retinoic acid inducible in neuroblastoma cells RAINB1 (LOC786779) 4.28 4.46 
15 gi_139949115 NM_001083796 VASN Vasorin 2.38 3.97 
16 gi_119908002 XM_588921 FAIM3 Fas apoptotic inhibitory molecule 3 2.07 3.62 
17 gi_119916372 XM_616030 SMAD7 SMAD family member 7 2.48 3.43 
18* gi_119906905 XM_001250441 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 2.45 3.41 
19 gi_119888296 XM_866583 FAM117B Family with sequence similarity 117, member B 2.04 3.35 
20 gi_119910070 XM_586929 MT2A Metallothionein 2A 4.50 3.30 
21 gi_77735772 NM_001034409 EEPD1 Endonuclease/exonuclease/phosphatase family domain containing 1 2.26 3.23 
22* gi_119919612 XM_584932 LONRF3 LON peptidase N-terminal domain and ring finger 3 2.32 3.17 
23 gi_119879453 XM_616928 PLCXD2 Phosphatidylinositol-specific phospholipase C, X domain containing 2 2.07 3.16 
24* gi_119919610 XM_001249810 LONRF3 LON peptidase N-terminal domain and ring finger 3 2.08 3.13 
25 gi_60993766 DN539166 – – - DN539166 1384921 MARC 7bovcdna 5' sequence 2.24 3.10 
26* gi_27806540 NM_174112 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 2.84 3.07 
27 gi_82809590 DV875361 – – - DV875361 LB02527.CR_C12 GC_BGC-25 cdna clone IMAGE:8209862 5' sequence 2.15 2.82 
28 gi_115496543 NM_001076011 ITPKC Inositol 1,4,5-trisphosphate 3-kinase C 2.46 2.82 
29* gi_119916246 XM_587139 TGIF1 TGFB-induced factor homeobox 1 5.31 2.80 
30 gi_119891800 XR_027344 LOC781850 Hypothetical protein (LOC781850) 2.42 2.75 
31 gi_61946697 DN641296 – – - DN641296 UMC-bof_0A01-015-b03 Ovarian follicle recruited bofcdna 3' sequence 7.44 2.68 
32 gi_119891399 XM_599768 JHDM1D Jumonji C domain containing histone demethylase 1 homolog D (S. Cerevisiae) 4.33 2.62 
33 gi_155372082 NM_001101178 ITPRIP Inositol 1,4,5-triphosphate receptor interacting protein 2.18 2.60 
34 gi_119912488 XM_001256211 LOC789463 Similar to retina copper-containing monoamine oxidase (LOC789463) 2.77 2.56 
35 gi_119916129 XM_597764 RNF125 Ring finger protein 125 6.32 2.50 
36 gi_122692454 NM_001080309 YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. Cerevisiae) 2.15 2.43 
37 gi_119908015 XM_604649 IL24 Interleukin 24 37.63 2.41 
38* gi_190360732 NM_001128499 TGIF1 TGFB-induced factor homeobox 1 4.16 2.31 
39 gi_119900349 XM_613366 CD274 CD274 molecule 2.07 2.29 
40 gi_111103930 EE242794 – – - EE242794 LB02227.CR_O10 GC_BGC-22cdna clone IMAGE:8260452 sequence 2.23 2.28 
41 gi_119912455 XR_028746 KCNH4 Potassium voltage-gated channel, subfamily H (eag-related), member 4 2.08 2.27 
42 gi_60456158 DN287548 – – - DN287548 1241808 MARC 7bovcdna 3' sequence 2.18 2.22 
43 gi_51807744 CO877828 – – - CO877828 bovgen_06153 normal cattle brain cdna clone rzpdp1056a1220q 5' sequence 3.81 2.21 
44 gi_148747149 NM_174363 INHBA Inhibin, beta A 3.05 2.17 
45 gi_119910262 XM_612960 CCNE1 Cyclin E1 2.13 2.15 
46 gi_31341980 NM_174445 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 20.46 2.12 
47 gi_51823760 CO893455 – – - CO893455 bovgen_21780 normal cattle brain cdna clone rzpdp1056k1350q 5' sequence 2.18 2.11 
48 gi_83035104 NM_001037617 C21orf91 Chromosome 21 open reading frame 91 2.55 2.10 
49 gi_119890536 XM_583937 GBX2 Gastrulation brain homeobox 2 2.24 2.08 
50 gi_115497081 NM_001075656 JUNB Jun B proto-oncogene 2.06 2.05 
51 gi_119894688 XM_001249956 ZSWIM4 Zinc finger, SWIM-type containing 4 4.09 2.03 
52 gi_118151325 NM_001078128 SOX4 SRY (sex determining region Y)-box 4 2.60 2.02 
Profile 2 n = 220     
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene symbol 
Gene name 
BoMac PMA 
vs BoMac 
Abs FC: 
TashAT2 PMA  vs 
PCAGGS PMA  
Abs: FC 
     
  
1* gi_28849922 NM_175700 CXCL2 Chemokine (C-X-C motif) ligand 2 12.41 -22.83 
2 gi_148223508 NM_001098056 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b 9.96 -16.34 
3 gi_119894606 XM_588006 PGLYRP2 Peptidoglycan recognition protein 2 9.73 -10.80 
4 gi_119910051 XM_595523 – – - Similar to fractalkine (LOC517354) 108.81 -10.46 
5 gi_31343250 NM_173925 IL8 Interleukin 8 12.97 -9.13 
6 gi_119912966 XM_612159 STC2 Stanniocalcin 2 6.08 -8.63 
7 gi_31342642 NM_174183 IL8 Selectin P (SELP) 5.51 -7.92 
8 gi_83721976 NM_001003904 FANK1 Fibronectin type III and ankyrin repeat domains 1 6.14 -7.91 
9 gi_119892044 XM_582930 KRT18 Keratin 18 13.61 -7.82 
10 gi_51884334 AJ816858 – – - AJ816858 AJ816858 KN206 Bos sp. cDNA clone C0005208o15 sequence 8.92 -7.67 
11 gi_31343615 NM_175827 CCL5 Chemokine (C-C motif) ligand 5 5.49 -7.53 
12 gi_119905157 XM_866719 IL15RA Interleukin 15 receptor, alpha 4.23 -7.24 
13 gi_164448607 NM_001076870 IHH Indian hedgehog 4.07 -7.09 
14 gi_119888971 XM_868383 CDA Cytidine deaminase 7.18 -7.04 
15 gi_77736420 NM_001034738 LTB4R Leukotriene B4 receptor 5.20 -6.80 
16 gi_119911895 XM_866482 PIK3R5 Phosphoinositide-3-kinase, regulatory subunit 5 3.57 -6.45 
17 gi_115496489 NM_001075341 CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 7.75 -6.17 
18 gi_119919428 XM_599739 FGF19 Fibroblast growth factor 19 5.51 -6.11 
19 gi_119908509 XM_607245 SCNN1D Sodium channel, nonvoltage-gated 1, delta 6.32 -6.01 
20 gi_125630654 NM_001081512 SPRY4 Sprouty homolog 4 (Drosophila) 15.66 -5.86 
21 gi_115497399 NM_001075256 KLK7 Kallikrein-related peptidase 7 5.48 -5.67 
22 gi_119912361 XM_875498 LOC514744 Hypothetical LOC514744, transcript variant 4 (LOC514744) 2.91 -5.52 
23 gi_31341396 NM_181022 GNAT1 Guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide1 4.52 -5.42 
24 gi_164452922 NM_001040512 LIMD2 LIM domain containing 2 (LIMD2) 2.83 -5.29 
25 gi_119874949 XR_027735 LOC510140 Hypothetical protein (LOC515053) 2.84 -5.07 
26 gi_157427775 NM_001105322 KRT17 Keratin 17 2.96 -5.07 
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27 gi_31342285 NM_174337 LOC281812 Fibroblast growth factor-binding protein (FGF-BP) (LOC281812) 8.23 -5.00 
28* gi_155372040 NM_001101158 VCAM1 Vascular cell adhesion molecule 1 3.45 -4.93 
29 gi_45430044 NM_205812 PKIG Protein kinase (camp-dependent, catalytic) inhibitor gamma 3.14 -4.76 
30 gi_119908887 XM_587667 TMEM154 Transmembrane protein 154 4.31 -4.65 
31 gi_115497953 NM_001076103 TRIB3 Tribbles homolog 3 (Drosophila) 7.30 -4.58 
32 gi_119894242 XM_001250804 LOC783341 Similar to fibroblast growth factor-binding protein (LOC783341) 7.47 -4.43 
33 gi_112210002 EE349629 SELP EE349629 LB02756.CR_B03 GC_BGC-27cdna clone IMAGE:8630885 sequence 6.14 -4.32 
34 gi_76636135 XM_865027 OMP Olfactory marker protein 2.94 -4.32 
35 gi_51801600 CO871768 – – - CO871768 bovgen_00093 normal cattle braincdna clone rzpdp1056l1557q 3' sequence 2.88 -4.32 
36 gi_119923241 XM_001252681 CCL5 Similar to multidrug resistance-associated protein (LOC784347) 2.26 -4.23 
37 gi_7055130 AW485024 – – - AW485024 63440 MARC 3bovcdna 5' sequence 2.37 -4.18 
38 gi_76620857 XM_871003 GDF15 Growth differentiation factor 15 3.43 -4.07 
39 gi_119905633 XM_611249 SLCO4A1 Solute carrier organic anion transporter family, member 4A1 4.93 -4.03 
40 gi_119938175 XM_001257028 LTB4R Similar to dual specificity phosphatase (EC 3.1.3.-) HVH2 - rat (LOC790602) 8.83 -4.02 
41 gi_94966792 NM_001040497 EGR4 Early growth response 4 2.93 -4.01 
42 gi_139948867 NM_001083732 GEM GTP binding protein overexpressed in skeletal muscle 3.80 -4.00 
43 gi_125630668 NM_001081520 LY6G6E Lymphocyte antigen 6 complex, locus G6E 2.43 -3.99 
44 gi_119913026 XM_589415 LOC507969 Similar to neuronal apoptosis inhibitory protein (LOC539780) 3.51 -3.95 
45 gi_76655846 XM_593654 BIRC3 Similar to dual specificity phosphatase (EC 3.1.3.-) HVH2 - rat (LOC540380) 2.76 -3.94 
46 gi_119892163 XM_591526 FMNL3 Formin-like 3 2.28 -3.89 
47 gi_31342739 NM_174147 PLAU Plasminogen activator, urokinase 6.38 -3.87 
48 gi_31342652 NM_174181 BDKRB2 Selectin E (SELE) 6.92 -3.85 
49 gi_119903277 XM_613518 CYP26B1 Cytochrome P450, family 26, subfamily B, polypeptide 1 8.31 -3.83 
50 gi_51883613 AJ816137 – – - AJ816137 AJ816137 KN206 Bos sp. Cdna clone C0005199e18 sequence 2.34 -3.80 
51 gi_119902263 XM_001253931 FMN1 Formin 1 2.83 -3.80 
52 gi_119901909 XM_608288 IGDCC3 Immunoglobulin superfamily, DCC subclass, member 3 2.04 -3.79 
53 gi_114052738 NM_001046298 FLI1 Friend leukemia virus integration 1 2.06 -3.79 
54 gi_119914056 XM_583508 BDKRB2 Bradykinin receptor B2 4.46 -3.77 
55* gi_49428238 AJ694819 LYST Lysosomal trafficking regulator 2.09 -3.76 
56 gi_157785620 NM_001105626 TTYH2 Tweety homolog 2 (Drosophila) 2.77 -3.73 
57 gi_27819627 NM_174359 IL2RG Interleukin 2 receptor, gamma 3.57 -3.71 
58 gi_119892376 XM_001251597 LOC781063 Hypothetical protein (LOC782937) 3.10 -3.71 
59* gi_119905155 XM_001252652 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 2.73 -3.69 
60 gi_119928947 XM_001253195 LOC537304 Hypothetical protein (LOC785053) 2.56 -3.68 
61 gi_156120610 NM_001101981 TBC1D2 TBC1 domain family, member 2 2.20 -3.68 
62 gi_117935052 NM_001024930 CCR7 Chemokine (C-C motif) receptor 7 5.43 -3.66 
63 gi_119920689 XM_581517 GYG2 Glycogenin 2 2.05 -3.66 
64 gi_119922372 XM_610090 LOC538598 Similar to FMN1 protein (LOC531592) 3.06 -3.64 
65 gi_119904445 XM_593034 OLFM4 Olfactomedin 4 2.52 -3.61 
66 gi_119904862 XM_593336 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 2.99 -3.61 
67 gi_115432044 NM_173888 ADM Adrenomedullin 2.13 -3.56 
68 gi_119936795 XM_001249731 – – - Similar to multidrug resistance-associated protein (LOC781332) 2.91 -3.54 
69 gi_119914998 XM_581556 MGLL Monoglyceride lipase 2.32 -3.53 
70* gi_119908050 XM_001252091 5430435G22Rik RIKEN cdna 5430435G22 gene 3.81 -3.51 
71 gi_119893320 XM_870947 CEBPB Similar to BIK1 (LOC618614) 7.37 -3.49 
72 gi_119892705 XM_607295 CHST11 Carbohydrate (chondroitin 4) sulfotransferase 11 6.48 -3.43 
73 gi_147906802 NM_001098101 ESM1 Endothelial cell-specific molecule 1 10.06 -3.40 
74 gi_119935945 XM_001257083 LOC614838 Hypothetical protein (LOC790672) 2.95 -3.40 
75 gi_51810587 CO880658 – – - CO880658 bovgen_08983 normal cattle braincdna clone rzpdp1056e2228q 5' sequence 2.03 -3.39 
76* gi_118150789 NM_001077837 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 3.85 -3.39 
77 gi_157427895 NM_001105385 KLF4 Kruppel-like factor 4 (gut) 5.20 -3.35 
78 gi_115432056 NM_001037100 BCL2A1 BCL2-related protein A1 3.60 -3.33 
79 gi_155371934 NM_001101102 MDFIC Myod family inhibitor domain containing 3.14 -3.31 
80 gi_119930084 XM_595414 LOC517246 Similar to cytochrome P450 CYP3A24 (LOC517246) 5.83 -3.30 
81 gi_119932216 XM_001256909 LOC511224 Hypothetical protein LOC790441 (LOC790441) 2.48 -3.28 
82 gi_126722714 NM_001082456 WNT11 Wingless-type MMTV integration site family, member 11 2.54 -3.23 
83 gi_119903421 XM_001251996 F2R Butyrate response factor 2 (ZFP36L2) 3.62 -3.22 
84 gi_119935611 XM_001257030 LOC790607 Similar to membrane cofactor protein (LOC790607) 2.30 -3.21 
85 gi_119892165 XM_001251013 AQP5 Aquaporin 5 2.39 -3.21 
86 gi_119890874 XM_617961 – – - Similar to semaphorin III/collapsin-1 (LOC537777) 2.11 -3.20 
87 gi_31342177 NM_174373 KCNJ2 Potassium inwardly-rectifying channel, subfamily J, member 2 2.54 -3.13 
88 gi_82651886 DV798971 FLT3LG DV798971 Hw_loin_61_050825_A06CF-24-HW loin cdna librarycdna sequence 3.08 -3.13 
89 gi_119900643 XM_604596 EGR3 Early growth response 3 3.76 -3.10 
90* gi_119910855 XM_001253556 FGF21 Fibroblast growth factor 21 3.11 -3.05 
91 gi_119908394 XM_580530 GPR157 G protein-coupled receptor 157 3.10 -3.04 
92 gi_45430034 NM_205806 ST3GAL4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 2.56 -3.04 
93 gi_68433683 AM031784 LOC784977 AM031784 AM031784 KN-252-spleen, Bos sp. Bos sp. Cdna clone C0007402j18 3' sequence 2.44 -3.03 
94 gi_156718123 NM_001103097 F2R Coagulation factor II (thrombin) receptor 3.43 -3.02 
95 gi_119915977 XM_588519 NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 3.45 -2.99 
96 gi_114051875 NM_001046118 LAPTM5 Lysosomal protein transmembrane 5 3.17 -2.98 
97* gi_119925448 XM_001251333 MYO10 Myosin X 2.73 -2.96 
98 gi_78369443 NM_001035293 BIRC3 Baculoviral IAP repeat containing 3 4.47 -2.95 
99 gi_119906122 XR_028705 LOC507766 Similar to breast cancer putative transcription factor (LOC507766) 2.66 -2.95 
100 gi_119913384 XM_596594 ANKRD33B Ankyrin repeat domain 33B 8.47 -2.95 
101 gi_119913029 XR_027889 LOC529061 Similar to Microtubule-associated serine/threonine-protein kinase 4 (LOC529061) 3.82 -2.95 
102 gi_156523181 NM_001102535 HR Hairless homolog (mouse) 2.22 -2.93 
103 gi_149642660 NM_001099057 LOC515333 Ankyrin repeat domain 55 (ANKRD55) 2.86 -2.91 
104 gi_60729463 DN519273 LOC781928 DN519273 1260085 MARC 7bovcdna 3' sequence 4.42 -2.90 
105* gi_119911031 XM_581045 AU018091 Expressed sequence AU018091 2.89 -2.90 
106 gi_126158902 NM_001081577 SLC1A4 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 2.39 -2.89 
107 gi_119925198 XM_001254231 EGR4 Hypothetical protein (LOC786597) 2.30 -2.87 
108 gi_61752704 CR451798 LOC781332 CR451798 CR451798 Normalized and Subtracted bovine embryonic and extraembryonic 
tissues (bcaz/BE03) cdna clone bcaz0015.n.11 5' sequence 
2.21 -2.86 
109 gi_119907746 XM_001253132 LOC504861 Similar to LOC387763 protein (LOC784977) 3.16 -2.86 
110 gi_114051987 NM_001046392 ARHGAP25 Rho gtpase activating protein 25 2.59 -2.85 
111 gi_119913658 XM_587247 SLC2A6 Similar to KIAA1745 protein, transcript variant 1 (LOC510140) 6.76 -2.85 
112 gi_119904470 XM_001250967 ANKRD55 Hypothetical protein (LOC782318) 2.13 -2.81 
113 gi_115496423 NM_001075725 TP53I11 Tumor protein p53 inducible protein 11 3.10 -2.81 
114 gi_119925527 XM_595233 LOC515053 Similar to ABCC4 protein (LOC517069) 2.53 -2.80 
115 gi_119935431 XM_001256981 LOC785195 Similar to alpha2,3-sialyltransferase (LOC790542) 2.43 -2.79 
116 gi_29255914 CB449532 – – - CB449532 703738 MARC 6bovcdna 5' sequence 8.64 -2.78 
117 gi_119909395 XR_027267 TBX3 T-box 3 4.03 -2.77 
118 gi_28603825 NM_176788 LPO CCAAT/enhancer binding protein (C/EBP), beta (CEBPB) 3.58 -2.77 
119 gi_51808063 CO878147 – – - CO878147 bovgen_06472 normal cattle braincdna clone rzpdp1056k0128q 5' sequence 10.85 -2.76 
120 gi_125991751 NM_174603 SLC2A3 Solute carrier family 2 (facilitated glucose transporter), member 3 2.71 -2.76 
121 gi_119909447 XM_595626 PXN Paxillin 2.31 -2.75 
122 gi_51887696 AJ820220 LOC790269 AJ820220 AJ820220 KN206 Bos sp. Cdna clone C0006017m22 sequence 3.21 -2.73 
123 gi_119913525 XM_583647 ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 4.15 -2.72 
124 gi_48675380 NM_001001601 CDH5 Cadherin 5, type 2 (vascular endothelium) 3.66 -2.72 
125 gi_156121346 NM_001102352 LOC540380 Rho gtpase activating protein 27 (ARHGAP27) 2.69 -2.72 
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126 gi_31342036 NM_174426 PLUNC Palate, lung and nasal epithelium associated 2.25 -2.71 
127 gi_51816867 CO886582 – – - CO886582 bovgen_14907 normal cattle brain cdna clone rzpdp1056h0512q 5' sequence 2.22 -2.70 
128 gi_149642860 NM_001099141 BMP2 Bone morphogenetic protein 2 3.33 -2.66 
129 gi_119904923 XM_001254844 – – - Similar to OPR (LOC787451) 2.35 -2.66 
130 gi_77735472 NM_001034259 DUSP18 Dual specificity phosphatase 18 2.59 -2.65 
131 gi_119907177 XM_864208 UBASH3B Ubiquitin associated and SH3 domain containing B 2.23 -2.64 
132 gi_119894051 XM_587301 IL2RB Interleukin 2 receptor, beta 2.66 -2.64 
133 gi_118150959 NM_001077930 ERRFI1 ERBB receptor feedback inhibitor 1 3.64 -2.64 
134 gi_148229402 NM_001098111 PCDH12 Protocadherin 12 2.13 -2.63 
135 gi_119904637 XM_001250734 – – - Hypothetical protein (LOC782141) 2.97 -2.61 
136 gi_51819617 CO889332 ARHGAP25 CO889332 bovgen_17657 normal cattle brain cdna clone rzpdp1056a0441q 5' sequence 2.16 -2.60 
137 gi_119908069 XM_610795 KLHDC8A Kelch domain containing 8A 3.51 -2.58 
138 gi_119901706 XM_596626 SYNJ2 Synaptojanin 2 2.28 -2.58 
139 gi_112244680 EE384448 LOC531141 EE384448 LB03075.CR_P10 GC_BGC-30cdna clone IMAGE:8512956 sequence 2.59 -2.57 
140 gi_51816802 CO886517 ST3GAL4 CO886517 bovgen_14842 normal cattle brain cdna clone rzpdp1056k249q 5' sequence 2.38 -2.56 
141 gi_119912895 XM_001256686 LOC790129 Similar to SOX9 (LOC790129) 9.07 -2.56 
142 gi_119912909 XM_607611 SLC16A6 Solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 2.48 -2.55 
143 gi_119914706 XM_609627 SEMA3F Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 2.58 -2.54 
144 gi_119916743 XM_864316 SOCS1 Suppressor of cytokine signaling 1 2.85 -2.53 
145 gi_51805159 CO875259 KCNJ2 CO875259 bovgen_03584 normal cattle brain cdna clone rzpdp1056d1057q 3' sequence 2.05 -2.49 
146 gi_51803597 CO873754 – – - CO873754 bovgen_02079 normal cattle brain cdna clone rzpdp1056b2154q 3' sequence 2.23 -2.48 
147 gi_156121054 NM_001102204 RIN2 Ras and Rab interactor 2 2.60 -2.48 
148 gi_164452932 NM_001035421 KCTD11 Potassium channel tetramerisation domain containing 11 2.07 -2.47 
149 gi_68427075 AM027990 LOC517069 AM027990 KN-252-lymph, Bos indicus Bos indicus cdna clone C0007394c04 3' sequence 4.33 -2.47 
150 gi_119903174 XR_028610 LOC515082 Similar to mitogen-activated protein kinase kinase kinase kinase 4 (LOC509109) 2.30 -2.46 
151* gi_82632008 gb_DV779132 GNG2 Guanine nucleotide binding protein (G protein), gamma 2 2.03 -2.44 
152 gi_139949110 NM_001083769 IRF8 Interferon regulatory factor 8 3.95 -2.43 
153* gi_115497587 NM_001075888 CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 8.12 -2.43 
154 gi_31342230 NM_174358 IL2RA Interleukin 2 receptor, alpha 2.35 -2.39 
155 gi_119909134 XR_028220 LOC790441 Similar to cytosolic branched-chain amino acid aminotransferase (LOC785193) 2.24 -2.39 
156 gi_119914094 XM_869719 CCDC85C Coiled-coil domain containing 85C 2.21 -2.38 
157 gi_119894841 XM_584508 LRRC8E Leucine rich repeat containing 8 family, member E 2.52 -2.38 
158 gi_157074163 NM_001103326 BCAT1 Mucin-like protocadherin (MUPCDH) 2.35 -2.37 
159* gi_150247091 NM_001099367 CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 14.16 -2.37 
160 gi_119901537 XM_584832 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 22.30 -2.36 
161 gi_15378656 BI537546 LOC529030 BI537546 416108 MARC 4bovcdna 5' sequence 2.24 -2.35 
162 gi_119926074 XM_001254560 LOC790542 Similar to AKNA protein (LOC787047) 2.35 -2.35 
163 gi_31340830 NM_174744 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kda gelatinase, 92kda type IV collagenase) 2.53 -2.35 
164 gi_77735806 NM_001034430 PDLIM2 PDZ and LIM domain 2 (mystique) 2.01 -2.35 
165* gi_119918132 XM_001250478 DPPA2 Developmental pluripotency associated 2 2.99 -2.35 
166 gi_119913047 XM_865521 ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 7.27 -2.32 
167* gi_31342121 NM_174394 MYO10 Myosin X 2.36 -2.32 
168 gi_119908995 XM_602397 SLC7A11 Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 5.78 -2.31 
169 gi_119905496 XM_866049 FERMT1 Fermitin family member 1 2.95 -2.31 
170 gi_154707907 NM_001099095 GZMA Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 2.81 -2.29 
171* gi_119903752 XM_001252683 MXD1 MAX dimerization protein 1 2.17 -2.28 
172 gi_119906930 XM_001254662 LOC787451 Hypothetical protein (LOC787190) 2.07 -2.28 
173 gi_119903689 XM_872068 MUpCDH Similar to KIAA0903-like protein, transcript variant 2 (LOC613399) 2.05 -2.28 
174 gi_76631782 XM_583252 CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3 2.81 -2.27 
175 gi_119888514 XM_581382 IRS1 Insulin receptor substrate 1 3.67 -2.26 
176 gi_119893184 XM_584724 WNT5B Wingless-type MMTV integration site family, member 5B 2.65 -2.26 
177 gi_10026167 BE665576 – – - BE665576 154662 MARC 4bovcdna 5' sequence 2.31 -2.24 
178 gi_122692524 NM_001080256 SLC2A6 Solute carrier family 2 (facilitated glucose transporter), member 6 2.86 -2.23 
179 gi_119916536 XM_870860 LOC786597 Similar to Kremen2 protein (LOC618527) 2.18 -2.22 
180 gi_119902633 XM_617463 OSBPL3 Oxysterol binding protein-like 3 3.90 -2.22 
181 gi_119892435 XM_595759 INHBE Inhibin, beta E 5.57 -2.22 
182* gi_119927606 XM_001253379 CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 11.27 -2.21 
183 gi_51881771 AJ814295 LOC518435 AJ814295 AJ814295 KN206 Bos sp. cDNA clone C0005204n18 sequence 2.87 -2.21 
184 gi_15379008 BI537898 – – - BI537898 428179 MARC 4bovcdna 5' sequence 4.83 -2.21 
185 gi_119895714 XR_027478 – – - Similar to PGC-1-related estrogen receptor alpha coactivator (LOC514750) 4.34 -2.21 
186 gi_41386686 NM_173931 LIF Leukemia inhibitory factor (cholinergic differentiation factor) 10.23 -2.21 
187 gi_119915466 XM_001249749 LOC784347 Chromosome 6 open reading frame 25 (c6orf25) 2.61 -2.20 
188 gi_149642596 NM_001098868 BOK BCL2-related ovarian killer 2.27 -2.18 
189 gi_119912654 XM_001253289 LOC785193 Hypothetical protein (LOC785195) 2.83 -2.18 
190 gi_119930998 XM_001256787 – – - Similar to multidrug resistance-associated protein (LOC790269) 2.81 -2.17 
191 gi_31341809 NM_181030 FLT3LG Fms-related tyrosine kinase 3 ligand 3.25 -2.16 
192 gi_157074011 NM_001103245 EFHD2 EF-hand domain family, member D2 2.15 -2.15 
193 gi_51887526 AJ820050 LOC617455 AJ820050 KN206 Bos sp. cDNA clone C0006017e07 sequence 3.37 -2.13 
194 gi_31343234 NM_173933 LPO Lactoperoxidase 2.82 -2.13 
195 gi_29263643 CB457261 LOC618527 CB457261 714599 MARC 6bovcdna 5' sequence 14.95 -2.12 
196 gi_51821600 CO891305 LOC514626 CO891305 bovgen_19630 normal cattle brain cdna clone rzpdp1056a0847q 5' seq 3.62 -2.11 
197 gi_160333614 NM_001110532 BAG4 BCL2-associated athanogene 4 2.36 -2.11 
198 gi_115496062 NM_001075755 MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
2.55 -2.11 
199 gi_51817723 CO887438 RILPL1 CO887438 bovgen_15763 normal cattle brain cdna clone rzpdp1056c0813q 5' sequence 2.36 -2.10 
200 gi_51819799 CO889514 PCDH12 CO889514 bovgen_17839 normal cattle brain cdna clone rzpdp1056l0438q 5' sequence 2.28 -2.09 
201 gi_51817431 CO887146 – – - CO887146 bovgen_15471 normal cattle brain cdna clone rzpdp1056a2317q 5' sequence 2.16 -2.09 
202 gi_119901959 XM_872521 TLE3 Transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) 3.81 -2.09 
203 gi_119912792 XM_596084 RHBDF2 Rhomboid 5 homolog 2 (Drosophila) 3.39 -2.08 
204 gi_51887200 AJ819724 LOC537777 AJ819724 KN206 Bos sp. Cdna clone C0006016e15 sequence 2.47 -2.08 
205 gi_115497773 NM_001075226 RILPL1 Rab interacting lysosomal protein-like 1 2.15 -2.08 
206 gi_51824812 CO894504 – – - CO894504 bovgen_22829 normal cattle braincdna clone rzpdp1056i0644q 5' sequence 2.10 -2.08 
207 gi_51822234 CO891936 – – - CO891936 bovgen_20261 normal cattle braincdna clone rzpdp1056m1641q 5' sequence 4.56 -2.07 
208 gi_119904633 XM_587329 SLC7A1 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 2.40 -2.07 
209 gi_119907587 XM_612432 P2RY2 Purinergic receptor P2Y, G-protein coupled, 2 2.03 -2.07 
210 gi_119905914 XM_614691 TOP1 Topoisomerase (DNA) I 2.58 -2.06 
211 gi_119879641 XM_589607 MFI2 Antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 2.01 -2.06 
212 gi_139948300 NM_001083644 BCAT1 Branched chain amino-acid transaminase 1, cytosolic 2.45 -2.05 
213* gi_119885538 XM_865626 RASA2 RAS p21 protein activator 2 3.99 -2.04 
214 gi_119931602 XM_001256019 FAM107B Similar to HPCL1 (LOC789196) 2.04 -2.04 
215 gi_126723073 NM_175801 FST Follistatin 3.26 -2.04 
216 gi_51808839 CO878915 P2RY2 CO878915 bovgen_07240 normal cattle brain cdna clone rzpdp1056d054q 5' sequence 2.31 -2.03 
217 gi_156121148 NM_001102252 PTK2B PTK2B protein tyrosine kinase 2 beta 2.07 -2.03 
218 gi_119900885 XM_592054 TNFSF15 Tumor necrosis factor (ligand) superfamily, member 15 2.08 -2.01 
219 gi_60456280 DN287670 LOC539803 DN287670 1241977 MARC 7bov cdna 3' sequence 2.11 -2.01 
220 gi_66792735 NM_001024507 SESN2 Sestrin 2 2.90 -2.00 
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1 gi_156121012 NM_001102183 ERG V-ets erythroblastosis virus E26 oncogene homolog (avian) 2.81 -511.27 
2 gi_119907136 XM_592427 OAF OAF homolog (Drosophila) 2.46 -223.43 
3* gi_113204619 NM_001015570 LGALS9 Lectin, galactoside-binding, soluble, 9 2.03 -146.46 
4 gi_114053308 NM_001046283 F2RL1 Coagulation factor II (thrombin) receptor-like 1 4.37 -119.55 
5 gi_31342788 NM_174128 NRG1 Neuregulin 1 (NRG1) 2.06 -110.75 
6 gi_31343056 NM_174006 CCL2 Chemokine (C-C motif) ligand 2 40.23 -104.77 
7 gi_31342385 NM_174300 CXCL5 Chemokine (C-X-C motif) ligand 5 10.66 -102.90 
8 gi_119913746 XM_602502 BNC1 Basonuclin 1 2.38 -64.63 
9 gi_89886135 NM_001013585 S1PR1 Sphingosine-1-phosphate receptor 1 12.56 -64.46 
10 gi_45430004 NM_205788 CEACAM8 Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) 2.72 -39.63 
11 gi_119902549 XM_603066 SHC4 SHC (Src homology 2 domain containing) family, member 4 3.96 -38.93 
12 gi_119941886 XM_001257225 LOC790854 Similar to oxysterol 7alpha-hydroxylase (LOC790854) 5.39 -36.95 
13 gi_148237696 NM_174083 HRH1 Histamine receptor H1 3.31 -34.42 
14 gi_148236122 NM_001098043 CLMP CXADR-like membrane protein 2.76 -33.85 
15 gi_83035050 NM_001037590 ASGR1 Asialoglycoprotein receptor 1 2.26 -31.39 
16* gi_114326490 NM_001048165 CXCL2 Chemokine (C-X-C motif) ligand 2 9.23 -30.31 
17 gi_115496605 NM_001076352 LMO2 LIM domain only 2 (rhombotin-like 1) 3.25 -30.10 
18 gi_49410464 AJ677881 – – - AJ677881 KN224cDNA clone KN224-024_P02 sequence 4.49 -29.00 
19 gi_84000286 NM_001038155 TNS4 Tensin 4 3.67 -27.85 
20* gi_114050914 NM_001046513 CXCL2 Chemokine (C-X-C motif) ligand 2 4.35 -27.60 
21 gi_115497387 NM_001076095 RAB39B RAB39B, member RAS oncogene family 3.61 -26.64 
22 gi_119916193 XM_612197 LOC532965 Similar to alpha3a chain laminin (LOC532965) 4.02 -25.49 
23* gi_41386706 NM_174484 VCAM1 Vascular cell adhesion molecule 1 11.81 -24.67 
24 gi_119894821 XM_607258 LOC528826 Similar to mucin 16 (LOC528826) 2.12 -24.09 
25 gi_119917473 XM_599002 LOC520752 Hypothetical (LOC520752) 2.13 -24.06 
26 gi_119906495 XM_608003 CYP7B1 Cytochrome P450, family 7, subfamily B, polypeptide 1 4.04 -23.27 
27 gi_119910630 XM_001256469 LOC789828 Similar to carcinoembryonic antigen-related cell adhesion molecule 1 isoform 3L  2.75 -21.31 
28 gi_158262744 NM_001109962 DCLK1 Doublecortin-like kinase 1 (DCLK1) 9.63 -21.00 
29 gi_119889464 XM_863903 TCHH Trichohyalin 10.34 -20.94 
30 gi_119902622 XM_869016 FGF7 Fibroblast growth factor 7 5.44 -20.68 
31 gi_115494923 NM_001075952 ASGR2 Asialoglycoprotein receptor 2 2.76 -20.22 
32 gi_51811539 gb_CO881610 – – - CO881610 bovgen_09935 normal cattle braincdna clone rzpdp1056k0421q 5' sequence 3.30 -18.80 
33 gi_42730748 CK778435 – – - CK778435 965595 MARC 3bovcdna 3' sequence 2.70 -17.65 
34 gi_51812192 CO882260 – – - CO882260 bovgen_10585 normal cattle braincdna clone rzpdp1056d208q 5' sequence 2.26 -15.74 
35 gi_119889196 XM_001251267 LOC783721 Hypothetical protein (LOC783721) 3.17 -14.39 
36 gi_119894823 XM_001254224 LOC786588 Similar to mucin 16 (LOC786588) 2.04 -14.29 
37 gi_115497119 NM_001075890 KLK10 Kallikrein-related peptidase 10 3.25 -13.83 
38 gi_119915324 XM_590184 GPR110 G protein-coupled receptor 110 3.32 -13.45 
39 gi_119940186 XM_607283 LOC528849 Similar to MER receptor tyrosine kinase (LOC528849) 3.11 -13.10 
40 gi_156120634 NM_001101994 SLC6A12 Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 2.35 -12.11 
41* gi_119923630 XM_591244 RAET1E Retinoic acid early transcript 1E 2.65 -10.37 
42 gi_119906362 XM_605757 FER1L6 Fer-1-like 6 (C. Elegans) 2.23 -10.14 
43 gi_119902777 XR_027766 LOC533088 Similar to glutathione peroxidase 2 (LOC533088) 3.90 -9.73 
44 gi_119903128 XM_580552 MERTK C-mer proto-oncogene tyrosine kinase 3.75 -8.57 
45 gi_119907990 XM_606934 LOC528508 Similar to DTX4 protein (LOC528508) 2.13 -8.47 
46 gi_51813662 CO883718 – – - CO883718 bovgen_12043 normal cattle braincdna clone rzpdp1056f2013q 5' sequence 2.52 -8.06 
47* gi_119908717 XM_877066 BATF3 Basic leucine zipper transcription factor, ATF-like 3 2.97 -7.89 
48 gi_119913440 XR_028647 SLC6A3 Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 3.08 -7.81 
49 gi_119918141 XM_865568 SLC7A2 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 2.00 -7.44 
50 gi_31340697 NM_178572 CA2 Carbonic anhydrase II 2.62 -7.35 
51 gi_119908662 XM_588297 LAMC2 Laminin, gamma 2 3.06 -7.20 
52 gi_119915151 XM_001256822 LOC790310 Hypothetical protein (LOC790310) 3.54 -7.14 
53 gi_119904218 XM_870651 PRDM12 PR domain containing 12 3.52 -7.09 
54 gi_115495492 NM_001075925 ADORA2B Adenosine A2b receptor 3.22 -6.76 
55 gi_119901000 XM_613776 TRAF1 TNF receptor-associated factor 1 2.38 -5.87 
56 gi_119909626 XM_870153 ADORA2A Adenosine A2a receptor 2.22 -5.81 
57 gi_157074015 NM_001103247 PPP1R3B Protein phosphatase 1, regulatory (inhibitor) subunit 3B 2.00 -5.68 
58 gi_77735388 NM_001034215 DIRAS3 DIRAS family, GTP-binding RAS-like 3 2.78 -5.40 
59 gi_119909181 XR_027532 LOC540363 Similar to transmembrane protein 132B (LOC540363) 2.38 -5.30 
60 gi_158341669 NM_001109980 SLC16A3 Solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 2.17 -5.18 
61 gi_122692576 NM_001080280 SLC20A2 Solute carrier family 20 (phosphate transporter), member 2 2.01 -5.14 
62 gi_119296266 EE959692 – – - EE959692 K29921A fnm cDNA clone K2992 3' sequence 2.08 -5.13 
63 gi_119907907 XM_607470 RTN4RL2 Reticulon 4 receptor-like 2 2.44 -4.92 
64 gi_51813747 CO883803 – – - CO883803 bovgen_12128 normal cattle brain cdna clone rzpdp1056e214q 5' sequence 2.11 -4.70 
65 gi_119911699 XR_028261 DOC2B Double C2-like domains, beta 2.12 -4.54 
66 gi_10870122 BF076357 – – - BF076357 225899 MARC 2bovcdna 5' sequence 2.02 -4.30 
67 gi_114051971 NM_001046393 FAM107B Family with sequence similarity 107, member B 2.05 -4.30 
68 gi_51823984 CO893679 – – - CO893679 bovgen_22004 normal cattle brain cdna clone rzpdp1056b1442q 5' sequence 2.06 -4.28 
69 gi_119910538 XM_598392 HIPK4 Homeodomain interacting protein kinase 4 2.12 -4.24 
70 gi_119905261 XM_587891 FRMD4A FERM domain containing 4A 2.09 -4.06 
       
 
3.3 List of PMA induced down-regulated genes (n = 211) showing 
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1 gi_77735740 NM_001034393 SFRP2 Secreted frizzled-related protein 2 -2.21 -150.59 
2 gi_51814063 CO884115 – – - Co884115 bovgen_12440 normal cattle brain cDNA clone rzpdp1056h2429q 5' sequence -2.46 -48.53 
3 gi_119904441 XM_580490 KBTBD6 Kelch repeat and BTB (poz) domain containing 6 -9.03 -23.66 
4 gi_119920522 XM_001252954 LOC784734 Hypothetical protein (LOC784734) -2.04 -22.36 
5 gi_51819965 CO889677 – – - Co889677 bovgen_18002 normal cattle brain cDNAclone rzpdp1056a1334q 5' sequence -2.71 -21.82 
6 gi_156631000 NM_174459 SEPP1 Selenoprotein p, plasma, 1 -2.11 -20.75 
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7 gi_119920520 XM_601227 LOC522938 Hypothetical protein (LOC522938) -2.30 -17.94 
8 gi_155372278 NM_001101282 PTER Phosphotriesterase related -2.80 -13.84 
9 gi_51817307 CO887022 – – - Co887022 bovgen_15347 normal cattle braincDNA  clone rzpdp1056p1323q 5' sequence -2.27 -12.92 
10 gi_119911365 XM_594205 HLF Hepatic leukemia factor -2.18 -12.13 
11 gi_116004188 NM_001076984 GLIPR1 Gli pathogenesis-related 1 -2.85 -11.68 
12 gi_51827054 CO896734 – – - Co896734 bovgen_25059 normal cattle brain cDNAclone rzpdp1056g181q 5' sequence -11.84 -10.67 
13 gi_119934268 XM_001252747 CGNL1 Cingulin-like 1 -3.82 -10.32 
14 gi_119921717 XM_606666 TLN2 Talin 2 -2.90 -10.11 
15 gi_119909284 XM_868620 HVCN1 Hydrogen voltage-gated channel 1 -2.09 -8.63 
16 gi_119919045 XM_869718 PKNOX2 PBX/knotted 1 homeobox 2 -2.87 -7.59 
17 gi_119893558 XM_001251198 LOC783187 Hypothetical protein (LOC783187) -2.95 -6.80 
18 gi_119891548 XM_593382 TMEM139 Transmembrane protein 139 -2.44 -5.97 
19* gi_51808233 gb_CO878313 RPS8 Ribosomal protein s8 -2.64 -5.97 
20 gi_119901355 XM_595871 GPR63 G Protein-coupled receptor 63 -4.94 -5.92 
21 gi_119917968 XM_866446 JAKMIP3 Janus kinase and microtubule interacting protein 3 -3.21 -5.88 
22 gi_126723194 NM_001082453 RHOBTB1 Rho-related btb domain containing 1 -2.02 -5.88 
23 gi_139948606 NM_001083721 FAM70A Family with sequence similarity 70, member a -2.38 -5.78 
24 gi_89191836 NM_174702 AQP1 Aquaporin 1 (colton blood group) -2.95 -5.38 
25 gi_119912745 XM_587641 EVPL Envoplakin -2.66 -5.35 
26 gi_119893332 XM_001253780 PNPLA3 Patatin-like phospholipase domain containing 3 -2.04 -4.76 
27 gi_51815966 CO885681 – – - Co885681 bovgen_14006 normal cattle brain cDNAclone rzpdp1056g0625q 5' sequence -2.46 -4.59 
28 gi_75870703 DT890296 – – - Dt890296 1471293 marc 7bovcDNA3' sequence -2.45 -4.56 
29 gi_139948704 NM_001083715 LMOD1 Leiomodin 1 (smooth muscle) -5.94 -4.51 
30 gi_51810144 CO880219 – – - Co880219 bovgen_08544 normal cattle brain cDNAclone rzpdp1056l2216q 5' sequence -2.04 -4.51 
31 gi_51816156 CO885871 – – - Co885871 bovgen_14196 normal cattle brain cDNAclone rzpdp1056m022q 5' sequence -5.31 -4.45 
32 gi_119911058 XM_001254384 LOC788991 Hypothetical protein (LOC788991) -2.08 -4.41 
33 gi_77736204 NM_001034629 EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) -2.09 -4.32 
34 gi_155372204 NM_001101243 CCDC92 Coiled-coil domain containing 92 -2.92 -4.03 
35 gi_111084835 EE223727 – – - EE223727 lb01821.cr_j13 gc_bgc-18 cDNAclone image:8293359 sequence -2.10 -4.03 
36 gi_51801578 CO871746 – – - Co871746 bovgen_00071 normal cattle brain cDNAclone rzpdp1056g2254q 3' sequence -6.71 -3.93 
37 gi_119895570 XM_581784 SLC23A1 Solute carrier family 23 (Nucleobase transporters), member 1 -2.35 -3.92 
38 gi_51804999 CO875099 – – - Co875099 bovgen_03424 normal cattle brain cDNAclone rzpdp1056i1557q 5' sequence -2.03 -3.82 
39 gi_119914113 XM_872590 LOC509824 Similar to os08g0528700, transcript variant 4 (loc509824) -2.43 -3.80 
40 gi_51804084 CO874235 – – - Co874235 bovgen_02560 normal cattle brain cDNAclone rzpdp1056j0258q 3' sequence -2.42 -3.74 
41 gi_119938792 XM_865450 LOC614607 Similar to 214k23.2.2 (novel protein, isoform 2), transcript variant 1 (LOC614607) -3.62 -3.69 
42 gi_119908450 XM_592463 PLCH2 Phospholipase c, eta 2 -2.47 -3.61 
43 gi_51821340 CO891047 – – - Co891047 bovgen_19372 normal cattle braincDNAclone rzpdp1056m0937q 5' sequence -2.93 -3.41 
44 gi_75748738 DT816862 – – - Dt816862 lb0165.cr_h07 gc_bgc-16cDNAclone image:8079513 5' sequence -2.35 -3.39 
45 gi_46415427 
CN436163 
– – - 
cn436163 be04008b1g04 be04 normalized and subtracted bovine embryonic and 
extraembryonic tissuecDNAclone be04008b1g04 5' sequence -2.38 -3.29 
46 gi_114051010 NM_001046474 PPM1K Protein phosphatase, mg2+/mn2+ dependent, 1k -5.47 -3.27 
47 gi_119915240 XM_865759 TRERF1 Transcriptional regulating factor 1 -2.72 -3.25 
48 gi_157427807 NM_001105340 TRAF5 TNF receptor-associated factor 5 -3.14 -3.09 
49 gi_119895746 XM_601340 FAT2 Fat tumor suppressor homolog 2 (drosophila) -2.61 -3.08 
50 gi_51814379 CO884385 – – - Co884385 bovgen_12710 normal cattle braincDNAclone rzpdp1056k1011q 5' sequence -5.23 -3.06 
51 gi_51808765 CO878841 – – - Co878841 bovgen_07166 normal cattle brain cDNAclone rzpdp1056k029q 5' sequence -2.02 -3.05 
52 gi_76656160 XM_596273 LOC518089 Hypothetical (LOC518089) -2.07 -3.02 
53 gi_119913583 XM_001253211 LOC785074 Hypothetical protein (LOC785074) -2.42 -2.97 
54 gi_119916232 XM_618609 MYOM1 Myomesin 1, 185kda -3.37 -2.87 
55 gi_51817833 CO887548 – – - Co887548 bovgen_15873 normal cattle brain cDNAclone rzpdp1056a1011q 5' sequence -2.05 -2.84 
56 gi_149643004 NM_001099089 ZFP3 Zinc finger protein 3 homolog (mouse) -9.04 -2.70 
57 gi_51822437 CO892136 – – - Co892136 bovgen_20461 normal cattle brain cDNAclone rzpdp1056c0239q 5' sequence -3.93 -2.67 
58 gi_156120782 NM_001102068 PDE7B Phosphodiesterase 7b -6.29 -2.66 
59 gi_76677151 XM_586975 LOC509911 Similar to solute carrier family 16 member 1 (LOC509911) -3.02 -2.56 
60 gi_164448635 NM_001113261 PTPRR Protein tyrosine phosphatase, receptor type, r (ptprr), transcript variant 2 -3.16 -2.53 
61 gi_51820161 CO889874 – – - Co889874 bovgen_18199 normal cattle brain cDNA clone rzpdp1056c0845q 5' sequence -2.12 -2.49 
62 gi_119909586 XM_596386 ZNF280A Zinc finger protein 280a -6.73 -2.45 
63 gi_156120854 NM_001102104 ANKRD29 Ankyrin repeat domain 29 -2.47 -2.42 
64 gi_78369255 NM_001035416 LDB3 Lim domain binding 3 (ldb3) -2.59 -2.40 
65 gi_119904597 XM_584268 FRY Furry homolog (drosophila) -2.01 -2.37 
66 gi_119914328 XM_589824 LOC615277 Similar to loc443715 protein, transcript variant 1 (LOC615277) -2.81 -2.36 
67* gi_156121314 NM_001102335 PGM5 Phosphoglucomutase 5 -2.12 -2.36 
68 gi_82617553 NM_001035457 PRSS35 Protease, serine, 35 -4.55 -2.35 
69 gi_51815100 CO884817 – – - Co884817 bovgen_13142 normal cattle brain cDNAclone rzpdp1056m0313q 5' sequence -2.99 -2.31 
70 gi_77736300 NM_001034678 HES1 Hairy and enhancer of split 1, (drosophila) -2.27 -2.30 
71* gi_119909503 XM_867110 Inpp5j Inositol polyphosphate 5-phosphatase j -2.47 -2.30 
72 gi_51826056 CO895740 – – - Co895740 bovgen_24065 normal cattle brain cDNAclone rzpdp1056c1438q 5' sequence -2.08 -2.30 
73 gi_51825154 CO894844 – – - Co894844 bovgen_23169 normal cattle brain cDNAclone rzpdp1056c0137q 5' sequence -2.02 -2.29 
74 gi_68319921 AM018729 – – - Am018729 kn-252-liver,bos taurus cDNAclone c0007412e16 5' sequence -2.03 -2.29 
75 gi_116004120 NM_001076949 SEPT3 Septin 3 -2.38 -2.29 
76 gi_51811352 CO881423 – – - Co881423 bovgen_09748 normal cattle braincDNAclone rzpdp1056g2014q 5' sequence -2.55 -2.26 
77 gi_119911113 XM_609306 LOC530828 Hypothetical loc530828 (LOC530828) -2.18 -2.24 
78 gi_51816763 CO886478 – – - Co886478 bovgen_14803 normal cattle brain cDNAclone rzpdp1056f186q 5' sequence -3.64 -2.23 
79 gi_51807037 CO877123 – – - Co877123 bovgen_05448 normal cattle brain cDNAclone rzpdp1056a1952q 3' sequence -2.29 -2.23 
80 gi_51808554 CO878630 – – - Co878630 bovgen_06955 normal cattle brain cDNAclone rzpdp1056e225q 5' sequence -2.38 -2.23 
81 gi_77735458 NM_001034252 FBXL21 F-box and leucine-rich repeat protein 21 (gene/pseudogene) -2.07 -2.22 
82 gi_148237208 NM_001098017 PTPN6 Protein tyrosine phosphatase, non-receptor type 6 -2.05 -2.21 
83 gi_61889064 NM_001001854 CLDN1 Claudin 1 -2.11 -2.20 
84 gi_119892874 XM_865269 SSPN Sarcospan (kras oncogene-associated gene) -3.18 -2.20 
85 gi_51818031 CO887746 – – - Co887746 bovgen_16071 normal cattle brain cDNAclone rzpdp1056a1216q 5' sequence -2.07 -2.16 
86 gi_51825825 CO895511 – – - Co895511 bovgen_23836 normal cattle brain cDNAclone rzpdp1056j0947q 5' sequence -2.83 -2.14 
87 gi_119933474 XM_001256893 LOC790417 Similar to proproteinase e (LOC790417) -6.77 -2.09 
88 gi_115495650 NM_001075552 PIK3IP1 Phosphoinositide-3-kinase interacting protein 1 -2.08 -2.07 
89 gi_45071668 CK837937 – – - Ck837937 4063255 barc 8bovcDNAclone 8bov_10b21 5' sequence -2.64 -2.06 
90 gi_51808976 CO879052 – – - Co879052 bovgen_07377 normal cattle brainc dna clone rzpdp1056o2328q 5' sequence -2.50 -2.02 
91 gi_51823406 CO893101 – – - Co893101 bovgen_21426 normal cattle brain cDNAclone rzpdp1056m1837q 5' sequence -2.76 -2.00 
       
Profile 5 n = 91     
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene symbol 
gene name 
BoMac PMA 
vs BoMac 
Abs FC: 
TashAT2 PMA  vs 
PCAGGS PMA  
Abs: FC 
     
  
1 gi_119889379 XM_613217 CGN Cingulin -4.01 5.23 
2 gi_119927684 XM_001254424 LOC786868 Similar to polydom protein (LOC786868) -3.00 5.14 
3 gi_119889682 XM_613047 KCNC4 Potassium voltage-gated channel, shaw-related subfamily, member 4 -2.27 4.41 
4 gi_51821139 CO890846 – – - Co890846 bovgen_19171 normal cattle brain cDNAclone rzpdp1056f1741q 5' sequence -2.35 4.36 
5 gi_119900832 XM_001249686 LOC781282 Similar to polydom (LOC781282) -2.25 4.36 
6 gi_31342442 NM_174278 CNGA1 Cyclic nucleotide gated channel alpha 1 -2.83 4.33 
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7 gi_94967001 NM_001040604 GADD45B Growth arrest and dna-damage-inducible, beta -2.54 4.30 
8* gi_119891767 XM_001249363 INSIG1 Insulin induced gene 1 -3.78 4.29 
9 gi_164420790 NM_001113252 TGFB2 Transforming growth factor, beta 2 -2.91 4.28 
10 gi_118151293 NM_001078111 ZC4H2 Zinc finger, c4h2 domain containing -2.23 4.25 
11* gi_118151149 NM_001078029 FAM13C Family with sequence similarity 13, member c -4.52 4.02 
12* gi_62460611 NM_001014959 DNAJB5 Dnaj (HSP40) homolog, subfamily b, member 5 -2.02 3.94 
13 gi_154152010 NM_001100299 CRISPLD2 Cysteine-rich secretory protein lccl domain containing 2 -2.02 3.88 
14 gi_119920254 XM_001253942 AR Androgen receptor -5.55 3.88 
15 gi_119942112 XM_001257229 LOC790860 Similar to histamine n-methyltransferase (LOC790860) -2.88 3.87 
16 gi_76666197 XM_588979 LOC539724 Similar to androgen receptor (dihydrotestosterone receptor) (LOC539724) -5.31 3.87 
17 gi_51824106 CO893799 – – - Co893799 bovgen_22124 normal cattle brain cDNAclone rzpdp1056b0846q 5' sequence -2.90 3.82 
18 gi_27807398 NM_174796 PIK3R3 Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) -2.48 3.68 
19 gi_119908963 XM_866831 RNF150 Ring finger protein 150 -3.29 3.68 
20 gi_51804591 CO874691 – – - Co874691 bovgen_03016 normal cattle braincDNAclone rzpdp1056a1457q 3' sequence -2.79 3.65 
21 gi_119890423 XM_001251596 LOC782936 Similar to phosphatidylinositol 3-kinase regulatory subunit (LOC782936) -2.29 3.57 
22* gi_119891769 XM_001249423 INSIG1 Insulin induced gene 1 -3.83 3.52 
23* gi_77735702 NM_001034378 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) -2.81 3.52 
24* gi_118150923 NM_001077909 INSIG1 Insulin induced gene 1 -3.67 3.51 
25 gi_78365290 NM_001035434 HNMT Histamine n-methyltransferase -2.38 3.47 
26 gi_37712997 CF763779 – – - Cf763779 ces005100skin cDNAlibrarycDNAclone ccl005100 5' sequence -3.92 3.41 
27* gi_119894560 XM_584000 BST2 Bone marrow stromal cell antigen 2 -2.72 3.41 
28 gi_51819098 CO888813 – – - Co888813 bovgen_17138 normal cattle brain cDNAclone rzpdp1056i0649q 5' sequence -5.57 3.35 
29 gi_119915318 XR_028520 LOC512304 Similar to enpp5 (LOC512304) -2.09 3.31 
30 gi_145562057 ES346223 – – - Es346223 u3g19ca.r1 cattle subcutaneous adipose tissue cDNA library cDNAclone u3g19ca 
5' sequence -3.03 3.31 
31 gi_119890099 XM_600332 RAVER2 Ribonucleoprotein, ptb-binding 2 -3.36 3.31 
32 gi_119931385 XM_001253959 LOC786203 Similar to hiv-1 rev binding protein-like (LOC786203) -2.09 3.28 
33 gi_51883802 AJ816326 – – - Aj816326 kn206 bos sp. cDNAclone c0005210h22 sequence -3.47 3.25 
34* gi_94967003 NM_001040606 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda -3.44 3.25 
35 gi_51826474 CO896157 – – - Co896157 bovgen_24482 normal cattle braincDNAclone rzpdp1056p0647q 5' sequence -2.40 3.24 
36 gi_119917854 XM_880481 FGFR2 Fibroblast growth factor receptor 2 -4.68 3.23 
37 gi_51881346 AJ813870 – – - Aj813870 kn206 bos sp. cDNAclone c0005205h15 sequence -2.84 3.21 
38 gi_119879761 XM_581912 THPO Thrombopoietin -2.40 3.19 
39 gi_119887370 XM_001251262 LOC783219 Hypothetical protein (LOC783219) -2.23 3.18 
40 gi_157074121 NM_001103303 SLC46A3 Solute carrier family 46, member 3 -3.45 3.15 
41 gi_119917192 XM_587493 AGFG2 Arfgap with fg repeats 2 -2.10 3.07 
42* gi_51821409 CO891116 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda -3.97 3.03 
43 gi_119888584 XM_584793 ZNF362 Zinc finger protein 362 -2.57 2.98 
44* gi_119905065 XM_001251706 FLRT3 Fibronectin leucine rich transmembrane protein 3 -8.26 2.96 
45 gi_148277667 NM_174547 GUCY2C Guanylate cyclase 2c (heat stable enterotoxin receptor) -2.38 2.94 
46* gi_51825967 gb_CO895653 CHRNA3 Cholinergic receptor, nicotinic, alpha 3 -3.12 2.85 
47 gi_51809329 CO879405 – – - Co879405 bovgen_07732 normal cattle braincDNAclone rzpdp1056g089q 5' sequence -2.03 2.85 
48 gi_119878572 XM_001249734 VGLL3 Vestigial like 3 (drosophila) -2.49 2.83 
49 gi_119233167 EE896593 – – - Ee896593 b03011a ffbcDNAclone b0301 3' sequence -2.64 2.77 
50 gi_61316453 NM_001013001 WNT2 Wingless-type mmtv integration site family member 2 -2.11 2.77 
51 gi_154366939 EV610519 – – - EV610519 lb004155.cr_p03 gc_bgc-04cDNAclone image:9065141 5' sequence -2.20 2.76 
52 gi_49423002 AJ690394 – – - Aj690394 aj690394 kn261cDNAclone kn261-053_k04 sequence -3.17 2.70 
53 gi_119901460 XM_618496 BACH2 BTB and cnc homology 1, basic leucine zipper transcription factor 2 -2.79 2.65 
54 gi_51884726 AJ817250 – – - Aj817250 kn206 bos sp. cDNAclone c0006006p18 sequence -2.00 2.61 
55 gi_119920249 XM_590017 KIAA2022 KIAA2022 -2.40 2.54 
56 gi_121583852 NM_001015635 RASL11B Ras-like, family 11, member b -7.62 2.54 
57 gi_119893809 XM_613340 RBM47 RNA binding motif protein 47 -3.52 2.54 
58 gi_119902721 XR_028578 LOC538778 Hypothetical loc538778 (loc538778) -4.06 2.52 
59 gi_51812194 CO882262 – – - Co882262 bovgen_10587 normal cattle braincDNAclone rzpdp1056c2420q 5' sequence -2.16 2.50 
60 gi_51808026 CO878110 – – - Co878110 bovgen_06435 normal cattle braincDNAclone rzpdp1056a1417q 5' sequence -2.55 2.45 
61* gi_119905063 XM_607863 FLRT3 Fibronectin leucine rich transmembrane protein 3 -7.06 2.45 
62 gi_62460603 NM_001014952 TRIM45 Tripartite motif containing 45 -2.38 2.45 
63 gi_119895914 XM_001249756 LOC781690 Hypothetical protein (LOC781690) -2.30 2.43 
64 gi_51807654 CO877738 – – - Co877738 bovgen_06063 normal cattle braincDNAclone rzpdp1056a0317q 5' sequence -2.59 2.42 
65 gi_119879589 XM_590786 MYLK Myosin, light polypeptide kinase (mylk) -2.50 2.38 
66 gi_51815587 CO885302 – – - Co885302 bovgen_13627 normal cattle braincDNAclone rzpdp1056a1213q 5' sequence -2.17 2.35 
67* gi_118151321 NM_001078125 ARMCX6 Armadillo repeat containing, x-linked 6 -2.27 2.34 
68 gi_77735632 NM_001034340 CYR61 Cysteine-rich, angiogenic inducer, 61 -2.65 2.33 
69* gi_119922570 XM_001254638 ARMCX6 Armadillo repeat containing, x-linked 6 -2.34 2.28 
70 gi_119914463 XM_585971 PDZRN3 PDZ domain containing ring finger 3 -2.88 2.26 
71 gi_119885610 XM_590531 SPSB4 spla/ryanodine receptor domain and socs box containing 4 -2.40 2.25 
72 gi_51818557 CO888272 – – - co888272 bovgen_16597 normal cattle brain cDNAclone rzpdp1056j1628q 5' sequence -2.08 2.22 
73* gi_31342492 NM_178108 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kda -2.90 2.21 
74 gi_125630662 NM_001081519 DDIT4L DNA-damage-inducible transcript 4-like -2.68 2.21 
75 gi_119908935 XM_615424 ZNF827 Zinc finger protein 827 -2.27 2.20 
76 gi_119922580 XM_868651 GPR137C G protein-coupled receptor 137c -3.20 2.20 
77 gi_157073967 NM_001103222 SLC2A2 Solute carrier family 2 (facilitated glucose transporter), member 2 -4.67 2.18 
78 gi_125630680 NM_001081523 HABP4 Hyaluronan binding protein 4 -2.33 2.18 
79 gi_75832087 NM_177501 FUT8 Fucosyltransferase 8 (alpha (1,6) fucosyltransferase) -2.91 2.17 
80 gi_119233198 EE896624 – – - EE896624 b03211a ffbcDNA clone b0321 3' sequence -2.48 2.16 
81 gi_114051857 NM_001045960 TCEAL1 Transcription elongation factor a (sii)-like 1 -2.30 2.14 
82 gi_115497913 NM_001076462 C1orf110 Chromosome 1 open reading frame 110 -4.56 2.10 
83 gi_51809241 CO879317 – – - Co879317 bovgen_07644 normal cattle brain cDNA clone rzpdp1056c1024q 5' sequence -3.24 2.08 
84 gi_114052465 NM_001045905 NUDT13 Nudix (nucleoside diphosphate linked moiety x)-type motif 13 -2.13 2.07 
85 gi_115497025 NM_001075661 ZPBP2 Zona pellucida binding protein 2 -2.07 2.07 
86 gi_119930546 XM_001255692 LOC788716 Similar to fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (LOC788716) -2.66 2.05 
87 gi_51802497 CO872657 – – - Co872657 bovgen_00982 normal cattle brain cDNAclone rzpdp1056d0757q 5' sequence -2.03 2.04 
88 gi_119879570 XM_610099 C3orf15 Chromosome 3 open reading frame 15 -2.42 2.04 
89 gi_77736302 NM_001034679 Rcan1 Regulator of calcineurin 1 -3.42 2.03 
90 gi_115497021 NM_001076059 FBXL4 F-box and leucine-rich repeat protein 4 -2.28 2.03 
91 gi_31343567 NM_175804 NR2F1 Nuclear receptor subfamily 2, group f, member 1 -2.97 2.03 
       
Profile 6 n = 29     
S.No 
 
SEQ. ID 
 
Acc. No. 
(RefSeq) 
Putative 
Gene symbol Gene Name 
BoMac PMA 
vs BoMac 
Abs FC: 
TashAT2 PMA  vs 
PCAGGS PMA  
Abs: FC 
    
   
1 gi_119903692 XM_871827 LRRTM4 Leucine rich repeat transmembrane neuronal 4 -11.60 47.50 
2 gi_126165231 NM_001081717 EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 -2.18 32.81 
3 gi_119920877 XM_001257254 NOVA1 Neuro-oncological ventral antigen 1 -2.60 25.39 
4 gi_156523203 NM_001102546 PDE4B Phosphodiesterase 4B, cAMP-specific -2.06 20.13 
5 gi_119892229 XM_592100 AMIGO2 Adhesion molecule with Ig-like domain 2 -2.94 14.81 
6 gi_51818729 CO888444 – – - CO888444 BovGen_16769 normal cattle brain cDNAclone RZPDp1056M0317Q 5' sequence -2.77 13.52 
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7 gi_119891169 XM_592060 HECW1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 -2.15 12.91 
8 gi_51818632 CO888347 – – - CO888347 BovGen_16672 normal cattle brain cDNAclone RZPDp1056M2030Q 5' sequence -2.51 10.99 
9 gi_51820224 CO889937 – – - CO889937 BovGen_18262 normal cattle brain cDNAclone RZPDp1056M1637Q 5' sequence -4.25 10.91 
10 gi_115497559 NM_001075897 JAKMIP2 Janus kinase and microtubule interacting protein 2 -2.17 10.61 
11 gi_119891802 XM_598424 LGR5 Leucine-rich repeat containing G protein-coupled receptor 5 -2.85 10.43 
12 gi_119885258 XM_866829 LOC615109 Similar to beta-galactoside alpha-2,6-sialyltransferase (LOC615109) -2.52 9.55 
13 gi_119929905 XM_001256313 LOC789611 Similar to membrane glycoprotein LIG-1 (LOC789611) -2.04 9.07 
14* gi_139948585 NM_001083776 FAM155A Family with sequence similarity 155, member A -2.18 8.71 
15 gi_119884936 XM_618021 VEPH1 Ventricular zone expressed PH domain homolog 1 (zebrafish) -2.67 8.66 
16* gi_119907214 XM_001250844 SOX6 SRY (sex determining region Y)-box 6 -2.79 7.95 
17 gi_119915236 XM_001252205 DAAM2 Dishevelled associated activator of morphogenesis 2 -2.11 7.59 
18 gi_51819474 CO889189 – – - CO889189 BovGen_17514 normal cattle brain cDNAclone RZPDp1056J1148Q 5' sequence -2.18 6.93 
19* gi_115497983 NM_001076473 PPAP2B Phosphatidic acid phosphatase type 2B -2.24 6.73 
20 gi_119922192 XM_616412 ITGB8 Integrin, beta 8 -2.17 6.66 
21* gi_150247128 NM_001099368 PCDHGA2 Protocadherin gamma subfamily A, 2 -2.15 6.58 
22* gi_119907210 XM_001250746 SOX6 SRY (sex determining region Y)-box 6 -2.56 6.53 
23 gi_157279998 NM_001105045 C5orf13 Chromosome 5 open reading frame 13 -2.28 6.52 
24 gi_51821825 CO891528 – – - CO891528 BovGen_19853 normal cattle brain cDNAclone RZPDp1056A1732Q 5' sequence -2.61 5.51 
25 gi_76638411 XM_612023 MBNL3 Muscleblind-like 3 (Drosophila) -2.24 5.49 
26 gi_119912551 XM_607943 TANC2 Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 -2.09 5.41 
27 gi_62117152 DN740977 – – - DN740977 1404247 MARC 7BOVcDNA3' sequence -2.17 5.34 
28 gi_119884953 XM_591264 PLCH1 Phospholipase C, eta 1 -2.22 4.52 
29 gi_115497789 NM_001075225 NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 -2.02 4.41 
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3.4 Full list of ‘biological function and disease categories’ in 
TashAT2/Infection modulated overlapping dataset (1,206 genes) 
 
Category   p-value 
    
1 Cancer  1.8E-22-1.15E-04 
2 Inflammatory Disease  1.83E-18-1.1E-04 
3 Cell Death  2.99E-18-1.34E-04 
4 Inflammatory Response  1.08E-17-1.25E-04 
5 Skeletal and Muscular Disorders  1.3E-17-1.1E-04 
6 Genetic Disorder  1.4E-17-1.09E-04 
7 Immunological Disease  1.98E-16-1.02E-04 
8 Cellular Movement  2.44E-16-1.28E-04 
9 Neurological Disease  2.66E-15-1.02E-04 
10 Cellular Growth and Proliferation  1.45E-14-6.81E-05 
11 Connective Tissue Disorders  8E-14-2.47E-05 
12 Gastrointestinal Disease  1.09E-13-1.02E-04 
13 Respiratory Disease  3.05E-13-1.03E-04 
14 Gene Expression  9.12E-13-6.54E-05 
15 Cell-To-Cell Signaling and Interaction  4.76E-12-1.25E-04 
16 Reproductive System Disease  4.97E-12-9.83E-05 
17 Cellular Development  6.46E-12-1.3E-04 
18 Cellular Function and Maintenance  1.78E-11-1.28E-04 
19 Dermatological Diseases and Conditions  7.93E-11-4.13E-05 
20 Organismal Injury and Abnormalities  2.26E-10-1.3E-04 
21 Hepatic System Disease  2.7E-10-1.02E-04 
22 Hematological Disease  3.19E-10-1.3E-04 
23 Free Radical Scavenging  1.09E-09-6.5E-05 
24 Cardiovascular Disease  4.11E-09-1.29E-04 
25 Cellular Compromise  6.37E-08-9.39E-05 
26 Cell Morphology  6.89E-08-1.14E-04 
27 Antigen Presentation  1.54E-07-1.25E-04 
28 Infectious Disease  3.27E-07-1.28E-04 
29 Lipid Metabolism  6.56E-07-1.28E-04 
30 Small Molecule Biochemistry  6.56E-07-1.28E-04 
31 Hypersensitivity Response  1.79E-06-1.79E-06 
32 Renal and Urological Disease  2.64E-06-6.57E-05 
33 Cellular Assembly and Organization  2.84E-06-1.27E-04 
34 Ophthalmic Disease  1.11E-05-1.11E-05 
35 Metabolic Disease  2.06E-05-1.27E-04 
36 Post-Translational Modification  2.27E-05-2.27E-05 
37 Cell Signaling  2.83E-05-1.12E-04 
38 Molecular Transport  3.11E-05-1.29E-04 
39 Vitamin and Mineral Metabolism  3.11E-05-1.12E-04 
40 Psychological Disorders  3.4E-05-3.4E-05 
41 DNA Replication, Recombination, and Repair  4.88E-05-4.88E-05 
42 Nutritional Disease  7.75E-05-7.75E-05 
43 Endocrine System Disorders  8.3E-05-1.27E-04 
44 Carbohydrate Metabolism  1.28E-04-1.28E-04 
45 Developmental Disorder  1.29E-04-1.29E-04 
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3.5 Full list of IPA Canonical and Custom Pathways identified in 
TashAT2 modulated overlapping dataset (1,206 genes) 
 Ingenuity Canonical Pathways -log(p-value) Ratio 
 
   
1 Production of Nitric Oxide and Reactive Oxygen Species 
in Macrophages 6.97E+00 1.07E-01 
2 HMGB1 Signaling 5.78E+00 1.40E-01 
3 IL-6 Signaling 5.04E+00 1.30E-01 
4 Role of Tissue Factor in Cancer 5.00E+00 1.23E-01 
5 IL-8 Signaling 4.94E+00 9.33E-02 
6 G-Protein Coupled Receptor Signaling 4.65E+00 6.60E-02 
7 TNFR2 Signaling 4.55E+00 2.06E-01 
8 NF-κB Signaling 4.54E+00 9.66E-02 
9 Role of JAK1 and JAK3 in γc Cytokine Signaling 4.54E+00 1.47E-01 
10 IL-2 Signaling 4.38E+00 1.55E-01 
11 Protein Kinase A Signaling 3.81E+00 7.01E-02 
12 CD40 Signaling 3.77E+00 1.29E-01 
13 Insulin Receptor Signaling 3.56E+00 9.29E-02 
14 ERK/MAPK Signaling 3.54E+00 7.84E-02 
15 PI3K Signaling in B Lymphocytes 3.53E+00 9.09E-02 
16 Acute Phase Response Signaling 3.50E+00 8.43E-02 
17 PKCθ Signaling in T Lymphocytes 3.50E+00 8.45E-02 
18 HIF1α Signaling 3.34E+00 1.02E-01 
19 Rac Signaling 3.30E+00 8.94E-02 
20 LPS-stimulated MAPK Signaling 3.28E+00 1.10E-01 
21 NF-κB Activation by Viruses 3.28E+00 1.10E-01 
22 CXCR4 Signaling 2.89E+00 7.69E-02 
23 IL-3 Signaling 2.72E+00 1.08E-01 
24 Integrin Signaling 2.72E+00 7.14E-02 
25 PAK Signaling 2.66E+00 8.41E-02 
26 Apoptosis Signaling 2.66E+00 9.38E-02 
27 Myc Mediated Apoptosis Signaling 2.57E+00 1.15E-01 
28 IL-1 Signaling 2.56E+00 8.41E-02 
29 JAK/Stat Signaling 2.49E+00 1.09E-01 
30 Role of PRR in Recognition of Bacteria and Viruses 2.46E+00 9.20E-02 
31 PPAR Signaling 2.44E+00 8.41E-02 
32 TNFR1 Signaling 2.39E+00 1.13E-01 
33 cAMP-mediated signaling 2.05E+00 6.39E-02 
34 IL-15 Signaling 1.88E+00 8.96E-02 
35 Inositol Phosphate Metabolism 1.87E+00 5.56E-02 
36 TGF-β Signaling 1.77E+00 7.87E-02 
37 Actin Cytoskeleton Signaling 1.70E+00 5.46E-02 
38 Interferon Signaling 1.65E+00 1.11E-01 
39 TREM1 Signaling 1.54E+00 7.58E-02 
40 Acute Myeloid Leukemia Signaling 1.43E+00 7.32E-02 
41 PI3K/AKT Signaling 1.43E+00 5.71E-02 
42 Role of JAK family kinases in IL-6-type Cytokine  signaling 1.35E+00 1.11E-01 
 Custom Pathway analysis -log(p-value) Ratio 
1 NF-κB response genes 8.58E+00 1.12E-01 
2 NF-κB dot org derived pathway/ Targets 5.49E+00 8.01E-02 
3 NF-κB Signaling 3.42E+00 5.74E-02 
4 AP1targets 3.13E+00 1.76E-01 
5 WNTsiganlling 2.02E+00 1.22E-01 
6 Toll-like Receptor Signaling 1.66E+00 8.89E-02 
7 ATF2network 1.63E+00 1.00E-01 
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3.6 Important genes identified in the biological function and disease 
categories in TashAT2/ infection modulated overlapping dataset 
Important Categories  Key Molecules modulated in TashAT2 in predicted manner 
Cancer (119/252) Cancer: 
ABAT,ABCC3,ABCG2,ADRB2,ALDH1A1,ANGPTL1,ANXA4, AOC3, 
APOD,BCAS1,BST2,CA2,CALCRL,CAPN3,CASP7, CD34, CD3G, 
CD8,CDC42BPA,CDKN2C,CEBPA,COL3A1, CPA4,CREB3L3,CSRP2, 
CYBA,CYP3A4,DIXDC1, DVL1,EAF2, EPAS1,EPS8,ERRFI1,ETV5, 
FAS, FCER2,FOS, HES1 (includes EG:15205),EY1,HK2,IER3, 
IFI27, IFI44,IFIT3, IFNAR2, IGFBP6,IKBKE,IL15RA,IL18, IL24, 
IL7R,IRF8, JUP, KIF1A, KRT17, KRT6A,LMO2,LTBP1, MAP3K1, 
MDK,MERTK, MT2A, MUM1L1, NAV3,NFE2,NGFR,NPC1,NTNG2, 
P2RX7, PDE3B, PDE7B, PIK3CD, PIK3IP1,PLAU,PLAUR,PNPLA4, 
PPP1R3C, PRDM1,PRKCZ,PRSS23,PTPN6,RASAL1, Rbpms, 
RNASEL, RPH3AL,S100A14,S1PR1,SCN2B,SERPINE1,SLC2A5, 
SLC7A11,SLC7A5, SMAD7,SPINT2,SPOCK2,ST5,STEAP3, 
SYNPO2,TIFA,TP63, TPM2,UGCG,VCAM1,VWA5A, XAF1, ZBTB20 
Cancer (106) 
Tumourigenesis (113) 
Neoplasia (107) 
Carcinoma (82) 
Formation of secondary tumor (4) 
Transformation (21) 
Cell Death (75/215)  Cell Death 
ABCC3,ABCG2,ALPK2,CA2,CASP7,CD82,CDC42BPA,CDKN2C,CEBPA, 
CYP3A4,DVL1,EPAS1,FAS,FCER2,FOS,GGT1,HCK,HES1 (includes 
EG:15205),IER3,IFNAR2,IGFBP6,IKBKE,IL15RA,IL18,IL24,IRF8,ITSN1, 
JUP,KIF1A,LASS1,LMO2,LTBP1,MAP3K1,MAPK10,MDK,MT2A,NGFR, 
NUPR1,PLAU,PLAUR,PMEPA1,PPP1R1B,PRDM1,PRKCZ,PTPN6,PTPRM, 
RNASEL,SERPINE1,SERPINI1,SLC7A11,SMAD7,TP63,TRAF1,UGCG, XAF1 
Cell death of cancer cells (55) 
Cell death of blood cells (25) 
Apoptosis of leukocytes (16) 
Cell viability (13) 
Inflammatory Response (56/ 130) Inflammatory Response 
 
DRB2,AIF1,AOC3,BST2,CA2,CALCRL,CD3G,CHN1,COL3A1,CYBA,CYBB, 
FAS,FCER2,FOS,GGT5,GM2A,GPR77,HCK,IER3,IFI44,IFNAR2, IKBKE, 
IL15RA,IL18,IL24,IL6ST,IL7R,IRF8,KRT17,LGALS9, LTBP1, MAPK10, 
MERTK,NPC1,NUPR1,P2RX7,PIK3CD,PLAU, PLAUR, PRDM1,PRKCZ, 
PTPN6,RNASEL,S100A14,S1PR1, SERPINE1,SIT1, SMAD7,TPST1, VCAM1 
Immune response (50) 
Inflammation (19) 
Phagocytosis of cells (10) 
Respiratory burst (7) 
Inflammatory response (23) 
Adhesion of phagocytes (7) 
Cellular Movement (51/133)  Cellular Movement 
ADRB2,AIF1,ANGPTL1,AOC3,CALCRL,CD34,CD82,CHST1,CYBB,EPAS1,EP
S8,ERRFI1,ETV5,FAS,FOS,GGT5,HCK,HEY1,IGFBP6,IL15RA,IL18, 
IL6ST,IRF8,ITGB7,JUP,KRT6A,LGALS9,MAP3K1, MCF2L,MDK,MRAS, 
MYL12B, NGFR,NPC1,P2RX7,PIK3CD, PIK3IP1,PLAU,PLAUR,PLTP, 
PRKCZ,PTPN6,PTPRM,S100A14,S1PR1, SCN2B, SERPINE1, SMAD7, TP63, 
VCAM1,VCL 
Cell movement (51) 
Migration of cells (47) 
Leukocyte migration (24) 
Cell movement of leukocytes (19) 
Dissemination of tumor cells (2) 
Cell Morphology (57/84) Cell Morphology 
 
ARHGEF9,BAIAP2,CD3G,CHN1,FAS,FOS,GAS7,HCK,HES1 
(includes EG:15205),LMO2,NGFR,P2RX7,PDE3B,PLAU, 
PLAUR,SERPINE1,SORBS3,TP63,VCAM1,VCL 
Shape change (20) 
Morphology of cells (18) 
Outgrowth of neuritis (14) 
Reorganization of cytoskeleton (8)  
Ruffling (5) 
  
The given table represents the most relevant biological process categories and key molecules from 
each category that can be linked to the phenotype of parasite infection and LPS stimulation of BL20 
cells. Similarly, prediction of whether the molecules promoted (pro) or inhibited (anti) the designated 
functional category identified by IPA is also indicated. The absolute fold change for each molecule is 
given in brackets.  
 
